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      i             Introduction 
Introduction 
In January of 1999, the National Birth Defects Prevention Network (NBDPN) established a Surveillance 
Guidelines and Standards Committee (SGSC) in order to develop and promote the use of standards and 
guidelines for birth defects surveillance programs in the United States. This set of guidelines is designed 
to serve as an important first step in the documentation of this process and as the vehicle for 
dissemination of the committee’s findings.  
 
The Guidelines for Conducting Birth Defects Surveillance (henceforth referred to as The Surveillance 
Guidelines) were developed with three major long-term objectives in mind:  
 
 To improve the quality of state birth defects surveillance data, including accuracy, comparability, 
completeness, and timeliness. 
 To enhance the utility of state birth defects surveillance data for research on the distribution and 
etiology of birth defects. 
 To encourage and promote the use of state birth defects surveillance data for the purposes of 
linking affected children with services and evaluation of those services. 
 
The technical guidelines that make up this document provide a way of improving the quality of birth 
defects surveillance data, which in turn enhances their use in support of the latter two objectives. 
Fundamental to quality is ensuring that procedures for all aspects of data definition, collection, 
management, and analysis are established and followed. Because state-based surveillance systems operate 
with different objectives and data needs, it is clear that, with respect to procedures and standards, “one 
size does not fit all.” It is also clear, however, that common guidelines can provide a basis for the 
development of system-specific operating procedures and supporting manuals.  
 
Variation among surveillance programs is manifest along several dimensions. These include: 
 Objectives, which can be very diverse but commonly include: 
• Providing baseline data on occurrence 
• Identifying populations at increased risk 
• Monitoring changes in occurrence 
• Investigating clusters 
• Collaborating with research 
• Estimating service needs 
• Referring affected children to services 
• Evaluating prevention programs 
 Case ascertainment methods 
• Active – case finding 
• Passive – case reporting 
• Combined 
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 Organizational location 




The first two dimensions – objectives and case ascertainment methods – are of particular significance in 
attempting to develop guidelines that have the breadth to be useful (i.e., universality), while at the same 
time making clear that there is not necessarily a common denominator across programs. Thus most of the 
guidelines in this volume are phrased as recommendations or “shoulds,” as opposed to standards, which 
could be interpreted as “musts.” The exception to the latter is Chapter 10, which refers the reader to 
information on how data are to be reported to NBDPN for the Annual Report. The relevance of 
organizational location to the guidelines is probably restricted to legislative issues, which are addressed in 
Chapter 2. 
 
The Surveillance Guidelines consist of a series of chapters covering the fundamental aspects of 
developing, planning, implementing, and conducting surveillance for birth defects and using the resulting 
data. Although the focus is on birth defects, most of the principles described are relevant and applicable to 
surveillance for any health outcome. Just as the methods and strategies developed for birth defects in the 
Metropolitan Atlanta Congenital Defects Program provided a blueprint for the subsequent development of 
the Metropolitan Atlanta Developmental Disabilities Surveillance Program, the information included in 
these guidelines can provide a blueprint for the development of surveillance for developmental disabilities 
among the states. 
 
On reviewing the guidelines, the reader will note that a number of the chapters are supported by 
appendices. In many instances these appendices are designed to provide additional information on 
technical issues considered. In some cases they provide extensive detail on procedures that are currently 
being used by surveillance programs. Because of their size, three documents cited as appendices will only 
be available in electronic format. These are the NBDPN Abstractor’s Instructions (Chapter 3, Appendix 
3.2) and the Texas Disease Index and the CDC Six-digit Codes (Chapter 5, Appendices 5.1 and 5.2, 
respectively). Information on how to access the electronic format is included in each appendix. 
 
The Surveillance Guidelines are being published in two formats: as print copy and through the NBDPN 
website. The Surveillance Guidelines and Standards Committee anticipates updating and revising the 
guidelines over time. Whenever a revision is published, a revision date will appear in the chapter header 
to distinguish that page or pages from previous versions. Because we anticipate this will be a living 
document, we encourage comments, suggestions, and corrections. If you have such, please submit them 
through the link to the Surveillance Guidelines and Standards Committee on the NBDPN website. 
 
This set of guidelines represents a great deal of work by a large number of individuals. The development 
of the document was carried out by the NBDPN Surveillance Guidelines and Standards Committee. A 
working group for each of the chapters did most of the writing. When chapters were completed in draft 
form, they were submitted to the SGSC Steering Group for review and suggested revisions. When a draft 
was considered acceptable to the Steering Group it was sent to Dr. Lowell Sever of Battelle Centers for 
Public Health Research and Evaluation, the editorial consultant for the reference manual. Dr. Sever then 
edited the chapter, returning it to the Steering Group, and working groups when necessary for clarification 
and acceptance of his revisions. Several of the chapters were also sent to specially assembled “Focus 
Teams” for review and assessment of the technical content. When the final content was agreed upon, the 
chapter was submitted to a Battelle technical writer and editor for finalization of structure and format.   
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1.1  Introduction 
The ultimate value of any public health surveillance program lies in the ways in which the data collected are 
used to improve the health of the public. State birth defects surveillance programs are no exception; they 
exist to improve public health. Every program must have clear goals and objectives that drive how their 
surveillance data are used toward improving public health. Public input through partnerships with state 
agencies and organizations and the effective utilization of advisory committees are essential to establishing 
and revising program objectives and ensuring that the resources exist to meet them. 
 
The purposes and objectives established by state birth defects surveillance programs are constantly evolving. 
Some objectives are traditional, such as those having to do with the epidemiologic purposes of surveillance; 
others have emerged more recently, serving to broaden the scope of surveillance programs. Birth defects 
surveillance programs increasingly use data for services planning and evaluation, for development and 
evaluation of prevention strategies, to inform parents of children with birth defects about available services, 
for studies of the societal impact of birth defects, for referral of families to needed services and resources, 
and for clinical research studies. The consistent theme among these emerging data uses is how birth defects 
surveillance may benefit other programs in the quest to improve the public’s health. In the face of fluctuating 
resources for public health and obstacles resulting from concerns about confidentiality of health records, the 
need to incorporate public input in planning and priority-setting has never been greater. This chapter will 
attempt to address some of the issues in the forefront as we plan for the future of birth defects surveillance. 
 
In the remainder of this chapter we present the rationale for conducting birth defects surveillance (Section 
1.2), key steps in establishing a state-based birth defects surveillance program (Section 1.3), and some 
important uses for birth defects surveillance data (Section 1.4). References cited in this chapter may be found 
in Section 1.5. 
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1.2  Rationale  
When contemplating initiating or enhancing a birth defects surveillance program, a number of questions 
come to mind: 
 What is the rationale for conducting birth defects surveillance? 
 Why is birth defects surveillance important? 
 How do birth defects surveillance data benefit other programs? 
 What are the barriers to collection and full utilization of birth defects surveillance data? 
 
In this chapter, we provide answers to these questions, which may help you advocate for and prepare to 
launch or expand a birth defects surveillance program in your area. 
1.2.1  What is the rationale for conducting birth defects surveillance? 
CDC defines public health surveillance as: 
The ongoing, systematic collection, analysis, and interpretation of health data essential to 
the planning, implementation and evaluation of public health practice, closely integrated 
with the timely dissemination of these data to those who need to know. The final link of the 
surveillance chain is the application of these data to prevention and control. A surveillance 
system includes a functional capacity for data collection, analysis, and dissemination linked 
to public health programs (Centers for Disease Control, 1988). 
 
It is clear from this definition that a birth defects surveillance program must establish goals and objectives for 
how data are to be collected, analyzed, disseminated, and used. It is through the latter (i.e., data use) that the 
efforts from the former are translated into public health action and health improvement. Thus, using data to 
meet a program’s objectives is the most important aspect of any public health surveillance program; merely 
collecting data is not enough. How data are being used is also what programs tout when they need to 
showcase their activities to agency officials and legislators.  
 
Because of the essential relationship of the ultimate uses of data to the design and conduct of birth defects 
surveillance, we begin these guidelines with a consideration of fundamental data-related issues, considering 
not only the rationale for birth defects surveillance but the key steps for establishing state-based birth defects 
surveillance programs, followed by a discussion of the use of surveillance data for improvement of the 
public’s health. Every surveillance program should have a plan for data utilization that incorporates public 
input on all phases of the process – from data development, through data collection, to data dissemination to 
the public. Suggestions for developing a data utilization plan are presented in Section 1.2 below. 
1.2.2  Why is birth defects surveillance important? 
States have many reasons for conducting birth defects surveillance. The value of birth defects surveillance 
lies in how the data are collected and how they are used, with respect to the goals of the program. All 
programs should establish goals and objectives, which make it clear that the ultimate rationale for conducting 
public health surveillance is to have data that can be used to improve the health of the public. Reporting the 
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data certainly qualifies as “using the data,” yet this should never be considered sufficient as it fails to meet 
the definition of public health surveillance cited above. 
 
The objectives of state birth defects surveillance programs have evolved over the past 40 years. Lynberg and 
Edmonds (1992) assessed the objectives that had been established by surveillance programs by the early 
1990s. Table 1.1 organizes these objectives under broad purposes originally suggested by Reed and Meaney 
(1988) with some slight modifications. A review of the table highlights the potentially broad mission of birth 
defects surveillance, providing state programs with a way of assessing how they are utilizing data currently 
and possible new uses. 
 
Table 1.1 Purposes and Objectives of Birth Defects Surveillance 
Purposes Objectives 
Epidemiologic Develop timely baseline birth defects rates 
 Monitor trends and relationships to environmental factors  
 Perform cluster investigations 
 Provide basis for ecologic and etiologic studies 
  
Planning/Prevention Provide data for services planning   
 Provide basis for prevention strategies 
 Evaluate efficacy of preventive services 
  
Educational/Social Inform public about public health importance 
 Inform parents about resources and care facilities 
 Provide data for studies of economic impact 
 Provide data for follow-up studies of long-term effects 
  
Healthcare and human services Refer children to services and resources 
 Evaluate services utilization  
  
Clinical Provide basis for clinical research 
Adapted from Lynberg and Edmonds (1992) and Reed and Meaney (1988) with modifications. 
1.2.3  How do birth defects surveillance data benefit other programs? 
The benefits of birth defects surveillance data to human service programs include: identifying children in 
need of services to ensure that they and their families are referred appropriately; evaluating service utilization 
by children with birth defects and their families; and planning the location of services for particular 
conditions in areas of highest frequency. An important use of surveillance data is monitoring birth defects 
trends following the initiation of prevention programs in order to evaluate their effectiveness. 
 
One of the public health benefits of the computer age is enhanced capacity for record linkage. Record linkage 
using public health data has a longer history than most people realize, beginning in the 1950s with the 
availability of computers in university settings. Pioneering investigators like Harold B. Newcombe (1962) 
recognized the utility of linking vital records data in studying human populations. The potential now exists 
for extensive computerized record linkage in birth defects surveillance programs, allowing for the tracking of 
children with a health-related condition from the point of identification through access to services. Many 
computer-based systems already exist for documenting health care delivery, including diagnostic and 
procedure codes. Birth defects surveillance records have been linked to many other public health program 
databases. These include, for example, newborn screening to conduct epidemiologic studies, special 
education data to predict the need for services for children with mental retardation, and early intervention 
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program data to assess the overlap and utility of a birth defects surveillance program as a “child find” 
resource.  
 
In the final section of this chapter we describe a number of applications of these approaches that can serve as 
models for states developing birth defects surveillance programs, as well as for programs considering 
expansion of the current uses of their data. To date, the potential for applications of these types exceeds 
available resources to support them and to overcome some of the obstacles discussed immediately below. 
1.2.4  What are the barriers to collection and full utilization of birth defects 
surveillance data? 
While improved methods and technological advances have increased our ability to collect data, there have 
been intensified efforts to protect the confidentiality of records and the information they contain. Many birth 
defects surveillance programs – based both in health departments and in other institutions such as universities 
– have encountered increasing concerns and pressures as a result of Health Insurance Portability and 
Accountability Act (HIPAA) regulations and issues surrounding their interpretation and implementation. A 
variety of HIPAA-related issues are discussed in Chapter 2 of these guidelines. Even though the HIPAA 
regulations include public health exclusions regarding access to records without a patient’s consent, 
programs have seen increased awareness and concerns on the part of hospitals and clinics reporting cases and 
data. These concerns are magnified when a surveillance program attempts to expand data usage through 
linkage to other databases covered under HIPAA regulations. 
 
Prior to HIPAA, concerns often surfaced about data sharing among officials in different programs within the 
same state agency or among programs located in different agencies. Such concerns were usually due to 
program-specific regulations about data use. Program regulations frequently impede attempts to link records 
between case-finding databases and service-delivery databases. As a result, attempts to meet the very 
reasonable public health goal of ensuring access to services by those in need may be thwarted. Thus, 
programs are strongly urged to consider strategies for surmounting these problems well in advance of 
undertaking data collection and record linkage.  
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1.3  Synopsis of Key Steps in Establishing State-Based Birth Defects 
Surveillance Programs 
In this section we outline some of the key steps in establishing a birth defects surveillance program. These 
include: 
 Defining the objectives and purposes of the program 
 Considering legal issues 
 Engaging external support 
 Leveraging resources 
 Considering record linkage 
 
Time devoted upfront to serious consideration of these issues will be well spent and will ensure that the 
resultant program is established on a firm footing. 
1.3.1  Defining the Objectives and Purposes of the Program 
The success of a birth defects surveillance program is likely to be highly dependent on the host agency’s 
commitment and support. Without programmatic commitment and resource support at the agency level, 
programs are apt to languish in circumstances that do not allow much beyond the collection and reporting of 
data. In these situations, using data in ways other than the calculation of rates and their dissemination in 
reports is usually not possible. Programs committed to expanding how birth defects surveillance data are 
used must establish programmatic objectives and demonstrate to agency officials how the data could be used. 
This involves prioritizing what uses would be of greatest utility in terms of meeting agency goals and 
objectives, demonstrating (or “marketing”) to the agency how beneficial these data uses could be, and 
working to achieve commitment of additional agency resources. 
 
Another strategy for increasing support from the agency in which the surveillance program resides is to 
gather support from other intra-agency programs and from external agencies that could benefit from the use 
of birth defects surveillance data to meet their own programmatic goals. Often other programs and agencies, 
given enough information about birth defects surveillance and the objectives of the program, will see 
potential uses of the data that are beyond the current scope of the surveillance program.  
 
There has been an increase in intra-agency collaboration during the last ten years through the availability of 
federal support for data linkage and integration. A prime example of data collaboration would be linking 
birth defects surveillance databases with Children with Special Health Care Needs (CSHCN) program 
databases that collect data on program enrollment and services. These linked data sets could then be used to 
evaluate the rates at which this long-term maternal and child health program is utilized. Such applications 
have been accomplished in some states through grant support from the Maternal and Child Health Bureau 
(MCHB) of the Health Resources and Services Administration (HRSA) and through cooperative agreements 
with the Centers for Disease Control and Prevention (CDC). Interagency collaboration in linking birth 
defects surveillance program databases with services databases (such as those for early intervention programs 
or developmental disabilities) have begun in a few states. The benefits to be gained in this way – i.e., by 
utilizing birth defects surveillance data as a means of identifying children eligible for special programs, such 
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as early intervention – is clearly a “selling point” that can lead to additional resource allocation, either from 
within the host agency for the birth defects program or from an external agency in need of the data. 
 
Most birth defects surveillance programs experience cyclical problems with availability of state resources, 
leading them to define precisely what they can and cannot do given the resources available to them. While it 
is certainly necessary for programs to realistically budget their resources to ensure continued viability, 
programs also need to engage both intra-agency and interagency support for their goals and objectives as a 
means to maintain and expand a surveillance program. At a minimum, programs should allocate personnel 
time to educate officials of their own agency and other agencies about birth defects surveillance and its 
importance and potential uses in the public health field. 
1.3.2  Considering Legal Issues 
To the extent possible, programs should consider the inclusion of references to data use in the legislation that 
authorizes birth defects surveillance. Given the relative ease with which rules – as compared to laws – can be 
changed, it is generally desirable to make references to potential data uses for surveillance data more general 
in the statute and more specific in the rules. Rules and regulations that refer to the authorizing statutes are the 
obvious choice as to where best to specify detailed uses to which surveillance data will be put. Relevant 
issues and legal considerations are discussed extensively in Chapter 2 of these guidelines. 
1.3.3  Engaging External Support 
Beyond seeking intra-agency and interagency support for a new surveillance program or for expansion of an 
existing surveillance program, program staff should also seriously consider means to attract the support of 
both non-governmental partnering organizations and the public.  
 
Partnering organizations. The importance of building partnerships with organizations such as the local 
March of Dimes can never be sufficiently stressed. In recent years, the success story of the birth defects 
surveillance program in North Carolina is arguably without peer. The program has consistently credited the 
partnership it built with the March of Dimes as a major contributor to its success in garnering additional 
resources for the program. In Texas, the March of Dimes was also instrumental recently in restoring funds to 
maintain the Texas Birth Defects Monitoring Division, funds that had not been requested in the budget put 
forward by the Texas Department of Health. These kinds of partnerships should be entered into with clear 
and consistent agreement among the players regarding the objectives of the program relative to data usage, 
prioritization of data uses, and planning toward future applications of the data. In other words, the 
contribution of organizations such as the March of Dimes can be beneficial from the design of data 
utilization plans through to the reporting of actual outcomes. 
 
Advisory committees with agency, organizational, and public representation, including political officials, are 
another means of obtaining input regarding uses of birth defects surveillance data. The available computer 
technologies such as listservs and webpages decrease the need for face-to-face meetings among interested 
parties, while increasing the frequency with which information about a program can be communicated and 
feedback solicited. New ideas about potential uses to which a program’s data can be put and the resources 
needed to accomplish programmatic activities can be shared with advisory committee members for 
immediate feedback as to the feasibility of the idea and its potential for success.  
 
Programs should create opportunities for formal input from advisors on a regular basis to ensure the 
availability of support in times of fiscal crises. Advisory group members’ knowledge of surveillance data 
collection activities and uses for surveillance data can be critical to securing resources for a program in times 
when limited resources require justification for program continuation. 
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Public involvement. Birth defects surveillance programs generally have not engaged consumer and parent 
participation other than through advisory group representation. Members of the public, including parents of 
children identified through these programs, are often not well informed about public health surveillance 
activities. If not already doing so, birth defects surveillance programs should engage both consumers – here 
defined as adults with birth defects, and parents and caretakers of children with birth defects – in the 
planning and implementation of any and all programmatic changes. There are a number of advocacy and 
parent support groups, such as the Spina Bifida Association of America, Family Voices, and the Alliance of 
Genetic Support Groups, that can play important roles in planning and conducting birth defects surveillance 
programs. 
 
Programs should embrace the concept of participatory action research (PAR) (Whyte, 1991). PAR is a way 
to obtain public input into programmatic activities from design though dissemination of results. PAR ensures 
input from the community members most affected by potential data uses. Again, as discussed with respect to 
advisory group input, computer technology can be immensely beneficial in obtaining feedback on new 
initiatives and more importantly in soliciting input about programmatic activities from community members. 
1.3.4  Leveraging Resources 
For birth defects surveillance, as for other public health surveillance programs, the ways in which data are 
used will influence continued availability of program resources. In the age of evidence-based medicine and 
increased emphasis on demonstrating program efficacy for continued support, birth defects surveillance 
programs should work toward expanding data use. Fiscal trends in states suggest that the likely survivors in 
times of increasingly fewer tax-based resources will be programs that adapt by reinventing themselves in 
terms of data utilization. While emphasizing the application of surveillance data to improving human 
services and then evaluating their impact will not ensure the survival of a program, it should increase its 
chances. 
 
Surveillance programs (particularly those housed in health departments) may be given adequate resources for 
data collection and management, but often do not have adequate personnel or resources for data analysis 
beyond simple descriptive reporting. Program managers and staff often use lack of adequate resources as an 
excuse to minimize the number of new initiatives they undertake, but this may well be a short-sighted 
approach. We have already discussed the importance of partnerships, advisory groups, and public 
involvement in increasing the probability of acquiring additional resources. While programs must, 
realistically, work within the limits of available resources, partnerships with agencies and institutions can 
represent a means to extend and enhance programmatic achievements. Universities, particularly those with 
public health training programs or medical schools, will have faculty and trainees potentially interested in 
birth defects. What a birth defects surveillance program lacks in resources for data analysis and research 
often can be compensated for through partnerships with interested faculty members willing to direct student 
theses and dissertations that focus on birth defects. New programs and programs that do not currently have 
such partnerships should give serious consideration to forming these types of collaborations, which can lead 
to additional resources through contracts and grants. 
1.3.5  Considering Record Linkage 
As touched upon in Section 1.3.1, the potential to link records and consolidate information from different 
databases contributes to the public health applications of surveillance data. For example, data from birth 
defects surveillance programs can be used to determine whether reported cases of birth defects represent 
existing cases in other databases, such as records in interdisciplinary clinics and schools with programs to 
assist children with disabilities. The ability to link records on individuals in more than one database can 
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streamline the treatment and referral processes and help maintain a certain level of fidelity and trust in 
prevalence data. Record linkage can streamline the research process by consolidating several different 
databases. Another utility of record linkage is the ability to supply crucial data required for various research 
efforts. Specifically, the data located in one database can be used to elicit information from a second. 
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1.4  Uses of Surveillance-based Birth Defects Data 
Most US states have implemented birth defects surveillance programs that monitor and disseminate 
information regarding birth defects. Public health staff and researchers nationwide have used these data in a 
variety of ways. The actual and potential uses of birth defects data are discussed and exemplified in the 
following sections. Data from birth defects surveillance programs can be employed to define the magnitude 
of a problem, to support research, as well as to assess the efficacy of prevention and treatment, playing a key 
role in the core public health function of assessment (Institute of Medicine, 1988).  
 
For convenience, the uses of birth defects surveillance data can be grouped into the following categories: 
 Prevalence studies 
 Epidemiologic studies 
 Mortality assessment 
 Needs assessment for services 
 Referral to clinics and services 
 Program evaluation 
 Clinical research 
 
Each of these categories of use will be discussed in further detail below. While comprehensive coverage of 
works in each of these categories is beyond the scope of this chapter, we have selected published studies that 
exemplify the kinds of research that can be conducted in each category. Naturally, what an individual 
program is able to do depends ultimately on its goals and objectives. When programs are faced with limited 
resources to conduct data analysis and research, collaborations with universities or contractors with 
epidemiologic expertise can often yield mutually satisfactory results. 
1.4.1  Prevalence Studies 
A common use of data produced by birth defects surveillance programs is to describe the occurrence 
(prevalence at birth) of the monitored conditions. Such uses of surveillance data include identification of 
trends in birth defects occurrence, definition and evaluation of clusters of congenital defects, and assessment 
of the need for resources and interdisciplinary services. 
 
Khoury et al. (1986) is an example of an early study by a state surveillance program that used data in this 
way. This study was the outcome of a partnership between the state health department-based surveillance 
program and university-based researchers. Khoury and co-workers used 1984 data collected from the 
Maryland Birth Defects Reporting and Information System (BDRIS) to determine rates of occurrence and to 
identify potential trends. The prevalence at birth of “sentinel” defects, as determined from the Maryland 
BDRIS data, was 52.7 per 10,000 qualified births. Furthermore, trends in the occurrence of several specific 
birth defects were identified. The study revealed an association of low birth weight and prematurity with 
birth defects, an association between twinning and the rate of birth defects, racial differences in the 
prevalence of neural tube defects, and a relationship between Down syndrome and advanced maternal age. 
The importance of determining prevalence at birth is that the data can be compared with similar data 
collected from other birth defects monitoring systems to assess differences in rates that may exist among 
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surveillance areas and to direct further research efforts in an attempt to identify the reasons behind the 
differences. 
 
An example of a more recent prevalence study is one reported by Ethen and Canfield (2002), who 
investigated the effects of including elective pregnancy terminations, prior to 20-weeks gestational age, on 
birth defects prevalence. In many surveillance programs, pregnancies ending prior to 20 weeks gestational 
age, including elective terminations, are not ascertained to be included among reported cases. The 
researchers concluded that when elective terminations at less than 20 weeks were considered, the prevalence 
of some congenital defects increased, while others remain unchanged. Specifically, anencephaly, spina 
bifida, and encephalocele increased substantially, while cleft palate did not change. The underlying 
assumption is that pregnancies resulting in debilitating or potentially terminal conditions are more likely to 
be terminated electively than those resulting in less severe or treatable malformations. 
 
These two studies show the potential usefulness of prevalence data to reveal important trends and 
associations. These types of data often provide the impetus to initiate subsequent research. A consequence of 
producing birth defects prevalence data is that it frequently opens other avenues of exploration. Quite simply, 
without basic prevalence data to lead inquiry, many research investigations never would be conceptualized, 
much less carried out. 
1.4.2  Epidemiologic Studies 
Cases from birth defects surveillance programs have played key roles in conducting etiologic research in the 
United States and internationally. Cases from the Metropolitan Atlanta Congenital Defects Program 
(MACDP) have provided the basis for numerous research studies that have shed light on both the causes 
(Khoury et al., 1982; Oakley, 1984; Erickson, 1991; Dott et al., 2003) and prevention (Roberts et al., 1995; 
Olney et al., 2002) of birth defects. Similarly, the California Birth Defects Monitoring Program (CBDMP) 
has been the source of cases and etiologic research that has resulted in dozens of seminal papers on a variety 
of specific congenital malformations and their risk factors (Croen et al., 1991; Shaw et al., 1996; Ritz et al., 
2002). Other state programs have contributed cases for epidemiologic studies leading to a growing number of 
multi-state investigations of specific risk factors (for example, Olney et al., 1995). Reference to the annual 
report of the International Clearinghouse for Birth Defects Monitoring Systems (International Centre for 
Birth Defects, 2002) demonstrates the large number of studies based on individual surveillance systems and 
collaborative projects among programs. 
 
An example of an early methodological study, based on surveillance data, is a study by Khoury et al. (1988) 
that assessed the patterns of maternal residential mobility between conception and delivery. The authors’ 
rationale was that most epidemiologic studies of environmental risk factors are based on maternal residence 
at the time of delivery. Such an assessment would be invalid, however, in instances where the mother had 
moved prior to delivery. The researchers examined demographic data for infants born with congenital 
defects. Both the demographic data as well as the birth defect data were taken from the Maryland BDRIS in 
1984. The researchers concluded that, on average, 21% of all mothers whose pregnancies resulted in a child 
affected by one of the birth defects included in the Maryland BDRIS had moved between conception and 
delivery. This is important for several reasons. First, it is well understood that the effects of environmental 
teratogens occur early in embryogenesis; so assessing the influence of environmental exposures must be 
related temporally to conception. In addition, potential exposures to teratogenic environmental factors could 
possibly be misrepresented if examined at delivery rather than around the time of conception. Maternal 
mobility could also skew data regarding geographic clusters of birth defects. This study was made possible 
because the Maryland BDRIS determines the residence of the mother not only at the time of delivery, but 
also at the time of conception. This is an important aspect of the Maryland BDRIS that is not common to all 
birth defects surveillance programs. 
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Examples of surveillance-based etiologic research of associations between maternal exposures and 
congenital defects include studies of cigarette smoking and orofacial clefts. Among the earliest research 
efforts investigating this association was a study by Khoury et al. (1987) using data collected in 1984 from 
the Maryland BDRIS. A case-control study examined the history of cigarette smoking among mothers of 
infants with orofacial clefts and a group of control mothers. The researchers concluded that odds ratios for 
cleft palate (2.39, CI 1.04-5.45) and cleft lip with and without cleft palate (2.56, CI 1.13-5.78) were increased 
for women who smoked. Furthermore, the researchers identified a dose-response effect. Khoury and his co-
workers also took into account possible confounding factors, including race, gender, residence, maternal age, 
parity, and several pregnancy exposures or complications. None of these affected the results significantly. 
This is a classic example of how surveillance-based birth defects data can be used to examine etiologic 
factors through the use of simple epidemiologic techniques. Sometimes the importance of earlier 
epidemiologic studies is not appreciated when comparing them to more recent research. It is worth noting 
that the association between maternal cigarette smoking and orofacial clefts has been corroborated through 
more recent studies using several surveillance-based investigations. The paper by Khoury et al. (1987) has 
been cited in many contemporary research publications (Shaw et al., 1996; Lieff et al., 1999). 
 
Some states have used surveillance data to look for associations between environmental factors that are 
known to cause specific birth defect syndromes and other birth defects. For example, maternal alcohol use 
during pregnancy is a known cause of the fetal alcohol syndrome, but its role in more common, isolated, 
craniofacial defects is not well understood. A population-based, case-control study of orofacial clefts was 
conducted in Iowa based on births from 1987-1991 (Munger et al., 1996). Cases were identified by the Iowa 
Birth Defects Registry and classified as having a cleft lip with or without cleft palate (CLP) or cleft palate 
only (CP) and as to whether the cleft was isolated or occurred with other birth defects. Controls were selected 
from normal Iowa births. Maternal alcohol use during pregnancy was classified according to self-reported 
drinks consumed per month. Compared to women who did not drink alcohol during pregnancy, the relative 
odds of isolated CLP rose with increasing level of maternal drinking as follows: 1-3 drinks per months, 1.5; 
4-10 drinks per month, 3.1; more than 10 drinks per month, 4.7 (chi-square test for trend, P = 0.003). 
Adjustment for maternal smoking, vitamin use, education, and household income did not substantially alter 
the results. No association was found between alcohol use and isolated cleft palate or clefts in children with 
multiple birth defects. Based on these data, alcohol use during pregnancy may be a cause of isolated cleft lip 
with or without cleft palate. 
 
As described, epidemiologic investigation is an important area of research supported by birth defects 
surveillance data. In the past, this research effort primarily focused on environmental exposures as possible 
etiologic factors. However, with the recent explosion of molecular genetics and a more thorough 
understanding of molecular biology, the avenues of epidemiologic investigation have widened significantly. 
Investigators now have an enhanced ability to examine the contributions of both maternal and fetal genotypes 
to disease risk. Examination of the interplay between genetic predispositions/susceptibilities and 
environmental exposures is a growing area of study, with potential major implications with respect to 
understanding birth defects etiology. This is illustrated by the genetic component of the National Birth 
Defects Prevention Study, a multicenter case-control study being conducted by CDC and participating state 
surveillance programs (Yoon et al., 2001; Rasmussen et al., 2002). 
 
Continuing with the study of the association between smoking and clefts, epidemiologic studies have focused 
on the relationship between certain alleles of a transforming growth factor and maternal cigarette smoking 
with regard to risk of orofacial clefts. The most promising associations are seen in polymorphisms of the 
transforming growth factor alpha (TGFα) gene taq1 and maternal cigarette smoke exposure. An example is a 
study by Hwang et al. (1995), supported by surveillance data, that examined this association. The data on 
infants born with orofacial clefts were taken from the Maryland BDRIS. The Maryland BDRIS was not only 
able to supply cases of orofacial clefts, but also information about maternal prenatal behaviors, including 
maternal smoking during pregnancy. Cases were genotyped and screened for the rare C2 taq1 polymorphism. 
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The researchers concluded that the C2 genotype, combined with maternal smoking, significantly increased 
the risk of orofacial clefts. Using data collected through a birth defects surveillance program, they were able 
to identify a possible interaction between an environmental exposure and a genetic predisposition with 
respect to risk for orfacial clefts. 
 
Studies like this represent another generation of epidemiologic research. The power of these molecular 
epidemiologic studies lies in their ability to elicit possible etiologies of birth defects beginning with 
prevalence data, demographic information, and biologic samples. While the epidemiologic research methods 
have evolved significantly, the ultimate goal of these studies has remained constant: namely, to identify, 
define, and associate birth defects with possible etiologic factors. The development and application of 
molecular genetic methods serve as stepping stones to future research based on surveillance-derived cases. 
1.4.3  Assessing Mortality Associated with Birth Defects 
A 1995 Texas study assessed survival rates for selected birth defects among babies born between January 1, 
1995 and December 31, 1997, by linking two databases: the state’s active birth defects registry and the infant 
death registry (Nembhard et al., 2001). The goal of the study was to determine mortality among cases with 
various birth defects identified through the birth defects surveillance system by matching those cases against 
infant death files. Specifically, the researchers found the birth defects with the lowest survival were 
anencephaly (0%) and trisomy 13 (7.4%), while the birth defects with the highest survival were gastroschisis 
(92.9%) and trisomy 21 (92.3%). These survival data were only for the first year of life.  
 
Another example of a mortality study is that carried out by Druschel et al. (1996), who examined infant 
mortality among children with orofacial clefts, comparing their mortality rates to those of children with no 
congenital malformations. In the absence of malformations in other organ systems (isolated clefts), mortality 
was not increased among children with orofacial clefts. The study revealed, however, that many children 
with orofacial clefts have other malformations that increase their risk of death. These findings suggest the 
need for careful evaluation of possible additional malformations among children with orofacial clefts as these 
children may be at higher risk of death. 
1.4.4  Estimating the Need for Services 
Estimating service needs based on birth defects prevalence has significant direct social consequences. 
Accurately predicting the demand for various interdisciplinary clinics and social and educational services is 
critical for children born with birth defects. Estimating future service needs allows for capacity building to 
ensure that necessary resources will be accessible and that appropriate professionals will be available to 
provide the services. 
 
Brewster et al. (1992) linked demographic and diagnostic data from1980 – 1982 in a birth defects 
surveillance program database (the Arkansas Reproductive Health Monitoring System) with education 
databases. The data were first used to estimate the percentages of infants with specific birth defects who were 
at risk for developmental disabilities and mental retardation. Once prevalence rates were determined, two 
clinicians estimated the various services that would be needed by children with the various birth defects most 
likely to contribute to developmental disabilities. This included academic and other services these infants 
would require as they matured. The researchers estimated that between 32% and 56% of all children in 
schools who were classified as mentally retarded were also identified by the Arkansas Reproductive Health 
Monitoring System.  
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This study showed that recognition of children with mental retardation, who were also identified years earlier 
as having congenital defects, allowed researchers to refine their estimates of the birth defects that will 
contribute most significantly to mental retardation in school-aged children. This is useful in improving the 
ability of health care professionals to predict accurately future needs of the current cohort of newborns with 
birth defects.  
1.4.5  Referral to Services 
Information collected as part of birth defects surveillance can be used to refer specific children and their 
families to appropriate services. Established referral networks serve as a resource for children and their 
families to learn about available medical services, community programs, and social support. Affected 
children and their families can be connected with appropriate services in a timely fashion.  
 
Many papers have been written detailing the process of identification and ultimate service referral. One of 
the first papers on this topic comes from the Maryland BDRIS, where investigators examined the referral of 
children identified with orofacial clefts through the surveillance program to the Maryland Crippled 
Children’s Service Program in the 1960s (White, 1981). This study examined referral rates to services. A 
more recent paper on referral and treatment patterns for orofacial clefts comes from Florida, where referral 
and treatment patterns of live-born Florida infants diagnosed with orofacial clefts identified through the 
Florida Birth Defects Registry were determined (Williams et al., 2003).  
 
Another example is a paper describing service referrals in Colorado that use birth defects data taken from 
their birth defects surveillance program (Montgomery and Miller, 2001). The Community Notification and 
Referral Program (CNRP), operating from within the state’s health department, uses birth defects data to link 
affected infants with an organization that can refer them and their families to agencies and interdisciplinary 
clinics. In 1998, 259 families were referred for services as a result of being identified through the birth 
defects registry. There are a number of services to which patients are commonly referred, including 
developmental screening and evaluation, public health programs, early intervention programs, financial 
assistance, parenting classes, medical services, recreational programs, and family support groups. 
Additionally, the effectiveness of this program has been assessed through the use of surveys and 
questionnaires.  
 
A review of the use of surveillance data relative to provision of early intervention services can be found in a 
recent paper on identification and referral programs by Farel and colleagues (2003). Having agencies use 
birth defects data to link patients with appropriate services is a critical data use that has immediate and direct 
impact on the lives of those affected. Although epidemiologic and laboratory efforts may illuminate 
etiologies and possible preventive measures for future use, the fact remains that effective therapeutic efforts 
in the present can significantly improve the lives of persons with birth defects; scientific studies take years to 
complete and primarily aid future patients. Meanwhile, there are people who require immediate assistance, 
and service referral is an important mechanism through which they can receive that help.  
1.4.6  Program Evaluation 
Another use of birth defects surveillance data is program evaluation. Typically, this use is employed 
subsequent to research efforts, many of which were also based on surveillance data and may represent a 
baseline from which post-intervention improvement can be measured. Program evaluation is a valuable and 
desired area of activity with important scientific, academic, social, and policy applications. Program 
evaluation can focus on different aspects of surveillance program activities, such as case referrals and clinical 
interventions. First, evaluating a program for service referral can give investigators information on the 
efficacy of their referral agencies or the appropriateness of the services offered. Second, evaluating clinical 
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intervention studies allows researchers to assess both the effectiveness of the intervention and the validity of 
their clinical assumptions.  
 
One study involving program evaluation of a clinical intervention using birth defects surveillance data was 
performed in Nuevo León, México (Martinez de Villarreal et al., 2002). The investigators assessed the 
effectiveness of a folic acid campaign in reducing the occurrence of neural tube defects. Investigators first 
developed a base rate for neural tube defects prior to administration of the folic acid and counseling services. 
An intervention was then initiated that included five mg of folic acid supplementation per week, as well as 
counseling and social services. After 28 months, the rates of neural tube defects were ascertained again. 
From the baseline in 1999 (95 cases of neural tube defects), neural tube defects declined by 50% in the next 
two years (59 cases in 2000, 55 cases in 2001). 
 
This study illustrates the wide range of uses for birth defects surveillance data in evaluation. First, data were 
used to assess an initial rate of neural tube defects and at the conclusion of the intervention to assess its 
appropriateness and efficacy. In addition, the study demonstrated the efficacy of folic acid supplementation 
in reducing the occurrence of neural tube defects and the fact that the methods of administration were 
clinically appropriate and effective.  
 
In another example of the use of surveillance data in program evaluation, Meyer and Oakley (2000) used 
data from the North Carolina Birth Defects Monitoring Program to assess the folic acid fortification 
mandates of the federal government. The results suggested that the decline in the occurrence of neural tube 
defects was marginal and not the predicted 50% decrease. The authors’ recommendation was to increase the 
folic acid fortification standards on a national level. 
1.4.7  Clinical Research 
Recently a group of researchers in the United Kingdom carried out surveillance in one Health Region using 
multiple sources to identify all individuals with specific conditions (Holland et al., 1998; Whittington et al., 
2001). The condition the researchers captured that is of greatest relevance to birth defects is Prader-Willi 
syndrome (PWS). The first step was to conduct population-based surveillance in the Cambridge Health 
District (eight English counties with a base population of 280,000 individuals) (Whittington et al., 2001). The 
birth prevalence of PWS was estimated to be 1:22,000 and the mortality rate more than 3% per year. The 
next step was to carry out population-based clinical research about phenotypic features, including the 
prevalence of behavioral and health problems in PWS. Clarke et al. (2002) reported the prevalence of 
compulsive and similar behaviors among individuals with PWS in this population. Butler et al. (2002) 
presented data on the prevalence of comorbidities in PWS that could contribute to reduced life expectancy 
for persons with this condition. Most recently Holland et al. (2003) reported on the specific behaviors that 
comprise the proposed behavioral phenotype in PWS.  
 
Although this work represents a non-traditional method of surveillance compared to state surveillance 
programs in the United States, it is important in terms of clinical research that has been conducted and the 
potential for conducting similar work using state-based surveillance data. A major advantage of these clinical 
studies is that they are population based. Even though all individuals identified through the surveillance work 
did not participate in the collection of behavioral and health data, the sample of individuals with PWS who 
participated in the clinical research can be compared to the total population of ascertained individuals to 
evaluate how representative the sample is of individuals in the Health Region who have PWS. Usually this is 
not possible using common methods of clinical research. 
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1.4.8  Using Birth Defects Data in the Future  
For the data collection process itself, abstracting methods continue to be refined. Quality assurance 
procedures and ongoing training, aimed at increasing data accuracy and validity, are being implemented in 
order to assure a certain level of fidelity and trust in the data collected. Improving and standardizing these 
procedures are among the objectives of these guidelines.  
 
The future uses of birth defects surveillance data are related to scientific advances in other areas of research. 
Several developing scientific fields will utilize birth defects data in novel ways. For example, our 
understanding of molecular biology has developed exponentially. With the successful sequencing of the 
human genome, the resulting information will provide significant information on genetic factors influencing 
disease risk. Consequently, these discoveries will be investigated for certain genetic regulatory mechanisms 
and environmental triggers. Using birth defects surveillance data, investigators will be able to examine 
possible environmental exposures that are etiologically associated with birth defects in the presence of a 
particular genetic background. Discoveries of gene-environment interaction will allow researchers to 
understand etiologic associations. Additionally, the way in which these environmental conditions regulate 
gene expression will further illuminate these associations. 
 
Future advancements in research supported by birth defects data will benefit from the integration of 
electronic medical records. Current methods for obtaining birth defects data are laborious. They frequently 
involve extensive abstraction procedures, reporting cases to the respective health department, entering the 
abstracts into the database, and categorizing the data. These methods will be streamlined, as medical records 
and birth defects surveillance systems are maintained electronically. This will have two general effects: first, 
it will help facilitate the abstraction process by eliminating bulky charts containing information not 
necessarily applicable to the birth defects surveillance program and, second, it will allow researchers to 
access these information-rich databases more quickly and efficiently. Furthermore, database search functions 
will allow researchers to identify cases of interest instantaneously without physically sifting through 
thousands of reported cases. Ultimately, researchers will be given access to the electronic surveillance 
database. Using surveillance systems researchers will able to search for cases of interest and refine their 
cohort by filtering cases by demographics, location, or maternal prenatal behaviors. A study that currently 
takes weeks to conclude would be completed in the course of several hours. 
 
Researchers continuously find new and exciting uses of the data from birth defects surveillance programs. 
Given the breakthroughs achieved through earlier studies using surveillance data, the possibilities of future 
revelations are staggering. In their relatively short existence, birth defects surveillance programs have 
changed the ways in which professionals view birth defects both clinically and socially. The importance of 
the impact of birth defects surveillance programs on clinical and public health research cannot be overstated, 
as such research is revolutionizing the way scientists, clinicians, and health care professionals approach, 
treat, and manage infants affected by birth defects, while also advancing our understanding of preventive 
measures.   
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2.1  Introduction 
Legislation supporting birth defects surveillance activities is important for several reasons. For example, 
legislation serves to define the purposes of surveillance activities, specifies the kinds of data or 
information to be collected, and designates who is responsible for this activity. The first birth defects 
legislation was passed in New Jersey in 1926. During the past 20 years, the majority of states have 
enacted legislation mandating reporting of birth defects to the health department. As of April 2004, 41 
states had existing legislation or rule related to birth defects surveillance.  
Although there are a number of advantages to having legislation that supports birth defects surveillance, 
some limitations may also accrue. Early in their planning process, new or relatively new state programs 
should consider both the benefits and the possible limitations of birth defects surveillance legislation. At 
this early stage in a program’s development, the opportunity exists to advocate for and perhaps assist in 
crafting clearly written, effective legislation that will serve the needs of the program in years to come.  
In this chapter we discuss the distinction between the terms ‘legislation’, ‘regulation’, and ‘authority’ 
(Section 2.2); key elements of model legislation (Section 2.3); and federal laws that can affect birth 
defects surveillance programs (Section 2.4). References cited in this chapter may be found in Section 2.5. 
To assist those interested in drafting or revising state legislation concerning birth defects surveillance, we 
append sample legislation from Arkansas, California, New Jersey, New York, Oklahoma, and Texas (see 
Appendix 2.1). Additional appendices include a table of birth defects legislation (Appendix 2.2), 
definitions used to determine ‘covered entity’ status under the Privacy Rule (Appendix 2.3), and an 
excerpt from the text of the Health Insurance Portability and Accountability Act (Appendix 2.4). 
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2.2  Legislation, Regulation, and Authority 
‘Authority’ to mandate the reporting of birth defects to a surveillance program can be granted through 
‘legislation’ or ‘regulation’. In this section we explore distinctions among these and other related terms. 
Legislation is the process of enacting laws by a legislative body. The type of law depends on the 
legislative authority granted. State legislatures and Congress have complex processes to enact legislation. 
These processes vary from state to state. In the simplest terms, state and federal legislative bodies create 
statutory law, also called a legislative act. These terms denote a bill that has been passed by one house in 
a bicameral legislature. After enactment by both houses, the terms ‘law’ and ‘act’ may be used 
interchangeably. A statute is the formal written enactment of a legislative body, whether federal, state, 
city, or county.  
State and federal agencies are arms of the executive branch of the government. Such agencies have broad 
power granted under state and federal law to make regulations that govern activities for which they are 
responsible. Leaders of public health and other state agencies are not elected, but rather appointed by the 
executive, usually the governor of a state. Under current public health legislation, public health authorities 
may make regulations that can be mandatory, voluntary, directive, or prohibitive.  
In sum, the term ‘legislation’ refers to a law enacted by an elected body, whereas ‘regulations’ are created 
by agencies.  
For an agency, such as a state public health department, to establish a regulation mandating the reporting 
of birth defects, the health department must have the power or the authority to establish that type of 
regulation. This power can be based on state law or on an act of the executive power of the state, such as 
the governor. If the health department does not already have such regulatory power, then two options 
exist, namely, proposing a state law mandating birth defects reporting or proposing a state law granting 
authority to the health department to establish a regulation.  
A state reporting law is straightforward and more democratic because it is enacted by elected 
representatives and gives an agency clear power or authority to do whatever the law states. However, a 
state reporting law also places the power to modify or change the law in the hands of the legislative body, 
despite the fact that the legislature may not be well informed about public health matters. Because most 
legislative bodies recognize the expertise of the people who run public health agencies, they generally 
grant them the necessary authority to conduct their work properly. Thus, the legislative bodies of many 
states have given the health department power to enact the regulations they deem necessary to protect the 
public health and welfare. 
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2.3  Key Elements of Model Legislation 
Birth defects legislation should be considered early in the developmental phase of a surveillance program, 
if possible. This allows for legislation to be written clearly to support facilitation of surveillance activities. 
Language should be broad and flexible enough to cover all of the areas necessary to meet programmatic 
objectives, yet not to be so vague as to be confusing or meaningless. Well-written legislation that 
facilitates birth defects surveillance should address the key elements outlined in the Sections 2.3.1 
through 2.3.8 below. These include: 
 Designation of agency authority 
 Purpose and priorities 
 Access to data and records 
 Ability to share data while maintaining confidentiality 
 Terminology and definitions 
 Opt-out clauses 
 Advisory committee 
 Funding 
2.3.1  Designation of Agency Authority 
Model state legislation for birth defects surveillance should specify the agency that has the overall grant 
of authority for the system. This authority usually resides within the department of health, which has the 
power to enact rules and regulations, establish criteria for reportable conditions, and implement and 
oversee procedures for reporting. In most cases, there is no need to detail the specific regulations in the 
legislation. However, legislation should specify that the department has the authority to enact and enforce 
the regulations.  
2.3.2  Purpose and Priorities 
The purpose of the program will drive decision-making about its scope and activities. The purpose will 
also help states define outcomes, ages to be covered, and the most important sources of data to be 
included. Language should clearly articulate what the system should do and what its priorities should be. 
For example, Hawaii’s legislation contains the following language: 
“The department of health shall establish the statewide birth defects program to: 
1) Collect surveillance information on birth defects and other adverse reproductive 
outcomes; 
2) Report the incidence, trends and causes of birth defects and other adverse 
reproductive outcomes; 
3) Report information for the development of prevention strategies to reduce the 
incidence of birth defects and other adverse reproductive outcomes; and 
4) Develop strategies to improve the access of children with birth defects to health and 
early intervention services.” (Hawaii Revised Statutes, Chapter 321, §321)
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2.3.3  Access to Data and Records 
Legislation should grant the birth defects surveillance program the authority to access hospital discharge 
data and medical records or to require reporting with access for follow-up as needed. Legislation that 
provides for access to medical records grants surveillance programs the opportunity to obtain more 
complete and reliable reporting of birth defects, while also ensuring that surveillance data sets are large 
enough to be useful to researchers and service providers.  
California’s birth defects surveillance law states that: 
“… The director shall require health facilities, with 15 days’ notice, to make available to 
authorized program staff the medical records of children suspected or diagnosed as 
having birth defects, including the medical records of their mothers. In addition, health 
facilities shall make available the medical records of mothers suspected or diagnosed 
with stillbirths or miscarriages and other records of persons who may serve as controls 
for interview studies about the causes of birth defects …” (California Health and Safety 
Code, Part 2, Chapter 1, §103830) 
Legislation with mandated reporting should include language that allows a program to access medical 
records for follow-up to ensure data quality. For example, New Jersey’s legislation stipulates that: 
“The Commissioner of Health, in consultation with the Public Health Council, shall 
require the confidential reporting to the Department of Health of all cases …” 
(New Jersey, Chapter 26:8-40.2) 
Then, in its regulations, the department of health addresses the follow-up component: 
“Every health facility and independent clinical laboratory shall allow access to, or 
provide necessary information on infants with birth defects …” (New Jersey Rules, 
Chapter 20, Subchapter 1, 8:20-1.2j) 
2.3.4  Ability to Share Data While Maintaining Confidentiality 
Legislation should specify who can have access to the data and how the confidentiality of the data will be 
protected. Many states have specific guidelines regarding the use of data for research purposes, and 
legislation may stipulate that persons who violate rules about data use or confidentiality are subject to 
civil penalties. For example, Texas’ legislation states that: 
“(a) Access to the central registry information is limited to authorized department 
employees and other persons with a valid scientific interest who are engaged in 
demographic, epidemiological, or other studies related to health and who agree in 
writing to maintain confidentiality. 
(b) The department shall maintain a listing of each person who is given access to the 
information in the central registry. The listing shall include: 
(1) the name of the person authorizing access;  
(2) the name, title, and organizational affiliation of each person given access; 
(3) the dates of access; and  
(4) the specific purpose for which the information was used.  
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(c) The listing is public information, is open to the public under the open records law, 
Chapter 424, Acts of the 63rd legislature … and may be inspected during the 
department's normal hours of operation.” (Texas Health and Safety Code, Subchapter D, 
§ 87.062) 
2.3.5  Terminology and Definitions 
Terminology should be defined clearly, but not in an overly narrow or restrictive manner. For instance, it 
is more effective to specify surveillance for the general category of ‘birth defects’ rather than for a narrow 
or finite list of specific defects such as spina bifida, anencephaly, Down syndrome, and so on.  
 
The state of California defines birth defect as: 
“… any medical problem of organ structure, function, or chemistry of possible genetic or 
prenatal origin.” (California Health and Safety Code, Chapter 1, §103825 [a]) 
The legislation also specifies that health facilities are: 
“… general acute care hospitals, and physician-owned or operated in clinics … that 
regularly provide services for the diagnosis or treatment of birth defects, genetic 
counseling, or prenatal diagnostic services.” (California Health and Safety Code, 
Chapter 1 §103830) 
 
Broader language is more flexible, inclusive, and comprehensive than narrow language and allows for 
future modifications in program priorities or activities, whereas revising or amending narrowly written 
legislation can be a lengthy and difficult process. Legislating surveillance of specific defects may prove to 
be problematic in the long run as conditions change or as it becomes necessary or desirable to collect data 
on additional defects or combinations of defects. Definitions should be in the agency’s regulations, not in 
the enabling legislation. 
2.3.6  Opt-out Clauses 
In most cases, parental consent is not required in order for a surveillance program to be able to collect 
data on children with birth defects from schools or health care providers. Some states, however, do 
require written consent from parents. Because obtaining written consent from parents can be problematic, 
some states handle this issue with an opt-out clause.  
 
For example, Ohio’s opt-out clause states that the health department shall adopt rules that will:  
“Establish a form for use by parents or legal guardians who seek to have information 
regarding their children removed from the system and a method of distributing the form 
to local health departments … and to physicians. The method of distribution must include 
making the form available on the internet.” (Ohio, House Bill No.534, § 3705.35[e]) 
 
Opt-out clauses assume consent unless otherwise stated, allowing the surveillance program to collect data 
unless a child’s parent or legal guardian submits a written request that their child’s information be 
removed from the surveillance system. Opt-out clauses eliminate the need for providers and surveillance 
program staff to obtain written consent from parents and contribute to more complete data collection.
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2.3.7  Advisory Committee 
States that consider the potential impact of legislation in the planning stages of their programs have the 
advantage of influencing the development of legislation that can support the overall growth and 
development of the program. In some states, for example, legislation calls for establishing an advisory 
committee to provide guidance and oversight for the design and implementation of birth defects 
surveillance. Advisory committees made up of experts from fields such as epidemiology, hospital 
administration, biostatistics, maternal and child health, and public health can develop recommendations 
and provide the expertise necessary to ensure that the program meets well-defined standards and goals. 
Some advisory committees also include parents of children with birth defects. For example, Vermont’s 
legislation calls for the establishment of a ‘birth information council’.  
 
“(a) The commissioner of health, in collaboration with the March of Dimes, shall appoint 
a birth information council to advise on the need for and implementation of a 
comprehensive, integrated, and confidential birth information system. 
(b) The council shall be composed of nine members, who represent each of the following 
interests: 
(1) obstetrics and gynecology; 
(2) pediatrics and genetics; 
(3) the Vermont Children’s Health Improvement Program; 
(4) a parent of a child with special medical needs; 
(5) an adult with special medical needs; 
(6) the commissioner of health, or his or her designee; 
(7) the Family, Infant, and Toddler Program; 
(8) the Vermont chapter of the March of Dimes; and 
(9) the Vermont Program for Quality Health Care.” (Vermont, H.636, § 5084) 
2.3.8  Funding 
Cost can be an impediment to establishing a birth defects surveillance system. 
 
Some states have legislation mandating special funds to cover the operating expenses of their birth defects 
surveillance program. Sources of special funds include marriage license, birth certificate, and newborn 
screening fees. For example, Iowa’s special fund is supported through birth registration fees: 
“It is the intent of the general assembly that the funds generated from the registration 
fees be appropriated and used as follows: 
(1) Beginning July 1, 2003, and ending June 30, 2005 … five dollars of each fee for 
the birth defects institute central registry established pursuant to section 136A.6. 
(2) Beginning July 1, 2005, … ten dollars of each fee for the birth defects institute 
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In summary, paying due consideration to how legislative language can affect the design, implementation, 
and operation of the surveillance program and further ensuring that the birth defects surveillance program 
itself has input into legislative language from the time the program is established can have a significant 
impact on the long-term success of the program.
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2.4  Federal Laws 
A broad range of federal laws must be considered when planning state legislation, local regulations, or 
new birth defects surveillance programs. While state laws will govern most of the activities of the 
program, the impact of federal privacy regulations must also be considered. Depending upon how the 
birth defects program is structured, it may need to follow the Health Insurance Portability and 
Accountability Act (HIPAA) discussed in Section 2.4.1, the Family Educational Rights and Privacy Act 
(FERPA) discussed in Section 2.4.2, and other federal regulations such as the Privacy Act (Section 2.4.3), 
the Public Health Service Act (Section 2.4.4), and the Freedom of Information Act (Section 2.4.5). The 
following sections provide basic information about major federal laws that must be considered when 
setting up a birth defects surveillance program. In Section 2.4.6 we discuss the supportive role that can be 
played by state health officials or staff of the Centers for Disease Control and Prevention (CDC) in 
conjunction with planning state legislation or local regulations for birth defects surveillance programs. 
2.4.1  Health Insurance Portability and Accountability Act (HIPAA) 
The Health Insurance Portability and Accountability Act was passed in 1996 to protect consumers of the 
insurance industry. The Privacy Rule (or PR, also referred to as the Rule), which implements the Act, 
became effective on April 14, 2001, and creates national standards to protect an individual’s medical 
records and other personal health information, known as protected health information (or PHI). The Rule 
gives patients more control over their health information and establishes appropriate safeguards that 
health care providers and other covered entities (or CEs) must establish to protect the privacy of PHI. 
Violators are subject to civil and criminal penalties if they violate patients’ privacy rights as stated in the 
Privacy Rule. The Rule allows for disclosure of some forms of data for activities carried out by public 
health authorities (or PHAs) but limits release of information to the minimum necessary for the purpose 
of the disclosure. In addition, the covered entity may rely on the public health authority for what 
constitutes the ‘minimum necessary’.  
 
The Privacy Rule requires health care providers who are covered entities to provide information to 
patients about their privacy rights and how their information can be used, to adopt clear privacy 
procedures and adequately train employees in these procedures, and to designate an individual to be 
responsible for seeing that the privacy procedures are adopted and followed. Privacy protections should 
not, however, interfere with a patient’s access to health care or the quality of health care delivered.  
Basic Provisions of the Privacy Rule That Affect Birth Defects Reporting 
A state, county, or local health department that performs functions that make it a covered entity, or 
otherwise meets the definition of a covered entity, may elect to call itself a hybrid entity. For example, a 
state Medicaid program is a covered entity (i.e., a health plan) as defined in the Privacy Rule. Some health 
departments operate health care clinics and thus are health care providers. If these health care providers 
transmit health information electronically, in connection with a transaction covered in the HIPAA 
Transactions Rule, they are covered entities.  
 
Most of the requirements of the Privacy Rule apply only to the hybrid entity’s health care provider 
component(s). If a health department elects to be a hybrid entity, there are restrictions on how its health 
care component(s) may disclose protected health information to other components of the health 
department. Birth defects surveillance components that provide genetic counseling and other types of 
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health care services will most likely be required to comply with the Rule’s ‘covered entities’ provisions, if 
they bill electronically for their services. (See 45 C.F.R. § 164.504 (a) – (c) for more information about 
hybrid entities.) 
 
For further information, see the definitions of ‘covered entity’, ‘health care provider’, ‘health plan’, and 





Uses and Disclosures for Which an Authorization or Opportunity to  
Agree or Object Is Not Required 
Section 164.512 of the Privacy Rule sets forth the conditions under which a covered entity, as defined 
previously, may disclose protected health information without the individual’s consent or authorization. 
Below is a discussion of the application of the Rule to the birth defects surveillance system. The actual 
text of the regulation can be found in Appendix 2.4.  
 
Consent and notice. The US Department of Health and Human Services (DHHS) made changes to the 
Privacy Rule effective August 14, 2002, to protect privacy while eliminating barriers to treatment. The 
notice requirement was strengthened, making consent for routine health care delivery purposes optional. 
The Rule requires covered entities to provide patients with notice of a patient’s privacy rights and the 
privacy practices of the covered entity. The strengthened notice requires direct treatment providers to 
make a good faith effort to obtain patients’ written acknowledgement of the notice of privacy rights and 
practices. The modified Rule removes mandatory consent requirements while providing covered entities 
with the option of developing a consent process that works for that entity. The Rule also allows consent 
requirements already in place to continue, but does not mandate any particular standard.  
 
In states where data collection for birth defects surveillance is ongoing and there is no mandatory 
reporting law, it would be helpful to approach the data source with a request to have the public health 
authority listed in the privacy notice that is provided to patients. Note, however, that this does not 
circumvent the accounting provisions of the Rule for the covered entity. 
 
Mandatory reporting – ‘Required by law’ versus ‘permitted’. Extensive discussion has ensued within 
the public and private health care sectors regarding the need for mandatory reporting laws in states in 
order for birth defect surveillance programs to collect data. Note that this section of the Rule, §164.512, 
has two subsections. 
 
(a) Standard: uses and disclosures required by law. 
(b) Standard: uses and disclosures for public health activities.  
 
Subsection (a) is the provision for disclosures that are required by law. If a state has a mandatory birth 
defects reporting law, then this is the provision in the Privacy Rule that allows that law to remain intact. 
The definitions in the section below explain what ‘required by law’ means under the Privacy Rule. 
However, if a state health department meets the definition below of a public health authority, then the 
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health department may have authority to collect birth defects data based on the department’s broad grant 
of authority from the state to protect and promote health, prevent and control disease, or other activity.  
 
As noted earlier, each state health department has specific authority granted it under the laws of that state. 
Most health departments do have some regulatory authority and can, therefore, make birth defects 
reporting mandatory under that authority. If the health department does not have the present authority to 
make such a regulation, or conduct such activity, then the health department may request that this 
authority be granted by the legislature, after which the department may promulgate its regulation. This 
method is acceptable under the Privacy Rule.  
 
The most significant distinction to make is that subsection (a) is for reporting required by law, whereas 
subsection (b) is for reporting authorized by law. Although there is no definition of ‘authorized by law’ in 
the Rule, DHHS has sought to make this point more clearly in the Preamble to the Rule (64 FR, page 
59929): 
“When we describe an activity as ‘authorized by law,’ we mean that a legal basis exists 
for the activity. The phrase ‘authorized by law’ is a term of art that includes both actions 
that are permitted and actions that are required by law.”  
 
In addition to this comment, new Office of Civil Rights (OCR) guidelines state: 
“The HIPAA Privacy Rule permits disclosures that are required by law. Furthermore, 
disclosures to public health authorities that are authorized by law to collect or receive 
information for public health purposes are also permissible under the Privacy 
Rule.”(OCR HIPAA Privacy Dec 3, 2002, http://www.hhs.gov/ocr/hipaa)  
 
In short, public health authorities have two different paths by which to access data for surveillance, a 
mandatory reporting law, or the regulatory or program authority to collect the data. (See Appendix 2.4 for 
OCR HIPAA privacy regulation text.) 
Data Sharing and Public Health Authorities 
A public health authority that has either a mandatory reporting law, or a regulation, or some other grant of 
authority to collect data under the previously discussed §164.512, may use those data in any way that is 
permitted under state and federal law. Data that are collected by a third party, such as a university, under a 
grant or a contract on behalf of a public health authority, such as the Centers for Disease Control and 
Prevention (CDC), whether a bona fide agent or not of that health department, falls under the Privacy 
Rule definition of a ‘public health authority’: 
“‘Public health authority’ means an agency or authority of the United States, a State, a 
territory, a political subdivision of a State or territory, or an Indian tribe, or a person or 
entity acting under a grant of authority from or contract with such public agency, 
including the employees or agents of such public agency or its contractors or persons or 
entities to whom it has granted authority, that is responsible for public health matters as 
part of its official mandate.”(45 CFR §164.512(b)(l)(i)) 
 
The Rule does not comment on what the public health authority may or may not do with the data it has 
legally collected. HIPAA seeks to regulate the release and use of protected health information by covered 
entities, and a public health authority is not a covered entity under the Rule (unless they have designated 
themselves as such). The grantee, holder of a cooperative agreement, or contractor conducting a public 
health activity, as a public health authority, as defined above, may share the data in ways that comport 
with all previously promulgated laws and regulations. Once data are in the possession of a public health 
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authority, the Rule should not be an issue for the PHA because the Rule does not regulate the use or 
disclosure of protected health information by a PHA. 
 
A number of health departments have designated some of their components as covered components 
because they provide health care as defined in the Rule. In this case, the entire health department may be 
called a ‘hybrid entity’. The consequences for data sharing are the same as if the designated component, 
or covered entity, were any other health care provider. The covered entity component of the health 
department can share the data it collects from individuals with the non-covered PHA component of the 
health department. The covered entity would have to provide the individual with the ‘notice of privacy 
practices’, which would include information to the effect that the covered entity was sharing data with 
other components of the health department. The covered component would also have to comply with all 
other provisions of the Rule, including accounting for disclosures to public health authorities. Some 
health departments may even provide consents to the individual based on the requirements of a state or 
local requirement, or to increase public confidence in the health department.  
 
Nor is the data-sharing that flows from a public health authority to a covered entity after data collection 
regulated by the Privacy Rule. In cases where the public health authority wishes to refer a case to another 
covered entity, such as a health care provider, for a public health intervention, and the covered entity may 
report back its findings, remember that the definition of ‘public health activities’ includes the following: 
“A public health authority that is authorized by law to collect or receive such information 
for the purpose of preventing or controlling disease, injury, or disability, including, but 
not limited to, the reporting of disease, injury, vital events such as birth or death, and the 
conduct of public health surveillance, public health investigations, and public health 
interventions.”(45 CFR §164512(b)(l)(i)) 
 
When requesting data from a covered entity, it is also important to note that even though public health 
authorities are exempted from the need for the authorization of the person for disclosure, the covered 
entity is only required to provide for the minimum necessary information to accomplish the public health 
mission of the PHA. In addition, the covered entity may, under the Rule, reasonably rely on the 
representation of the PHA for what constitutes the ‘minimum necessary’ information.  
 
Some state grantees conducting birth defects and other kinds of surveillance funded by CDC have asked 
what kind of proof of identification (ID) they need to show to the covered entity to assure them that they 
are in fact a PHA and have the authority to obtain the data they seek from the CE. Business cards, 
government identification badges, letterhead, or other types of official representation are sufficient. 
Because there are so many different types of ID, DHHS chose to be very broad in this area by not 
specifying one type.  
Data Clearinghouses and Business Associates 
Some state health departments do not carry out actual surveillance and data collection; instead, hospitals 
voluntarily report birth defects data to a data collection entity or clearinghouse that compiles the data and 
then reports the information in some form to the health department. In these cases, the hospital and 
clearinghouse are required to execute a data use agreement, and the covered entity must disclose this 
information in the privacy notice provided to patients. The clearinghouse may provide the data to the 
public health authority under that Rule just as the covered entity could do, without the authorization or 
consent of the person for purposes of public health activities, surveillance, and, under some 
circumstances, research.  
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Surveillance versus research under the Privacy Rule. Research is covered under a separate section of 
the Privacy Rule. Unlike the public health authority provisions discussed above, the research provisions 
do not exempt public health authorities from compliance with the Rule as research is not a public health 
activity as defined in the Privacy Rule. The Rule defines research as: 
“A systematic investigation, including research development, testing, evaluation, 
designed to develop or contribute to generalizable knowledge.” (45CFR 164.501) 
 
The recent revision in the Privacy Rule sought to bring the definition of ‘research’ in the Rule in line with 
the definition for the same term in the Common Rule. The Common Rule definition of ‘research’ is the 
one used by CDC (45 CFR 46.102[e]). 
 
De-identified data use. For research purposes, a covered entity may always use or disclose health 
information that has been de-identified (45 CFR 164.502(d) and 164.514[a]-[c]). The Rule has a very 
strict definition of ‘de-identified’ that truly eliminates all possibility of re-identification of the individual. 
However, a covered entity may enter into a data use agreement with a researcher that would allow the CE 
to disclose to the researcher a limited data set for the purposes of research, public health, or health care 
operations (45 CFR 164.514[e]). A limited data set is specifically defined in the Privacy Rule to exclude 
certain direct identifiers; however, the limited data set contains sufficient geographical and vital 
information – such as birth, death, admit and discharge data – that it can be very useful for birth defects 
research. In addition, there are other specific requirements that must be included in the data use 
agreement. These include: 
 Stating the permitted uses and disclosures of the limited data set  
 Limiting who can receive the data 
 Requiring the researcher to agree to: 
⎯ Abide by and not violate a data use agreement 
⎯ Protect the data from re-disclosure  
⎯ Report any unauthorized use or disclosure  
 Binding all contractors or agents to the data use agreement 
 Refraining from identifying or contacting the individual 
 
Another way to obtain access to protected health information for research without authorization from the 
individual is to obtain documented Institutional Review Board (IRB) or Privacy Board approval for an 
exemption (45 CFR 164.512[i][l][i]). This provision is most practical for conducting records searches 
when use of de-identified data is not useful. There are extensive requirements under this section of the 
Rule that must be adhered to. Another way to obtain access to data for research without authorization of 
the individual is when preparing a research protocol preparatory to research (45 CFR 164.512 [i][l][ii]). 
Except for these limited exceptions, the disclosure or use of protected health information for research 
purposes requires the written authorization of the individual. 
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2.4.2  Family Educational Rights and Privacy Act (FERPA) 
The Family Educational Rights and Privacy Act (20 U.S.C. § 1232g; 34 CFR Part 99) is a federal law that 
protects the privacy of student education records. The law applies to all schools that receive funds under 
an applicable program of the US Department of Education. There are some privately funded schools to 
which FERPA does not apply. 
 
FERPA gives parents specific rights with respect to their children’s educational records. These rights 
transfer to the student when he or she reaches the age of 18 or attends a school beyond the high school 
level. Students to whom the rights have transferred are defined as eligible students in FERPA. 
 
 Parents or eligible students have the right to inspect and review the student’s education records 
maintained by the school.  
 Parents or eligible students have the right to request that a school correct records that they believe 
to be inaccurate or misleading.  
 Generally, schools must have written permission from the parent or eligible student in order to 
release any information from a student’s education record.  
 
However, FERPA allows schools to disclose those records, without consent, to the following parties or 
under the following conditions (34 CFR § 99.31): 
 School officials with legitimate educational interest 
 Other schools to which a student is transferring 
 Specified officials for audit or evaluation purposes 
 Appropriate parties in connection with financial aid to a student 
 Organizations conducting certain studies for or on behalf of the school 
 Accrediting organizations 
 Appropriate officials in cases of health and safety emergencies 
 State and local authorities, within a juvenile justice system, pursuant to specific state law 
 To comply with a judicial order or lawfully issued subpoena  
 
Access to educational records can be necessary to a birth defects surveillance program for follow-up and 
early intervention services. FERPA generally prohibits access to educational records without the prior 
written consent of the parent or guardian.  
 
Surveillance versus research under FERPA. For compliance with FERPA, there is no distinction made 
between surveillance and research. The issue in FERPA is who holds the data and who wants access to 
the data and why. The fact that the information in the educational record is medical, behavioral, 
sociological, or psychological in nature in no way alters the inability to access the information without 
parental consent. All information, other than student directory information, in an educational record 
maintained by a school, regardless of the nature of the information, is considered to be an educational 
record. It is important to note that HIPAA specifically states that nothing in HIPAA in any way alters 
FERPA. As a result, FERPA, unlike HIPAA, defines its ‘protected records’ simply by who possesses 
them, whereas in HIPAA the analysis of what is protected and the exceptions are more complex.  
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2.4.3  Privacy Act 
The Privacy Act of 1974, 5 U.S.C. § 552a (2000), which has been in effect since September 27, 1975, can 
generally be characterized as an omnibus ‘code of fair information practices’ that attempts to regulate the 
collection, maintenance, use, and dissemination of personal information by federal executive branch 
agencies. However, the Act’s imprecise language, limited legislative history, and somewhat outdated 
regulatory guidelines have rendered it a difficult statute to decipher and apply. Moreover, even after more 
than 25 years of administrative and judicial analysis, numerous Privacy Act issues remain unresolved or 
unexplored. Adding to difficulties in interpretation is the fact that many Privacy Act cases are 
unpublished district court decisions. The general rule contained in the Privacy Act is: 
“No agency shall disclose any record which is contained in a system of records by any 
means of communication to any person, or to another agency, except pursuant to a 
written request by, or with the prior written consent of, the individual to whom the record 
pertains [subject to 12 exceptions].” (5 U.S.C. § 552a[b])  
 
States have adopted similar laws that should be considered when drafting legislation for a birth 
defects surveillance program. For further information, see the Department of Justice website at 
http://www.doj.gov.  
2.4.4  Public Health Service Act   
The Public Health Service Act of July 1, 1944 (42 U.S.C. §201), consolidated and substantially revised all 
existing legislation relating to the US Public Health Service, of which the CDC is a part. The Public 
Health Service Act is a broad compilation of authorities under which CDC administers national and 
international programs for the prevention and control of communicable and vector-borne diseases and 
other preventable conditions. The Public Health Service Act is only applicable to federal agencies within 
the Public Health Service.  
 
Title III of the Public Health Service Act sets forth the general powers and duties of the Public Health 
Service. Within this title, Sections 301, 307, 311, and 317 provide CDC and other agencies within the 
Service with general operating authorities, including but not limited to: 
 Encourage, cooperate with and render assistance to other appropriate public health authorities, 
scientific institutions, and scientists in the conduct and promotion of activities relating to the 
causes, diagnosis, treatment, control, and prevention of physical and mental diseases.  
 Make grants-in-aid to universities, hospitals, laboratories, and other public and private research 
institutions. 
 Participate with other countries in cooperative endeavors in biomedical research, health care 
technology, and health services research for the purpose of advancing the status of health sciences 
in the United States. 
 Cooperate with and assist states and their political subdivisions in the prevention and suppression 
of communicable diseases and other public health matters. 
 
In regard to provisions of the Public Health Service Act which promote, encourage, and influence 
activities in the area of birth defects study and prevention, Section 317C was added to the Public Health 
Service Act by the Children’s Health Act of 2000. Section 317C provides the general operating authority 
for the National Center on Birth Defects and Developmental Disabilities (NCBDDD), a center within the 
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CDC. This authority was recently renewed in accordance with the Birth Defects and Developmental 
Disabilities Prevention Act of 2003. In part, Section 317C allows NCBDDD to: 
 Collect, analyze, and make available data on birth defects and developmental disabilities. 
 Operate regional centers for the conduct of applied epidemiological research on the prevention of 
such defects and disabilities. 
 Provide information and education to the public on the prevention of such defects and disabilities. 
 
The Public Health Service Act is codified in Title 42 of the United States Code.  
2.4.5  Freedom of Information Act 5 USC §522 (FOIA) 
All federal agencies are generally required under the Freedom of Information Act (FOIA) to disclose 
records they maintain when requested in writing by any person. Most states have adopted state laws that 
mirror the federal law. Therefore, it is important for a state birth defects surveillance program to be aware 
of the state law and know which records they may have to provide to the public when requested. 
However, federal agencies may withhold information pursuant to nine exemptions and three exclusions 
contained in the statute, and states have generally adopted similar exemptions. The exemptions that are 
most pertinent here are the FOIA exemptions 3 and 6.  
 
Exemption Number 3: 
Specifically exempted from mandatory disclosure by statute (other than the Privacy Act), 
provided that such statute: 
(i) Requires that the matters be withheld from the public in such a manner as not to 
leave any discretion on the issue, or 
(ii) Establishes particular criteria for withholding or refers to particular criteria for 
withholding or refers to particular types of matters to be withheld.  
This exemption is useful for protecting birth records in surveillance programs when the authorizing 
legislation specifically exempts the information in the statute. 
Exemption Number 6: 
Personnel and medical files and similar files the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.  
 
The FOIA applies only to federal agencies and does not create a right of access to records held by 
Congress, the courts, or by state or local government agencies. Each state has its own public access laws 
that should be consulted for access to state and local records. Each federal agency is responsible for 
meeting its FOIA responsibilities for its own records. Likewise, each federal agency component is 
responsible for processing FOIA requests for the records that it maintains. For more information and a list 
of FOIA federal contacts, see the Department of Justice website at http://www.doj.gov.  
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2.4.6  Advocacy 
In this section we discuss advocacy for the development and implementation of surveillance systems in 
terms of both the state’s role and CDC’s role in such advocacy. 
The role of the state in advocacy. State health officials and surveillance staff can be important partners 
for advocates in the development and implementation of surveillance systems. While state employees 
may be limited in terms of what activities they can participate in within advocacy, they can work together 
with advocates throughout the process in order to create or improve birth defects systems. State officials 
and health department surveillance staff bring planning, technical assistance, and an understanding of the 
political environment to the planning and implementation process.  
 
The role of the CDC in advocacy. The CDC can also work with states and with advocates to provide 
technical assistance in the design, planning, and implementation stages of a birth defects surveillance 
system and can make recommendations for improving ongoing programs. CDC can also play a substantial 
role in educating policymakers and the public about the benefits of a birth defects surveillance program. 
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Alabama Alabama Birth Defects 
Surveillance and 
Prevention Program 
Yes 2001 Code of Ala. § 22-10A-2 
Alaska Alaska Birth Defects 
Registry (ABDR) 
Yes 1996 (enact) 7AAC 27.012 
Arizona Arizona Birth Defects 
Monitoring Program 
Yes 1988 (enacted); 
1991 (adopted); 
2001 (revised) 
Statue: ARS § 36-133 
Rule: Title 9, Chapter 4, Articles 1 &5 
A.R.S. § 36-133 (2001) 
Arkansas Arkansas Reproductive 
Health Monitoring 
System 
Yes 1985 (enacted); 
1999 (revised) 
Bill 214  (1985) A.C.A. § 20-16-201 
California California Birth Defects 
Monitoring Program 
Yes 1982 (enacted); 
1996 
(recodified) 
Health and Safety Code, Division 102, Part 2, Chapter 1, 
Sections 103825-103855, effective 1982. 
Recodified 1996: § 103825, 103855, 103830, 103835, 
125050, 103840, 103850, 125000 
Colorado Colorado Responds To 
Children With Special 
Needs 
Yes 1985 (enacted) Colorado Revised Statutes 25-1.5-101 - 25-1.5-105 
Connecticut Connecticut Birth 
Defects Registry 
Yes  1991 (enacted) Sec. 10a-132b transferred to sec 19a-56a in 1999 
§ 19a-56a, 19a-56b (2001) 
State has 2 statutes which mandate the reporting of 
children with birth defects. They are:  Sec. 19a-53. 
(Formerly Sec. 19-21). Reports of physical defects of 
children; Sec. 19a-54. (Formerly Sec. 19-21a). 
Registration of physically handicapped children; Sec. 
19a-56a for Birth defects surveillance program, and Sec. 
19a-56b, add Sec. 19a-56c Advisory committee. 
Delaware Delaware Birth Defects 
Surveillance Project 
Yes 1997 (enacted) House Bill No. 197, an act to amend Title 16 of Del. 
Code 16 Code §203 (2000); §201, §202 
District of 
Columbia 
District of Columbia Birth 
Defects Surveillance and 
Prevention Program 
No   
Florida Florida Birth Defects 
Registry 
Yes 1999 Sec 381.0031 (1, 2) provides for a list of reportable 
diseases/conditions in Florida.  Congenital anomalies 
were added in 1999.   
Georgia 1) Metropolitan Atlanta 
Congenital Defects 
Program (MACDP)   




Yes 2002 (GBDRIS 
system) 
MACDP: Official Code of GA (OCGA) 31-12-2 
GBDRIS: Birth Defects reporting activated statewide in 
2002; Citation:  Add GA 31-1-3.2 and DHR Rules 290-5-
3-.02 and 290-5-24 
Hawaii Hawaii Birth Defects 
Program 
Yes 1989 (enacted) 
2002 (modified)  
8/15/1988 to 6/30/2002 - Hawaii Revised Statutes 
(HRS), Sections 321-31 and 338-2 in conjunction per 
Executive Chamber ruling by Governor on 6/16/1989.  
HRS Sections 324-1 and 324-2 for additional legislative 
authority (1990 Amendments).  7/1/02 to Present - Act 
252 - Relating to Birth Defects (SB 2763, SD 2, HD 2, 
CD 1). 
Idaho No birth defects surveillance program 
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Illinois Adverse Pregnancy 
Outcomes Reporting 
System 
Yes 1985 (enacted)  IL Health and Hazardous Substances Registry Act (410 
ILCS 525); 235 ILCS 5/6-24a (2001) 
Indiana Indiana Birth Defects 
and Problems Registry 
Yes 2001 (enacted) IC 16-38-4, Rule 410 IAC 21-3 
Iowa Iowa Birth Defects 
Registry 
Yes 1983 (enacted); 
2001, 2003 
(revised) 
IA Code  136A.1, 136A.2, 136A.3, 136A.5, 136A.6; 
135.40 Administrative Code of IA  641-1.3(139A);  
641-4.1, 641-4.7(136A) (revised 2001) 
The administrative rules for the Birth Defects Institute 
(which includes the Registry and other programs such 
as newborn screening) are undergoing revision in 
procedures for newborn screening & prenatal screening, 
but the revision does not affect the Registry's rules. 
Kansas Birth Defects Reporting 
System 
Yes 1979 (enacted) KSA 65-102 
Kentucky Kentucky Birth 
Surveillance Registry 
Yes 1992 (enacted); 
1997  
KRS 211.651-211.670  (1992);  HB372  
KRS §211.660, §211.665, §211.670 (2001) 
KY SB 219 (2002) 
Louisiana Louisiana Birth Defects 
Monitoring Network 
Yes 2001 (enacted) R.S. 40:31.41-40.31.48, Act No. 194 (2002) 
Maine Maine Birth Defects  
Program 
Yes 1999 22MRSA c. 1687 
 
Maryland Maryland Birth Defects 
Reporting and 
Information System 
Yes 1982 Health-General Article, Section 18-206; Annotated Code 
of MD 
Massachusetts Massachusetts Center 
For Birth Defects 
Research and 
Prevention, Birth Defects 
Monitoring Program 
Yes 1963 (enacted); 
2002 (revised) 
Massachusetts General Laws, Chapter 111, Section 
67E.  In 2002 the Massachusetts Legislature amended 
this statute, expanding the birth defects monitoring 
program.  The new law: 1) increases mandated reporting 
up to age three; 2) requires physicians to report to 
MDPH within 30 days of diagnosis; 3) sets out 
requirements for the use of this data; 4) requires MDPH 
to promulgate regulations governing the operation of the 
Birth Defects Monitoring Program. 
Michigan Michigan Birth Defects 
Registry 
Yes 1988 Public Health Act 236 of 1988 
 
Minnesota Minnesota Birth Defects 
Information System 
Yes 2004 MS 144.2215 
Mississippi Mississippi Birth Defects 
Registry 
Yes 1997 Sec. 41-21-205 of MS Code 
Missouri Missouri Birth Defects 
Registry 
No   
Montana Montana Birth Outcomes 
Monitoring System 
No   
Nebraska Nebraska Birth Defects 
Registry 
Yes 1972 Laws 1972, LB 1203, §1, §2, §3, §4 (alternate citation: 
Public Health and Welfare [Codes] §71-645, §71-646, 
§71-647, §71-648, §71-649) 
Nevada Nevada Birth Defects 
Registry 
Yes 1999 NRS 442.300-442.330; regulation - NAC 442 
New Hampshire New Hampshire Birth 
Conditions Program 
No   
New Jersey Special Child Health 
Services Registry 
 
Yes 1983 (enacted); 
2000 
(readopted) 
Bill 757,  NJSA 26:8, NJAC 8:20 (enacted 8-4-1983 with 
effective date of 3-4-1985) 
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New Mexico New Mexico Birth 
Defects Prevention and 
Surveillance System 
Yes 2000 (enacted) In January 2000, birth defects became a reportable 
condition.  These conditions are updated by the Office of 
Epidemiology.  This did not involve legislation, only a 
change in regulations. 
New York New York State 
Congenital 
Malformations Registry 
Yes 1982 Public Health Law Art. 2, Title, II, Sect 225(5)(t) and Art. 
2 Title I, sect 206(1)(j): Codes, Rules and Regulations, 
Chap 1, State Sanitary Code, part 22.3 






15A NCAC 26C.0101-0106 
NC adopted rules in 2001 to support the statute.  
North Dakota North Dakota Birth 
Defects Monitoring 
System 
Yes  ND Centry Code 50-10 
Ohio Ohio Connections for 
Children with Special 
Needs 
Yes 2000 (enacted) House Bill 354 
The legislation authorizes the state to have a birth 
defects system, but until funding is identified/ secured, 
does not require the Ohio Dept. of Health to implement a 
system.  The document is available at: 
www.legislature.state.oh.us/BillText123/123_HB_534_5
_Y.htm  
Oklahoma Oklahoma Birth Defects 
Registry 
Yes 1992 63 O.S. Sec 1-550.2 (1992) 
Oregon No birth defects surveillance program 
Pennsylvania Pennsylvania Follow-Up 
Outreach, Referral and 
Education For Families  
No   
Puerto Rico Puerto Rico Folic Acid 
Campaign and Birth 
Defects Surveillance 
System 
No   
Rhode Island Rhode Island Birth 
Defects Surveillance 
Program 
Yes 2003 House 5390, Senate 105 (Title 23, Chapter 13.3 of the 
General Laws) 
South Carolina South Carolina Birth 
Defects Surveillance And 
Prevention 
No   
South Dakota No birth defects surveillance program 
Tennessee Tennessee Birth Defects 
Surveillance Project 
Yes 2000 TCA 68-5-506 
 
Texas Texas Birth Defects 
Monitoring Division 
Yes 1993 (enacted) Health and Safety Code, Title 2, Subtitle D, Section 1, 
Chapter 87. 
 
Utah Utah Birth Defect 
Network 
Yes 1999 Birth Defect Rule (R398-5) 
Vermont Vermont Birth 
Information Network 
Yes 2003 Act 32 
Virginia Virginia Congenital 
Anomalies Reporting 
and Education system 
Yes 198 (enacted); 
1986, 1988 
(amended) 
Bill 396, HL 32.1.69.1, Art. 8 1985 (1986) 
 




Yes 2004 HB1105, notifiable conditions WAC 246-101 (2000) 
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State Birth Defects Legislation – April 2004 









Yes 1991 (enacted); 
2002 (updated) 
HB1747, SS Sec: 16-5-12a (1991); 16-40-1 (2002) 
*old legislation is still in effect but additional legislation 
that now calls for advisory committee to the Birth 
Defects Information System has been added in a 
different section of code.  
*this occurred during the 2002 session - SB 672. *new 
code citation is 16-40-1  
*legislative rules are in process of being completed for 
inclusion during the 2004 session. 
Wisconsin Wisconsin Birth Defects 
Prevention and 
Surveillance Program 
Yes 2003 1999 WA 114 
Statute 253.12; HFS 116--effective April 1, 2003 
Wyoming No birth defects surveillance program 
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Definitions Used to Determine Covered Entity Status  
Under the Privacy Rule
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Appendix 2.3 





A health plan, a health care clearinghouse, or a health care provider who 





Care, services, or supplies related to the health of an individual. It includes, 
but is not limited to, the following: 
• Preventive, diagnostic, rehabilitative, maintenance, or palliative care, 
and counseling, service, assessment, or procedure with respect to the 
physical or mental condition, or functional status, of an individual or 
that affects the structure or function of the body 
• Sale or dispensing of a drug, device, equipment, or other item in 




Transactions for which the Secretary of Health and Human Services has 
adopted standards and which can be found at 45 C.F.R. Part 162. If a health 
care provider uses another entity (such as a clearinghouse) to conduct 
covered transactions in electronic form on its behalf, the health care 
provider is considered to be conducting the transaction in electronic form.  
 
Required by Law 
 
A mandate contained in law that compels an entity to use or to disclose 
protected health information, and that is enforceable in a court of law. 
Required by law includes, but is not limited to, court orders and court-
ordered warrants; subpoenas or summons issued by a court, grand jury, a 
governmental or tribal inspector general, or an administrative body 
authorized to require the production of information; a civil or an authorized 
investigative demand; Medicare conditions of participation with respect to 
health care providers participating in the program; and statutes or 
regulations that require the production of information, including statutes or 
regulations that require such information if payment is sought under a 




Systematic investigation, including research development, testing, and 
evaluation, designed to develop or contribute to generalizable knowledge. 
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Appendix 2.4 
Office of Civil Rights (OCR) HIPAA Privacy Regulation Text 
 
Below is the actual text of the HIPAA privacy regulation, then the comments from the Privacy Rule’s 
preamble, or the modification guidance issued with the Rule. 
Office for Civil Rights (OCR)/HIPAA Privacy Regulation Text 
§ 164.512 Uses and disclosures for which an authorization or opportunity to agree or 
object is not required. 
A covered entity may use or disclose protected health information without the written 
authorization of the individual, as described in § 164.508, or the opportunity for the 
individual to agree or object as described in § 164.510, in the situations covered by this 
section, subject to the applicable requirements of this section. When the covered entity is 
required by this section to inform the individual of, or when the individual may agree to, 
a use or disclosure permitted by this section, the covered entity’s information and the 
individual’s agreement may be given orally. 
(a) Standard: uses and disclosures required by law. 
(1) A covered entity may use or disclose protected health information to the 
extent that such use or disclosure is required by law and the use or disclosure 
complies with and is limited to the relevant requirements of such law. 
(2) A covered entity must meet the requirements described in paragraph (c), (e), 
or (f) of this section for uses or disclosures required by law. 
(b) Standard: uses and disclosures for public health activities. 
(1) Permitted disclosures. A covered entity may disclose protected health 
information for the public health activities and purposes described in this 
paragraph to: 
(i) A public health authority that is authorized by law to collect or receive 
such information for the purpose of preventing or controlling disease, injury, 
or disability, including, but not limited to, the reporting of disease, injury, 
vital events such as birth or death, and the conduct of public health 
surveillance, public health investigations, and public health interventions;… 
[Balance of the regulation section omitted. The reader is referred to the OCR website for further details: 
http://www.os.dhhs.gov/ocr/hipaa/.] 
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3.1  Introduction 
A case definition is a set of criteria that define the parameters of what is included for quantitative 
description and analysis. In birth defects surveillance a case refers to an individual with characteristics 
that fit into the defined parameters. Important characteristics in birth defects surveillance include the 
diagnosis, pregnancy outcome information, and demographics.  
 
In the absence of a single national birth defects surveillance program in the United States, pooled data 
from state-based programs across the country serve to estimate national rates, indicate regional variations, 
and describe the epidemiology of defects that occur rarely. Because, at any given time, these programs 
may be in different stages of development, employ different methods of ascertainment, and have different 
goals and objectives, the elements of the case definition used by each must be clearly identified in order 
to make valid comparisons and to minimize birth defects rate variations across surveillance programs and 
among individual defects ascertained by the same program. 
 
Therefore, it is necessary for a surveillance program to develop a clear, concise case definition. Consistent 
application of a standard definition facilitates the accurate monitoring of clinically relevant conditions, 
identification of true changes over time, and comparison among populations in order to meet surveillance 
goals.   
 
In the remainder of this chapter we discuss what is meant by the term ‘birth defect’ (Section 3.2), some 
important terminology for case definition (Section 3.3), and case definition criteria (Section 3.4). The 
relationship between case definition and the two terms ‘sensitivity’ and ‘specificity’ is discussed in 
Section 3.5. References cited in this chapter may be found in Section 3.6. Appendices to this chapter 
include birth defects included in the NBDPN’s case definition (Appendix 3.1), the NBDPN Abstractor’s 
Instructions (Appendix 3.2, available in electronic format at http://www.nbdpn.org/bdsurveillance.html), 
examples of minor anomalies (Appendix 3.3), and conditions related to prematurity (Appendix 3.4). 
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3.2  What Is Meant by a ‘Birth Defect’ 
The general term ‘birth defect’ may take on a variety of meanings depending on the context in which it is 
used and the perspective of the person using it. ‘Congenital abnormality’, ‘congenital anomaly’, and 
‘congenital malformation’ are terms often used as synonyms for ‘birth defect’. However, the word 
‘congenital’ may describe any condition present at birth, regardless of its etiology or timing of 
occurrence. In the broadest sense, the term birth defect encompasses a diversity of conditions including 
physical malformations, sensory deficits, chromosomal abnormalities, metabolic defects, 
neurodevelopmental disorders, and complications related to prematurity and low birth weight, among 
others.  
 
While such a broad definition may be very helpful when seeking legislation and funding for screening, 
intervention, or prevention programs, a more specific definition is needed for surveillance purposes. 
Traditionally, birth defects surveillance programs have monitored major structural and genetic defects 
that adversely affect health and development (Correa-Villaseñor et al., 2003). The specific conditions 
monitored by an individual program will vary depending on the goals and objectives of that program, the 
case ascertainment methods used, and the resources available. 
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A congenital abnormality that requires medical or surgical treatment, has a 
serious adverse effect on health and development, or has significant cosmetic 
impact. Individual major anomalies occur in less than 1 percent of the 
population. Together, they are seen in approximately 3 percent of births. 
Examples include cleft lip and tracheo-esophageal fistula. 
 
Minor anomaly A congenital abnormality that does not require medical or surgical treatment, 
does not seriously affect health and development, and does not have significant 
cosmetic impact. Individual minor anomalies generally occur in less than 4 
percent of the population. The presence of multiple minor anomalies in the same 
child may provide clues to the timing of a prenatal insult and may indicate the 
presence of an undiagnosed major anomaly, syndrome, or functional deficit. 
Examples of minor anomalies are listed in Appendix 3.3. 
 
Normal variant A minor anomaly that occurs in approximately 4 percent or more of the 
population. Examples of normal variants include webbing of the second and 
third toes and a single umbilical artery in an otherwise normal infant. 
  




A major anomaly that arises during the initial formation of a structure, i.e., 
during organogenesis. For most organs, this occurs during the first eight weeks 
after fertilization. The resulting structure may be abnormally formed, 
incompletely formed, or may fail to form altogether. Examples of 
malformations include spina bifida and hypoplastic left heart. The term 
‘congenital malformation’ is also used more broadly to indicate any major 
anomaly. 
 
Disruption A major anomaly that results from alteration of a structure after its initial 
formation. The resulting structure may have an altered shape and 
configuration, abnormal division or fusion of its component parts, or loss of 
parts that were previously present. Examples of disruption defects include 
intestinal atresia and possibly gastroschisis. 
 
Deformation A major anomaly that results from molding of part of a structure, usually over 
a prolonged time, by mechanical forces after its initial formation. Examples of 
forces that may lead to a deformation include oligohydramnios (diminished 
amniotic fluid) and intrauterine crowding in twin, triplet, or higher order 
pregnancies. Examples of deformations include the compression (Potter’s) 
facies seen with bilateral renal agenesis and some instances of clubfoot. 
                                                 
1 Stevenson, et al., 1993; Jones, 1997; Cunningham et al., 2001; Moore, 1977; National Center for Health Statistics, 
2002. 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 06/04 
Chapter 3     3-4         Case Definition 




A pattern of anomalies that form a specific diagnosis for which the natural 
history and recurrence risk are usually known. Use of the term ‘syndrome’ 
implies that the anomalies have a common specific etiology. Examples 
include Beckwith-Weidemann syndrome and Rubinstein-Taybi syndrome.  
 
Sequence A pattern of anomalies that results from a single primary anomaly or 
mechanical factor. The presence of the initial anomaly or factor leads to one 
or more secondary anomalies, which may then lead to one or more tertiary 
anomalies, etc., in cascade fashion. Examples include Robin sequence 
(micrognathia, posterior displacement of the tongue, cleft soft palate) and the 
oligohydramnios, or Potter, sequence (pulmonary hypoplasia, flattened facies, 
abnormal positioning of the limbs). 
 
Association A nonrandom pattern of anomalies that occur together more frequently than 
expected by chance alone, but for which no etiology has been demonstrated. 
Examples include VACTERL association (Vertebral, Anal, Cardiac, Tracheo-
Esophageal, Renal, and Limb anomalies) and CHARGE association 
(Colobomas, Heart defects, choanal Atresia, Retarded growth and 
development and/or central nervous system anomalies, Genital anomalies 
and/or hypogondaism, Ear anomalies and/or deafness). Use of the term 
‘association’ does not indicate that a specific diagnosis has been made. 
 




Failure of an organ to form.  
 
Dysgenesis Anomalous or disorganized formation of an organ. 
 
Aplasia Absence of a tissue or organ due to lack of cell proliferation.  
 
Dysplasia Disorganized cell structure or arrangement within a tissue or organ. 
 
Hypoplasia Undergrowth of a tissue or organ due to insufficient proliferation of otherwise 
normal cells. 
 
Hyperplasia Overgrowth of a tissue or organ due to excess proliferation of otherwise 
normal cells. 
 




The first eight weeks after fertilization, during which most, but not all, 
organs are formed.  
 





The first 28 days following delivery of a live-born infant.  
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Terminology Related to the Timing of Gestation and Delivery (continued) 
Prenatal Before delivery. 
 
Perinatal Before, during, or after delivery. The exact time period may vary from 20 to 
28 completed weeks of gestation through 7 to 28 days after delivery, 
depending on the context in which the term is used. 
 
Postnatal After delivery. 
 




Spontaneous delivery of an infant that exhibits signs of life, including a 
heartbeat, spontaneous breathing, or movement of voluntary muscles. 
Transient cardiac contractions and fleeting respiratory efforts or gasps are 
not necessarily considered signs of life by all programs.  
 
Fetal death (stillbirth) Spontaneous delivery of an infant or fetus at 20 weeks or greater gestation 
that does not exhibit signs of life. Transient cardiac contractions and 
fleeting respiratory efforts or gasps are not necessarily considered signs of 
life by all programs. A late fetal death is a fetal death that occurs at 28 





Spontaneous delivery of a fetus at less than 20 weeks gestation.  
Induced abortion  
(elective termination)   
The purposeful interruption of pregnancy with the intention other than to 
produce a live birth and which does not result in a live birth.  
 
Term infant An infant born after 37 completed weeks and before 42 completed weeks of 
gestation.  
 
Preterm infant An infant born before 37 completed weeks of gestation. 
 
Postterm infant An infant born after 42 completed weeks of gestation. 
 
Low birth weight Birth weight less than 2,500 grams, regardless of gestational age. 
 
Very low birth weight Birth weight less than 1,500 grams, regardless of gestational age. 
 
Extremely low birth 
weight 
 
Birth weight less than 1,000 grams, regardless of gestational age. 
 
Neonatal death Death of a live-born infant within the first 28 days after birth. Early 
neonatal death refers to death during the first 7 days. Late neonatal death 




Death of a live-born infant before 12 months of age. 
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3.4  Case Definition Criteria 
In this section we discuss the various components of the case definition, that is, the criteria a birth defects 
surveillance program uses to define a case. These include diagnoses to be included (Section 3.4.1), 
residence (Section 3.4.2), pregnancy outcome (Section 3.4.3), gestational age (Section 3.4.4), age at 
which defects are diagnosed (Section 3.4.5), as well as the issue of pregnancies resulting from assisted 
reproductive technology (Section 3.4.6). Each of these criteria is discussed further below. 
3.4.1  Diagnoses to Be Included 
For the purposes of generating and reporting birth defects surveillance data across multiple states, the 
National Birth Defects Prevention Network (NBDPN) recommends the 45 major anomalies listed in 
Appendix 3.1. These were chosen on the basis of their frequency, their impact on public health, the state 
of knowledge about their etiologies and risk factors, and other considerations. Individual surveillance 
programs may want to expand this list to include additional defects of interest. Programs with limited 
resources may need to ascertain a subset of this list. Descriptions of each of the 45 diagnoses, its ICD-9-
CM and CDC/BPA codes, inclusion and exclusion criteria, and defect-specific information that may be 
helpful when abstracting medical records are provided in the NBDPN Abstractor’s Instructions posted on 
the NBDPN website (see Appendix 3.2). Examples of conditions considered to be minor anomalies are 
provided in Appendix 3.3. Conditions related to prematurity that are not considered to be major anomalies 
are listed in Appendix 3.4. 
3.4.2  Residence  
When monitoring the frequency of any condition, it is critical to define the population in which the cases 
occur. This allows one to calculate rates within the population, evaluate changes in these rates over time, 
plan for prevention and intervention services, and assess program goals and effectiveness. Population-
based birth defects surveillance programs should strive to ascertain defects that occur among the offspring 
of all women who reside within a defined geographic area at the time of pregnancy outcome.  
 
While this charge for surveillance programs appears straightforward, there are some special 
considerations. One such consideration is the fact that women who reside in one state or community may 
travel outside that area – such as to an adjacent state, specialty care center, or military facility – for 
obstetric care. In these instances, the mother’s place of residence at the time of delivery (rather than the 
actual location of the delivery) should be used to determine whether to include her pregnancy in the 
surveillance. Including in-area residents who deliver outside the surveillance area, and excluding out-of-
area residents who deliver within the surveillance area, is essential in order to conduct comprehensive 
surveillance. Whether an individual program attains this level of comprehensiveness will depend on how 
frequently women travel outside the surveillance area for delivery, the magnitude of the potential impact 
this may have on defect rates, the staff and resources available, and, most importantly, the existence of 
data-sharing relationships with facilities and programs outside the surveillance area. Recent changes in 
regulations concerning the privacy of medical records under the Health Information Portability and 
Accountability Act (HIPAA) have added to the complexity of these data-sharing relationships. The 
HIPAA regulations are discussed further in Chapter 2 on Legislation. 
 
Another consideration is the fact that a surveillance program may identify more than one residential 
address for an individual woman. For example, the address of the health insurance policyholder listed in a 
hospital delivery record may differ from the mother’s address listed on a birth certificate. If a patient 
changes residence during pregnancy, programs that employ multisource ascertainment may identify one 
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address from prenatal or laboratory records and another from the hospital delivery record. For these 
reasons, surveillance programs should develop standard procedures for deciding which of multiple 
addresses to accept as the mother’s residence at delivery. Usually, this is the address at the time of 
delivery as listed on the vital record. If a vital record is not available or is not generated, as when an 
elective termination is performed outside the hospital setting, considering the mother’s address from the 
termination record or from the prenatal visit closest in time to the delivery may be appropriate 
alternatives.  
 
A third consideration requires detailing the method of determining whether a particular address lies within 
the surveillance area, particularly if the population under surveillance is not that of an entire state. For 
example, zip codes often cross city or county boundaries, streets may be renamed, new zip codes may be 
added, and city or county boundaries may change over time. Addresses that contain only a post office box 
number do not provide information about a person’s actual place of residence. For these reasons, 
surveillance programs should develop standard procedures for distinguishing addresses that lie within or 
outside their surveillance area. Potential reference sources include street maps, United States Postal 
Service listings, tax assessor records, census tracts, and the latitude and longitude of the surveillance area 
(geocoding). While the latter can be extremely precise, the accuracy of geocoding will depend upon the 
accuracy of the addresses to which the latitude and longitude are assigned. 
3.4.3  Pregnancy Outcome  
Ideally, for births defects surveillance to be comprehensive with high sensitivity, all defects occurring in a 
population should be ascertained regardless of whether a pregnancy ends in live birth, fetal death, or 
spontaneous abortion, or whether an elective termination is performed. It is estimated that approximately 
10 to 15 percent of all recognized pregnancies end in spontaneous abortion, and approximately 6 to 7 
percent of those that reach 20 weeks gestation end in fetal death (Gabbe et al., 1996; National Center for 
Health Statistics, 2001). Surveillance systems that ascertain defects only among live-born infants may 
report incomplete data for defects that occur frequently among these outcomes. However, it is important 
to recognize that even late fetal deaths may not be scrutinized for defects as closely or as systematically as 
are live births. Unless an autopsy (including internal examination) and chromosome analysis are 
performed routinely, defects present in fetal deaths, yet not immediately evident in the delivery room, 
may remain unidentified. Even if an autopsy and chromosome analysis are performed, the presence of 
minor defects may not be recognized and syndromes may not be diagnosed. Whether it is beneficial for an 
individual program to ascertain defects reported in outcomes other than live births will depend upon the 
program’s goals and objectives, the staff and resources available, the accessibility of information about 
these outcomes, and the magnitude of the potential impact on individual defect rates of excluding them. 
 
The development and widespread use of prenatal diagnostic technology has posed additional issues for 
birth defects surveillance. These procedures have provided women with the option of electively 
terminating affected pregnancies, particularly those with defects that are life-threatening or that are likely 
to result in significant mental or functional impairment, usually before 20 weeks gestation. In the absence 
of prenatal diagnosis, many of these pregnancies would end in live birth or fetal death and would be 
included in birth defects surveillance data from many programs. Failure to ascertain prenatal diagnoses 
among electively terminated pregnancies may, therefore, limit the comprehensiveness and sensitivity of 
surveillance programs for some defects, such as neural tube defects and chromosomal abnormalities, even 
when defects among fetal deaths are ascertained. And – because the availability and utilization of prenatal 
diagnosis and elective termination may vary among populations, across geographic regions, and over time 
– the ability to make valid comparisons of some defect rates may be compromised unless pregnancies 
electively terminated after prenatal diagnosis are regularly ascertained.  
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Unfortunately, including these prenatal diagnoses will likely require expansion of a program’s case 
ascertainment sources to include settings such as prenatal diagnostic clinics and termination centers. 
Furthermore, as is the case with fetal deaths, pregnancies that are electively terminated may not be fully 
scrutinized for confirmation of the prenatal diagnosis or the presence of additional defects or syndromes 
upon completion of the procedure. Again, whether it is beneficial for an individual program to ascertain 
defects reported in these pregnancies will depend upon the program’s goals and objectives, the staff and 
resources available, the accessibility of information about these outcomes, and the magnitude of the 
potential impact on individual defect rates of excluding them. Regardless, it is important for birth defects 
surveillance programs to clearly state which outcomes are included when reporting surveillance data and 
to include pregnancies electively terminated after prenatal diagnosis whenever possible.  
3.4.4  Gestational Age  
Another important component of the case definition is the gestational age at delivery of the cases included 
in the surveillance data. The frequency of some defects may vary by gestational age, leading to variations 
in their rates depending on the length of gestation. For example, some defects are identified more 
frequently among preterm infants (Rasmussen et al., 2001; Shaw et al., 2001). Others, such as patent 
ductus arteriosus and undescended testes, may be abnormal in term infants but physiologically normal in 
preterm infants. Some ventricular septal defects that are present at birth in preterm infants might have 
closed during the last weeks of gestation if the pregnancy had continued to term. If surveillance systems 
differ in the gestational age at delivery of cases they include, or in their use of exclusion criteria based on 
gestational age, their rates of some defects may not be comparable.  
 
Again, the inclusion of pregnancies electively terminated after prenatal diagnosis poses additional issues. 
Many of these pregnancies would have delivered spontaneously at a considerably later gestational age 
had they not been terminated. In order not to underestimate the frequency of defects for which elective 
termination may be performed, pregnancies terminated after prenatal diagnosis should be included in 
surveillance data regardless of the gestational age at which they were terminated. However, this may 
slightly overestimate the frequency of some defects relative to their frequency in the absence of prenatal 
diagnosis. For example, the majority of pregnancies electively terminated before 20 weeks gestation 
would have otherwise continued beyond 20 weeks to be included in birth defects surveillance programs 
that monitor pregnancies of 20 weeks or greater. However, a small proportion might have ended in 
spontaneous abortion before 20 weeks and would not appropriately be included in data from these 
programs. While the frequency of spontaneous abortion for pregnancies with Down syndrome has been 
estimated for each week of gestation, the natural history of pregnancies with other defects has not been 
well described (Hook et al., 1995). The frequency of spontaneous abortion by gestational week probably 
varies depending on the defect. Unfortunately, this effect is likely to be greater the earlier in gestation that 
affected pregnancies are terminated.  
 
For the purposes of generating and reporting birth defects surveillance data across multiple states, the 
NBDPN recommends monitoring defects among live births and fetal deaths of 20 weeks or greater and 
among pregnancies electively terminated after prenatal diagnosis at any gestational age. Gestational age 
may be derived in various ways based on the date of the last menstrual period, measurement of the fetus 
by prenatal ultrasound, or the newborn clinical exam. Because these methods may not be equally accurate 
and may yield conflicting results, an important consideration is which method to use to determine whether 
a case fulfills the gestational age criterion for inclusion in surveillance data (Alexander et al., 1990; Hall, 
1990). The methods below are listed in descending order of their generally accepted accuracy for 
calculating gestational age: 
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 Prenatal ultrasound with a reported gestational age of less than 14 weeks  
 Date of the last menstrual period  
 Prenatal ultrasound with a reported gestational age of 14 weeks or greater  
 Clinical examination after delivery 
 
When multiple estimates of gestational age are ascertained for an individual case, the NBDPN 
recommends that the value derived using the method highest on this list be used to determine case status. 
Regardless of which method is used, it is important for birth defects surveillance programs to clearly state 
the gestational ages of the cases included when reporting surveillance data.  
3.4.5  Age at Which Defects Are Diagnosed 
The age at which a defect is diagnosed is also an important component of the case definition. The 
frequency of some defects may vary depending on the age of the child at diagnosis. While defects that are 
visible in the delivery room or symptomatic shortly after birth may be ascertained by most surveillance 
systems with high sensitivity, some internal defects may not be apparent for weeks or months after birth. 
Examples include cardiac defects that do not produce overt cyanosis, such as many atrial or ventricular 
septal defects, many obstructive renal defects, and some instances of intestinal malrotation. In addition, 
some chromosomal abnormalities may not be diagnosed until a year or more after birth when 
developmental delay or behavioral symptoms prompt a more in-depth evaluation. The rates of such 
conditions reported by surveillance systems that ascertain defects only among infants in the newborn 
nursery may not be comparable with those from systems that ascertain defects among older infants and 
children.  
 
For the purposes of generating and reporting birth defects surveillance data across multiple states, the 
NBDPN recommends monitoring defects among live-born infants up to one year of age. Whether an 
individual program is able to ascertain defects beyond the newborn period will depend on the accessibility 
of information from sources other than the newborn nursery and the availability of staff and resources to 
add these additional sources. Programs should regularly state the range of ages at diagnosis included 
when reporting surveillance data. 
 
As with other case definition criteria, the inclusion of defects that are diagnosed prenatally poses 
additional issues. The sensitivity and specificity of fetal ultrasound may vary for different defects 
depending on the gestational age, the skill and experience of the technician, the presence of maternal 
obesity, and other factors. The sensitivity and specificity of fetal ultrasound also may differ from that of 
newborn ultrasound and other postnatal diagnostic procedures. In addition, some conditions identified at 
mid-gestation by prenatal ultrasound may resolve spontaneously before delivery. Examples include renal 
obstructions, such as pyelectasis and uretero-pelvic junction obstructions, choroid plexus cysts of the 
brain, and some ventricular septal defects. Even chorionic villus sampling (CVS) may yield placental 
cells that contain chromosomal mosaicism not actually present in the fetus. For these reasons, many 
abnormalities diagnosed or suspected prenatally must be evaluated postnatally to determine their true 
nature. When such postnatal assessment is not possible or the medical records are not available, decisions 
about whether to include these defects in the surveillance must be made individually based on the 
certainty and specificity of the prenatal diagnosis for each case. General abstractor’s instructions for the 
inclusion and exclusion of prenatal diagnoses for the 45 defects reported by the NBDPN are provided in 
Appendix 3.2. When reporting surveillance data, it is important for birth defects surveillance programs to 
state clearly the ages at which the defects were diagnosed and whether prenatal diagnoses without 
postnatal confirmation are included. 
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3.4.6  Pregnancies Resulting from Assisted Reproductive Technology 
The use of assisted reproductive technology raises unique issues for birth defects surveillance, 
particularly in pregnancies where the egg from one woman (the biological mother) is used to conceive, 
but the pregnancy is carried by another woman (the birth mother). In this instance, genetic characteristics 
of the biological mother will be transmitted to the infant, but the birth mother’s environment and lifestyle 
during pregnancy may also affect the infant. This situation may become quite complex when examining 
etiologic factors for birth defects. However, for surveillance purposes, the NBDPN recommends that the 
person listed on the child’s birth certificate should be mother of record.  
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3.5  Case Definition and Sensitivity and Specificity 
Use of a consistent case definition is critical when evaluating the sensitivity and specificity of 
surveillance data and the efficiency and utility of surveillance programs. 
  
The sensitivity of a surveillance program is defined as the proportion of cases occurring within a 
population that the program ascertains. Factors that may affect the sensitivity of a birth defects 
surveillance program include which pregnancy outcomes are ascertained (live births, fetal deaths, elective 
terminations), the gestational age at which they are ascertained (term infants only, pregnancies > 20 
weeks, all pregnancies), the child’s age at the time the defect is diagnosed (prenatally, in the newborn 
period, before one year, at any age), and the diagnostic setting and methods used for ascertainment. For 
example, defects that are symptomatic in a live born infant may not be recognized in pregnancies that end 
in fetal death unless an autopsy is performed. Defects that are not immediately life-threatening, such as 
many cardiac septal defects, may not be diagnosed until several weeks or months after birth. If managed 
solely in the outpatient setting, these defects may be missed entirely by hospital-based programs unless 
surgical correction is required.  
 
The specificity of a surveillance program is defined as the proportion of cases within a population that are 
ascertained by the program and that truly have defects. Factors that affect the sensitivity of a birth defects 
surveillance program may also affect its specificity. For example, patent ductus arteriosus (PDA) may be 
entirely normal in a preterm or one-day-old term infant but distinctly abnormal in a three-month-old 
child. Inclusion of all occurrences of PDA, regardless of gestational or postnatal age, may lead to 
ascertainment of false positive cases. Variations in the quality of prenatal ultrasound and in the natural 
course of some prenatal conditions necessitate postnatal confirmation of many diagnoses to avoid 
including false positive or clinically nonsignificant cases. Such confirmation may not be possible for 
pregnancies that end in fetal death or elective termination unless fetal autopsies are performed. Similarly, 
the exact nature of a congenital heart defect may not be finalized until the time of corrective surgery.  
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Appendix 3.1 
Birth Defects Included in the Case Definition of the National Birth Defects 
Prevention Network 
 
Birth Defects ICD-9-CM Codes CDC/BPA Codes 
Central Nervous System 
Anencephalus 740.0 - 740.1 740.00 - 740.10 
Spina bifida without anencephalus 741.0, 741.9  
w/o 740.0 -740.10 
741.00 - 741.99  
w/o 740.0 - 740.10 
Hydrocephalus without Spina Bifida 742.3 w/o 741.0, 741.9 742.30 - 742.39  
w/o 741.00 - 741.99 
Encephalocele 742.0 742.00 - 742.09 
Microcephalus 742.1 742.10 
Eye 
Anophthalmia/microphthalmia 743.0, 743.1 743.00 - 743.10 
Congenital cataract 743.30 - 743.34 743.32 - 743.326 
Aniridia 743.45 743.42 
Ear 
Anotia/microtia 744.01, 744.23 744.01, 744.21 
Cardiovascular 
Common truncus 745.0 745.00 - 745.01 
Transposition of great arteries 745.10, .11, .12, .19 745.10 - 745.19 
Tetralogy of Fallot 745.2 745.20 - 745.21, 746.84 
Ventricular septal defect 745.4 
 
745.40 - 745.490 
(exclude 745.498) 
Atrial septal defect 745.5 
 
745.50 - 745.59 
(exclude 745.50) 
Endocardial cushion defect 745.60, .61, .69 745.60 - 745.69 
Pulmonary valve atresia and stenosis 746.01, 746.02 746.00 - 746.01 




Ebstein's anomaly 746.2 746.20 
Aortic valve stenosis 746.3 746.30 
Hypoplastic left heart syndrome 746.7 746.70 
Patent ductus arteriosus 
(Include only if weight=>2500 grams or 








Coarctation of aorta 747.10 747.10 - 747.19 
Orofacial 
Cleft palate without cleft lip 749.0 749.00 - 749.09 
Cleft lip with and without cleft palate 749.1, 749.2 749.10 - 749.29 
Choanal atresia 748.0 748.00 
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Gastrointestinal 
Birth Defects ICD-9-CM Codes CDC/BPA Codes 
Esophageal atresia/tracheoesophageal 
fistula 750.3 750.30 - 750.35 
Rectal and large intestinal 
atresia/stenosis 751.2 751.20 - 751.24 
Pyloric stenosis 750.5 750.51 
Hirshsprung's disease (congenital 
megacolon) 751.3 751.30 - 751.34 
Biliary atresia 751.61 751.65 
Genitourinary 
Renal agenesis/hypoplasia 753.0 753.00 - 753.01 
Bladder exstrophy 753.5 753.50 
Obstructive genitourinary defect 753.2, 753.6 753.20-29 - 753.60- 69 
Hypospadias and Epispadias 752.61, 752.62 752.600 - 752.627  
(excluding 752.621) 
Musculoskeletal 
Reduction deformity, upper limbs 755.20 - 755.29 755.20 - 755.29 
Reduction deformity, lower limbs 755.30 - 755.39 755.30 - 755.39 
Gastroschisis 756.79 756.71 
Omphalocele 756.79 756.70 
Congenital hip dislocation 754.30, .31, .35 754.30 
Diaphragmatic hernia 756.6 756.610 - 756.617 
Chromosomal 
Trisomy 13 758.1 758.10 - 758.19 
Down syndrome (Trisomy 21) 758.0 758.00 - 758.09 
Trisomy 18 758.2 758.20 - 758.290 
Other 
Fetal alcohol syndrome 760.71 760.71 
Amniotic bands No code 658.80 
 
Appendix 3.2 
NBDPN Abstractor’s Instructions 
 
Appendix 3.2             Case Definition 
Appendix 3.2 
NBDPN Abstractor’s Instructions 
 
Format for Birth Defect Descriptions A3.2-1
  
Central Nervous System  
Anencephalus ................................................................................................................................... A3.2-2
Spina bifida without anencephalus................................................................................................... A3.2-3













Common truncus .............................................................................................................................. A3.2-15
Transposition of great arteries .......................................................................................................... A3.2-16
Tetralogy of Fallot............................................................................................................................ A3.2-18
Ventricular septal defect................................................................................................................... A3.2-19
Atrial septal defect ........................................................................................................................... A3.2-20
Endocardial cushion defect .............................................................................................................. A3.2-21
Pulmonary valve atresia and stenosis ............................................................................................... A3.2-23
Tricuspid valve atresia and stenosis ................................................................................................. A3.2-24
Ebstein’s anomaly ............................................................................................................................ A3.2-25
Aortic valve stenosis ........................................................................................................................ A3.2-26
Hypoplastic left heart syndrome....................................................................................................... A3.2-27
Patent ductus arteriosus .................................................................................................................... A3.2-28
Coarctation of aorta .......................................................................................................................... A3.2-30
 
Orofacial  
Cleft palate without cleft lip ............................................................................................................. A3.2-31
Cleft lip with and without cleft palate .............................................................................................. A3.2-32
Choanal atresia ................................................................................................................................. A3.2-33
Esophageal atresia/tracheoesophageal fistula ................................................................................... A3.2-34
Rectal and large intestinal atresia/stenosis........................................................................................ A3.2-35
Pyloric stenosis................................................................................................................................. A3.2-36
Hirshsprung’s disease (congenital megacolon) ................................................................................ A3.2-37
Biliary atresia ................................................................................................................................... A3.2-39




Bladder exstrophy ............................................................................................................................ A3.2-42
Obstructive genitourinary defect ...................................................................................................... A3.2-44
Hypospadias and Epispadias ............................................................................................................ A3.2-46
 
Musculoskeletal  
Reduction deformity, upper limbs .................................................................................................... A3.2-48
Reduction deformity, lower limbs .................................................................................................... A3.2-51
Gastroschisis .................................................................................................................................... A3.2-54
Omphalocele .................................................................................................................................... A3.2-56
Congenital hip dislocation................................................................................................................ A3.2-58
Diaphragmatic hernia ....................................................................................................................... A3.2-59
 
Chromosomal  
Trisomy 13 ....................................................................................................................................... A3.2-60
Down syndrome (Trisomy 21).......................................................................................................... A3.2-62
Trisomy 18 ....................................................................................................................................... A3.2-64
 
Other  
Fetal alcohol syndrome..................................................................................................................... A3.2-66
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Appendix 3.2 
NBDPN Abstractor’s Instructions 






Description of the defect.   
Inclusions Other names or conditions that should be included in the code 




Other names or conditions that should not be included in the 
code for the defect. 
 
ICD-9-CM Codes Applicable ICD-9-CM codes for the defect. 
 
CDC/BPA Codes Applicable CDC/BPA codes for the defect. 
 
Diagnostic Methods Postnatal procedures by which the defect may be accurately and 
reliably diagnosed. 
 
Prenatal Diagnoses Not Confirmed 
Postnatally 
Guidance on whether cases with only a prenatal diagnosis 
should be included in the defect code. 
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Anencephalus 
Description Partial or complete absence of the brain and skull. 
  
Inclusions Acrania – Absence of skull bones with some brain tissue 
present. 
Absent brain, with or without skull bones present. 
Anencephalus 
Anencephaly  
Craniorachischisis – Anencephaly continuous with an open 
posterior spinal defect with no meninges covering the neural 
tissue. 
  
Exclusions Encephalocele  
Iniencephaly 
Rachischisis – When used alone, this term refers only to the 
spinal defect and should be coded as spina bifida without 
anencephalus. 
  
ICD-9-CM Codes 740.0 – 740.1 
  
CDC/BPA Codes 740.00 – 740.10 
  
Diagnostic Methods Anencephalus is easily recognized on physical examination at 
delivery. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Anencephalus may be included when only diagnosed prenatally. 
However, if it is possible to ascertain the degree of certainty of 
the prenatal diagnosis, this should factor into the decision as to 
whether or not to include an individual case in the surveillance 
data. 
  
Additional Information:  
Anencephalus is one of a group of defects that result from failure of the neural tube to close. 
 
Maternal serum alphafetoprotein (MSAFP) and/or amniotic fluid alphafetoprotein (AFAFP) and 
amniotic fluid acetylcholinesterase (ACHE) may be elevated with anencephalus. However, these 
screening tests alone are not sufficient to diagnose the condition. 
 
In cases where both anencephalus and spina bifida are present but are not continuous (i.e., not 
craniorachischisis), both anencephalus and spina bifida should be coded. 
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Spina Bifida without Anencephalus 
Description Incomplete closure of the vertebral spine (usually posteriorly) 
through which spinal cord tissue and/or the membranes covering 




Meningocele – Herniation of meninges only. 
Meningomyelocele, Myelomeningocele – Herniation of 




Open spina bifida 
Rachischisis – Open spina bifida without meninges covering the 
spinal cord tissue. 
Spina bifida aperta 
Spina bifida cystica 
  




Spina bifida with coexisting anencephalus – Code only as 
anencephalus. 
Spina bifida occulta  
Syringomyelia 
Tethered spinal cord 
  
ICD-9-CM Codes 741.0 or 741.9 without 740.0 – 740.1 
  
CDC/BPA Codes 741.00 – 741.99 without 740.00 – 740.10 
  
Diagnostic Methods The majority of defects result in a direct opening on the infant’s 
back that is easily recognized on physical examination at 
delivery. However, the exact nature of the defect (meningocele 
vs. myelomeningocele) may only be distinguished by CT or 
MRI scan, at surgery, or at autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Spina bifida may be included when only diagnosed prenatally. 
However, if it is possible to ascertain the degree of certainty of 
the prenatal diagnosis, this should factor into the decision as to 
whether or not to include an individual case in the surveillance 
data. In addition, the absence of spina bifida on prenatal 
ultrasound does not necessarily mean that it will not be 
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Additional Information:  
Spina bifida is one of a group of defects that result from failure of the neural tube to close. 
 
Open lesions (spina bifida cystica, spina bifida aperta) are those with no covering or with only 
meninges covering the neural tissue. They usually leak cerebrospinal fluid. Closed lesions are 
covered by normal skin. 
 
Closed lesions, or spina bifida occulta, do not produce an opening in the infant’s back and may 
result only in a defect of the vertebral spine without significant herniation of neural tissue or 
neurologic impairment. When asymptomatic, it may be detected as an incidental finding on an x-
ray or other test performed for a different indication.  
 
Hydrocephalus and Arnold-Chiari malformation of the brain frequently, though not always, result 
from spina bifida. When present, there is no need to code them separately from the spina bifida. 
 
Maternal serum alphafetoprotein (MSAFP) and/or amniotic fluid alphafetoprotein (AFAFP) and 
amniotic fluid acetylcholinesterase (ACHE) may be elevated in spina bifida. However, these 
screening tests alone are not sufficient to diagnose the condition. 
 
In cases where both anencephalus and spina bifida are present but are not continuous (i.e., not 
craniorachischisis), both anencephalus and spina bifida should be coded.  
 
If the defect coding system includes unique codes for different levels of spina bifida (cervical; 
thoracic; lumbar; sacral) and a defect involves more than one level (cervicothoracic; 
thoracolumbar; lumbosacral), the highest level at which it occurs should be coded (i.e., cervical; 
thoracic; lumbar). The highest level of involvement determines the degree of associated neurologic 
impairment. 
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Hydrocephalus without Spina Bifida 
Description An increase in the amount of cerebrospinal fluid (CSF) within 
the brain resulting in enlargement of the cerebral ventricles and 
increased intracranial pressure. 
  
Inclusions Aqueductal stenosis – Narrowing or incomplete patency of the 
aqueduct of Sylvius between the third and fourth ventricles. 
This is the most common type of obstructive hydrocephalus (see 
below). 
 
Atresia of the foramina of Magendie and Luschka – Incomplete 
patency of the openings in the roof of the fourth ventricle 
through which CSF normally flows out of the brain.  
 
Communicating hydrocephalus – Impaired absorption of CSF, 
leading to an increased amount of CSF within the brain.  
 
Dandy-Walker malformation  
Hydranencephaly  
Hydrocephalus, type not specified 
Obstructive (noncommunicating) hydrocephalus – Obstruction 
of the flow of CSF within or out of the brain. 
  
Exclusions Hydrocephalus that results from a prior intracranial hemorrhage. 
This may be seen particularly in preterm infants. 
 
Hydrocephalus that occurs in association with spina bifida. Only 




ICD-9-CM Codes 742.3 without 741.0 or 741.9 
  
CDC/BPA Codes 742.30 – 742.39 without 741.00 – 741.99 
  
Diagnostic Methods While severe cases may be suspected by physical examination at 
delivery, hydrocephalus may be conclusively diagnosed only 
through direct visualization of the brain by cranial ultrasound, 
CT or MRI scan, surgery, or autopsy. While a child’s head 
circumference may be increased for age, this measurement alone 
is not sufficient to make the diagnosis. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While hydrocephalus may be identified by prenatal ultrasound, 
it generally should not be included in surveillance data without 
postnatal confirmation. However, if it is possible to ascertain the 
degree of certainty of the diagnosis on prenatal ultrasound, this 
should factor into the decision as to whether or not to include an 
individual case in the surveillance data. Severe cases may be 
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included without postnatal confirmation. Live-born children 
who survive should always have confirmation of the defect 
postnatally before being included. 
  
Additional Information:  
Hydrocephalus has a variety of etiologies, including infection, hemorrhage, and tumors, as well as 
anatomic lesions of the brain such as agenesis of the corpus callosum, encephalocele, cysts, and 
some bone dysplasias. In many cases, the etiology is not known. 
 
In its true form, Dandy-Walker malformation is a malformation of the cerebellum and not a form 
of hydrocephalus. However, the term Dandy-Walker variant has been used to denote atresia of the 
foramina of Magendie and Luschka, dilatation of the cisterna magna (the space between the 
cerebellum and the brainstem), or cerebellar cysts, all of which have the appearance of increased 
fluid in the posterior fossa of the brain. It is, somewhat incorrectly, included in the defect codes for 
hydrocepahlus. 
 
In hydranencephaly, the cerebral hemispheres are largely replaced by fluid-filled sacs within a 
normal skull. Hydranencephaly is not a true form of hydrocephalus. It is, somewhat incorrectly, 
included in the defect codes for hydrocepahlus. 
 
Ventriculomegaly refers to enlargement of the cerebral ventricles, as measured by ultrasound 
(either prenatal or postnatal), CT or MRI scan. The distinction between hydrocephalus and 
ventriculomegaly has not been clearly defined, and these terms may be used interchangeably. 
Ventriculomegaly may be described as mild, moderate, or severe. How these designations correlate 
with the presence of true hydrocephalus, particularly when seen on prenatal ultrasound, also has 
not been clearly defined. 
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Encephalocele 
Description Herniation of brain tissue and/or meninges through a defect in 
the skull. The hernia sac is usually covered by skin. 
  
Inclusions Cephalocele 
Cranial meningocele – Herniation of meninges only. 
Encephalocele 
Encephalomyelocele - Herniation through a defect in a portion 









ICD-9-CM Codes 742.0 
  
CDC/BPA Codes 742.00 – 742.09 
  
Diagnostic Methods Most cases of encephalocele are recognizable on physical 
examination after delivery. However, they may be conclusively 
diagnosed only through direct visualization of the brain by 
cranial ultrasound, CT or MRI scan, surgery, or autopsy. This 
is particularly true for internal herniations through the 
sphenoid, maxillary, or ethmoid bones, the orbit, or pharynx. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Encephalocele may be included when only diagnosed 
prenatally. However, if it is possible to ascertain the degree of 
certainty of the prenatal diagnosis, this should factor into the 
decision as to whether or not to include an individual case in 
the surveillance data. In addition, the absence of a small 
encephalocele on prenatal ultrasound does not necessarily mean 
that it will not be diagnosed after delivery. 
  
Additional Information:  
Encephaloceles are often included as one of a group of defects that result from failure of the neural 
tube to close. 
 
Maternal serum alphafetoprotein (MSAFP) and/or amniotic fluid alphafetoprotein (AFAFP) and 
amniotic fluid acetylcholinesterase (ACHE) may be elevated with encephaloceles. However, these 
screening tests alone are not sufficient to diagnose the condition. 
 
Occipital encephalocele is a component of Meckel-Gruber syndrome. 
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Microcephalus 
Description A cranial vault that is smaller than normal for age. The size of 





Primary or True Microcephalus 
  
Exclusions Microcephalus that is secondary to a birth or delivery 
complication or to a postnatal insult or trauma. 
  
ICD-9-CM Codes 742.1 
  
CDC/BPA Codes 742.10 
  
Diagnostic Methods Microcephaly is usually easily diagnosed on physical 
examination by measurement of the occipitofrontal 
circumference (OFC, head circumference). However, there is 
difference of opinion as to what the lower limit of a normal 
head circumference should be (see below). Cranial ultrasound, 
CT or MRI scans may also reflect the diagnosis and contribute 
to the diagnosis of any underlying brain abnormalities. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of microcephalus on 
prenatal ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
Microcephalus may be defined variously as an OFC less than the 10th, 5th, or 3rd percentile, or less 
than 2 or 3 standard deviations below the mean for age. There is no single accepted standard. 
Reference graphs differ in terms of the cut-off values displayed and the reference population used. 
Reference graphs for postnatal OFC growth usually are displayed separately for males and 
females.  
 
In addition, it must be recognized that a proportion of normal children will have an OFC below 
any single cut-off value (i.e., 5% of the population has an OFC below the 5th percentile by 
definition). For this reason, only children who have been given a clinical diagnosis of 
microcephalus should be included in birth defects surveillance data. The diagnosis should not be 
assigned based on the OFC measurement at birth without corroborating evidence from the medical 
record that the child carries the diagnosis of microcephalus.  
 
Microcephalus itself is not a primary malformation, but a sign that the brain is small. It has a wide 
variety of causes. It is a component of a number of genetic syndromes. It also may result from a 
primary brain abnormality or a prenatal, perinatal, or postnatal insult. Examples of the latter 
include intrauterine infection, such as rubella or cytomegalovirus (CMV); in utero exposure to 
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alcohol and some medications, such as isotretinoin or dilantin; hypoxia during delivery; chronic 
hypoxia complicating prematurity; postnatal meningitis; head trauma. Only cases of microcephalus 
that have onset before delivery should be included in surveillance data. Unfortunately, the timing 
of onset and the etiology often are not known. 
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Anophthalmia/Microphthalmia 
Description Anophthalmia – Total absence of eye tissue or apparent absence 
of the globe in an otherwise normal orbit. 
 
Microphthalmia – Reduced volume of the eye. The corneal 
diameter is usually less than 10 millimeters, or the 




Nanophthalmia – Microphthalmia with normal internal eye 
(intraocular) structures. This is a distinct genetic condition. 
  
Exclusions Small eyes or small palpebral fissures for which the diagnosis of 
microphthalmia or anophthalmia has not been made. 
 
Microcornea with otherwise normal eye size. 
  
ICD-9-CM Codes 743.0,  743.1 
  
CDC/BPA Codes 743.00 – 743.10 
  
Diagnostic Methods These conditions are usually recognized on physical 
examination after delivery, especially by an ophthalmologist. 
However, the anteroposterior diameter of the globe may be 
measured only by ultrasound, CT or MRI scan, or at autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal ultrasound, 
they should not be included in surveillance data without 
postnatal confirmation. In addition, the absence of anophthalmia 
or microphthalmia on prenatal ultrasound does not necessarily 
mean that it will not be diagnosed after delivery. 
  
Additional Information:  
Microphthalmia may occur in association with colobomas (gaps) in the uvea, iris, choroid and/or 
optic nerve (colobomatous microphthalmia). 
 
Anophthalmia and microphthalmia often are accompanied by malformations of the brain and face, 
and frequently are components of genetic syndromes. 
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Congenital Cataract 
Description An opacity of the lens of the eye that has its origin prenatally. 
  
Inclusions Anterior polar cataract 
Cataract, type not specified 
Infantile cataract  
Lamellar cataract 
Nuclear cataract 
Posterior lentiglobus/lenticonus cataract 




Exclusions Any of the above types of cataract that has its origin after birth  
Corneal opacities 
  
ICD-9-CM Codes 743.30 – 743.34 
  
CDC/BPA Codes 743.320 – 743.326 
  
Diagnostic Methods Some cataracts are readily apparent on physical examination. 
Others are visible with an ophthalmoscope. However, they may 
be conclusively diagnosed only through examination by an 
ophthalmologist. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, it 
should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of a cataract on prenatal 
ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
Cataracts may be congenital, acquired, or inherited. They may involve all or only part of the lens 
of either or both eyes. They may be an isolated finding in an otherwise normal eye, or may be part 
of a more general eye malformation. They may be seen with metabolic disorders, such as 
galactosemia; genetic syndromes, such as chondrodysplasia punctata; chromosomal abnormalities, 
such as Trisomy 21; intrauterine infection, such as congenital rubella; or trauma.  
 
In some instances, the severity of the cataract progresses over time. The need for surgical treatment 
depends on the degree of visual impairment. 
 
When congenital cataract occurs with microphthalmia in the same infant, both conditions should 
be coded. 
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Aniridia 
Description Hypoplasia of the iris of both eyes. 
  
Inclusions Aniridia 
Hypoplasia of the iris 
  
Exclusions Axenfeld-Rieger syndrome 
Chandler syndrome 





ICD-9-CM Codes 743.45 
  
CDC/BPA Codes 743.42 
  
Diagnostic Methods Aniridia may be apparent on physical examination. However, it 
may be conclusively diagnosed only through examination by an 
ophthalmologist. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Aniridia should not be included in surveillance data unless 
diagnosed postnatally. 
  
Additional Information:  
Aniridia is usually associated with other abnormalities of the eye, including a persistent pupillary 
membrane; displaced lens; glaucoma; corneal and retinal abnormalities; hypoplasia of the optic 
nerve. While there is often near-total absence of the iris, it is never completely absent. Aniridia 
may be a component of Peters anomaly (abnormal development of the cornea and anterior 
chamber of the eye). 
 
Aniridia has been associated with Wilms tumor of the kidney and certain chromosomal 
abnormalities. It may be inherited or may occur sporadically. 
 
When aniridia occurs with a cataract in the same infant, both conditions should be coded. 
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Anotia/Microtia 
Description Anotia – Total absence of the external ear and canal. 
 






Exclusions Small ears that retain most of the overall structure of the 
normal auricle, including lop or cup ear defects. In these, the 
auditory meatus is usually patent and defects of the ossicular 
chain of the middle ear are infrequent. However, these defects 
are sometimes designated as Type I Microtia. 
 
Isolated absence, atresia, stenosis or malformation of the ear 
canal with a normal external ear. 
 
Congenital absence of the ear not diagnosed as anotia or 
microtia. 
  
ICD-9-CM Codes 744.01,  744.23 
  
CDC/BPA Codes 744.01,  744.21 
  
Diagnostic Methods Anotia and microtia are usually easily recognized on physical 
examination after delivery. However, abnormalities of the 
middle and inner ear may be conclusively diagnosed only by 
CT or MRI scan, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they should not be included in surveillance data 
without postnatal confirmation. In addition, the absence of 
anotia or microtia on prenatal ultrasound does not necessarily 
mean that they will not be diagnosed after delivery. 
  
Additional Information:  
The spectrum of severity of microtia may range from a measurably small external ear with minimal 
structural abnormality to major structural alteration of the external ear with an absent or blind-
ending canal. Following is the classification system of Meurman (modified from Marks): 
Type I B – Generally small ears that retain most of the overall structure of the normal auricle. 
These should not be coded as microtia. 
Type II B – A moderately severe anomaly with a longitudinal mass of cartilage with some 
resemblance to a pinna. The rudimentary auricle may be hook-shaped, have an S-shape, or the 
appearance of a question mark. 
Type III B – The ear is a rudiment of soft tissue and the auricle has no resemblance to a normal 
pinna. 
Type IV B – Complete absence of all external ear structures (anotia). 
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Abnormalities that may be associated with anotia/microtia include anomalies of the middle and/or 
inner ear, the mandible and face, and hearing loss. 
 
Anotia/microtia may be a component of Goldenhar and other syndromes. 
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Common Truncus (Truncus Arteriosus or TA) 
Description Failure of separation of the aorta and the pulmonary artery, 
resulting in a single common arterial trunk carrying blood from 
the heart to both the body and lungs. 
  
Inclusions Common truncus  
Truncus arteriosus (TA) 
  
Exclusions Aorto-pulmonary window 
  
ICD-9-CM Codes 745.0 
  
CDC/BPA Codes 745.00 – 745.01 
  
Diagnostic Methods While truncus defects may be suspected by clinical 
presentation, they may be conclusively diagnosed only through 
direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included as cases when only 
diagnosed prenatally. However, if it is possible to ascertain the 
degree of certainty of the prenatal diagnosis, this should factor 
into the decision as to whether or not to include an individual 
case in the surveillance data. Live-born children who survive 
should always have confirmation of the defect postnatally. 
  
Additional Information:  
A ventricular septal defect is often present in association with truncus defects and should be coded 
separately. 
 
Truncus arteriosus is one of several abnormalities of the outflow tract of the heart known as 
conotruncal defects. Some infants with these defects have a deletion on the short arm of 
chromosome 22 (22q11 deletion). This deletion is diagnosed using fluorescent in situ 
hybridization (FISH) and will not necessarily be detected on a routine karyotype analysis. 
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Transposition of the Great Arteries (TGA) 
Description Transposition of the aorta and the pulmonary artery such that 
the aorta arises from the right ventricle (instead of the left) and 
the pulmonary artery arises from the left ventricle (instead of 
the right). 
  
Inclusions Complete transposition (d-TGA without a VSD) 
Corrected transposition (l-TGA) 
Incomplete transposition (d-TGA with a VSD) 
Transposition of the Great Arteries (TGA), not otherwise 
specified 




ICD-9-CM Codes 745.10,  745.11,  745.12,  745.19 
  
CDC/BPA Codes 745.10 – 745.19 
  
Diagnostic Methods While transposition defects may be suspected by clinical 
presentation, they may be conclusively diagnosed only through 
direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included as cases when only 
diagnosed prenatally. However, if it is possible to ascertain the 
degree of certainty of the prenatal diagnosis, this should factor 
into the decision as to whether or not to include an individual 
case in the surveillance data. Live-born children who survive 
should always have confirmation of the defect postnatally. 
  
Additional Information:  
In order for a child with d-TGA to survive, a communication must be present between the 
pulmonary and systemic circulations to allow oxygenated blood from the lungs to reach the right 
ventricle for distribution to the rest of the body through the abnormally placed aorta. In most 
instances, this communication is through a ventricular septal defect (incomplete TGA). If a VSD is 
not present, oxygenated blood from the lungs is returned directly to the lungs without being 
distributed to the rest of the body (complete TGA).  
 
If the defect coding system does not include unique codes to differentiate TGA with and without a 
VSD (complete vs. incomplete), the VSD should be coded separately when present. 
 
l-TGA (corrected transposition) is a defect in which the ventricle on the right side of the heart has 
the anatomic appearance of the left ventricle, and the ventricle on the left side of the heart has the 
anatomic appearance of the right ventricle (ventricular inversion). The pulmonary artery arises 
from the anatomic left ventricle and the aorta arises from the anatomic right ventricle (hence the 
designation of transposition). Because blood from the ventricle on the right flows through the 
pulmonary artery, and that from the ventricle on the left flows through the aorta, circulation is 
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normal as long as there are no other defects. 
 
Transposition of the great arteries is one of several abnormalities of the outflow tract of the heart 
known as conotruncal defects. Some infants with these defects have a deletion on the short arm of 
chromosome 22 (22q11 deletion). This deletion is diagnosed using fluorescent in situ 
hybridization (FISH) and will not necessarily be detected on a routine karyotype analysis. 
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Tetralogy of Fallot 
Description The simultaneous presence of a ventricular septal defect (VSD), 
pulmonic stenosis, a malpositioned aorta that overrides the 
ventricular septum, and right ventricular hypertrophy. 
  
Inclusions Pentalogy of Fallot – Tetralogy of Fallot with an associated 
inter-atrial communication, either a patent foramen ovale (PFO) 
or an atrial septal defect (ASD). 




Some coding systems may also include Trilogy of Fallot, or 
Fallot’s Triad – the simultaneous presence of an atrial septal 
defect, pulmonic stenosis, and right ventricular hypertrophy. 
  
Exclusions Simultaneous occurrence of a VSD and pulmonary stenosis that 
has TOF physiology but has not been diagnosed as Tetralogy of 
Fallot. 
  
ICD-9-CM Codes 745.2 
  
CDC/BPA Codes 745.20 – 745.21,  746.84 
  
Diagnostic Methods While Tetralogy of Fallot may be suspected by clinical 
presentation, it may be conclusively diagnosed only through 
direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included as cases when only diagnosed 
prenatally. However, if it is possible to ascertain the degree of 
certainty of the prenatal diagnosis, this should factor into the 
decision as to whether or not to include an individual case in the 
surveillance data. Live-born children who survive should always 
have confirmation of the defect postnatally. 
  
Additional Information:  
Children with Tetralogy of Fallot may experience episodes of cyanosis or hypoxia that result from 
shunting of unoxygenated blood across the VSD from the right to the left ventricle. Children who 
have a coexisting VSD and pulmonary stenosis, but do not have Tetralogy of Fallot, may 
experience similar episodes. Thus, the occurrence of cyanosis or hypoxia does not necessarily 
mean a child has been diagnosed with Tetralogy of Fallot. 
 
Tetralogy of Fallot is one of several abnormalities of the outflow tract of the heart known as 
conotruncal defects. Some infants with these defects have a deletion on the short arm of 
chromosome 22 (22q11 deletion). This deletion is diagnosed using fluorescent in situ 
hybridization (FISH) and will not necessarily be detected on a routine karyotype analysis. 
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Ventricular Septal Defect (VSD) 
Description An opening in the septum that separates the left and right 
ventricles of the heart. 
  
Inclusions Ventricular septal defect 
VSD 
  
Exclusions Ventricular septal defects that occur as part of Tetralogy of 
Fallot or an endocardial cushion defect. Inflow-type, 
subtricuspid, and canal-type VSDs are assumed to be part of an 
endocardial cushion defect and should not be coded separately . 
  
ICD-9-CM Codes 745.4 
  
CDC/BPA Codes 745.40 – 745.59, excluding 745.498 
  
Diagnostic Methods Some isolated VSDs may be diagnosed on physical examination 
and/or EKG without direct imaging of the heart. However, many 
VSDs may be conclusively diagnosed only through direct 
visualization of the heart by cardiac echo (echocardiography), 
catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While VSDs may be identified by prenatal ultrasound, many 
close spontaneously before delivery. For this reason, VSDs that 
are diagnosed prenatally should not be included unless they 
have been confirmed postnatally. In addition, the absence of a 
VSD on prenatal ultrasound does not necessarily mean that a 
VSD will not be diagnosed after delivery, as it is not always 
possible to accurately visualize the entire ventricular septum by 
prenatal ultrasound. 
  
Additional Information:  
VSDs may be of several types, depending on the location of the opening along the ventricular 




However, in many instances the type of VSD may not be specified in the medical record. 
 
Many muscular, membranous and perimembranous VSDs may close spontaneously in the first 
weeks or months of life without treatment.  
 
An aneurysm of the ventricular septum indicates a membranous or perimembranous VSD that is in 
the process of closing. 
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Atrial Septal Defect (ASD) 
Description An opening in the septum that separates the left and right atria 
of the heart. 
  
Inclusions Atrial septal defect, type not specified 
ASD  
Secundum ASD (ASD 2 or ASD II) 
 
ASD vs. PFO – In the first days of life, it may not be possible 
to distinguish whether the opening in the atrial septum is a true 
ASD or a patent foramen ovale that has not yet closed (see 
below). ASD vs. PFO should be included only if the exact 
nature of the condition was never resolved. 
  
Exclusions Atrioventricular septal defects (AVSD) – These are included 
under endocardial cushion defects (see below). 
 
Patent foramen ovale (PFO) – A PFO is normal in utero and 
frequently does not close until 24 to 48 hours after birth.  
 
Primum ASD (1° ASD) – These are included under 
endocardial cushion defects (see below). 
  
ICD-9-CM Codes 745.5 
  
CDC/BPA Codes 745.50 – 745.59, excluding 745.50 
  
Diagnostic Methods Some isolated ASDs may be diagnosed based on physical 
examination and/or EKG without direct imaging of the heart. 
However, many ASDs may be conclusively diagnosed only 
through direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While ASDs may be identified by prenatal ultrasound, they 
may close spontaneously before delivery. For this reason, 
ASDs that are diagnosed prenatally should not be included 
unless they have been confirmed postnatally. In addition, the 
absence of an ASD on prenatal ultrasound does not necessarily 
mean that an ASD will not be diagnosed after delivery, as it is 
not always possible to accurately visualize the entire atrial 
septum by prenatal ultrasound. 
  
Additional Information:  
Secundum ASDs are usually located toward the middle of the atrial septum. Some close 
spontaneously without treatment. 
 
Primum ASDs are located in the lower portion of the atrial septum, are etiologically related to 
endocardial cushion (AV canal) defects, and never close spontaneously. 
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Endocardial Cushion Defect 
Description A defect in both the lower portion of the atrial septum and the 
upper portion of the ventricular septum, producing a large 
opening (canal) in the central part of the heart. The adjacent 
parts of the mitral and tricuspid valves may also be abnormal, 
resulting in a single common atrioventricular valve. In extreme 
cases, virtually the entire atrial and ventricular septae may be 
missing. 
  
Inclusions Atrioventricular septal defect (AVSD) 
Common or complete atrioventricular (AV) canal 
Common atrioventricular (AV) orifices 
Endocardial cushion defect 
 
Primum atrial septal defect (1° ASD) – A defect only in the 
lower portion of the atrial septum. While this does not also 
involve a defect in the upper portion of the ventricular septum, 
it is etiologically related to the more complete form. A cleft 
mitral valve is often present. 
 
Common atrium – A very large primum ASD. 
Incomplete AV canal (incomplete endocardial cushion defect) 
– Same as a primum ASD. 
 
Inflow-type, subtricuspid, or canal-type ventricular septal 
defect (VSDAVC) – A defect in the upper (inflow) portion of 
the ventricular septum. While this does not also involve a 
defect in the lower portion of the atrial septum, it is 
etiologically related to the more complete form. 
  
Exclusions Secundum ASDs that coexist with a VSD. In this instance, 
both the ASD and the VSD should be coded. 
  
ICD-9-CM Codes 745.60,  745.61,  745.69 
  
CDC/BPA Codes 745.60 – 745.69 
  
Diagnostic Methods While endocardial cushion defects may be suspected by clinical 
presentation, examination, and EKG changes, it may be 
conclusively diagnosed only through direct visualization of the 
heart by cardiac echo (echocardiography), catheterization, 
surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included as cases when only 
diagnosed prenatally. However, if it is possible to ascertain the 
degree of certainty of the prenatal diagnosis, this should factor 
into the decision as to whether or not to include an individual 
case in the surveillance data, as it may be difficult to 
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distinguish this condition from other abnormalities of the 
cardiac septae prenatally. Live-born children who survive 
should always have confirmation of the defect postnatally. 
  
Additional Information:  
Endocardial cushion defects are known to be associated with Down syndrome. Approximately 
20% of children with Down syndrome have some type of endocardial cushion defect. Conversely, 
approximately 70% of children with an endocardial cushion defect have Down syndrome. 
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Pulmonary Valve Atresia and Stenosis 
Description Pulmonary valve atresia – Lack of patency, or failure of 
formation altogether, of the pulmonary valve, resulting in 
obstruction of blood flow from the right ventricle to the 
pulmonary artery.  
 
Pulmonary valve stenosis – Obstruction or narrowing of the 
pulmonary valve, which may impair blood flow from the right 
ventricle to the pulmonary artery. 
  
Inclusions Pulmonary valve atresia 
Pulmonary valve stenosis 
Pulmonic stenosis (PS) 
  
Exclusions Atresia or stenosis of the main or branch (right or left) 
pulmonary arteries, not involving the pulmonary valve. 
Pulmonary stenosis that occurs as part of Tetralogy or 
Pentalogy of Fallot. 
Supra-valvular or sub-valvular pulmonic stenosis. 
  
ICD-9-CM Codes 746.01,  746.02 
  
CDC/BPA Codes 746.00 – 746.01 
  
Diagnostic Methods While pulmonary valve atresia or stenosis may be suspected by 
clinical presentation, it may be conclusively diagnosed only 
through direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they should not be included in surveillance data 
without postnatal confirmation. In addition, the absence of 
pulmonary valve atresia or stenosis on prenatal ultrasound does 
not necessarily mean that it will not be diagnosed after 
delivery. 
  
Additional Information:  
Pulmonary valve atresia or stenosis may occur with or without a coexisting ventricular septal 
defect. When it occurs with a VSD, the child may experience episodes of cyanosis or hypoxia 
similar to those seen in children with Tetralogy of Fallot. This results from shunting of 
unoxygenated blood across the VSD from the right to the left ventricle. Thus, the occurrence of 
cyanosis or hypoxia does not necessarily mean that the child has Tetralogy of Fallot. 
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Tricuspid Valve Atresia and Stenosis 
Description Tricuspid valve atresia – Lack of patency, or failure of 
formation altogether, of the tricuspid valve, resulting in 
obstruction of blood flow from the right atrium to the right 
ventricle.  
 
Tricuspid valve stenosis – Obstruction or narrowing of the 
tricuspid valve, which may impair blood flow from the right 
atrium to the right ventricle. 
  
Inclusions Tricuspid atresia 
Tricuspid stenosis 
  
Exclusions Tricuspid regurgitation without specific mention of tricuspid 
atresia or stenosis. 
  
ICD-9-CM Codes 746.1 
  
CDC/BPA Codes 746.10 (excluding 746.105) 
  
Diagnostic Methods While tricuspid valve atresia or stenosis may be suspected by 
clinical presentation, it may be conclusively diagnosed only 
through direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they should not be included in surveillance data 
without postnatal confirmation. In addition, the absence of 
tricuspid valve atresia or stenosis on prenatal ultrasound does 
not necessarily mean that it will not be diagnosed after 
delivery. 
  
Additional Information NA 
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Ebstein’s Anomaly 
Description Downward displacement if the tricuspid valve into the right 
ventricle. The tricuspid valve is usually hypoplastic and 
regurgitant. 
  





ICD-9-CM Codes 746.2 
  
CDC/BPA Codes 746.20   
  
Diagnostic Methods While Ebstein’s anomaly may be suspected by clinical 
presentation, it may be conclusively diagnosed only through 
direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of Ebstein’s anomaly on 
prenatal ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
Ebstein’s anomaly has been associated with lithium exposure during gestation. However, the 
magnitude of this association is probably very small. 
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Aortic Valve Stenosis 
Description Obstruction or narrowing of the aortic valve, which may impair 
blood flow from the left ventricle to the aorta. 
  
Inclusions Stenosis of the aortic valve 
  
Exclusions Stenosis of the aorta without mention of the aortic valve. 
Supra-valvular or sub-valvular aortic stenosis. 
  
ICD-9-CM Codes 746.3 
  
CDC/BPA Codes 746.30   
  
Diagnostic Methods While aortic valve stenosis may be suspected by clinical 
presentation, it may be conclusively diagnosed only through 
direct visualization of the heart by cardiac echo 
(echocardiography), catheterization, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of aortic valve stenosis 
on prenatal ultrasound does not necessarily mean that it will not 
be diagnosed after delivery. 
  
Additional Information NA 
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Hypoplastic Left Heart Syndrome (HLHS) 
Description A condition in which the structures on the left side of the heart 
and the aorta are extremely small. Classically, this condition 
includes hypoplasia of the left ventricle, atresia or severe 
hypoplasia of the mitral and aortic valves, and hypoplasia and 
coarctation of the aorta. 
  
Inclusions Any diagnosis of hypoplastic left heart syndrome, regardless of 
whether all conditions in the classical definition are present. 
  
Exclusions Hypoplasia or diminished size of the left ventricle alone 
without involvement of other structures on the left side of the 
heart or the aorta. 
 
Hypoplastic left heart or small left ventricle that occurs as part 
of another complex heart defect, such as an endocardial 
cushion defect (AV canal). 
  
ICD-9-CM Codes 746.7 
  
CDC/BPA Codes 746.70   
  
Diagnostic Methods While hypoplastic left heart may be suspected by clinical 
presentation, examination, and EKG changes, it may be 
conclusively diagnosed only through direct visualization of the 
heart by cardiac echo (echocardiography), catheterization, 
surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included as cases when only 
diagnosed prenatally. However, if it is possible to ascertain the 
degree of certainty of the prenatal diagnosis, this should factor 
into the decision as to whether or not to include an individual 
case in the surveillance data, as it may be difficult to 
distinguish this condition from other abnormalities of the left 
ventricle prenatally. Live-born children who survive should 
always have confirmation of the defect postnatally before being 
included. 
  
Additional Information NA 
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Patent Ductus Arteriosus (PDA) 
Description Abnormally persistent blood flow through the ductus arteriosus 
beyond the first few days of life. 
  
Inclusions Patent ductus arteriosus in infants with birth weight ≥ 2,500 
grams who have not been given prostaglandin (see below). 
  
Exclusions Patent ductus arteriosus in infants with birth weight < 2,500 
grams. 
Patent ductus arteriosus in infants ≥ 2,500 grams who have 
been given prostaglandin (see below). 
  
ICD-9-CM Codes 747.0 
  
CDC/BPA Codes 747.00 
  
Diagnostic Methods Some instances of patent ductus arteriosus may be diagnosed 
on physical examination. However, many PDAs may be 
diagnosed conclusively only through direct visualization of the 
heart by cardiac echo (echocardiography), catheterization, 
surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Because a patent ductus arteriosus is normal and necessary 
during fetal life, this condition should not be included in 
surveillance data unless diagnosed postnatally at an appropriate 
age. 
  
Additional Information:  
In the normal fetal circulation, blood flows from the right ventricle to the pulmonary artery, then 
crosses the ductus arteriosus to the aorta for distribution to the body and the placenta. This 
bypasses much of the pulmonary circulation, since fetal blood is oxygenated by the placenta and 
not the lungs. Over the first hours after a normal full-term birth, smooth muscle in the wall of the 
ductus contracts and thickens to prevent blood flow through the ductus. Over the subsequent 2 to 3 
weeks of life, the ductus is replaced by fibrous tissue and the communication is permanently 
sealed. Persistence of a patent ductus through which blood may flow beyond that time is abnormal. 
 
In preterm infants, the ability of the ductus to constrict and close after delivery is not fully 
developed. Patent ductus arteriosus in a preterm infant is more likely to be a consequence of 
prematurity rather than an inherent abnormality. In these infants, it should not be coded as a defect. 
 
The length of time required for the ductus to close is somewhat variable among term infants, and 
there is disagreement among specialists about the length of time after which patency is abnormal. 
Some birth defects surveillance programs only include PDAs that have been present for at least 6 
weeks after birth. 
  
Term infants who have additional heart defects may have abnormal patterns of blood flow or 
abnormal pressures in the pulmonary artery and aorta which prevent the ductus from closing. In 
these instances, the PDA is not an inherent abnormality but secondary to the additional defects.  
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In some severe heart defects, such as pulmonary atresia or d-TGA without a VSD, the infant’s 
initial survival may depend on the presence of a patent ductus arteriosus in order for blood to reach 
the lungs for oxygenation. Prostaglandin (PGE) may be administered intravenously to maintain the 
patency of the ductus. In these instances, the PDA is an artifact of treatment of the underlying 
condition and should not be coded as a defect.   
 
Patent ductus arteriosus may be a component of persistent transitional (fetal) circulation, in which 
the fetal pattern of blood flow through the ductus and bypassing the lungs, persists after birth. This 
is often a physiologic response to hypoxia from respiratory suppression, as may be seen with 
meconium aspiration. 
 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 06/04 
 
Appendix 3.2     A3.2-30         Case Definition 
 
Coarctation of the Aorta 
Description Narrowing of the descending aorta, which may obstruct blood 
flow from the heart to the rest of the body. The most common 
site of coarctation occurs distal to the origin of the left 
subclavian artery in the region of the ductus arteriosus. 
  
Inclusions Coarctation of the aorta, type not specified  
Preductal, juxtaductal, and postductal coarctations – These 
terms refer to the exact placement of the segment of coarctation 




ICD-9-CM Codes 747.10 
  
CDC/BPA Codes 747.10 – 747.19   
  
Diagnostic Methods While coarctation of the aorta may be suspected by clinical 
presentation and examination, it may be conclusively 
diagnosed only through direct visualization of the heart by 
cardiac echo (echocardiography), catheterization, surgery, or 
autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of coarctation of the 
aorta on prenatal ultrasound does not necessarily mean that it 
will not be diagnosed after delivery. 
  
Additional Information:  
Left-sided obstructive lesions of the heart, such as coarctation, have been associated with Turner 
syndrome (karyotype 45,X and other variants). 
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Cleft Palate without Cleft Lip 
Description An opening in the roof of the mouth resulting from incomplete 
fusion of the shelves of the palate. The opening may involve 
the hard palate only, the soft palate only, or both. 
  
Inclusions Bifid or cleft uvula 
Cleft palate, type not specified 
Cleft hard palate 
Cleft soft palate 
Submucous cleft palate – A cleft in the soft palate that is 
covered by the mucosa or a thin muscle layer. 
  
Exclusions Cleft palate that coexists with a cleft lip. These should be 
coded as cleft lip only (see below). 
  
ICD-9-CM Codes 749.0 
  
CDC/BPA Codes 749.00 – 749.09   
  
Diagnostic Methods Cleft palate is usually easily recognized on physical 
examination by direct visualization of the pharynx after 
delivery. It may also be seen on CT or MRI scan, at surgery or 
autopsy. However, submucous cleft palate may be difficult to 
diagnose by physical examination during the first year of life. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of cleft palate on 
prenatal ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
Cleft palate may be unilateral, bilateral, or central in location. If the defect coding system includes 
unique codes for these different types, the location of the cleft should be coded. 
 
Cleft palate sometimes may be described as U-shaped or V-shaped. This distinction is not 
clinically meaningful and these conditions should not be coded differently. 
 
Bifid uvula is often seen in association with a submucous cleft palate. However, bifid uvula also 
may occur alone. The presence of submucous cleft palate does not necessarily mean that a bifid 
uvula is present. 
 
Cleft palate is one component of the Pierre Robin sequence, which also includes micrognathia and 
glossoptosis (when the tongue falls backward into the posterior pharynx). When diagnosed, Pierre 
Robin sequence should be coded separately. 
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Cleft Lip with and without Cleft Palate 
Description A defect in the upper lip resulting from incomplete fusion of 
the parts of the lip. 
  
Inclusions Complete cleft lip – The defect extends through the entire lip 
into the floor of the nose.  
Incomplete cleft lip – The defect extends through part of the lip 
but not into the floor of the nose. 
  
Exclusions Pseudocleft lip – An abnormal linear thickening, depressed 
grove, or scar-like pigmentary change on the skin of the lip 
without an actual cleft.  
 
Oblique facial clefts 
Cleft palate without an associated cleft lip 
  
ICD-9-CM Codes 749.1,  749.2 
  
CDC/BPA Codes 749.10 – 749.29   
  
Diagnostic Methods Cleft lip is usually easily recognized on physical examination 
after delivery. It may also be seen on CT or MRI scan, at 
surgery or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be identified by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of cleft lip on prenatal 
ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
Cleft lip may be unilateral, bilateral, or central in location. If the defect coding system includes 
unique codes for these different types, the location of the cleft should be coded. 
 
Cleft lip may also be seen in association with amniotic bands. In this instance, the amniotic bands 
should also be coded. 
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Choanal Atresia 
Description Congenital obstruction of the opening of the nasal cavity into 
the nasopharynx on either side. This prevents communication 
of the nasal cavity with the pharynx. 
  
Inclusions Choanal atresia, type not specified 
Choanal stenosis  
Membranous choanal atresia, with or without a bony rim 




ICD-9-CM Codes 748.0 
  
CDC/BPA Codes 748.00 
  
Diagnostic Methods Bilateral choanal atresia is usually easily recognized at birth 
from the clinical presentation of obligate mouth-breathing. 
Unilateral choanal atresia may be suspected by clinical 
examination. Both conditions may be diagnosed by the inability 
to pass a feeding tube from the nasal passage(s) into the 
posterior pharynx. Both conditions may also be seen on CT or 
MRI scan, at surgery or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they should not be included in surveillance data 
without postnatal confirmation. In addition, the absence of 
choanal atresia on prenatal ultrasound does not necessarily 
mean that it will not be diagnosed after delivery. 
  
Additional Information:  
Choanal atresia or stenosis may be unilateral or bilateral. If the defect coding system includes 
unique codes for these different types, the location should be coded. 
 
Choanal atresia is one of the defects reported as part of the CHARGE association, which may also 
include colobomas, heart defects, retarded growth and development, genital hypoplasia, and ear 
anomalies and/or deafness. 
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Esophageal Atresia/Tracheoesophageal Fistula 
Description Esophageal atresia – A condition in which the esophagus ends 
in a blind pouch and fails to connect with the stomach.  
 
Tracheoesophageal fistula – An abnormal communication 
between the esophagus and the trachea. This is almost always 
associated with some form of esophageal atresia. 
  
Inclusions Esophageal atresia alone  
Esophageal atresia with tracheoesohpageal (TE) fistula 
Esophageal stenosis, stricture, ring, or web 
TE fistula 
Tracheoesophageal fistula, all types 
  
Exclusions Tracheal atresia  
Tracheoesophageal cleft 
  
ICD-9-CM Codes 750.3 
  
CDC/BPA Codes 750.30 – 750.35 
  
Diagnostic Methods The diagnosis may be suspected by the clinical presentation of 
polyhydramnios, vomiting, or respiratory distress. Esophageal 
atresia may be diagnosed by x-ray documentation of failure of a 
feeding tube to pass from the pharynx into the stomach. 
Tracheoesophageal atresia may be conclusively diagnosed only 
by CT or MRI scan, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included when only diagnosed 
prenatally. However, if it is possible to ascertain the degree of 
certainty of the prenatal diagnosis, this should factor into the 
decision as to whether or not to include an individual case in 
the surveillance data. Live-born children who survive should 
always have confirmation of the defect postnatally before being 
included. 
  
Additional Information:  
In some instances, TE fistula without esophageal atresia may not be diagnosed until weeks, 
months, or even a year or more after birth if the communication between the esophagus and 
stomach remains patent. 
 
TE fistula is one of the defects reported as part of the VATER, or VACTERL, association, which 
may also include vertebral and cardiac defects, anal atresia, renal defects, and limb anomalies. 
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Rectal and Large Intestinal Atresia/Stenosis 
Description Complete or partial occlusion of the lumen of one or more 
segments of the large intestine and/or rectum. 
  
Inclusions Anal atresia or stenosis 
Colonic atresia or stenosis 
Imperforate anus 
Large intestinal atresia or stenosis 
Rectal atresia or stenosis 
  
Exclusions Apple peel intestinal atresia 
Duodenal atresia or stenosis 
Ileal atresia or stenosis 
Jejunal atresia or stenosis 
Small intestinal atresia or stenosis 
  
ICD-9-CM Codes 751.2 
  
CDC/BPA Codes 751.20 – 751.24 
  
Diagnostic Methods Anal atresia (imperforate anus) is usually easily recognized at 
birth by physical examination. While large intestinal and rectal 
atresia or stenosis may be suspected by the clinical presentation 
of failure to pass meconium or stool, they may be conclusively 
diagnosed only through direct imaging of the bowel by x-ray, 
barium enema, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they should not be included in surveillance data 
without postnatal confirmation. In addition, the absence of 
intestinal, rectal or anal atresia or stenosis on prenatal 
ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
These conditions may occur with or without a fistula.  
 
Anal atresia is one of the defects reported as part of the VATER, or VACTERL, association, 
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Pyloric Stenosis 
Description Hypertrophy (thickening) of the muscles of the pylorus 
connecting the stomach to the duodenum, resulting in complete 
or partial obstruction of the passage of food and gastric 
contents. 
  
Inclusions Infantile (congenital) hypertrophic pyloric stenosis 
Pyloric stenosis 
  
Exclusions Pylorospasm (intermittent spasm of the pyloric muscles) 
without permanent narrowing of the lumen. 
  
ICD-9-CM Codes 750.5 
  
CDC/BPA Codes 750.51 
  
Diagnostic Methods Many instances of pyloric stenosis may be diagnosed by the 
clinical presentation and physical examination. However, other 
cases may be diagnosed conclusively only by abdominal 
ultrasound or contrast x-ray of the stomach. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
In rare cases, pyloric stenosis may develop prenatally and may 
be identified on prenatal ultrasound. However, it should not be 
included in surveillance data without postnatal confirmation. In 
addition, the absence of pyloric stenosis on prenatal ultrasound 
does not mean that it will not develop after delivery (see 
below). 
  
Additional Information:  
Pyloric stenosis most typically presents with intractable vomiting in a 3- to 4-week-old infant. 
While it may appear late in gestation, it develops more commonly in the first month or two after 
birth. As such, it may not be a truly congenital defect.  
 
The etiology of pyloric stenosis remains unclear, but is probably multifactorial with both genetic 
and environmental influences. Pyloric stenosis has been associated with erythromycin use in 
newborn infants. 
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Hirschsprung Disease (Congenital Megacolon) 
Description Hirschsprung disease – Absence of the parasympathetic 
ganglion nerve cells (aganglionosis) of the wall of the colon or 
rectum, which may result in congenital megacolon. 
 
Megacolon – Enlargement of the diameter of part or all of the 
colon. 
  
Inclusions Aganglionic megacolon 
Congenital megacolon 
Hirschsprung disease, type not specified 
Long-segment Hirschsprung disease (Type II) 
Short-segment Hirschsprung disease (Type I) 
Total colon (intestinal) aganglionosis 
  
Exclusions Psychogenic megacolon 
  
ICD-9-CM Codes 751.3 
  
CDC/BPA Codes 751.30 – 751.34 
  
Diagnostic Methods Hirschsprung disease (congenital megacolon) may be suspected 
by contrast x-ray (barium enema). However, it may be 
diagnosed conclusively only through direct assessment of the 
presence or absence of ganglion cells in rectal tissue at biopsy, 
surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be suspected by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of congenital megacolon 
on prenatal ultrasound does not necessarily mean that it will not 
be diagnosed after delivery. 
  
Additional Information:  
Megacolon may result from any condition that inhibits normal passage of the intestinal contents. 
Primary underlying conditions include Hirschsprung disease, rectal and large intestinal 
atresia/stenosis, imperforate anus, and voluntary stool retention (psychogenic megacolon). In 
Hirschsprung disease, the aganglionic segment of intestine is small and empty, while the normally 
enervated segment proximal to the affected area is enlarged and filled with fecal matter.  
 
Hirschsprung disease is classified according to the extent of aganglionosis. In 80% of cases, 
aganglionosis extends from the anal sphincter and rectum to the middle of the sigmoid colon; in 
10% to 20% of cases, it extends further to the transverse or right colon; in 3% of cases, 
aganglionosis involves the entire colon.   
 
Possible complications of Hirschsprung disease/congenital megacolon include bowel perforation, 
enterocolitis (intestinal inflammation), peritonitis (inflammation of the lining of the abdomen), and 
septicemia (bloodstream infection). 
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Approximately 3% of infants with Down syndrome have aganglionosis of the colon. When Down 
syndrome and Hirschsprung disease/congenital megacolon occur in the same infant, both 
conditions should be coded. 
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Biliary Atresia 
Description Congenital absence of the lumen of the extrahepatic bile ducts. 
  
Inclusions Agenesis, absence, hypoplasia, obstruction or stricture of the 
bile duct(s) 
  
Exclusions Congenital or neonatal hepatitis 
Intrahepatic biliary atresia (absence or paucity of bile ducts 
within the liver) not associated with extrahepatic biliary atresia 
  
ICD-9-CM Codes 751.61 
  
CDC/BPA Codes 751.65 
  
Diagnostic Methods Biliary atresia may be suspected by the clinical presentation 
and the presence of elevated direct bilirubin and liver function 
tests. However, it may be conclusively diagnosed only through 
direct assessment of the bile ducts by abdominal ultrasound, 
CT or MRI scan, biliary excretion study (HIDA scan), surgery, 
or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While biliary atresia may be suspected by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of biliary atresia on 
prenatal ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
The liver contains within its substance intrahepatic bile ducts and passages that join and coalesce 
to form two main ducts that carry bile out of the liver. 
 
The extrahepatic bile ducts include the hepatic duct (formed by the two main ducts that carry bile 
out of the liver), the cystic duct (which carries bile out of the gallbladder where it is stored), and 
the common bile duct (formed by the junction of the hepatic duct and the cystic duct), which 
carries bile into the duodenum for excretion.  
 
When extrahepatic biliary atresia is present, the intrahepatic bile ducts may also be abnormal or 
atretic.  
 
Patients with biliary atresia may have jaundice due to direct hyperbilirubinemia, which is not 
treated with phototherapy. The more common type of neonatal jaundice due to indirect 
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Renal Agenesis/Hypoplasia 
Description Renal agenesis – Complete absence of the kidney 
Renal hypoplasia – Incomplete development of the kidney 
  
Inclusions Renal agenesis, dysgenesis, aplasia, or hypoplasia 
Potter syndrome secondary to renal agenesis/hypoplasia 
  
Exclusions Cystic renal dysplasia 
Cystic kidney disease 
Multicystic kidney 
Multicystic dysplastic kidney 





ICD-9-CM Codes 753.0 
  
CDC/BPA Codes 753.00 – 753.01 
  
Diagnostic Methods Bilateral renal agenesis is usually easily recognized on physical 
examination after delivery. Bilateral renal hypoplasia may or 
may not be recognized after delivery, depending on the severity 
and degree of residual kidney function.  
 
Unilateral renal agenesis or hypoplasia may not be symptomatic 
at delivery if the contralateral kidney is not impaired.  
 
Each of these diagnoses may be conclusively diagnosed only 
through direct assessment by abdominal ultrasound, CT or MRI 
scan, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Bilateral renal agenesis may be included when only diagnosed 
prenatally. However, if it is possible to ascertain the degree of 
certainty of the prenatal diagnosis, this should factor into the 
decision as to whether or not to include an individual case in 
the surveillance data. Live-born children who survive should 
always have confirmation of the defect postnatally before being 
included.  
 
While bilateral renal hypoplasia and unilateral renal 
agenesis/hypoplasia may be suspected by prenatal ultrasound, 
they should not be included in surveillance data without 
postnatal confirmation. Lack of visualization of a kidney on 
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Additional Information:  
Renal agenesis and hypoplasia may be unilateral or bilateral. If the defect coding system includes 
unique codes for these different types, the location should be coded. 
 
Bilateral renal agenesis, or any condition that significantly impairs the function of both kidneys in 
utero, may lead to the oligohydramnios sequence (Potter syndrome) due to lack of fetal urine 
production and the resulting decreased amniotic fluid volume. The sequence includes minor facial 
dysmorphism (flat face, small chin, large ears), pulmonary hypoplasia, and joint contractures. 
 
Bilateral renal agenesis is incompatible with long-term survival unless a kidney transplant is 
performed. In contrast, unilateral renal agenesis/hypoplasia may not be diagnosed until weeks, 
months, or even years after birth if the contralateral kidney function is normal. Some unilateral 
cases may be diagnosed only as incidental findings during evaluation for other conditions, and 
some may never be recognized. 
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Bladder Exstrophy 
Description A defect in the lower abdominal wall and anterior wall of the 
bladder through which the lining of the bladder is exposed to 
the outside. 
  
Inclusions Classic bladder exstrophy 
Ectopia vesicae 
Epispadias-exstrophy complex 
Extroversion of the bladder 
Variants of bladder exstrophy 
Vesical exstrophy 
  




ICD-9-CM Codes 753.5 
  
CDC/BPA Codes 753.50 
  
Diagnostic Methods Bladder exstrophy is easily recognized on physical examination 
at delivery. However, the exact nature of the defect and 
associated anomalies may only be distinguished by abdominal 
ultrasound, contrast x-ray studies, CT or MRI scan, surgery, or 
autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
These conditions may be included when only diagnosed 
prenatally. However, if it is possible to ascertain the degree of 
certainty of the prenatal diagnosis, this should factor into the 
decision as to whether or not to include an individual case in 
the surveillance data, as it may be difficult to distinguish 
bladder exstrophy from cloacal exstrophy. Live-born children 
who survive should always have confirmation of the defect 
postnatally before being included. 
  
Additional Information:  
In the classic form of bladder exstrophy, the entire urinary tract is open anteriorly from the urethral 
meatus to the umbilicus. The pubic bones are widely separated, as are the abdominal muscles and 
fascia. There is eversion/exposure of the posterior bladder wall. The genitalia of either gender may 
be involved and may be bifid or duplicated. The classic form of bladder exstrophy occurs more 
frequently in males.  
 
Variants of bladder exstrophy occur more rarely and affect females more often then males. 
Included among these variants are superior vesical fistula, closed exstrophy, duplicate exstrophy, 
pseudoexstrophy, inferior vesicle. Epispadias is almost uniformly present, but should not be coded 
separately.  
 
Ambiguous genitalia may be noted in patients with bladder exstrophy if an obvious scrotum and 
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testes are not present. However, ambiguous genitalia should not be coded as a separate defect in 
these instances.  
 
Bladder exstrophy should be distinguished from cloacal exstrophy, in which the urinary, intestinal, 
and genital structures open into a common cavity (the cloaca). The distinction may only be 
possible with detailed diagnostic studies, surgery, or at autopsy. In cloacal exstrophy, bladder 
exstrophy and imperforate anus are also present. In bladder exstrophy without cloacal exstrophy, 
the anus is patent. When both bladder and cloacal exstrophy are present, only cloacal exstrophy 
should be coded. 
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Obstructive Genitourinary Defect 
Description Partial or complete obstruction of the flow of urine at any level 
of the genitourinary tract from the kidney to the urethra. 
  
Inclusions Atresia, stenosis, stricture or occlusion of one or both ureters, 
the bladder neck, the urethra or urethral meatus  





Posterior urethral valves 
Obstruction of the ureteropelvic junction (UPJ), the 
ureterovesical (UV) junction, or the vesicourethral (VU) 
junction  
Urethral valves, type not specified 
  
Exclusions Inhibition of urinary flow at any of the above sites resulting 
solely from neurologic impairment. 
  
ICD-9-CM Codes 753.2,  753.6 
  
CDC/BPA Codes 753.20 – 753.29,  753.60 – 753.69 
  
Diagnostic Methods Genitourinary tract obstruction may be suspected by the clinical 
presentation. However, the exact nature of the defect and the 
level of obstruction may only be distinguished by direct 
visualization. The upper urinary tract (kidneys and ureters) is 
usually visualized with renal ultrasound, radionuclide scan, or a 
contrast study such as intravenous pyelography (IVP). The 
lower urinary tract (bladder and urethra) is usually visualized 
directly with cystoscopy or urethral endoscopy, or with contrast 
studies such as voiding cystourethrogram (VCUG) and 
sometimes IVP. Obstructions also may be diagnosed at surgery 
or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While obstructive genitourinary defects may be identified by 
prenatal ultrasound, many lesions diminish or resolve 
spontaneously prior to birth. For this reason, they should not be 
included in surveillance data without postnatal confirmation 
(see below). In addition, the absence of genitourinary 
obstruction on prenatal ultrasound does not necessarily mean 
that an obstructive defect will not be diagnosed after delivery. 
  
Additional Information:  
When urine flow is obstructed, the portion of the genitourinary tract proximal to the affected area 
may become enlarged and dilated with urine. Mild lesions may produce only partial or intermittent 
urinary obstruction without permanent damage. More severe lesions may substantially or 
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completely obstruct urine flow, resulting in permanent damage to proximal structures, and 
sometimes impaired kidney function, if not relieved by surgery.  
 
Increased use of ultrasound screening has led to the recognition of asymptomatic genitourinary 
tract obstructions in the fetus and newborn, many of which resolve without treatment and would 
not otherwise have been diagnosed. Inclusion of these lesions in birth defects surveillance data 
may inflate the apparent frequency of significant obstructive genitourinary defects. If it is possible 
to correlate the findings on prenatal and/or newborn ultrasound with the clinical course of 
symptoms and treatment, this should factor into the decision as to which obstructive lesions to 
include in the surveillance data. 
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Hypospadias and Epispadias 
Description Hypospadias – Displacement of the opening of the urethra 
(urethral meatus) ventrally and proximally (underneath and 
closer to the body) in relation to the tip of the glans of the 
penis. 
 
Epispadias – Displacement of the opening of the urethra 
(urethral meatus) dorsally and proximally (on the top and closer 
to the body) in relation to the tip of the glans of the penis. 
  
Inclusions First-degree hypospadias – The urethral meatus is located on 
the glans of the penis. Also called primary, 1°, glandular, or 
coronal hypospadias. 
 
Second-degree hypospadias – The urethral meatus is located on 
the shaft of the penis. Also called secondary, 2°, or penile 
hypospadias. 
 
Third-degree hypospadias – The urethral meatus is located at 
the base of the penis on the scrotum or perineum. Also called 
tertiary, 3°, scrotal, penoscrotal, or perineal hypospadias. 
 
Hypospadias, degree not specified 
Hypospadias of any type with chordee 
Epispadias 
  
Exclusions Chordee alone without associated hypospadias 
Ambiguous genitalia 
  
ICD-9-CM Codes Hypospadias  752.61 
Epispadias  752.62 
  
CDC/BPA Codes Hypospadias  752.600 – 752.607,  752.620,  752.605 – 
752.607 
Epispadias  752.621 
  
Diagnostic Methods Both hypospadias and epispadias are usually easily recognized 
on physical examination at delivery. They may also be seen on 
contrast x-rays of the urinary tract, at surgery or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be diagnosed by prenatal 
ultrasound, they should not be included in surveillance data 
without postnatal confirmation. In addition, the absence of 
hypospadias or epispadias on prenatal ultrasound does not 
necessarily mean that they will not be diagnosed after delivery. 
  
Additional Information:  
Chordee indicates a ventral (downward) curve of the penis, which may result from cutaneous or 
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fibrous restriction. It is present in approximately 35% to 50% of cases of hypospadias. 
 
In mild forms of first-degree hypospadias, the foreskin may appear hooded but there may be no 
overt clinical symptoms.  
 
In contrast, third-degree hypospadias may be described as ambiguous genitalia. In this instance, it 
is important to search the medical record for detailed information (including chromosome, 
molecular, and hormone analyses; genetics and endocrinology consultations; surgery or autopsy 
reports) that may clarify the anatomy and/or indicate whether an underlying genetic condition or 
endocrinopathy associated with ambiguous genitalia is present. Ambiguous genitalia should not be 
coded if hypospadias is the only diagnosis. Hypospadias generally should not be coded if a normal 
female karyotype (46,XX) is reported.  
 
Epispadias is almost uniformly present with bladder exstrophy. In these cases, only the bladder 
exstrophy should be coded. 
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Reduction Deformity, Upper Limbs 
Description Complete or partial absence of the upper arm (humerus), lower 
arm (radius and/or ulna), wrist (carpals), hand (metacarpals), or 
fingers (phalanges). 
  
Inclusions Transverse limb reduction – Complete or partial absence of the 
distal (furthest from the body) structures of the arm in a 
transverse (cross-wise) plane at the point where the deficiency 
begins. Structures proximal to the point where the deficiency 
begins remain essentially intact. Types of transverse limb 
reductions include: 
 
Acheiria – Absence of a hand 
Adactyly – Absence of digits (fingers), excluding 
isolated missing thumb (see below) 
Aphalangia – Absence of phalanges. Fingers contain 3 
phalanges each. The thumb contains 2 phalanges. 
 
Amelia – Complete absence of the upper limb (humers, 
radius, ulna, wrist, hand and fingers). 
 
Hemimelia, Meromelia – Partial absence of a limb. 
This may refer to either transverse or longitudinal 
reductions. 
 
Oligodactyly – Fewer than 5 digits. 
 
Transverse terminal deficiency – Complete absence of 
the distal structures of the arm with the proximal 
structures intact. This term usually refers to reduction 
defects below the elbow. 
 
Congenital amputation, type not specified. 
 
Longitudinal limb reduction – Partial absence of the arm in 
parallel with the long axis of the arm. These may involve 
preaxial (on the thumb side), postaxial (on the fifth finger side), 





Isolated missing thumb 
Lobster claw hand 
Radial aplasia or hypoplasia 
 
Split-hand malformation (split hand/split foot 
malformation, SHSF) – A central longitudinal limb 
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reduction in which there is complete or partial absence 
of one or more of the central rays (second through 
fourth fingers and their associated metacarpal bones) of 
the hand. 
 
Ulnar aplasia or hypoplasia 
 
Intercalary limb reduction – Complete or partial absence of the 
proximal (closest to the body) or middle segments of the arm 
with all or part of the distal segment present.  
 
Phocomelia is a general term for any type of intercalary limb 
reduction.  
 
Reduction deformities of the upper limb not elsewhere coded 
or of unspecified type – Complete or partial absence of the arm 
that does not fall within the above categories or for which there 
is no specific description. 
  
Exclusions Shortened arms, forearms, hands, or fingers that have all of 
their component parts, including those that are part of a 




ICD-9-CM Codes 755.20 – 755.29 
  
CDC/BPA Codes 755.20 – 755.29 
  
Diagnostic Methods Limb reductions are usually easily recognized on physical 
examination at delivery. However, the exact nature of the 
defect may only be distinguished by x-ray, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they generally should not be included in 
surveillance data without postnatal confirmation. However, if it 
is possible to ascertain the degree of certainty of the prenatal 
diagnosis, this should factor into the decision as to whether or 
not to include an individual case in the surveillance data. Lack 
of visualization of a bone or limb on prenatal ultrasound does 
not necessarily mean that the bone or limb truly is not present. 
Live-born children who survive should always have 
confirmation of the defect postnatally before being included. 
  
Additional Information:  
The terminology for limb reduction deformities is often confusing. Some terms (such as 
“phocomelia”), have been misused and others (such as “ectrodactyly”), have been used for both 
longitudinal and transverse defects. If medical record review is available, it is important to look for 
a complete description of all structures that are present and absent in order to verify the diagnosis. 
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Preaxial refers to the side of the arm on which the thumb and radius are located. 
Postaxial refers to the side of the arm on which the fifth finger and ulna are located. 
 
Transverse limb reductions may be seen in association with amniotic bands. When both are 
present, both conditions should be coded. 
 
Rudimentary or nubbin fingers may be present at the distal end of a transverse limb reduction. 
Their presence alone does not change the classification of the defect as transverse.  
 
Joint contractures are commonly seen in association with longitudinal limb deficiencies. 
 
Intercalary reduction deformities (phocomelia) have been associated with the use of thalidomide 
during early pregnancy. However, thalidomide use may result in a number of other defects, 
including longitudinal reduction deformities. Intercalary defects also may occur without exposure 
to thalidomide.  
 
Reduction deformities are one of the defects that may be reported as part of: 
 
The VATER or VACTERL association, which also may include vertebral, cardiac and renal 
defects, TE fistula, and anal atresia. 
 
Poland anomaly, which also includes deficiency of the pectoralis muscle on the same side.  
 
Moebius anomaly (Oromandibular-Limb Hypogenesis Spectrum), which also may include a 
small mouth, small chin (micrognathia), small tongue (hypoglossia), sixth and seventh cranial 
nerve palsies. 
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Reduction Deformity, Lower Limbs 
Description Complete or partial absence of the upper leg (femur), lower leg 
(tibia and/or fibula), ankle (tarsals), foot (metatarsals), or toes 
(phalanges). 
  
Inclusions Transverse limb reduction – Complete or partial absence of the 
distal (furthest from the body) structures of the leg in a 
transverse (cross-wise) plane at the point where the deficiency 
begins. Structures proximal to the point where the deficiency 
begins remain essentially intact. Types of transverse limb 
reductions include: 
 
Adactyly – Absence of digits (toes)  
Aphalangia – Absence of phalanges. The smaller toes 
contain 3 phalanges each. The big toe contains 2 
phalanges. 
 
Amelia – Complete absence of the lower limb (femur, 
tibia, fibula, ankle, foot, and toes). 
 
Hemimelia, Meromelia – Partial absence of a limb. 
This may refer to either transverse or longitudinal 
reductions. 
 
Oligodactyly – Fewer than 5 digits. 
 
Transverse terminal deficiency – Complete absence of 
the distal structures of the leg with the proximal 
structures intact.  
 
Congenital amputation, type not specified 
 
Longitudinal limb reduction – Partial absence of the leg in 
parallel with the long axis of the leg. These may involve 
preaxial (on the big toe side), postaxial (on the fifth toe side), 





Fibular aplasia or hypoplasia 
 
Split-foot malformation (split hand/split foot 
malformation, SHSF) – A central longitudinal limb 
reduction in which there is complete or partial absence 
of one or more of the central rays (second through 
fourth toes and their associated metatarsal bones) of the 
foot.  
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Tibial aplasia or hypoplasia 
 
Intercalary limb reduction – Complete or partial absence of the 
proximal (closest to the body) or middle segments of the leg 
with all or part of the distal segment present.  
 
Phocomelia – A general term for any type of intercalary limb 
reduction.  
 
Reduction deformities of the lower limb not elsewhere coded or 
of unspecified type – Complete or partial absence of the leg 
that does not fall within the above categories or for which there 
is no specific description. 
  
Exclusions Shortened upper and/or lower legs, feet, or toes that have all of 
their component parts, including those that are part of a 




ICD-9-CM Codes 755.30 – 755.39 
  
CDC/BPA Codes 755.30 – 755.39 
  
Diagnostic Methods Limb reductions are usually easily recognized on physical 
examination at delivery. However, the exact nature of the 
defect may only be distinguished by x-ray, surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While these conditions may be identified by prenatal 
ultrasound, they generally should not be included in 
surveillance data without postnatal confirmation. However, if it 
is possible to ascertain the degree of certainty of the prenatal 
diagnosis, this should factor into the decision as to whether or 
not to include an individual case in the surveillance data. Lack 
of visualization of a bone or limb on prenatal ultrasound does 
not necessarily mean that the bone or limb truly is not present. 
Live-born children who survive should always have 
confirmation of the defect postnatally before being included. 
  
Additional Information:  
The terminology for limb reduction deformities is often confusing. Some terms (such as 
“phocomelia”) have been misused and others (such as “ectrodactyly”) have been used for both 
longitudinal and transverse defects. If medical record review is available, it is important to look for 
a complete description of all structures that are present and absent in order to verify the diagnosis. 
 
Preaxial refers to the side of the leg on which the big toe and tibia are located. 
Postaxial refers to the side of the leg on which the fifth toe and fibula are located. 
 
Transverse limb reductions may be seen in association with amniotic bands. When both are 
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present, both conditions should be coded. 
 
Rudimentary or nubbin toes may be present at the distal end of a transverse limb reduction. Their 
presence alone does not change the classification of the defect as transverse.  
 
Joint contractures are commonly seen in association with longitudinal limb deficiencies. 
 
Intercalary reduction deformities (phocomelia) have been associated with the use of thalidomide 
during early pregnancy. However, thalidomide use may result in a number of other defects, 
including longitudinal reduction deformities. Intercalary defects also may occur without exposure 
to thalidomide.  
 
Reduction deformities are one of the defects that may be reported as part of: 
 
The VATER or VACTERL association, which also may include vertebral, cardiac and renal 
defects, TE fistula, and anal atresia. 
 
Moebius anomaly (Oromandibular-Limb Hypogenesis Spectrum), which also may include a 
small mouth, small chin (micrognathia), small tongue (hypoglossia), sixth and seventh cranial 
nerve palsies. 
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Gastroschisis 
Description A congenital opening or fissure in the anterior abdominal wall 
lateral to the umbilicus through which the small intestine, part 
of the large intestine, and occasionally the liver and spleen, 
may herniate. The opening is separated from the umbilicus by a 
small bridge of skin, and the herniating organs are not covered 
by a protective membrane. Gastroschisis usually occurs on the 






ICD-9-CM Codes 756.79 
  
CDC/BPA Codes 756.71 
  
Diagnostic Methods Gastroschisis is usually easily recognized on physical 
examination after delivery. However, in some instances, it may 
be conclusively distinguished from omphalocele only at surgery 
or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Gastroschisis may be included when only diagnosed prenatally. 
However, it may be difficult to distinguish gastroschisis from 
omphalocele on prenatal ultrasound, and the terms sometimes 
are used interchangeably. If it is possible to ascertain the degree 
of certainty of the prenatal diagnosis and the location of the 
umbilical cord insertion relative to the abdominal defect, this 
should factor into the decision as to whether or not to include 
an individual case in the surveillance data. Live-born children 
who survive should always have confirmation of the defect 
postnatally before being included. In addition, the absence of 
gastroschisis on prenatal ultrasound does not necessarily mean 
that it will not be diagnosed after delivery. 
  
Additional Information:  
The distinction between gastroschisis and omphalocele is important because they have different 
etiologies and different implications for treatment and long-term survival.  
 
In gastroschisis, the umbilicus and cord are normal and separated from the abdominal wall defect 
by a small bridge of skin. The herniating organs are not covered by a protective membrane. 
However, they may appear matted and covered by a thick fibrous material as a result of prolonged 
exposure to amniotic fluid in utero.  
 
In omphalocele, abdominal organs herniate through the umbilicus into the umbilical cord. There is 
no bridge of skin between the abdominal wall defect and the umbilicus and cord. While the 
herniating organs are covered by a protective membrane, this may rupture before, during, or after 
delivery.  
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Gastroschisis may be one of the defects reported as part of the Limb-Body Wall complex. This is a 
disruption complex of the lateral body wall, which may also include limb reductions, neural tube 
defects, heart defects, and other anomalies. 
 
Maternal serum alphafetoprotein (MSAFP) and/or amniotic fluid alphafetoprotein (AFAFP) may 
be elevated with gastroschisis. However, these screening tests alone are not sufficient to diagnose 
the condition. 
 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 06/04 
 
Appendix 3.2     A3.2-56         Case Definition 
 
Omphalocele 
Description A defect in the anterior abdominal wall in which the umbilical 
ring is widened, allowing herniation of abdominal organs, 
including the small intestine, part of the large intestine, and 
occasionally the liver and spleen, into the umbilical cord. The 








ICD-9-CM Codes 756.79 
  
CDC/BPA Codes 756.70 
  
Diagnostic Methods Omphalocele is usually easily recognized on physical 
examination after delivery. However, in some instances, it may 
be conclusively distinguished from gastroschisis only at surgery 
or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Omphalocele may be included when only diagnosed prenatally. 
However, it may be difficult to distinguish omphalocele from 
gastroschisis on prenatal ultrasound, and the terms sometimes 
are used interchangeably. If it is possible to ascertain the degree 
of certainty of the prenatal diagnosis and the location of the 
umbilical cord insertion relative to the abdominal defect, this 
should factor into the decision as to whether or not to include 
an individual case in the surveillance data. Live-born children 
who survive should always have confirmation of the defect 
postnatally before being included. In addition, the absence of 
omphalocele on prenatal ultrasound does not necessarily mean 
that it will not be diagnosed after delivery. 
  
Additional Information:  
The distinction between omphalocele and gastroschisis is important because they have different 
etiologies and different implications for treatment and long-term survival.  
 
In omphalocele, abdominal organs herniate through the umbilicus into the umbilical cord. There is 
no bridge of skin between the abdominal wall defect and the umbilicus and cord. While the 
herniating organs are covered by a protective membrane, this may rupture before, during, or after 
delivery.  
 
In gastroschisis, the umbilicus and cord are normal and separated from the abdominal wall defect 
by a small bridge of skin. The herniating organs are not covered by a protective membrane. 
However, they may appear matted and covered by a thick fibrous material as a result of prolonged 
exposure to amniotic fluid in utero. 
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Omphalocele is one of the defects reported as part of the Omphalocele-Exstrophy-Imperforate 
Anus-Spina Bifida (OEIS) complex.  
 
Maternal serum alphafetoprotein (MSAFP) and/or amniotic fluid alphafetoprotein (AFAFP) may 
be elevated with omphalocele. However, these screening tests alone are not sufficient to diagnose 
the condition. 
 
In contrast to omphalocele, umbilical hernias are completely covered by normal skin. 
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Congenital Hip Dislocation 
Description Location of the head of the femur (bone of the upper leg) 
outside its normal location in the cup-shaped cavity formed by 
the hip bones (acetabulum). 
  
Inclusions Congenital hip dislocation, unilateral or bilateral 
Developmental dysplasia of the hip 
Teratologic hip dislocation 
  
Exclusions Flexion deformity/contracture of the hip 
Hip click  
Predislocation of the hip 
Preluxation of the hip 
Subluxation of the hip 
Unstable hip 
  
ICD-9-CM Codes 754.30,  754.31,  754.35 
  
CDC/BPA Codes 754.30 
  
Diagnostic Methods Hip dislocation may be suspected, and sometimes diagnosed, 
by physical examination. However, ultrasound or x-ray are the 
definitive diagnostic tests. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While this condition may be suspected by prenatal ultrasound, 
it should not be included in surveillance data without postnatal 
confirmation. In addition, the absence of hip dislocation on 
prenatal ultrasound does not necessarily mean that it will not be 
diagnosed after delivery. 
  
Additional Information:  
The terminology describing congenital hip dislocation is often confusing. An unstable hip, in 
which the femoral head may be moved in and out of the acetabulum on physical examination, 
often resolves spontaneously in young infants. A truly dislocated hip, in which the femoral head 
remains out of the acetabulum for a prolonged period, may result in acetabular deformity unless 
treated. Hence, the designation developmental dysplasia of the hip.  
The stability of the hip joint may be evaluated on physical examination. In the Barlow test, lateral 
pressure is applied to the hip with the knees flexed in an attempt to move the head of the femur out 
of the hip joint (acetabulum) into a dislocated position. In the Ortolani maneuver, a laterally 
dislocated femoral head is moved back into normal position in the acetabulum by applying 
pressure medially. The presence of either sign indicates a hip dislocation is present. However, their 
absence does not always mean that a dislocation is not present. In some instances, the femoral head 
may be fixed in a dislocated position and it may not be possible to move it in and out of the joint. 
Congenital hip dislocation occurs more frequently after footling or breech deliveries and is more 
common in females than males. It is most often an isolated condition, although hip dysplasia may 
occur with generalized skeletal abnormalities and in some genetic syndromes. Some instances of 
congenital hip dislocation are probably familial. 
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Diaphragmatic Hernia 
Description Incomplete formation of the diaphragm through which a 
portion of the abdominal contents herniate into the thoracic 
cavity. 
  
Inclusions Absence of the diaphragm 
Bochdalek hernia – Herniation through a defect in the 
posterolateral portion of the diaphragm. 
 
Diaphragmatic hernia, type not specified 
Hemidiaphragm 
 
Morgagni hernia – Herniation through a defect in the anterior 
portion of the diaphragm. 
 
Paraesophageal hernia – Herniation through a defect in the 
central portion of the diaphragm surrounding the esophagus. 
  
Exclusions Eventration of the diaphragm – Weakness in, or absence of, the 
muscles of the diaphragm which allows upward displacement 
of a portion of the abdominal contents. However, there is no 
true herniation of contents through the diaphragm into the 
thoracic cavity. 
  
ICD-9-CM Codes 756.6 
  
CDC/BPA Codes 756.610 – 756.617 
  
Diagnostic Methods While diaphragmatic hernia may be suspected by the clinical 
presentation of respiratory distress, feeding intolerance, and/or 
cardiac compromise, it may be conclusively diagnosed only 
through x-ray, contrast study of the bowel, CT or MRI scan, 
surgery, or autopsy. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Diaphragmatic hernia may be included in surveillance data 
when only diagnosed prenatally. However, if it is possible to 
ascertain the degree of certainty of the prenatal diagnosis, this 
should factor into the decision as to whether or not to include 
an individual case in the surveillance data. Live-born children 
who survive should always have confirmation of the defect 
postnatally before being included. 
  
Additional Information:  
Children with diaphragmatic hernia often have accompanying abnormalities of the heart, intestine, 
and lungs, including hypoplastic lungs, which result from the abnormal location of abdominal 
organs within the thoracic cavity during development. 
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Trisomy 13 
Description The presence of three copies of all or a large part of 
chromosome 13. 
  
Inclusions Patau syndrome 
Mosaic Patau syndrome 
Mosaic trisomy 13  
Translocation Patau syndrome 
Translocation trisomy 13 
Trisomy 13, not otherwise specified 
Trisomy D1, not otherwise specified 
  
Exclusions Balanced translocations involving chromosome 13 
  
ICD-9-CM Codes 758.1 
  
CDC/BPA Codes 758.10 – 758.19 
  
Diagnostic Methods Trisomy 13 may be suspected on physical examination. 
However, it may be diagnosed conclusively only through direct 
analysis of the infant’s chromosomes (karyotype). The 
chromosomes may be obtained from blood or tissue cells. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Trisomy 13 may be included when only diagnosed through 
direct analysis of fetal chromsomes obtained from 
amniocentesis, chorionic villus sampling (CVS), or 
percutaneous umbilical blood sampling (PUBS). However, 
when mosaic trisomy 13 is noted, the defect should be 
confirmed postnatally on a specimen obtained directly from the 
infant or fetus after birth (see below). 
  
Additional Information:  
When the two copies of chromosome 13 from one parent do not separate during egg or sperm 
formation, three copies of the entire chromosome 13 will be present in the fetus. In this instance, 
the karyotype is written as 47,XX,+13 or 47,XY,+13. This is the most common type of trisomy 13 
and is associated with advanced maternal age, particularly of 35 years or greater.  
 
Translocation trisomy 13 occurs when two separate copies of chromosome 13 are present, but a 
third copy of part of chromosome 13 is attached to another chromosome. In this instance, there are 
46 total chromosomes present, but 3 copies of part of chromosome 13.  
 
Mosaic trisomy 13 occurs when some, but not all, of the cells in the body contain three copies of 
all or a large part of chromosome 13. In this instance, the karyotype is written as 
46,XY/47,XY,+13, for example. Because the placenta may contain mosaic cell lines not present in 
the fetus, mosaic trisomy 13 diagnosed through chorionic villus sampling should always be 
confirmed by direct examination of fetal chromosomes from amniocentesis, PUBS, or preferably 
postnatal blood or tissue samples.   
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Approximately 80% of infants with trisomy 13 do not survive beyond the first month of life. Major 
malformations associated with trisomy 13 may include holoprosencephaly, microcephaly, 
meningomyelocele, cleft lip and/or palate, microphthalmia, retinal dysplasia, polydactyly, heart 
defects (most commonly a VSD), omphalocele, and genitourinary defects, among others. Among 
children who survive the newborn period, severe developmental delay is virtually always present 
as may be deafness, visual impairment, minor motor seizures, and apneic spells.  
 
Infants with mosaic trisomy 13 may be less severely affected with variable degrees of 
developmental delay and longer survival. Infants with partial trisomy for the proximal segment of 
chromosome 13 (13pter→q14) exhibit a nonspecific pattern of abnormalities with near-normal 
survival. Approximately 25% of infants with partial trisomy for the distal segment of chromosome 
13 (13q14→qter) die during early postnatal life. 
 
Children who survive exhibit severe developmental delay and specific abnormalities.  
 
Major malformations that occur with trisomy 13 in the same infant should be coded separately, as 
their presence may varies among affected individuals. 
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Down Syndrome (Trisomy 21) 
Description The presence of three copies of all or a large part of 
chromosome 21. 
  
Inclusions Down syndrome 
Mosaic Down syndrome 
Mosaic trisomy 21  
Translocation Down syndrome 
Translocation trisomy 21 
Trisomy 21, not otherwise specified 
  
Exclusions Balanced translocations involving chromosome 21 
“Downs facies” without associated trisomy 21. 
  
ICD-9-CM Codes 758.0 
  
CDC/BPA Codes 758.00 – 758.09 
  
Diagnostic Methods Down syndrome may be suspected on physical examination. 
However, it may be diagnosed conclusively only through direct 
analysis of the infant’s chromosomes (karyotype). The 
chromosomes may be obtained from blood or tissue cells. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Down syndrome may be included when only diagnosed 
through direct analysis of fetal chromsomes obtained from 
amniocentesis, chorionic villus sampling (CVS), or 
percutaneous umbilical blood sampling (PUBS). However, 
when mosaic trisomy 21 is noted, the defect should be 
confirmed postnatally on a specimen obtained directly from the 
infant or fetus after birth (see below). 
  
Additional Information:  
When the two copies of chromosome 21 from one parent do not separate during egg or sperm 
formation, three copies of the entire chromosome 21 will be present in the fetus. In this instance, 
the karyotype is written as 47,XX,+21 or 47,XY,+21. This is the most common type of trisomy 21 
and is associated with advanced maternal age, particularly of 35 years or greater.  
 
Translocation trisomy 21 occurs when two separate copies of chromosome 21 are present, but a 
third copy of part of chromosome 21 is attached to another chromosome. In this instance, there are 
46 total chromosomes present, but 3 copies of part of chromosome 21.  
 
Mosaic trisomy 21 occurs when some, but not all, of the cells in the body contain three copies of 
all or a large part of chromosome 21. In this instance, the karyotype is written as 
46,XY/47,XY,+21, for example. Because the placenta may contain mosaic cell lines not present in 
the fetus, mosaic trisomy 21 diagnosed through chorionic villus sampling should always be 
confirmed by direct examination of fetal chromosomes from amniocentesis, PUBS, or preferably 
postnatal blood or tissue samples.   
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Infants with Down syndrome have a typical appearance and other characteristics, including 
decreased muscle tone (hypotonia), a weak startle (Moro) reflex, hyperflexible joints, a flattened 
facial profile, upslanting eyes, abnormally shaped external ears (auricles), loose skin on the back of 
the neck, dysplasia of the pelvic bones, incurving of the fifth finger (clinodactyly), and a single 
transverse crease in the palm of the hand (Simian crease). Developmental delay is virtually always 
present. Major malformations associated with Down syndrome include heart defects (most notably 
endocardial cushion defects), gastrointestinal defects, and vertebral abnormalities, among others.  
 
Major malformations that occur with Down syndrome in the same infant should be coded 
separately, as their presence may varies among affected individuals. 
 
Mongolism is an outdated term for Down syndrome. 
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Trisomy 18 
Description The presence of three copies of all or a large part of 
chromosome 18. 
  
Inclusions Edwards syndrome 
Mosaic Edwards syndrome 
Mosaic trisomy 18  
Translocation Edwards syndrome 
Translocation trisomy 18 
Trisomy 18, not otherwise specified 
  
Exclusions Balanced translocations involving chromosome 18 
  
ICD-9-CM Codes 758.2 
  
CDC/BPA Codes 758.20 – 758.290 
  
Diagnostic Methods Trisomy 18 may be suspected on physical examination. 
However, it may be diagnosed conclusively only through direct 
analysis of the infant’s chromosomes (karyotype). The 
chromosomes may be obtained from blood or tissue cells. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
Trisomy 18 may be included when only diagnosed through 
direct analysis of fetal chromsomes obtained from 
amniocentesis, chorionic villus sampling (CVS), or 
percutaneous umbilical blood sampling (PUBS). However, 
when mosaic trisomy 13 is noted, the defect should be 
confirmed postnatally on a specimen obtained directly from the 
infant or fetus after birth (see below). 
  
Additional Information:  
When the two copies of chromosome 18 from one parent do not separate during egg or sperm 
formation, three copies of the entire chromosome 18 will be present in the fetus. In this instance, 
the karyotype is written as 47,XX,+18 or 47,XY,+18. This is the most common type of trisomy 18 
and is associated with advanced maternal age, particularly of 35 years or greater.  
 
Translocation trisomy 18 occurs when two separate copies of chromosome 18 are present, but a 
third copy of part of chromosome 18 is attached to another chromosome. In this instance, there are 
46 total chromosomes present, but 3 copies of part of chromosome 18.  
 
Mosaic trisomy 18 occurs when some, but not all, of the cells in the body contain three copies of 
all or a large part of chromosome 18. In this instance, the karyotype is written as 
46,XY/47,XY,+18, for example. Because the placenta may contain mosaic cell lines not present in 
the fetus, mosaic trisomy 18 diagnosed through chorionic villus sampling should always be 
confirmed by direct examination of fetal chromosomes from amniocentesis, PUBS, or preferably 
postnatal blood or tissue samples.   
 
Most pregnancies affected with trisomy 18 result in spontaneous abortion. Approximately 50% of 
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live-born infants with trisomy 18 do not survive beyond the first week of life. Only 5% to 10% 
survive beyond the first year of life. Major malformations associated with trisomy 18 may include 
microcephaly, micrognathia, cleft lip and/or palate, heart defects, omphalocele, and renal defects, 
among others. Minor anomalies associated with trisomy 18 may include low-set malformed 
auricles (external ears), overlapping of the index and fifth fingers over the third and fourth fingers, 
absent distal crease on the fifth finger, hirsutism (excess hair) of the forehead and back, lateral 
deviation of the hands, a hypoplastic thumb, a single transverse palmar crease, and rocker-bottom 
feet, among others. Developmental delay is virtually always present, as may be hypertonicity, a 
weak cry, growth retardation, hypoplasia of skeletal muscle and subcutaneous fat, and clenched 
hands.  
 
Infants with mosaic trisomy 18 may be less severely affected, with variable degrees of 
developmental delay and longer survival. Infants with trisomy of only the short arm of 
chromosome 18 (partial trisomy 18) exhibit a nonspecific pattern of abnormalities with mild to no 
developmental delay. Infants with trisomy of the short arm, centromere, and proximal third of the 
long arm of chromosome 18 exhibit features of trisomy 18 but not the entire spectrum of 
abnormalities. Infants with trisomy of only one-third to one-half of the long arm of chromosome 
18 exhibit features of trisomy 18 but have longer survival and less severe developmental delays. 
 
Major malformations that occur with trisomy 18 in the same infant should be coded separately, as 
their presence varies among affected individuals. 
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Fetal Aclohol Syndrome (FAS) 
Description A spectrum of abnormalities resulting from exposure to alcohol 
in utero. While the specific abnormalities vary among 
individuals, the hallmarks include growth deficiency, 
microcephaly, facial dysmorphisms, and neurodevelopmental 
abnormalities. 
  
Inclusions Fetal alcohol syndrome (FAS) 
  
Exclusions Fetal alcohol effects/facies, without diagnosis of FAS 
  
ICD-9-CM Codes 760.71 
  
CDC/BPA Codes 760.71 
  
Diagnostic Methods While fetal alcohol syndrome may be suspected from a history 
of maternal alcohol use during pregnancy, the condition may be 
conclusively diagnosed only through direct examination of the 
infant by a physician (usually a dysmorphologist or 
developmental specialist) familiar with the spectrum of FAS 
abnormalities. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
While fetal alcohol syndrome may be suspected from a history 
of maternal alcohol use during pregnancy, the condition should 
not be included in surveillance data without postnatal 
confirmation. 
  
Additional Information:  
A number of minor malformations may be present with fetal alcohol syndrome, most notably 
hypoplasia of the maxillary bone (middle) of the face, and a thin upper lip with smooth philtrum 
(crease). However, these are often subtle in the newborn and may not be recognized until later in 
childhood. Older children with FAS may manifest poor coordination, irritability, hyperactivity, and 
neurodevelopmental abnormalities. 
 
Fetal alcohol syndrome is the extreme of a spectrum of effects on growth and development 
resulting from alcohol exposure in utero. At low levels of exposure, the only apparent effect may 
be a reduction in birth weight. The clinical features and neurodevelopmental abnormalities become 
increasingly prominent with increasing levels of exposure. 
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Amniotic Bands 
Description Strands of tissue that float in the amniotic fluid as a 
consequence of tears or ruptures in the amniotic membrane 
which surrounds the fetus during development. 
  
Inclusions Amniotic bands 
Amniotic band sequence, syndrome, or disruption complex 
Amniotic rupture sequence 
Streeter bands 
Constriction rings – Soft tissue depressions or grooves 




ICD-9-CM Codes NA 
  
CDC/BPA Codes 658.80 
  
Diagnostic Methods Structural defects resulting from amniotic bands usually are 
readily apparent on physical examination after delivery. 
However, the fact that they are a consequence of amniotic 
bands may not be apparent unless a remnant of an amniotic 
strand is present or amniotic bands were noted on prenatal 
ultrasound. 
  
Prenatal Diagnoses Not 
Confirmed Postnatally 
When amniotic bands are seen on prenatal ultrasound, their 
presence should be correlated with any structural defects noted, 
and the guidelines for including those defects when only 
diagnosed prenatally should be followed. Live-born children 
who survive should always be examined for evidence of 
amniotic bands postnatally. In addition, the absence of amniotic 
bands on prenatal ultrasound does not necessarily mean that 
they are not truly present. 
  
Additional Information:  
Amniotic bands may be present in the amniotic sac without impacting the fetus. When noted as an 
isolated condition without associated structural defects, they should not be coded.  
 
Structural defects that may occur as a result of amniotic bands include: 
Pseudosyndactyly (digits compressed together by an encircling band)  
Distal limb amputation, hypoplasia, lymphedema, or deformation  
Oral clefts  
Encephalocele  
Anencephaly  
Other disruptive defects of the skull 
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Appendix 3.3 
Examples of Conditions Considered to Be Minor Anomalies2 
Eye 
 Epicanthal folds 
 Iris freckles, Brushfield spots 
 Upward or downward palpebral slant 
 
Ear 
 Darwinian point or tubercle 
 Thickened or excessively folded helix 
 Lack of helical folding 
 Creased, notched, or bifid ear lobe 
 Lop, cup-shaped, or retroverted ear 
 Preauricular sinus, cyst, pit, or skin tag 
 
Head, Face and Neck 
 Flat occiput 
 Frontal bossing 
 Flat brow 
 Flat or prominent bridge of nose 
 Anteverted nostrils 
 Long nasal septum 
 Webbed or redundant neck skin 
 
Hands and Feet  
 Single or horizontal palmar crease 
 Clinodactyly 
 Tapered fingers 
 Overlapping digits 
 Webbed or widely spaced 2nd and 3rd toes  
 Prominent heel 
 
Other 
 Sacral dimples 
 Nevi  
 Cafe-au-lait spots 
 Mongolian spots 
 Accessory nipples 
 Umbilical hernia 
 Vaginal tag 
 Single umbilical artery
                                                 
2 This is not a comprehensive list. The exact abnormalities considered to be minor defects may vary among experts. 
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Appendix 3.4 







 Blue sclera 
 
 Fused eyelids 
 
 Absent or decreased ear cartilage 
 
 Patent foramen ovale 
 
 Patent ductus arteriosus 
 
 Hypoplastic lungs 
 
 Small or hypoplastic nipples 
 
 Hypoplastic labia majora 
 
 Undescended testicles 
 
 Inguinal hernia 
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4.1  Introduction 
The potential data sources available to birth defects programs contain a wide variety of information. Each 
item of information a birth defects program collects requires staff time to locate, abstract, code, and 
evaluate, as well as computer space to store it. Thus, due to limited resources, a birth defects program must 
be efficient in the scope of the information it collects and the manner in which the information is collected 
and stored. 
 
In this chapter we discuss a number of issues relating to the data variables that comprise a birth defects 
surveillance system. In Section 4.2, for example, we discuss the criteria that should be considered in 
selecting the variables that will be collected by a surveillance system. In Section 4.3, we present the three 
possible origins of surveillance data variables; that is, variables may be abstracted, derived or created. 
Other topics include possible formats for data variables (Section 4.4), logic checks that can be used to 
ensure data fall within an expected range (Section 4.5), sources for data variables (Section 4.6), and issues 
concerning a subset of variables related to birth defects risk factors (Section 4.7). In Section 4.8, we 
introduce two tables that summarize core (Table 4.1) and recommended (Table 4.2) data variables for a 
birth defects surveillance system. Additional detail on each of these core and recommended variables is 
provided in Appendices 4.1and 4.2, respectively. 
 
It is our hope that the information in this chapter of The Surveillance Guidelines will promote and guide 
standardization of data elements across birth defects surveillance programs. Using standard data elements 
is particularly important when aggregating data for regional or national analysis. Standardization allows 
and supports comparisons and collaborations between states.  
 
Whether a surveillance program is based on active or passive case ascertainment, our recommendation is 
that vital records information or copies (including birth, death or fetal death certificates as appropriate) be 
obtained. This allows the collection of some data using sources from which population-based demographic 
information can also be obtained.  
 
Note that we are indebted to Lynberg and Edmonds (1994) for much of the information in this chapter. 
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4.2  Criteria to be Considered in Selection of Data Variables 
A birth defects program should consider a number of different criteria when deciding which variables to 
collect. These include type of case ascertainment, program objectives, and data characteristics. Each of 
these criteria is discussed further below. The criteria considered in compiling the lists of core and 
recommended variables are summarized for each variable under the heading ‘Justification’ in 
Appendices 4.1 and 4.2. 
4.2.1  Type of Case Ascertainment 
The case identification methods used by a surveillance program may place constraints on the data variables 
collected. The available data source(s) for program variables are determined primarily by these methods. 
For example, birth certificate files usually offer limited data for diagnostic confirmation of the birth defect 
or a precise description of the defect. An infant’s medical record, other than the newborn record, is not 
likely to include data on the prenatal care received by the mother (see Chapter 6 on Case Ascertainment 
Methods). 
4.2.2  Program Objectives 
A surveillance program should limit the information collected to those items needed to fulfill its stated 
objectives. However, it can be difficult to determine what constitutes this essential information. Often 
individuals, groups, or organizations that utilize surveillance information may request data on variables 
that are not really needed and will not be used. One guideline a surveillance program might follow is that 
information should not be collected if it does not serve at least one programmatic objective. 
 
CDC defines surveillance as “the ongoing systematic collection, analysis, and interpretation of health data 
essential to the planning, implementation and evaluation of public health practice, closely integrated with 
the timely dissemination of these data to those who need to know” (Centers for Disease Control and 
Prevention, 1988). Under this definition, it is clear there are a number of functions and objectives for 
which a birth defects program might need to collect data:  
 Descriptive epidemiology and monitoring. Data can be examined to determine and describe the 
distribution of a disease (condition) within a population along the parameters of place, person, and 
time. Monitoring offers quantitative estimates of the magnitude of the disease.  
 Research. Data can be used to test hypotheses or in planning research to learn the causes of a 
disease. 
 Service/planning. Increasingly, surveillance programs are using information on newly identified 
children with birth defects to refer them for services. These include specialized medical care, 
educational and early intervention programs, and genetic counseling.  Data can also be applied to 
evaluate services and prevention measures within a population. Knowledge about the disease or 
condition and changes in the population can assist in optimizing available resources and services. 
 Linkage. Variables may be used to link to other databases such that data in those databases may be 
associated at the case level to complement and enrich case-specific data. Linkage is also an 
essential surveillance management tool needed to identify and consolidate duplicates. 
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4.2.3  Data Characteristics 
Among the important data characteristics a surveillance program should consider are availability, 
consistency, accuracy, uniqueness, definability, collectability, and comparability. We discuss each of these 
in turn below. 
 Availability. Data must be retrievable from the data sources and be available to the birth defects 
program. Many data variables are collected and stored at data sources in clinical and administrative 
databases, facilitating availability and retrievability. In most cases, information should only be 
collected if it is consistently available. This is particularly true if the information is to be used for 
statistical analyses or for identifying or contacting case families. If information can be found only 
in a small portion of the data sources, then staff will spend considerable time looking for 
unavailable information. The birth defects program may want to either limit collection of such 
information or work to identify a data source where the same information is consistently available. 
An exception to this may be where the information is important even if it is only occasionally 
found in the data sources (e.g., the fact that the infant is in foster care or has been placed for 
adoption). However, as noted before, this information may be difficult to find and time-consuming 
to collect. 
 Consistency. It is important that the information assembled within the surveillance system has a 
consistent meaning from report to report. When obtaining information from a range of data 
sources, it is essential to have a usable level of consistency from source to source. This is 
especially important for passive data collection and data mining. Simple issues, such as field 
content and even field size, can significantly affect the comparability and usefulness of the data. 
Coding rules and practices are special areas of concern.  
 Accuracy. The information collected should be accurate. If the information is of questionable 
veracity, then it should not be collected. Second-hand information found in medical records may 
be incomplete or inaccurate. If information such as medication use and exposures is important, it 
should be collected from a reliable source, such as through direct contact with the mother, rather 
than from medical records.  
 Uniqueness. Programs should avoid the collection of redundant information. Information should 
not have to be recorded in more than one field. For example, if the infant or fetus delivery date and 
the mother’s date of birth are collected, then the mother’s age at delivery does not need to be 
collected. 
 Definability. There should be clear definitions for each of the data variables a birth defects 
program collects.  
 Collectability. The data variables should lend themselves to easy abstraction. This is a potential 
problem with complex or subjective information. If it takes an excessive amount of time to track 
down and collect the information, or if there is a high degree of inter-staff variability in how the 
information is collected, then the information recorded in the birth defects program’s database will 
be of dubious quality and reliability (Horwitz and Yu, 1984; Demlo et al., 1978). In addition, 
extensive efforts may be necessary for quality control. 
 Comparability. The birth defects program may want to consider whether other birth defects 
programs have access to the same sources and types of data. If the program uses a unique data 
source or collects a unique data variable that other birth defects programs do not, then the program 
may not be able to compare its data to those of other programs. This may be of limited importance, 
however, if the data are being collected to meet specific programmatic objectives, where 
comparison between different states or programs is unimportant. 
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4.3  The Origins of Data Variables 
Data variables may be abstracted, derived, or created. 
 Abstracted data variables. These are data that are available only from the data sources, and the 
data sources must supply them. 
 Derived data variables. Some data variables are not collected directly from data sources but are 
rather derived from other information collected from the data sources, e.g., census tract numbers, 
standardized geographic tables, disease codes. 
 Created data variables. Some data variables may need to be created by the birth defects program, 
e.g., unique case and staff IDs. 
 
Some data variables may fall into more than one of the above categories. For example, if the mother’s age 
at delivery is not available from the data sources, it may be derived using the date of delivery and the 
mother’s date of birth. The origins of each of the core and recommended variables are summarized under 
the heading ‘Source’ in Appendices 4.1 and 4.2. 
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4.4  The Formats of Data Variables 
Data may be stored in a computer database in a variety of formats, including as a numerical field, a date 
field, a text field, a checkbox, or a coded data field. Each of these formats is briefly described below. The 
format for each of the core and recommended variables is also summarized under the heading ‘Type’ in 
Appendices 4.2 and 4.2. 
 Numerical field. A field that includes only numbers. 
 Date field. A field that includes only dates, which are comprised of month, day, and year in a 
variety of orders and combinations. 
 Text field. A field that can contain letters, numbers, and punctuation. Text fields are often of a 
fixed width. Text fields of infinite width are often called Amemo@fields. 
 Checkbox. A field that contains only two options – yes/no, on/off. 
 Coded data field. Data may be collected and stored as they appear in the data source, or they may 
be ‘coded’. A code may contain numbers or letters or both. Whether a birth defects program 
collects and stores data as coded or not depends on the types of data, as well as on potential uses. 
If a birth defects program plans to use a field for analysis, then it is important that the field be easily coded 
or categorized, permitting ready analysis rather than having to sort through a large collection of free-form 
text. This is because information such as race/ethnicity, diagnoses, and conditions can be described in a 
number of different ways. For example, a person may be described as ‘African-American’ or ‘black’. A 
‘cleft lip’ may also be described as a ‘lip cleft’ or a ‘harelip’. 
 
Coding eliminates the problem of having to sort through a variety of differing descriptions. It allows for 
timely and efficient analysis of data and referral of cases. Coding also enables researchers to know that 
they are talking about the same thing, and it allows for comparability between different birth defects 
programs using the same or comparable coding systems. 
 
Whenever possible, a birth defects program should use coding systems consistent or compatible with those 
used by other groups, particularly other birth defects programs, thus allowing for efficient comparison of 
data. This applies not only to diagnostic codes but also to characteristics such as maternal race and 
ethnicity. 
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4.5  Data Variable Logic Checks 
Errors may occur in the data collection by a birth defects program, either because of errors in data listed in 
the data source or because of errors in abstraction. A birth defects program should have some method to 
identify and correct errors (see Chapter 7 on Data Quality Management). One means of identifying and 
correcting errors is through logic checks that ensure data occur within expected ranges. 
 
Many of the core variables in a birth defects surveillance system have a limited number of options or 
ranges of values. For example, a gestational age of 75 weeks is highly unlikely to occur. And other 
variables may have certain logical relationships to one another. For example, the mother’s date of birth 
must always be earlier than the infant’s date of birth. 
 
Suggested logic checks for each of the core and recommended variables are summarized under the heading 
‘Checks’ in Appendices 4.1 and 4.2. 
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4.6  Data Variable Location 
A birth defects surveillance program may have access to a variety of data sources and will collect data on a 
number of different variables. Clearly, the same variable may be available from several sources. 
Abstracting data from a variety of sources allows for greater thoroughness in data collection. If a variable is 
missing in one data source, it may be available in another source.  
 
Staff collecting data should know where a given data variable is likely to be found, as well as the 
prioritization of sources for those variables retrievable from multiple data sources, since data sources may 
disagree as to the value for a particular variable. For example, the infant’s delivery medical record and the 
birth certificate might record different values for birth weight. A birth defects program should prioritize the 
data sources for particular variables. In the above instance, for example, a birth defects program may 
decide that the birth weight in the medical record takes precedence over the birth weight from a birth 
certificate. 
 
For each of the core and recommended variables, the data source – as well as the location within the data 
source where the variable is most likely to be consistently found – are summarized under the heading 
‘Location’ in Appendices 4.1 and 4.2. 
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4.7  Risk Factor Variables 
Risk factors in birth defects include:  conditions, illnesses, or complications during pregnancy, labor, or 
delivery 
 
Selected conditions, such as maternal diabetes and thyroid disease, have been associated with increased 
risk for certain birth defects (Becerra et al., 1990; Khoury et al., 1989). Information on conditions and 
complications during pregnancy and delivery may be useful for making syndromic classifications or 
identifying causality of birth defects, such as diabetic embryopathy. 
 
However, there are a large number of conditions and complications possible during pregnancy and 
delivery, and birth defects programs could create lists of dozens to hundreds of them. Such long lists would 
require additional computer storage space and training of field staff regarding where to find the 
information and how to collect it. Even then, confusion may ensue over which conditions and 
complications to abstract and subjective differences between staff in their abstraction of this information. 
Moreover, the information in the data sources commonly available to birth defects programs may not 
necessarily be consistent or accurate (Olson et al., 1997). 
 
For all of these reasons, birth defects surveillance programs should give careful consideration to the 
potential thoroughness and usefulness of routine data collection regarding risk factors as relevant to their 
goals and objectives. In general, programs are more likely to obtain useful information on conditions and 
complications during pregnancy and delivery through contact with parents, as is done in case-control 
research studies, than through medical records abstraction. 
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4.8  Data Variable Tables 
In the late 1980s, before creation of the National Birth Defects Prevention Network, Larry Edmonds of the 
Centers for Disease Control and Prevention (CDC) – along with F. John Meaney of Arizona and Susan 
Panny of Maryland and others – collaborated on development of a set of core data items relevant to birth 
defects surveillance (Edmonds et al., 1988), based on an earlier list developed by CDC’s National Center 
for Health Statistics. We used the list developed by Edmonds et al. as the foundation for developing the 
current list of data variables that the NBDPN recommends for birth defects surveillance programs, adding 
a number of different variables in order to reflect the fact that birth defects surveillance programs have 
evolved considerably since the 1980s into programs with a variety of objectives and multiple areas of 
interest.  
 
The data variables in Tables 4.1 and 4.2 (as well as in their corresponding appendices) are categorized as 
to whether they are infant, maternal, paternal, or contact information variables. For each data variable, we 
also note in Tables 4.1 and 4.2 the usefulness of that data item relative to a program’s specific objectives, 
which may include descriptive epidemiology and monitoring, research, service and planning, and linkage 
capability (see Section 4.2.2. for further discussion of program objectives).  
 
To provide a sense of the relative importance of the data variables for a new or expanding surveillance 
program, we have further distinguished between minimum (or core) variables (Table 4.1 and Appendix 
4.1) and recommended variables (Table 4.2 and Appendix 4.2).  
 
 Minimum (core) variables are those that are considered necessary to fulfill the most basic 
programmatic objectives and that also meet most or all of the supplemental criteria discussed 
earlier in this chapter.  
 
 Recommended variables are those that have the potential to enhance surveillance capability or to 
support broader programmatic objectives.  
 
By glancing down the column for a specific programmatic objective (e.g., ‘research’), the reader can 
determine – based on the relevant check marks – which elements are considered ‘core’ and which other 
data elements are ‘recommended’ to support a given program objective. These data variables can be 
abstracted using a minimum number of data sources, including maternal records, infant records, and vital 
records. Birth defects programs that use the passive case ascertainment approach will find the vital record 
particularly useful as a data source for many of the maternal core data variables.  
 
After reviewing these lists, birth defects surveillance staff may also wish to add further data variables they 
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Table 4.1 
Minimum (Core) Data Variables   







Unique ID     
Date of Pregnancy Outcome     


























Source of Report     
Medical Record Number(s)     
Vital Record Certificate 
Number 
    
Place of Pregnancy Outcome     
Pregnancy Outcome      
Birth Weight     
Plurality     
Gestational Age     
Diagnosis Code     
Contact Information 
Name of Responsible Party     
Address of Responsible 
Party 
    
Telephone Number of 
Responsible Party  
    
Mother 
Mother’s Date of Birth     
Mother’s Race     





















Mother’s Residence At Time 
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Table 4.2 
Recommended Data Variables 
 








Text Description of Birth 
Defect  
    
Date of Death     
Birth Length     
Apgar Score     
Birth Order     
Cytogenetic Analyses 
Performed  
    
Diagnostic Tests and 
Procedures Performed 
    
Autopsy Performed     
Physicians of Record     
Mother 
Date of Last Menstrual 
Period (LMP) 
    
Date of Ultrasound     
Gestational Age at 
Ultrasound 
    
Mother’s Medical Record 
Number(s) 
    
Prenatal Diagnosis     
Mother’s Social Security 
Number 
    
Census Tract of Maternal 
Residence at Pregnancy 
Outcome 
    
Mother’s Telephone 
Number 
    
Mother’s Education     
Prior Pregnancy History     
Prenatal Care     
Father 
Father’s Date of Birth     
Father’s Name     
Father’s Education     
Father’s Race     
Father’s Ethnicity     
Father’s Social Security #     
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Appendix 4.1 
Descriptions of Minimum (Core) Data Variables 
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Contact Information  
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Mother  
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Appendix 4.1 
Descriptions of Minimum (Core) Variables 
Format for Variable Descriptions 
 
Variable Name Name of data collection variable 
 
Definition Definition of data collection variable 
 
Justification Reason the birth defects program may want to include variable in 
its database 
 
Source Where variable comes from – abstracted, derived, created 
 
Location Data sources and location within data sources where variable is 
most likely to be consistently found 
 
Type How variable should be stored – text, number, date, code (letters 
and/or numbers), checkbox 
 
Checks Any limits, ranges, or other criteria the variable should meet 
 
Comments Other notes or comments about the variable 
 
Options Recommended options for the variable 
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Variable Name Unique ID 
Definition Identification code or number; a code or number that uniquely 
identifies each case or record 
Justification With a unique ID code, the birth defects program can refer to a 
particular case more easily than having to refer to a set of other 
variables. For example, it is easier to refer to an abstract with ID 
1234567 than to an abstract of John Doe, date of birth 04/27/1999, 
born to mother Jane Doe. 
 
The ID permits easy linkage between multiple data sets as long as each 
table contains the ID as one of its fields. This is essential for data 
transfer and processing, so that data for a particular case do not get 
mixed up with data from other cases. This field permits linking 
multiple case reports for individual children. 
Source Created by the registry as cases are added. 
Location N/A 
Type Code 
Checks Every individual in the database should have a unique ID. 
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Variable Name Date of pregnancy outcome 
Definition Date of delivery or end of the index pregnancy 
Justification In conjunction with other fields, such as mother’s last name, this field 
helps to identify a case uniquely. It is useful to researchers and social 
workers in verifying that they are referring to the pregnancy of interest 
when contacting mothers who may have had other pregnancies. 
 
The birth defects program may require that, for live births, a diagnosis 
be made within a certain time period after the date of delivery (e.g., 
within one year) or by a particular age (e.g., prior to age 6). The date of 
delivery is necessary in order to determine whether the diagnosis was 
made within the time limit. 
 
Secular trends have been reported for certain birth defects (Nielsen et 
al., 2000; O’Leary et al., 1996; Centers for Disease Control and 
Prevention, 1992). The birth defects program can use the date of 
delivery in order to produce statistics and reports by delivery year and 
to examine secular trends in birth defects. 
 
Cluster investigations are based on a defined diagnosis, geographical 
area, and time period. Knowing the delivery date allows investigators 
to determine which cases qualify to be included in a particular 
investigation. 
Source Abstracted 
Location • Mother’s delivery medical record (labor and delivery record) 
• Infant’s medical record (face sheet, labor and delivery record, birth 
certificate worksheet) 
• Vital record 
Type Date 
Checks Every record must have a pregnancy outcome date, except in cases of 
prenatal diagnosis where the pregnancy has not ended yet. The 
pregnancy outcome date should be after the mother’s and father’s date 
of birth, date of last menstrual period, and date of conception; on or 
after any prenatal diagnostic procedure date or prenatal ultrasound date; 
and on or before a postnatal procedure date. 
Comments Date of pregnancy outcome can be: date of birth, date of fetal demise, 
or date pregnancy ends.  
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Variable Name Sex 
Definition Sex of the infant or fetus 
Justification Birth defect risk may be associated with sex (Whiteman et al., 2000). 
The birth defects program can use the sex of the infant or fetus in order 
to evaluate differences in birth defect rates by sex. 
Source Abstracted 
Derived (from the karyotype) 
Location • Mother’s delivery medical record (labor and delivery record) 
• Infant’s medical record (face sheet, labor and delivery record, birth 
certificate worksheet) 
• Vital record 
Type Code 
Checks Every record should have sex recorded. 
Comments If a karyotype was performed, the sex should match the karyotype, 
except in rare cases of such discordances as XY females and XX males. 
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Variable Name Infant’s name 
Definition Name of infant or fetus 
Justification Field staff can use the infant’s name and date of birth or pregnancy 
outcome date to locate medical records.  
 
The birth defects program will use the name to unduplicate the reported 
cases and may employ the infant’s name in addition to other fields to 
link to other data sets, such as vital records. 
 
The infant’s name is helpful when referring the family to social work, 
treatment, and prevention agencies. 
Source Abstracted 
Location • Infant’s medical record (face sheet, birth certificate worksheet) 
• Vital record 
Type Text 
Checks If the infant’s last name is the same as the father’s or mother’s last 
name, or a combination of the two, the spelling should usually match. 
Comments This variable may be collected as a single field or multiple fields. 
Separate fields for first, middle, last name, and suffix are recommended 
to improve unduplication and record linkage success. Individual fields 
of up to 25 digits each should be considered to avoid truncated names. 
This variable should include at least the infant’s first and last name and 
may include the infant’s middle name and any suffixes. An infant may 
be given more than one name or alias, sometimes referred to as “also 
known as” or AKA. The birth defects program may want to record all 
of the names, for easier linkage with other databases, to prevent 
duplication of cases in the database and to remain current with name 
use. 
 
Fetuses resulting from fetal deaths and elective terminations often do 
not have names. The birth defects program should consider using the 
surname of the mother and inserting a standard first name (e.g., fetus) 
so that name data fields are complete in the database. 
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Variable Name Source of report 
Definition Any data source where information was obtained or where a case report 
originated. 
Justification The source of report allows the birth defects program to identify where 
information in a case abstract comes from. This is important for 
resolving data edit issues, for confirming the data, and for conducting 
audits of facility reporting. 
 
The data source fields permit the birth defects program to evaluate the 
usefulness of utilizing specific facilities as data sources. 
Source Abstracted 
Location Any data source pertinent to program objectives 
Type Code, with allowance for multiple sources 
Checks This field should always be filled out and should be a valid code. 
Comments There can be multiple data sources for a given case. For example, an 
infant may be identified with a birth defect at the delivery hospital, 
tertiary care hospital, cytogenetics laboratory, etc. (see also Chapter 6 
on Case Ascertainment Methods). 
Options It is useful to maintain a list of potential data sources and standard 
codes (hospitals, clinics, laboratories, autopsy, etc.) unique to each 
program. 
 
Variable Name Medical record number(s) 
Definition Medical record number(s) used by the source from which the 
information was obtained. 
Justification A medical record number allows facilities to retrieve records easily. 
Although it may be possible to locate medical records using the 
patient’s name and date of birth, the birth defects program may have a 
name different than that recorded at the data source. 
Source Abstracted 
Location • Infant’s medical record (face sheet) 
Type Code 
Comments Medical record numbers are not the same as visit, service, or encounter 
numbers. Although not standard practice, multiple ‘real’ medical 
record numbers may be assigned to the same person, so it is important 
to identify each number for a given data source. Medical record 
numbers may also be very long. The birth defects program should make 
certain the computer program and registry database allow for entry of 
the entire medical record number. 
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Variable Name Vital record certificate number 
Definition Unique number assigned to a certificate by Vital Records. 
Justification Vital record certificate numbers can be linked to other vital records 
certificates. Often, vital records will reference or link the death 
certificate to the birth certificate for infant deaths.  
 
Programs can use an algorithm of data variables to find a potential 
match to a vital record. This process assists in identifying unique cases, 
establishing residency, and securing all of the data variables on the vital 
record.  
 
Birth certificate and fetal death certificate numbers can be the unique 
ID numbers for a program. Other ‘program’ numbers can be created 
using a similar format for cases that do not match to a birth certificate 
or fetal death certificate. 
Source Abstracted 
Location On the certificate of birth, death, or fetal death and in the vital records 
database 
Type Number 
Comments Separate fields for the live birth or fetal death and for the death record 
number are recommended. 
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Variable Name Place of pregnancy outcome 
Definition Location where the delivery or pregnancy outcome occurred 
Justification Mother and infant records at the delivery facility often provide 
important information not found in tertiary care facility records (unless 
the delivery records are copied into the tertiary care records). The birth 
defects program can use the delivery location (hospital, midwifery, 
residence, etc.) to identify where delivery records need to be reviewed 
and abstracted. 
 
The birth defects program may employ the delivery location in addition 
to other fields to link to other data sets, such as vital records. 
 
The location where the delivery occurred allows the birth defects 
program to provide facility-specific statistics. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s delivery medical record (face sheet) 
• Vital record 
Type Code 
Checks This field should always be filled out and must be a valid code. 
Comments This includes those situations where delivery occurs outside of health 
care facilities as well as inside health care facilities. 
Options It is useful to maintain a list of potential data sources (hospitals, etc.) 
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Variable Name Pregnancy outcome 
Definition Outcome of the index pregnancy 
Justification The pregnancy outcome, in conjunction with gestational age fields, 
may determine whether a record should be included in the birth defects 
program. 
 
At a minimum birth defect programs should distinguish the outcomes 
of live birth, fetal death, and induced termination.  
 
Part of the mission of the birth defects program may be to refer families 
to social services. Since only live births would be referred to many of 
the services, it is important to know whether a given case is a live birth. 
Knowing which cases are elective terminations aids in evaluating 
trends in prenatal diagnosis, as well as evaluating the impact of 
prevention strategies such as folic acid supplementation and 
fortification. 
 
Pregnancy outcome can be used to evaluate rates of birth defect by 
pregnancy outcome. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet, discharge summary, 
labor and delivery record) 
• Vital records 
Type Code 
Checks This field should always be filled out, except in cases of prenatal 
diagnosis where the pregnancy has not yet ended. 
Comments See Chapter 3 on Case Definition for definitions of pregnancy outcomes. 
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Variable Name Birth weight 
Definition Weight of the infant or fetus at delivery 
Justification The birth weight may be needed for case definition if 
inclusion/exclusion criteria for selected birth defects, such as for 
undescended testes and patent ductus arteriosus, are based on birth 
weight. 
 
In conjunction with gestational age, length, and head circumference, 
birth weight can be used to assess prenatal growth retardation, a 
characteristic of fetal alcohol syndrome. 
Source Abstracted 
Location • Mother’s delivery medical record (labor and delivery record) 
• Infant’s medical record (admission summary, labor and delivery 
record, birth certificate worksheet) 
• Vital records 
Type Number 
Checks The birth weight must range between 0 and 10,000 grams or 0 and 50 
pounds. 
Comments The data source may report birth weight in grams or kilograms, pounds 
and ounces, or pounds with decimals. The birth defects program may 
decide to record the weight in the units reported or in a uniform 
fashion, such as always as grams and kilograms. In this latter case, the 
birth defects program must be able to convert from one type of unit to 
another while collecting the data. Data fields can have computerized 
calculation functions.  
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Variable Name Plurality 
Definition Number of fetuses or infants. 
Justification The plurality, in association with other fields such as county of 
residence and mother’s social security number, can be used to avoid 
duplication of records in the birth defects program. 
 
Knowing that the infant is from a multiple birth alerts the birth defects 
program that more effort may be needed to link to a particular vital 
record (Forrester and Canfield, 2000). 
 
The birth defects program can use this data item to evaluate differences 
in birth defect rates for singletons and multiple births. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet, admission summary, 
discharge summary, prenatal care record, labor and delivery record) 
• Infant’s medical record (face sheet, admission summary, discharge 
summary, prenatal care record, labor and delivery record, birth 
certificate worksheet). 
• Vital records 
Type Number 
Checks This field should always be filled out. 
Comments Because some twin pregnancies are anomalous (for example, conjoined 
twins or fetus papyraceus), there may not be the expected two vital 
records for a pregnancy that is identified as a twin pregnancy. 
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Variable Name Gestational age 
Definition Gestational age at pregnancy outcome 
Justification Gestational age can be used to determine whether a pregnancy outcome 
meets the case definition for the birth defects program. 
 
Certain diagnoses are considered birth defects only when the infant is 
of a particular gestational age. For example, patent ductus arteriosus is 
common among premature infants and is often subject to exclusion 
criteria before being counted as a birth defect. 
Source Abstracted 
Derived (see comments) 
Location • Mother’s delivery medical record (labor and delivery record) 
• Infant’s delivery medical record (admission summary, discharge 
summary, gestational age score record, labor and delivery record, 
birth certificate worksheet) 
• Vital records 
Type Number 
Checks The gestational age should range between 0 and 52 weeks. 
Comments The gestational age can be derived via several methods, and conflicting 
gestational age information may be reported in the medical record 
(Alexander et al., 1990; Hall, 1990). As a result, the birth defects 
program will want to have a method for prioritizing gestational age 
estimates from different sources. 
Options See Chapter 3 on Case Definition for further information.  
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Variable Name Diagnosis code 
Definition Code used for the diagnosis 
Justification Coding birth defects eliminates the problem of having to sort through a 
variety of differing descriptions. It allows for timely and efficient 
analyses of data and identification of cases for research and referral. 
Coding of birth defects enables birth defects researchers to know that 
they are talking about the same birth defect, and allows for 
comparability between different birth defects registries using the same 




Checks Every case should have at least one diagnosis code (except if the birth 
defects program includes non-malformed controls, in which case the 
program may create specific ‘disease codes’ for use as the data variable 
in the diagnosis code field). 
 
A case may have more than one diagnosis code. Every diagnosis 
description should have a corresponding code and vice versa. 
Comments The International Classification of Disease (ICD) coding system is the 
standard used in the health care delivery system. NBDPN currently 
requires that programs report cases using ICD-9-CM codes. The 
registry should accommodate a minimum of 15 unique diagnostic 
codes per case.  
Options The recommended coding system is the CDC 6-digit code, which is 
easily converted to ICD-9-CM. See the Chapter 5 on Classification and 
Coding for further information. 
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Variable Name Name of responsible party 
Definition Name of parent, custodial parent, or guardian 
Justification Useful in programs that refer a family to services when contact with a 
parent may be inappropriate. 
Source Abstracted 
Location • Face sheet, signed authorization, social worker’s notes, birth 
certificate worksheet 
• Immunization registry, metabolic screening database 
• Vital record 
Type Text 
Comments The name may be collected as a single field or multiple fields for first, 
middle, and last name. Allowing for up to 25 characters for each 
portion of the name should be considered. 
 
Variable Name Address of responsible party 
Definition Address of parent, custodial parent, or guardian 
Justification Useful in programs that refer a family to services when contact with a 
parent may be inappropriate. 
Source Abstracted 
Location • Face sheet, signed authorization, social worker’s notes, birth 
certificate worksheet 
• Immunization registry, metabolic screening database 
• Vital record 
Type Text 
Comments Include fields for the street address, city, state, and zip code. Allow at 
least 25 digits for street address and 20 digits for city name. If the 
residence address and the mailing address of the responsible party are 
different, collect the mailing address for this item. 
 
Variable Name Telephone number of responsible party 
Definition Telephone number of child’s parent, custodial parent, or guardian 
Justification Useful in programs that refer a family to services when contact with a 
parent may be inappropriate and when telephone contact may be 
indicated. 
Source Abstracted 
Location • Face sheet, signed authorization, social worker’s notes, birth 
certificate worksheet 
• Immunization registry, metabolic screening database 
• Vital record 
Type Number 
Comments Include area code with number. 
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Variable Name Mother’s date of birth 
Definition Birth mother’s date of birth 
Justification In conjunction with other fields, such as mother’s name, the birth 
defects program field staff can use the mother’s date of birth to locate 
medical records when the mother’s medical record number is not 
known. The birth defects program can use the mother’s date of birth 
and other fields to determine whether a case has been abstracted or 
added to the registry under a different ID. 
 
The birth defects program can employ the mother’s date of birth in 
addition to other fields to link to other data sets, such as vital records or 
Medicaid. 
 
The birth defects program can use the mother’s date of birth and 
infant’s date of delivery in order to calculate the mother’s age at 
delivery. The mother’s age at delivery can then be used in clinical 
review.  
Source Abstracted 
Location • Mother’s delivery medical record (face sheet, prenatal care record) 
• Infant’s medical record (face sheet, prenatal care record, birth 
certificate worksheet) 
• Vital records 
Type Date 
Checks This date must be earlier than all other dates except possibly the 
father’s date of birth. Medical records may sometimes confuse maternal 
and paternal information. If the mother’s date of birth is the same as the 
father’s date of birth, the birth defects program should double check to 
make certain that this is true. 
Comments See also Chapter 6 on Case Ascertainment Methods, the section on 
Data Sources. 
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Variable Name Mother’s race 
Definition Birth mother’s race 
Justification The birth defects program can use the mother’s race in order to present 
data on birth defect rates by maternal race, one of the most important 
person variables in descriptive epidemiology. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet, prenatal care record) 
• Infant’s medical record (admission summary, prenatal care record, 
birth certificate worksheet) 
• Vital records 
Type Code 
Comments Racial categories and codes used by birth defects surveillance programs 
should be compatible with the federal standards in current use for race. 
 
Variable Name Mother’s ethnicity 
Definition Birth mother’s ethnicity 
Justification Ethnicity is a designation separate from maternal race. The birth defects 
program can use the mother’s ethnicity in order to evaluate differences 
in birth defect rates by maternal ethnicity. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet, prenatal care record) 
• Infant’s medical record (admission summary, prenatal care record, 
birth certificate worksheet) 
• Vital records 
Type Code 
Comments It is important to collect ethnicity data that meets the needs of the 
registry to monitor the health of the ethnic populations within the state. 
Generally, each state Department of Public Health will have identified 
the populations of special interest to that state. Ethnicity categories and 
codes should be compatible with the federal standards in current use 
for ethnicity. 
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Variable Name Mother’s name 
Definition Full name of birth mother 
Justification In conjunction with other fields, such as mother’s date of birth, the 
birth defects program field staff can use the mother’s name to locate 
medical records when the mother’s medical record number is not 
known. The birth defects program can employ the mother’s name in 
addition to other fields to unduplicate case reports and to link to other 
data sets, such as vital records or Medicaid. 
 
The mother’s name is needed so that she can be contacted by 
researchers conducting approved studies and by social workers or 
others for outreach efforts. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s medical record (face sheet, birth certificate worksheet) 
• Vital records 
Type Text 
Comments This variable may be collected as a single field or multiple fields. This 
variable should include at least the mother’s first and last name and 
may include the mother’s middle name and maiden name (name before 
marriage). A woman may have more than one name or alias (also 
known as or AKA). Separate fields for first, middle, and last name and 
for maiden name are recommended. Field lengths of 25 characters or 
larger for each portion of the name should be considered. The birth 
defects program should record all of the names, for easier linkage with 
other databases and to prevent entering duplicate cases in the database. 
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Variable Name Mother’s street address of residence at pregnancy outcome 
Definition Street address of birth mother’s residence at the time of the outcome of 
the index pregnancy 
Justification Street address is necessary for geocoding location of residence and 
linking with other data systems through geographical information 
systems (GIS). The street address field may be needed when assigning 
the county of residence, particularly when a city includes part of more 
than one adjacent county. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s delivery medical record (face sheet, birth certificate 
worksheet) 
• Vital records 
Type Text 
Comments Include apartment numbers, etc. A field length of up to 40 characters 
should be considered.  
 
If there is a difference between residence address and mailing address, 
choose residence address. Only use P.O. Box if there is no physical 
address for the mother. 
 
Variable Name Mother’s city of residence at pregnancy outcome 
Definition City of address of birth mother’s residence at the time of the outcome 
of the index pregnancy 
Justification The city at delivery field is often needed when assigning the county of 
residence. 
Source Abstracted 
Derived (from zip code or census tract number) 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s delivery medical record (face sheet, birth certificate 
worksheet) 
• Vital records 
Type Text 
Comments If there is a difference between residence address and mailing address, 
choose residence address. Allow for up to 25 characters for city name 
text fields. A separate city code field may be used to correspond with 
the city name to facilitate statistical analysis. City coding structures 
should be compatible with Federal Information Processing Standards 
(FIPS). 
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Variable Name Mother’s county of residence at pregnancy outcome 
Definition County code of birth mother’s county of residence at the time of the 
outcome of the index pregnancy 
Justification The county of residence, in association with other fields such as 
plurality and mother’s social security number, can be used to avoid 
duplication of records in the registry. 
Source Abstracted 
Derived (from street address and city, zip code, or census tract number) 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s delivery medical record (face sheet, birth certificate 
worksheet) 
• Vital records 
Type Code 
Comments If there is a difference between residence address and mailing address, 
choose residence address. County coding schemes should be 
compatible with standard federal FIPS codes. 
 
Variable Name Mother’s state of residence at pregnancy outcome 
Definition State in which birth mother resided at the time of the outcome of the 
index pregnancy  
Justification The state in which the mother resided is needed if the birth defects 
program’s inclusion criteria include only residents of a certain state. 
The state of residence, along with other address components, is needed 
so that researchers and social workers can contact the family, provided 
a more recent address is not known. 
Source Abstracted 
Derived (from other residence information such as city, zip code, and 
census tract number) 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s delivery medical record (face sheet, birth certificate 
worksheet) 
• Vital records 
Type Standard 2-letter state codes used by US Postal Service 
Comments If there is a difference between residence address and mailing address, 
choose residence address. Procedures for reporting information for 
places outside the US need to be contemplated. 
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Variable Name Mother’s zip code of residence at time of pregnancy outcome 
Definition Zip code of birth mother’s residence at the time of the outcome of the 
index pregnancy 
Justification Cluster investigations are based on a defined diagnosis, geographical 
area, and time period. Knowing the zip code of residence may allow 
investigators to determine which cases qualify to be included in cluster 
investigations. 
 
The zip code, along with other address components, is needed so that 
researchers, social workers, and others can contact the family, provided 
a more recent address is not known. 
Source Abstracted 
Derived (from other residence information such as street address and 
city or census tract number) 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s delivery medical record (face sheet, birth certificate 
worksheet) 
• Vital records 
Type Number 
Comments If there is a difference between residence address and mailing address, 
choose residence address. This code only applies to United States zip 
codes and may be the 5-digit or the 9-digit code. 
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Appendix 4.2 
Descriptions of Recommended Data Variables 
Format for Variable Descriptions A4.2-1
  
Infant  
Text Description of Birth Defect ...................................................................................................... A4.2-2
Date of Death ................................................................................................................................... A4.2-3
Birth Length ..................................................................................................................................... A4.2-3
Apgar Score...................................................................................................................................... A4.2-4
Birth Order ....................................................................................................................................... A4.2-4
Cytogenetic Analyses Performed...................................................................................................... A4.2-5
Diagnostic Tests and Procedures Performed .................................................................................... A4.2-6
Autopsy Performed........................................................................................................................... A4.2-7
Physicians of Record ........................................................................................................................ A4.2-8
 
Mother  
Date of Last Menstrual Period (LMP).............................................................................................. A4.2-9
Data of Ultrasound ........................................................................................................................... A4.2-10
Gestational Age at Ultrasound.......................................................................................................... A4.2-11
Mother’s Medical Record Number(s)............................................................................................... A4.2-11
Prenatal Diagnosis............................................................................................................................ A4.2-12
Mother’s Social Security Number .................................................................................................... A4.2-13
Census Tract of Maternal Residence at Pregnancy Outcome ........................................................... A4.2-13
Mother’s Telephone Number ........................................................................................................... A4.2-14
Mother’s Education.......................................................................................................................... A4.2-14
Prior Pregnancy History ................................................................................................................... A4.2-15
Prenatal Care .................................................................................................................................... A4.2-15
 
Father  
Father’s Data of Birth....................................................................................................................... A4.2-16
Father’s Name .................................................................................................................................. A4.2-16
Father’s Education ........................................................................................................................... A4.2-17
Father’s Race.................................................................................................................................... A4.2-17
Father’s Ethnicity ............................................................................................................................. A4.2-18
Father’s Social Security Number...................................................................................................... A4.2-18
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Appendix 4.2 
Descriptions of Recommended Data Variables 
Format for Variable Descriptions 
 
Variable Name Name of data collection variable 
 
Definition Definition of data collection variable 
 
Justification Reason the birth defects program may want to include variable in 
its database 
 
Source Where variable comes from – abstracted, derived, created 
 
Location Data sources and location within data sources where variable is 
most likely to be consistently found 
 
Type How variable should be stored – text, number, date, code (letters 
and/or numbers), checkbox 
 
Checks Any limits, ranges, or other criteria the variable should meet 
 
Comments Other notes or comments about the variable 
 
Options Recommended options for the variable 
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Variable Name Text description of birth defect 
Definition Description of diagnosis 
Justification A birth defect may be diagnosed based on more than one procedure or 
examination. Moreover, two procedures or clinicians may provide 
different details about the birth defect. For example, one procedure 
may report that the infant had a myelomeningocele, while a second may 
mention a lumbar spina bifida. These should all be combined into a 
single description such as lumbar myelomeningocele. Or one procedure 
may mention the infant had a cleft lip and palate, while a second notes 
that the cleft lip was only on the left side of the mouth. These should be 
combined into something like left cleft lip and palate. 
 
The birth defect description recorded in text format in the data makes it 
easier to assign disease codes when the medical record is no longer 
available. 
Source Abstracted 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record, prenatal diagnostic procedure reports) 
• Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record, birth certificate worksheet) 
• Vital records 
Type Text 
Checks Every case should have at least one diagnosis description (unless the 
birth defects program includes non-malformed controls). A case may 
have more than one diagnosis description. Every diagnosis description 
should have a corresponding code and vice versa. 
Comments See Chapter 5 on Classification and Coding. 
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Variable Name Date of death 
Definition The date when the death occurred 
Justification The date of death permits the birth defects program to know that most 
postnatal procedures will not occur after this date, the exceptions being 
such procedures as autopsies, cytogenetic analyses, and other 
laboratory analyses. 
 
The delivery date for a live birth along with the date of death can be 
used to determine length of survival. Researchers can use this to 
calculate survival rates for specific lengths of time. 
Source Abstracted 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record, prenatal diagnostic procedure reports) 
• Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record) 
• Vital records 
Type Date 
Checks This field should only be filled out if the pregnancy outcome is “live 
birth”. The date of death should be on or after the date of delivery. 
 
Variable Name Birth Length 
Definition Length of newborn at birth 
Justification In conjunction with gestational age, birth weight, and head 
circumference, length can be used to assess prenatal growth retardation, 
a characteristic of fetal alcohol syndrome. However, these 
circumstances account for only a small subset of cases a birth defects 
program will collect, and it may not be worth collecting the information 
on all cases. 
Source Abstracted 
Location • Infant’s medical record (labor and delivery record) 
• Vital records in some states 
Type Number 
Checks Edit checks for range and for consistency with gestational age are 
recommended. 
Options Best collected as centimeters. 
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Variable Name Apgar score 
Definition Clinical assessment score of newborn at delivery 
Justification Apgar scores are a gross measure of early neonatal health. If the scores 
are low, that means that the newborn had cardiorespiratory problems 
immediately after delivery. These problems may or may not be related 
to a birth defect in the infant. For example, some postnatal 
complications that correlate with low Apgar scores (intestinal 
perforations, intraventricular hemorrhage) overlap with problems 
caused by birth defects.  
Source Abstracted 
Location • Infant’s medical record (labor and delivery record), birth certificate 
work sheet. 
• Vital records 
Type Code 
Checks Values from 0 through 10 or coded unknown/not applicable. 
Comments Apgar scores at 1 minute, 5 minutes, and 10 minutes are often 
available. Vital records generally provide 1- and 5-minute scores, with 
a change to 5- and 10-minute scores for low 5-minute scores being 
implemented nationwide. 
 
Variable Name Birth order 
Definition Order of delivery for multiple births. 
Justification Birth order is the order in which infants of a multiple gestation 
pregnancy are delivered.  
 
In cases of multiple gestation pregnancies, delivery records might not 
refer to the infants or fetuses by name but by some other designation 
such as Twin A and Twin B. This might make it difficult to determine 
which vital records a particular infant or fetus should be linked to. Vital 
records may record birth order. Thus birth order might be useful for 
linkage with vital records in cases of multiple gestation pregnancies. 
However, other variables such as infant or fetus sex and birth weight 
might prove as useful for linkage. 
Source Abstracted 
Location • Infant’s medical record (labor and delivery record), birth certificate 
worksheet. 
• Vital records 
Type Number 
Checks Must be less than or equal to plurality. 
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Variable Name Cytogenetic analyses performed 
Definition Whether or not a cytogenetics analysis was performed. 
Justification Certain structural birth defects are associated with chromosomal 
abnormalities (Boudjemline et al., 2001; Bullen et al., 2001; Torfs and 
Christianson, 1998). Structural defects in the presence of a 
chromosomal abnormality are often considered to be secondary to or 
the result of the chromosomal abnormality. Such cases may not be 
considered suitable for research into potential environmental causes of 
structural defects. And analyses of the proportion of structural defects 
associated with chromosomal abnormalities often are based on the 
number of cases where the karyotype is known, because some of the 
cases without a chromosome analysis may be expected to have 
chromosomal abnormalities. Infants with certain chromosomal 
abnormalities also have higher mortality and morbidity than infants 
without chromosomal abnormalities. Thus it may be important to know 
whether a chromosomal abnormality is present when deciding whether 
to refer cases for intervention or prevention activities. 
 
It is also important to know whether a chromosome analysis was 
performed at all, even if the results of the analysis are not in the 
medical record. If time and resources are available, and the 
chromosome analysis results are considered important, the birth defects 
program may attempt to track down the results of the analysis. 
Knowledge that a chromosome analysis was not performed (e.g., 
because the parents refused) or that a chromosome analysis failed will 
prevent a birth defects program from wasting resources searching for 
chromosome analysis results that do not exist. 
Source Abstracted 
Location • Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record) 
Type Number/Code 
Checks Must be yes, no, or unknown. 
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Variable Name Diagnostic tests and procedures performed 
Definition Method used to reach diagnosis. 
Justification Different procedures can be used in the diagnosis of a birth defect. 
Moreover, procedures differ in their accuracy and reliability in 
diagnosing certain birth defects. For example, Down syndrome can 
usually be considered to be more definite when it is based on a 
chromosome analysis than on a physical examination of the 
infant/fetus. Thus it is often not enough to know that a birth defect was 
mentioned in a medical record; it is important to know how the birth 
defect diagnosis was made. Moreover, the researcher may only be 
interested in birth defects identified by particular procedures. For 
example, researchers may only be interested in cases of a heart defect 
identified through fetal echocardiography. 
 
If a birth defects program has clearly defined case inclusion criteria 
(e.g., infants and fetuses with certain birth defects are only included if 
diagnoses were made by certain procedures), then basic research can be 
conducted. An example would be for a birth defects program to only 
include cardiac defects diagnosed by echocardiography, cardiac 
catheterization, prenatal ultrasound, or autopsy. 
Source Abstracted 
Location • Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record) 
Type Code 
Checks Any limits, ranges, or other criteria the data variable should meet.  
Comments Must develop an appropriate coding structure or select a coding 
standard such as CPT coding to aid in capturing and tabulating the 
information. 
Options May collect primary diagnostic method using a specific hierarchy based 
on diagnostic accuracy or include multiple procedures fields. 
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Variable Name Autopsy performed 
Definition Indicates whether an autopsy was conducted. 
Justification The autopsy is considered one of the more definitive procedures for 
identifying structural birth defects. 
 
However, even if an autopsy is performed, the autopsy information is 
not always added to the medical record. As long as a birth defects 
program has clearly defined case inclusion criteria (e.g., infants and 
fetuses with certain birth defects are only included if diagnoses were 
made by certain procedures), then basic research can be conducted. An 
example of such inclusion criteria would be for a birth defects program 
to only include cardiac defects diagnosed by echocardiography, cardiac 
catheterization, prenatal ultrasound, or autopsy. 
Source Abstracted 
Location • Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record) 
• Death certificate, fetal death report. 
Type Code 
Checks Not applicable for live births still living. 
Options Values would include yes, no, or unknown/not applicable. 
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Variable Name Physicians of record 
Definition Physician(s) identified as being responsible for admission and 
discharge records. 
Justification A birth defects program might want to have information on the 
physicians of record in order to obtain additional information, to 
determine if all appropriate referrals were made, to alert physician to 
need for folic acid recommendations, or to obtain permission to contact 
the family.  
Source Abstracted 
Location • Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record) 
• Newborn metabolic screening data 
• Vital record 
Type Data are stored as text (names and addresses) 
Checks N/A 
Comments To be useful, this information should include name and address for the 
physician. Allow for 40 characters for entry of each name. There may 
be interest in collecting multiple physicians and their role, as in 
pediatrician, obstetrician, or family practice physician to clarify 
appropriate physician depending upon circumstance. 
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Variable Name Date of last menstrual period (LMP) 
Definition First day of last menstrual period 
Justification Date of LMP, along with date of delivery, can be used to calculate 
gestational age at delivery. Gestational age at delivery can be used for 
determining if a spontaneous fetal death or pregnancy termination 
meets the case definition for the registry. 
Source Abstracted 
Derived (see comments) 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record) 
• Infant’s delivery medical record (prenatal care record, labor and 
delivery record) 
• Vital records 
Type Date 
Checks The LMP date must be before the date of delivery, estimated date of 
delivery, prenatal ultrasound date, and prenatal and postnatal procedure 
dates. The LMP date should not be more than one year before the date 
of delivery, estimated date of delivery, prenatal ultrasound date, and 
prenatal procedure dates. 
Comments If the LMP date is recorded in both the prenatal records and the 
admission interview, use the LMP date in the prenatal records. If more 
than one LMP date is found in the prenatal records, record the earliest 
LMP date in this field. 
Options See Chapter 3 on Case Definition for further information. 
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Variable Name Date of ultrasound 
Definition Date of the earliest identified ultrasound used to assess gestational age 
Justification Date of ultrasound, along with gestational age at time of ultrasound and 
delivery date, can be used to calculate gestational age at delivery. 
Source Abstracted 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record) 
• Infant’s delivery medical record (prenatal care record, labor and 
delivery record) 
Type Date 
Checks The date of ultrasound field should only be filled in when the 
gestational age at ultrasound is also known. The ultrasound date must 
be before or on delivery date and postnatal procedure dates and after 
the LMP date. The ultrasound date should not be more than 10 months 
before the date of delivery. 
Comments Only record information present in the medical record. DO NOT 
calculate gestational ages or dates. 
 
If multiple ultrasounds were done to determine gestational age, record 
the date of the earliest ultrasound. 
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Variable Name Gestational age at time of ultrasound 
Definition Gestational age (in weeks) at the time of ultrasound, as estimated by the 
earliest ultrasound performed 
Justification Gestational age at ultrasound combined with date of pregnancy 
outcome can be used for determining if a spontaneous fetal death or 
pregnancy termination meets the case definition for the registry. 
 
Certain diagnoses are considered birth defects only when the infant is 
of a particular gestational age. For example, patent ductus arteriosus is 
common among premature infants and is only considered a birth defect 
if found in infants born at term. 
Source Abstracted 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record) 
• Infant’s delivery medical record (prenatal care record, labor and 
delivery record) 
Type Number 
Checks This field should only be filled in when the date of ultrasound is also 
known. The gestational age at ultrasound should range between five 
menstrual weeks and birth. 
Comments Only record information present in the medical record. Do not calculate 
gestational ages or dates. 
 
If multiple ultrasounds were done to determine gestational age, record 
the date of the earliest ultrasound. 
 
Variable Name Mother’s medical record number(s) 
Definition Birth mother’s medical record number(s) 
Justification A medical record number allows facilities to retrieve records more 
easily. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet) 
Type Code 
Comments The mother may have more than one medical record at a given hospital. 
Medical record numbers may also be very long. Allow for up to 12 
alphanumeric characters for this field. The birth defects program 
should make certain the computer program allows for entry of the 
entire medical record number. 
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Variable Name Prenatal diagnosis 
Definition The diagnosis made before birth by prenatal diagnostic procedures and 
tests and neither confirmed nor ruled out by postnatal procedures and 
tests 
Justification Prenatal diagnostic procedures used to detect structural birth defects 
may not be considered to support as definitive a diagnosis as postnatal 
procedures, and prenatal detection of a birth defect is frequently 
considered to be tentative. Often physicians will attempt to verify or 
refine the prenatal diagnosis postnatally, such as through physical 
examinations, x-rays, or ultrasounds of the live birth or through autopsy 
of fetal deaths and elective terminations. Thus birth defects program 
staff should determine whether postnatal procedures and tests were 
performed and the results of such procedures and tests. However, 
postnatal confirmation or clarification of prenatally detected birth 
defects may not always be possible. In such cases the diagnoses 
identified through prenatal diagnostic procedures and tests are the best 
information available. Thus it may be useful for the birth defects 
program to indicate those diagnoses based solely on prenatal 
procedures. 
Source Abstracted 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record, prenatal diagnostic procedure reports) 
• Infant’s medical record (face sheet, admission summary, discharge 
summary, procedure reports, consultation reports, labor and 
delivery record, birth certificate worksheet) 
• Vital records 
Type Checkbox 
Comments Prenatal cytogenetic tests may also be considered suspect. Depending 
on the source of the cell sample used, the sample could have been 
contaminated by maternal cells. Or, as in the case of chorionic villus 
sampling, any chromosomal abnormalities identified may be limited to 
the source of the cell sample and may not affect the fetus. However, 
prenatal cytogenetic tests are usually considered to be of greater 
validity than prenatal procedures for identifying structural defects. 
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Variable Name Mother’s Social Security number 
Definition Birth mother’s Social Security number 
Justification The mother’s Social Security number, in association with other fields 
such as plurality and county of residence, can be used to avoid 
duplication of records in the registry. 
 
The birth defects program can employ the mother’s Social Security 
number to link to other data sets, such as the Medicaid database. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet, prenatal care record) 
• Infant’s medical record (face sheet, prenatal care record, birth 
certificate worksheet) 
• Vital records 
Type Number 
Checks Medical records may sometimes confuse maternal and paternal 
information. The mother’s and father’s Social Security numbers should 
not be the same. 
 
Variable Name Census tract of maternal residence at pregnancy outcome 
Definition Census tract number of birth mother’s residence at the time of the 
outcome of the index pregnancy 
Justification The geographical areas in most cluster investigations to date have been 
counties, cities, or particular zip codes. However, in the future, cluster 
and other investigations may focus on geographical areas defined in 
other ways. Knowing the census tract number at delivery may allow 
investigators to determine which cases qualify to be included in such 
future investigations. 
Source Derived 
Abstracted (from vital records files) 
Location • Vital records 
Type Number 
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Variable Name Mother’s telephone number 
Definition Birth mother’s most recent telephone number: area code and telephone 
number 
Justification The mother’s telephone number is needed so that researchers and social 
workers can contact the family. 
Source Abstracted 
Location • Mother’s delivery medical record (face sheet) 
• Infant’s medical record (face sheet) 
Type Number 
Comments Enter the area code and seven-digit telephone number. If the area code 
is not known, enter only the seven-digit telephone number. Note that 
the telephone number found in a tertiary care facility is more likely to 
be current than the telephone number at the birth hospital. 
 
Variable Name Mother’s education 
Definition Birth mother’s highest level of education attained 
Justification Education can be used as an indicator of socioeconomic status (SES). 
Collecting maternal education would allow the birth defects program to 
evaluate its relationship to birth defect risk. 
Source Abstracted 
Location • Birth certificate worksheet 
• Birth certificate, fetal death report 
Type Code 
Checks Any limits, ranges, or other criteria the data variable should meet. 
Comments Since maternal education is not reported consistently in medical 
records, this information can be obtained more easily by linking to vital 
record certificates. 
Options Method for storing the information should permit identifying cases 
with less than high school, high school, some college, and college 
graduate. 
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Variable Name Prior pregnancy history 
Definition Prior live births and fetal deaths to the birth mother 
Justification Information can be used to identify women with a significant history of 
fetal loss or infant death. 
Source Abstracted 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record, prenatal diagnostic procedure reports) 
Type Number 
Comments This information reflects the number of prior live births and fetal 
deaths the mother has experienced. Vital record would provide prior 
live births now living and prior live births now deceased. Medical 
record can provide parity and gravida. 
 
Variable Name Prenatal care 
Definition Information on the initiation and extent of prenatal care 
Justification Data on prenatal care (such as month of prenatal care and number of 
prenatal visits), may be useful to a birth defects program. Knowing that 
the mother did or did not have prenatal care may be useful for birth 
defects program staff in evaluating other fields on the form. E.g., if it is 
known that the mother did not have prenatal care, there is less 
likelihood of finding information on prenatal tests or mother’s medical 
history. And prenatal care may be used as an indication of other factors 
such as socioeconomic status (SES). 
 
However, birth defects usually occur before pregnancy is recognized 
and prenatal care can begin. Furthermore, prenatal care may not be 
consistently or accurately reported in the medical record – the mother 
may move or change health care providers or the prenatal care visit 
information may not be counted consistently. There may be differences 
of opinion as to what qualifies as a prenatal visit. 
Source Abstracted 
Derived 
Location • Mother’s delivery medical record (prenatal care record, labor and 
delivery record, prenatal diagnostic procedure reports) 
Type Number 
Checks Range checks and consistency with woman’s age 
Comments The information to be considered for inclusion would be month 
prenatal care began and number of prenatal visits. 
Options The prenatal care information can be summarized using the Kotelchuck 
or possibly the Kessner Index to standardize the information for more 
meaningful analysis. 
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Variable Name Father’s date of birth 
Definition Date of birth for father 
Justification The birth defects program may employ the father’s date of birth in 
addition to other fields to link to other data sets, such as Medicaid. 
Paternal age may be associated with risk for certain birth defects 
(McIntosh et al., 1995; Olshan et al., 1994). The information can be 
useful in studies of paternal occupational or exposure cohort studies 
into associations with birth defects in progeny.    
 
The birth defects program can use the father’s date of birth and infant’s 
date of delivery in order to calculate the father’s age at delivery. The 
father’s age at delivery can then be used in analyzing birth defect rates 
by paternal age. 
Source Abstracted 
Location • Medical record, birth certificate worksheet 
• Birth/fetal death, death record 
Type Text 
Checks Range checks for father’s ages under 12. 
 
Variable Name Father’s name 
Definition Name of father 
Justification The birth defects program may employ the father’s name in addition to 
other fields to link to other data sets, such as vital records or Medicaid.  
 
However, information on the birth father is not consistently found in 
medical records or vital records. 
Source Abstracted 
Location • Medical record and birth record worksheet 
• Birth/fetal death and death record 
Type Text 
Comments The name may be a single field or may be stored as separate first, 
middle, last, and surname suffix fields. Separate fields greatly facilitate 
record linkage. Providing 25 character fields for first, middle, and last 
names should be considered. 
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Variable Name Father’s education 
Definition Father’s highest level of education attained 
Justification Socioeconomic status (SES) can influence risk of having an infant with 
a birth defect. Collecting paternal education would allow the birth 
defects program to evaluate its impact on birth defect risk. 
Source Abstracted 
Location • Birth certificate worksheet 
• Birth/fetal death record 
Type Code 
Checks Consistency between father’s age and education 
Comments Since paternal education is not reported consistently in medical records, 
this information can be obtained more easily by linking to vital record 
certificates. 
Options Method for storing the information should permit identifying cases 
with less than high school, high school, some college, and college 
graduate. 
 
Variable Name Father’s race 
Definition Race of father 
Justification The birth defects program can use the birth father’s race in order to 
evaluate differences in birth defect rates and examine program goals 
and activities by paternal race. 
Source Abstracted 
Location • Birth certificate worksheet  
• Birth/fetal death record 
Type Code 
Comments Racial categories and codes used by birth defects surveillance programs 
should be compatible with the federal standards in current use for race. 
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Variable Name Father’s ethnicity 
Definition Ethnicity of father 
Justification Ethnicity is a designation separate from race. The birth defects program 
can use the father’s ethnicity in order to evaluate differences in birth 
defect rates or outreach effort goals and activities by father’s ethnicity. 
Source Abstracted 
Location • Birth certificate worksheet 
• Birth/fetal death record 
Type Code 
Checks Should be valid code. 
Comments Must develop a code structure that meets registry needs and reflects 
available data on ethnicity. Should be compatible with federal standard 
for ethnicity classification. 
 
Variable Name Father’s Social Security number 
Definition Social Security number of the father 
Justification The birth defects program can employ the father’s Social Security 
number to link to other data sets, such as the Medicaid database. 
Source Abstracted 
Location • Medical record, birth certificate worksheet 
• Birth/fetal death record 
Type Number 
Checks Medical records may sometimes confuse maternal and paternal 
information. The mother’s and father’s Social Security numbers should 
not be the same. 
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Chapter 5     5-1        Classification and Coding 
5.1  Introduction 
The National Birth Defects Prevention Network (NBDPN) promotes the use of coded information 
that is comparable across birth defects programs and methods of case ascertainment, especially for 
conditions that are reported annually to NBDPN. The proper and accurate coding of diagnostic 
information is an essential aspect of birth defects surveillance. 
 
A disease classification system plays an important role in the ability of surveillance systems to 
collect, code, retrieve, and translate information regarding diagnoses and procedures. These 
activities depend on the ability to assign specific codes to medical information, based on a 
standardized classification scheme. There are two important ways that classification systems and 
the coding of birth defects within those systems are central to the surveillance process. 
Classification and coding rely on a standardized set of rules and procedures for case ascertainment 
based on medical information, as well as on a standardized way of describing and organizing 
“cases” based on their clinical conditions. 
 
Coded medical information has become an important part of the health care delivery system. 
Coding rules, guidelines, and standards have evolved for practically every type of health service 
encounter. Surveillance systems should understand the various factors that affect the quality of the 
coding of birth defects and should implement procedures to improve the utility of coding. 
 
In this chapter we discuss disease classification systems (Section 5.2), classification issues that 
affect surveillance systems (Section 5.3), guidelines for effective coding (Section 5.4), quality 
issues related to coded data (Section 5.5), and tips and hints to assist with the classification and 
coding aspects of managing a surveillance system (Section 5.6). References cited in this chapter 
may be found in Section 5.7. 
 
The two appendices to this document may be viewed or downloaded from the NBDPN website at 
http://www.nbdpn.org/bdsurveillance.html. Appendix 5.1 is the Texas Disease Index and 
Appendix 5.2 is the listing of CDC 6-digit codes. 
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5.2  Disease Classification Systems 
Over time, a number of systems for classifying pathology, diseases, injuries, and clinical procedures have 
been developed. This has led to a classification system known as the International Classification of 
Diseases (ICD). At present, the World Health Organization (WHO) and 10 international centers coordinate 
classification efforts and promote a standardized classification system for organizing coded data for 
storage, retrieval, and analysis. Using a standardized system, disease information that is collected by 
various medical professionals can be compared, grouped, and tabulated for statistical purposes. Definitive 
information about disease classification in the United States is available from the National Center for 
Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) (see 
http://www.cdc.gov/nchs/icd9.htm). 
 
The ninth revision of the International Classification of Diseases (ICD-9) was in use from 1979 to 1998. 
The United States uses the standard ICD version for coding deaths and in 1979 developed a ‘clinical 
modification’ for use in hospitals (i.e., ICD-9-CM). The clinical modification of the ICD-9 expanded the 
general categories, permitted greater detail and description, and included codes for clinical procedures. A 
large body of ICD-CM coding guidelines and rules was also developed. Since most of the information 
about birth defects comes from clinical records, the discussion below refers primarily to ICD-9-CM. 
However, comments regarding structure and organization are applicable to ICD-9 codes as well. 
 
In 1999, the tenth revision (ICD-10) became operational for coding causes of death on death certificates. 
Although the classification structure is basically unchanged, ICD-10 reflects a significant revision from 
ICD-9. The codes are alphanumeric instead of numeric (as was the case in ICD-9), there are more general 
categories, and the codes are described in greater detail than in earlier versions. As of 2002, NCHS is 
developing the clinical modification ICD-10-CM. (This reference manual will not discuss ICD-10-CM 
until it is implemented).  
 
Of importance to birth defects surveillance is the fact that, although ICD-9-CM is an acknowledged 
standard for coding medical information, it is not optimal for the level of detail required for coding many 
birth defects. 
 
In 1979 the British Paediatric Association (BPA) developed a classification of diseases by modifying ICD-
9-CM (British). In 1983, staff in CDC’s birth defects branch modified the BPA coding system and 
developed a classification system specific to birth defects coding. The 6-digit CDC code is a classification 
system that allows coding of more detailed descriptions of birth defects and related conditions (see 
Appendix 5.2 for a complete listing of the 6-digit CDC codes). 
5.2.1  Description and Format 
The ICD-9-CM and the 6-digit CDC coding systems are divided into general categories that include body 
systems, medical conditions, and other health-related issues. The codes are hierarchical and expand to 
reflect specific conditions within a general category. Each code category is populated with specific diseases 
and related conditions. In ICD-9-CM the majority of the codes used in birth defects programs is between 
the code categories 740 and 759, which come under the general heading of ‘congenital anomalies’. The 
ICD-9-CM and the 6-digit CDC coding systems utilize a similar format for categorizing disease. ICD-9-
CM utilizes up to five digits, while the CDC coding system utilizes six. 
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5.2.2  ICD-9-CM and the 6-digit CDC Code – A Comparison 
In most cases, the first four digits of the 6-digit CDC code are identical to the first four digits of the ICD-9-
CM code. This enables birth defects programs to utilize the coded data collected from hospital data sets, 
while at the same enhancing the level of coding detail for birth defects program use. Since, the 6-digit 
CDC code usually collapses into the ICD-9-CM at the fourth-digit level, programs that use ICD-9-CM 
codes have data that are comparable between states.  
 
The most significant difference between ICD-9-CM and the 6-digit CDC code is reflected in the level of 
detail indicated by the sixth digit. The sixth digit can be used to indicate one of three aspects of the defect: 
 Laterality of the defect   
.001  Left side only 
.002  Right side only 
.003  Unilateral, unknown which side 
.004  Bilateral; both sides 
 Greater specificity for a particular defect  
.005  Example: 756.615 Diaphragmatic hernia (Bochdalek) 
.006  Example: 756.616 Diaphragmatic hernia (Morgagni) 
.007  Example: 756.617 Hemidiaphragm  
 Incomplete confirmation of a defect (includes possible or probable or only diagnosed prenatally)  
.008  Example: 745.498 Probable Ventricular Septal Defect (VSD)
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5.3  Classification Issues That Affect Surveillance Systems 
It is important to recognize that there are advantages and disadvantages associated with both the ICD-9-
CM and 6-digit CDC coding systems. Programs need to be aware of the ways in which these may affect 
data quality and other surveillance activities.  
 
 Any coding system is limited to the number of literal descriptions assigned to a code in the system. In 
other words, there may be synonyms for one birth defect, or many related birth defects may be 
assigned to one code. The disease index provided in Appendix 5.1 is a tool that can be used to assist 
with coding. This alphabetic cross-linked index of birth defects and corresponding 6-digit CDC codes 
was developed by the Texas Birth Defects Monitoring Program. The cross-linked index is an 
expansion of the ICD-9-CM Congenital Anomalies category 740-759.9 and includes multiple disease 
descriptions, synonyms, and other descriptive terms that are used to describe birth defects. 
 Classification systems provide a framework for coding but often do not provide compatible definitions 
of diagnoses. Clinical case definitions and case definitions used for public health surveillance are not 
always the same. Surveillance systems must specify how clinical documentation should be used to 
determine the appropriate disease code. See Chapter 3 on Case Definition for a discussion of ways to 
determine how birth defects should be coded.  
 Diagnostic categories are not consistent in the amount of detail they provide, nor are they always 
clear. For instance, the chromosomal anomaly category (758) is very general. The musculoskeletal 
system (754-756) is not well-defined. Additionally, all birth defects are not identified with an explicit 
code, so there can be questions about how to code a particular defect or whether it should be coded at 
all.  
 A single ICD-9-CM code may be used to describe several different defects. This may make it difficult 
to use the code to recover specific information. For example, codes such as those listed below present 
challenges because of the potential heterogeneity of the defects included under a given code:  
• 742.2  Reduction deformities of brain (includes holoprosencephaly and absent corpus 
callosum) 
• 747.21  Anomalies of aortic arch (includes overriding aorta and double aortic arch) 
• 753.0  Renal agenesis and dysgenesis (includes absent kidney and hypoplasia of kidney) 
• 756.0  Anomalies of skull and face bones (includes hypertelorism and craniosynostosis) 
• 756.79  Other congenital anomalies of abdominal wall (includes gastroschisis and 
omphalocele)  
 ICD-9-CM codes do not reflect the status of the diagnosis. For example, a condition may be possible 
or probable. This is problematic when birth defects are reported to the surveillance system in coded 
format, or when programs use the hospital disease index in case finding.  
 How information is coded in an administrative database (e.g., hospital disease index, hospital 
discharge data, Medicaid data) is determined by the methods used to assign codes and by the 
objectives of those who maintain the database. In other words, code use is defined by the “business 
operations” of the facility or organization doing the coding. For example, the ICD-9-CM classification 
system is used primarily in hospitals and other care settings to comply with federal financial 
justification for payment. Coding decisions made by someone with that goal in mind could be different 
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from those made by someone coding for a surveillance system. 
 Professional disease coding training and courses for ICD-9-CM are beneficial in providing a good 
foundation for training staff regardless of the surveillance approach being used (i.e., active or passive 
case ascertainment). Information on such courses is available from the American Health Information 
Management Association (http://www.ahima.org).
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5.4  Guidelines for Effective Coding 
As noted earlier, the primary goal in coding information is to provide accurate, consistent, and 
concise representation of that information. Coded diagnostic information is easier to analyze, 
compare, retrieve, and store. All of these attributes promote the use and dissemination of 
information between systems. The use of computer technology and the development of particularly 
large databases have accelerated the demand for coded information. The standardization of 
information that is translated into a code or discrete data element is one of the objectives of the 
Health Insurance Portability and Accountability Act of 1996 (HIPAA). For a thorough discussion 
of birth defects coding, see Rasmussen and Moore (2001). 
 
Programs should:  
 
 Develop well-defined surveillance case definitions. This includes identifying the 
characteristics of eligibility (e.g., demographics, pregnancy outcome, gestational age), and 
specific birth defects or diagnosis. These issues are discussed in Chapter 3 on Case Definition.  
 Understand that the disease classification system and associated coding guidelines are 
developed to standardize results and assist in decision-making. The coding rules for ICD-9-
CM as used by hospitals are established at the federal level through a set of guidelines 
administered, maintained, and updated by NCHS. To comply with these federal standards, a 
hospital coder may be required to use codes that differ from those used by a surveillance 
system coder. The 6-digit CDC code is supported by a body of guidelines and procedures that 
specifically address issues in assigning codes to birth defects. Coding rules for the 6-digit 
CDC code are detailed and have many exceptions. For example, when using the 6-digit CDC 
code, there may be exceptions in the laterality rule (i.e., does not apply to all diagnoses).  
 Adapt surveillance procedures and the database to disease code changes as they occur. ICD-9-
CM codes and code definitions are subject to rule changes, additions, deletions, and edits. 
ICD-9-CM changes are usually timed to coincide with the beginning of the federal fiscal year. 
It is essential for programs that use administrative databases to be aware of these code 
changes.  
 Track disease code changes. Consider adding a date field to each disease code listed in the 
database. Disease codes are added, deleted, or edited by the authoritative agency, usually on an 
annual basis. Any code assignment change may affect statistical analysis or other evaluation 
activities. Tracking disease code changes will be an essential task when ICD-10-CM replaces 
ICD-9-CM. 
 Assign a disease code to each diagnosis that is reportable to the program. This facilitates 
building a database of eligible disease codes (conditions), which can be incorporated into 
abstracting software (e.g., drop-down windows) and used to develop queries and generate lists. 
  
 Identify the disease classification system that is to be used. Some programs may use more 
than one disease classification system.  
 
Examples:  
• An active case ascertainment system might only use the 6-digit CDC code.  
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• A passive case ascertainment system might only use the ICD-9-CM classification 
system. 
• A passive case ascertainment system might use the 6-digit CDC code if the program 
receives case reports in a descriptive or literal format and if surveillance staff assign 
codes. 
• A passive case ascertainment system might use ICD-9-CM for case reports that are 
submitted to the program, but might use the 6-digit CDC code when staff actively 
review medical charts or for special projects.  
 Promote the use of the 6-digit CDC code where possible. Because the CDC code conveys 
greater detail, surveillance systems should ideally incorporate this coding system into regular 
program operations. This may be easier for active ascertainment systems, as passive case 
ascertainment systems are often limited to the standard classification system in use at hospitals 
(i.e., ICD-9-CM). However, in order to promote consistency, accuracy, completeness, and 
comparability across birth defects programs, passive case ascertainment should use the 6-digit 
CDC code whenever possible.  
 Use the NBDPN Abstractor’s Instructions cited in Chapter 3 on Case Definition. This tool 
should be used as a reference for the birth defects that are central to the NBDPN. It describes 
the diagnosis and identifies the appropriate disease code.  
 Use technical reference materials. For example, The International System for Human 
Cytogenetic Nomanclature (ISCN) is the definitive guide to understanding the classification 
system used in cytogenetics (Mitelman, 1995). The text provides information on definitions, 
on how to read and understand karyotypes, and on other technologies used in laboratory 
analysis. Surveillance systems can use the ISCN as a tool to assist in assigning a disease code 
to a case with a chromosomal anomaly.  
 Use clinicians for advice on understanding medical conditions and for providing guidance on 
assignment of disease codes.  
 Develop coding procedures for abstractors, especially as relates to standardized methods for 
translating medical information into a disease code. Document decision items that result from 
coding discussions through the use of a decision log or similar record-keeping system. 
Surveillance systems that are research based may require a different set of procedures than a 
surveillance system that is focused on providing services. The NBDPN Abstractor’s 
Instructions cited in Chapter 3 on Case Definition provide a good foundation.  
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5.5  Coded Data Quality Issues 
Many factors can affect the quality of coded data. As mentioned earlier, any disease coding system 
has limitations. Additionally, the translation of a medical diagnosis into a disease code requires 




 Promote coding to the highest degree of accuracy, completeness, and consistency as required 
by the surveillance system and as recommended by the NBDPN.  
 Develop methods to identify situations that may result in inconclusive or incomplete 
diagnoses. This is particularly important for programs that work with or receive diagnosis 
information in coded format. Programs can use length-of-stay patterns, type of diagnosis, and 
type of data source (e.g., prenatal diagnosis center) to determine whether follow-up is 
necessary. For example, a chromosomal anomaly diagnosed during the newborn period may be 
a ‘suspect’ condition at discharge, pending receipt of laboratory results.  
 Code all individual defects associated with a chromosomal anomaly, syndrome, or association, 
unless a coding rule or the NBDPN Abstractor’s Instructions cited in Chapter 3 on Case 
Definition specify otherwise (see next recommendation). Code the major chromosomal 
anomaly or syndrome as well. Some of the most frequently diagnosed syndromes are listed in 
the category 759.8 in the 6-digit CDC code (see Appendix 5.2). 
• Chromosomal anomalies should be coded to the highest degree of detail that is provided 
by the karyotype. 
• Birth defects that are components of syndromes identified by 759.8x should be coded 
separately.  
 Identify those birth defects that are exceptions to the ‘code all defects’ rule outlined above. 
For some diagnoses, all birth defects related to the condition may not need to be coded. Refer 
to the NBDPN Abstractor’s Instructions cited in Chapter 3 on Case Definition for a listing and 
description of these conditions. Develop methods to query the database to find potentially 
“extra” disease codes. This often occurs with passive case ascertainment using multiple data 
sources. Some sources may report the major birth defect, while others may report each defect 
within the major diagnosis. 
 Code at the most specific level possible. For example, if the specific heart defect is known, it 
is essential to list the specific defect rather than a more general description such as ‘congenital 
heart disease’. Passive case ascertainment systems may find it useful to develop data quality 
audits to identify diagnoses that frequently are assigned general or non-specific codes and that 
may merit follow-up.  
 Develop computer edit checks to identify problems with code use. For example, some 
conditions should be combined under a single code. These include spina bifida and 
hydrocephalus, imperforate anus and anal fistula, esophageal atresia and tracheoesophageal 
fistula, tetralogy of fallot, and cleft lip and palate. Edit checks can also be developed for 
gender-specific conditions and for conditions that may also be acquired (e.g., hydrocephalus, 
skeletal deformations). Edit checks can further be used to identify codes for defects that should 
not be counted due to gestational age, birth weight, or other established eligibility criteria.  
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 Develop methods for identifying general or non-specific codes, miscodes, inappropriate or 
redundant codes, or unusual combinations of coded data in a case abstract or case record.  
 Evaluate the accuracy and consistency of code assignment. Conduct evaluations to determine 
the level of agreement in code assignment among program staff, as well as between staff and 
acute care coders in hospitals. This is particularly effective in identifying differences that result 
due to federal ICD-9-CM coding guidelines. Identify problem areas and implement quality 
control procedures as necessary. 
 Develop coding procedures documentation especially regarding decision items, discussion 
points, or code assignments. Identify implementation dates.  
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5.6  Tips and Hints 
 Coded data can be used to enhance surveillance capability, as they are easily 
manipulated and queried in a database. For example:   
• Birth defects case records that have multiple disease codes can be identified and 
investigated further to determine whether an underlying condition or syndrome is 
present.  
• Birth defects codes that are included or excluded due to specific criteria can be 
identified and flagged.  
 Administrative databases, especially hospital discharge data, use the ICD-9-CM coding 
system. Discharge data can be used for specific screening purposes. For example: 
• Maternal pregnancy disease codes may identify potential birth defects cases, especially 
if the pregnancy results in a fetal demise. 
• Possible cases of birth defects can be queried using disease codes for prematurity, low 
birth weight, stillbirths, etc. 
 Some programs may find it helpful to retain the complete descriptive text of the birth 
defect. As previously stated, disease coding systems have limitations. While birth defects 
are translated to the most accurate disease code, the code may not be precise enough in 
describing the birth defect.  
 Patterns of disease code assignment for particular birth defects may vary between 
hospital disease coders. During case finding and abstracting and when reviewing medical 
records, it is helpful to be observant of coding patterns and inclinations. In many 
instances, disease codes are listed in the medical records, which helps with these informal 
assessments. 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                          rev. 06/04 
Chapter 5     5-11        Classification and Coding 
5.7  References 
American Health Information Management Association. The lead organization in the development 
of professional practice standards for health information management, including training in ICD-9-
CM. http://www.ahima.org 
 
British Paediatric Association (BPA). Classification of Diseases. London, England: British 
Paediatric Association; 1979. 
 
Centers for Disease Control and Prevention, Metropolitan Atlanta Congenital Defects Program. 
1998 Procedures Manual, Appendices A and B, CDC 6-digit code list. January 1998. For copies 
send request by e-mail to macdp@cdc.gov or fax 404-498-3040. 
 
Mitelman FS, ed. International System for Human Cytogenetic Nomenclature. Farmington, CT: 
Karger Publishers, Inc.; 1995.  
 
National Center for Health Statistics (NCHS). The authoritative agency for ICD-9-CM. 
http://www.cdc.gov/nchs/icd9.htm 
 
National Center for Health Statistics (NCHS). International Classification of Diseases, 9th 
Revision, Clinical Modification. Washington, DC: National Center for Health Statistics and the 
Health Care Financing Agency; 1998.  
 
Rasmussen SA, Moore CA. Effective coding in birth defects surveillance. Teratology. 2001;64:53-
57. 
 
Rev. 05/30/03 1 
 
Appendix 5.1 
Texas Disease Index 
 
 
The Texas Birth Defects Monitoring Division (TBDMD) created the Texas Disease Index to be used in 
conjunction with the six-digit codes for reportable birth defects developed by the National Center for 
Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention (CDC). 
The six-digit birth defect codes, commonly called the BPA code, were developed based on the British 
Pediatric Association (BPA) Classification of Diseases (1979) and the World Health Organization’s 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) (1979). 
 
The Texas Disease Index was developed for use by the TBDMD, which utilizes active case ascertainment. 
In addition to being useful to other surveillance programs that carry out active case ascertainment, it is 
also a valuable resource for systems that have passive case ascertainment based on reporting by standard 
ICD-9-CM codes.   
 
It should be noted that the TBDMD made some modifications to the BPA code list. Therefore the Texas 
Disease Index may deviate slightly from the six-digit CDC code list used by other active case 
ascertainment surveillance programs, which is included as an appendix to these guidelines by reference to 
the website. Most of the modifications relate to birth defects that were not listed explicitly in the original 
BPA codes. These additional birth defects have been reviewed by various TBDMD staff, including two 
clinical geneticists, and appropriate BPA codes have been assigned to them.   
 
Note that for ease of use a diagnosis may be listed in more than one format in this index. For example, 
‘absent eye’ may be found under ‘absent, eye’ or ‘eye, absent. 
 
The TBDMD revises this index periodically, indicating the revision date on each page. New revisions will 
be made available through the surveillance guidelines and standards webpage. 
 




British Paediatric Association (BPA). Classification of Diseases. London, England: British Paediatric 
Association; 1979. 
 
National Center for Health Statistics (NCHS). International Classification of Diseases, 9th Revision, 
Clinical Modification. Washington, DC: National Center for Health Statistics and the Health Care 
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Aarskog syndrome - 759.800 
Abdominal 
cyst NOS - 759.990 
mass NOS - 759.990 
Abdominal wall 
benign neoplasm - # 216.500 
other and unspecified anomalies - 756.790 
Abduction 
foot - L 754.690 
hip - x 
Aberrant 
innominate artery - L 747.640 
subclavian artery - L 747.640 
Ablepharon - L * 743.630 
Absent - see also agenesis, atresia 
adrenal gland - L 759.100 
alimentary tract, NOS (complete or partial) - 751.800 
anus 
with fistula - 751.230 
without fistula - 751.240 
aorta - 747.200 
aortic valve - 746.480 
appendix - 751.200 
arm - L 755.200 
auditory canal (without hypoplastic pinna) - L 744.000 
auricle - L 744.010 
bladder - 753.800 
brain - 740.000 
breast 
nipple absent - L 757.600 
nipple present - L 757.610 
broad ligament - L 752.100 
bronchus - L 748.350 
carotid artery - L 747.640 
cervix (genital) - 752.400 
clitoris - * 752.450 
colon - 751.200 
diaphragm - L 756.600 
digestive system, NOS (complete or partial) - 751.800 
digit, NOS - L 755.440 
duodenum - 751.100 
ear - L 744.010 
ear canal (without hypoplastic pinna) - L 744.000 
external genitalia 
female - * 752.440 
male - 752.880 
eye - L 743.000 
eyebrow - L 744.880 
eyelash - L * 743.630 
eyelid - L * 743.630 
face - L 744.880 
fallopian tube - L 752.100 
femur (total or partial) 
only - L 755.320 
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with absent tibia and fibula (total or partial)- L 755.310 
with absent tibia, fibula, and foot - L 755.300 
fibula 
only (total or partial) - L 755.366 
with absent femur (total or partial) and tibia - L 755.310 
with absent femur (total or partial), tibia, and foot - L 755.300 
with absent tibia - L 755.320 
with absent tibia and foot - L 755.330 
finger 
fifth (with or without fourth) - L 755.270 
first (thumb) - L 755.260 
first (thumb) and absent radius (total or partial) - L 755.260 
NOS - L 755.240 
third (with or without second, fourth) - L 755.250 
with absent forearm long bone - L 755.265 
fontanelle - # 754.040 
foot 
only - L 755.340 
with absent femur (total or partial), tibia, and fibula - L 755.300 
with absent lower leg - L 755.330 
with absent tibia and fibula (total or partial) - L 755.330 
forearm 
long bone with absent fingers - L 755.265 
only - L 755.220 
with absent hand - L 755.230 
with absent upper arm - L 755.210 
foreskin - 752.860 
genitalia (sex unknown) - * 752.790 
hand 
only - L 755.240 
with absent forearm - L 755.230 
with absent humerus (total or partial), radius, and ulna - L 755.200 
with absent radius and ulna (total or partial) - L 755.230 
head - 740.080 
humerus (total or partial) 
only - L 755.220 
with absent radius, and ulna - L 755.210 
with absent radius, ulna, and hand - L 755.200 
ileum - 751.120 
intestine 
large - 751.200 
small - 751.190 
small, with fistula - 751.195 
iris - L 743.420 
jejunum - 751.110 
kidney 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
lacrimal apparatus - L 743.640 
leg - L 755.300 
lens - L 743.300 
limb, NOS - L 755.400 
liver, total or partial - 751.600 
long bone leg with absent toe - L 755.360 
lower leg 
only - L 755.320 
 
    L  = code laterality           # = conditional inclusion   
    x  = exclusion             * = special instruction 
Rev. 05/30/03
4 
with absent foot - L 755.330 
with absent thigh - L 755.310 
lung - L 748.500 
meatus (external auditory, ear) - L 744.000 
mitral valve - 746.505 
muscle - L 756.810 
nail - L 757.500 
nares - 748.100 
nasal septum - # 748.180 
neck - # 744.900 
nipple 
only - L 757.630 
with absent breast - L 757.600 
nose - 748.100 
olfactory nerve - 742.270 
ovary - L 752.000 
palate 
hard - 749.030 
NOS - 749.090 
soft - 749.070 
pancreas - 751.700 
patella - L 755.647 
penis - 752.850 
phalange (isolated) 
finger - L 755.240 
toe - L 755.340 
pinna (ear) - L 744.010 
pulmonary arteriovenous - L 747.340 
pulmonary artery - L 747.300 
pulmonary valve - 746.000 
punctum lacrimale - L 743.640 
radius 
only (total or partial) - L 755.260 
with absent humerus (total or partial) and ulna - L 755.210 
with absent humerus (total or partial), ulna, and hand - L 755.200 
with absent thumb - L 755.260 
with absent ulna - L 755.220 
rectum 
with fistula - 751.210 
without fistula - 751.220 
renal artery - L 747.610 
respiratory organ NOS - 748.900 
rib - L 756.300 
right superior vena cava - x 
septum between aorta and pulmonary artery - 745.000 
septum pellucidum - 742.210 
skin - 757.395 
spleen - 759.000 
sternocleidomastoid muscule - L 754.100 
sternum - 756.350 
stomach 
with absent GI tract - 750.780 
with rest of GI tract intact - 750.700 
superior vena cava, right - x 
tarsal bones - L 755.340 
tendon - L 756.820 
testicle - L 752.800 
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thigh and lower leg - L 755.310 
thymus - * 759.240 
tibia 
only (total or partial) - L 755.365 
with absent femur (total or partial) and fibula (total or partial)- L 755.310 
with absent femur (total or partial), fibula, and foot - L 755.300 
with absent fibula - L 755.320 
with absent fibula (total or partial) and foot - L 755.330 
with absent first toe (with or without second toe) - L 755.365 
toe 
fifth (with or without fourth) - L 755.366 
first toe (with or without second toe) - L 755.365 
first toe (with or without second toe) and tibia (total or partial) - L 755.365 
NOS - L 755.340 
third (with or without second, fourth)- L 755.350 
with absent long bone leg - L 755.360 
tongue - 750.100 
ulna 
only (total or partial) - L 755.270 
with absent humerus (total or partial) and radius - L 755.210 
with absent humerus (total or partial), radius, and hand - L 755.200 
with absent radius - L 755.220 
upper arm 
only - L 755.220 
with absent forearm - L 755.210 
ureter - L 753.400 
urethra - 753.800 
uterus - 752.300 
uvula - 749.080 
vagina (complete or partial) - 752.410 
vena cava (except left superior) - 747.480 
vulva - * 752.440 
Acardiac twins - 759.480 
Accessory - see also extra 
adrenal gland - L 759.120 
auricle - L # 744.100 
carpal bone - L 755.525 
breast (with accessory nipple) - L 757.620 
digit - see polydactyly 
finger - see polydactyly 
kidney - L 753.300 
lung lobe - L 748.620 
nipple 
only - L # 757.650 
with accessory breast - L 757.620 
nose - 748.110 
ovary - L 752.020 
pancreas - 751.710 
spleen - 759.040 
toe - see polydactyly 
ureter - L 753.410 
Achalasia of cardia - 750.720 
Achilles tendon, short - L 754.720 
Achondrogenesis 
type I - 756.480 
type II - 756.480 
Achondroplastic dwarfism - 756.430 
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Acne, neonatal - x 
Acrania - 740.010 
Acrocallosal syndrome - 759.890 
Acrocephalosyndactyly 
NOS - 756.050 
other specified - 756.057 
type I - 756.055 
type II - 756.055 
type III - 756.056 
Acrocephaly - 754.080 
Acrodactylia  
finger - L # 755.500 
toe - L # 755.600 
Acyanotic congenital heart disease - 746.920 
Adams-Oliver syndrome - 759.840 
Adduction foot - L 754.590 
Adductus 
metatarsus - L # 754.520 
Adhesion of omentum and peritoneum - 751.420 
Adrenal gland 
absent - L 759.100 
accessory - L 759.120 
dysgenesis - L 759.180 
ectopic - L 759.130 
enlarged - L 759.180 
fused  - L 759.180 
hyperplasia, congenital 
classical (salt) water - # 255.200 
classical (simple virilizer) - # 255.210 
NOS - # 255.290 
other than 21-OHP deficiency - # 255.240 
hypoplasia - L 759.110 
other specified anomalies - L 759.180 
unspecified anomalies - L 759.190 
Adrenogenital syndrome - # 255.290 
Aganglionosis of intestine 
beyond the rectum - 751.310 
involving no more than the anal sphincter and the rectum - 751.320 
total - 751.300 
Agenesis - see also absent 
bile duct - 751.650 
cervix (genital) - 752.400 
gallbladder - 751.630 
hepatic duct - 751.650 
kidney 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
liver, total or partial - 751.600 
lung - L 748.500 
nose - 748.100 
ovary - L 752.000 
pancreas - 751.700 
uterus - 752.300 
vagina (complete or partial) - 752.410 
vertebrae 
cervical - 756.146 
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lumbar - 756.166 
sacral - 756.170 
thoracic - 756.156 
Aglossia - 750.100 
Agnathia - * 524.000 
Agnathia formation complex - 759.800 
Agyria - 742.240 
Aicardi syndrome - 759.890 
Alae nasae hypoplasia - # 748.180 
Alagille syndrome - 759.870 
Albers-Schonberg syndrome - 756.540 
Albinism - # 270.200 
Albright-McCune-Sternberg syndrome - 756.510 
Alimentary tract 
absent (complete or partial) - 751.800 
duplication - 751.810 
ectopic - 751.820 
obstruction, NOS - 752.900 
other specified anomalies - 751.880 
unspecified anomalies - 751.900 
Almond shaped eye - L # 743.800 
Alopecia - 757.400 
Alport syndrome - 759.870 
Ambiguous genitalia - * 752.790 
Amelia 
arm - L 755.200 
leg - L 755.300 
limb, NOS - L 755.400 
Amniotic 
bands - # 658.800 
cyst - # 658.800 
Amputation, NOS 
arm - L 755.285 
leg - L 755.385 
limb, NOS - L 755.420 
Amsterdam dwarf - 759.820 
Amyelia - 742.500 
Amyoplasia congenita - 756.840 
Amyotrophia congenital - 756.840 
Anasarca - # 778.000 
Androgen insensitivity syndrome - 257.800 
Anencephaly - 740.020 
other - 740.080 
Aneurysm 
aorta - 747.270 
arteriovenous (brain) - L 747.800 
atrial septum - x 
pulmonary artery - 747.330 
sinus of Valsalva - 747.240 
tricuspid valve - 746.100 
Angelman syndrome - 759.890 
Angulation of tibia - L * 755.630 
Aniridia - L 743.420 
Anisocoria - L 743.440 
Ankle 
anomalies - L 755.620 
other specified deformities - L 754.780 
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Ankyloblepharon - L * 743.630 
Ankyloglossia - # 750.000 
Annular pancreas - 751.720 
Anomalous portal vein termination - 747.440 
Anomalous pulmonary venous return 
partial - 747.430 
total - 747.420 
total/partial not specified - 747.480 
Anonychia - L 757.500 
Anophthlmos - L 743.000 
Anotia - L 744.010 
Anovaginal fistula - 752.420 
Anterior 
frenulum (tongue, lingual) - # 750.000 
segment of eye 
other specified colobomas - L 743.480 
other specified anomalies - L 743.480 
unspecified anomalies - L 743.490 
urethral valve - 753.620 
Anteversion of femur - L 755.650 
Antimongolian syndrome - 758.300 
Antimongoloid slant to eyes - L # 743.800 
Anus/anal 
absent 
with fistula - 751.230 
without fistula - 751.240 
atresia 
with fistula - 751.230 
without fistula - 751.240 
benign neoplasm - # 216.500 
displaced - 751.530 
duplication - 751.500 
dysgenesis with fistula - 751.230 
dysgenesis without fistula - 751.240 
ectopic - 751.530 
fissure - x 
fistula - 751.540 
imperforate 
with fistula - 751.230 
without fistula - 751.240 
stenosis 
with fistula - 751.230 
without fistula - 751.240 
Aorta/Aortic 
artery 
absent - 747.200 
absent septum between pulmonary artery and - 745.000 
aneurysm - 747.270 
atresia - 747.200 
coarctation  
distal - 747.110 
juxtaductal - 747.190 
postductal - 747.110 
preductal - 747.100 
proximal - 747.100 
unspecified - 747.190 
collateral vessel involving - 747.280 
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dextroposition - 747.260 
dilatation - 747.270 
double arch - 747.250 
enlarged - 747.270 
hypoplasia - 747.210 
interrupted arch - 747.215 
large - 747.270 
malaligned - 747.260 
narrow - 747.210 
other specified anomalies - 747.280 
overriding - 747.260 
pseudocoarctation - 747.280 
right arch - 747.230 
small - 747.210 
supra-aortic stenosis - 747.220 
supravalvular - 747.220 
unspecified - 747.290 
NOS 
septal defect - 745.010 
stenosis - 746.300 
subvalvular stenosis - 746.300 
valve 
abnormal - 746.490 
absent - 746.480 
atresia - 746.480 
bicuspid - * 746.400 
dysmorphic - 746.480 
dysplastic - 746.480 
hypoplastic - 746.480 
incompetence - * 746.400 
insufficiency - * 746.400 
other specified - 746.480 
quadricuspid - 746.480 
regurgitation - * 746.400 
small - 746.300 
stenosis - 746.300 
thickened - 746.480 
unspecified - 746.490 
Aortic annulus - see aortic valve 
Aortopulmonary window - 745.010 
Apert syndrome - 756.055 
Aphakia - L 743.300 
Aplasia - see also absent, agenesis 
cutis  
not involving scalp - 757.395 
scalp - 757.800 
eye - L 743.100 
penis - 752.850 
red cell - # 284.000 
scrotum - L * 752.810 
testicle - L * 752.810 
Appendix 
absent - 751.200 
atresia - 751.200 
duplication - 751.500 
stenosis - 751.200 
testicle - L 752.870 
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transposition - 751.510 
Aqueductal stenosis (without spina bifida) - 742.300 
Aqueduct of Sylvius anomalies without spina bifida - 742.300 
Arachnodactyly 
finger - L # 755.500 
toe - L # 755.600 
Arachnoid cyst - x 
Arm 
absent - L 755.200 
amelia - L 755.200 
amputation, NOS - L 755.285 
benign neoplasm - L # 216.600 
hyperextensibility - L 755.580 
hypomelia - L 755.585 
hypoplasia - L 755.585 
intercalary reduction defect - L 755.210 
long - x 
longitudinal reduction defect 
NOS - L 755.265 
postaxial - L 755.270 
preaxial - L 755.260 
other anomalies (whole) - L 755.560 
other specified anomalies - L 755.580 
other specified reduction defect - L 755.280 
phocomelia - L 755.210 
positional deformity - L 755.580 
short - L 755.580 
transverse reduction defect, NOS - L 755.285 
unspecified anomalies - L 755.590 
unspecified reduction defect - L 755.290 
Arnold-Chiari malformation 
with spina bifida - 741.010 
without spina bifida - 742.480 
Arrhinencephaly - 742.270 
Arrhythmias, cardiac, NOS - 427.900 
Arteriovenous malformation 
brain - L 747.800 
peripheral - L 747.620 
Arthrogryposis multiplex congenita - L 755.800 
Ascites, congenital - # 778.000 
Asphyxiating thoracic dystrophy - 756.400 
Asplenia - * 759.000 
Association - see syndrome 
Astragaloscaphoid synostosis - L 755.620 
Asymmetry 
brain - x 
calvarium - 754.055 
chest - 754.820 
crying facies - L 351.000 
ears - x 
eyes - x 
face - 754.000 
gluteal cleft - x 
head - 754.055 
jaw - * 756.080 
mouth - L 744.880 
nipples - # 757.680 
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nose - # 748.180 
skull - 754.055 
Atelomyelia - 742.510 
Atresia 
anus 
with fistula - 751.230 
without fistula - 751.240 
aorta - 747.200 
aortic valve - 746.480 
appendix - 751.200 
bile duct - 751.650 
biliary - 751.650 
bladder neck - 753.610 
other and unspecified - 753.690 
cervix (genital) - 752.400 
choanal - L 748.000 
colon - 751.200 
duodenum - 751.100 
esophageal 
without tracheoesophageal fistula - 750.300 
with tracheoesophageal fistula - 750.310 
hepatic duct - 751.650 
ileum - 751.120 
intestine 
large - 751.200 
small - 751.190 
small, with fistula - 751.195 
jejunum - 751.110 
lung - L 748.500 
meatus (urethral, urinary) - 753.630 
mitral valve - 746.505 
nares - L 748.000 
piriform aperature - L 748.000 
pulmonary 
artery 
without septal defect - L 747.300 
with septal defect - L 747.310 
NOS (heart) - 746.995 
valve - 746.000 
vein - 747.480 
pyloric - 751.100 
rectum 
with fistula - 751.210 
without fistula - 751.220 
trachea - 748.330 
tricuspid valve - 746.100 
ureter - L 753.210 
urethra 
anterior - 753.620 
other and unspecified - 753.690 
urinary meatus - 753.630 
vagina (complete or partial) - 752.410 
vas deferens - L 752.830 
Atrioventricular canal 
common - * 745.630 
common, with VSD - * 745.620 
complete - * 745.630 
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complete, with VSD - * 745.620 
Atriventricular septal defect - see atriventricular canal 
Atrioventricular valve 
left - see mitral valve 
right - see tricuspid valve 
single - 746.900 
insufficiency - 746.900 
regurgitation - 746.900 
Atrium/atrial 
common - 745.610 
dilatation - x 
enlarged - x 
hypoplastic - 746.887 
inversion - 746.880 
other defects - 746.887 
septal defect 
aneurysm - x 
fenestrated - 745.510 
fossa ovalis - 745.510 
NOS - * 745.590 
ostium primum - * 745.600 
ostium secundum - 745.510 
other specified - 745.580 
primum - * 745.600 
secundum - 745.510 
vs PFO - * 745.590 
single - 745.610 
Atrophy 
cerebellar - 742.230 
cerebral - 742.480 
cortical (brain) - 742.480 
muscle (specified muscle) B L 756.880 
optic nerve - L 743.520 
testicle - L * 752.810 
umbilicus - # 759.900 
vermian - 742.230 
Auditory canal 
absent - L 744.000 
benign neoplasm - L # 216.200 
small - L 744.000 
stenosis - L 744.000 
Auditory meatal stenosis - L 744.000 
Auricle - see pinna 
Auricular 
pit (ear) - L # 744.410 
septal defect (heart) - * 745.590 
Autosome (chromosome) 
deletion - see deletion 
marker - 758.580 
mosaic - see mosaic 
other specified anomalies - 758.580 
translocation - see translocation 
trisomy - see trisomy  
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Balantic hypospadias - 752.605 
Balantic hypospadias with chordee  - 752.625 
Baller-Gerold syndrome - 759.840 
Band 
amniotic - # 658.800 
heart, anomalous - 746.910 
intestine - 751.420 
Ladd=s - 751.420 
omentum - 751.420 
peritoneum - 751.420 
Barrel chest - 754.820 
Bart syndrome - 757.330 
Basilar craniosynostosis - 756.030 
Bat ear - L # 744.220 
Bathocephaly - * 756.080 
Beaded hair - 757.410 
Beals syndrome - 759.860 
Beckwith syndrome - 759.870 
Beckwith-Wiedemann syndrome - 759.870 
Beemer Langer syndrome - 759.860 
Bell shaped chest - 754.820 
Bell=s palsy - L # 351.000 
Benign external hydrocephaly - x 
Bent nose - # 754.020 
Bicornate uterus - L 752.380 
Bicuspid 
aortic valve - 746.400 
pulmonary valve - 746.080 
tricuspid valve - 746.100 
Bifid - see also cleft, accessory 
nose - 748.120 
rib - L 756.310 
scrotum - 752.820 
sternum - 756.380 
thumb - L 755.010 
uvula - 749.080 
vertebrae 
cervical - 756.140 
lumbar - 756.160 
NOS - 756.180 
sacral - 756.170 
thoracic - 756.150 
xyphoid process - 756.380 
Bilateral superior vena cava - 747.410 
Bile duct 
agenesis - 751.650 
atresia - 751.650 
other anomalies - 761.670 
Biliary  
atresia - 751.650 
dysgenesis - 751.670 
obstruction - x 
Biliary tract anomalies, NOS - 751.680 
Bilirubin excretion disorders - # 277.400 
Bilobar right lung - 748.625 
Biparietal narrowing - * 756.080 
Birthmark, NOS - # 757.385 
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Bitemporal narrowing - * 756.080 
Bladder 
absent - 753.800 
cystocele - 753.820 
diverticulum - 753.820 
ectopic - 753.810 
enlarged - x 
exstrophy - 753.500 
extroversion - 753.500 
hernia - 753.820 
hypertrophy - x 
hypoplasia - 753.880 
hypoplastic - 753.880 
neck 
atresia - 753.610 
other and unspecified atresia and stenosis - 73.690 
stenosis - 753.610 
neurogenic - x 
other specified anomalies - 753.880 
outlet obstruction - 753.690 
prolase (mucosa) - 753.830 
small - x 
thickened - x 
trabeculated - x 
unspecified anomalies - 753.920 
Blepharophimosis - L 743.635 
Blepharophimosis syndrome - 759.800 
Blepharoptosis - L 743.600 
Block, heart - 746.870 
Bloom syndrome - 759.890 
Blue 
baby - 746.930 
Mongolian spot - x 
nevus - see skin-benign neoplasm 
sclera - L * 743.450 
Blueberry muffin spots - x 
BOR syndrome - 759.800 
Body stalk anomaly - 756.790 
Bone 
unspecified anomalies - 756.920 
Bonneville-Ullrich syndrome, NOS - 758.690 
Bourneville=s disease - 759.500 
Bowed/bowing 
femur - L 754.400 
legs, NOS - 754.420 
lip - L 744.880 
lower leg - L 754.410 
fibula - L 754.410 
tibia - L 754.410 
ulna without Madelung deformity - L 755.530 
Box shaped head - 754.080 
Brachial plexus palsy - L # 767.600 
Brachiocephalic trunk, common - L 747.640 
Brachycephaly - 754.080 
Brachydactyly  
finger - L # 755.500 
toe - L # 755.600 
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Bradycardia - x 
Brain 
absent - 740.000 
asymmetry - x 
atrophy - 742.480 
enlarged - * 742.400 
other specified anomalies - 742.480 
small - 742.486 
unspecified - 742.900 
Brainstem  
anomalies - 742.480 
hypoplastic - 742.280 
reduction defect - 742.280 
small - 742.280 
Branch pulmonary artery stenosis - L * 747.325 
Branchial arch syndrome - 759.800 
Branchial cleft 
cyst - L 744.400 
fistula - L 744.400 
other anomalies - L 744.480 
pit - L 744.400 
remnant - L 744.400 
sinus - L 744.400 
Breast 
absent 
nipple absent - L 757.600 
nipple present - L 757.610 
accessory (with accessory nipple) - L 757.620 
benign neoplasm - # 216.500 
ectopic (with nipple) - L 757.620 
hypertrophy - x 
hypoplastic (with hypoplastic nipple) - L 757.610 
other specified anomalies - # 757.680 
small - x 
Broad 
face - 744.910 
hand - L 755.510 
neck - # 744.500 
Broad ligament 
absent - L 752.100 
other and unspecified anomalies - L 752.190 
Bronchiectasis - L 748.610 
Bronchoesophageal fistula - 750.330 
Bronchogenic cyst - L 748.350 
Bronchomalacia - x 
Bronchopulmonary dysplasia - x 
Bronchopulmonary fistula - L 748.350 
Bronchus 
absent - L 748.350 
other anomalies - L 748.350 
other specified anomalies - L 748.380 
stenosis - L 748.340 
unspecified anomalies - 748.390 
Brown syndrome - # 378.000 
Brushfield spots - L # 743.800 
Bulging eye - L # 743.800 
Bullosa 
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epidermolysis - 757.330 
ichthyosis - 757.115 
Bullous type ichthyosis congenita - 757.115 
Buphthalmos - L 743.200 
Buried penis - 752.860 
Butterfly vertebra 
cervical - 756.140 
lumbar - 756.160 
NOS - 756.180 
sacral - 756.170 




Café au lait spots - # 757.390 
Caffey syndrome - 756.530 
Calcaneovalgus - L 754.600 
Calcaneovarus - L 754.510 
Calvarium - see aso skull 
absent - 740.020 
asymmetry - 754.055 
Camptodactyly  
finger - L # 755.500 
toe - L # 755.600 
Camptomelic dysplasia - 756.480 
Camurati-Engelmann syndrome - 756.550 
Canal of Nuck cyst - 752.470 
Cardiomegaly - * 746.860 
Cardiomyopathy - * 746.860 
Cardiomyopathy, hypertrophic - * 746.860 
Cardiospasm - 750.720 
Cardio-splenic syndrome - 759.890 
Cardiovascular system, other specified anomalies - L 747.880 
Carotid artery 
absent - L 747.640 
Carpal bone 
accessory - L 755.525 
Carpenter syndrome - 759.840 
Carp shaped mouth - L 744.880 
Cartilage (ear) 
absent - L * 744.230 
decreased - L * 744.230 
unspecified anomalies - 756.930 
Cat eye syndrome - 758.580 
Cataract 
anterior polar - L 743.325 
NOS - L 743.320 
other specified - L 743.326 
Cauda equina anomalies, other - 742.530 
Caudal dysplasia - 759.840 
Caudal regression syndrome - 759.840 
Cauliflower ear - L * 744.230 
Cavum septum pellucidum - x 
Cebocephaly - 759.800 
Cecum 
duplication - 751.500 
malrotation - 751.400 
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Central nervous system (CNS) hemorrhage - x 
Cephalohematoma - x 
Cephalopagus conjoined twins - 759.410 
Cerebellar atrophy - 742.230 
Cerebellum anomalies - 742.230 
Cerebral/cerebrum 
atrophy - 742.480 
cortical dysplasia - 742.480 
cyst - 742.420 
lipidoses - # 330.100 
reduction deformities - 742.200 
Cerebral vessels, other anomalies - L 747.810 
Cerebro-oculo-facial-skeletal syndrome - 759.890 
Cervical rib - L # 756.200 
Cervix (genital) 
absent - 752.400 
agenesis - 752.400 
atresia - 752.400 
doubling - * 752.480 
other specified anomalies - * 752.480 
unspecified anomalies - 752.490 
Chalasia - x 
CHARGE association - 759.890 
 
Chediak-Higashi syndrome - 757.300 
Cheek 
hypoplastic -L 744.880 
skin tag - L # 744.110 
Chest 
asymmetry - 754.820 
barrel - 754.820 
bell shaped - 754.820 
benign neoplasm - # 216.500 
deformed - 754.820 
funnel - 754.810 
narrow - 754.820 
other anomalies - 754.820 
pigeon - 754.800 
shield - 754.825 
small - 754.820 
Chin  
cleft - x 
dimple - x 
pointed - * 756.080 
receding - 524.000 
small - 524.000 
Choanal 
atresia - L 748.000 
stenosis - L 748.000 
Choledochal cyst - 751.660 
Chondroectodermal dysplasia - 756.520 
Chondrodysplasia - 756.410 
other specified - 756.480 
punctata - 756.575 
with hemangioma - 756.420 
Chondrodystrophy 
other specified - 756.480 
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unspecified - 756.490 
Chordee (penile) 
with hypospadias 
coronal - 752.625 
first degree - 752.625 
glandular - 752.625 
NOS - 752.620 
penile - 752.626 
perineal - 752.627 
scrotal - 752.627 
second degree - 752.626 
third degree - 752.627 
without hypospadias - 752.621 
Choroid (eye) 
coloboma - L 743.535 
specified anomalies - L 743.530 
Choroid plexus cyst 
bilateral - * 742.485 
multiple - * 742.485 
unilateral - x 
Chorioretinitis - # 363.200 
Chromosome 
autosome - see autosome 
NOS 
additional , NOS - 758.910 
deletion, NOS - 758.920 
duplication, NOS - 758.930 
mosaicism, NOS - 758.900 
unspecified anomaly - 758.990 
sex - see sex chromosome 
Chylothorax - # 457.800 
Circulatory system, unspecified anomalies - 747.900 
Cisterna magna, enlarged - 742.380 
Clavicle anomalies - L 755.550 
Claw 
foot - L 755.350 
hand - L 755.250 
Cleft 
alveolar ridge/alveolus - 749.100 
branchial - L 744.400 
chin - x 
ear - L * 744.230 
face/facial - L 744.880 
foot - L 755.350 
gingiva - 749.100 
gum - 749.100 
hand - L 755.250 
laryngotracheoesophageal - 748.385 
larynx - 748.385 
lip 
lateral - 744.800 
with any cleft palate - L 749.200 
central - 749.220 
midline - 749.220 
without cleft palate - L 749.100 
central - 749.120 
midline - 749.120 
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mandible - * 756.080 
mitral valve - 746.505 
mouth, lateral - 744.800 
nose - 748.120 
palate 
with cleft lip - see cleft lip with any cleft palate 
without cleft lip 
hard palate (alone) - L 749.000 
central - 749.020 
midline - 749.020 
NOS (hard/soft not specified) - 749.090 
soft and hard palate - 749.090 
soft palate (alone) - L 749.040 
central - 749.060 
midline - 749.060 
submucosal  
hard - 749.020 
NOS (hard/soft not specified) - 749.090 
soft - 749.060 
tongue - 750.140 
tricuspid valve - 746.100 
uvula - 749.080 
vertebrae 
cervical - 756.140 
lumbar - 756.160 
NOS - 756.180 
sacral - 756.170 
thoracic - 756.150 
Cleidocranial dysostosis - 755.555 
Clenched hand or fist - L # 755.500 
Clenched toes - L # 755.600 
Click, hip - x 
Clifford=s syndrome - x 
Clinodactyly  
finger - L # 755.500 
toe - L # 755.600 
Clitoris 
absent - * 752.450 
enlarged - * 752.450 
hypertrophy - * 752.450 
other anomaly - * 752.450 
prominent - * 752.450 
prominent prepuce - x 
Clitoromegaly - * 752.450 
Cloaca 
exstrophy - 751.550 and 756.790 
persistent - 751.550 
Close set eyes - * 756.080 
Cloudy cornea - L 743.400 
Cloverleaf head shape - 756.000 
Club/clubbed 
fingers - L 754.840 
foot, NOS - L 754.730 
hand - L 754.840 
nail - L 757.540 
Coarctation of aorta 
distal - 747.110 
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juxtaductal - 747.190 
postductal - 747.110 
preductal - 747.100 
proximal - 747.100 
unspecified - 747.190 
Cockayne syndrome - 759.820 
Coffin-Siris syndrome - 759.800 
COFS syndrome - 759.890 
Collateral vessel 
involving aorta - 747.280 
involving pulmonary artery (and not aorta) - L 747.380 
not involving aorta or pulmonary artery - L 747.880 
Collodian baby - 757.110 
Coloboma 
anterior segment 
other - L 743.480 
unspecified - L 743.490 
choroid - L 743.535 
eyelid - L 743.636 
iris - L 743.430 
lens - L 743.340 
NOS - L 743.490 
optic disc/nerve - L 743.520 
retina - L 743.535 
Colon 
absent - 751.200 
atresia - 751.200 
hypoplastic - 751.520 
malrotation - 751.400 
short - 751.520 
small - 751.520 
stenosis - 751.200 
transposition - 751.510 
Colpocephaly - 742.280 
Common 
atrioventricular canal - * 745.630 
atrioventricular canal with VSD - * 745.620 
atrium - 745.610 
brachiocephalic trunk - L 747.640 
ventricle  (heart) - 745.300 
Complete  
atrioventricular canal - * 745.630 
atrioventricular canal with VSD - * 745.620 
mirror reversal of abdominal organs with normal thoracic organs - 759.330 
mirror reversal of all organs - 759.300 
mirror reversal of thoracic organs with normal abdominal organs - 759.320 
Complex - see syndrome 
Concealed penis - 752.860 
Conduction defects (heart) - 746.880 
Cone shaped head - 754.080 
Congenital anomaly, NOS - 759.990 
Congenital contractural arachnodactyly syndrome - 759.860 
Congenital encephalopathy - x 
Congenital heart disease 
acyanotic - 746.920 
cyanotic - 746.930 
NOS - 746.990 
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cephalopagus - 759.410 
craniopagus (head-joined twins) - 759.410 
dicephalus (two heads) - 759.400 
ischiopagus - 759.480 
other specified - 759.480 
pelvis-joined twins - 759.480 
pygophagus (buttock-joined twins) - 759.440 
thoracopagus (thorax-joined twins) - 759.420 
unspecified - 759.490 
xiphopagus (xiphoid-joined twins) - 759.430 
Conjunctivitis - x 
Connective tissue 
other specified anomalies - L 756.880 
unspecified anomalies - 756.940 
Conradi syndrome - 756.575 
Constriction band syndrome - # 658.800 
Contracture 
joint (flexion, individual) - L 755.800 
sternocleidomastoid muscule - L 754.100 
Cor biloculare - 745.700 
Cornea 
cloudy - L 743.400 
enlarged - L 743.220 
leukoma - L 743.400 
opacity - L 743.400 
other specified - L 743.410 
Cornelia de Lange syndrome - 759.820 
Coronal suture 
closed - L 756.010 
craniosynostosis - L 756.010 
fused - L 756.010 
Coronary artery anomalies - 746.885 
Coronary sinus anomalies - 746.885 
Corpus callosum  
anomalies - 742.210 
cyst - 742.420 
Cortex/cortical 
anomalies - 742.200 
atrophy - 742.480 
dysplasia (cerebral) - 742.480 
hyperostosis, infantile - 756.530 
Cor triatriatum - 746.820 
Cor triloculare biatriatum - 745.300 
Costello syndrome - 759.800 
Coxa 
valga - L 755.660 
vara - L 755.660 
Cranial nerve defects - 742.480 
Craniofacial 
abnormality NOS - 756.090 
craniofacial disproportion - 756.090 
dysostosis - 756.040 
other syndromes - 756.046 
Craniorachischisis - 740.100 
Cranioschisis - 740.020 
Craniosynostosis 
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basilar - 756.030 
coronal - L 756.010 
lambdoidal - L 756.020 
metopic - 756.006 
NOS - 756.000 
other - 756.030 
sagittal - 756.005 
squamosal - 756.000 
Craniotabes - x 
Cranium, square - 754.080 
Crease  
ear - L 744.280 
infraorbital - L # 743.800 
palm or hand - see palmar crease 
Crepitus hip - x 
Cri du chat syndrome - 758.310 
Cross fused renal ectopia - 753.320 
Crossed eyes - # 368.000 
Crouzon=s disease - 756.040 
Cryptophthalmos - L 743.000 
Cryptorchidism 
bilateral - * 752.514 
left - L * 752.501 
NOS - * 752.520 
right - L * 752.502 
unilateral - L * 752.500 
Cubitus valgus - L 755.540 
Curvature of spine (postural), NOS - 754.220 
Curved sternum - 754.820 
Cutis aplasia 
not involving scalp - 757.395 
scalp - 757.800 
Cutis laxa hyperelastica - 757.370 
Cutis marmorata - x 
Cyanotic congenital heart disease - 746.930 
Cyclops - 759.800 
Cyst/cystic 
abdominal NOS - 759.990 
adenomatoid malformation lung - L 748.480 
amniotic - # 658.800 
arachnoid - x 
branchial cleft - L 744.400 
bronchogenic - L 748.350 
canal of Nuck - 752.470 
cerebral - 742.420 
choledochal - 751.660 
choroid plexus 
bilateral - * 742.485 
multiple - * 742.485 
unilateral - x 
corpus callosum - 742.420 
dysplasia kidney - L 753.160 
duplication - 751.500 
embryonal (vagina) - # 752.460 
embryonic remnants (male) - L 752.870 
enterogenous - 751.500 
ependymal - 742.420 
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epoophoron - L 752.110 
fimbrial - L 752.120 
Gartner=s duct - L 752.110 
glioependymal - 742.420 
gum - x 
hydatid of Morgagni - L 752.870 
hygroma - 228.100 
intracranial - 742.420 
kidney (single) - L 753.100 
lacrimal apparatus/duct - L 743.660 
liver - 751.610 
lung 
multiple - L 748.410 
other specified - L 748.480 
single - L 748.400 
mediastinum - 748.810 
mesenteric remnant - L 752.110 
ovarian 
multiple - L 752.085 
single - L 752.080 
pancreatic - 751.740 
parovarian - L 752.120 
periventricular - 742.420 
porencephalic - * 742.410 
posterior fossa - 742.230 
preauricular - L # 744.410 
renal (single) - L 753.100 
skin - # 757.390 
spleen - 759.080 
subependymal - 742.420 
thyroglossal - 759.220 
tongue - x 
urachus - # 753.700 
vagina 
embryonal - # 752.460 
other - 752.470 
ventricular (brain) - * 742.485 
vulva - 752.470 
Wharton duct - x 
Wolffian duct - L 752.870 
Cystic fibrosis, no mention of meconium ileus - # 277.000 
Cystic fibrosis, with mention of meconium ileus - # 277.010 
Cystic kidney NOS - L 753.180 
Cystocele bladder - 753.820 




Dacryocystocele - L 743.660 
Dacryostenosis - L # 743.650 
Dandy-Walker syndrome - * 742.310 
Deafness, congenital - L * 744.090 
Defect 
Gerbode - 745.420 
Deletion (chromosome) 
4 - 758.320 
5 - 758.310 
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13 (long arm, q) - 758.330 
17 (long arm, q) - 758.340 
17 (short arm, p) - 758.350 
18 (long arm, q) - 758.340 
18 (short arm, p) - 758.350 
21 (partial or total) - 758.300 
B, NOS - 758.310 
B, NOS - 758.320 
D, NOS (long arm, q) - 758.330 
E (long arm, q) - 758.340 
E (short arm, p) - 758.350 
G, NOS (partial or total) - 758.300 
NOS (unspecified chromosome) - 758.920 
other specified (autosomal) - 758.380 
unspecified (autosomal) - 758.390 
X (partial) - 758.610 
Depressions in skull - # 754.040 
Dermal 
sinus of head - L 744.480 
sinus spine - # 685.100 
Dermoid cyst 
epibulbar - L 743.810 
eye - L 743.810 
Deviation nasal septum - # 754.020 
Dextrocardia 
with complete situs inversus - 759.300 
with situs solitis - 746.800 
without situs inversus - 746.800 
Dextroposition 
aorta - 747.260 
heart - see dextrocardia 
Diamond-Blackfan syndrome (anemia) - # 284.000 
Diaphragm/diaphragmatic 
absent - L 756.600 
elevated - x 
eventration - L 756.620 
hernia 
Bochdalek - L 756.615 
Morgagni - L 756.616 
NOS - L 756.610 
Posterolateral - L 756.615 
other specified anomalies - L 756.680 
paralysis - L 756.680 
unspecified anomalies - L 756.690 
Diaphyseal dysplasia, progressive - 756.550 
Diastasis recti - x 
Diastematomyelia - 742.520 
Diastrophic dwarfism - 756.445 
Didelphys uterus - 752.200 
Diencephalic syndrome - 253.820 
DiGeorge syndrome - 279.110 
Digestive system, NOS 
absent (complete or partial) - 751.800 
duplication - 751.810 
ectopic - 751.820 
fistula 
with urinary tract - 753.860 
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with uterus - 752.320 
obstruction, NOS - 752.900 
other specified anomalies - 751.880 
unspecified anomalies - 751.900 
Digit, NOS 
absent - L 755.440 
accessory - see polydactyly 
extra - see polydactyly 
overlapping - L 755.880 
Digitalized great toe - L # 755.600 
Digitalized thumb - L # 755.500 
Dilatation/dilated/dilation - see also large 
aorta - 747.270 
atrium - x 
esophagus - 750.400 
pulmonary artery - 747.330 
pulmonary valve - 746.080 
renal collecting system 
central - L 753.380 
lower - L 753.480 
upper - L 753.480 
renal pelvis - L 753.380 
tricuspid valve - 746.100 
ureter - L 753.220 
vena cava - 747.480 
ventricle (brain) - 742.390 
ventricle (heart) - x 
Dimple in chin - x 
Disappearing penis syndrome - 752.860 
Disease - see syndrome 
Dislocatable hip - L 754.310 
Dislocation 
elbow - L 754.830 
hip - L 754.300 
knee - L 754.440 
shoulder - x 
tongue - 750.130 
Displaced anus - 751.530 
Displacement 
cardiac through esophageal hiatus - 750.600 
esophagus - 750.410 
stomach - 750.730 
tongue - 750.130 
uterus - 752.310 
Distal arthrogryposis syndrome - L 755.800 
Diverticulum 
bladder - 753.820 
esophagus - 750.420 
Meckel=s - # 751.010 
stomach - 750.740 
urethral - 753.880 
Divisum, pancreas - 751.780 
Dolichocephaly - * 754.030 
Dorsiflexion of foot - L 754.780 
Double - see also duplication 
aortic arch - 747.250 
collecting system (renal) - L 753.410 
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inlet left ventricle - 745.300 
inlet right ventricle - 745.300 
kidney (and renal pelvis) - L 753.310 
meatus (urethral, urinary) - 753.840 
ossification center in the manibrium - 756.380 
outlet left ventricle - 745.180 
outlet right ventricle - 745.180 
ureter - L 753.410 
urethra - 753.840 
urethral orifice - 753.840 
Double orifice mitral valve - 746.505 
Doubling 
cervix - * 752.480 
uterus - 752.200 
vagina - * 752.480 
Down syndrome 
facies - 744.910 
karyotype trisomy 21 - 758.000 
karyotype trisomy G, NOS - 758.010 
mosaic - 758.040 
NOS - 758.090 
translocation trisomy (duplication of a 21) - 758.020 
translocation trisomy (duplication of a G, NOS) - 758.030 
Downturned mouth - L 744.880 
Duane syndrome - # 378.000 
Duct 
bile 
agenesis - 751.650 
atresia - 751.650 
hepatic 
agenesis - 751.650 
atresia - 751.650 
omphalomesenteric - 751.000 
vitelline - 751.000 
Duodenum 
absent - 751.100 
atresia - 751.100 
stenosis - 751.100 
web - 751.560 
Du Pan syndrome - 759.840 
Duplex renal collecting system - L 753.410 
Duplication - see also double/doubling 
alimentary tract, NOS - 751.810 
chromosome - see also trisomy 
NOS - 758.930 
collecting system (renal) - L 753.410 
digestive system, NOS - 751.810 
esophagus - 750.430 
gallbladder - 751.640 
intestine - 751.500 
nail - L 757.580 
pylorus - 751.500 
renal collecting system - L 753.410 
stomach - 750.750 
Dwarf/dwarfism 
Amsterdam - 759.820 
achondroplastic - 756.430 
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diastrophic - 756.445 
hypochondrodysplastic - 756.480 
metatrophic - 756.446 
NOS - 756.490 
thanatophoric - 756.447 
Dysautonomia, familial - 742.810 
Dysgenesis 
adrenal gland - L 759.180 
biliary - 751.670 
Dysostosis 
cleidocranial - 755.555 
craniofacial - 756.040 
mandibulofacial - 756.045 
metaphyseal - 756.450 
radioulnar - L 755.536 
spondylocostal - 756.480 
Dysmorphic  
aortic valve - 746.480 
mitral valve - 746.505 
pulmonary valve - 746.080 
Dysplasia - see also hypoplasia 
aortic valve - 746.480 
bronchopulmonary - x 
caudal - 759.840 
chondroectodermal - 756.520 
cortical (cerebral) - 742.480 
dyssegmental - 756.480 
ears - L * 744.230 
ectodermal 
NOS - 757.340 
other specified - 757.346 
X-linked type - 757.345 
eye - L 743.100 
fronto-nasal - 756.046 
hip 
bilateral - 755.667 
NOS - 755.665 
unilateral - L 755.666 
kidney 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
kyphomelic - 756.480 
mitral valve - 746.505 
multiple epiphyseal - 756.570 
nail - L 757.580 
oculoauriculovertebral - 756.060 
pulmonary valve (not hypoplasia) - 746.080 
polystotic fibrous - 756.510 
progessive diaphyseal - 756.550 
pulmonary valve - 746.080 
rib - L 756.340 
Septo-optic - 742.880 
spondyloepiphyseal - 756.460 
spondylometaphyseal - 756.480 
spondylothoracic - 756.480 
Streeter syndrome/dysplasia - # 658.800 
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tricuspid valve - 746.100 
Dyssegmental dysplasia - 756.480 
Dystrophy/dystrophic 
asphyxiating thoracic - 756.400 
myotonic - 759.890 




Eagle-Barrett=s syndrome - 756.720 
Ear 
absent - L 744.010 
absent carilage - L * 744.230 
anomaly NOS - L 744.300 
appendage (not preauricular) - L # 744.120 
asymmetry - x 
bat - L # 744.220 
benign neoplasm - L # 216.200 
cauliflower - L * 744.230 
cleft - L * 744.230 
crease - L 744.280 
decreased cartilage - L * 744.230 
deformity NOS - L 744.300 
dysplastic - L * 744.230 
elfin - L * 744.230 
hypoplastic (not microtia) - L * 744.230 
inner ear anomalies - L 744.030 
large - L 744.200 
lobule (not preauricular) - L # 744.120 
lop - L * 744.230 
low set - L # 744.245 
malformed - L * 744.230 
middle ear anomalies - L 744.020 
misplaced - L 744.240 
other misshapen - L * 744.230 
other specified - L 744.280 
papilloma - L # 744.120 
pit (not preauricular) - L 744.280 
pit (preauricular) - L # 744.210 
pixie-like - L * 744.230 
pointed - L * 744.230 
posteriorly rotated - L # 744.246 
rotated - L # 744.246 
small (not microtia) - L * 744.230 
tag (not preauricular) - L # 744.120 
unspecified anomalies - L 744.300 
unspecified, with hearing impairment - L * 744.090 
Ear canal - see auditory canal 
Ebstein=s anomaly - 746.200 
Echogenic kidney - x 
Ectodermal dysplasia 
NOS - 757.340 
other specified - 757.346 
X-linked type - 757.345 
Ectopia (ectopic) cordia - 746.880 
Ectopia vesicae - 753.500 
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Ectopic - see also displacement 
adrenal gland - L 759.130 
alimentary tract, NOS - 751.820 
anus - 751.530 
bladder - 753.810 
breast (with accessory nipple) - L 757.620 
digestive system, NOS - 751.820 
heart - 746.880 
kidney - L 753.330 
lung tissues - L 748.600 
nipple 
only - L # 757.650 
with accessory breast - L 757.620 
pancreas - 751.730 
pupil - L 743.440 
spleen - 759.050 
testicle - L 752.530 
ureter - L 753.420 
urethra - 753.850 
urethral orifice - 753.850 
Ectrodactyly 
foot - L 755.350 
hand - L 755.250 
NOS - L 755.440 
Ectrodactyly-Ectodermal dysplasia-Clefting syndrome - 759.840 
Ectropion - L 743.610 
Edema 
hereditary, of legs - 757.000 
not of legs - x 
Edwards syndrome 
karyotype normal (Edwards phenotype) - 758.295 
karyotype trisomy 18 - 758.200 
karyotype trisomy E, NOS - 758.210 
mosaic - 758.240 
NOS - 758.290 
translocation trisomy 18 (duplication or an 18) - 758.220 
translocation trisomy 18 (duplication or an E, NOS) - 758.230 
EEC syndrome - 759.840 
Ehlers-Danlos syndrome - 756.850 
Eisenmenger=s syndrome - 745.410 
Elbow 
anomalies - L 755.540 
dislocation - L 754.830 
hyperextension - L 755.540 
webbed - L 755.800 
Elevated diaphragm - x 
Elfin ear - L * 744.230 
Ellis-van Creveld syndrome - 756.525 
Elongated - see long 
Embryonic remnants (male) cyst - L 752.870 
Embryopathia, NEC - 759.910 
Emphysema, lobar - L 748.880 
Encephalocele 
frontal - 742.085 
frontonasal - 742.085 
occipital - 742.000 
occipitocervical - 742.000 
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other specified site - 742.080 
parietal - 742.086 
posterior - 742.000 
sphenoid - 752.080 
unspecified site - 742.090 
Encephalocutaneous angiomatosis - 759.610 
Encephalopathy, congenital - x 
Enchondromatosis - 756.410 
Endocardial cushion defect 
NOS - 745.690 
other - 745.680 
Endocardial fibroelastosis - 425.300 
Endocrine gland 
other specified anomalies - 759.280 
unspecified anomalies - 759.290 
Endothelial vessel - L 747.880 
Engelmann syndrome - 756.550 
Enlarged - see large 
Enophalmia - L # 743.800 
Enophthalmos - L # 743.800 
Enterogenous - 751.500 
Entropion - L 743.620 
Ependymal cysts - 742.420 
Epiblepharon - L * 743.630 
Epicanthal folds - L # 743.800 
Epidermal nevus syndrome - 757.300 
Epidermolysis bullosa - 757.330 
Epigastric hernia - 756.795 
Epiglottis  
anomalies - 748.300 
hypoplastic - 748.300 
Epiloia - 759.500 
Epiphyseal dysplasia, multiple - 756.570 
Epispadias - 752.610 
Epoophoron cyst - L 752.110 
Epstein=s pearls - x 
Epulis - x 
Equinovalgus - L 754.680 
Equinovarus - L 754.500 
Equinus foot - L 754.730 
Erb=s palsy - L # 767.600 
Escobar syndrome - 759.840 
Esophagus/esophageal 
atresia 
without tracheoesophageal fistula - 750.300 
with tracheoesophageal fistula - 750.310 
dilatation - 750.400 
displacement - 750.410 
diverticulum - 750.420 
duplication - 750.430 
fistula - 750.480 
giant - 750.400 
other specified anomalies - 750.480 
pouch - 750.420 
short - x 
stenosis - 750.340 
unspecified anomalies - 750.910 
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web - 750.350 
Esotropia - # 368.000 
Ethmocephaly - 759.800 
Eustacian tube 
absent - L 744.250 
anomaly - L 744.250 
Eustacian valve - x 
Eventration of diaphragm - L 756.620 
Eversion/everted eyelid - L 743.610 
Eversion foot - L 754.680 
Exencephaly - 740.020 
Exomphalos - 756.700 
Exophthalmos - L # 743.800 
Exostosis - 756.470 
Exotropia - # 378.000 
Exstrophy 
bladder - 753.500 
cloaca - 751.550 and 756.790 
lung - L 748.690 
External auditory meatal stenosis - L 744.000 
External genitalia, absent 
female - * 752.440 
male - 752.880 
Extra - see also accessory 
chromosome - see trisomy 
digit - see polydactyly 
finger - see polydactyly 
renal pelvis - L 753.380 
rib 
in cervical region - L # 756.200 
other - L 756.330 
toe - see polydactyly 
Extremity - see limb 
Extroversion bladder - 753.500 
Eye/eyes 
absent - L 743.000 
agenesis - L 743.000 
almond shaped - L # 743.800 
aplasia - L 743.100 
asymmetry - x 
bulging - L # 743.800 
close set - * 756.080 
crossed - # 368.000 
deep set - L # 743.800 
dysplasia - L 743.100 
enlarged - L 743.210 
flat - L # 743.800 
fused 
closed - L * 743.630 
together - 759.800 
Harlequin deformity - L 743.670 
hypoplasia - L 743.100 
mesodermal dysgenesis - L 743.900 
other specified - L # 743.800 
prominent - L # 743.800  
protruding - L # 743.800 
rudimentary - L 743.100 
 
    L  = code laterality           # = conditional inclusion   
    x  = exclusion             * = special instruction 
Rev. 05/30/03
32 
slant (upward, downward) - L # 743.800 
small - L 743.100 
sunken - L # 743.800 
sun-setting - x 
unspecified - L 743.900 
wide set - 756.085 
Eyebrow 
absent - L 744.880 
Eyelash 
absent - L * 743.630 
long - L * 743.630 
Eyelid 
absent - L * 743.630 
benign neoplasm - L # 216.100 
coloboma - L 743.636 
eversion/everted - L 743.610 
fused - L * 743.630 
other specified - L * 743.630 





absent - L 744.880 
anomaly NOS - 744.910 
asymmetry - 754.000 
asymmetry crying - L 351.000 
benign neoplasm - # 216.300 
broad - 744.910 
cleft - L 744.880 
flat profile - 744.910 
microsomia - L 756.065 
other specified anomalies - L 744.880 
other specified bone anomalies - * 756.080 
palsy - L # 351.000 
skin tag - L # 744.110 
small - 744.910 
teratoma - 238.010 
triangular - 744.910 
unspecified bone anomalies - 756.090 
Facies - see also features 
compression - 754.010 
Down syndrome - 744.910 
flat - 744.910 
Potter=s - 754.010 
Facio-auricular-digital syndrome - 759.800 
Facio-auriculo-vertebral syndrome - 756.060 
Fallopian tube 
absent - L 752.100 
hypoplastic - L 752.190 
other and unspecified anomalies - L 752.190 
Fallot=s pentalogy - 745.210 
Fallot=s tetralogy - 745.200 
Familial dysautonomia - 742.810 
Fascia 
other specified anomalies - L 756.880 
Features 
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abnormal - 744.910 
Down syndrome - 744.910 
dysmorphic - 744.910 
Trisomy 21 - 744.910 
Female genitalia (external)  
benign neoplasm - # 221.000 
other specified anomalies - * 752.480 
unspecified anomalies - 752.490 
Femoral fibular hypoplasia B unusual facies syndrome - 759.840 
Femoral hypoplasia B unusual facies syndrome - 759.840 
Femur 
absent 
only - L 755.320 
with absent tibia and fibular (total or partial)- L 755.310 
with absent tibia, fibula, and foot - L 755.300 
anteversion - L 755.650 
bowed - L 754.400 
hypoplastic - L 755.650 
other specified anomalies - L 755.650 
short - L 755.650 
torsion - L 755.650 
Femur-fibula-ulna syndrome - 759.840 
Fenestrated ASD - 745.510 
Fetal 
Accutane (Isoretinoin) syndrome - 760.760 
akinesia deformation sequence - 759.840 
alcohol 
effect - 760.720 
syndrome - 760.710 
Dilantin syndrome - 760.750 
hydantoin syndrome - 760.750 
FG syndrome - 759.800 
Fibroelastosis, endocardial - 425.300 
Fibromatosis colli - L 754.100 
Fibrosis 
liver - 751.610 
myocardial - 425.300 
Fibula 
absent 
only (total or partial) - L 755.366 
with absent femur (total or partial) and tibia (total or partial)- L 755.310 
with absent femur (total or partial), tibia, and foot - L 755.300 
with absent tibia - L 755.320 
with absent tibia and foot - L 755.330 
bowed - L 754.410 
hypoplastic - L * 755.630 
other specified anomalies - L * 755.630 
short - L * 755.630 
Fibular hemimelia - L 755.366 
Fibular ray defect, NOS - L 755.366 
Filum terminale, fat - x 
Fimbrial cyst - L 752.120 
Finger 
absent 
fifth (with or without fourth) - L 755.270 
first (thumb) - L 755.260 
first (thumb) with absent radius (total or partial) - L 755.260 
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NOS - L 755.240 
third (with or without second, fourth) - L 755.250 
acrodactylia - L # 755.500 
anomalies - L # 755.500 
arachnodactyly - L # 755.500 
bifid (thumb) - L 755.010 
brachydactyly - L # 755.500 
camptodactyly - L # 755.500 
clinodactyly - L # 755.500 
club - L 754.840 
cortical (thumb) - x 
digitalized (thumb) - L # 755.500 
flexion deformity - L # 755.500 
fused - L 755.100 
hyperextension - L # 755.500 
hypoplastic 
all other - L 755.585 
thumb (isolated) - L 755.260 
incurving - L # 755.500 
long - L # 755.500 
nubbin - L 755.240 
overlapping - L # 755.500 
rudimentary - L 755.240 
short - L # 755.500 
small, all other - L # 755.500 
small, thumb - L # 755.500 
symbrachydactyly - L #  755.500 and L 755.190-755.199 (depending on the laterality) 
symphalangism - L # 755.500 
syndactyly, unspecified 
bilateral - 755.192 
NOS - 755.193 
unilateral - 755.191 
triphalangeal (thumb) - L # 755.500 
webbed - L 755.110 
Fissure 
anal - x 
rectal - * 751.580 
thin palpebral - L 743.635 
Fistula 
anal - 751.540 
anourethral - 753.860  
anovaginal - 752.420 
anovesical - 753.860 
branchial cleft - L 744.400 
bronchoesophageal - 750.330 
bronchopulmonary - L 748.350 
digestive tract with uterus - 752.320 
digestive-urinary tract - 753.860 
esophageal - 750.480 
Fourchette - * 752.480 
hepatic artery-portal vein - 747.450 
lip - 750.260 
portal vein-hepatic artery - 747.450 
rectal - 751.540 
rectourethral - 753.860 
rectovaginal - 752.420 
rectovesical - 753.860 
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H type - 750.325 
with esophageal atresia - 750.310 
without esophageal atresia - 750.320 
urethral, NOS - 753.870 
urethrorectal - 753.860 
urinary tract with uterus - 752.320 
uterointestinal - 752.320 
uterovesical - 752.320 
uterus with digestive or urinary tract - 752.320 
vesicovaginal - 752.420 
Flat 
eye - L # 743.800 
facial profile - 744.910 
facies - 744.910 
foot - L 754.610 
hand - L 754.880 
head - 754.080 
midface 744.910 
occiput - * 756.080 
side of head - L * 754.050 
Flexed wrist - L 755.520 
Flexion deformity finger - L # 755.500 
Flexion deformity toe - L # 755.600 
Fontanelle 
absent - # 754.040 
large - # 754.040 
small - # 754.040 
three - # 754.040 
Foot 
abduction - L 754.690 
absent 
only - L 755.340 
with absent femur (total or partial), tibia, and fibula - L 755.300 
with absent lower leg - L 755.330 
with absent tibia and fibula (total or partial) - L 755.330 
adduction - L 754.590 
anomalies - L 755.610 
broad - L 755.610 
claw - L 755.350 
cleft - L 755.350 
clubbed - L 754.730 
deformities, NOS - L 754.735 
dorsiflexion - L 754.780 
ectrodactyly - L 755.350 
equinus - L 754.730 
eversion - L 754.680 
flat - L 754.610 
hyperextended - L 754.780 
hypoplasia - L 755.685 
inversion - L 754.590 
large - L 755.610 
lobster-claw - L 755.350 
long - L 755.610 
oligodactyly - L 755.340 
other specified anomalies - L 754.780 
plantar crease, deep - L 755.610 
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plantar furrow - L 755.610 
positional defect, NOS - L 754.780 
rocker-bottom - L # 755.616 
short - L 755.610 
small - L 755.610 
split - L 755.350 
turns 
inward - L 754.590 
outward - L 754.690 
upward - L 754.780 
vertical talus - L # 755.616 
Foramina of Magendie and Luschka atresia - * 742.310 
Forearm 
absent 
only - L 755.220 
with absent hand - L 755.230 
with absent upper arm - L 755.210 
anomalies - L 755.530 
hemimelia - L 755.230 
short - L 755.530 
Forehead 
hirsute - # 744.910 
other anomalies - * 756.080 
Forelock, white - # 757.390 
Foreskin 
absent - 752.860 
hooded - 752.860 
incomplete - x 
redundant - x 
Fossa ovalis atrial septal defect - 745.510 
Fourchette fistula - * 752.480 
Fragile X syndrome - 758.880 
Fragilitas ossium - 756.506 
Franceschetti syndrome - 756.045 
Frasier syndrome - 759.800 
Freeman Sheldon syndrome - 759.800 
Frenulum (tongue, lingual) 
anterior - # 750.000 
short - # 750.000 
thick - x 
Frenulum (upper lip)  
anomalies - 750.270 
thick - x  
Frontal bossing - 754.080 
Frontal lobe anomalies - 742.200 
Fronto-nasal dysplasia - 756.046 
Fryn syndrome - 759.840 
Fukuyama congenital muscular dystrophy - 759.890 
Funnel chest - 754.810 
Fused/fusion 
adrenal glands  - L 759.180 
eyes 
closed - L * 743.630 
together - 759.800 
eyelid - L * 743.630 
fingers - L 755.100 
kidney - 753.320 
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legs - 759.840 
lung lobes - L 748.580 
ossicles (ear)- L 744.020 
penoscrotal - 752.880 
radius and ulna - L 755.536 
rib - L 756.320 
sacroiliac joint - L 755.670 
scrotum - x 
suture 
basilar - 756.030 
coronal - L 756.010 
lambdoidal - L 756.020 
metopic - 756.006 
NOS - 756.000 
other - 756.030 
sagittal - 756.005 
thalami - 742.260 
toes - L 755.120 
ulna and radius - L 755.536 
vertebrae 
cervical - 756.140 
lumbar - 756.160 
NOS - 756.180 
sacral - 756.170 
thoracic - 756.150 




Galactokinase deficiency - # 271.110 
Galactosemia 
classic - # 271.100 
NOS - # 271.190 
Gallbladder 
agenesis - 751.630 
duplication - 751.640 
hypoplasia - 751.630 
other anomalies - 751.640 
small - x 
Gangliosidosis - # 330.100 
Gartner=s duct cyst - L 752.110 
Gardner syndrome - 759.630 
Gastric volvulus - x 
Gastroesophageal reflux (GER) - x 
Gastroschisis - 756.710 
Gaucher disease Type II - 759.870 
Genitalia absent (sex unknown) - * 752.790 
Genital organs, unspecified anomalies - 752.900 
Genu 
recurvatum - L 754.430 
valgum - L 755.645 
varum - L 755.646 
Gerbode defect - 745.420 
Giant 
esophagus - 750.400 
kidney - L 753.340 
Gingiva, cleft - 749.100 
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Glabella, prominent - # 748.180 
Glaucoma - L 743.200 
Glioependymal cysts - 742.420 
Glossoptosis - 750.130 
Glottic web - 748.205 
Gluteal cleft, asymmetric - x 
Glycogen storage disease - # 271.000 
Goiter, congenital - 759.210 
Goldenhar syndrome - 756.060 
Goltz syndrome - 757.300 
Gonadal dysgenesis, pure - 752.720 
Gracile rib - L 756.340 
Great veins 
other specified anomalies - 747.480 
unspecified anomalies - 747.490 
Gum 
cleft - 749.100 
hypertrophy - 750.280 
hypoplastic - x 
other anomalies - 750.280 





beaded - 757.410 
Taenzer=s - 757.430 
twisted - 757.420 
other specified anomalies - 757.480 
unspecified anomalies - 757.910 
whorl anomalies - # 757.390 
Hairline 
low anterior - # 744.910 
low NOS - # 744.900 
low posterior - # 744.900 
Hairy nevus - *216.920 
Hallermann-Streiff syndrome - 756.046 
Hallux 
valgus - L 755.605 
varus - L 755.606 
Hamartoma 
other specified - 759.680 
unspecified - 759.690 
Hammer toe - L # 755.600 
Hand 
abnormal position  
with mention of forearm/wrist bone abnormality - L 754.840 
without mention of forearm/wrist bone abnormality- L 755.520 
absent 
only - L 755.240 
with absent forearm - L 755.230 
with absent humerus (total or partial), radius, and ulna - L 755.200 
with absent radius and ulna (total or partial) - L 755.230 
anomalies - L 755.510 
broad - L 755.510 
claw - L 755.250 
cleft - L 755.250 
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clenched - L # 755.500 
club - L 754.840 
ectrodactyly - L 755.250 
finger-like (thumb) - L # 755.500 
flat - L 754.880 
hyperflexion - x 
hypoplasia - L 755.585 
large - L 755.510 
lobster-claw - L 755.250 
long - L 755.510 
narrow - x 
oligodactyly - L 755.240 
other specified anomalies - L 754.880 
short - L 755.510 
small - L 755.510 
spade-like - L 754.850 
split - L 755.250 
ulnar deviation - L 755.520 
Harelip - see cleft lip 
Harlequin deformity of eye - L 743.670 
Harlequin fetus - 757.100 
Head  
abnormal shape NOS - 754.090 
absent - 740.080 
asymmetric - 754.055 
box shaped - 754.080 
cloverleaf shape - 756.000 
cone shaped - 754.080 
elongated - * 754.030 
enlarged - * 742.400 
flat - 754.080 
flat side of - L * 754.050 
misshapen - 754.090 
small - 742.100 
square - 754.080 
teratoma - 238.010 
tower - 754.080 
triangular shape - 754.070 
Heart 
band, anomalous - 746.910 
block - 746.870 
conduction defects - 746.880 
disease 
acyanotic - 746.920 
cyanotic - 746.930 
NOS - 746.990 
displacement through esophageal hiatus - 750.600 
enlarged - * 746.860 
Ahole in the heart@ - 745.900 
hypoplastic left - 746.700 
hypoplastic NOS - 746.880 
hypoplastic right - 746.882 
large - * 746.860 
murmur - x 
other specified - 746.880 
tumor - 746.880 
Heel, prominent - L 755.610 
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Hemangioendothelioma liver - L  * 228.040 
Hemangioma 
intra-abdominal - L * 228.040 
intracranial - * 228.020 
other sites - L * 228.090 
retinal - L * 228.030 
skin and subcutaneous - * 228.010 
unspecified site - * 228.000 
with chondrodysplasia - 756.420 
Hemianencephaly - 740.030 
Hemiazygos vein anomalies - L 747.650  
Hemicephaly - 740.030 
Hemidiaphragm - L 756.617 
Hemifacial microsomia - L 756.065 
Hemihypertrophy - 759.890 
Hemimelia, fibular - L 755.366 
Hemimelia forearm - L 755.230 
Hemimelia tibia - L 755.365 
Hemipelvis - L 755.670 
Hemivertebra 
cervical - 756.145 
lumbar - 756.165 
NOS - 756.185 
sacral - * 756.170 
thoracic - 756.155 
Hemophilia (all types) - # 286.000 
Hemorrhage, central nervous system (CNS) - x 
Hepatic artery-portal vein fistula - 747.450 
Hepatic duct 
agenesis - 751.650 
atresia - 751.650 
other anomalies - 751.670 
Hepatic vein 
stenosis - L 747.650 
Hepatitis, neonatal 
NOS - # 774.490 
other specified - # 774.480 
Hepatomegaly - # 751.620 
Hepatosplenomegaly - # 751.620 and # 759.020 
Hereditary 
edema of legs - 757.000 
trophedema - 757.000 
Hermaphroditism, true - 752.700 
Hernia 
bladder - 753.820 
diaphragmatic 
Bochdalek - L 756.615 
Morgagni - L 756.616 
NOS - L 756.610 
Posterolateral - L 756.615 
epigastric - 756.795 
hiatal/hiatus - 750.600 
inguinal 
incarcerated - L * 550.100 
with mention of gangrene - L * 550.000 
with obstruction - L * 550.100 
without obstruction without mention of gangrene - L * 550.900 
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paraesophageal - 750.600 
umbilical - # 553.100 
Herpes simplex, congenital (in utero infection) - # 771.220 
Heterotaxy syndrome - * 759.390 
Heterotopia pancreas - 751.780 
Hiatal/hiatus 
hernia - 750.600 
High arched palate - # 750.240 
Hip 
abduction - x 
anomalies - L 755.660 
Barlow positive - L 754.310 
benign neoplasm - L # 216.700 
click - x   
crepitus - x 
dislocatable - L 754.310 
dislocation - L 754.300 
dysplasia 
bilateral - 755.667 
NOS - 755.665 
unilateral - L 755.666 
hyperextended - L 755.660 
hypoplasic 
bilateral - 755.667 
NOS - 755.665 
unilateral - L 755.666 
laxity - x 
loose - x 
Ortolani positive - L 754.310 
positive Barlow - L 754.310 
positive Ortolani - L 754.310 
predislocation - L 754.310 
preluxation - L 754.310 
subluxable - L 754.310 
subluxation - L 754.310 
unstable - L 754.310 
webbed - L 755.800 
Hirschsprung=s disease 
NOS - 751.330 
long-segment - 751.310 
short-segment - 751.320 
Hirsutism 
forehead - # 744.910 
other - # 757.450 
AHole in the heart@ - 745.900 
Holoprosencephaly - 742.260 
Holt-Oram syndrome - 759.840 
Honeycomb lung - L 748.420 
Hooded foreskin - 752.860 
Horner syndrome - L 744.880 
Horseshoe kidney - 753.320 
Humerus 
absent (total or partial) 
only - L 755.220 
with absent radius and ulna - L 755.210 
with absent radius, ulna, and hand - L 755.200 
hypoplastic - L 755.540 
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other specified anomalies - L 755.540 
short - L 755.540 
Hurler syndrome - 277.510 
Hyaline membrane disease - x 
Hydatid of Morgagni cyst - L 752.870 
Hydranencephaly - 742.320 
Hydrocele, congenital - L # 778.600 
Hydrocephaly, without spina bifida 
benign external - x 
communicating - 742.380 
ex-vacuo - x 
non-communicating - 742.380 
other - 742.380 
secondary to intraventricular hemorrhage (IVH) or CNS bleed - x 
unspecified, NOS - 742.390 
with spina bifida - see spina bifida 
Hydrocolpos - * 752.430 
Hydrocytoma - see skin-benign neoplasm 
Hydrometrocolpos - * 752.430 
Hydromyelia - 742.540 
Hydronephrosis - L 753.200 
Hydrophthalmos - L 743.200 
Hydrops fetalis - # 778.000 
Hydrorachis - 742.540 
Hydroureter - L 753.220 
Hydroureteronephrosis - L 753.200 and L 753.220 
Hymen 
imperforate - * 752.430 
tag - * 752.480 
Hyperconvex nail - L 757.580 
Hyperextended/hyperextensibility 
arm - L 755.580 
elbow - L 755.540 
finger - L # 755.500 
foot - L 754.780 
hip - L 755.660 
joints - L 755.880 
knee - L 755.640 
leg - L 755.680 
thigh - x 
toe - L # 755.600 
Hyperflexion hand - x 
Hyperostosis, infantile cortical - 756.530 
Hyperpigmentation of skin - # 757.390 
Hyperplasia/hyperplastic 
adrenal, congenital 
classical (salt) water - # 255.200 
classical (simple virilizer) - # 255.210 
NOS - # 255.290 
other than 21-OHP deficiency - # 255.240 
kidney - L 753.340 
lung - x 
primary vitreous, persistent - L 743.500 
pulmonary - x 
spleen - # 759.020 
Hypertelorism - 756.085 
Hypertelorism-hypospadias syndrome - 759.800 
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Hypertension, primary pulmonary artery - L * 747.680 
Hypertrichosis - # 757.450 
Hypertrophic/hypertrophy 
bladder - x 
breast - x 
cardiomyopathy - * 746.860 
clitoris - * 752.450 
gum - 750.280 
kidney - L 753.340 
nail - L 757.510 
pyloric stenosis - 750.510 
thymus - * 759.240 
urethra - x 
ventricle/ventricular (heart) - L * 746.886 
ventricular septum - * 746.860 
Hypochondrodysplasia - 756.480 
Hypochondrogenesis - 756.480 
Hypoglossia - 750.110 
Hypoglossia-hypodactylia syndrome - 759.840 
Hypoglycemia, idiopathic - # 251.200 
Hypognathia - 524.000 
Hypomelia 
arm - L 755.585 
Hypoparathyroidism, congenital - # 252.100 
Hypophosphatasia, congenital - # 275.330 
Hypophosphatemic rickets - # 275.330 
Hypopigmentation of skin - # 757.390 
Hypopituitarism, congenital - #253.280 
Hypoplasia/hypoplastic 
adrenal gland - L 759.110 
alae nasae - # 748.180 
aorta - 747.210 
aortic valve - 746.480 
arm - L 755.585 
atrium - 746.887 
bladder - 753.880 
brainstem - 742.280  
breast (with hypoplastic nipple) - L 757.610 
cheek - L 744.880 
colon - 751.520 
ear (not microtia) - L * 744.230 
epiglottis - 748.300 
eye - L 743.100 
fallopian tube - L 752.190 
femur - L 755.650 
fibula - L * 755.630 
finger 
all other - L 755.585 
thumb (isolated) - L 755.260 
foot - L 755.685 
gallbladder - 751.630 
gum - x 
hand - L 755.585 
heart, NOS - 746.880 
hip 
bilateral - 755.667 
NOS - 755.665 
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unilateral - L 755.666 
humerus - L 755.540 
innominate vein - L 747.650 
jugular vein - L 747.650 
kidney 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
labia (majora or minora) - * 752.440 
larynx - 748.300 
left heart syndrome - 746.700 
left ventricle - 746.881 
leg - L 755.685 
lip - # 744.830 
lung - L * 748.510 
malar - * 756.080 
mandible - 524.000 
maxillary - * 756.080 
mid-facial - * 756.080 
mitral valve - 746.505 
muscle - L 756.810 
nail - L 757.585 
nasal bridge - # 748.180 
nipple 
only - L * 757.640 
with hypoplastic breast - L 757.610 
nose - 748.100 
olfactory nerve - 742.270 
ovary - L 752.080 
pancreas - 751.700 
penis - 752.865 
pontine - 742.280 
pulmonary 
artery - L 747.380 
lung - L * 748.510 
NOS (heart) - 746.995 
valve - 746.000 
radius - L 755.530 
rib - L 756.340 
right heart - 746.882 
right ventricle - 746.882 
scrotum - L * 752.810 
septum pellucidum - 742.210 
spleen - 759.010 
sternocleidomastoid muscule - L 754.100 
supraorbital ridges - * 756.080 
testicle - L * 752.810 
thalamus - 742.280 
thymus - * 759.240 
tibia - L * 755.630 
toe 
all other - L 755.685 
first - L 755.365 
tricuspid valve - 746.100 
ulna - L 755.530 
umbilical artery - # 747.500 
ureter - L 753.210 
 
    L  = code laterality           # = conditional inclusion   
    x  = exclusion             * = special instruction 
Rev. 05/30/03
45 
ventricle (heart) NOS - 746.883 
vertebrae 
cervical - 756.140 
lumbar - 756.160 
NOS - 756.180 
sacral - 756.170 
thoracic - 756.150 
Hypospadias 
with chordee 
balantic - 752.625 
coronal - 752.625 
first degree - 752.625 
glandular - 752.625 
NOS - 752.620 
penile - 752.626 
perineal - 752.627 
scrotal - 752.627 
second degree - 752.626 
subcoronal - 752.625 
third degree - 752.627 
without chordee 
balantic - 752.605 
coronal - 752.605 
first degree - 752.605 
glandular - 752.605 
mild - 752.605 
NOS - 752.600 
penile - 752.606 
perineal - 752.607 
scrotal - 752.607 
second degree - 752.606 
subcoronal - 752.605 
third degree - 752.607 
Hypotelorism - * 756.080 
Hypothalamus anomalies - 742.220 
Hypothyroidism 
congenital - # 243.990 




Ichthyosiform erythroderma - 757.197 
Ichthyosis congenita 
bullous type - 757.115 
other - 757.190 
unspecified - 757.190 
X-linked - 757.196 
Ichthyosis vulgaris - 757.195 
Icterus - x 
Ileum 
absent - 751.120 
atresia - 751.120 
stenosis - 751.120 
Ilium anomalies - L 755.670 
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with fistula - 751.230 
without fistula - 751.240 
hymen - * 752.430 
meatus (urethral, urinary) - 753.630 
Incontinentia pigmenti - 757.350 
Incurving  
finger - L # 755.500 
toe - L # 755.600 
Indeterminate sex NOS - * 752.790 
Infantile cortical hyperostosis - 756.530 
Infantile myofibromatosis - 759.680 
Infantile spasms, congenital - # 345.600 
Infantile spinal muscular atrophy - 335.000 
Infection, congenital (in utero infection) 
cytomegalovirus (CMV) - # 771.100 
herpes simplex - # 771.220 
human immunodeficiency virus (HIV) - x 
other specified - # 771.280 
parvovirus - 771.280 
rubella - 771.000 
syphilis - # 090.000 
TORCH, unspecified - # 771.090 
toxoplasmosis - # 771.200 
varicella - # 052.000 
Inferior vermis anomalies - 742.230 
Infraorbital crease - L # 743.800 
Inguinal hernia 
incarcerated - L * 550.100 
with mention of gangrene - L * 550.000 
with obstruction - L * 550.100 
without obstruction without mention of gangrene - L * 550.900 
Iniencephaly 
closed - 740.200 
open - 740.210 
unspecified - 740.290 
Innominate artery, aberrant - L 747.640 
Innominate vein anomalies - L 747.650 
Insufficiency 
aortic valve - * 746.400 
mitral valve - * 746.600 
pulmonary valve - * 746.020 
single atrioventricular valve - 746.900 
tricuspid valve - * 746.105 
truncal valve - 746.900 
Integument 
other specified anomalies - 757.800 
unspecified anomalies - 757.990 
Intercalary reduction defect 
arm - L 755.210 
leg - L 755.310 
limb, NOS - L 755.410 
Interrupted aortic arch - 747.215 
Interrupted inferior vena cava - 747.480 
Intestine 
adhesion - 751.420 
aganglionosis 
beyond the rectum - 751.310 
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involving no more than the anal sphincter and the rectum - 751.320 
total - 751.300 
band - 751.420 
duplication - 751.500 
large 
absent - 751.200 
atresia - 751.200 
malrotation - 751.400 
stenosis - 751.200 
obstruction - x 
other specified anomalies - * 751.580 
small 
absent - 751.190 
absent, with fistula - 751.195 
atresia - 751.190 
atresia, with fistula - 751.195 
malrotation - 751.495 
short - 751.190 
stenosis - 751.190 
stenosis , with fistula - 751.195 
transposition - 751.510 
unspecified anomalies - 751.590 
Intracranial cyst - 742.420 
Intussusception - x 
Inversion 
atrium (heart) - 746.880 
foot - L 754.590 
ventricular - 745.120 
Inverted nipples - x 
Iris 
absent - L 743.420 
coloboma - L 743.430 
other specified - L 743.440 
Ischiopagus conjoined twins - 759.480 
Ischium anomalies - L 755.670 




Jackson-Weiss syndrome - 756.046 
Jacobsen syndrome - 757.300 
Jadassohn-Lewandasky syndrome - 759.890 
Jarcho Levin syndrome - 756.480 
Jaw 
asymmetry - * 756.080 
size abnormalities - 524.000 
shape abnormalities - * 756.080 
Jaw-winking syndrome - 742.800 
Jejunal/jejunum 
absent - 751.110 
asymmetric - * 756.080 
atresia - 751.110 
stenosis - 751.110 
web - * 751.580 
Jeune syndrome - 756.400 
Johansen-Blizzard syndrome - 759.870 
Joints, hyperextended - L 755.880 
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Kabuki syndrome - 759.800 
Kalischer=s disease - 759.610 
Kartagener syndrome (triad) - 759.340 
Kast syndrome - 756.420 
Kawasaki disease - x 
Keratitis-ichthyosis-deafness syndrome - 757.190 
Keratoglobus - L 743.220 
KID syndrome - 757.190 
Kidney - see also renal 
absent 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
accessory - L 753.300 
agenesis 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
cyst (single) - L 753.100 
cystic dysplasia - L 753.160 
cystic NOS - L 753.180 
double (and pelvis) - L 753.310 
dysplasia 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
echogenic - x 
ectopic - L 753.330 
fused - 753.320 
giant - L 753.340 
horseshoe - 753.320 
hyperplastic - L 753.340 
hypertrophy - L 753.340 
hypoplasia 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
large - L 753.340 
lobulated - 753.320 
malrotated - L 753.330  
medullary cystic disease 
adult type - 753.150 
juvenile type - 753.140 
medullary sponge kidney - 753.150 
multicystic (dysplasia) - L 753.160 
other specified anomalies - L 753.380 
other specified cystic disease - L 753.180 
pelvic - L 753.330 
polycystic 
adult type - 753.120 
autosomal dominant - 753.120 
autosomal recessive - 753.110 
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infantile type - 753.110 
NOS - 753.130 
small 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
triple (and pelvis) - L 753.310 
unspecified anomalies - L 753.900 
Kinky hair syndrome - 759.870 
Klinefelter syndrome 
karyotype 47,XXY - 758.700 
karyotype 48,XXXY - 758.710 
karyotype 48,XXYY - 758.710 
karyotype 49,XXXXY - 758.710 
NOS - 758.790 
other karyotype with additional X chromosomes - 758.710 
Klippel-Feil syndrome - 756.110 
Klippel-Trenaunay-Weber syndrome - 759.840 
Knee 
anomalies - L 755.640 
dislocation - L 754.440 
hyperextended - L 755.640 
laxity - L 754.440 
subluxation - L 754.440 
valgus - L 755.645 
webbed - L 755.640 
Koilonychia, congenital - 757.520 
Kyphomelic dysplasia - 756.480 
Kyphoscoliosis - 756.120 




Labia (minora or majora) 
enlarged - * 752.440 
hypoplastic - * 752.440 
prominent - * 752.440 
Lacrimal aparatus/duct 
absent - L 743.640 
cyst - L 743.660 
obstruction - L # 743.650 
other specified - L 743.660 
stenosis - L # 743.650 
Ladd=s bands - 751.420 
Lagophthalmos - x 
Lambdoidal suture 
closed - L 756.020 
craniosynostosis - L 756.020 
fused - L 756.020 
Lanugo, persistent or excessive - # 757.450 
Large - see also dilatation 
adrenal gland - L 759.180 
aorta - 747.270 
atrium - x 
bladder - x 
clitoris - * 752.450 
cornea - L 743.220 
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eye - L 743.210 
fontanelle - # 754.040 
foot - L 755.610 
hand - L 755.510 
heart - * 746.860 
kidney - L 753.340 
labia (minora or majora) - * 752.440 
lips - # 744.820 
liver - # 751.620 
mouth - 744.800 
nail - L 757.510 
penis - 752.880 
pulmonary artery - 747.330 
pulmonary valve - 746.080 
renal pelvis - L 753.380 
septum pellucidum - x 
spleen - # 759.020 
testicle - 752.820 
thymus - * 759.240 
tongue - 750.120 
tricuspid valve - 746.100 
urethra - x 
vena cava - 747.480 
ventricle (brain) - 742.390 
ventricle (heart) - x 
uvula - x 
Larsen=s syndrome - 755.810 
Laryngotracheoesophageal  cleft - 748.385 
Laryngomalacia - x 
Laryngotracheomalacia - x 
Larynx/laryngeal 
anomalies of  (and supporting cartilage) - 748.300 
cleft - 748.385 
hypoplastic - 748.300 
other specified anomalies - L 748.380 
stenosis 
NOS - 748.300 
subglottic - * 748.310 
stridor - * 748.360 
subglottic stenosis - * 748.310 
unspecified anomalies - 748.390 
web 
glottic - 748.205 
NOS - 748.209 
subglottic - 748.206 
Laurence-Moon-Biedl syndrome - 759.820 
Laxity  
hip - x 
knee - L 754.440 
Left 
atrioventricular valve - see mitral valve 
semilunar valve - see aortic valve 
superior vena cava - 747.410 
Left-sided liver - # 751.620 
Leg 
absent - L 755.300 
amelia - L 755.300 
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amputation, NOS - L 755.385 
benign neoplasm - L # 216.700 
bowed lower leg - L 754.410 
bowed, NOS - 754.420 
deformity, NOS - L 754.490 
edema, hereditary - 757.000 
fused - 759.840 
hyperextended - L 755.680 
hypoplasia - L 755.685 
intercalary reduction defect, NOS - L 755.310 
longitudinal reduction defect 
NOS - L 755.360 
postaxial - L 755.366 
preaxial - L 755.365 
lymphedema - 757.000 
other specified anomalies - L 755.680 
other specified reduction defect - L 755.380 
phocomelia, NOS - L 755.310 
positional deformity - L 755.680 
short - L 755.680 
short lower leg - L * 755.630 
single (fused legs, not one absent) - 759.840 
transverse reduction defect, NOS - L 755.385 
unspecified anomalies - L 755.690 
unspecified reduction defect - L 755.390 
Lens 
absent - L 743.300 
coloboma - L 743.340 
displaced - L 743.330 
other specified - L 743.380 
spherical - L 743.310 
unspecified - L 743.390 
Lenticonus - L 743.380 
Leprechaunism - 759.870 
Lethal multiple pterygium syndrome - 759.840 
Leukoma cornea - L 743.400 
Leukonychia, congenital - 757.530 
Levocardia 
only - x 
with situs inversus - 759.310 
Limb, NOS 
absent - L 755.400 
amelia - L 755.400 
amputation - L 755.420 
intercalary reduction defect - L 755.410 
phocomelia - L 755.410 
upper - see arm 
longitudinal reduction defect 
NOS - L 755.430 
postaxial - L 755.430 
preaxial - L 755.430 
lower - see leg 
other specified anomalies - L 755.880 
other specified reduction defect - 755.480 
transverse reduction defect, NOS - L 755.420 
unspecified anomalies - L 755.900 
unspecified reduction defect - L 755.490 
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Limb-body wall complex - 759.840 
Lip 
benign neoplasm - # 216.000 
bowed - L 744.880 
cleft 
lateral - 744.800 
with any cleft palate - L 749.200 
central - 749.220 
midline - 749.220 
without cleft palate - L 749.100 
central - 749.120 
midline - 749.120 
fistula - 750.260 
hpoplastic - # 744.830 
large - # 744.820 
notched - 750.270 
other anomalies - 750.270 
pit - 750.260 
small - # 744.830 
smooth - 750.270 
thin - # 744.830 
Lipochondrodystrophy - 277.510 
Lipoma 
intra-abdominal organs - L # 214.300 
intrathoracic organs - L # 214.200 
lumbar - # 214.810 
other specified sites - L # 214.800 
paraspinal - # 214.810 
sacral - # 214.810 
skin and cutaneous tissue 
face - # 214.000 
other - # 214.100 
spermatic cord - # 214.400 
unspecified site - # 214.900 
Lipomeningocele - see spina bifida 
Lipomyelomeningocele - see spina bifida 
Lissencephaly - 742.240 
Liver 
absent, total or partial - 751.600 
agenesis, total or partial - 751.600 
cyst - 751.610 
cystic disease - 751.610 
fibrocystic disease - 751.610 
enlarged - # 751.620 
fibrosis - 751.610 
hemangioendothelioma liver - L  * 228.040 
left-sided - # 751.620 
other anomalies - # 751.620 
transverse - # 751.620 
Lobster-claw 
foot - L 755.350 
hand - L 755.250 
Lobulated kidney - 753.320 
Lobulated spleen - 759.030 
Lop ear - L * 744.230 
Long 
arm - x 
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finger - L # 755.500 
foot - L 755.610 
hand - L 755.510 
head - * 754.030 
neck - # 744.900 
philtrum - 750.270 
skull - * 754.030 
sternum - 756.380 
toe - L # 755.600 
Long QT syndrome - 746.880 
Longitudinal reduction defect 
arm 
NOS - L 755.265 
postaxial - L 755.270 
preaxial - L 755.260 
leg 
NOS - L 755.360 
postaxial - L 755.366 
preaxial - L 755.365 
limb, NOS 
NOS - L 755.430 
postaxial - L 755.430 
preaxial - L 755.430 
Loose hip - x 
Lordosis (postural) - 754.210 
Loss of chromosomal material - see deletion (chromosome) 
Lowe syndrome - 759.870 
Lower leg 
absent 
only - L 755.320 
with absent foot - L 755.330 
with absent thigh - L 755.310 
anomalies - L * 755.630 
bowed - L 754.410 
short - L * 755.630 
Lower limb - see leg 
Low-lying umbilicus - # 759.900 
Low set ears - L # 744.245 
Lung 
absent - L 748.500 
accessory lobe - L 748.620 
agenesis - L 748.500 
atresia - L 748.500 
bilobar right - 748.625 
cyst 
multiple - L 748.410 
other specified - L 748.480 
single - L 748.400 
cystic adenomatoid malformation - L 748.480 
ectopic tissues - L 748.600 
emphysema, lobar - L 748.880 
exstrophy - L 748.690 
four or more lobes (right) - L 748.620 
fused lobes - L 748.580 
honeycomb - L 748.420 
hyperplasia - x 
hypoplasia - L * 748.510 
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incomplete separation of lobes - L 748.580 
lobar emphysema - L 748.880 
lymphangiectasia - L 748.880 
one lobe (left or right) - L 748.580 
other specified anomalies - L 748.690 
other specified dysplasia - L 748.580 
polycystic - L 748.410 
right lung with left lung bronchial pattern - 748.625 
sequestration - L 748.520 
small - L * 748.510 
three lobes (right) - x 
three or more lobes (left) - L 748.620 
two lobes (left) - x 
unspecified anomalies - L 748.690 
unspecified dysplasia - L 748.590 
Lutembacher=s syndrome - 745.520 
Lymphangiectasis of lung - L 748.880 
Lymphangioma (any site) - 228.100 
Lymphatics, other specified disorders - # 457.800 
Lymphedema  
of legs - 757.000 




Macrocephaly - * 742.400 
Macrocheilia - # 744.820 
Macrocolon, not aganglionic - 751.340 
Macrocornea - L 743.220 
Macrogenitalia (male) - 752.880 
Macroglossia - 750.120 
Macrognathia - 524.000 
Macrostomia - 744.800 
Macrotia - L 744.200 
Madelung deformity - L * 755.526 
Maffucci syndrome - 756.420 
Malaligned aorta - 747.260 
Malar hypoplasia - * 756.080 
Male genitalia (external) 
benign neoplasm - # 222.000 
other specified anomalies - 752.880 
Malrotation 
bowel - 751.490 
cecum - 751.400 
colon - 751.400 
kidney - L 753.330 
large bowel - 751.400 
large intestine - 751.400 
midgut - 751.495 
other - 751.490 
small bowel - 751.495 
small intestine alone - 751.495 
unspecified - 751.490 
Mandible 
cleft - * 756.080 
hypoplasia - 524.000 
Mandibulofacial dysostosis - 756.045 
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Manibrium, double ossification center - 756.380 
Marble bones - 756.540 
Marcus Gunn syndrome - 742.800 
Marfan syndrome - 759.860 
Maxilla 
hypoplasia - * 756.080 
prominent - * 756.080 
Meatus/meatal (external auditory, ear) 
absent - L 744.000 
stenosis - L 744.000 
stricture - L 744.000 
Meatus/meatal (urethral, urinary) 
atresia - 753.630 
double - 753.840 
imperforate - 753.630 
obstruction - 753.630 
stenosis - 753.630 
Meckel-Gruber syndrome - 759.890 
Meckel=s diverticulum - # 751.010 
Meconium 
peritonitis - # 777.600 
plug syndrome - # 777.100 
stained nails - x 
stained skin - x 
Mediastinum cyst - 748.810 
Medullary cystic disease kidney 
adult type - 753.150 
juvenile type - 753.140 
Medullary sponge kidney - 753.150 
Megalencephaly - * 742.400 
Megalocolon - 751.340 
Megalocornea - L 743.220 
Megalogastria - 750.710 
Megaloureter - L 753.220 
Megameatus - 753.880 
Megaurethra - 753.880 
Melnick-Fraser syndrome - 759.800 
Membranous labyrinth (ear) anomalies - L 744.030 
Meningocele - see spina bifida 
cervical - 741.085 
occipital - 742.000 
thoracic - 741.086 
lumbar - 741.087 
sacral - 741.087 
Meningomyelocele - see spina bifida 
with unspecified hydrocephalus 
cervical - 741.030 
cervicothoracic - 741.030 
lumbar - 741.050 
lumbosacral - 741.050 
sacral - 741.060 
sacrococcygeal - 741.060 
thoracic - 741.040 
thoracolumbar - 741.040 
Menkes syndrome - 759.870 
Mermaid syndrome - 759.840 
Mesentary anomalies - 751.410 
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Mesenteric remnant cyst - L 752.110 
Mesocardia - 746.880 
Mesodermal dysgenesis eye - L 743.900 
Metaphyseal dysostosis - 756.450 
Metatarsus 
adductus - L # 754.520 
varus - L # 754.520 
Metatrophic dwarfism - 756.446 
Metopic suture 
closed - 756.006 
craniosynostosis - 756.006 
fused - 756.006 
Microcephalus - 742.100 
Microcheilia - # 744.830 
Microcolon - 751.520 
Microcoria - L 743.440 
Microcornea - L 743.410 
Microgastria - 750.700 
Microgenitalia (male) - 752.880 
Microglossia - 750.110 
Micrognathia - 524.000 
Microgyria - 742.250 
Micromelia 
arm - L 755.580 
leg - L 755.680 
Micropenis - 752.865 
Microphthalmos - L 743.100 
Microsomia 
facial - L 756.065 
hemifacial - L 756.065 
Microstomia - 744.810 
Microtia - L 744.210 
(hypoplastic pinna and absence or stricture of external auditory meatus) 
Midface 
flat - 744.910 
hypoplasia - * 756.080 
Midgut malrotation - 751.495 
Miller-Dieker syndrome - 759.800 
Milroy=s disease - 757.000 
Misshapen 
rib - L 756.310 
skull - 754.090 
speen - 759.030 
sternum - 756.360 
Mitral valve 
abnormal - 746.505 
absent - 746.505 
anomaly - 746.505 
atresia - 746.505 
cleft - 746.505 
double orifice - 746.505 
dysmorphic - 746.505 
dysplastic - 746.505 
hypoplasia - 746.505 
insufficiency - * 746.600 
parachute - 746.505 
prolapse - 746.505 
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redundant - x 
regurgitation - * 746.600 
small - 746.505 
stenosis - 746.500 
thickened - 746.500 
Moebius syndrome - 352.600 
Mohr syndrome - 759.800 
Mongolian blue spot - x 
Mongoloid slant to eyes - L # 743.800 
Monilethix - 757.410 
Monodactyly 
hand - L 755.250 
foot - L 755.350 
Monorchidism - L 752.800 
Monosomy G mosaicism - 758.360 
Mosaic 
45,X/46,XX (excludes Turner phenotype) - 758.800 
46,XY/47,XXY (excludes Klinefelter phenotype) - 758.820 
49,XXXXY (excludes Klinefelter phenotype) - 758.830 
Down syndrome - 758.040 
Edwards syndrome - 758.240 
Monosomy G - 758.360 
NOS - 758.900 
Patau syndrome - 758.140 
Turner syndrome - 758.610 
XO/XX (excludes Turner phenotype) - 758.810 
XO/XY (excludes Turner phenotype) - 758.800 
XXXXY (excludes Klinefelter phenotype) - 758.830 
XY/XXY (excludes Klinefelter phenotype) - 758.820 
XYY male - 758.840 
Mouth 
abnormal shape - L 744.880 
asymmetry - L 744.880 
carp shape - L 744.880 
downturned - L 744.880 
large - 744.800 
lateral cleft - 744.800 
other specified anomalies - 750.280 
small - 744.810 
unspecified anomalies - 750.900 
Mucocele - x 
Multicystic (dysplasia) 
kidney - L 753.160 
pancreas - 751.780 
renal - L 753.160 
Multiple congenital anomalies - 759.700 
Multiple epiphyseal dysplasia - 756.570 
Multiple pterygium syndrome - 759.840 
Muscle 
absent - L 756.810 
pectoralis major - L 756.810 
atrophy, infantile spinal - 335.000 
atrophy (specified muscle) - L 756.880 
hypoplastic - L 756.810 
other specified anomalies - L 756.880 
sternocleidomastoid - see sternocleidomastoid muscule 
unspecified anomalies - 756.900 
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Muscle-eye-brain disease - 759.890 
Muscular dystrophy, Fukuyama congenital - 759.890 
Musculoskeletal system, NOS 
unspecified anomalies - 756.990 
Myelocele - see spina bifida 
Myelodysplasia - 742.510 
Myelomeningocele - see spina bifida 
with unspecified hydrocephalus 
cervical - 741.030 
cervicothoracic - 741.030 
lumbar - 741.050 
lumbosacral - 741.050 
sacral - 741.060 
sacrococcygeal - 741.060 
thoracic - 741.040 
thoracolumbar - 741.040 
Myocardial fibrosis - 425.300 
Myocardium anomalies - * 746.860 
Myofibroma (cardiac) - 425.300 
Myofibromatosis, infantile - 759.680 
Myopathy, congenital, NOS - L 756.880 
Myopia - x 




Nager syndrome - 756.046 
Nail 
absent - L 757.500 
club - L 757.540 
duplication - L 757.580 
dysplastic - L 757.580 
dystrophic - L 757.580 
enlarged - L 757.510 
hyperconvex - L 757.580 
hypertrophic - L 757.510 
hypoplastic - L 757.585 
meconium stained - x 
narrow - L 757.585 
other specified anomalies - L 757.580 
short - x 
small - L 757.585 
unspecified anomalies - 757.920 
Nail-patella syndrome - 756.830 
Nares 
absent - 748.100 
atresia - L 748.000 
small - # 748.180 
Narrow/narrowing 
aorta - 747.210 
biparietal - * 756.080 
bitemporal - * 756.080 
chest - 754.820 
hand - x 
nails - L 757.585 
palate - 750.250 
pulmonary artery - L 747.320 
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temporal - * 756.080 
truncal valve - 746.900 
Nasal bridge 
broad - # 748.180 
flat - # 748.180 
hypoplasia - # 748.180 
wide - # 748.180 
Nasal septum 
absent - # 748.180 
deviation - # 754.020 
perforated - 748.140 
Neck 
absent - #  744.900 
anomaly NOS - # 744.900 
benign neoplasm - # 216.400 
broad - # 744.500 
long - # 744.900 
other specified anomalies - L 744.880 
redundant skin folds - # 744.500 
short - # 744.900 
skin folds - # 744.500 
skin tag - L # 744.110 
teratoma - 238.020 
thick - # 744.500 
webbed - # 744.500 
wide - #  744.500 
Nephrocalcinosis - x 
Nephromegaly - L 753.340 
Nephrotic syndrome, congenital - L 753.380 
Nervous system 
other specified - 742.880 
unspecified - 742.990 
Neu-Laxova syndrome - 759.890 
Neurocutaneous melanosis syndrome - 757.300 
Neurofibromatosis - 237.700 
Neurofibromatosis-Noonan syndrome - 237.700 
Nevus - see also skin-benign neoplasm 
blue - see skin-benign neoplasm 
flammeus - # 757.380 
hairy - *216.920 
not elsewhere classified - # 757.380 
Nipple 
absent 
only - L 757.630 
with absent breast - L 757.600 
accessory 
only - L # 757.650 
with accessory breast - L 757.620 
asymmetric - # 757.680 
ectopic 
only - L # 757.650 
with ectopic breast - L 757.620 
hypoplastic 
only - L * 757.640 
with hypoplastic breast - L 757.610 
inverted - x 
small - L * 757.640 
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wide spaced - # 757.680 
Noonan syndrome - 759.800 
Norrie disease - 759.890 
Nose 
absent - 748.100 
accessory - 748.110 
agenesis - 748.100 
asymmetry - # 748.180 
benign neoplasm (external) - # 216.300 
bent - # 754.020 
bifid - 748.120 
broad bridge - # 748.180 
cleft - 748.120 
fissured - 748.120 
flat bridge - # 748.180 
hypoplastic - 748.100 
notched - 748.120 
other specified anomalies - # 748.180 
skin tag - L # 744.110 
small - # 748.180 
tubular - 748.185 
underdevelopment - 748.100 
unspecified anomalies - 748.190 
wide bridge - # 748.180 
Nostril 
single - 748.185 
small - # 748.180 
Notched lip - 750.270 
Nubbin 
finger - L 755.240 
toe - L 755.340 
Nuchal folds - # 744.500 




OAV syndrome - 756.060 
Obstruction 
alimentary tract, NOS - 751.900 
biliary - x 
bladder outlet - 753.690 
digestive system, NOS - 751.900 
intestinal - x 
lacrimal - L # 743.650 
meatus (urethral, urinary) - 753.630 
pyloric - 750.580 
ureteropelvic junction - L 753.210 
urethra (anterior) - 753.620 
urinary meatus - 753.630 
ventricular outflow tract (left or right) - 746.880 
Obstructive uropathy 
at level of bladder or urethra - 753.690 
unilateral - L 753.290 
Occipitocervical encephalocele - 742.000 
Occiput 
flat - * 756.080 
prominent - * 756.080 
 
    L  = code laterality           # = conditional inclusion   
    x  = exclusion             * = special instruction 
Rev. 05/30/03
61 
short - * 756.080 
Occult spina bifida - 756.100 
Ochoa syndrome - 759.800 
Oculoauriculovertebral dysplasia - 756.060 
Oculomandibulofacial syndrome - 756.046 
Oeis syndrome - 759.890 
OFD syndrome, type I - 759.800 
Olfactory nerve  
absent - 742.270 
hypoplastic - 742.270  
Oligodactyly 
foot - L 755.340 
hand - L 755.240 
NOS - L 755.440 
Ollier syndrome - 756.410 
Omentum 
adhesion - 751.420 
band - 751.420 
Omphalocele - 756.700 
Omphalomesenteric duct - 751.000 
Ondine=s Curse syndrome - x 
Onychauxis - 757.515 
Opitz G/BBB syndrome - 759.800 
Optic disc/nerve 
atrophy - L 743.520 
coloboma - L 743.520 
hypoplastic - L 743.520 
specified anomalies - L 743.520 
Oral-facial-digital syndrome, type I - 759.800 
Orbit (eye) anomalies - L 743.670 
Orofaciodigital syndrome, type II - 759.800 
Oro-mandibular-limb hypogenesis syndrome - 759.840 
Organ of Corti anomalies - L 744.030 
Ortolani positive hip - L 754.310 
Ossicles (ear) 
fusion - L 744.020 
Osteochondrodysplasia - 756.490 
Osteodystrophy 
other specified - 756.580 
unspecified - 756.590 
Osteogenesis imperfecta - 756.500 
Osteopenia - x 
Osteopetrosis - 756.540 
Osteopoikilosis - 756.560 
Osteoporosis - x 
Osteopsathyrosis - 756.505 
Ostium primum defect - * 745.600 
Ostium secundum defect - 745.510 
Oto-palato-digital syndrome - 759.800 
Ovary 
absent - L 752.000 
accessory - L 752.020 
agenesis - L 752.000 
cyst 
multiple - L 752.085 
single - L 752.080 
hypoplastic - L 752.080 
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other specified anomalies - L 752.080 
streak - L 752.010 
torsion - L 752.080 
unspecified - L 752.090 
Overlapping 
digit, NOS - L 755.880 
fingers - L # 755.500 
sutures - x 
toes - L # 755.600 
Overriding 
aorta - 747.260 
pulmonary artery - L 747.380 
sutures - x 
Ovotestis - 752.700 




Pachygyria - 742.280 
Pachyonychia - 757.516 
Palate 
absent 
hard - 749.030 
NOS - 749.090 
soft - 749.070 
anterior - see hard 
cleft 
with cleft lip - see cleft lip with any cleft palate 
without cleft lip 
hard palate (alone) - L 749.000 
central - 749.020 
midline - 749.020 
NOS (hard/soft not specified) - 749.090 
soft and hard palate - 749.090 
soft palate (alone) - L 749.040 
central - 749.060 
midline - 749.060 
submucosal  
hard - 749.020 
NOS (hard/soft not specified) - 749.090 
soft - 749.060 
high arched - # 750.240 
narrow - 750.250 
other anomalies - 750.250 
posterior - see soft 
small - 750.250 
Palatoschisis - 749.090 
Palmar creases 
abnormal - L # 757.200 
simian - L # 757.200 
transverse - L # 757.200 
Palpebral fissures 
narrow - L 743.635 
slanting (up-, down-) - L # 743.800 
small - L 743.635 
thick - x 
thin - L 743.635 
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Bell=s - L # 351.000 
brachial plexus - L # 767.600 
Erb=s - L # 767.600 
facial - L # 351.000 
Pancreas 
absent - 751.700 
accessory - 751.710 
agenesis - 751.700 
annular - 751.720 
cyst - 751.740 
divisum - 751.780 
ectopic - 751.730 
heterotopia - 751.780 
hypoplasia - 751.700 
multicystic - 751.780 
other specified anomalies - 751.780 
small - 751.700 
unspecified anomalies - 751.790 
Papilloma - see skin-benign neoplasm 
Parachute mitral valve - 746.505 
Paraesophageal hernia - 750.600 
Paralysis 
diaphragm - L 756.680 
vocal cord - x 
Parathyroid gland anomalies - 759.230 
Parovarian cyst - L 752.120 
Partial anomalous pulmonary venous return - 747.430 
Partial foramen ovale - * 745.590 
Parvovirus infection, congenital - 771.280 
Patau syndrome 
karyotype trisomy 13 - 758.100 
karyotype trisomy D, NOS - 758.110 
NOS - 758.190 
mosaic - 758.140 
translocation trisomy 13 - duplication or a 13 - 758.120 
translocation trisomy 13 - duplication or a D, NOS - 758.130 
Patella 
absent - L 755.647 
rudimentary - L 755.647 
Patent 
ductus arteriosus - * 747.000 
foramen ovale  
NOS - * 745.500 
vs ASD - * 745.590 
vs secundum ASD - * 745.590 
urachus - # 753.700 
Pearson syndrome - 759.870 
Pectoralis major muscle, absent - L 756.810 
Pectus 
carinatum - 754.800 
excavatum - 754.810 
NOS - 754.820 
Pelvicaliectasis - L 753.380 
Pelvic kidney - L 753.330 
Pelviectasis - L 753.380 
Pelvis 
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anomalies - L 755.670 
Pena-Shokier syndrome - L 755.800 
Pena-Shokeir II syndrome - 759.840  
Penis 
absent - 752.850 
adhesions - 752.860 
aplasia - 752.850 
buried - 752.860 
concealed - 752.860 
disappearing penis syndrome - 752.860 
hypoplastic - 752.865 
large - 752.880 
other anomalies - 752.860 
palmae - 752.860 
small - 752.865 
torsion - 752.860 
webbed - 752.621 
Penoscrotal fusion - 752.880 
Penoscrotal transposition - 752.880 
Penoscrotal web - 752.860 
Pentalogy of Cantrell - 759.890 
Perforated nasal septum - 748.140 
Pericardium anomalies - 746.850 
Peripheral arteries, other anomalies - L 747.640 
Peripheral pulmonary artery branch stenosis - L * 747.325 
Peripheral pulmonary stenosis - L * 747.325 
Peripheral vascular system 
other specified anomalies - L * 747.680 
unspecified anomalies - L 747.690 
Peripheral veins, other anomalies - L 747.650 
Peritoneum 
adhesion - 751.420 
band - 751.420 
Peritonitis, meconium - # 777.600 
Periventricular cyst - 742.420 
Persistent hyperplastic primary vitreous - L 743.500 
Persistent omphalomesenteric duct - 751.000 
Persistent vitelline duct - 751.000 
Pes 
cavus - L 754.700 
planus - L 754.610 
valgus - L 754.615 
varus - L 754.590 
Petechiae - x 
Peter=s anomaly - L 743.440 
Peutz-Jegher syndrome - 759.600 
Pfeiffer syndrome - 756.057 
PHACE syndrome - 759.890 
Phalange 
absent (individual) 
finger - L 755.240 
toe - L 755.340 
Pharynx/pharyngeal 
other anomalies - L 750.210 
other specified anomalies - 750.280 
pouch - L 750.200 
unspecified anomalies - 750.900 
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classic - # 270.100 
hyperphenylalaninemia variant - # 270.110 
NOS - # 270.190 
Philtrum 
long - 750.270 
prominent - 750.270 
smooth - 750.270 
Phimosis - x 
Phlebectasia - L 747.630 
Phocomelia 
arm - L 755.210 
leg - L 755.310 
limb, NOS - L 755.410 
Pierre-Robin sequence - * 524.080 
Pigeon chest - 754.800 
Pili torti - 757.420 
Pilonidal sinus - # 685.100 
Pinna 
absent - L 744.010 
accessory - L # 744.100 
benign neoplasm - L # 216.200 
enlarged - L 744.200 
hypoplastic - L 744.210 
large - L 744.200 
Piriform aperature 
atresia - L 748.000 
stenosis - L 748.000 
Pit 
auricular - L 744.280 
branchial cleft - L 744.400 
ear - L 744.280 
lip - 750.260 
preauricular - L # 744.410 
Pituitary gland anomalies - 759.200 
Pixie-like - L * 744.230 
Plagiocephaly - L * 754.050 
Plantar crease, deep - L 755.610 
Plantar furrow - L 755.610 
Platycephaly - 754.080 
Platyspondyly - * 756.180 
Pleura anomaly - L 748.800 
Pneumothorax - x 
Pointed chin - * 756.080 
Pointed ear - L * 744.230 
Poland syndrome or anomaly - L 756.800 
Polycoria - L 743.440 
Polycystic 
kidney 
adult type - 753.120 
autosomal dominant - 753.120  
autosomal recessive - 753.110 
infantile type - 753.110 
NOS - 753.130 
lung - L 748.410 
Polydactyly 
digit, NOS - L 755.090 
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Type A - L 755.005 
Type B - L * 755.006 
NOS - L 755.095 
preaxial  
index finger - L 755.010 
thumb - L 755.010 
postaxial  
finger - L 755.005 
finger vs skin tag - L 755.007 
NOS - L 755.007 
skin tag - L * 755.006 
thumb - L 755.010 
toe 
big toe - L 755.030 
NOS - L 755.096 
preaxial - L 755.030 
postaxial - L 755.020 
second toe - L 755.030 
Polymicrogyria - 742.250 
Polyorchidism - 752.820 
Polyotia - L # 744.100 
Polyploidy - 758.585 
Polysplenia - 759.040 
Polystotic fibrous dysplasia - 756.510 
Polythelia - L # 757.650 
Pontine hypoplasia - 742.280 
Porencephalic cyst - * 742.410 
Porencephaly - * 742.410 
Portal vein 
anomalous termination - 747.440 
hepatic artery fistula - 747.450 
Port wine stain - # 757.380 
Positional deformity 
arm - L 755.580 
foot - L 754.780 
leg - L 755.680 
Posterior encephalocele - 742.000 
Posterior fossa cyst - 742.230 
Posteriorly rotated ears - L # 744.246 
Posterior segment of eye 
specified anomalies - L 743.580 
unspecified anomalies - L 743.590 
Posterior urethral obstruction - 753.600 
Posterior urethral valves - 753.600 
Posterolateral diaphragmatic hernia - L 756.615 
Potter=s facies - 754.010 
Potter=s syndrome - 753.000 
Potter=s sequence - 753.000 
Pouch 
esophageal - 750.420 
phayngeal - L 750.200 
Prader-Willi syndrome - 759.870 
Preauricular 
appendage - L # 744.110 
cyst - L # 744.410 
lobule - L # 744.110 
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pit - L # 744.410 
sinus - L # 744.410 
tag - L # 744.110 
Predislocation of hip - L 754.310 
Preluxation of hip - L 754.310 
Premature atrial contractions (PACs) - x 
Primary pulmonary artery hypertension - L * 747.680 
Primary vitreous, persistent hyperplastic - L 743.500 
Proboscis - 748.185 
Progressive diaphyseal dysplasia - 756.550 
Prolapse 
bladder (mucosa) - 753.830 
mitral valve - 746.505 
tricuspid valve - 746.100 
Prominent 
clitoris - * 752.450 
eye - L # 743.800 
glabella - # 748.180 
gum - 750.280 
heel - L 755.610 
labia (minora or majora) - * 752.440 
occiput - * 756.080 
philtrum - 750.270 
prepuce of clitoris - x 
renal pelvis - L 753.380 
tongue - x 
xyphoid process - x 
Proptosis - L # 743.800 
Prostate 
other anomalies - 752.840 
Proteus syndrome - 759.890 
Protruding/protuberant 
eye - L # 743.800 
tongue - x 
Proximal femoral focal deficiency - L 755.380 
Prune belly syndrome - 756.720 
Pseudocircumcision - x 
Pseudocoarctation of aorta - 747.280 
Pseudohermaphroditism 
female - 752.720 
male - 752.710 
NOS - 752.730 
Pseudotruncus arteriosus - 747.200 
Ptosis - L 743.600 
Pterygium colli - # 744.500 
Pubis anomalies - L 755.670 
Pulmonary/pulmonic 
arteriovenous malformation or aneurysm - L 747.340 
artery 
absent - L 747.300 
absent septum between aorta and - 745.000 
agenesis - L 747.300 
aneurysm - 747.330 
atresia  
without septal defect - L 747.300 
with septal defect - L 747.310 
collateral vessel involving (but not involving aorta) - L 747.380 
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dilatation - 747.330 
enlarged - 747.330 
hypertension, primary - L * 747.680 
hypoplasia - L 747.380 
narrow - L 747.320 
other specified anomalies - L 747.380 
overriding - L 747.380 
small - L 747.380 
stenosis - L 747.320 
stenosis, branch - L * 747.325 
stenosis, peripheral - L * 747.325 
unspecified anomaly - L 747.390 
hyperplasia - x 
hypoplasia (lung) - L * 748.510 
infundibular stenosis - 746.830 
insufficiency or regurgitation - * 746.020 
NOS (heart) 
atresia - 746.995 
hypoplasia - 746.995 
stenosis - 746.995 
subvalvular stenosis - 746.830 
supravalvular stenosis - L 747.320 
valve 
absent - 746.000 
atresia - 746.000 
bicuspid - 746.080 
dilated - 746.080 
dysmorphic - 746.080 
dysplasia - 746.080 
enlarged - 746.080 
hypoplasia - 746.000 
insufficiency - * 746.020 
other specified anomalies - 746.080 
redundant - 746.080 
regurgitation - * 746.020 
small - 746.000 
stenosis - 746.010 
thickened - 746.080 
unspecified - 746.090 
vein 
atresia - 747.480 
stenosis - 747.480 
Punctum lacrimale, absent - L 743.640 
Pupil - see also iris 
ectopic - L 743.440 
Pyelectasis - L 753.380 
Pyelocaliectasis - L 753.380 
Pyelon duplex or triplex - L 753.310 
Pyloric 
atresia - 751.100 
duplication - 751.500 
obstruction - 750.580 
spasm - # 750.500 
stenosis - 750.510 
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Rachischisis - see spina bifida 
Radial ray defect, NOS - L 755.260 
Radioulnar 
dysostosis - L 755.535 
synostosis - L 755.536 
Radius/radial 
absent 
only (total or partial) - L 755.260 
with absent humerus (total or partial) and ulna - L 755.210 
with absent humerus (total or partial), ulna, and hand - L 755.200 
with absent thumb - L 755.260 
with absent ulna - L 755.220 
with absent ulna (total or partial) and hand - L 755.230 
deviation of hand/wrist with no mention of radial defect - L 755.520 
deviation of hand/wrist with mention of radial defect - L 754.840 
fused with ulna - L 755.536 
hypoplastic - L 755.530 
other specified anomalies - L 755.530 
short - L 755.530 
Ranula - x 
Receding chin - 524.000 
Rectourethral fistula - 753.860 
Rectovaginal fistula - 752.420 
Rectovesical - 753.860 
Rectum/rectal 
absent 
with fistula - 751.210 
without fistula - 751.220 
atresia 
with fistula - 751.210 
without fistula - 751.220 
fissure - * 751.580 
fistula - 751.540 
short  - 751.220 
small - 751.220 
stenosis 
with fistula - 751.210 
without fistula - 751.220 
Red cell aplasia - # 284.000 
Reduction defect of the brain 
brainstem - 742.280 
other - 742.280 
unspecified - 742.290 
Redundant foreskin - x 
Redundant  
mitral valve - x 
pulmonary valve - 746.080 
tricuspid valve - 746.100 
Reflux 
gastroesophageal (GER) - x 
vesicoureteral - L 753.485 
Regurgitation 
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aortic valve - * 746.400 
mitral valve - * 746.600 
pulmonary valve - * 746.020 
single atrioventricular valve - 746.900 
tricuspid valve - * 746.105 
truncal valve - 746.900 
Rieger=s anomaly - L 743.480 
Renal - see also kidney 
agenesis, NOS - 753.009 
artery 
absent - L 747.610 
other anomalies - L 747.610 
stenosis - L 747.600 
calculi - L 753.350 
collecting system 
dilation (central) - L 753.380 
dilation (lower) - L 753.480 
dilation (upper) - L 753.480 
duplex - L 753.410 
cyst (single) - L 753.100 
dysplasia, NOS - 753.009 
multicystic (dysplasia) - L 753.160 
pelvis 
dilated - L 753.380 
enlarged - L 753.380 
extra - L 753.380 
other and unspecified obstructive defects - L 753.290 
prominent - L 753.380 
Renomegaly - L 753.340 
Respiratory system 
anomaly NOS - 748.900 
other specified anomalies - L 748.880 
unspecified anomalies - 748.900 
Retina 
aneurysm - L 743.510 
coloboma - L 743.535 
degeneration, peripheral - 362.600 
hemangioma - L * 228.030 
specified anomalies - L 743.510 
unspecified anomalies - L 743.590 
Retinitis pigmentosa -362.700 
Retractile testicle - x 
Retrognathia - 524.000 
Reversal 
complete mirror reversal of abdominal organs with normal thoracic organs - 759.330 
complete mirror reversal of all organs - 759.300 
complete mirror reversal of thoracic organs with normal abdominal organs - 759.320 
Rhabdomyoma 
heart - * 746.860 
organs other than the heart - 759.680 
Rhizomelia 
arm - L 755.540 
extremity NOS - L 755.880 
leg - L 755.650 
Rib 
absent - L 756.300 
bifid - L 756.310 
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cervical - L # 756.200 
dysplasia - L 756.340 
extra 
in cervical region - L # 756.200 
other - L 756.330 
fused - L 756.320 
gracile - L 756.340 
hypoplastic - L 756.340 
less than 12 - L 756.300 
misshapen - L 756.310 
more than 12 - L 756.330 
other anomalies - L 756.340 
rudimentary - L 756.340 
short - L 756.340 
small - L 756.340 
thin - L 756.340 
Rickets, hypophosphatemic - # 275.330 
Rieger=s anomaly - L 743.480 
Rieger syndrome - 759.800 
Right 
aortic arch - 747.230 
atrioventricular valve - see tricuspid valve 
lung with left lung bronchial pattern - 748.625 
semilunar valve - see pulmonary valve 
superior vena cava, absent -x  
Right sided stomach - 750.730 
Riley-Day syndrome - 742.810 
Ring 
chromosome 
X - 758.610 
vascular - 747.250 
Roberts phocomelia syndrome - 759.840 
Robinow syndrome - 759.800 
Robin sequence - * 524.080 
Rocker-bottom foot - L # 755.616 
Roger=s disease - 745.400 
Rokitansky sequence - 759.890 
Rotated ear - L # 744.246 
Rubella 
congenital (in utero infection) - 771.000 
syndrome, congenital - 771.00 
Rubenstein-Taybi syndrome - 759.840 
Rudimentary 
eye - L 743.100 
finger - L 755.240 
patella - L 755.647 
rib - L 756.340 
toe - L 755.340 





agenesis - 756.170 
anomalies - 756.170 
dimple - # 685.100 
hair tuft - x 
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hemivertebrae - * 756.170 
mass, NOS - 756.179 
sinus - # 685.100 
teratoma - 238.040 
Sacroiliac joint fusion - L 755.670 
Saethre-Chotzen syndrome - 756.056 
Sagittal suture 
closed - 756.005 
craniosynostosis - 756.005 
fused - 756.005 
Salivary glands or ducts, other anomalies - L 750.230 
Salmon patches - # 757.380 
Scalp defects 
aplasia cutis - 757.800 
benign neoplasm - # 216.400 
NOS - 757.800 
Scaphocephaly (no mention of craniosynostosis) - * 754.060 
Scaphoid abdomen - x 
Scapula anomalies - L 755.550 
Schinzel-Giedion syndrome - 759.860 
Schizencephaly - 742.280 
Schwachman Diamond syndrome - 759.870 
Scimitar syndrome - L 748.690 
Sclera, blue - L * 743.450 
Sclerocornea - L 743.410 
Scoliosis 
cervical - 754.200 
lumbar - 754.200 
NOS - 754.200 
postural - 754.200 
sacral - 754.200 
thoracic - 754.200 
Scrotum 
aplasia - L * 752.810 
bifid - 752.820 
fused - x 
hypoplasia - L * 752.810 
other anomalies - 752.820 
shawl - 752.820 
small - L * 752.810 
underdeveloped/undeveloped - L * 752.810 
Seckel syndrome - 759.820 
Semilunar valve 
left - see aortic valve 
right - see pulmonary valve 
Septal closure - see septal defect 
Septal defect (heart) 
aortic - 745.010 
atrial 
NOS - * 745.590 
fenestrated - 745.510 
fossa ovalis - 745.510 
ostium primum - * 745.600 
ostium secundum - 745.510 
other specified - 745.580 
primum - * 745.600 
secundum - 745.510 
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vs PFO - * 745.590 
atrioventricular - see atroventricular canal 
auricular - * 745.590 
other - 745.800 
unspecified - 745.900 
ventricular (heart) 
apical - 745.480 
cystalline - 745.480 
malalignment - 745.480 
membranous - 745.480 
mid-muscular - 745.480 
muscular - 745.480 
NOS - 745.490 
other specified - 745.480 
perimembranous - 745.480 
septal - 745.480 
sub-cystalline - 745.480 
type I - 745.480 
type II - 745.480 
Septo-optic dysplasia - 742.880 
Septum pellucidum 
absent - 742.210 
cavum - x 
enlarged - x 
hypoplasia - 742.210 
Sequence - see syndrome 
Sequestration lung - L 748.520 
Sex chromosome 
additional, NOS - 758.860 
see also trisomy 
mosaic - see mosaic 
other specified anomalies - 758.880 
translocation - see translocation 
trisomy - see trisomy 
unspecified anomalies - 758.890 
Shawl scrotum - 752.820 
Shield chest - 754.825 
Shone=s complex - 746.880 
Short 
achilles tendon - L 754.720 
arm - L 755.580 
colon - 751.520 
esophagus - x 
extremity NOS - L 755.880 
femur - L 755.650 
fibula - L * 755.630 
finger - L # 755.500 
foot - L 755.610 
forearm - L 755.530 
frenulum (tongue, lingual) - # 750.000 
hand - L 755.510 
humerus - L 755.540 
leg - L 755.680 
lower leg - L * 755.630 
nail - x 
neck - # 744.900 
occiput - * 756.080 
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radius - L 755.530 
rectum - 751.220 
rib - L 756.340 
small intestine - 751.190 
sterum - 756.380 
thigh - L 755.650 
tibia - L * 755.630 
toe - L # 755.600 
ulna - L 755.530 
umbilical cord - # 759.900 
ureter - L 753.480 
vagina - 752.410 
Shoulder 
anomalies - L 755.550 
benign neoplasm - L # 216.600 
dislocation - x 
Sickle cell disease 
SS - # 282.600 
SC - # 282.630 
other - # 282.690 
Simian crease - L # 757.200 
Single 
atrioventricular valve - 746.900 
atrium - 745.610 
leg (fused, not one absent) - 759.840 
lung cyst 
multiple - L 748.410 
single - L 748.400 
nostril - 748.185 
umbilical artery - # 747.500 
ventricle (heart) - 745.300 
Sinus 
branchial cleft - L 744.400 
dermal, of head - L 744.480 
pilonidal - # 685.100 
preauricular - L # 744.410 
sacral - # 685.100 
urachal - # 753.700 
Sinus of Valsalva aneurysm - 747.240 
Sinus wall (nose) anomalies - 748.130 
Sirenomelia - 759.840 
Situs ambiguous - * 759.390 
Situs inversus 
abdominis - 759.330 
complete, with dextrocardia - 759.300 
thoacis - 759.320 
unspecified - * 759.390 
with levocardia - 759.310 
with sinusitis and bronchitis - 759.340 
Sjogren-Larsson syndrome - 757.120 
Skeletal dysplasia - 756.490 
Skin 
absent - 757.395 
benign neoplasm 
abdominal wall - #216.500 
anus - #216.500 
arm - L # 216.600 
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auditory canal, external - L # 216.200 
auricle - L # 216.200 
axillary fold - #216.500 
back - #216.500 
breast - #216.500 
buttock - #216.500 
cheek, external - #216.300 
chest wall - #216.500 
ear - L # 216.200 
eyebrow - #216.300 
eyelid, including canthus - L # 216.100 
face, other and unspecified parts - #216.300 
genital organs 
female - #221.000 
male - # 222.000 
groin - #216.500 
hip - L # 216.700 
leg - L # 216.700 
lip - # 216.000 
neck - # 216.400 
nose, external - #216.300 
other specified sites - L # 216.800 
perianal - # 216.500 
perineum - # 216.500 
pinna - L # 216.200 
scalp - #216.400 
shoulder - L # 216.600 
temple - # 216.300 
trunk - # 216.500 
umbilicus - # 216.500 
unspecified site - # 216.900 
cyst - # 757.390 
hemangioma - * 228.010 
hyperpigmentation - # 757.390 
hypopigmentation - # 757.390 
lipoma 
face - # 214.000 
other - # 214.100 
meconium stained - x 
other specified anomalies - # 757.390 
specified syndromes, not elsewhere classified, involving skin anomalies - 757.300 
tag 
cheek - L # 744.110 
ear - L # 744.120 
face - L # 744.110 
finger (postaxial) - L * 755.006 
hymen - * 752.480 
neck - L # 744.110 
nose - L # 744.110 
other - # 757.310 
preauricular - L # 744.110 
unspecified - # 757.310 
vagina - * 752.480 
unspecified anomalies - 757.900 
Skull 
asymmetry - 754.055 
deformity, NOS - 754.090 
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depressions - # 754.040 
elongated - * 754.030 
localized defects - * 756.080 
misshapen - 754.090 
other specified bone anomalies - * 756.080 
other specified deformity (no mention of craniosynostosis) - 754.080 
tower - 754.080 
unspecified bone anomalies - 756.090 
Slanting (up-, down-) palpebral fissures - L # 743.800 
Small - see also hypoplastic, stenosis 
aorta - 747.210 
aortic valve - 746.300 
auditory canal - L 744.000 
bladder - x 
brainstem - 742.280 
breast - x 
chest - 754.820 
chin - 524.000 
colon - 751.520 
ear (not microtia) - L * 744.230 
face - 744.910 
finger, all other - L # 755.500 
finger, thumb - L # 755.500 
fontanelle - # 754.040 
foot - L 755.610 
gallbladder - x 
hand - L 755.510 
head - 742.100 
kidney 
bilateral - 753.000 
NOS - 753.009 
unilateral - L 753.010 
lips - # 744.830 
lung - L * 748.510 
mitral valve - 746.505 
mouth - 744.810 
nail - L 757.585 
nares - # 748.180 
nipple - L * 757.640 
nose - # 748.180 
nostril - # 748.180 
oral cavity - 744.810 
palate - 750.250 
pancreas - 751.700 
penis - 752.865 
pulmonary artery - x 
pulmonary valve - 746.000 
rectum - 751.220 
rib - L 756.340 
scrotum - L * 752.810 
spleen - 759.010 
stomach - 750.700 
testicle - L * 752.810 
thymus - * 759.240 
trachea - 748.330 
tricuspid valve - 746.100 
umbilical cord - # 759.900 
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uterus - L 752.380 
uvula - x 
vagina - 752.410 
vena cava (inferior or superior) - 747.400 
Smith-Lemli-Opitz syndrome - 759.820 
Smith-Magenis syndrome - 759.800 
Smooth  
lip - 750.270 
philtrum - 750.270 
Sotos syndrome - 759.890 
Spade-like hand - L 754.850 
Spasms, infantile, congenital - # 345.600 
Spermatic cord, torsion - L # 608.200 
Sphenoid encephalocele - 752.080 
Spherophakia - L 743.310 
Sphrintzen syndrome - 759.890 
Spina bifida 
aperta - see open lesions 
cystica - see closed lesions 
closed lesions (open vs closed not stated) 
with hydrocephalus 
other - 741.080 
with aqueductal stenosis, any site - 741.020 
with Arnold-Chiari malformation, any site - 741.010 
with hydrocephalus of late onset, any site - 741.070 
without Arnold-Chiari malformation or aqueductal stenosis 
cervical - 741.030 
cervicothoracic - 741.085 
lumbar - 741.050 
lumbosacral - 741.087 
sacral - 741.060 
site unknown - 741.090 
thoracic - 741.040 
thoracolumbar - 741.086 
without hydrocephalus 
cervical - 741.910 
cervicothoracic - 741.980 
lipomeningocele - 741.985 
lipomyelomeningocele, any site - 741.985 
lumbar - 741.930 
lumbosacral - 741.980 
sacral - 741.940 
site unknown - 741.990 
thoracic - 741.920 
thoracolumbar - 741.980 
occipital - 742.000 
occulta - 756.100 
open lesions 
with hydrocephalus, any site - 741.000 
without hydrocephalus, any site - 741.900 
Spinal cord 
dysplasia - 742.510 
hypoplasia - 742.510 
other specified - 742.580 
tethered - 742.580 
unspecified - 742.910 
Spinal dysraphism 
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cervical - 756.140 
lumbar - 756.160 
NOS - 756.180 
sacral - 756.170 
thoracic - 756.150 
Spinal muscular atrophy, infantile - 335.000 
Spine 
unspecified anomalies - 756.190 
Spleen 
absent - 759.000 
accessory - 759.040 
cyst - 759.080 
ectopic - 759.050 
enlarged - # 759.020 
hyperplasia - # 759.020 
hypoplasia - 759.010 
lobulated - 759.030 
misshapen - 759.030 
on right in heterotaxy syndrome - 759.050 
other specified anomalies - 759.080 
small - 759.010 
unspecified anomalies - 759.090 
Splenomegaly - # 759.020 
Split - see also cleft 
hand - L 755.250 
foot - L 755.350 
Spondylocostal dysostoses - 756.480 
Spondyloepiphyseal dysplasia - 756.460 
Spondylolisthesis - 756.130 
Spondylometaphyseal dysplasia - 756.480 
Spondylothoracic dysplasia - 756.480 
Sprengel=s deformity - L 755.556 
Squamosal craniosynostosis - 756.000 
Square cranium - 754.080 
Square head - 754.080 
Stenosis 
anus 
with fistula - 751.230 
without fistula - 751.240 
aortic - 746.300 
aortic valve - 746.300 
appendix - 751.200 
aqueductal (without spina bifida) - 742.300 
bladder neck - 753.610 
other and unspecified - 753.690 
bronchus - L 748.340 
choanal - L 748.000 
colon - 751.200 
duodenum - 751.100 
esophageal - 750.340 
hepatic vein - L 747.650 
ileum - 751.120 
intestine 
large - 751.200 
small - 751.190 
small, with fistula - 751.195 
jejunum - 751.110 
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lacrimal duct - L # 743.650 
larynx (not subglottic) - 748.300 
meatus (urethral, urinary) - 753.630 
meatus (external auditory, ear) - L 744.000 
mitral valve - 746.500 
piriform aperature - L 748.000 
pulmonary 
artery - L 747.320 
artery, branch - L * 747.325 
artery, peripheral - L * 747.325 
infundibular - 746.830 
NOS (heart) - 746.995 
subvalvular - 746.830 
valve - 746.010 
vein - 747.480 
pyloric - 750.510 
rectum 
with fistula - 751.210 
without fistula - 751.220 
renal artery - L 747.600 
subglottic - * 748.310 
subvalvular aortic - 746.300 
subvalvular pulmonary - 746.830 
supra-aortic - 747.220 
supravalvular aortic - 747.220 
supravalvular pulmonary - L 747.320 
trachea - 748.330 
tricuspid valve - 746.100 
truncal valve - 746.900 
ureter - L 753.210 
ureteropelvic junction - L 753.210 
urethral  
anterior - 753.620 
other and unspecified - 753.690 
urinary meatus - 753.630 
vena cava (inferior or superior) - 747.400 
Sternocleidomastoid muscule 
absent - L 754.100 
anomalies - L 754.100 
contracture - L 754.100 
hypoplastic - L 754.100 
tumor - L 754.100 
Sternum 
absent - 756.350 
bifid - 756.380 
curved - 754.820 
long - 756.380 
misshapen - 756.360 
other anomalies - 756.380 
short - 756.380 
wide - 756.380 
Stickler syndrome - 759.860 
Stomach 
absent 
with absent GI tract - 750.780 
with rest of GI tract intact - 750.700 
displacement - 750.730 
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diverticulum - 750.740 
duplication - 750.750 
other specified anomalies - 750.780 
partial thoracic - 750.600 
right sided - 750.730 
small - 750.700 
transposition - 750.730 
unspecified - 750.920 
Stork bite - # 757.380 
Strabismus, NOS - # 378.900 
Streak ovary - L 752.010 
Streeter syndrome/dysplasia - # 658.800 
Stricture - see also stenosis 
meatus (external auditory, ear) - L 744.000 
ureter - L 753.210 
urethral - 753.690 
Stridor, laryngeal - * 748.360 
Sturge-Weber syndrome - 759.610 
Subclavian artery, aberrant - L 747.640 
Subcoronal hypospadias with chordee - 752.625 
Subcoronal hypospadias without chordee - 752.605 
Subependymal cyst - 742.420 
Subglottic 
stenosis - * 748.310 
web - 748.206 
Subluxable hip - L 754.310 
Subluxation knee - L 754.440 
Subluxation of hip - L 754.310 
Sunken eye - L # 743.800 
Sun-setting eyes - x 
Superior vena cava, right, absent - x 
Supernumerary - see accessory, extra 
Supraorbital ridges, hypoplastic - * 756.080 
Suture 
closed 
basilar - 756.030 
coronal - L 756.010 
lambdoidal - L 756.020 
metopic - 756.006 
NOS - 756.000 
other - 756.030 
sagittal - 756.005 
fused 
basilar - 756.030 
coronal - L 756.010 
lambdoidal - L 756.020 
metopic - 756.006 
NOS - 756.000 
other - 756.030 
sagittal - 756.005 
overlapping - x 
overriding - x 
Symblepharon - L * 743.630 
Symbrachydactyly fingers - L #  755.500 and L 755.190-755.199 (depending on the laterality)  
Symbrachydactyly toes - L #  755.600 and L 755.190-755.199 (depending on the laterality) 
Symphalangism finger - L # 755.500 
Symphalangism toe - L # 755.600 
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Syndactyly (fused vs webbed unspecified) 
fingers 
bilateral - 755.192 
NOS - 755.193 
unilateral - L 755.191 
NOS - L 755.190 
NOS - 755.199 
toes 
bilateral - 755.195 
NOS - 755.196 
unilateral - L 755.194 
Syndrome (also anomaly, association, disease, sequence) 
Aarskog syndrome - 759.800 
Acrocallosal syndrome - 759.890 
Adams-Oliver syndrome - 759.840 
Adrenogenital syndrome - # 255.290 
Agnathia formation syndrome - 759.800 
Aicardi syndrome - 759.890 
Alagille syndrome - 759.870 
Albers-Schonberg syndrome - 756.540 
Albright-McCune-Sternberg syndrome - 756.510 
Alport syndrome - 759.870 
Amniotic band syndrome - # 658.800 
Androgen insensitivity syndrome - 257.800 
Angelman syndrome - 759.890 
Antimongolian syndrome - 758.300 
Apert syndrome - 756.055 
Baller-Gerold syndrome - 759.840 
Bart syndrome - 757.330 
Beals syndrome - 759.860 
Beckwith syndrome - 759.870 
Beckwith-Wiedemann syndrome - 759.870 
Beemer Langer syndrome - 759.860 
Blepharophimosis syndrome - 759.800 
Bloom syndrome - 759.890 
BOR syndrome - 759.800 
Bonneville-Ullrich syndrome, NOS - 758.690 
Bourneville=s disease - 759.500 
Branchial arch syndrome - 759.800 
Brown syndrome - # 378.000 
Caffey syndrome - 756.530 
Camurati-Engelmann syndrome - 756.550 
Cardio-splenic syndrome - 759.890 
Carpenter syndrome - 759.840 
Cat eye syndrome - 758.580 
Caudal regression syndrome - 759.840 
Cerebro-oculo-facial-skeletal syndrome - 759.890 
CHARGE association - 759.890 
Chediak-Higashi syndrome - 757.300 
Clifford=s syndrome - x 
Cockayne syndrome - 759.820 
Coffin-Siris syndrome - 759.800 
COFS syndrome - 759.890 
Congenital contractural arachnodactyly syndrome - 759.860 
Congenital rubella syndrome - 771.000 
Conradi syndrome - 756.575 
Constriction band syndrome - # 658.800 
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Cornelia de Lange syndrome - 759.820 
Costello syndrome - 759.800 
Cri du chat syndrome - 758.310 
Crouzon=s disease - 756.040 
Diamond-Blackfan syndrome (anemia) - # 284.000 
Diencephalic syndrome - 253.820 
DiGeorge syndrome - 279.110 
disappearing penis syndrome - 752.860 
distal arthrogryposis syndrome - L 755.800 
Down syndrome 
karyotype trisomy 21 - 758.000 
karyotype trisomy G, NOS - 758.010 
mosaic - 758.040 
NOS - 758.090 
translocation trisomy (duplication of a 21) - 758.020 
translocation trisomy (duplication of a G, NOS) - 758.030 
Duane syndrome - # 378.000 
Du Pan syndrome - 759.840 
Eagle-Barrett=s syndrome - 756.720 
Ebstein=s anomaly - 746.200 
Ectrodactyly-Ectodermal dysplasia-Clefting syndrome - 759.840 
Edwards syndrome 
karyotype normal (Edwards phenotype) - 758.295 
karyotype trisomy 18 - 758.200 
karyotype trisomy E, NOS - 758.210 
mosaic - 758.240   
NOS - 758.290 
translocation trisomy 18 (duplication or an 18) - 758.220 
translocation trisomy 18 (duplication or an E, NOS - 758.230 
EEC syndrome - 759.840 
Ehlers-Danlos syndrome - 756.850 
Eisenmenger=s  syndrome - 745.410 
Ellis-van Creveld syndrome - 756.525 
Engelmann syndrome - 756.550 
Escobar syndrome - 759.840 
epidermal nevus syndrome - 757.300 
Facio-auricular-digital syndrome - 759.800 
Facio-auriculo-vertebral syndrome - 756.060 
Femoral fibular hypoplasia B unusual facies syndrome - 759.840 
Femoral hypoplasia B unusual facies syndrome - 759.840 
Femur-fibula-ulna syndrome - 759.840 
Fetal Accutane (Isoretinoin) syndrome - 760.760 
Fetal alcohol syndrome - 760.710 
Fetal Dilantin syndrome - 760.750 
Fetal hydantoin syndrome - 760.750 
FG syndrome - 759.800 
fragile X syndrome - 758.880 
Franceschetti syndrome - 756.045 
Frasier syndrome - 759.800 
Freeman Sheldon syndrome - 759.800 
Fryn syndrome - 759.840 
Gardner syndrome - 759.630 
Gaucher disease Type II - 759.870 
Gerbode syndrome - 745.420 
Goldenhar syndrome - 756.060 
Goltz syndrome - 757.300 
Hallermann-Streiff syndrome - 756.046 
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Heterotaxy syndrome - * 759.390 
Holt-Oram syndrome - 759.840 
Horner syndrome - L 744.880 
Hurler syndrome - 277.510 
Hypertelorism-hypospadias syndrome - 759.800 
Hypoglossia-hypodactylia syndrome - 759.840 
hypoplastic left heart syndrome - 746.700 
immotile cilia syndrome - 759.340 
Ivemark syndrome - 759.005 
Jackson-Weiss syndrome - 756.046 
Jacobsen syndrome - 757.300 
Jadassohn-Lewandasky syndrome - 759.890 
Jarcho Levin syndrome - 756.480 
Jaw-winking syndrome - 742.800 
Jeune syndrome - 756.400 
Johansen-Blizzard syndrome - 759.870 
Kabuki syndrome - 759.800 
Kalischer=s disease - 759.610 
Kartagener (triad) syndrome - 759.340 
Kast syndrome - 756.420 
Kawasaki disease - x 
Keratitis-ichthyosis-deafness syndrome - 757.190 
KID syndrome - 757.190 
kinky hair syndrome - 759.870 
Klinefelter syndrome 
karyotype 47,XXY - 758.700 
karyotype 48,XXXY - 758.710 
karyotype 48,XXYY - 758.710 
karyotype 49,XXXXY - 758.710 
NOS - 758.790 
other karyotype with additional X chromosomes - 758.710 
Klippel-Feil syndrome - 756.110 
Klippel-Trenaunay-Weber syndrome - 759.840 
Larsen=s syndrome - 755.810 
Laurence-Moon-Biedl syndrome - 759.820 
Lethal multiple pterygium syndrome - 759.840 
Limb-body wall complex - 759.840 
Long QT syndrome - 746.880 
Lowe syndrome - 759.870 
Lutemabcher=s syndrome - 745.520 
Maffucci syndrome - 756.420 
Marcus Gunn syndrome - 742.800 
Marfan syndrome - 759.860 
Meckel-Gruber syndrome - 759.890 
Meconium plug syndrome - # 777.100 
Melnick-Fraser syndrome - 759.800 
Menkes syndrome - 759.870 
Mermaid syndrome - 759.840 
Miller-Dieker syndrome - 759.800 
Milroy=s disease - 757.000 
Moebius syndrome - 352.600 
Mohr syndrome - 759.800 
Multiple pterygium syndrome - 759.840 
Muscle-eye-brain disease - 759.890 
Nager syndrome - 756.046 
Nail-patella syndrome - 756.830 
Nephrotic syndrome, congenital - L 753.380 
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Neu-Laxova syndrome - 759.890 
Neurocutaneous melanosis syndrome - 757.300 
Neurofibromatosis-Noonan syndrome - 237.700 
Noonan syndrome - 759.800 
Norrie disease - 759.890 
OAV syndrome - 756.060 
Ochoa syndrome - 759.800 
oculoauriculovertebral syndrome - 756.060 
oculomandibulofacial syndrome - 756.046 
Oeis syndrome - 759.890 
OFD syndrome, type I - 759.800 
Ollier syndrome - 756.410 
Opitz G/BBB syndrome - 759.800 
oral-facial-digital syndrome, type I - 759.800 
orofaciodigital syndrome, type II - 759.800 
Oro-mandibular-limb hypogenesis syndrome - 759.840 
other specified syndromes 
affecting facial appearance - 759.800 
associated with short stature - 759.820 
involving limbs - 759.840 
not elsewhere clasified - 759.890 
with metabolic disturbances - 759.870 
with other skeletal changes - 759.860 
Oto-palato-digital syndrome - 759.800 
Patau syndrome 
karyotype trisomy 13 - 758.100 
karyotype trisomy D, NOS - 758.110 
mosaic - 758.140 
NOS - 758.190 
translocation trisomy 13 (duplication or a 13) - 758.120 
translocation trisomy 13 (duplication or a D, NOS) - 758.130 
Pearson syndrome - 759.870 
Pena-Shokier syndrome - L 755.800 
Pena-Shokeir II syndrome - 759.840 
Peter=s anomaly - L 743.440 
Peutz-Jegher syndrome - 759.600 
Pfeiffer syndrome - 756.057 
PHACE syndrome - 759.890 
Pierre-Robin sequence - * 524.080 
Poland syndrome (anomaly) - L 756.800 
Potter=s sequence (syndrome) - 753.000 
Prader-Willi syndrome - 759.870 
Proteus syndrome - 759.890 
Prune belly syndrome - 756.720 
Rieger=s anomaly - L 743.480 
Rieger syndrome - 759.800 
Riley-Day syndrome - 742.810 
Roberts phocomelia syndrome - 759.840 
Robinow syndrome - 759.800 
Robin sequence - * 524.080 
Roger=s disease - 745.400 
Rokitansky sequence - 759.890 
Rubella, congenital syndrome - 771.000 
Rubenstein-Taybi syndrome - 759.840 
Russell-Silver syndrome - 759.820 
Saethre-Chotzen syndrome - 756.056 
Schinzel-Giedion syndrome - 759.860 
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Schwachman Diamond syndrome - 759.870 
Scimitar syndrome - L 748.690 
Seckel syndrome - 759.820 
Shone=s complex - 746.880 
Short rib-polydactyly syndrome - 756.480 
Sjogren-Larsson syndrome - 757.120 
Smith-Lemli-Opitz syndrome - 759.820 
Smith-Magenis syndrome - 759.800 
Sotos syndrome - 759.890 
Sphrintzen syndrome - 759.890 
Stickler syndrome - 759.860 
Streeter syndrome/dysplasia - # 658.800 
Sturge-Weber syndrome - 759.610 
TAR syndrome - 759.840 
Taussig-Bing - 745.100 
Tay-Sachs disease - # 330.100 
Testicular feminization syndrome - 257.800 
Thrombocytopenia-absent radius syndrome - 759.840 
Townes-Brock syndrome - 759.890 
Treacher-Collins syndrome - 756.045 
Turner syndrome 
isochromosome - 758.610 
karyotype 45,X [XO] - 758.600 
mosaic (including XO) - 758.610 
NOS - 758.610 
partial X deletion - 758.610 
ring - 758.610 
variant karyotypes - 758.610 
Uhl=s syndrome - 746.882 
VACTERL association - 759.890 
VATER association - 759.890 
Velocardiofacial syndrome (VCFS) - 279.110 
Von Hipple-Lindau syndrome - 759.620 
Von Willebrand syndrome - # 286.400 
Waardenburg syndrome - 759.800 
Walker-Warburg syndrome - 742.880 
Weaver syndrome - 759.890  
Werdnig-Hoffman syndrome - 335.00 
whistling face syndrome - 759.800 
Wiedemann-Beckwith syndrome - 759.870 
Wildervanck syndrome - 756.110 
Williams syndrome - 759.800 
Wilson-Mikity syndrome - x 
Wolff-Hirschorn syndrome - 758.320 
Wolff-Parkinson-White syndrome - 426.705 
Zellweger syndrome - 759.870 
Synophrys - L 744.880 
Synostosis 
astragaloscaphoid - L 755.620 
cranial - see craniosynostosis 
radioulnar - L 755.536 
Synotia - L 744.240 
Syphilis, congenital (in utero infection) - # 090.000 
Syringoadenoma - see skin-benign neoplasm 
Syringohydromyelia - 742.540 
Syringomyelia - 742.540 
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Tag - see skin tag 
Talipes 
calcaneovalgus - L 754.600 
calcaneovarus - L 754.510 
equinovalgus - L 754.680 
equinovarus - L 754.500 
NOS - L 754.730 
Talipomanus - L 754.840 
Taenzer=s hair - 757.430 
Tarsal bones, absent - L 755.340 
TAR syndrome - 759.840 
Taussig-Bing syndrome - 745.110 
Tay-Sachs disease - # 330.100 
Teeth, natal - # 520.600 
Telecanthus - 756.085 
Temporal narrowing - * 756.080 
Tendon 
absent - L 756.820 
other specified anomalies - L 756.880 
unspecified anomalies - 756.910 
Teratoma 
abdomen - 238.030 
coccygeal - 238.040 
face - 238.010 
head - 238.010 
neck - 238.020 
NOS - 238.000 
other specified - 238.080      
sacral/sacrococcygeal - 238.040 
Testicle/testis 
absent - L 752.800 
aplasia - L * 752.810 
appendix - L 752.870 
atrophy - L * 752.810 
ectopic - L 752.530 
hypoplasia - L * 752.810 
in inguinal canal - see undescended 
 
large - 752.820 
non-palpable - see undescended 
other anomalies - 752.820 
regression - L 752.800 
retractile - x 
small - L * 752.810 
torsion - L # 608.200 
undescended 
bilateral - * 752.514 
NOS - * 752.520 
unilateral - L * 752.500 
vanishing - L 752.800 
Testicular feminization syndrome - 257.800 
Tethered spinal cord - 742.580 
Tetralogy of Fallot 
with ASD - 745.210 
without ASD - 745.200 
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Thalami, fused - 742.260 
Thalamus, hypoplastic - 742.280 
Thanatophoric dwarfism - 756.447 
Thick/thickened 
aortic valve - 746.480 
bladder - x 
frenulum - x 
mitral valve - 746.500 
neck - # 744.500 
palpebral fissure - x 
pulmonary valve - 746.080 
tongue - 750.120 
tricuspid valve - 746.100 
urethra - x 
ventricular septum - * 746.860 
Thigh 
absent 
with absent lower leg - L 755.310 
hyperextended - x 
short - L 755.650 
Thin 
lips - # 744.830 
palpebral fissure - L 743.635 
rib - L 756.340 
Thoracic cage 
unspecified anomalies - 756.390 
Thoracic-pelvic-phalangeal dysplasia - 756.400 
Thorax - see chest 
Thrombocytopenia-absent radius syndrome - 759.840 
Thumb - see finger 
Thymus 
absent - * 759.240 
anomalies - * 759.240 
enlarged - * 759.240 
hypoplastic - * 759.240 
hypertrophy - * 759.240 
small - * 759.240 
Thyroglossal cyst - 759.220 
Thyroglossal duct anomalies - 759.220 
Thyroid gland anomalies - 759.210 
Tibia 
absent 
only (total or partial) - L 755.365 
with absent femur (total or partial) and fibula (total or partial)- L 755.310 
with absent femur (total or partial), fibula, and foot - L 755.300 
with absent fibula - L 755.320 
with absent fibula (total or partial) and foot - L 755.330 
with absent first toe (with or without second toe) - L 755.365 
angulation - L * 755.630 
bowed - L 754.410 
hemimelia - L 755.365 
hypoplastic - L * 755.630 
other specified anomalies - L * 755.630 
short - L * 755.630 
torsion - L * 755.630 
Tibial ray defect, NOS - L 755.365 
Toe 
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fifth (with or without fourth) - L 755.366 
first toe (with or without second toe) - L 755.365 
first toe (with or without second toe) and tibia (total or partial) - L 755.365 
NOS - L 755.340 
third (with or without second, fourth)- L 755.350 
with absent long bone leg - L 755.360 
acrodactylia - L # 755.600 
anomalies - L # 755.600 
arachnodactyly - L # 755.600 
brachydactyly - L # 755.600 
camptodactyly - L # 755.600 
clinodactyly - L # 755.600 
digitalized (great toe) - L # 755.600 
flexion deformity - L # 755.600 
fused - L 755.120 
hammer - L # 755.600 
hyperextension - L # 755.600 
hypoplastic 
all other - L 755.685 
first - L 755.365 
incurving - L # 755.600 
long - L # 755.600 
nubbin - L 755.340 
other specified deformities - L 754.780 
overlapping - L # 755.600 
rudimentary - L 755.340 
short - L # 755.600 
symbrachydactyly - L #  755.600 and L 755.190-755.199 (depending on the laterality) 
symphalangism - L # 755.600 
syndactyly, unspecified 
bilateral - 755.195 
NOS - 755.196 
unilateral - L 755.194 
triphalangeal (geat toe) - L # 755.600 
webbed - L * 755.130 
widely spaced first and second - L # 755.600 
Tongue 
absent - 750.100 
cleft - 750.140 
cyst - x 
dislocation - 750.130 
displacement - 750.130 
large - 750.120 
other specified - 750.180 
prominent - x 
protruding - x 
small - 750.110 
thick - 750.120 
tie - # 750.000 
unspecified - 750.190 
Tooth, natal - # 520.600 
TORCH infection, unspecified - # 771.090 
Torsion 
femur - L 755.650 
ovary - L 752.080 
penile -  752.860 
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spermatic cord - L # 608.200 
testicle - L # 608.200 
tibia - L * 755.630 
Torticollis - L 756.860 
Total anomalous pulmonary venous return - 747.420 
Tower head - 754.080 
Tower skull - 754.080 
Townes-Brock syndrome - 759.890 
Toxoplasmosis, congenital (in utero infection) - # 771.210 
Trabeculated bladder - x 
Trachea 
atresia - 748.330 
other anomalies - 748.330 
small - 748.330 
stenosis - 748.330 
unspecified anomalies - 748.390 
Tracheomalacia - x 
Tracheoesophageal 
fistula 
H type - 750.325 
with esophageal atresia - 750.310 
without esophageal atresia - 750.320 
other anomalies - 750.380 
Translocation 
balanced autosomal (in normal individual) - 758.400 
other (autosome) - 758.540 
trisomy 13 - 758.120 
trisomy 18 - 758.220 
trisomy 21 - 758.020 
trisomy D, NOS - 758.130 
trisomy E, NOS - 758.230 
trisomy G, NOS - 758.030 
Transposition of 
great arteries 
complete - 745.100 
corrected - 745.120 
incomplete - 745.110 
L- - 745.120 
other - 745.180 
unspecified - 745.190 
with inlet VSD - 745.110 
with muscular VSD - 745.100 and 745.480 
without VSD - 745.100 
with perimembraneous VSD - 745.110 
with VSD - 745.110 
great vessels - see great arteries 
penoscrotal - 752.880 
stomach - 750.730 
Transverse liver - # 751.620 
Transverse reduction defect, NOS 
arm - L 755.285 
leg - L 755.385 
limb, NOS - L 755.420 
Treacher-Collins syndrome - 756.045 
Triangular  
face - 744.910 
head shape - 754.070 
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abnormal - 746.100 
aneurysm - 746.100 
atresia - 746.100 
bicuspid - 746.100 
cleft - 746.100 
dilated - 746.100 
dysplastic - 746.100 
enlarged - 746.100 
hypoplasia - 746.100 
incompetence - * 746.105 
insufficiency - * 746.105 
other specified anomalies - 746.100 
prolapse - 746.100 
redundant - 746.100 
regurgitation - * 746.105 
small - 746.100 
stenosis - 746.100 
thickened - 746.100 
Trigonocephaly (no mention of craniosynostosis) - 754.070 
Trilogy of Fallot - 746.840 
Triphalangeal (thumb) - L # 755.500 
Triphalangeal (great toe) - L # 755.600 
Triploidy - 758.586 
Trisomy 
1 - 758.520 
2 - 758.520 
3 - 758.520 
4 - 758.520 
5 - 758.520 
6 - 758.510 
7 - 758.510 
8 - 758.500 
9 - 758.510 
10 - 758.510 
11 - 758.510 
12 - 758.510 
13 - 758.100 
14 - 758.520 
15 - 758.520 
16 - 758.520 
17 - 758.520 
18 - 758.200 
19 - 758.520 
20 - 758.520 
21 - 758.000 
22 - 758.520 
C, NOS - 758.510 
D, NOS - 758.110 
E, NOS - 758.210 
G, NOS - 758.010 
NOS (autosome) - 758.520 
NOS - 758.910 
other total (autosome) - 758.520 
partial (autosome) - 758.530 
XXX female - 758.850 
XYY male - 758.840 
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Trophedema, hereditary - 757.000 
Truncal valve - 746.900 
insufficiency - 746.900 
narrow - 746.900 
regurgitation - 746.900 
stenosis - 746.900 
Truncus arteriosus - 745.000 
Tuberous sclerosis - 759.500 
Tubular hypoplasia of aorta - 747.210 
Tumor 
heart - 746.880 
sternocleidomastoid muscule - L 754.100 
Turner syndrome 
isochromosome - 758.610 
karyotype 45,X [XO] - 758.600 
mosaic (including XO) - 758.610 
NOS - 758.610 
partial X deletion - 758.610 
ring - 758.610 
variant karyotypes - 758.610 
Turricephaly - 754.080 
Twin reversed arterial perfusion (TRAP) sequence - 759.890 
Twins 
acardiac - 759.480 
conjoined 
craniopagus (head-joined twins) - 759.410 
dicephalus (two heads) - 759.400 
ischiopagus - 759.480 
other specified - 759.480 
pelvis-joined twins - 759.480 
pygophagus (buttock-joined twins) - 759.440 
thoracopagus (thorax-joined twins) - 759.420 
unspecified - 759.490 
xiphopagus (xiphoid-joined twins) - 759.430 
Twisted hair - 757.420 
Two vessel umbilical cord - # 747.500 




Uhl=s disease - 746.882 
Ulna/ulnar 
absent 
only (total or partial) - L 755.270 
with absent humerus (total or partial) and radius - L 755.210 
with absent humerus (total or partial), radius, and hand - L 755.200 
with absent radius - L 755.220 
with absent radius (total or partial) and hand - L 755.230 
bowed without Madelung deformity - L 755.530 
deviation of hand/wrist with no mention of ulnar defect - L 755.520 
deviation of hand/wrist with mention of ulnar defect - L 754.840 
fused with radius - L 755.536 
hypoplastic - L 755.530 
other specified anomalies - L 755.530 
short - L 755.530 
Ulnar ray defect, NOS - L 755.270 
Umbilical artery hypoplasia - # 747.500 
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anomalies - # 759.900 
atrophy - # 759.900 
benign neoplasm - # 216.500 
Four vessel - L * 747.680 
hernia - # 553.100 
low-lying - # 759.900 
short - # 759.900 
single artery - # 747.500 
small - # 759.900 
two vessels - # 747.500 
Underdevelopment 
nose - 748.100 
Undescended testicle 
bilateral - * 752.514 
NOS - * 752.520 
unilateral - L * 752.500 
Unicornate uterus - L 752.380 
Unstable of hip - L 754.310 
Upper 
alimentary tract 
other specified anomalies - 750.800 
unspecified anomalies - 750.990 
arm 
absent 
only - L 755.220 
with absent forearm - L 755.210 
anomalies - L 755.540 
leg - see also thigh 
anomalies - L 755.650 
limb - see arm 
Urachus/urachal 
cyst - 753.710 
other and unspecified anomaly - 753.790 
patent - # 753.700 
remnant - 753.790 
sinus - # 753.700 
Ureter 
absent - L 753.400 
accessory - L 753.410 
atresia - L 753.210 
dilated - L 753.220 
double - L 753.410 
ectopic - L 753.420 
hypoplastic - L 753.210 
other and unspecified obstructive defects - L 753.290 
other specified anomalies - L 753.480 
short - L 753.480 
stenosis - L 753.210 
stricture - L 753.210 
unspecified anomalies - L 753.910 
Ureterectasis - L 753.220 
Ureterocele - L 753.480 
Ureteropelvic junction 
obstruction - L 753.210 
stenosis - L 753.210 
Ureterovesical junction - see ureteropelvic junction 
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absent - 753.800 
anterior 
atresia - 753.620 
obstruction - 753.620 
stenosis - 753.620 
valve - 753.620 
diverticulum - 753.880 
double - 753.840 
ectopic - 753.850 
enlarged - x 
fistula, NOS - 753.870 
hypertrophy - x 
obstruction (posterior) - 753.600 
orifice 
ectopic - 753.850 
other and unspecified atresia and stenosis - 753.690 
other specified anomalies - 753.880 
stricture - 753.690 
thickened - x 
unspecified anomalies - 753.930 
valves (posterior) - 753.600 
Urethrorectal fistula - 753.860 
Urinary meatus 
atresia - 753.630 
double - 753.840 
obstruction - 753.630 
stenosis - 753.630 
Urinary system/tract 
fistula with digestive system - 753.860 
unspecified anomalies - 753.990 
Urogenital sinus malformation - 753.880 
Uropathy, obstructive 
at level of bladder or urethra - 753.690 
unilateral - L 753.290 
Urticaria pigmentosa - 757.320 
Uterointestinal fistula - 752.320 
Uterovesical fistula - 752.320 
Uterus 
absent - 752.300 
agenesis - 752.300 
bicornate - L 752.380 
didelphys - 752.200 
displaced - 752.310 
doubling - 752.200 
fistula (with digestive or urinary tract) - 752.320 
other anomalies - L 752.380 
septate - L 752.380 
small - L 752.380 
unicornate - L 752.380 
unspecified anomalies - 752.390 
Uvula 
absent - 749.080 
bifid - 749.080 
cleft - 749.080 
enlarged - x 
small - x 
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VACTERL association - 759.890 
Vagina 
absent (complete or partial) - 752.410 
agenesis (complete or partial) - 752.410 
atresia (complete or partial) - 752.410 
cyst 
embryonal - # 752.460 
other - 752.470 
doubling - * 752.480 
other specified anomalies - * 752.480 
short - 752.410 
small - 752.410 
tag - * 752.480 
unspecified anomalies - 752.490 
Vaginocele - * 752.480 
Valga/valgum/valgus 
coxa - L 755.660 
cubitus - L 755.540 
genu - L 755.645 
hallux - L 755.605 
knee - L 755.645 
other specified deformities of foot - L 754.680 
pes - L 754.615 
unspecified deformities of foot - L 754.690 
Valve 
aortic 
absent - 746.480 
atresia - 746.480 
bicuspid - * 746.400 
dysmorphic - 746.480 
dysplastic - 746.480 
hypoplastic - 746.480 
incompetence - * 746.400 
insufficiency - * 746.400 
other specified - 746.480 
quadricuspid - 746.480 
regurgitation - * 746.400 
small - 746.300 
stenosis - 746.300 
thickened - 746.480 
unspecified - 746.490 
mitral 
absent - 746.505 
anomaly - 746.505 
atresia - 746.505 
cleft - 746.505 
dysmorphic - 746.505 
dysplastic - 746.505 
hypoplasia - 746.505 
insufficiency - * 746.600 
parachute - 746.505 
prolapse - 746.505 
redundant - x 
regurgitation - * 746.600 
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small - 746.505 
stenosis - 746.500 
thickened - 746.500 
pulmonary 
absent - 746.000 
atresia - 746.000 
bicuspid - 746.080 
dilated - 746.080 
dysmorphic - 746.080 
dysplasia - 746.080 
enlarged - 746.080 
hypoplasia - 746.000 
insufficiency - * 746.020 
other specified anomalies - 746.080 
redundant - 746.080 
regurgitation - * 746.020 
small - 746.000 
stenosis - 746.010 
thickened - 746.080 
unspecified - 746.090 
tricuspid  
abnormal - 746.100 
aneurysm - 746.100 
atresia - 746.100 
bicuspid - 746.100 
cleft - 746.100 
dilated - 746.100 
dysplastic - 746.100 
enlarged - 746.100 
hypoplasia - 746.100 
incompetence - * 746.105 
insufficiency - * 746.105 
other specified anomalies - 746.100 
prolapse - 746.100 
redundant - 746.100 
regurgitation - * 746.105 
small - 746.100 
stenosis - 746.100 
thickened - 746.100 
unspecified anomalies - 746.900 
Vanishing testicle - L 752.800 
Varix- L 747.630 
Vara/Varum/varus 
complex deformities - L 754.530 
coxa - L 755.660 
genu - L 755.646 
hallux - L 755.606 
metatarsus - L # 754.520 
unspecified (of feet) - L 754.590 
Varicella, congenital (in utero infections) - # 052.000 
Vascular ring - 747.250 
Vas deferens 
atresia - L 752.830 
other anomalies - 752.840 
VATER association - 759.890 
Vein of Galen anomalies - L 747.810 
Velocardiofacial syndrome (VCFS) - 279.110 
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absent (except left superior) - 747.480 
bilateral inferior - 747.480 
bilateral superior - 747.410 
dilated - 747.480 
enlarged - 747.480 
interrupted inferior - 747.480 
left superior - 747.410 
small (inferior or superior) - 747.400 
stenosis (inferior or superior) - 747.400 
Ventri in version - 745.120 
Ventricle/ventricular (brain) 
cyst - * 742.485 
dilatation - 742.390 
enlarged - 742.390 
Ventricle/ventricular (heart) 
common - 745.300 
dilatation - x 
double inlet left - 745.300 
double inlet right - 745.300 
double outlet left - 745.180 
double outlet right - 745.180 
enlarged - x 
hypertrophy - L * 746.886 
hypoplastic left - 746.881 
hypoplastic NOS - 746.883 
hypoplastic right - 746.882 
inversion - 745.120  
outflow tract obstruction (left or right) - 746.880 
septal defect 
apical - 745.480 
cystalline - 745.480 
hypertrophy - * 746.860 
malalignment - 745.480 
membranous - 745.480 
mid-muscular - 845.480 
muscular - 745.480 
NOS - 745.490 
other specified - 745.480 
perimembranous - 745.480 
septal - 745.480 
sub-cystalline - 745.480 
thickened - * 746.860 
type I - 745.480 
type II - 745.480 
single - 745.300 
Ventriculomegaly - 742.390 
Vermian atrophy - 742.230 
Vermis (inferior) anomalies - 742.230 
Vertebra 
cervical 
agenesis - 756.146 
anomalies - 756.140 
bifid - 756.140 
butterfly - 756.140 
cleft - 756.140 
fused - 756.140 
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hypoplastic - 756.140 
segmentation anomalies - 756.140 
lumbar 
agenesis - 756.166 
anomalies - 756.160 
bifid - 756.160 
butterfly - 756.160 
cleft - 756.160 
fused - 756.160 
hypoplastic - 756.160 
segmentation anomalies - 756.160 
NOS 
bifid - 756.180 
butterfly - 756.180 
cleft - 756.180 
fused - 756.180 
hypoplastic - 756.180 
other specified anomalies - 756.180 
segmentation anomalies - 756.180 
unspecified anomalies - 756.190 
sacral/sacrum 
agenesis - 756.170 
anomalies - 756.170 
bifid - 756.170 
butterfly - 756.170 
cleft - 756.170 
fused - 756.170 
hypoplastic - 756.170 
segmentation anomalies - 756.170 
thoracic 
agenesis - 756.156 
anomalies - 756.150 
bifid - 756.150 
butterfly - 756.150 
cleft - 756.150 
fused - 756.150 
hypoplastic - 756.150 
segmentation anomalies - 756.150 
Vertical talus foot - L # 755.616 
Vesicoureteral reflux - L 753.485 
Vesicovaginal fistula - 752.420 
Vesiculobullous dermatosis - x 
Vitelline duct - 751.000 
Vitreous humor anomalies - L 743.500 
Vocal cord paralysis - x 
Volvulus 
gastric - x 
intestinal - x 
Von Hipple-Lindau syndrome - 759.620 
Von Willebrand disease - # 286.400 
Vulva 
absent - * 752.440 
cyst - 752.470 
fused - * 752.440 
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Waardenburg syndrome - 759.800 
Walker-Warburg syndrome - 742.880 
Weaver syndrome - 759.890 
Web/webbed 
duodenal - 751.560 
elbow - L 755.800 
esophageal - 750.350 
fingers - L 755.110 
hip - L 755.800 
jejunal - * 751.580 
knee - L 755.640 
larynx 
glottic - 748.205 
NOS - 748.209 
subglottic - 748.206 
neck - # 744.500 
penis - 752.621 
penoscrotal - 752.860 
toes - L * 755.130 
Werdnig-Hoffman disease - 335.000 
Werner mesomelic dysplasia - 756.480 
Wharton duct cyst - x 
Whistling face syndrome - 759.800 
White forelock - # 757.390 
Widely spaced first and second toes - L # 755.600 
Widely spaced nipples - # 757.680 
Wide neck - # 744.500 
Wide set eyes - 756.085 
Wide sternum - 756.380 
Wiedemann-Beckwith syndrome - 759.870 
Wildervanck syndrome - 756.110 
Williams syndrome - 759.800 
Wilson-Mikity syndrome - x 
Wolff-Hirschorn syndrome - 758.320 
Wolff-Parkinson-White syndrome - 426.705 
Wolffian duct cyst - L 752.870 
Wrist 
anomalies - L 755.520 
flexed - L 755.520 




Xeroderma pigmentosum - 757.360 
XK aprosencephaly - 759.800 
Xyphoid process 
bifid - 756.380 
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45,X - 758.600 
45,X,inv(9) - 758.600 
45,X/46,X+mar - 758.610 
45,X/46,X,9(X)(q10) - 758.610 
45,X/46,X,r - 758.610 
45,X/46,X,r(X)(p22.3;q24) - 758.610 
45,X/46,XX (with Turner syndrome phenotype) - 758.610 
45,X/46,XX (without Turner syndrome phenotype) - 758.810 
45,X/46,XX/46,X,+15/47,XX+15 - 758.520 
45,X/46,XX/46,X,+15/47,XX+15 - 758.880 
45,X/46,XY - 758.800 
45,X/46X,r(X) - 758.610 
45,X/47,XXX - 758.610 
45,XX,der(14;21)(q10;q10)/46,XX,der(14;21)(q10;q10),+21 - 758.040 
45,XX,der(14;21)(q10;q10)/46,XX,der(14;21)(q10;q10),+21 - 758.020 
45,XX,der(5)(5;15)(p15.3;q13),-15.15Hder(5)(PML+D15S10-,141-,D5S23+74+) - 758.540 
45,XX,der(7)+(7;21)(q35;q10)-21 - 758.540 
45,XX,der,(16;22)(p13.3;q11,2),-22 - 758.380 
45,XY,?dic(7;20)(p22;?p13)/46,XY,?dic(7;20)(p22;?p13),+mar - 758.540 
46 XY,+21,der(21;21)(q10;q10) - 758.020 
46,del(13q) - 758.330 
46,X,del(X)(p22.2) - 758.610 
46,X,i(Xq) - 758.610 
46,X,inv(Y)+mar - 758.580 
46,XX,+21,der(21;21) - 758.020 
46,XX,+21,der(21;21)(q10;q10) - 758.020 
46,XX,-14,+t(13;14)/45XX,-14,+t(13;14) - 758.120 
46,XX,-18,+der(18)+(18;?)(q12.3;?),var(14) - 758.530 
46,XX,-18,+der(18)+(18;?)(q12.3;?),var(14) - 758.340 
46,XX,-20,+mar - 758.580 
46,XX,-21,+t(21q;21q) - 758.020 
46,XX,?del(15)(q11.2)/47,XX+mar/46,XX - 758.380 
46,XX,?del(15)(q11.2)/47,XX+mar/46,XX - 758.580 
46,XX,9,qh+ - 758.580 
46,XX,add(4)(p16) - 758.530 
46,XX,add(4)(p16) - 758.530 
46,XX,add(6)(p15.1) - 758.530 
46,XX,add(8)(p23) - 758.530 
46,XX,del(1)(p22) - 758.380 
46,XX,del(1)(p36.3) - 758.380 
46,XX,del(1)(p36.3),inv(9)(p11;q12)ish del(1)(P36.3)(P58-,D1Z2) - 758.380 
46,XX,del(11)(q23) - 758.380 
46,XX,del(14;21)(q10;q10)mat,+21 - 758.020 
46,XX,del(15)(q11.2;q13) - 758.380 
46,XX,del(17)(p11.2;p13) - 758.380 
46,XX,del(18)(p11.2) - 758.350 
46,XX,del(18)(q?21.1) - 758.340 
46,XX,del(22)(q11.2;q11.2) - 758.380 
46,XX,del(22)(q11.2;q11.2)(D22575-) - 758.380 
46,XX,del(22)(q11.2;q11.2)(D22S75) - 758.380 
46,XX,del(3)(q23;q25 or q25;q26.2)DISH del(3)(WCP3+) - 758.380 
46,XX,del(4)(q32.1) - 758.380 
46,XX,del(5)(p14) - 758.310 
46,XX,del(9)(p22) - 758.380 
46,XX,del(9)(p22-pter) - 758.380 
46,XX,der(?18)t(13;18)(?q11;?p11.1).ISH 46,XX,der(18)t(13;18)(q12;p11.2)(D18Z1+) - 758.120 
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46,XX,der(13)+(2;13)(q37.1;q32.2) - 758.540 
46,XX,der(13)t(13;?)(q;?) - 758.330 
46,XX,der(13)t(13;?)(q;?) - 758.530 
46,XX,der(14)+(14;17)(p12;p11.2)pat.ISH der(14)+(14;17)(p12;p11.2)(D17S29-)pat - 758.380 
46,XX,der(14)+(14;17)(p12;p11.2)pat.ISH der(14)+(14;17)(p12;p11.2)(D17S29-)pat - 758.530 
46,XX,der(14;21)(q10;q10),+21 - 758.020 
46,XX,der(15)t(15.15)(p13;q26.1) - 758.580 
46,XX,der(21)+(5:21) - 758.530 
46,XX,der(21)+(5:21) - 758.540 
46,XX,der(21:21)(q10;q10),+21 - 758.020 
46,XX,der(5)+(5;10)(p15.1;p11.21).ISH der(5)+(5;10)(p15.1;p11.21)WCP 10+,D5S23-) - 758.540 
46,XX,der(7) - 758.580 
46,XX,der(8p) - 758.580 
46,XX,dup(4)(q28;q33) - 758.530 
46,XX,dup(5)(q11.2;q12) - 758.530 
46,XX,inv(2) - 758.580 
46,XX,inv(3)(?p13;?q21) - 758.580 
46,XX,inv(6)(p21.3;q15)pat - 758.580 
46,XX,inv(9)(p11;q12),r(13)(p11.2;q22)/45,XX,inv(9)(p11;q12),-13 - 758.380 
46,XX,inv(9)(p12;q13) - 758.580 
46,XX,inv(9),(p11;q13) - 758.580 
46,XX,inv(9),(p12;q13) - 758.580 
46,XX,ish del(15)(q11.2;q11.2)(SNRPN-) - 758.380 
46,XX male - 758.880 
46,XX,r(22)(p11.2;q13.3) - 758.580 
46,XX,r(8) - 758.580 
46,XX,rob(21q;21q) - 758.020 
46,XX,t(11;12)(q22.1;q23) - 758.400 
46,XX,t(14;21)(q10;q10),+21 - 758.020 
46,XX,t(14q;21q) - 758.020 
46,XX,t(21;21)(q10;q10),+21 - 758.020 
46,XX,t(21q;21q) - 758.020 
46,XX,t(6;7)(p22.2;15.3) - 758.540 
46,XX,t(9:13)(q22;q14)pat - 758.400 
46,XX.ISH del(22)(q11.2;q11.2)(D22S75-) - 758.380 
46,XX.ISH del(22)(q11.2;q11.2)(F5-)/46,X,fra(X)(q27.3).ISH del(22)(q11.2;q11.2)(F5-_ - 758.880 
46,XX.ISH del(22)(q11.2;q11.2)(F5-)/46,X,fra(X)(q27.3).ISH del(22)(q11.2;q11.2)(F5-_ - 758.380 
46,XX.ISH del(22q11.2;q11.2)(D22575-) - 758.380 
46,XX/45,X - 758.610 
46,XX/46,XX,fra(X)(q28) - 758.880 
46,XX/47,XX,+13 - 758.100 
46,XX/47,XX,+21 - 758.040 
46,XXI(18)(q10) - 758.220 
46,XY,+13,der(13;13)(q10;q10) - 758.120 
46,XY,+13,der(13;14)(q10;q10) - 758.120 
46,XY,+21,der(21;21)(q10;q10) - 758.020 
46,XY,+21,der(21;21)(q10;q10)de novo - 758.020 
46,XY,-10,der(10)t(3;10)(p25;q26)mat - 758.400 
46,XY,-14,+der(14)rob(13q;14q) - 758.120 
46,XY,-14,+t(13:14)(p11;q11) - 758.120 
46,XY,-14,+t(14q;21q) - 758.020 
46,XY,-21,+der(21) - 758.000 
46,XY,-21,+t(21q;21q) - 758.020 
46,XY,?del(7)(q36) - 758.380 
46,XY,1qh+ - 758.580 
46,XY,add(20)(p16qh+) - 758.530 
46,XY,add(8)(p23) - 758.530 
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46,XY,del(13p) - 758.380 
46,XY,del(15)(q11.2;q13) - 758.380 
46,XY,del(22)(q11.2).ISH del(22)(q11.2;q11.2)(D22S7S-) - 758.380 
46,XY,del(3)(q21;q23) - 758.380 
46,XY,del(4)(p15.2) - 758.320 
46,XY,del(5)(p14.1) - 758.310 
46,XY,del(6)(q25.1;q25.31) - 758.380 
46,XY,del(p13) - 758.310 
46,XY,der(13)+(13:?)(q32:?) - 758.530 
46,XY,der(13)+(13:?)(q32:?) - 758.540 
46,XY,der(13:13)(q10;q10),+13 - 758.120 
46,XY,der(13;14)(q10;q10)+14/45,XY,der(13;14)(q10;q10) - 758.520 
46,XY,der(14:21)(q10;q10),+21 - 758.020 
46,XY,der(14;21)(q10,q10) - 758.020 
46,XY,der(21;21)(q10;q10),+21 - 758.020 
46,XY,der(4)(p15.3).ISH DER (4) (WCP4-, D4F26-, D4596-) - 758.320 
46,XY female, with a diagnosis of androgen insensitivity - 257.800 
46,XY female, without a diagnosis of androgen insensitivity - 758.880 
46,XY,inv(1)(p32;q31),3+der(3)+(1;3)(q31;p24) - 758.400 
46,XY,inv(12) - 758.580 
46,XY,inv(9)(p11;q12) - 758.580 
46,XY,inv(9)(p12;q13) - 758.580 
46,XY,inv(9)(p12;q13)mat,17 CHEV,+pat - 758.580 
46,XY,inv(9)(pg12a13) - 758.580 
46,XY,ISH del(22)(q11.2;q11.2)(D22S75-) - 758.380 
46,XY,rob(14q;21q) - 758.540 
46,XY,rob(14q;21q) - 758.020 
46,XY,t(14q;21q) - 758.020 
46,XY,t(16;17)(q13;q23) - 758.540 
46,XY,t(17;19)(q21.2;q13.2) - 758.400 
46,XY,t(3;18)(p13;q23) - 758.400 
46,XY,t(4;14) - 758.400 
46,XY,var(15)(q11.2) - 758.580 
46,XY,var(15q) - 758.580 
46,XY,var(22) - 758.580 
46,XY,var21(+p) - 758.580 
46,XY.ISH del(22)(q11.2;q11.2)(D22S75-) - 758.380 
46,XY.ISH del(22)(q11.2;q11.2)(D22S75-) - 758.380 
46,XY.ISH del(22)(q11.2)(D22S75X2) - 758.380 
46,XY/45,X - 758.800 
46,XY/45,XY,-14-18,+der(14)+(14;18) (q11.1;p11.2) - 758.540 
46,XY/45,XY,-14-18,+der(14)+(14;18)(q11.1;p11.2) - 758.380 
46,XY/45,XY,-19 - 758.380 
46,XY/46,XY,-20,+der(20) - 758.580 
46,XY/47,XXY (without Klinefelter syndrome phenotype) - 758.820 
46,XY/47,XY+mar - 758.580 
46,XY/47,XY,+16 - 758.520 
46,XY/47,XY,+18 - 758.200 
46,XY/47,XY,+21 - 758.040 
46,XY/49,XXXXY (without Klinefelter syndrome phenotype) - 758.830 
46,Y,der(X) - 758.880 
47,X,fra(X)(q27.3)/47,XX,+21 - 758.000 
47,XX,+(15;17)(q11.2?;q25),+18 - 758.200 
47,XX,+1 - 758.520 
47,XX,+10 - 758.510 
47,XX,+11 - 758.510 
47,XX,+12 - 758.510 
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47,XX,+13 - 758.100 
47,XX,+13,inv(9)(pg12;q13) - 758.100 
47,XX,+13,inv(9)(pg12;q13) - 758.580 
47,XX,+14 - 758.520 
47,XX,+15 - 758.520 
47,XX,+16 - 758.520 
47,XX,+17 - 758.520 
47,XX,+18 - 758.200 
47,XX,+19 - 758.520 
47,XX,+2 - 758.520 
47,XX,+20 - 758.520 
47,XX,+20(p10)/46,XX - 758.520 
47,XX,+21 - 758.000 
47,XX,+21,16(qh+) - 758.000 
47,XX,+21,16qht - 758.000 
47,XX,+21/46,XX - 758.040 
47,XX,+21;inv(9)(p11;q12) - 758.000 
47,XX,+22 - 758.520 
47,XX,+3 - 758.520 
47,XX,+4 - 758.520 
47,XX,+5 - 758.520 
47,XX,+6 - 758.510 
47,XX,+7 - 758.510 
47,XX,+8 - 758.500 
47,XX,+8/46,XX - 758.500 
47,XX,+9 - 758.510 
47,XX,9qht,+21 - 758.000 
47,XX,inv(9)(p11;q13),+21/46,XX,inv(9)(p11;q13) - 758.040 
47,XX,inv(9)(p11;q13),+21/46,XX,inv(9)(p11;q13) - 758.580 
47,XX,t(7;8)(q11.2;p21.1)+21 - 758.540 
47,XX,t(7;8)(q11.2;p21.1),+21 - 758.000 
47,XXX - 758.850 
47,XXY - 758.700 
47,XXY/46,XY - 758.820 
47,XY,+1 - 758.520 
47,XY,+10 - 758.510 
47,XY,+11 - 758.510 
47,XY,+12 - 758.510 
47,XY,+13 - 758.100 
47,XY,+14 - 758.520 
47,XY,+15 - 758.520 
47,XY,+16 - 758.520 
47,XY,+17 - 758.520 
47,XY,+18 - 758.200 
47,XY,+18,inv(9)(p11;q12) - 758.200 
47,XY,+19 - 758.520 
47,XY,+2 - 758.520 
47,XY,+20 - 758.520 
47,XY,+21 - 758.000 
47,XY,+21,+22 PSS - 758.000 
47,XY,+21,1qht - 758.000 
47,XY,+21/46,XY - 758.040 
47,XY,+22 - 758.520 
47,XY,+8/46,XY - 758.500 
47,XY,+3 - 758.520 
47,XY,+4 - 758.520 
47,XY,+5 - 758.520 
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47,XY,+6 - 758.510 
47,XY,+7 - 758.510 
47,XY,+8 - 758.500 
47,XY,+9 - 758.510 
47,XY,+del(18)(q21.2) - 758.200 
47,XY,+der(22) - 758.530 
47,XY,+der(22)t(11,22)(q23;q11)mat - 758.530 
47,XY,+mar - 758.580 
47,XY,i(21)(q10)+mar - 758.580 
47,XY,i(21)(q10)+mar - 758.020 
47,XY,inv(2)(p11.2;q13),+21 - 758.000 
47,XY,inv(9)(p11;q12),+21 - 758.000 
47,XY,inv(9)(p11;q12),+21 - 758.000 
47,XY,t(2;9)(p25.1;q34.11),+21 - 758.020 
47,XYY - 758.840 
47,XYY/46,XY - 758.840 
48,XXXY - 758.710 
48,XXYY - 758.710 
48,XY,+21,+mar(pat) - 758.000 
48,XY,+21,+mar(pat) - 758.580 
49,XXXXY - 758.710 
69,XXX - 758.586 
69,XXY - 758.586 
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R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A - 33 
 Explanation of 6-Digit Code 
 
   
6th Digit Code - Master 
.000 Blank 
.001 Left Only 
.002 Right Only 
.003 Unilateral Unspecified 
.004 Bilateral 
.005     
.006     
.007     
.008 Possible, Probable, Borderline, or Rule Out; 
  Defects only diagnosed prenatally should be coded with the last digit 8 
when the prenatal diagnosis is not definitive.  





An asterisk (*) beside a disease code indicates that the code was created by 
CDC. 
 
A pound symbol (#) beside a disease code indicates that the condition or 
defect is listed on the MACDP Exclusion List.   
 
A check (Τ) beside a disease code indicates that an addition/revision was 
made since the last printing of the Procedure Manual. Use of the code should 
be according to the exclusion list criteria.   
 
The abbreviations NEC and NOS used in this code are defined as not elsewhere 
classified and as not otherwise specified, respectively. 
 
 
R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A - 34 
 CONGENITAL ANOMALIES 
 
 




740.000 Absence of brain 
740.010 Acrania 
740.020 Anencephaly 









740.200 Closed iniencephaly 
740.210 Open iniencephaly 
740.290 Unspecified iniencephaly 
 
 
 741 Spina Bifida 
Includes: Spina bifida aperta (open lesions) 
myelocele 
rachischisis 




Excludes: Spina bifida occulta (see 756.100) 
craniorachischisis (see 740.100) 
 
741.0 Spina Bifida with Hydrocephalus 
 
741.000 Spina bifida aperta, any site, with hydrocephalus 
 
741.010 Spina bifida cystica, any site, with hydrocephalus 
and Arnold-Chiari malformation  
Arnold-Chiari malformation, NOS 
741.020 Spina bifida cystica, any site, with stenosed 
aqueduct of Sylvius 
741.030 Spina bifida cystica, cervical, with unspecified 
 hydrocephalus 
Spina bifida cystica, cervical, with 
hydrocephalus but without mention of 
Arnold-Chiari malformation or aqueduct stenosis 
741.040 Spina bifida cystica, thoracic, with unspecified 
hydrocephalus, no mention of Arnold-Chiari 
741.050 Spina bifida cystica, lumbar, with unspecified 
hydrocephalus, no mention of Arnold-Chiari 
741.060 Spina bifida cystica, sacral, with unspecified 
hydrocephalus, no mention of Arnold-Chiari 




R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A - 35 
741.080 Other spina bifida, meningocele of specified site 
with hydrocephalus 
741.085 Spina bifida, meningocele, cervicothoracic, with 
hydrocephalus 
741.086 Spina bifida, meningocele thoracolumbar, with 
hydrocephalus 
741.087 Spina bifida, meningocele, lumbosacral with 
hydrocephalus 
741.090 Spina bifida of any unspecified type 
with hydrocephalus 
 
741.9 Spina bifida without mention of hydrocephalus 
 
741.900 Spina bifida (aperta), without hydrocephalus 
741.910 Spina bifida (cystica), cervical, without hydrocephalus 
741.920 Spina bifida (cystica), thoracic, without hydrocephalus 
741.930 Spina bifida (cystica), lumbar, without hydrocephalus 
741.940 Spina bifida (cystica), sacral, without hydrocephalus 
741.980 Spina bifida, other specified site, without hydrocephalus 
Includes: cervicothoracic, thoracolumbar, lumbosacral 
   741.985 Lipomyelomeningocele 
741.990 Spina bifida, site unspecified, without hydrocephalus 
(myelocoele, myelomeningocele, meningomyelocele) 
  
 




742.000 Occipital encephalocele 
742.080 Other encephalocele of specified site  
(includes midline defects) 
742.085 Frontal encephalocele  
742.086 Parietal encephalocele 





742.2 Reduction deformities of brain 
 
742.200 Anomalies of cerebrum 
742.210 Anomalies of corpus callosum 
742.220 Anomalies of hypothalamus 
742.230 Anomalies of cerebellum 
742.240 Agyria and lissencephaly 
742.250 Microgyria, polymicrogyria 
742.260 Holoprosencephaly 
742.270 Arrhinencephaly 
742.280 Other specified reduction defect of brain 
742.290 Unspecified reduction defect of brain 
 
742.3 Congenital hydrocephalus 
Excludes:hydrocephalus with any condition in 741.9 (use 741.0) 
 
742.300 Anomalies of aqueduct of Sylvius 
742.310 Atresia of foramina of Magendie and Luschka 
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Dandy-Walker syndrome 
   742.320 Hydranencephaly 
742.380 Other specified hydrocephaly  
Includes: communicating hydrocephaly 
# 742.385 Hydrocephalus secondary to intraventricular 
hemorrhage (IVH) or CNS bleed 
742.390 Unspecified hydrocephaly, NOS 
 
 
742.4 Other specified anomalies of brain 
 




Includes: porencephalic cysts 
742.420 Cerebral cysts 
742.480 Other specified anomalies of brain 
Includes: cortical atrophy 
 cranial nerve defects 
742.485 Ventricular cysts  
Excludes: arachnoid cysts  
742.486 Small brain 
 
742.5 Other specified anomalies of spinal cord 
 
742.500 Amyelia 




742.530 Other cauda equina anomalies 
742.540 Hydromyelia 
Hydrorachis 
742.580 Other specified anomalies of spinal cord and membranes 
Includes: congenital tethered cord 
 
742.8 Other specified anomalies of nervous system 
Excludes: congenital oculofacial paralysis  
Moebius syndrome (use 352.600) 
 
742.800 Jaw-winking syndrome 
Marcus Gunn syndrome 
742.810 Familial dysautonomia 
Riley-Day syndrome 
742.880 Other specified anomalies of nervous system 
 
742.9 Unspecified anomalies of brain, spinal cord and nervous systems 
 
742.900 Brain, unspecified anomalies 
742.910 Spinal cord, unspecified anomalies 
742.990 Nervous system, unspecified anomalies 
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743  Congenital Anomalies of Eye 
 
743.000  Anophthalmos 
agenesis of eye   
cryptophthalmos 
743.100 Microphthalmos, small eyes 
aplasia of eye   
hypoplasia of eye 








743.210 Enlarged eye, NOS 




743.3 Congenital cataract and lens anomalies 
 
743.300 Absence of lens 
congenital aphakia 
743.310 Spherical lens 
Spherophakia 
743.320 Cataract, NOS 
743.325 Cataract, anterior polar 
743.326 Cataract, other specified 
743.330 Displaced lens 
743.340 Coloboma of lens 
743.380 Other specified lens anomalies 
743.390 Unspecified lens anomalies 
 
743.4 Coloboma and other anomalies of anterior segments 
 
743.400 Corneal opacity 
743.410 Other corneal anomalies 
Excludes: megalocornea (use 743.220) 
743.420 Absence of iris 
aniridia 
743.430 Coloboma of iris 




  #  Excludes: brushfield spots (use 743.800) 
 743.450 Blue sclera 
#   If <36 weeks gestation, code only if another reportable  
    defect is present.  
    Always code if ≥36 weeks gestation. 
743.480 Other specified colobomas and anomalies of anterior segments 
Rieger's anomaly 
743.490 Unspecified colobomas and anomalies of anterior eye segments 
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743.5 Congenital anomalies of posterior segment 
 
743.500 Specified anomalies of vitreous humour 
743.510 Specified anomalies of retina 
congenital retinal aneurysm 
Excludes: Stickler syndrome (use 759.860) 
743.520 Specified anomalies of optic disc 
hypoplastic optic nerve 
    coloboma of the optic disc 
743.530 Specified anomalies of choroid 
743.535 Coloboma of choroid 
743.580 Other specified anomalies of posterior segment of eye 
743.590 Unspecified anomalies of posterior segment of eye 
 






# 743.630 Other anomalies of eyelids 
absence of eyelashes 
long eyelashes  
weakness of eyelids 
 Τ #  fused eyelids (exclude if <25 weeks gestation unless another  
    reportable defect is present) 
743.635 Blepharophimosis 
small or narrow palpebral fissures 
743.636 Coloboma of the eyelids 
743.640 Absence or agenesis of lacrimal apparatus 
absence of punctum lacrimale 
# 743.650 Stenosis or stricture of lacrimal duct 
743.660 Other anomalies of lacrimal apparatus (e.g., cyst) 
743.670 Anomalies of orbit 
 
743.8 Other specified anomalies of eye 
 
# 743.800 Other specified anomalies of eye 
Includes: exophthalmos      
     epicanthal folds 
      antimongoloid slant      
      upward eye slant 
     Brushfield spots 
Excludes:  congenital nystagmus (use 379.500) 
retinitis pigmentosa (use 362.700) 
ocular albinism (use 270.200) 
wide spaced eyes, hypertelorism (use 756.085) 
 
* 743.810 Epibulbar dermoid cyst 
 
743.9 Unspecified anomalies of eye 
 
743.900 Unspecified anomalies of eye 
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744  Congenital Anomalies of Ear, Face, and Neck 
 
744.0 Anomalies of ear causing impairment of hearing 
 
744.000 Absence or stricture of auditory canal 
744.010 Absence of auricle (pinna) 
absence of ear, NOS 
744.020 Anomaly of middle ear 
fusion of ossicles 
744.030 Anomaly of inner ear 
Includes: congenital anomaly of membranous  
  labyrinth organ of Corti 
744.090 Unspecified anomalies of ear with hearing impairment 
Includes: congenital deafness, NOS 
 
744.1 Accessory auricle 
 
# 744.100 Accessory auricle 
       Polyotia 
# 744.110 Preauricular appendage, tag, or lobule 
(in front of ear canal) 
# 744.120 Other appendage, tag, or lobule include papillomas, 
ear tags 
 
744.2 Other specified anomalies of ear 
 
744.200 Macrotia (enlarged pinna) 
744.210 Microtia (hypoplastic pinna and absence or 
stricture of external auditory meatus) 
744.220 Bat ear 
 Τ # 744.230 Other misshapen ear 
pointed ear  
elfin  
pixie-like 
lop ear   
cauliflower ear 
cleft in ear  
malformed ear 
absent or decreased cartilage 
744.240 Misplaced ears 
# 744.245 Low set ears 
# 744.246 Posteriorly rotated ears 
744.250 Absence or anomaly of eustachian tube 
744.280 Other specified anomalies of ear (see also 744.230) 
#  Excludes: Darwin's tubercle 
 
 
744.3 Unspecified anomalies of ear 
 
744.300 Unspecified anomalies of ear 
Congenital:  ear (any part) 
  anomaly, deformity, NOS 
 
744.4 Branchial cleft, cyst, or fistula; preauricular sinus 
 
744.400 Branchial cleft, sinus, fistula cyst, or pit 
# 744.410 Preauricular sinus, cyst, or pit 
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744.480 Other branchial cleft anomalies 
Includes: dermal sinus of head 
# 744.500 Webbing of neck 
Includes: pterygium colli, 
redundant neck skin folds 
 
 744.8 Other unspecified anomalies of face and neck 
 
744.800 Macrostomia (large mouth) 
744.810 Microstomia (small mouth) 
# 744.820 Macrocheilia (large lips) 
# 744.830 Microcheilia (small lips) 
744.880 Other specified anomalies of face/neck 
 
744.9 Unspecified anomalies of face and neck 
 
# 744.900 Congenital anomaly of neck, NOS 
Includes: short neck 
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745  Bulbus Cordis Anomalies and Anomalies of Cardiac Septal Closure 
 
745.0 Common truncus (see 747.200 for pseudotruncus) 
 
745.000 Persistent truncus arteriosus 
absent septum between aorta and pulmonary 
artery 
745.010 Aortic septal defect 
Includes: aortopulmonary window 
Excludes: atrial septal defect (use 745.590) 
 
745.1 Transposition of great vessels 
 
745.100 Transposition of great vessels, complete (no VSD) 
745.110 Transposition of great vessels, incomplete (w/ VSD) 
Taussig-Bing syndrome 
745.120 Corrected transposition of great vessels, 
L-transposition, ventri in version 
Excludes: dextrocardia (use 746.800)  
 N  745.130 Double outlet right ventricle (DORV) with normally  
 related  great vessels 
 N  745.140 Double outlet right ventricle (DORV) with transposed  
    great vessels 
 N  745.150 Double outlet right ventricle (DORV), relationship of great  
    vessels not specified 
 N  745.180 Other specified transposition of great vessels,   
    no mention of double outlet right ventricle (DORV) 
745.190 Unspecified transposition of great vessels 
 
745.2 Tetralogy of Fallot 
 
745.200 Fallot's tetralogy 
745.210 Fallot's pentalogy 
Fallot's tetralogy plus ASD 
 
745.3 Single ventricle 
 
745.300 Single ventricle 
Common ventricle 
Cor triloculare biatriatum 
 
745.4 Ventricular septal defect 
 
 N  745.400 Roger's disease 
    Note:  This is an oudated term and the code is no longer 
           used. If this diagnostic term is encountered in  
                the medical record, code it as a ventricular septal  
           defect. 
745.410 Eisenmenger's syndrome 
745.420 Gerbode defect 
 Τ  745.480 Other specified ventricular septal defect  
    Includes:  cystalline 
        sub-cystalline 
        subarterial 
        conoventricular 
 N   745.485 Perimembranous VSD 
    Includes:  membranous VSD 
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 N   745.486   Muscular VSD 
    Includes:  mid-muscular and apical VSDs 
 N   745.487 Inlet VSD 
    Includes:  common atrioventricular (AV) canal type VSD 
    Note:  Code common atrioventricular (AV) canal as  
           745.630  
           Code common atrioventricular (AV) canal with  
           muscular VSD as 745.620  
    745.490 Ventricular septal defect, NOS 
Excludes: common atrioventricular canal type (use 
 745.620) 
    745.498 Probable VSD 
 
 745.5 Ostium secundum type atrial septal defect 
 
Ν # 745.500 Nonclosure of foramen ovale, NOS 
Patent foramen ovale (PFO) 
1)Always code if ≥36 weeks of gestation at birth and defect 
last noted at ≥6 weeks of age. 
    2)If ≥36 weeks gestation at birth and defect last noted  
    <6 weeks of age, code only if another reportable heart  
    defect is present. 
    3)Never code if <36 weeks gestation at birth regardless  
    of presence of other defects. 
   745.510 Ostium (septum) secundum defect 
 N  745.520 Lutembacher's syndrome 
 Note:  This is an outdated term and the code is no  
        longer used. If this diagnostic term is  
        encountered in the medical record, code the  
        individual components, not the syndrome. 
745.580 Other specified atrial septal defect 
745.590 ASD (atrial septal defect), NOS 
Auricular septal defect, NOS 
Partial foramen ovale 
PFO vs. ASD 
 
745.6 Endocardial cushion defects 
 
745.600 Ostium primum defects 
745.610 Single common atrium, cor triloculare biventriculare 
 N  745.620 Common atrioventricular canal with ventricular  
 septal defect (VSD) 
 Includes: Common AV canal with muscular VSD 
 Excludes: Inlet VSD or common AV canal type VSD (code as  
 745.487 
745.630 Common atrioventricular canal 
745.680 Other specified cushion defect 
745.690 Endocardial cushion defect, NOS 
 
745.7 Cor biloculare 
 
745.700 Cor biloculare 
 
745.8 Other specified defects of septal closure 
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745.9 Unspecified defect of septal closure 
 
745.900 Unspecified defect of septal closure 
 
 
  746  Other Congenital Anomalies of Heart 
 
746.0 Anomalies of pulmonary valve 
 
 N  746.000 Atresia, hypoplasia of pulmonary valve 
Note:  Code pulmonary artery atresia as 747.300 
       Code pulmonary artery hypoplasia as 747.380 
       Code “pulmonic” or “pulmonary” atresia or  
       hypoplasia, NOS (no mention of valve or  
       artery) as 746.995 
 N  746.010 Stenosis of pulmonary valve 
  #  Excludes: pulmonary infundibular 
stenosis (use 746.830) 
Note:  Code pulmonary artery stenosis as 747.320 
       Code “pulmonic” or “pulmonary” stenosis, NOS (no  
       mention of valve or artery) as 746.995 
Ν   # 746.020 Pulmonary valve insufficiency or regurgitation,  
   congenital 
Never code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic'. 
Code cases designated as ‘moderate’ or ‘severe’ and those 
where the degree is not specified (NOS) only if another 
reportable heart defect is present.  
746.080 Other specified anomalies of pulmonary valve 
  #  Excludes: pulmonary infundibular 
stenosis (use 746.830) 
746.090 Unspecified anomaly of pulmonary valve 
 
746.1 Tricuspid atresia and stenosis 
 
 N  746.100  Tricuspid atresia only  
Excludes:  tricuspid stenosis and hypoplasia 
Ν # 746.105 Tricuspid valve insufficiency or regurgitation,  
   congenital 
 Never code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic'. 
Code cases designated as ‘moderate’ or ‘severe’ and those 
where the degree is not specified (NOS) only if another 
reportable heart defect is present.  
 N   746.106 Tricuspid stenosis or hypoplasia 
 
746.2 Ebstein's anomaly 
 
746.200 Ebstein's anomaly 
 
746.3 Congenital stenosis of aortic valve 
 
746.300 Congenital stenosis of aortic valve 
Includes: congenital aortic stenosis 
 subvalvular aortic stenosis 
Excludes: supravalvular aortic stenosis (747.220) 
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746.4 Congenital insufficiency of aortic valve 
 
Ν  # 746.400 Aortic valve insufficiency or regurgitation, congenital 
     Excludes:  bicuspid aortic valve. 
Never code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic'. 
Code cases designated as ‘moderate’ or ‘severe’ and those 
where the degree is not specified (NOS) only if another 
reportable heart defect is present.  
  N  746.470 Bicuspid aortic valve 
 * 746.480 Other specified anomalies of the aortic valves 
Includes: aortic valve atresia 
Excludes: supravalvular aortic stenosis (747.220) 
* 746.490 Unspecified anomalies of the aortic valves 
 
746.5 Congenital mitral stenosis 
 
746.500 Congenital mitral stenosis 
 
 
 746.505 Absence, atresia, or hypoplasia of mitral valve 
746.6 Mitral valve insufficiency or regurgitation, congenital 
 
Ν  # 746.600 Mitral valve insufficiency or regurgitation, congenital 
Never code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic'. 
Code cases designated as ‘moderate’ or ‘severe’ and those 
where the degree is not specified (NOS) only if another 
reportable heart defect is present.  
 
746.7 Hypoplastic left heart syndrome 
 
746.700 Hypoplastic left heart syndrome 
Atresia, or marked hypoplasia of the  
ascending aorta and defective development 
of left ventricle (with mitral valve atresia) 
 
746.8 Other specified anomalies of the heart 
 
746.800 Dextrocardia without situs inversus (situs solitus) 
Dextrocardia with no mention of situs inversus 
Excludes: dextrocardia with situs inversus use 759.300)  
 N  746.810  Levocardia   
    Note:  This condition has been moved to the never code  
           list.  
746.820 Cor triatriatum 
746.830 Pulmonary infundibular (subvalvular) stenosis 
746.840 Trilogy of Fallot 
746.850 Anomalies of pericardium 
 N # 746.860 Anomalies of myocardium 
cardiomegaly, congenital, NOS 
cardiomyopathy, congenital   
cardiomyopathy, hypertrophic  
Note: Do not code cardiomyopathy of any type in a  
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746.870 Congenital heart block 
 
746.880 Other specified anomalies of heart 
Includes: ectopia (ectopic) cordis (mesocardia),  
  conduction defects, NOS 
746.881 Hypoplastic left ventricle 
Excludes: hypoplastic left heart syndrome (746.700) 
746.882 Hypoplastic right heart (ventricle) 
Uhl's disease 
* 746.883 Hypoplastic ventricle, NOS 
746.885 Anomalies of coronary artery or sinus 
 N  746.886 Ventricular hypertrophy (right or left) 
Note: Do not code ventricular hypertrophy of any type in  
a newborn of a diabetic mother (either gestational or  
pre-existing diabetes). 
746.887 Other defects of the atria 
Excludes: congenital Wolfe-Parkinson-White  
(use 426.705) 
rhythm anomalies (use 426.-, 427.-) 
 
746.9 Unspecified anomalies of heart 
 
746.900 Unspecified anomalies of heart valves 
746.910 Anomalous bands of heart 
746.920 Acyanotic congenital heart disease, NOS 
746.930 Cyanotic congenital heart disease, NOS 
Blue baby 
 746.990 Unspecified anomaly of heart: 
Includes:  congenital heart disease (CHD) 
 N  746.995 "Pulmonic" or "pulmonary" atresia, stenosis, or  
  hypoplasia, NOS (no mention of valve or artery) 
Note:  Code pulmonary valve atresia or hypoplasia as  
       746.000 
       Code pulmonary valve stenosis as 746.010  
       Code pulmonary artery atresia as 747.300 
       Code pulmonary artery stenosis as 747.320 
       Code pulmonary artery hypoplasia as 747.380 
 
747 Other Congenital Anomalies of Circulatory System 
 
Ν  # 747.000 Patent ductus arteriosus (PDA) 
Note: 1)Always code if ≥36 weeks of gestation at birth and 
defect last noted at ≥6 weeks of age. 
    2)If ≥36 weeks gestation at birth and defect last noted  
    <6 weeks of age, code only if the PDA was treated (e.g.  
    by ligation or indomethicin) or if another reportable  
    heart defect is present. 
    3)Never code if <36 weeks gestation at birth or if  
    treated with prostaglandins regardless of gestational  
    age. (See PDA Tree Appendix) 
747.008  Probable PDA 
 
747.1 Coarctation of aorta 
 
747.100 Preductal (proximal) coarctation of aorta 
747.110 Postductal (distal) coarctation of aorta 
747.190 Unspecified coarctation of aorta 
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747.2 Other anomalies of aorta 
 
747.200 Atresia of aorta 
absence of aorta 
pseudotruncus arteriosus 
747.210 Hypoplasia of aorta 
tubular hypoplasia of aorta 
 N  747.215 Interrupted aortic arch, Type A 
 N  747.216 Interrupted aortic arch, Type B 
 N  747.217 Interrupted aortic arch, Type C 
747.220 Supra-aortic stenosis (supravalvular) 
Excludes: aortic stenosis, 
          congenital (see 746.300) 
747.230 Persistent right aortic arch 
747.240 Aneurysm of sinus of Valsalva 
747.250 Vascular ring (aorta) 
double aortic arch 
Includes: vascular ring compression of trachea 
747.260 Overriding aorta 
dextroposition of aorta 
747.270 Congenital aneurysm of aorta 
congenital dilatation of aorta 
747.280 Other specified anomalies of aorta 
 N  747.285 Interrupted aortic arch, NOS, type not specified 
747.290 Unspecified anomalies of aorta 
 
 
747.3 Anomalies of pulmonary artery 
 
 N  747.300 Pulmonary artery atresia, absence or agenesis 
Note:  Code pulmonary valve atresia as 746.000 
       Code “pulmonic” or “pulmonary” atresia, NOS (no  
       mention of valve or artery) as 746.995 
747.310 Pulmonary artery atresia with septal defect 
 N  747.320 Pulmonary artery stenosis 
 Includes: Stenosis of the main pulmonary artery or of  
    the right or left main branches 
Note:  Code pulmonary valve stenosis as 746.010  
       Code “pulmonic” or “pulmonary” stenosis, NOS (no  
       mention of valve or artery) as 746.995 
 N  747.325 Peripheral pulmonary artery stenosis 
Includes: Stenosis of a pulmonary artery peripheral to  
   the main right or left main branches 
   Peripheral pulmonic stenosis (PPS), NOS,  
   documented by echocardiogram 
  #  Excludes: Peripheral pulmonic stenosis (PPS) murmur only 
      (not documented by echocardiogram) 
Note: 1)Always code if ≥36 weeks of gestation at birth and 
defect last noted at ≥6 weeks of age. 
    2)If ≥36 weeks gestation at birth and defect last noted  
    <6 weeks of age, code only if another reportable heart 
    defect is present. 
    3)Never code if <36 weeks gestation at birth.  
    (See PPS Tree Appendix) 
747.330 Aneurysm of pulmonary artery 
dilatation of pulmonary artery 
747.340 Pulmonary arteriovenous malformation or aneurysm 
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747.380 Other specified anomaly of pulmonary artery 
Includes: pulmonary artery hypoplasia 
Note:  Code pulmonary valve hypoplasia as 746.000 
       Code “pulmonic” or “pulmonary” hypoplasia, NOS 
       (no mention of valve or artery) as 746.995 
747.390 Unspecified anomaly of pulmonary artery 
 
  747.4 Anomalies of great veins 
 
747.400 Stenosis of vena cava (inferior or superior) 
747.410 Persistent left superior vena cava 
747.420 (TAPVR) Total anomalous pulmonary venous return 
747.430 Partial anomalous pulmonary venous return 
747.440 Anomalous portal vein termination 
747.450 Portal vein - hepatic artery fistula 
747.480 Other specified anomalies of great veins 
747.490 Unspecified anomalies of great veins 
 
747.5 Absence or hypoplasia of umbilical artery 
 
# 747.500 Single umbilical artery 
 
747.6 Other anomalies of peripheral vascular system 
 
747.600 Stenosis of renal artery 
747.610 Other anomalies of renal artery 
747.620 Arteriovenous malformation (peripheral) 
Excludes: pulmonary (747.340) 
  cerebral (747.800) 
  retinal (743.510) 
747.630 Congenital phlebectasia 
congenital varix 
747.640 Other anomalies of peripheral arteries 
Includes: aberrant subclavian artery 
747.650 Other anomalies of peripheral veins 
Excludes: Budd-Chiari - occlusion of hepatic vein (use 
453.000) 
 Ν  747.680 Other anomalies of peripheral vascular system 
 #   Includes: primary pulmonary artery hypertension ONLY if  
    it is present in an infant at >7 days of age  
747.690 Unspecified anomalies of peripheral vascular system 
 
 
747.8 Other specified anomalies of circulatory system 
 
747.800 Arteriovenous (malformation) aneurysm of brain 
747.810 Other anomalies of cerebral vessels 
Includes: vein of Galen 
747.880 Other specified anomalies of circulatory system 
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ruptured cerebral aneurysm
747.9 Unspecified anomalies of circulatory system 
 (430.000) 
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748  Congenital Anomalies of Respiratory System 
 
748.0 Choanal atresia 
 
748.000 Choanal atresia 
atresia of nares, anterior or posterior 
congenital stenosis 
 
748.1 Other anomalies of nose 
 
748.100 Agenesis or underdevelopment of nose 
748.110 Accessory nose 
748.120 Fissured, notched, or cleft nose 
748.130 Sinus wall anomalies 
748.140 Perforated nasal septum 
# 748.180 Other specified anomalies of nose 
flat bridge of nose 
wide nasal bridge 
small nose and nostril 
absent nasal septum 
748.185 Tubular nose, single nostril, proboscis 
748.190 Unspecified anomalies of nose 
Excludes: congenital deviation of the nasal 
  septum (use 754.020) 
 
748.2 Web of larynx 
 
748.205 Web of larynx-glottic 
748.206 Web of larynx-subglottic 
748.209 Web of larynx-NOS 
 
748.3 Other anomalies of larynx, trachea, and bronchus 
 
748.300 Anomalies of larynx and supporting cartilage 
 Τ  748.310 Congenital subglottic stenosis – Never code if chart states 
 the condition was acquired or secondary to endotracheal (ET) 
 intubation or ventilation 
748.330 Other anomalies of trachea 
 #   Excludes: vascular ring compression of the 
  trachea (use 747.250) 
748.340 Stenosis of bronchus 
748.350 Other anomalies of bronchus 
748.360 Congenital laryngeal stridor, NOS 
748.380 Other specified anomalies of larynx and bronchus 
748.385 Cleft larynx, laryngotracheoesophageal cleft 
748.390 Unspecified anomalies of larynx, trachea, and bronchus 
 
748.4 Congenital cystic lung 
 
748.400 Single cyst, lung or lung cyst 
748.410 Multiple cysts, lung 
Polycystic lung 
748.420 Honeycomb lung 
748.480 Other specified congenital cystic lung 
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748.5 Agenesis or aplasia of lung 
 
748.500 Agenesis or aplasia of lung    
Τ   748.510 Hypoplasia of lung; Pulmonary hypoplasia  
 #  Exclude if isolated defect in infants <36 weeks gestation. 
748.520 Sequestration of lung 
748.580 Other specified dysplasia of lung 
Fusion of lobes of lung 
* 748.590 Unspecified dysplasia of lung 
 
748.6 Other anomalies of lung 
 
748.600 Ectopic tissues in lung 
748.610 Bronchiectasis 
748.620 Accessory lobe of lung 
748.625 Bilobar right lung or right lung with left lung bronchial 
pattern 
748.690 Other and unspecified anomalies of lung 
 
748.8 Other specified anomalies of respiratory system 
 
748.800 Anomaly of pleura 
748.810 Congenital cyst of mediastinum 
748.880 Other specified respiratory system anomalies 
Includes: congenital lobar emphysema 
   lymphangiectasia of lungs 
 
748.9 Unspecified anomalies of respiratory system 
 
748.900 Unspecified anomalies of respiratory system 
Absence of respiratory organ, NOS 
Anomaly of respiratory system, NOS 
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749  Cleft Palate and Cleft Lip 
 
749.0 Cleft palate alone 
(If description of condition includes Pierre Robin sequence,  
 use additional code, 524.080) 
 
749.000 Cleft hard palate, unilateral 
749.010 Cleft hard palate, bilateral 
749.020 Cleft hard palate, central 
749.030 Cleft hard palate, NOS 
749.040 Cleft soft palate, alone unilateral 
749.050 Cleft soft palate, alone bilateral 
749.060 Cleft soft palate, alone central 
749.070 Cleft soft palate, alone, NOS 
749.080 Cleft uvula 
749.090 Cleft palate, NOS 
palatoschisis 
 
749.1 Cleft lip alone 
Includes: alveolar ridge cleft 
cleft gum 
harelip 
749.100 Cleft lip, unilateral 
749.110 Cleft lip, bilateral 
749.120 Cleft lip, central 
749.190 Cleft lip, NOS (fused lip) 
cleft gum 
 
749.2 Cleft lip with cleft palate  
 
749.200 Cleft lip, unilateral, with any cleft palate 
749.210 Cleft lip, bilateral, with any cleft palate  
749.220 Cleft lip, central, with any cleft palate  
749.290 Cleft lip, NOS, with any cleft palate  
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750  Other Congenital Anomalies of Upper Alimentary Tract 
 
# 750.000 Tongue tie  
Ankyloglossia 
 
750.1 Other anomalies of tongue 
Excludes: protruding tongue (never a defect) 
 
750.100 Aglossia 
Absence of tongue 
750.110 Hypoglossia (small tongue) 
Microglossia 
750.120 Macroglossia (large tongue) 
750.130 Dislocation or displacement of tongue 
Glossoptosis 
750.140 Cleft tongue or split tongue 
750.180 Other specified anomalies of tongue 
750.190 Unspecified anomalies of tongue 
 
750.2 Other specified anomalies of mouth and pharynx 
 
750.200 Pharyngeal pouch 
750.210 Other pharyngeal anomalies 
750.230 Other anomalies of salivary glands or ducts 
  # 750.240 High arched palate 
750.250 Other anomalies of palate 
750.260 Lip fistulae or pits 
750.270 Other lip anomalies 
Includes: notched lip, prominent philtrum, 
 long philtrum 
Excludes: cleft lip (see 749) 
750.280 Other specified anomalies of mouth and pharynx 
Excludes: receding jaw (see 524.0) 
      large and small mouth (see 744.8) 
  
750.3 Tracheoesophageal (T-E) fistula, esophageal atresia and stenosis 
 
750.300 Esophageal atresia without mention of T-E fistula 
750.310 Esophageal atresia with mention of T-E fistula 
750.320 Tracheoesophageal fistula without mention of esophageal atresia 
750.325 Tracheoesophageal fistula - "H" type 
750.330 Bronchoesophageal fistula with or without mention of esophageal 
atresia 
750.340 Stenosis or stricture of esophagus 
750.350 Esophageal web 
750.380 Other tracheoesophageal anomalies 
 
750.4 Other specified anomalies of esophagus 
 
750.400 Congenital dilatation of esophagus 
giant esophagus 
750.410 Displacement of esophagus 
750.420 Diverticulum of esophagus 
esophageal pouch 
750.430 Duplication of esophagus 
750.480 Other specified anomalies of esophagus 
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750.5 Congenital hypertrophic pyloric stenosis 
 
# 750.500 Pylorospasm 
750.510 Congenital hypertrophic pyloric stenosis 
750.580 Other congenital pyloric obstruction 
 
750.6 Congenital hiatus hernia 
 
750.600 Congenital hiatus hernia 
Cardia displacement through esophageal hiatus 
Partial thoracic stomach 
Excludes: congenital diaphragmatic hernia (756.610) 
 





achalasia of cardia, congenital 
750.730 Displacement or transposition of stomach 
750.740 Diverticulum of stomach 
750.750 Duplication of stomach 
750.780 Other specified anomalies of stomach 
 
750.8 Other specified anomalies of upper alimentary tract 
 
750.800 Other specified anomalies of upper alimentary tract 
 
750.9 Unspecified anomalies of upper alimentary tract 
 
750.900 Unspecified anomalies of mouth and pharynx 
750.910 Unspecified anomalies of esophagus 
750.920 Unspecified anomalies of stomach 
750.990 Unspecified anomalies of upper alimentary tract 
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751  Other Congenital Anomalies of Digestive System 
 
751.0 Meckel's diverticulum 
 
751.000 Persistent omphalomesenteric duct 
persistent vitelline duct 
# 751.010 Meckel's diverticulum 
 
751.1 Atresia and stenosis of small intestine 
 
751.100 Stenosis, atresia or absence of duodenum 
751.110 Stenosis, atresia or absence of jejunum 
751.120 Stenosis, atresia or absence of ileum 
751.190 Stenosis, atresia or absence of small intestine 
751.195 Stenosis, atresia or absence of small intestine with fistula 
 
751.2 Atresia and stenosis of large intestine, rectum and anal canal 
 
751.200 Stenosis, atresia or absence of large intestine 
Stenosis, atresia or absence of appendix 
751.210 Stenosis, atresia or absence of rectum with fistula 
751.220 Stenosis, atresia or absence of rectum without mention of 
fistula 
751.230 Stenosis, atresia or absence of anus with fistula 
Includes: imperforate anus with fistula 
751.240 Stenosis, atresia or absence of anus without mention of fistula  
Includes: imperforate anus without fistula 
 
751.3 Hirschsprung's disease and other congenital functional disorders of the 
colon 
 
751.300 Total intestinal aganglionosis 
751.310 Long-segment Hirschsprung's disease; aganglionosis beyond the 
rectum 
751.320 Short-segment Hirschsprung's disease; aganglionosis involving 
no more than the anal sphincter and the rectum 
751.330 Hirschsprung's disease, NOS 
751.340 Congenital megacolon 
congenital macrocolon, not aganglionic 
 
751.4 Anomalies of intestinal fixation 
 
751.400 Malrotation of cecum and/or colon 
751.410 Anomalies of mesentery 
751.420 Congenital adhesions or bands of omentum and peritoneum; Ladd's 
bands 
751.490 Other specified and unspecified malrotation 
751.495 Malrotation of small intestine alone 
 
 
751.5 Other anomalies of intestine 
 
751.500 Duplication of anus, appendix, cecum, or intestine 
enterogenous cyst 
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751.530 Ectopic (displaced) anus 
751.540 Congenital anal fistula 
751.550 Persistent cloaca 
 R  751.555 Exstrophy of cloaca 
    Excludes exstrophy of urinary bladder not associated with 
    imperforate anus (use 753.500) 
* 751.560 Duodenal web 
# 751.580 Other specified anomalies of intestine 
Includes: rectal fissures 
751.590 Unspecified anomalies of intestine 
 
751.6 Anomalies of gallbladder, bile ducts, and liver 
 
751.600 Absence or agenesis of liver, total or partial 
751.610 Cystic or fibrocystic disease of liver 
# 751.620 Other anomalies of liver 
hepatomegaly 
hepatosplenomegaly (also use code 759.020) 
Excludes: Budd-Chiari (use 453.000) 
751.630 Agenesis or hypoplasia of gallbladder 
751.640 Other anomalies of gallbladder 
duplication of gallbladder 
751.650 Agenesis or atresia of hepatic or bile ducts 
Includes: biliary atresia 
Excludes: congenital or neonatal hepatitis 
   (use 774.480 or 774.490) 
751.660 Choledochal cysts 
751.670 Other anomalies of hepatic or bile ducts 
751.680 Anomalies of biliary tract, NEC 
 
 
751.7 Anomalies of pancreas 





751.700 Absence, agenesis or hypoplasia of pancreas 
751.710 Accessory pancreas 
751.720 Annular pancreas 
751.730 Ectopic pancreas 
751.740 Pancreatic cyst 
751.780 Other specified anomalies of pancreas 
751.790 Unspecified anomalies of pancreas 
 
751.8 Other specified anomalies of digestive system 
 
751.800 Absence of alimentary tract, NOS 
(complete or partial)  
751.810 Duplication of alimentary tract 
751.820 Ectopic digestive organs, NOS 
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751.9 Unspecified anomalies of digestive system 
 
751.900 Unspecified anomalies of digestive system 
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752  Congenital Anomalies of Genital Organs 
Excludes: congenital hydrocele (778.600) 
testicular feminization syndrome (257.800) 
syndromes associated with anomalies in  
number and form of chromosomes (758) 
 
752.0 Anomalies of ovaries 
 
752.000 Absence or agenesis of ovaries 
752.010 Streak ovary 
752.020 Accessory ovary 
752.080 Other specified anomalies of ovaries 
752.085 Multiple ovarian cysts 
752.090 Unspecified anomalies of ovaries 
 
752.1 Anomalies of fallopian tubes and broad ligaments 
 
752.100 Absence of fallopian tube or broad ligament 
752.110 Cyst of mesenteric remnant 
epoophoron cyst 
cyst of Gartner's duct 
752.120 Fimbrial cyst 
parovarian cyst 
752.190 Other and unspecified anomalies of fallopian tube 
and broad ligaments 
 
752.2 Doubling of uterus 
 
752.200 Doubling of uterus 
doubling of uterus (any degree) or 
associated with doubling of cervix and 
vagina 
 
752.3 Other anomalies of uterus 
 
752.300 Absence or agenesis of uterus 
752.310 Displaced uterus 
752.320 Fistulae involving uterus with digestive or 
urinary tract 
Includes: uterointestinal fistula 
 uterovesical fistula 
752.380 Other anomalies of uterus 
bicornuate uterus 
unicornis uterus 
752.390 Unspecified anomalies of uterus 
 
752.4 Anomalies of cervix, vagina, and external female genitalia 
 
752.400 Absence, atresia or agenesis of cervix 
752.410 Absence or atresia of vagina, complete or partial 
752.420 Congenital rectovaginal fistula 
# 752.430 Imperforate hymen 
# 752.440 Absence or other anomaly of vulva 
     fusion of vulva 
hypoplastic labia majora – Always code if ≥36weeks gestation. If 
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# 752.450 Absence or other anomaly of clitoris 
Includes: clitoromegaly 
 enlarged clitoris 
 clitoral hypertrophy 
 prominent clitoris 
# 752.460 Embryonal cyst of vagina 
752.470 Other cyst of vagina, vulva, or canal of Nuck 
# 752.480 Other specified anomalies of cervix, vagina, or external female 
genitalia 
Includes: vaginal tags 
 hymenal tags 
752.490 Unspecified anomalies of cervix, vagina, or external female 
genitalia 
 
752.5 Undescended testicle 
  #     1)If < 36 weeks gestation, code only if there is a 
   medical/surgical intervention for this problem;  
   2)If ≥36 weeks gestation and defect last noted at <1  
   year of age, code only if there was a medical/surgical  
   intervention for this problem or if another reportable  
   defect is present 
   3)Always code if ≥36 weeks gestation and defect first  
   noted at ≥1 of age.  
 
# 752.500 Undescended testicle, unilateral 
undescended, unpalpable 
# 752.501 Left undescended testicle 
# 752.502 Right undescended testicle 
# 752.514 Undescended testicle, bilateral 
  # 752.520 Undescended testicle, NOS (Cryptorchidism) 
752.530 Ectopic testis, unilateral and bilateral 
 
752.6 Hypospadias and epispadias 
 
752.600 Hypospadias (alone), NOS 
752.605 1o, glandular,coronal 
752.606 2o, penile 
752.607 3o, perineal, scrotal 
752.610 Epispadias 
752.620 Congenital chordee (with hypospadias), NOS 
752.621 Congenital chordee alone (chordee w/o hypospadias) 
752.625 Cong. chordee with 1o, coronal hypospadias  
752.626 Cong. chordee with 2o, penile hypospadias  
752.627 Cong. chordee with 3o, perineal, scrotal hypospadias 
 
752.7 Indeterminate sex and pseudohermaphroditism 
Excludes: pseudohermaphroditism: 
female, with adrenocortical disorder (see 255.200) 
male, with gonadal disorder with specified chromosomal anomaly 
(see 758) 
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752.710 Pseudohermaphroditism, male 
752.720 Pseudohermaphroditism, female 
pure gonadal dysgenesis 
Excludes: gonadal agenesis (758.690) 
752.730 Pseudohermaphrodite, NOS 
   752.790 Indeterminate sex, NOS 
ambiguous genitalia 
 
752.8 Other specified anomalies of male genital organs 
 
752.800 Absence of testis 
monorchidism, NOS 
# 752.810 Aplasia or hypoplasia of testis and scrotum 
752.820 Other anomalies of testis and scrotum 
polyorchidism 
bifid scrotum 
Excludes: torsion of the testes or spermatic 
 cord (use #608.200) 
752.830 Atresia of vas deferens 
752.840 Other anomalies of vas deferens and prostate 
752.850 Absence or aplasia of penis 
# 752.860 Other anomalies of penis 
absent or hooded foreskin 
#  redundant foreskin (never a defect) 
752.865 Small penis, hypoplastic penis, or micropenis 
752.870 Cysts of embryonic remnants 
cyst: hydatid of Morgagni 
      Wolffian duct 
      appendix testis 




752.9 Unspecified anomalies of genital organs 
 
752.900 Unspecified anomalies of genital organs 
Congenital: of genital organ, NEC 
anomaly, NOS or deformity, NOS 
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753  Congenital Anomalies of Urinary System 
 
753.0 Renal agenesis and dysgenesis 
 
753.000 Bilateral absence, agenesis, dysplasia, or 
hypoplasia of kidneys 
Potter's syndrome 
753.009 Renal agenesis, NOS 
753.010 Unilateral absence, agenesis, dysplasia or 
hypoplasia of kidneys 
 
753.1 Cystic kidney disease 
 
753.100 Renal cyst (single) 
753.110 Polycystic kidneys, infantile type 
753.120 Polycystic kidneys, adult type 
753.130 Polycystic kidneys, NOS 
753.140 Medullary cystic disease, juvenile type 
753.150 Medullary cystic disease, adult type 
Medullary sponge kidney 
753.160 Multicystic renal dysplasia 
Multicystic kidney 
753.180 Other specified cystic disease 
     Includes: cystic kidneys, NOS 
 
753.2 Obstructive defects of renal pelvis and ureter 
 
753.200 Congenital hydronephrosis 
753.210 Atresia, stricture, or stenosis of ureter 
Includes: ureteropelvic junction obstruction/stenosis 
 ureterovesical junction obstruction/stenosis 
 hypoplastic ureter 
753.220 Megaloureter, NOS 
Includes: hydroureter 
753.290 Other and unspecified obstructive defects of renal  
pelvis and ureter 
 
753.3 Other specified anomalies of kidney 
 
753.300 Accessory kidney 
753.310 Double or triple kidney and pelvis 
pyelon duplex or triplex 
753.320 Lobulated, fused, or horseshoe kidney 
753.330 Ectopic kidney 
753.340 Enlarged, hyperplastic or giant kidney 
753.350 Congenital renal calculi 
753.380 Other specified anomalies of kidney 
 
753.4 Other specified anomalies of ureter 
 
753.400 Absence of ureter 
753.410 Accessory ureter 
double ureter, duplex collecting system 
753.420 Ectopic ureter 
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753.485 Variations of vesicoureteral reflux 
 
 
753.5 Exstrophy of urinary bladder 
 
753.500 Exstrophy of urinary bladder 
ectopia vesicae 
extroversion of bladder 
 
753.6 Atresia and stenosis of urethra and bladder neck 
 
753.600 Congenital posterior urethral valves or posterior urethral 
    obstruction 
753.610 Other atresia, or stenosis of bladder neck 
753.620 Obstruction, atresia or stenosis of anterior urethra 
753.630 Obstruction, atresia or stenosis of urinary meatus 
Includes: meatal stenosis 
753.690 Other and unspecified atresia and stenosis of urethra and 
 bladder neck 
 
753.7 Anomalies of urachus 
 
Τ # 753.700 Patent urachus 
753.710 Cyst of urachus 
753.790 Other and unspecified anomaly of urachus 
 
753.8 Other specified anomalies of bladder and urethra 
 
753.800 Absence of bladder or urethra 
753.810 Ectopic bladder 
753.820 Congenital diverticulum or hernia of bladder 
753.830 Congenital prolapse of bladder (mucosa) 
753.840 Double urethra or urinary meatus 
753.850 Ectopic urethra or urethral orifice 
753.860 Congenital digestive-urinary tract fistulae 
rectovesical fistula 
753.870 Urethral fistula, NOS 
753.880 Other specified anomalies of bladder and urethra 
 
753.9 Unspecified anomalies of urinary system 
 
753.900 Unspecified anomaly of kidney 
753.910 Unspecified anomaly of ureter 
753.920 Unspecified anomaly of bladder 
753.930 Unspecified anomaly of urethra 
753.990 Unspecified anomaly of urinary system, NOS 
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754  Certain Congenital Musculoskeletal Anomalies 
 
754.0 Of skull, face, and jaw 
Excludes: dentofacial anomalies (524.0) 
Pierre Robin sequence (524.080) 
syphilitic saddle nose (090.000) 
 
754.000 Asymmetry of face 
754.010 Compression (Potter's) facies 
# 754.020 Congenital deviation of nasal septum 
bent nose 
 Τ  754.030 Dolichocephaly 
    Always code if ≥36 weeks gestation 
  #  If <36 weeks gestation, code only if another reportable 
defect is present 
# 754.040 Depressions in skull 
Includes: large fontanelle 
 small fontanelle 
754.050 Plagiocephaly 
754.055 Asymmetric head 
Τ # * 754.060 Scaphocephaly, no mention of craniosynostosis 
* 754.070 Trigonocephaly, no mention of craniosynostosis 
    Always code if ≥36 weeks gestation 
  #  If <36 weeks gestation, code only if another reportable 
defect is present 






* 754.090  Deformity of skull, NOS 
 
754.1 Anomalies of sternocleidomastoid muscle 
 
754.100 Anomalies of sternocleidomastoid muscle 
*  Includes: absent or hypoplastic sternocleidomastoid 
  contracture of sternocleidomastoid muscle 
  sternomastoid tumor 
Excludes: congenital sternocleidomastoid torticollis 
(use 756.860) 
 
754.2 Certain congenital musculoskeletal deformities of spine 
 
754.200 Congenital postural scoliosis 
754.210 Congenital postural lordosis 
754.220 Congenital postural curvature of spine, NOS 
 
754.3 Congenital dislocation of hip 
 
754.300 Congenital dislocation of hip 
754.310 Unstable hip 
preluxation of hip 
subluxation of hip 
predislocation status of hip at birth 
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754.4 Congenital genu recurvatum and bowing of long bones of leg 
 
754.400 Bowing, femur 
754.410 Bowing, tibia and/or fibula 
754.420 Bow legs, NOS 
754.430 Genu recurvatum 
754.440 Dislocation of knee, congenital 
754.490 Deformity of leg, NOS 
 
754.5 Varus (inward) deformities of feet 
 
754.500 Talipes equinovarus 
754.510 Talipes calcaneovarus 
  # 754.520 Metatarsus varus or metatarsus adductus 
754.530 Complex varus deformities 
754.590 Unspecified varus deformities of feet 
 
754.6 Valgus (outward) deformities of feet 
 
754.600 Talipes calcaneovalgus 
754.610 Congenital pes planus 
754.615 Pes valgus 
754.680 Other specified valgus deformities of foot 
754.690 Unspecified valgus deformities of foot 
 
754.7 Other deformities of feet 
 
754.700 Pes cavus 
Claw foot (use 755.350 for claw foot) 
754.720 Short Achilles tendon 
754.730 Clubfoot, NOS 
talipes, NOS 
754.735 Congenital deformities of foot, NOS 
754.780 Other specified deformities of ankle and/or toes 
Includes: dorsiflexion of foot 
Excludes: widely spaced 1st and 2nd toes (use 755.600) 
 
754.8 Other specified congenital musculoskeletal deformities  
 
754.800 Pigeon chest (pectus carinatum) 
754.810 Funnel chest (pectus excavatum) 
754.820 Other anomalies of chest wall  
Includes: deformed chest, barrel chest 
754.825 Shield chest 
754.830 Dislocation of elbow 
754.840 Club hand or fingers 
754.850 Spade-like hand 
754.880 Other specified deformity of hands 
(see 755.500 for specified anomalies of fingers) 
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755.005 Accessory fingers (postaxial polydactyly, Type A) 
# 755.006 Skin tag (postaxial polydactyly, Type B) 
  Exclude: Do not code in black infants. 
755.007 Unspecified finger or skin tag (postaxial polydactyly, NOS) 
755.010 Accessory thumbs (preaxial polydactyly) 
755.020 Accessory toes (postaxial) 
755.030 Accessory big toe (preaxial) 
755.090 Accessory digits, NOS (hand/foot not specified) 
755.095 Accessory digits hand, NOS (preaxial, postaxial not 
 specified) 
755.096 Accessory digits foot, NOS (preaxial, postaxial not 




755.100 Fused fingers 
755.110 Webbed fingers 
755.120 Fused toes 
Τ  # 755.130 Webbed toes  
Code webbing of the second and third toes only if another 
reportable defect is present. Always code webbing of other toes 
regardless of whether another reportable defect is present 
755.190 Unspecified syndactyly (see below for specified site) 
755.191 Unspecified syndactyly thumb and/or fingers, unilateral 
755.192 Unspecified syndactyly thumb and/or fingers, bilateral 
755.193 Unspecified (webbed vs. fused) syndactyly thumb and/or fingers, 
NOS 
755.194 Unspecified syndactyly toes unilateral 
755.195 Unspecified syndactyly toes bilateral 
755.196 Unspecified syndactyly toes, NOS 
755.199 Unspecified syndactyly (i.e., webbed vs. fused) digits not 
known 
 
755.2 Reduction defects of upper limb 
Τ  If description of the condition includes amniotic or constricting  
 bands use additional code, 658.800 (Only use 658.800 if another 
 reportable defect is present) 
   Excludes shortening of upper limb (use 755.580) or hypoplasia of  
   upper limb (use 755.585) 
 
   755.200  Absence of upper limb 
       Absent:   humerus (total or partial), radius,ulna and hand 
       Includes: amelia of upper limb, NOS 
       infants with rudimentary or nubbin fingers  
       attached to stump of humerus or shoulder girdle 
   755.210  Absence of upper arm and forearm  
                      Absent:   humerus (total or partial), radius and ulna  
       (total or partial) 
                      Present:  hand (total or partial) 
       Includes: phocomelia of upper limb, NOS; 
                intercalary reduction defect of upper limb, NOS 
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   755.220  Absence of forearm only or upper arm only 
                 Absent:   radius and ulna 
                     Present:  humerus, hand (total or partial) 
       or 
                 Absent:   humerus 
                     Present:  radius, ulna, and hand 
   755.230  Absence of forearm and hand 
                 Absent:   radius and ulna (total or partial) and hand  
       Includes: infants with rudimentary or nubbin fingers  
       attached to stump of forearm or elbow 
   755.240  Absence of hand or fingers  
                      Absent:   hand or fingers (total or partial) not in  
       conjunction with ray or long bone reduction 
                      Includes: rudimentary or nubbin fingers; 
       absent individual phalanges; 
       absent or missing fingers, NOS 
       Excludes: isolated absent or hypoplastic thumb  
       (use 755.260) 
   755.250  Split-hand malformation 
                      Absent:   central fingers (third with or without second,  
       fourth) and metacarpals (total or partial) 
       Includes: monodactyly;  
       lobster-claw hand   
       Excludes: isolated absent central fingers without  
       metacarpal defects (use 755.240)  
            755.260  Preaxial longitudinal reduction defect of upper limb 
                      Absent:   radius (total or partial) and/or thumb with or  
       without second finger (total or partial)    
                      Includes: isolated absent or hypoplastic thumb; 
       radial ray defect, NOS 
   755.265  Longitudinal reduction defect of upper limb, NOS 
       Includes: absent forearm long bone with absent fingers,  
       NOS 
   755.270  Postaxial longitudinal reduction defect of upper limb 
                      Includes: isolated absent ulna (total or partial); 
       absent fifth with or without fourth finger  
       (total or partial) only if ulna or fifth ±  
       fourth metacarpal also totally or partially  
       absent; 
                           ulnar ray defect, NOS  
            755.280  Other specified reduction defect of upper limb 
   755.285  Transverse reduction defect of upper limb, NOS 
       Includes: congenital amputation of upper limb, NOS 
            755.290  Unspecified reduction defect of upper limb 
 
755.3  Reduction defects of lower limb 
 Τ  If description of condition includes amniotic or constricting bands  
 use additional code, 658.800 (Only use this code if another 
 reportable defect is present) 
 
   Excludes shortening of lower limb (use 755.680) and hypoplasia of  
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        755.300  Absence of lower limb 
                 Absent:   femur (total or partial), tibia, fibula, and 
       foot 
       Includes: amelia of lower limb, NOS 
       infants with rudimentary or nubbin toes  
       attached to stump of femur or pelvic girdle  
           755.310  Absence of thigh and lower leg 
                      Absent:   femur (total or partial), tibia and fibula  
       (total or partial)  
                      Present:  foot (total or partial) 
       Includes: phocomelia of lower limb, NOS; 
                intercalary reduction defect of lower limb, NOS 
    755.320  Absence of lower leg only or femur only 
                      Absent:   tibia and fibula  
       Present:  femur, foot (total or partial) 
       or 
               Absent:   femur 
                      Present:  tibia, fibula, and foot  
   755.330  Absence of lower leg and foot 
                      Absent:   tibia and fibula (total or partial), foot 
       Includes: infants with rudimentary or nubbin toes attached  
       to stump of leg or knee 
   755.340  Absence of foot or toes 
                      Absent:   foot or toes (total or partial) not in  
       conjunction with ray or long bone reduction 
                      Includes: rudimentary or nubbin toes; 
       absent individual phalanges; 
                                absent or missing toes, NOS  
       Excludes: isolated absent or hypoplastic great toe  
       (use 755.365) 
   755.350  Split-foot malformation 
                      Absent:   central toes (third with or without second,  
       fourth) and metatarsals (total or partial) 
       Includes: monodactyly; 
        lobster claw foot 
       Excludes: isolated absent central toes without metatarsal 
       defects (use 755.340)  
                      Note: preaxial lower limb reductions can occur with  
        split-hand malformations of the upper limb and these  
            lower limb defects should be coded 755.365 
   755.360  Longitudinal reduction defect of lower limb, NOS 
       Includes: absent long bone of leg with absent toes, NOS 
   755.365  Preaxial longitudinal reduction defect of lower limb 
                      Absent:   tibia (total or partial) and/OR great toe with  
       or without second toe (total or partial) 
       Includes: isolated absent or hypoplastic great toe;  
       tibial ray defect, NOS  
           755.366  Postaxial longitudinal reduction defect of lower limb 
                      Includes: isolated absent fibula (total or partial); 
          absent fifth with or without fourth toe (total  
       or partial) only if fibula or fifth ± fourth  
       metatarsal also totally or partially absent; 
                           fibular ray defect, NOS 
            755.380  Other specified reduction defect of lower limb 
            755.385  Transverse reduction defect of lower limb, NOS 
       Includes: congenital amputation of lower limb, NOS     
       755.390  Unspecified reduction defect of lower limb             
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755.4  Reduction defects of unspecified limb 
 Τ  If description of condition includes amniotic or constricting bands  
   use additional code, 658.800 (note: 658.00 should only be used with 
   another reportable defect) 
 
             755.400  Absence of limb, NOS 
       Includes: amelia, NOS 
            755.410  Phocomelia, NOS 
                Includes: intercalary reduction defect, NOS 
   755.420  Transverse reduction defect, NOS 
       Includes: congenital amputation of unspecified limb 
            755.430  Longitudinal reduction defect, NOS 
                Includes: preaxial or postaxial reduction defect, NOS 
   755.440  Absent digits, not specified whether fingers or toes 
   755.480  Other specified reduction defect of unspecified limb 
             755.490  Unspecified reduction defect of unspecified limb       
 
755.5 Other anomalies of upper limb, including shoulder girdle 
Includes: complex anomalies involving all or part of upper limb 
 
# 755.500 Anomalies of fingers 
Includes: camptodactyly   
  clinodactyly 
macrodactylia   
brachydactyly 
triphalangeal thumb  
incurving fingers 
    Excludes: acrocephalosyndactyly (see 756.050) 
Apert's syndrome (see 756.055) 
755.510 Anomalies of hand 
Excludes: simian crease (use 757.200) 
755.520 Anomalies of wrist 
755.525 Accessory carpal bones 
755.526 Madelung's deformity 
755.530 Anomalies of forearm, NOS 
755.535 Radioulnar dysostosis 
755.536 Radioulnar synostosis 
755.540 Anomalies of elbow and upper arm 
755.550 Anomalies of shoulder 
755.555 Cleidocranial dysostosis 
755.556 Sprengel's deformity 
755.560 Other anomalies of whole arm 
755.580 Other specified anomalies of upper limb 
Includes: hyperextensibility of upper limb 
 shortening of arm 
755.585 Hypoplasia of upper limb 
Includes: hypoplasia of fingers, hands, or arms 
Excludes: aplasia or absent upper limb (see 755.2) 
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755.6 Other anomalies of lower limb, including pelvic girdle 
Includes: complex anomalies involving all 
or part of lower limb 
 
# 755.600 Anomalies of toes 
Includes: overlapping toes 
      hammer toes 
 widely spaced first and second toes 
755.605 Hallux valgus 
755.606 Hallux varus 
755.610 Anomalies of foot 
Includes: plantar furrow 
Excludes: lobster claw foot (use 755.350) 
# 755.616 Rocker-bottom foot  
755.620 Anomalies of ankle 
astragaloscaphoid synostosis 
# 755.630 Anomalies of lower leg 
angulation of tibia, tibial torsion 
(exclude if clubfoot present) 
755.640 Anomalies of knee 
hyperextended knee 
755.645 Genu valgum 
755.646 Genu varum 
755.647 Absent patella or rudimentary patella 
755.650 Anomalies of upper leg 
anteversion of femur 
755.660 Anomalies of hip 
Includes: coxa vara 
 coxa valga 
 other abnormalities of hips 
755.665 Hip dysplasia, NOS 
755.666 Unilateral hip dysplasia 
755.667 Bilateral hip dysplasia 
755.670 Anomalies of pelvis 
fusion of sacroiliac joint 
755.680 Other specified anomalies of lower limb 
hyperextended legs 
shortening of legs  
755.685 Hypoplasia of lower limb 
Includes: hypoplasia of toes, feet, legs 
Excludes: aplasia or absent lower limb (see 755.3) 
755.690 Unspecified anomalies of legs 
 
 
755.8 Other specified anomalies of unspecified limb 
 
755.800 Arthrogryposis multiplex congenita 
Includes: distal arthrogryposis syndrome 
755.810 Larsen's syndrome 
755.880 Other specified anomalies of unspecified limb  
Includes: overlapping digits, NOS 
hyperextended joints, NOS 
Excludes: hyperextended knees (use 755.640) 
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755.900 Unspecified anomalies of unspecified limb 
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756  Other Congenital Musculoskeletal Anomalies 
 
756.0 Anomalies of skull and face bones 
Excludes: skull and face deformities in 754 
Pierre Robin sequence (use 524.080) 
 
756.000 Craniosynostosis, NOS 
craniostenosis, NOS 
closed-skull sutures, NOS 
756.005 Sagittal craniosynostosis 
756.006 Metopic craniosynostosis 
756.010 Coronal craniosynostosis 
756.020 Lambdoidal craniosynostosis 
756.030 Other types of craniosynostosis 
Includes: basilar craniosynostosis 
756.040 Craniofacial dysostosis 
Includes: Crouzon's disease 
756.045 Mandibulofacial dysostosis 
Includes: Franceschetti syndrome 
 Treacher-Collins syndrome 
756.046 Other craniofacial syndromes 
Includes: oculomandibulofacial syndrome 
 Hallermann-Streiff syndrome 
756.050 Acrocephalosyndactyly, NOS 
756.055 Acrocephalosyndactyly types I or II 
Apert syndrome 
756.056 Acrocephalosyndactyly type III 
756.057 Other specified acrocephalosyndactylies 
756.060 Goldenhar syndrome 
oculoauriculovertebral dysplasia 
756.065 Hemifacial microsomia 
756.080 Other specified skull and face bone anomalies 
Includes: localized skull defects 
  #    flat occiput 
 mid-facial hypoplasia 
  #    prominent occiput 
 prominent maxilla 
 hypotelorism 
Excludes: macrocephaly (use 742.400) 
 small chin (see 524.0) 
 Pierre Robin sequence (use 524.080) 
756.085 Hypertelorism, telecanthus, wide set eyes 
756.090 Unspecified skull and face bone anomalies 
Excludes: dentofacial anomalies (524.0) 
skull defects associated with brain anomalies 
such as: 





756.1 Anomalies of spine 
 
756.100 Spina bifida occulta 
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756.120 Kyphosis 
kyphoscoliosis 
756.130 Congenital spondylolisthesis 
756.140 Anomalies of cervical vertebrae 
756.145 Hemivertebrae (cervical) 
756.146 Agenesis (cervical) 
756.150 Anomalies of thoracic vertebrae 
756.155 Hemivertebrae of thoracic vertebrae 
756.156 Agenesis of thoracic vertebrae 
756.160 Anomalies of lumbar vertebrae 
756.165 Hemivertebrae of lumbar vertebrae 
756.166 Agenesis of lumbar vertebrae 
756.170 Sacrococcygeal anomalies 
Includes: agenesis of sacrum 
Excludes: pilonidal sinus (see 685.100) 
756.179 Sacral mass, NOS 
756.180 Other specified vertebral anomalies 
756.185 Hemivertebrae, NOS 
756.190 Unspecified anomalies of spine 
 
756.2 Cervical rib 
 
# 756.200 Cervical rib 
supernumerary rib in cervical region 
 
756.3 Other anomalies of ribs and sternum 
 
756.300 Absence of ribs 
756.310 Misshapen ribs 
756.320 Fused ribs 
756.330 Extra ribs 
756.340 Other anomalies of ribs 
756.350 Absence of sternum 
756.360 Misshapen sternum 
756.380 Other anomalies of sternum 
Includes: double ossification center in the manubrium, 
bifid sternum, short sternum 
756.390 Anomalies of thoracic cage, unspecified  




756.400 Asphyxiating thoracic dystrophy 
Jeune syndrome 
thoracic-pelvic-phalangeal dysplasia 
Excludes: homozygous achondroplasia 
756.410 Chondrodysplasia 
Ollier syndrome, enchondromatosis 
756.420 Chondrodysplasia with hemangioma 
Kast syndrome 
Maffucci syndrome 
756.430 Achondroplastic dwarfism 
756.440 Other specified chondrodystrophies 
Excludes: Conradi's (use 756.575) 
756.445 Diastrophic dwarfism 
756.446 Metatrophic dwarfism 
756.447 Thanatophoric dwarfism 
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756.450 Metaphyseal dysostosis 
756.460 Spondyloepiphyseal dysplasia 
756.470 Exostosis  
Excludes: Gardner syndrome (see 759.630) 
756.480 Other specified chondrodystrophy 
756.490 Unspecified chondrodystrophy 




756.500 Osteogenesis imperfecta 
756.505 Osteopsathyrosis 
756.506 Fragilitas ossium 
756.510 Polyostotic fibrous dysplasia 
Albright-McCune-Sternberg syndrome 
756.520 Chondroectodermal dysplasia 
756.525 Ellis-van Creveld syndrome 









756.570 Multiple epiphyseal dysplasia 
756.575 Conradi syndrome 
chondrodysplasia punctata 
Excludes: warfarin embryopathy 
756.580 Other specified osteodystrophies 
756.590 Unspecified osteodystrophies 
 
756.6 Anomalies of diaphragm 
 
756.600 Absence of diaphragm 
756.610 Congenital diaphragmatic hernia 
756.615 Diaphragmatic hernia (Bochdalek)  
756.616 Diaphragmatic hernia (Morgagni) 
756.617 Hemidiaphragm 
756.620 Eventration of diaphragm 
756.680 Other specified anomalies of diaphragm 
756.690 Unspecified anomalies of diaphragm 
 
756.7 Anomalies of abdominal wall 
 
756.700 Exomphalos, omphalocele 
756.710 Gastroschisis 
Excludes: umbilical hernia (553.100) 
756.720 Prune belly syndrome 
   756.790 Other and unspecified anomalies of abdominal wall 
756.795 Epigastric hernia 
 
756.8 Other specified anomalies of muscle, tendon, fascia and connective tissue 
 
756.800 Poland syndrome or anomaly 
756.810 Other absent or hypoplastic muscle 
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Includes: absent pectoralis major 
Excludes: prune belly syndrome (use 756.720) 
756.820 Absent tendon 
756.830 Nail-patella syndrome 
756.840 Amyotrophia congenita 
756.850 Ehlers-Danlos syndrome 
756.860 Congenital torticollis 
(see also 754.100, anomalies of sternocleidomastoid muscle) 
756.880 Other specified anomalies of muscle, tendon, fascia and 
connective tissue 
Includes: myopathy, congenital NOS 
 
756.9 Unspecified anomalies of musculoskeletal system 
 
756.900 Unspecified anomalies of muscle 
756.910 Unspecified anomalies of tendon 
756.920 Unspecified anomalies of bone 
756.930 Unspecified anomalies of cartilage 
756.940 Unspecified anomalies of connective tissue 
756.990 Unspecified anomalies of musculoskeletal system 
 
 
R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A - 74 
757  Congenital Anomalies of the Integument 
 




757.1 Ichthyosis congenita 
 
757.100 Harlequin fetus 
757.110 Collodion baby 
757.115 Bullous type 
757.120 Sjogren-Larsson syndrome 
757.190 Other and unspecified 
757.195 Ichthyosis vulgaris 
757.196 X-linked ichthyosis 
757.197 Ichthyosiform erythroderma 
 
757.2 Dermatoglyphic anomalies 
 
# 757.200 Abnormal palmar creases 
Includes: simian creases, transverse palmar creases 
 
757.3 Other specified anomalies of skin 
Excludes: pigmented mole (216.900) 
hemangioma (see 228.0) 
 
757.300 Specified syndromes, not elsewhere classified, involving skin  
 anomalies 
# 757.310 Skin tags 
Includes: anal tags 
Excludes: preauricular tag (see 744.110) 
 vaginal tags (see 752.480) 
757.320 Urticaria pigmentosa 
757.330 Epidermolysis bullosa 
757.340 Ectodermal dysplasia 
Excludes: Ellis-van Creveld syndrome (756.525) 
757.345 X-linked type ectodermal dysplasia 
757.346 Other specified ectodermal dysplasias 
757.350 Incontinentia pigmenti 
757.360 Xeroderma pigmentosum 
757.370 Cutis laxa hyperelastica 
# 757.380 Nevus, not elsewhere classifiable 
Includes: port wine stain or nevus flammeus 
 Τ   Excludes: hairy nevus (use 216.920) 
      Sturge-Weber syndrome (use 759.610) 
# 757.385 Birthmark, NOS 
# 757.386 Mongolian blue spot 
# 757.390 Other specified anomalies of skin 
Includes:  cafe au lait spots    
   hyperpigmented areas 
   skin cysts        
   hypoplastic dermal patterns 
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757.4 Specified anomalies of hair 
Excludes: kinky hair syndrome (use 759.870) 
 
757.400 Congenital alopecia 
Excludes: ectodermal dysplasia (use 757.340) 
757.410 Beaded hair 
Monilethrix 
757.420 Twisted hair 
Pili torti 
757.430 Taenzer's hair 
# 757.450 Persistent or excessive lanugo 
Includes: hirsutism 
757.480 Other specified anomalies of hair 
 
757.5 Specified anomalies of nails 
 
757.500 Congenital anonychia 
Absent nails 
757.510 Enlarged or hypertrophic nails 
    757.515 Onychauxis 
757.516 Pachyonychia 
757.520 Congenital koilonychia 
757.530 Congenital leukonychia 
757.540 Club nail 
757.580 Other specified anomalies of nails 
757.585 Hypoplastic (small) fingernails and/or toenails 
 
757.6 Specified anomalies of breast 
 
757.600 Absent breast with absent nipple 
757.610 Hypoplastic breast with hypoplastic nipple 
757.620 Accessory (ectopic) breast with nipple 
757.630 Absent nipple 
 Τ # 757.640 Small nipple (hypoplastic) 
    Always code if ≥36 weeks gestation 
  #  If <36 weeks gestation, code only if another reportable defect 
is present 
# 757.650 Accessory (ectopic) nipple, supernumerary 
# 757.680 Other specified anomalies of breast 
Widely spaced nipples 
Excludes: inverted nipples (never a defect) 
 
757.8 Other specified anomalies of the integument 
 
757.800 Includes: scalp defects 
For specified anomalies of skin see 757.390 
For specified anomalies of hair see 757.480 
For specified anomalies of nails see 757.580 
 
757.9 Unspecified anomalies of the integument 
 
757.900 Unspecified anomalies of skin 
757.910 Unspecified anomalies of hair, NOS 
757.920 Unspecified anomalies of nail, NOS 
757.990 Unspecified anomalies of the integument, NOS 
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758  Chromosomal Anomalies 
 
758.0 Down syndrome 
Clinical Down syndrome karyotype identified as: 
 
 Τ  758.000 Down syndrome, karyotype trisomy 21, cytogenetics  
 result in record 
 Τ  758.008 Down syndrome suspected, cytogenetics pending 
758.010 Down syndrome, karyotype trisomy G, NOS 
758.020 Translocation trisomy - duplication of a 21 
758.030 Translocation trisomy - duplication of a G, NOS 
758.040 Mosaic Down syndrome 
 Τ  758.090 Down syndrome, NOS (i.e. chart states a diagnosis of 
 Trisomy 21 or Downs syndrome, but no cytogenetics  
 result in record) 
 Τ  758.098 Down syndrome suspected, cytogenetics never done 
 
758.1 Patau syndrome 
Clinical Patau syndrome karyotype identified as: 
 
 Τ  758.100 Patau syndrome, karyotype trisomy 13, cytogenetics  
 result in record 
758.108 Patau syndrome suspected, cytogenetics pending 
758.110 Patau syndrome, karyotype trisomy D, NOS 
758.120 Translocation trisomy - duplication of a 13 
758.130 Translocation trisomy - duplication of a D, NOS 
 Τ  758.190 Patau syndrome, NOS (i.e. chart states a diagnosis of 
 Trisomy 13 or Patau syndrome, but no cytogenetics  
 result in record) 
 Τ  758.198 Patau syndrome suspected, cytogenetics pending 
 
758.2 Edwards syndrome 
Clinical Edwards syndrome karyotype identified as: 
 
 Τ  758.200 Edwards syndrome, karyotype trisomy 18, cytogenetics  
 result in record 
 Τ  758.208 Edwards syndrome suspected, cytogenetics pending 
758.210 Edwards syndrome, karyotype trisomy E, NOS 
758.220 Translocation trisomy - duplication of an 18 
758.230 Translocation trisomy - duplication of an E, NOS 
758.290 Edwards syndrome, NOS (i.e. chart states a diagnosis of 
 Τ   Trisomy 18 or Edwards syndrome, but no cytogenetics  
 result in record) 
758.295 Edwards phenotype - normal karyotype 
 Τ  758.298 Edwards syndrome suspected, cytogenetics pending 
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758.3 Autosomal deletion syndromes 
 
758.300 Antimongolism syndrome 
Clinical antimongolism syndrome: 
  karyotype - partial or total deletion of: 
21 
G, NOS 
  NOS 
758.310 Cri du chat syndrome 
Clinical Cri du chat syndrome: 
  karyotype - deletion of: 
5 
B, NOS 
  NOS 
758.320 Wolff-Hirschorn syndrome 
Clinical Wolff-Hirschorn syndrome: 
  karyotype - deletion of: 
4 
B, NOS 
  NOS 
758.330 Deletion of long arm of 13 
deletion of long arm of D, NOS 
758.340 Deletion of long arm of E 
deletion of long arm of 17 or 18 
758.350 Deletion of short arm of E 
deletion of short arm of 17 or 18 
758.360 Monosomy G mosaicism 
758.370 Deletion in band 11 of long arm of 22 (22q11 deletions) 
 Note: Code added for use with births on or after 4/1/2001  
758.380 Other loss of autosomal material 
758.390 Unspecified autosomal deletion syndromes 
 
758.4 Balanced autosomal translocation in normal individual 
 
758.400 Balanced autosomal translocation in normal individual 
 
758.5 Other conditions due to autosomal anomalies 
 
758.500 Trisomy 8 
758.510 Other trisomy C syndromes 
Trisomy: 6, 7, 9, 10, 11, 12, or C, NOS 
758.520 Other total trisomy syndromes 
Trisomy 22 
Trisomy, NOS 
758.530 Partial trisomy syndromes 
758.540 Other translocations 
Excludes: balanced translocation in normal 
 individual (use 758.400) 
758.580 Other specified anomalies of autosomes, NOS 
Includes: marker autosome 
758.585 Polyploidy 
758.586 Triploidy 
758.590 Unspecified anomalies of autosomes 
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758.6 Gonadal Dysgenesis 
Excludes: pure gonadal dysgenesis (752.720) 
Noonan syndrome (759.800) 
 
758.600 Turner's phenotype, karyotype 45, X [XO] 
758.610 Turner's phenotype, variant karyotypes 
karyotype characterized by: 
isochromosome 
mosaic, including XO 
partial X deletion 
ring chromosome 
Excludes: Turner's phenotype, karyotype normal XX 
(use 759.800, Noonan syndrome) 
758.690 Turner syndrome, karyotype unspecified, NOS 
Bonneville-Ullrich syndrome, NOS 
 
758.7 Klinefelter syndrome 
 
758.700 Klinefelter's phenotype, karyotype 47, XXY 






758.790 Klinefelter syndrome, NOS 
 
758.8 Other conditions due to sex chromosome anomalies 
 
758.800 Mosaic XO/XY, 45X/46XY 
Excludes: with Turner's phenotype (758.610) 
758.810 Mosaic XO/XX 
Excludes: with Turner's phenotype (758.610) 
758.820 Mosaic XY/XXY,46XY/47XXY 
Excludes: Klinefelter's phenotype (758.710) 
758.830 Mosaic including XXXXY,49XXXXY 
Excludes: with Klinefelter's phenotype (use 758.710) 
758.840 XYY, male, 47XYY 
mosaic XYY male 
758.850 XXX female,47XXX 
758.860 Additional sex chromosomes, NOS 
758.880 Other specified sex chromosome anomaly 
Includes:  fragile X 
758.890 Unspecified sex chromosome anomaly 
 
758.9 Conditions due to anomaly of unspecified chromosomes 
 
758.900 Mosaicism, NOS 
758.910 Additional chromosome(s), NOS 
758.920 Deletion of chromosome(s), NOS 
758.930 Duplication of chromosome(s), NOS 
758.990 Unspecified anomaly of chromosome(s) 
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759  Other and Unspecified Congenital Anomalies 
 
759.0 Anomalies of spleen 
 
759.000 Absence of spleen 
asplenia 
759.005 Ivemark syndrome 
759.010 Hypoplasia of spleen 
# 759.020 Hyperplasia of spleen 
splenomegaly 
hepatosplenomegaly (also use code 751.620) 
759.030 Misshapen spleen 
759.040 Accessory spleen 
759.050 Ectopic spleen 
759.080 Other specified anomalies of spleen 
759.090 Unspecified anomalies of spleen 
 
759.1 Anomalies of adrenal gland 
 
759.100 Absence of adrenal gland 
759.110 Hypoplasia of adrenal gland 
759.120 Accessory adrenal gland 
759.130 Ectopic adrenal gland 
759.180 Other specified anomaly of adrenal gland 
Excludes: congenital adrenal hyperplasia  
 (use 255.200) 
759.190 Unspecified anomalies of adrenal gland 
 
759.2 Anomalies of other endocrine glands 
 
759.200 Anomalies of pituitary gland 
759.210 Anomalies of thyroid gland 
759.220 Thyroglossal duct anomalies 
thyroglossal cyst 
759.230 Anomalies of parathyroid gland 
# 759.240 Anomalies of thymus 
thymic hypertrophy 
absent thymus 
759.280 Other specified anomalies of endocrine gland 
759.290 Unspecified anomaly of endocrine gland 
 
759.3 Situs inversus 
 
759.300 Dextrocardia with complete situs inversus 
759.310 Situs inversus with levocardia 
759.320 Situs inversus thoracis 
759.330 Situs inversus abdominis 
759.340 Kartagener syndrome (triad) 
759.390 Unspecified situs inversus 
Excludes: dextrocardia (746.800) not 
  associated with complete situs inversus 
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xiphoid- and pelvis-joined twins 
759.440 Pygopagus 
buttock-joined twins 
759.480 Other specified conjoined twins 
759.490 Unspecified conjoined twins 
 
759.5 Tuberous sclerosis 
 




759.6 Other hamartoses, not elsewhere classified 
 
759.600 Peutz-Jeghers syndrome 
759.610 Encephalocutaneous angiomatosis 
Kalischer's disease 
Sturge-Weber syndrome 
759.620 Von Hippel-Lindau syndrome 
759.630 Gardner syndrome 
759.680 Other specified hamartomas 
759.690 Unspecified hamartomas 
 
759.7 Multiple congenital anomalies, 
 
759.700 Multiple congenital anomalies, 
anomaly, multiple, NOS 
deformity, multiple, NOS 
 
759.8 Other specified anomalies and syndromes 
 
759.800 Cong malformation syndromes affecting facial appearance 
cyclops 
Noonan syndrome 
oral-facial-digital (OFD) syndrome, type I 
Orofaciodigital syndrome, type II (Mohr syndrome) 
Waardenburg syndrome 
whistling face syndrome 
759.820 Cong malformation syndromes associated with short stature 












thrombocytopenia-absent radius (TAR) syndrome 
759.860 Cong malformation syndromes with other skeletal changes 
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Marfan syndrome 
Stickler syndrome 
759.870 Cong malformation syndromes with metabolic disturbances 
Alport syndrome 
Beckwith (Wiedemann-Beckwith) syndrome 
leprechaunism 
Menkes syndrome (kinky hair syndrome) 
Prader-Willi syndrome 
Zellweger syndrome 
759.890 Other specified anomalies 
Includes: hemihypertrophy 
 Meckel-Gruber syndrome 
 
759.9 Congenital anomaly, unspecified 
 
# 759.900 Anomalies of umbilicus 
low-lying umbilicus 
umbilical cord atrophy 
759.910 Embryopathia, NEC 
759.990 Congenital anomaly, NOS 
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Other Specified Codes Used in Metro Atlanta Congenital Defects Program 
 
 
List ordered alphabetically 
 
524.000 Abnormalities of jaw size 
micrognathia 
macrognathia Τ   
255.200 Adrenogenital syndrome 
# 270.200 Albinism 
# 277.620 Alpha-1 antitrypsin deficiency 
 Τ # 658.800 Amniotic bands (constricting bands, amniotic cyst) 
# 270.600 Arginosuccinic aciduria 
# 778.000 Ascites, congenital  
 
216  Benign neoplasm of skin 
Τ  (NOTE: All neoplasms should be coded ONLY if another reportable code  
  is present) 
Includes: blue nevus  pigmented nevus 
  papilloma dermatofibroma 
  syringoadenoma hydrocystoma 
*   * dermoid cyst syringoma 
Excludes: skin of female genital organs (use 221.000),  
  skin of male genital organs (use 222.000) 
 Τ # 216.200 Benign neoplasm of skin, ear and external auditory canal 
Includes:  auricle ear  
    external meatus 
   auricular canal  
        external canal 
   pinna 
Excludes: cartilage of ear  
 Τ # 216.100 Benign neoplasm of skin, eyelid, including canthus 
Excludes: cartilage of eyelid  
 Τ # 216.000 Benign neoplasm of skin, lip 
Excludes: vermillion border of lip  
 Τ # 216.700 Benign neoplasm of skin, lower limb, hip 
 Τ # 216.300 Benign neoplasm of skin, other and unspecified parts of face 
Includes: cheek, external nose, external eyebrow 
  temple 
 Τ # 216.800 Benign neoplasm of skin, other specified sites of skin 
Excludes: epibulbar dermoid cyst (use 743.810) 
 Τ # 216.400 Benign neoplasm of skin, scalp and skin of neck 
 Τ # 216.900 Benign neoplasm of skin, site unspecified 
  # 216.500 Benign neoplasm of skin, trunk, except scrotum 
Includes: axillary fold 
 perianal skin 
 skin of: chest wall, abdominal wall, groin, 
buttock, anus, perineum, back, umbilicus, 
breast 
Excludes: anal canal  
 anus, NOS  
 skin of scrotum  
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 Τ # 216.600 Benign neoplasm of skin, upper limb, shoulder 
# 221.000 Benign skin neoplasm of female genital organs 
# 222.000 Benign skin neoplasm of male genital organs 
453.000 Budd-Chiari, occlusion of hepatic vein 
427.900 Cardiac arrhythmias, NEC. Never code premature atrial  
         contractions, PACs. 
# 330.100 Cerebral lipidoses 
Includes: Tay-Sachs disease, gangliosidosis 
363.200 Chorioretinitis 
279.200 Combined immunodeficiency syndrome 
771.280 Congenital infection, other specified 
Excludes: human immunodeficiency virus (HIV) 
 infection and acquired immunodeficiency 
 syndrome (AIDS) 
# 277.000 Cystic fibrosis 
No mention of meconium ileus 
# 277.010 Cystic fibrosis 
With mention of meconium ileus 
228.100 Cystic hygroma 
Lymphangioma, any site 
771.100 Cytomegalovirus (CMV) (in utero infections only) 
253.820 Diencephalic syndrome 
279.110 DiGeorge syndrome 
277.400 Disorders of bilirubin excretion  
425.300 Endocardial fibroelastosis 
553.200 Epigastric hernia 
# 767.600 Erb's palsy 
# 368.000 Esotropia 
# 378.000 Exotropia 
# 351.000 Facial palsy 
331.890 Familial degenerative CNS disease 
760.710 Fetal alcohol syndrome  
760.718 Fetal alcohol syndrome, probable  
Includes:  "facies" 
760.750 Fetal hydantoin (Dilantin) syndrome 
# 282.200 Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency 
# 271.000 Glycogen storage diseases 
 Τ  216.920  Hairy nevus 
Τ 228.0 Hemangioma 
 Include if greater than 4-inches diameter, if multiple  
 hemangiomas, or if cavernous hemangioma 
 
228.040 Hemangioma, intra-abdominal (Always code regardless of size, type or 
 number) 
228.020 Hemangioma, intracranial (Always code regardless of size, type or 
 number) 
228.090 Hemangioma, of other sites (Always code regardless of size, type or 
 number) 
# 228.000 Hemangioma, of unspecified site. Always code if multiple hemangiomas 
  of any size are present, if one or more cavernous hemangiomas of any  
  size are present, or if a single hemangioma measuring ≥ 4cm in 
  diameter or desribed as large, huge, or of medical significance is  
  present. 
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# 286.000 Hemophilia (all types) 
Continued: Other Specified Codes Used in Metro Atlanta Congenital Defects Program 
 
# 228.010 Hemangioma, skin & subcutaneous, NOS Always code if multiple 
 hemangiomas of any size are present, if one or more cavernous 
 hemangiomas of any size are present, or if a single hemangioma  
 measuring ≥ 4cm in diameter or desribed as large, huge, or of medical 
 significance is present. 
 
774.490 Hepatitis, neonatal, NOS 
774.480 Hepatitis, neonatal, other specified  
# 282.100 Hereditary elliptocytosis 
  # 282.000 Hereditary spherocytosis 
 
771.220 Herpes simplex (in utero infections only) 
Includes: encephalitis 
meningoencephalitis 
202.300 Histiocytosis, malignant 
277.510 Hurler syndrome 
Includes: lipochondrodystrophy 
# 778.600 Hydrocele, congenital  
# 270.700 Hyperglycinemia 
# 251.200 Hypoglycemia, idiopathic  
# 252.100 Hypoparathyroidism, congenital  
# 275.330 Hypophosphatemic rickets 
253.280 Hypopituitarism, congenital 
 # 243.990 Hypothyroidism, congenital (Exclude even if other 
 defects are present only if the record specifies  
    hypothyroidism of prematurity. Other types of  
 hypothyroidism or hypothyroidism NOS should continue 
    to be on the routine exclusion list.) 
345.600 Infantile spasms, congenital 
 # 550.000  Inguinal hernia or patent processus vaginalis never   
  -550.900  code in infants if <36 weeks gestation regardless of  
  the presence of a reportable defect.  
   NOTE: for those ≥36 weeks: 
  Code in males only if another reportable defect is present; 
 Code in females, always code even if found in isolation 
208.000 Leukemia, congenital, NOS 
214  Lipoma 
 
214.300 Lipoma, intra-abdominal organs 
214.200 Lipoma, intrathoracic organs 
214.810 Lipoma, lumbar or sacral lipoma  
        paraspinal lipoma 
214.100 Lipoma, other skin and subcutaneous tissue 
214.800 Lipoma, other specified sites 
214.000 Lipoma, skin and subcutaneous tissue of face 
214.400 Lipoma, spermatic cord 
214.900 Lipoma, unspecified site 
  # 457.800 Lymphatics - other specified disorders of (including chylothorax) 
524.000 Macrognathia 
# 270.300 Maple syrup urine disease 
# 777.600 Meconium peritonitis 
# 777.100 Meconium plug syndrome 
524.000 Micrognathia 
352.600 Moebius syndrome 
 
 
R = Rev. 6/07 
Ν = Rev. 5/07 
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# = on the MACDP Excl List 
A - 86 
# 520.600 Natal teeth 
239.200 Neck cyst 
774.490 Neonatal hepatitis, NOS 
 
Continued: Other Specified Codes Used in Metro Atlanta Congenital Defects Program 
 
 
774.480 Neonatal hepatitis, other specified 
159.800 Neoplasms of the abdomen, other specified 
191.000 Neoplasms of the CNS 
Includes: medulloblastoma, gliomas 
171.800 Neoplasms of the connective tissue  
Includes: Ewing's sarcoma 
 fibrosarcoma 
155.000 Neoplasms of the liver 
Includes: hepatoblastoma 
 hemangio-epithelioma 
162.800 Neoplasms of the lung 
186.000 Neoplasms of the testes 
194.000 Neuroblastoma 
237.700 Neurofibromatosis 
# 379.500 Nystagmus 
# 270.100 Phenylketonuria (PKU) 
* 524.080 Pierre Robin sequence 
# 685.100 Pilonidal sinus (sacrodermal), sacral sinus, sacral dimple 
# 277.630 Pseudocholinesterase enzyme deficiency 
# 284.000 Red cell aplasia 
362.600 Retinal degeneration, peripheral 
362.700 Retinitis pigmentosa 
190.500 Retinoblastoma 
771.000 Rubella, congenital (in utero infections only) 
# 685.100 Sacral dimple 
 Τ #  216.910  Sebaceous cyst 
# 282.600 Sickle cell anemia 
  # 090.000 Syphilis, congenital (in utero infections only) 
238.030 Teratoma, abdomen 
238.010 Teratoma, head and face 
238.020 Teratoma, neck 
238.000 Teratoma, NOS 
238.080 Teratoma, other specified  
238.040 Teratoma, sacral, coccygeal 
257.800 Testicular feminization syndrome 
771.090 TORCH infection, unspecified (in utero infections only) 
# 608.200 Torsion of the testes or spermatic cord 
771.210 Toxoplasmosis (in utero infections only) 
# 553.100 Umbilical hernia 
# 286.400 von Willebrand disease 
335.000 Werdnig-Hoffman disease 
189.000 Wilms tumor (nephroblastoma) 
426.705 Wolfe-Parkinson-White syndrome, congenital  
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 Other Specified Codes Used in Metro Atlanta Congenital Defects Program 
 
List ordered by 6-digit code number 
 
  # 090.000 Syphilis, congenital (in utero infections only) 
155.000 Neoplasms of the liver 
Includes: hepatoblastoma 
 hmangio-epithelioma 
159.800 Neoplasms of the abdomen 
162.800 Neoplasms of the lung 
171.800 Neoplasms of connective tissue 
Includes: Ewing's sarcoma 
      fibrosarcoma 
186.000 Neoplasms of the testes 
189.000 Wilms tumor (nephroblastoma) 
190.500 Retinoblastoma 




202.300 Histiocytosis, malignant 
208.000 Leukemia, congenital, NOS 
 
214   Lipoma 
214.000 Lipoma, skin and subcutaneous tissue of face  
214.100 Lipoma, other skin and subcutaneous tissue 
214.200 Lipoma, intrathoracic organs 
214.300 Lipoma, intra-abdominal organs 
214.400 Lipoma, spermatic cord 
214.800 Lipoma, other specified sites 
214.810 Lipoma, lumbar or sacral lipoma 
paraspinal lipoma 
214.900 Lipoma, unspecified site 
 
Τ 216   Benign neoplasm of skin 
    (NOTE: All benign neoplasms should be coded ONLY if  
             another reportable code is present) 
Includes: blue nevus  pigmented nevus 
 papilloma dermatofibroma 
 syringoadenoma  
 *dermoid cyst 
 hydrocystoma  
 syringoma 
Excludes: skin of female genital organs (use 221.000),  
 skin of male genital organs (use 222.000) 
  # 216.000 Skin of lip 
Excludes: vermillion border of lip  
  # 216.100 Eyelid, including canthus 
     Excludes: cartilage of eyelid  
  # 216.200 Ear and external auditory canal 
Includes: auricle ear  
  external meatus 
 auricular canal  
 external canal 
 pinna 
Excludes: cartilage of ear  
 
 
R = Rev. 6/07 
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  # 216.300 Skin of other and unspecified parts of face 
Includes: cheek, external nose,  
  external eyebrow  temple 
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  # 216.400 Scalp and skin of neck  
  # 216.500 Skin of trunk, except scrotum 
              Includes: axillary fold 
                               perianal skin 
     skin of: chest wall 
abdominal wall 







Excludes: anal canal  
 anus, NOS   
 skin of scrotum  
  # 216.600 Skin of upper limb, shoulder 
  # 216.700 Skin of lower limb, hip 
  # 216.800 Other specified sites of skin 
Excludes: epibulbar dermoid cyst (use 743.810) 
# 216.900 Site unspecified 
  # 216.910 Sebaceous cyst  
   216.920  Hairy nevus 
# 221.000 Benign skin neoplasm of female genital organs 
# 222.000 Benign skin neoplasm of male genital organs 
 
Τ 228.0  Hemangioma 
Include if greater than 4-inches diameter, if multiple  
hemangiomas, or if cavernous hemangioma 
# 228.000 Hemangioma, of unspecified site  
  Always code if multiple hemangiomas of any size are present, if one  
  or more cavernous hemangiomas of any size are present, or if a single  
  hemangioma measuring ≥ 4cm in diameter or desribed as large, huge, or  
  of medical significance is present. 
# 228.010 Hemangioma, skin & subcutaneous, NOS 
  Always code if multiple hemangiomas of any size are present, if one  
  or more cavernous hemangiomas of any size are present, or if a single  
  hemangioma measuring ≥ 4cm in diameter or desribed as large, huge, or  
  of medical significance is present. 
228.020 Hemangioma, intracranial(Always code regardless of size, type or 
 number) 
228.030 Hemangioma, retinal (Always code regardless of size, type or number) 
228.040 Hemangioma, intra-abdominal(Always code regardless of size, type or  
 number) 
228.090 Hemangioma, of other sites(Always code regardless of size, type or  
 number) 
228.100 Cystic hygroma   
Lymphangioma, any site 
237.700 Neurofibromatosis 
238.000 Teratoma, NOS 
238.010 Teratoma, head and face 
238.020 Teratoma, neck 
238.030 Teratoma, abdomen 
238.040 Teratoma, sacral, coccygeal 
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238.080 Teratoma, other specified  
239.200 Neck cyst 
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 # 243.990 Hypothyroidism, congenital  
    (Exclude even if other defects are present only if the record  
     specifies hypothyroidism of prematurity <36 weeks. Include other  
     types of hypothyroidism and hypothyroidism NOS only when another  
     reportable defect is present regardless of gestational age)  
  # 251.200 Hypoglycemia, idiopathic  
    # 252.100 Hypoparathyroidism, congenital  
253.280 Hypopituitarism, congenital 
253.820 Diencephalic syndrome 
255.200 Adrenogenital syndrome (adrenal hyperplasia) 
257.800 Testicular feminization syndrome 
# 270.100 Phenylketonuria (PKU) 
# 270.200 Albinism 
# 270.300 Maple syrup urine disease 
# 270.600 Arginosuccinic aciduria 
# 270.700 Hyperglycinemia 
# 271.000 Glycogen storage diseases 
# 275.330 Hypophosphatemic rickets 
# 277.000 Cystic fibrosis with no mention of meconium ileus 
# 277.010 Cystic fibrosis with mention of meconium ileus 
277.400 Disorders of bilirubin excretion 
277.510 Hurler syndrome 
Includes: lipochondrodystrophy 
# 277.620 Alpha-1 antitrypsin deficiency 
# 277.630 Pseudocholinesterase enzyme deficiency 
279.110 DiGeorge syndrome 
279.200 Combined immunodeficiency syndrome 
# 282.000 Hereditary spherocytosis 
# 282.100 Hereditary elliptocytosis 
   # 282.200 Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency 
# 282.600 Sickle cell anemia 
# 284.000 Red cell aplasia 
# 286.000 Hemophilia (all types) 
# 286.400 von Willebrand disease 
# 330.100 Cerebral lipidoses 
Includes: Tay-Sachs disease 
 gangliosidosis 
331.890 Familial degenerative CNS disease 
335.000 Werdnig-Hoffman disease 
345.600 Infantile spasms, congenital 
# 351.000 Facial palsy 
352.600 Moebius syndrome 
362.600 Retinal degeneration, peripheral 
362.700 Retinitis pigmentosa 
363.200 Chorioretinitis 
# 368.000 Esotropia 
# 378.000 Exotropia 
# 379.500 Nystagmus 
425.300 Endocardial fibroelastosis 
426.705 Congenital Wolfe-Parkinson-White syndrome 
427.900 Cardiac arrhythmias, NEC. Never code premature atrial  
         contractions, PACs. 
453.000 Budd-Chiari, occlusion of hepatic vein 
  # 457.800 Other specified disorders of lymphatics (including chylothorax) 
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# 520.600 Natal teeth 
524.000 Abnormalities of jaw size 
micrognathia 
     macrognathia 
* 524.080 Pierre Robin sequence 
 #  550.000- Inguinal hernia or patent processus vaginalis never   
              550.900 code in infants if <36 weeks gestation regardless of the  
      presence of a reportable defect.   
      NOTE: for those ≥36 weeks:  
   Code in males only if another reportable defect is present; 
   in females, always code even if found in isolation 
# 553.100 Umbilical hernia 
553.200 Epigastric hernia 
# 608.200 Torsion of testes or spermatic cord 
 Τ # 658.800 Amniotic bands (constricting bands, amniotic cyst) 
# 685.100 Pilonidal sinus (sacrodermal), sacral sinus, sacral dimple 
760.710 Fetal alcohol syndrome 
760.718 Probable fetal alcohol syndrome 
Includes: "facies" 
760.750 Fetal hydantoin (Dilantin) syndrome 
# 767.600 Erb's palsy 
 
771   Congenital infections (in utero infections only) 
Excludes: congenital syphilis (use 090.000) 
 
771.000 Rubella, congenital 
771.090 TORCH infection, unspecified 
771.100 Cytomegalovirus (CMV) 
771.210 Toxoplasmosis 
771.220 Herpes simplex 
Includes: encephalitis 
 meningoencephalitis 
771.280 Congenital infection, other specified 
Excludes: human immunodeficiency virus (HIV) infection and  
 acquired immunodeficiency syndrome (AIDS) 
774.480 Hepatitis, neonatal, other specified 
774.490 Hepatitis, neonatal, NOS 
# 777.100 Meconium plug syndrome 
# 777.600 Meconium peritonitis 
# 778.000 Ascites, congenital 
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 EXCLUSION LIST for the MACDP 
 Nonreportable birth defects 
 
Conditions Never to be Reported
 
The following newborn and infant conditions include those descriptions considered to 
be excludable or nonreportable conditions in the MACDP.  This includes certain 
biochemical disorders not considered part of the present MACDP case definition. 
 
 






Atrial contractions, premature 
Breast hypertrophy 
Bronchopulmonary dysplasia (Wilson-Mikity syndrome) 
Cephalohematoma 






Gum cysts - Includes epulis, ranula, mucocele 
Hydrocephalus secondary to intraventricular hemorrhage (IVH) or   
 CNS bleed 
Hip click, with no follow-up or therapy 
 Τ  Heart murmur 
Hyaline membrane disease 
 Τ  Intestinal obstruction - requires chart review to determine if 
   cause of obstruction is a reportable defect. If so, code only  
   the cause.  
 Τ  Intussusception - requires chart review to determine if 
   cause of intussusception is a reportable defect. If so, code only  
   the cause.  
Inverted nipples 
Laryngotracheomalacia or tracheomalacia 
Meconium stained skin or nails 
Mucocele 
Neonatal acne 










 Τ  Volvulus - requires chart review to determine if cause of volvulus 
         is a reportable defect. If so, code only the cause. 
Wilson-Mikity syndrome 
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 EXCLUSION LIST for the MACDP  
 Nonreportable birth defects 
 
Conditions Which may be Included Under Certain Conditions
 
The following newborn and infant conditions include those descriptions considered to 
be excludable or nonreportable conditions in the MACDP,  but which may be included 
under certain circumstances.
 
The following rules apply to coding these conditions: 
 
A. If a condition or defect listed appears in a chart, singly or in any 
combination with other defects listed only on the Exclusion List, do not 
fill out the case record form. 
B. If one of these conditions listed accompanies a reportable birth defect 
(from the 6-digit code manual and not on the exclusion list), then use 
the listed 6-digit code and record all defects (including those from 
this list) from the hospital record onto the case abstraction form. 
 
 
Alphabetical list of conditions requiring no record abstraction to be performed 
unless associated with a reportable defect.  The addition or revision dates of the 




Date     Code    Description
 
744.100 Accessory auricle  
757.650 Accessory nipple (supernumerary nipple, or skin tag) 
270.200 Albinism 
277.620 Alpha 1-antitrypsin deficiency 
 Τ 658.800 Amniotic bands (constricting bands, amniotic cyst) 
757.310 Anal tags 
10/1/92   Τ 746.400 Aortic valve insufficiency or regurgitation, 
congenital -  
   Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
270.600 Argininosuccinic aciduria 
Τ 778.000 Ascites or anasarca, congenital. Includes: hydrops  
  fetalis 
744.220 Bat ear 
 Τ # 216.200 Benign neoplasm of skin, ear and external auditory canal 
 Includes:  auricle ear  
      external meatus 
     auricular canal  
        external canal 
     pinna 
 Excludes: cartilage of ear  
 Τ # 216.100 Benign neoplasm of skin, eyelid, including canthus 
 Excludes: cartilage of eyelid  
 Τ # 216.000 Benign neoplasm of skin, lip 
 Excludes: vermillion border of lip  
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 Τ # 216.700 Benign neoplasm of skin, lower limb, hip 
 Τ # 216.300 Benign neoplasm of skin, other and unspecified parts of face 
 Includes: cheek, external nose, external eyebrow, temple 
  
 EXCLUSION LIST for the MACDP 
 Nonreportable birth defects 
 




Date     Code    Description
 
 Τ # 216.800 Benign neoplasm of skin, other specified sites of skin 
 Excludes: epibulbar dermoid cyst (use 743.810) 
 Τ # 216.400 Benign neoplasm of skin, scalp and skin of neck 
 Τ # 216.900 Benign neoplasm of skin, site unspecified 
  # 216.500 Benign neoplasm of skin, trunk, except scrotum 
 Includes: axillary fold 
 perianal skin 
 skin of: chest wall, abdominal wall, groin, buttock, anus, 
  perineum, back, umbilicus, breast 
 Excludes: anal canal, anus, NOS skin of scrotum 
  # 216.600 Benign neoplasm of skin, upper limb, shoulder 
221.000 Benign skin neoplasm of female genital organs 
222.000 Benign skin neoplasm of male genital organs 
754.020 Bent nose, deviation of nasal septum 
744.820 Big lips 
757.385 Birth mark, NOS 
743.450 Blue sclera - if <36 weeks gestation, code only if  
  another reportable defect is present. Always code if  
  ≥36 weeks gestation. 
743.800 Brushfield spots 
757.390 Cafe au lait spots 
746.860 Cardiomegaly, congenital NOS 
744.230 Cauliflower ear 
330.100 Cerebral lipidoses (e.g., Tay-Sachs, gangliosidoses, 
etc.)  
756.200 Cervical rib 
755.500 Clinodactyly (incurving of fifth finger) 
1/1/93 752.520 Cryptorchidism (see undescended testicle) 
277.010 Cystic fibrosis, with mention of meconium ileus 
277.000 Cystic fibrosis, with no mention of meconium ileus 
744.280 Darwin's tubercle 
1/1/96   Τ 754.030 Dolichocephaly - if <36 weeks gestation, code only if  
  another reportable defect is present. Always code if  
  ≥36 weeks gestation. 
1/1/93 743.800 Downward eye slant (antimongoloid) 
744.110 Ear tags, preauricular  
744.120 Ear tags, other 
744.230 Elfin ear, absent or decreased ear cartilage - if <36 
weeks gestation, code only if another reportable 
defect is present.  
743.800 Epicanthal folds 
767.600 Erb's palsy 
368.000 Esotropia 
378.000 Exotropia 
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351.000 Facial palsy 
757.380 Flammeus nevus or port wine stain 
748.180 Flat bridge of nose 
754.040 Fontanelle (large or small) 
Τ 743.630 Fused eyelids - never code if <25 weeks gestation 
  unless another reportable defect is present 
EXCLUSION LIST for the MACDP 
 Nonreportable birth defects 
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752.440 Fusion of vulva 
282.200 Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency 
271.000 Glycogen storage disease 
746.990 Heart murmur - if chart review does not confirm a 
heart defect within 6 months, do not code as a defect 
even if other codable defects are present 
286.000 Hemophilia 
751.620 Hepatomegaly 
282.100 Hereditary elliptocytosis 
282.000 Hereditary spherocytosis 
3/4/91 750.240 High arched palate 
778.600 Hydrocele, congenital 
752.480 Hymenal tags 
270.700 Hyperglycinemia 
251.200 Hypoglycemia, idiopathic 
252.100 Hypoparathyroidism, congenital 
275.330 Hypophosphatemic rickets 
1/1/96      Τ 752.440 Hypoplastic labia majora - if <36 weeks gestation, 
  code only if another reportable defect is present.  
  Always code if ≥36 weeks gestation. 
3/4/91 Τ 748.510 Hypoplasia of lung; pulmonary hypoplasia - exclude 
   only if an isolated defect in infants <36 weeks 
   gestation 
752.810 Hypoplastic scrotum - exclude if secondary to 
undescended testes 
 Τ 243.990 Hypothyroidism, congenital (Exclude hypothyroidism  
of prematurity in infants <36 weeks gestation even if 
other reportable defects are present. Include other 
types of hypothyroidism and hypothyroidism NOS when 
another reportable defect is present regardless of 
gestational age)   
752.430 Imperforate hymen 
755.500 Incurving fingers (clinodactyly) 
 Τ 550.000-  Inguinal hernia or patent processus vaginalis. Never   
550.900 code in infants <36 weeks gestation regardless of the  
550.901 presence of a reportable defect. For infants ≥36  
550.902 weeks: 
  In males, code only if another reportable defect is 
  present; 
    In females, always code even if found in isolation 
757.450 Lanugo, excessive or persistent 
754.040 Large fontanelle 
Revised 5/07 (EXCL1088) 
Replaces 6/93 Exclusion List 
 
 
R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A -  97
755.500 Long fingers and toes 
744.230 Lop ear 
744.245 Low set ears 
744.820 Macrocheilia (big lips) 
270.300 Maple syrup urine disease 
751.010 Meckel's diverticulum 
777.600 Meconium peritonitis  
777.100 Meconium plug 
9/10/90 754.520 Metatarsus varus or adductus 
EXCLUSION LIST for the MACDP 
Nonreportable birth defects 
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744.830 Microcheilia (small lips) 
10/1/92 Τ 746.600 Mitral valve insufficiency or regurgitation, 
congenital -  
   Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
757.386 Mongolian spots 
743.650 Nasal lacrimal duct obstruction 
520.600 Natal teeth  
745.500 Nonclosure of foramen ovale, NOS (see PFO) 
379.500 Nystagmus 
9/10/90 756.080 Occiput, flat or prominent 
3/5/90 457.800 Other specified disorder of lymphatics, including 
chylothorax 
755.600 Overlapping toes 
10/14/92  Τ 747.000 Patent ductus arteriosus (PDA) 
1)Always code if ≥36 weeks of gestation and defect last 
  noted at ≥6 weeks of age. 
  2)If ≥36 weeks gestation and defect last noted <6 weeks 
  of age, code only if the PDA was treated )e.g. by  
    ligation or indomethicin) or if another reportable   
    defect is present. 
3)Never code if <36 weeks gestation or if treated with  
       prostaglandins regardless of gestational age. 
10/14/92 Τ # 745.500 Nonclosure of foramen ovale, NOS 
Patent foramen ovale (PFO) 
1)Always code if ≥36 weeks of gestation and defect last 
  noted at ≥6 weeks of age. 
 2)If ≥36 weeks gestation and defect last noted <6 weeks 
  of age, code only if another reportable defect is 
   present. 
3)Never code if <36 weeks gestation regardless of 
  presence of other defects. 
 Τ 753.700 Patent urachus 
744.820 Patulous lips (wide lips) 
8/1/93 747.325 Peripheral pulmonic stenosis (PPS) murmur - do collect 
Revised 5/07 (EXCL1088) 
Replaces 6/93 Exclusion List 
 
 
R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A -  98
if PPS documented by echocardiogram 
270.100 Phenylketonuria (PKU) 
685.100 Pilonidal or sacral dimple 
744.230 Pixie-like ear 
744.230 Pointed ear 
755.006 Polydactyly in blacks (postaxial, type B), includes 
only skin tags on hands or feet. All other types of 
postaxial polydactyly (i.e. extra finger with bone, 
nail, etc.) should always be coded. 
744.246 Posteriorly rotated ears 
744.410 Preauricular sinus, cyst or pit 
744.110 Preauricular tags 
EXCLUSION LIST for the MACDP 
 Nonreportable birth defects 
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 Τ 747.680     Primary pulmonary artery hypertension 
752.450 Prominent clitoris 
277.630 Pseudocholinesterase enzyme deficiency 
10/1/92 Τ 746.020 Pulmonary valve insufficiency or regurgitation, 
congenital  
Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
750.500 Pylorospasm (intermittent pyloric stenosis) 
751.580 Rectal fissures 
284.000 Red cell aplasia 
744.500 Redundant neck skin folds 
755.616 Rocker-bottom feet 
685.100 Sacral dimple 
1/1/96  Τ     754.060 Scaphocephaly, no mention of craniosynostosis 
      Always code if ≥36 weeks gestation.  
   #  If <36 weeks gestation, code only if another reportable  
      defect is present. 
1/1/96 Τ 216.910 Sebaceous cysts 
744.900 Short neck 
282.600 Sickle cell anemia 
757.200 Sidney line 
757.200 Simian crease (transverse palmar crease) 
747.500 Single umbilical artery  
757.390 Skin cysts 
754.040 Small fontanelle 
744.830 Small lips 
1/1/96 Τ 757.640 Small nipple (hypoplastic) 
      Always code if ≥36 weeks gestation.  
   #  If <36 weeks gestation, code only if another reportable  
      defect is present 
10/1/92 Τ 759.020 Splenomegaly 
7/13/92  090.000 Syphilis, congenital 
759.240 Thymic hypertrophy 
Revised 5/07 (EXCL1088) 
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R = Rev. 6/07 
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* = code created by CDC 
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755.630 Tibial torsion 
750.000 Tongue-tie 
608.200 Torsion of spermatic cord 
608.200 Torsion of testes 
10/1/92 Τ 746.105 Tricuspid valve insufficiency or regurgitation, 
    congenital -  
Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
759.900 Umbilical cord atrophy 
553.100 Umbilical hernias (completely covered by skin) 
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1/1/93 Τ 752.500- Undescended testicle (cryptorchidism)  
 Τ 752.520 1)If < 36 weeks gestation, code only if there is a 
   medical/surgical intervention for this problem;  
   2)If ≥36 weeks gestation and defect last noted at <1  
   year of age, code only if there was a medical/surgical  
   intervention for this problem or if another reportable  
   defect is present 
   3)Always code if ≥36 weeks gestation and defect first  
   noted at ≥1 of age.  
748.180 Upturned nose 
743.800 Upward eye slant (mongoloid) 
752.460 Vaginal cysts 
752.480 Vaginal tags 
286.400 von Willebrand's disease 
3/14/91 Τ 755.130 Webbed toes  
Code webbing of the second and third toes only if 
another reportable defect is present. Always code 
webbing of other toes regardless of whether another 
reportable defect is present 
744.500 Webbing of neck 
748.180 Wide nasal bridge 
755.600 Widely spaced first and second toes 
757.680 Widely spaced nipples 
Revised 5/07 (EXCL1088) 
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Numerical list of conditions requiring no record abstraction unless associated with 
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Date      Code    Description
 
7/13/92  090.000 Syphilis congenital 
   216  Benign neoplasm of skin 
     (NOTE: All benign neoplasms should be coded ONLY if  
              another reportable code is present) 
 Includes: 
  blue nevus    
  pigmented nevus 
 papilloma  
 dermatofibroma 
 syringoadenoma  
 *dermoid cyst 
 hydrocystoma  
 syringoma 
Excludes: skin of female genital organs (use 221.000),  
 skin of male genital organs (use 222.000) 
  # 216.000 Skin of lip 
 Excludes: vermillion border of lip  
  # 216.100 Eyelid, including canthus 
      Excludes: cartilage of eyelid  
  # 216.200 Ear and external auditory canal 
 Includes: auricle ear  
   external meatus 
  auricular canal  
  external canal 
  pinna 
 Excludes: cartilage of ear  
  # 216.300 Skin of other and unspecified parts of face 
 Includes: cheek,external nose, external eyebrow, temple 
  # 216.400 Scalp and skin of neck  
  # 216.500 Skin of trunk, except scrotum 
               Includes: axillary fold 
                               perianal skin 
      skin of:   chest wall 
     abdominal wall 
                                    groin 
     buttock 
     anus 
     perineum 
     back 
     umbilicus 
     breast 
 Excludes: anal canal  
  anus, NOS   
  skin of scrotum  
  # 216.600 Skin of upper limb, shoulder 
  # 216.700 Skin of lower limb, hip 
  # 216.800 Other specified sites of skin 
 Excludes: epibulbar dermoid cyst (use 743.810) 
Revised 5/07 (EXCL1088) 
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R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
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# = on the MACDP Excl List 
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# 216.900 Site unspecified 
 # 216.910 Sebaceous cyst 
  
EXCLUSION LIST for the MACDP 
 
Numerical list of conditions requiring no record abstraction unless associated with 
a reportable defect.  The addition or revision dates of the changes in the list of 
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221.000 Benign skin neoplasm of female genital organs 
222.000 Benign skin neoplasm of male genital organs 
 Τ  243.990 Hypothyroidism, congenital (Exclude even if other 
defects are present only if the record specifies  
     hypothyroidism of prematurity <36 weeks. Include other  
     types of hypothyroidism and hypothyroidism NOS only  
when another reportable defect is present regardless 
of gestational age.  
251.200 Hypoglycemia, idiopathic 
252.100 Hypoparathyroidism, congenital 
270.100 Phenylketonuria (PKU) 
270.200 Albinism 
270.300 Maple syrup urine disease 
270.600 Argininosuccinic aciduria 
270.700 Hyperglycinemia 
271.000 Glycogen storage diseases 
275.330 Hypophosphatemic rickets 
277.000 Cystic fibrosis, with no mention of meconium ileus 
277.010 Cystic fibrosis, with mention of meconium ileus 
277.620 Alpha 1-antitrypsin deficiency 
277.630 Pseudocholinesterase enzyme deficiency 
282.000 Hereditary spherocytosis 
282.100 Hereditary elliptocytosis 
282.200 Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency 
282.600 Sickle cell anemia 
284.000 Red cell aplasia 
286.000 Hemophilia 
286.400 von Willebrand's disease 
330.100 Cerebral lipidoses (e.g., Tay-Sachs, gangliosidoses, 
  etc.) 




3/5/90  457.800 Other specified disorder of lymphatics, including 
chylothorax   
  520.600 Natal teeth  
 Τ 550.000-  Inguinal hernia or patent processus vaginalis never   
550.900 code in infants if <36 weeks gestation regardless of 
            the presence of a reportable defect.   
            NOTE: for those ≥36 weeks: 
  in males, code only if another reportable defect is 
  present; 
      in females, always code even if found in isolation 
553.100 Umbilical hernias (completely covered by skin) 
Revised 5/07 (EXCL1088) 
Replaces 6/93 Exclusion List 
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608.200 Torsion of spermatic cord 
608.200 Torsion of testes 
 Τ 658.800 Amniotic bands (constricting bands, amniotic cyst) 
685.100 Pilonidal or sacral dimple 
EXCLUSION LIST for the MACDP 
Nonreportable birth defects 
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 Τ 743.450 Blue sclera - if <36 weeks gestation, code only if  
  another reportable defect is present. Always code if  
  ≥36 weeks gestation. 
Τ 743.630 Fused eyelids - never code if <25 weeks gestation 
  unless another reportable defect is present 
743.650 Nasal lacrimal duct obstruction 
743.800 Brushfield spots 
743.800 Downward eye slant (antimongoloid) 
743.800 Epicanthal folds 
743.800 Upward eye slant (mongoloid) 
744.100 Accessory auricle  
744.110 Ear tags, preauricular  
744.120 Ear tags, other 
744.220 Bat ear 
744.230 Cauliflower ear 
744.230 Elfin ear, absent or decreased ear cartilage  
  If <36 weeks gestation, code only if another 
  reportable defect is present. 
744.230 Lop ear 
744.230 Pixie-like ear 
744.230 Pointed ear 
744.245 Low set ears 
744.246 Posteriorly rotated ears 
744.280 Darwin's tubercle 
744.410 Preauricular sinus, cyst or pit 
744.500 Redundant neck skin folds 
744.500 Webbing of neck 
744.820 Macrocheilia (big lips) 
744.820 Patulous lips (wide lips) 
744.830 Microcheilia (small lips) 
744.900 Short neck 
745.500 Nonclosure of foramen ovale, NOS (see PFO) 
10/14/92  Τ     745.500 Patent foramen ovale (PFO) 
1)Always code if ≥36 weeks of gestation and defect last 
noted at ≥6 weeks of age. 
2)If ≥36 weeks gestation and defect last noted <6 weeks 
of age, code only if another reportable defect is 
present. 
3)Never code if <36 weeks gestation regardless of 
presence of other defects. 
10/1/92 Τ 746.020 Pulmonary valve insufficiency or regurgitation, 
congenital -  
Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
Revised 5/07 (EXCL1088) 
Replaces 6/93 Exclusion List 
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present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
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10/1/92 Τ 746.105 Tricuspid valve insufficiency or regurgitation, 
congenital -  
    Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
10/1/92 Τ 746.400 Aortic valve insufficiency or regurgitation, 
congenital -  
    Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
10/1/92 Τ 746.600 Mitral valve insufficiency or regurgitation, 
congenital -  
    Code cases designated as 'mild', minimal', 'trivial', 
or 'physiologic' only if another reportable defect is 
present. Code all other degrees of insufficiency or 
regurgitation, including those where the degree is not 
specified, regardless of whether another reportable 
defect is present. 
746.860 Cardiomegaly, congenital NOS 
746.990 Heart murmur - if chart review does not confirm a 
heart defect within 6 months, do not code as a defect 
even if other codable defects are present 
10/14/92 Τ  747.000 Patent ductus arteriosus (PDA)  
1)Always code if ≥36 weeks of gestation and defect last 
  noted at ≥6 weeks of age. 
2)If ≥36 weeks gestation and defect last noted <6   
  weeks of age, code only if the PDA was treated )e.g. 
  by ligation or indomethicin) or if another    
  reportable defect is present. 
     3)Never code if <36 weeks gestation or if treated with  
  prostaglandins regardless of gestational age. 
8/1/93  747.325 Peripheral pulmonic stenosis (PPS) murmur - do collect 
if PPS documented by echocardiogram 
747.500 Single umbilical artery 
747.680     Primary pulmonary artery hypertension 
Revised 5/07 (EXCL1088) 
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R = Rev. 6/07 
Ν = Rev. 5/07 
778.000 Ascites or anasarca. Includes: hydrops fetalis  
748.180 Flat bridge of nose 
748.180 Upturned nose 
748.180 Wide nasal bridge 
3/4/91 Τ 748.510 Hypoplasia of lung; pulmonary hypoplasia - exclude if 
isolated defect in infants <36 weeks gestation. 
750.000 Tongue-tie 
3/4/91  750.240 High arched palate 
750.500 Pylorospasm (intermittent pyloric stenosis) 
751.010 Meckel's erticulum div
EXCLUSION LIST for the MACDP 
Nonreportable birth defects 
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751.580 Rectal fissures 
751.620 Hepatomegaly 
752.430 Imperforate hymen 
752.440 Fusion of vulva 
1/1/96 Τ 752.440 Hypoplastic labia majora - if <36 weeks gestation, 
  code only if another reportable defect is present.  
  Always code if ≥36 weeks gestation. 
3/4/91  752.450 Prominent clitoris 
752.460 Vaginal cysts 
752.480 Vaginal tags 
752.480 Hymenal tags 
1/1/93 Τ 752.500- Undescended testicle (cryptorchidism)  
 Τ 752.520 1)If < 36 weeks gestation, code only if there is a 
   medical/surgical intervention for this problem;  
   2)If ≥36 weeks gestation and defect last noted at <1  
   year of age, code only if there was a medical/surgical  
   intervention for this problem or if another reportable  
   defect is present 
   3)Always code if ≥36 weeks gestation and defect first  
   noted at ≥1 of age.  
1/1/93  752.520 Cryptorchidism (see undescended testicle) 
752.810 Hypoplastic scrotum - exclude if secondary to  
  undescended testes 
753.700 Patent urachus 
754.020 Bent nose, deviation of nasal septum 
1/1/96 Τ 754.030 Dolichocephaly - if <36 weeks gestation, 
  code only if another reportable defect is present.  
  Always code if ≥36 weeks gestation. 
1/1/93  754.040 Fontanelle (large or small) 
1/1/96        754.060 Scaphocephaly, no mention of craniosynostosis  
   If <36 weeks gestation, code only if another 
   reportable defect is present.  
  Always code if ≥36 weeks gestation. 
1/1/93  754.520 Metatarsus varus or adductus 
755.006 Polydactyly in blacks (postaxial, type B), includes 
only skin tags on hands or feet. All other types of 
postaxial polydactyly (i.e. extra finger with bone, 
nail, etc.) should always be coded.
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List 
A -  104
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 3/14/91 Τ 755.130 Webbed toes  
Code webbing of the second and third toes only if 
another reportable defect is present. Always code 
webbing of other toes regardless of whether 
another reportable defect is present 
    755.500 Clinodactyly (incurving of fifth finger) 
  755.500 Long fingers and toes 
  755.600 Overlapping toes 
  755.600 Widely spaced first and second toes 
  755.616 Rocker-bottom feet 
  755.630 Tibial torsion 
   756.080 Occiput, flat or prominent 
  756.200 rib  Cervical 
EXCLUSION LIST for the MACDP 
Nonreportable birth defects 
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  757.200 Sidney line 
  757.200 Simian crease (transverse palmar crease) 
  757.310 Anal tags 
  757.380 Flammeus nevus or port wine stain 
  757.385 Birth mark, NOS 
  757.386 Mongolian spots 
  757.390 Cafe au lait spots 
  757.390 Skin cysts 
  757.450 Lanugo, excessive or persistent 
 1/1/96  Τ 757.640 Small nipple (hypoplastic) 
  If <36 weeks gestation, code only if another  
  reportable defect is present.  
  Always code if ≥36 weeks gestation. 
 9/10/90   757.650 Accessory nipple (supernumerary nipple, or skin 
tag) 
  757.680 Widely spaced nipples 
  759.020 Splenomegaly 
  759.240 Thymic hypertrophy 
  759.900 Umbilical cord atrophy 
  767.600 Erb's palsy 
  777.100 Meconium plug 
  777.600 Meconium peritonitis  
  778.000 Ascites or anasarca, congenital 
  778.600 Hydrocele, congenital 
Revised 5/07 (EXCL1088) 
Replaces 6/93 Exclusion List 
 
 
R = Rev. 6/07 
Ν = Rev. 5/07 
Τ = Rev. 6/04 
* = code created by CDC 
# = on the MACDP Excl List A -  106
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Chapter 6        6-1                  Case Ascertainment Methods 
6.1  Introduction 
The National Birth Defects Prevention Network (NBDPN) is committed to improving the quality, 
accuracy, completeness, comparability, and timeliness of birth defects surveillance data. Information on 
the prevalence of birth defects reported by surveillance systems can vary considerably due to differences 
in case definition, method of case ascertainment, and the types of data sources used. 
 
This chapter describes two major approaches to birth defects surveillance: active case ascertainment and 
passive case ascertainment. The active case ascertainment approach is the intensive level of case 
identification that involves staff finding cases at strategic data sources. Ascertainment is usually very 
complete, and each diagnosis in the database is confirmed. In the passive case ascertainment approach 
the surveillance program receives case reports of birth defects from data sources. The completeness of 
ascertainment is highly dependent on the number and types of data sources used by the surveillance 
program and on the consistency of case reporting from the data sources. Since case reports usually are not 
confirmed by staff in a passive case ascertainment program, it is particularly important for these programs 
to implement quality assurance procedures aggressively. 
 
Although the two surveillance approaches are operationally different, it is possible to achieve comparable 
levels of data quality. Programs should evaluate their surveillance approaches regularly for accuracy, 
completeness, and timeliness and should be creative in identifying strategic means of quality 
improvement. 
 
In this chapter we first introduce some relevant terminology (Section 6.2). We then discuss general 
surveillance development (Section 6.3) and introduce approaches to case identification (Section 6.4). In 
Sections 6.5 and 6.6 we present in some detail information on the two main approaches to case 
identification (active and passive case ascertainment, respectively). The remaining sections cover 
additional topics in case ascertainment, including data sources (Section 6.7), sources of information that 
may be available at a given data source (Section 6.8), and issues relating to infant risk factors and case 
identification (Section 6.9). References cited in this chapter may be found in Section 6.10. 
 
Appendices to this chapter provide additional detail on the following important data sources for birth 
defects surveillance: vital records (Appendix 6.1), hospital data sets (Appendix 6.2), hospital and patient 
services logs (Appendix 6.3), and genetic services (Appendix 6.4). 
Chapter 6        6-2                  Case Ascertainment Methods 
6.2  Terminology 
Surveillance (public 
health) 
The ongoing, systematic collection, analysis, and interpretation of health 
data essential to the planning, implementation and evaluation of public 
health practice, closely integrated with the timely dissemination of these 
data to those who need to know (Centers for Disease Control and 
Prevention, 1988). 
 
Monitoring The performance and analysis of routine measurements using statistical 
methods aimed at detecting changes in the environment or health status of 
populations (Last, 1995). 
 
Registry A system of ongoing registrations, such that cases of a disease or other 
health-relevant condition are defined in a population and can be related to 
a population base. Birth and death registration systems are examples. 
Some disease registries, like the cancer registry, closely resemble public 
health surveillance systems and have epidemiologic value (Last, 1995).  
 
Case ascertainment or 
identification 
The process of identifying – from existing sources and using defined case 
definitions – embryos, fetuses, neonates, infants, and children who have a 
birth defect. 
 
Active case  
ascertainment 
A surveillance approach to case identification that is based on surveillance 
staff being engaged intensively in all activities related to finding and 
confirming potential birth defects cases. Surveillance staff seek out data 
sources and conduct systematic investigations of pertinent sources of 
information to identify potential cases of birth defects. Data collection 
sites include hospital medical records, diagnostic indices, unit logs, 
pathology departments, and specialty sites.   
 
Passive case ascertainment A surveillance approach to case identification whereby birth defects 
programs receive case reports from data sources. Passive case 
ascertainment programs receive case reports from one or many different 
data sources and may accommodate multiple reporting formats including 
hard copy, electronic, and web-based reports, as well as administrative 
data sets. There may be variability in the completeness and accuracy of 




Surveillance that identifies a population under study, usually defined by 
geopolitical boundaries, and establishes the denominator from which cases 
come. A data source that is population based covers an entire population 
within a defined area. Some examples of population-based data sources 
are: vital records (birth, death, and fetal death), statewide newborn genetic 
screening programs, and statewide newborn hearing screening programs.   
 
Chapter 6        6-3                  Case Ascertainment Methods 
Data source Any facility, site, or entity that has cases or potential cases of birth defects 
or other pertinent medical information. This includes a hospital, clinic, 
physician’s office, laboratory, prenatal diagnosis center, as well as 
administrative databases. 
 
Reportable disease A disease, laboratory result, or health condition of public health 
significance that requires notification of its occurrence to a public health 
agency. Authorizing legislation or regulations usually define which 
conditions are reportable, which data sources are required to report, 
timelines for reporting, and what demographic information is required, at a 
minimum, in a case report.  
 
Reporting source A data source that is required, by law, to report or allow access to cases of 
birth defects and other pertinent medical conditions to the birth defects 
program.   
 
Administrative data set A data set or database that is created to fulfill operational or managerial 
objectives. Many are developed as information management systems with 
multiple functions. Examples include hospital discharge data, Medicaid 
data, vital records master index, clinical management information systems, 
health care billing and insurance claims systems.  
 
Unit A component, section, or department within a data source that serves a 
specific function or performs a specific activity. Examples include health 
information management department, labor and delivery unit, neonatal 
intensive care unit, and pathology department 
 
Data collection The process of gathering information, which includes receiving, 
retrieving, accessing, abstracting, and extracting information from 
information sources.  
 
Medical records review 
(information review) 
The process of reading, identifying, interpreting, and translating 
documentation per specific program objectives. Medical records review 
precedes abstracting. 
 
Abstracting The process of recording information, identified when reviewing 
documentation in a medical record or other information source, and 
entering the information into data fields in a specified format. Information 
may be recorded on hard copy forms or through formatted data entry 
computer screens. 
 
Disease coding The process of assigning a standardized disease code (e.g., ICD-9-CM or 
6-digit CDC code) to medical information.  
 
Case abstract or case 
record 
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6.3  General Surveillance Development  
Birth defects surveillance systems should be developed to facilitate the essential activities of data 
collection, data analysis, data evaluation, and information dissemination consistent with a program’s 
established goals and objectives. The general guidelines below can be applied to developing a new system 
or improving an existing system. We are indebted to Mausner and Bahn (1974) and Teutsch and Churchill 
(2000) for much of the information in this section. 
 
In the following sections we discuss planning and documenting the system (Section 6.3.1), identifying 
data sources (Section 6.3.2), obtaining knowledge about individual data sources (Section 6.3.3), 
implementing data quality procedures (Section 6.4.3), and evaluating surveillance method and analytical 
capability (Section 6.3.5). 
6.3.1  Plan and Document 
A birth defects surveillance program must be organized and have supporting documentation before 
beginning operations. The program can begin to process case reports once the logistics of case 
identification and data collection are established with data sources. Therefore, it is important to engage 
surveillance staff, data sources, stakeholders, advisors, and others affected by program operations early in 
the planning process. 
 
The program should: 
 Understand the legal authority and restrictions that shape surveillance operations, including 
processes for changing or amending legislation (see Chapter 2 on Legislation). 
 Develop a mission statement and define the surveillance program’s goals and objectives. 
Determine what outcome measurements are desired by the program. For example, the program 
may want to describe the distribution of birth defects in their population, calculate rates and 
perform statistical analyses, and identify children who require services. Ideally, the development 
of goals, objectives, and outcome measurements will be done in collaboration with stakeholders 
and with internal and external advisory groups. 
 Define the parameters of case definition for the surveillance program, including residency, 
pregnancy outcomes, eligible diagnoses, and age range. Define the minimum criteria for an 
eligible case report (see Chapter 3 on Case Definition). 
 Define the method of case identification that will be used. Usually, a program will develop an 
infrastructure to support functions of active or passive case ascertainment. It is essential to 
document procedures, protocols, decision items, and methods of data collection (the program’s 
surveillance approach). Records review and data collection procedures should be defined 
precisely.  
 Determine the data variables needed to fulfill program goals and objectives. Define the minimum 
information that must be collected and address other information that would be beneficial to the 
surveillance program (see Chapter 4 on Data Variables). 
 Document protocol and procedures regarding the privacy of the individual and the confidentiality 
of health information. 
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 Design forms for reporting, data collection, and abstracting that are adaptable to computer 
technology. This could include web-based reporting and forms that provide for easy data entry or 
scanning and that support abstracting medical records in the field (see Chapter 9 on Data 
Management and Security). 
 Develop a database that has record linkage capability and that also functions as an information 
management system. The database should be flexible, adaptable, and able to accept electronic 
transfer of data files, web-based case reports, and case record abstracts from multiple sources. 
The database should support identification of all sources of information through which a 
diagnosis is identified or reported. It is also useful to be able to track and monitor medical records 
requests and perform other information management functions (see Chapter 9 on Data 
Management and Security). 
6.3.2 Identify Data Sources 
A key component in surveillance is identifying data sources for case ascertainment. A program needs to 
understand and evaluate the traits, characteristics, and operating procedures of all data sources. This is 
particularly important if there are potential sources of bias or underreporting associated with the way 
cases may be identified at a source.  
 
The program should: 
 Identify all potential data sources able to provide information that will help to fulfill the 
program’s mission (e.g., hospitals, genetics and specialty clinics, cytogenetics laboratories, 
administrative data sets, vital records).  
 Determine which data sources are included in any legislation mandating reporting and any 
additional sources for voluntary reporting. Consideration should be given to recommending 
legislative changes if program objectives change or are expanded, or if important data sources are 
omitted from mandatory reporting. For example, when adding prenatal diagnosis surveillance to 
program operations, it may be necessary to amend legislative language to include new data 
sources or facilities. 
6.3.3 Obtain Knowledge about Individual Data Sources 
For each reporting data source the program should: 
 Know the data source’s mission or goals.  
 Identify professional or legal mandates governing operations of the data source that may affect 
access to, or quality of, data from that source.  
 Describe the population served by the data source.  
 Chart the flow of information that is relevant to the surveillance program through the unit 
and/or data source. This is a good way to determine how the information is collected originally 
and whether or not the information is forwarded to a central repository (e.g., centralized 
computer file, medical records department, administrative database).  
 Maintain an up-to-date directory of names and contact information for relevant people at the 
data source (e.g., medical records personnel). 
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 Utilize multiple data sources. Surveillance programs should use multiple data sources, both for 
case identification and data collection. It is important for the surveillance program to realize 
that one source rarely fills all of a surveillance system’s needs for case record accuracy, 
completeness, and timeliness.  
 Develop record linkage procedures to facilitate matching all reports to the correct case record. 
This is especially important when programs utilize multiple data sources (see Chapter 9 on 
Data Management and Security). 
6.3.4  Implement Data Quality Procedures 
Surveillance programs should evaluate data for completeness, accuracy, timeliness, and comparability to 
other birth defects programs. At a minimum, programs should develop quality assurance procedures 
(manual and/or computerized) to identify potential issues in data quality. This includes accuracy, 
completeness, and timeliness. Additionally, programs should maintain documentation on data collection, 
data abstraction, and medical records review procedures. This will reduce the risk of multiple 
interpretations that lead to an inconsistent application of procedures and interpretation of medical 
information. For further details, see Chapter 7 on Data Quality Management. 
6.3.5  Evaluate Surveillance Method and Analytical Capability 
Surveillance programs should evaluate the surveillance approach and determine whether the surveillance 
system is meeting program objectives. Additionally, outcome measurements should be evaluated. 
NBDPN recommends the guidelines offered in the document Updated Guidelines for Evaluating Public 
Health Surveillance Systems (Centers for Disease Control and Prevention, 2001).  
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6.4  Birth Defects Surveillance – Approaches to Case Identification  
Cases of birth defects are generally identified in one of two ways: through ‘active case ascertainment’ 
(i.e., staff conduct case finding) or through ‘passive case ascertainment’ (i.e., case reports are received by 
the program). While some surveillance systems use both kinds of ascertainment approaches for case 
identification, program activities are generally structured around one or the other approach. 
 
Birth defects rates are directly related to the method of case identification and type of surveillance 
approach. Table 6.1 presents birth defects rates based on various surveillance approaches (Edmonds, 
1997). 
 
Table 6.1  Birth Defects Rates by Surveillance Approach 
Data Source % of Babies Reported with Birth Defects 
Birth Certificates in 1996 1.5 
Newborn Hospital Discharge Data (Florida) 4.3-7.1 
Mandatory Hospital Reporting (New York) 3.4 
Linked Data Sources (North Carolina) 4.7 
Active Hospital Surveillance (Atlanta 1992-1996) 2.6  




Although a physical examination of each infant provides the most complete assessment of birth defects 
among births, and therefore the highest prevalence, few programs can sustain this type of intensive case 
ascertainment. At the other extreme, the prevalence at birth of defects is clearly underreported when only 
birth certificates are used in case ascertainment. The NBDPN promotes case ascertainment approaches 
that provide a more complete description of birth defects prevalence in the US.  
 
Whereas the previous section on general surveillance development (Section 6.3) provides a foundation for 
surveillance systems, the following two sections (Sections 6.5 and 6.6) discuss unique issues that arise in 
using either active or passive case ascertainment approaches in the identification of birth defect cases. We 
are indebted to Lynberg and Edmonds (1992) for much of the information in Sections 6.5 and 6.6. 
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6.5  Active Case Ascertainment  
With active case ascertainment, cases of birth defects are identified at data sources by surveillance staff. 
The case-finding process includes identifying potential birth defects cases, reviewing and abstracting 
information from medical records, and conducting follow-up in order to complete abstracts or verify 
information. Programs take measures to ensure complete case ascertainment by using multiple data 
sources and multiple units within data sources. Case-finding activities may vary depending on the 
program’s resources and objectives. A program’s resources, as well as program goals and objectives, 
should be used to determine the intensity of case finding. Regardless of the case-finding methods used, 
active surveillance programs should provide detailed instructions on the case-finding process, document 
procedures for collecting information and completing case abstracts, nurture relationships between the 
program and its data sources, evaluate the quality and effectiveness of all steps in the case-finding 
process, and implement quality improvement methods.  
 
In the sections below we discuss characteristics of active case ascertainment (Section 6.5.1), a 
recommended approach for active case ascertainment (Section 6.5.2), data quality issues in active case 
ascertainment (Section 6.5.3), evaluation (Section 6.5.4), and tips and hints for active case ascertainment 
(Section 6.5.5). 
6.5.1  Characteristics of Active Case Ascertainment  
 Surveillance staff identify birth defects cases by visiting data sources. Staff should follow a 
thorough and systematic set of investigative methods so that all potential birth defects cases are 
identified. 
 Surveillance staff are trained to find birth defects cases. Staff learn how to find (or cull) cases in 
hospitals, medical facilities, clinics, laboratories (e.g., cytogenetics laboratories, genetics clinics, 
prenatal diagnostic centers), and in medical records that relate to each potential case (e.g., 
prenatal, maternal delivery, newborn, infant, pediatric). 
 Staff are trained to gather information from information sources and medical records. This 
includes following abstracting procedures and documentation guidelines. Staff are trained in birth 
defects coding and learn how to conduct follow-up. 
 Multiple information sources are used to obtain data. All potential data sources should be part of 
the case-finding investigative process, and some are essential (e.g., birth hospitals, unit logs in 
birth hospitals). Surveillance systems should evaluate the effectiveness of case finding at each 
data source. 
 Case abstract forms are detailed and comprehensive and usually include a number of variables 
pertaining to the pregnancy, delivery, and outcome. Information on the mother and infant is often 
collected in detail, including medical and prenatal care history, complications of pregnancy or 
delivery, reproductive history, physical examinations, postnatal procedures, and birth defects 
diagnosis. 
 Clinical reviewers, usually physicians, are trained to confirm, qualify, and evaluate the 
diagnostic information collected by the surveillance abstractors. 
 Active case-finding surveillance should result in accurate and complete identification of birth 
defects cases. The data are of high quality due to extensive staff training. The data collected are 
comprehensive and result in a detailed case abstract.  
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6.5.2  Approach to Active Case Ascertainment  
Active surveillance is based on surveillance staff investigating data sources and finding potential birth 
defects cases. Although other activities may be part of the active surveillance approach, case finding is the 
primary task. There are various approaches to the case-finding process. Some programs have staff review 
all pertinent data sources and information reports, while others limit case finding to the most important 
information sources. Some use existing databases or lists of potential cases that are generated by the data 
source. Because case finding is labor intensive, most programs evaluate case-finding activities and 
determine ways to identify cases effectively and efficiently, yet still be relatively sure that case 
ascertainment is complete. It is necessary to take into account the legal or legislative issues that govern 
program activities. 
 
Essential program activities for active case ascertainment include those listed below. 
 Identify program objectives. It is important to develop or enhance the case-finding approach 
based on the purpose and objectives of the surveillance system. For example, if information is 
used to refer children to services, then the case-finding process should be designed to collect 
identifying and contact information early enough in the process to make the referral in a timely 
manner.  
 Develop a flow chart of the case-finding process. Identify the data sources that are consistently 
used for case finding. At a minimum the program must conduct extensive case finding at birth 
and major pediatric hospitals. Within the data sources, the program should identify which units 
and departments will always be used. Important units and departments to consider are labor and 
delivery, nursery, surgery, and pathology (see list of data sources in Section 6.7). Some programs 
use the medical records department to generate a list of diagnoses (i.e., disease codes) from the 
disease index.  
 Define the type of information to look for and collect during the case-finding process. 
Information gathered may be sketchy, incomplete, and general. This is especially true when 
gathering information from unit logs. The case-finding process may also include gathering 
information for the conditions of low birth weight, prematurity, and other conditions that may 
potentially lead to a case.  
 Define the frequency of case-finding activities (i.e., visiting sources of information and 
completing abstracts). Frequency and consistency of case-finding activities affect the timeliness 
of the surveillance database. For example, if the program identifies a child who needs to be 
referred for services, it is usually important for the referral to be made in a timely manner. 
Timeliness can be measured by setting goals for the maximal length of time between birth and 
referral.  
 Conduct case finding (culling). This is the systematic and ongoing process of identifying birth 
defects cases. Potential cases at the data source are found by surveillance staff through one or 
more procedures: (1) reviewing information at unit logs within a data source and creating a list of 
medical records to be pulled by the health information department within the data source; and/or 
(2) requesting a line listing of potential cases from the data source or unit, usually by identifying 
the cases by ICD codes (e.g., hospital index); or (3) reviewing the medical records for every 
delivery, termination, miscarriage, etc. occurring at the data source. 
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 Conduct medical records reviews. Potential cases of birth defects identified by the case-finding 
process are further investigated through medical records reviews. Requests for medical records 
are provided to staff of medical records departments at hospitals (or other sites), who pull the 
charts and make them available to surveillance system staff. Surveillance staff, who determine if 
the child or fetus meets the eligibility criteria for inclusion as a case, review the medical records. 
Multiple medical records may be reviewed during this process. These may include: maternal 
medical records during prenatal care, hospital admits during the pregnancy, and the delivery 
record. Medical records for a child include the newborn delivery record and any medical 
(hospital) records generated after the birth.  
 Abstract information. As medical records are reviewed, surveillance staff abstract (record) the 
required information and record it on the case abstract form. Trained surveillance staff follow 
program guidelines and procedures for completing the data elements on the case abstract, 
confirming a diagnosis, and conducting follow-up to find cases at data sources and within units at 
data sources. Although a surveillance program develops its own set of abstracting guidelines and 
procedures, these should be based on established guidelines when available. In some programs, 
the abstractor assigns the disease code. In others, assigning the disease code occurs separately 
from abstracting.    
 Perform a clinical review. Some programs have an expert in medical diagnosis issues review the 
case abstract after it is complete. The abstract is evaluated for incomplete data variables (i.e., data 
fields), accuracy of the medical information, and accuracy of the disease code assigned. Some 
clinical reviews result in the further classification of the case with a summary diagnosis, as an 
isolated or syndromic case, or other classification.  
6.5.3  Data Quality Issues in Active Case Ascertainment 
Active case finding requires surveillance staff to review and collect information from medical records. 
Staff are involved directly in verifying and confirming medical information and determining whether 
further follow-up or investigation is needed. In these programs, the burden of maintaining the quality of 
the database rests with the surveillance staff. It is essential to understand the challenges to data quality 
that occur in active surveillance and to implement strategies to identify and to correct them (see also 
Chapter 7 on Data Quality Management). 
 Field work (case finding, record review, abstracting) should be evaluated for accuracy, 
incomplete data variables, and consistency. Desired outcome benchmarks in each of these areas 
should be identified and improvements implemented and tracked. 
 Data sources and individual units should be evaluated with respect to the staff resources 
expended and the results obtained. Since case finding is labor intensive, programs should 
streamline and improve operations whenever possible. The value of the output of each unit or 
department utilized should be evaluated against the staff resources used. The program should 
determine whether unnecessary medical records are being reviewed and identify which non-
anomaly ICD codes are most effective in identifying potential cases. 
 The surveillance database should be evaluated for timeliness. This includes measuring how 
current the database is in relation to calculating disease rates. Although programs may collect 
information on individual birth defects cases over many months or years, they should set 
benchmarks for finalizing an individual case record or meeting a level of productivity by 
specified times. 
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6.5.4  Active Case Ascertainment Surveillance Evaluation 
Evaluation of active ascertainment surveillance methods should occur at two levels. Both levels directly 
impact data quality and the program’s ability to meet goals and objectives. One level targets case 






Programs should develop outcome measurements that will improve data quality and are important to meet 
program needs and surveillance objectives.  See Chapter 7 on Data Quality Management for a more 
detailed discussion of this topic. 
 
The other level focuses on the surveillance system itself. For a comprehensive approach to evaluating 
surveillance systems refer to CDC’s Updated Guidelines for Evaluating Surveillance Systems (Centers for 
Disease Control and Prevention, 2001). 
6.5.5  Tips and Hints in Active Case Ascertainment  
 Establish precise guidelines and criteria for data requests to data sources. The process of active 
case ascertainment includes requesting information from data sources. Specific criteria or data 
variable parameters should be provided (e.g., ad hoc reports generated from an existing database, 
extracted information from databases). 
 Visit tertiary care (e.g., major pediatric site) hospitals first. These sites usually have the most 
complete diagnostic information on a birth defects case. Surveillance staff can follow the case 
back to the birth hospital for the remaining information. Often a delivery that occurs in a rural 
hospital is transferred to the tertiary care facility. 
 Coordinate the schedule of site visits with the data sources to minimize inconvenience for them.  
 Form relationships with staff in medical record departments (directors, coders, those 
coordinating release of information, record retrievers), birth registrar at the hospital, and 
hospital unit staff. Discuss the purposes of the surveillance program with them and describe the 
work that surveillance staff perform at their sites.  
 Know key information technology or data processing staff at the data source. These individuals 
often can access and retrieve specific pieces of information collected at the data source or within 
a component unit.  
 Use caution with ICD lists or an ICD disease index generated by medical records (or information 
technology) staff. Hospital medical records coders are required to adhere to a set of federal 
guidelines when assigning a disease code to the medical record. Surveillance staff use a set of 
abstracting guidelines developed by the program (or NBDPN). Measure the benefit of using a 
disease code from an index against the output gained and resources used. For example, evaluate 
the results of a medical records review after using disease codes from an index.  
 Use laptops. Design computer screens to assist in the case-finding process. Direct data entry 
during information gathering is more efficient, and likely more accurate, than recording 
information on paper forms and then entering it into the database. 
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 Be conscious of HIPAA, especially as this relates to the privacy and security rules that covered 
entities (i.e., health care facilities) are required to follow. Be knowledgeable about public health 
exemptions in HIPAA. Provide reassuring documentation to sites as appropriate (see Chapter 2 
on Legislation). 
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6.6  Passive Case Ascertainment 
With passive case ascertainment, case reports are submitted by data sources to the surveillance program. 
The level of interaction between programs and reporting sources varies, as do the methods of reporting. 
Some programs create birth defects case reporting forms and instruct reporting sources on how to 
complete them. Other programs merge or extract pertinent information into the surveillance program’s 
database from a data source’s existing database. Many use a combination of reporting methods to develop 
as complete an identification of birth defects cases as possible within the resources available. Regardless 
of the methods used, operating a surveillance system that receives case reports from data sources requires 
the program to identify and use multiple data reporting sources, provide detailed instructions to case 
reporting sources, nurture the relationship between the program and the reporting data source, and 
evaluate the quality of the case reports received.  
 
In the sections below we discuss characteristics of passive case ascertainment (Section 6.6.1), a 
recommended approach for passive case ascertainment (Section 6.6.2), data quality issues in passive case 
ascertainment (Section 6.6.3), evaluation (Section 6.6.4), and tips and hints for passive case ascertainment 
(Section 6.6.5). 
6.6.1  Characteristics of Passive Case Ascertainment 
 Birth defects cases are reported by data sources to the surveillance program.  
 Medical information is received by the program as a case report and is generally accepted as 
reported (i.e., the program does not confirm every case report for accuracy or comprehensiveness 
of diagnostic information). 
 The operational procedures used by each data source influence the accuracy, totality, definition, 
and timeliness of reported diagnoses. This, in turn, influences the quality of the data in the 
surveillance program’s database.  
 Information is usually reported from multiple reporting sources. Data sources often serve 
different purposes for a program. Many can be used as major sources of clinical information (e.g., 
hospital reports, hospital discharge index, cytogenetics laboratories). Some are used as a source of 
demographic and statistical information (e.g., vital records). Others are used primarily for 
tracking or follow-up (e.g., genetics clinics, pathology and autopsy reports, specialty treatment 
clinics, and developmental centers). See the list of data sources in Section 6.7.  
 The database is developed to accommodate various reporting formats. Information may be 
submitted in many ways and formats, including web-based reporting, electronic transfer and 
digital format, computerized reports, and hard copy reporting forms. Medical information may be 
reported in text format or in ICD code.  
 Record-matching procedures are used since data are collected from multiple sources and existing 
databases. Case report information is extracted from administrative databases (e.g., hospital 
discharge data set, Medicaid data, vital records) and from existing databases within a facility 
(e.g., laboratories, specialty clinics, prenatal diagnostic centers).  
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6.6.2  Approach to Passive Case Ascertainment 
Passive case ascertainment is based on case reports submitted to the program by data reporting sources. 
Reporting sources may include mandatory hospital reporting and physician reporting and/or 
administrative databases (e.g., hospital discharge data set, Medicaid data, vital records). Completeness in 
the surveillance system is improved by using multiple data sources, especially when data sources are 
selected to fill a gap in case identification (e.g., fetal death certificates, pathology and autopsy reports). 
Customized reporting forms may be used, or a program may elect to use other methods for receiving case 
reports. All legal or legislative issues that govern program operations must be taken into account.  
 
Essential program activities for passive case ascertainment include those listed below.  
 Establish the type and scope of passive case ascertainment that defines program operations, 
including whether surveillance includes fetal deaths. Some programs have limited disease 
reporting guidelines and a smaller set of data sources that are required to report. Some programs 
may have more liberal disease reporting guidelines but, due to limited resources, have to limit the 
scope of program operations. Generally, programs that use multiple data sources will have more 
complete case ascertainment than those that use only one or two data sources. If programs use the 
birth certificate as a data source for case reports, they should use another data source for case 
identification.  
 Identify the case identification data sources. These include birth and major pediatric hospitals. If 
fetal death is an outcome that is ascertained, it is important to use the fetal death certificate, and 
possibly cytogenetics laboratories, as a source of case identification. See the list of data sources in 
Section 6.7. 
 Define case reporting requirements precisely for each data source. This includes identifying the 
required or minimum data variables that should be reported. Some data sources will only report 
the required minimum data variables, while others, like an administrative database, may be able 
to furnish the program with additional pieces of information. Refer to Chapter 4 on Data 
Variables. 
 Develop data reporting methods and procedures for each data source, including data format, 
timeliness, or reporting schedules. When possible, encourage electronic or web-based reporting. 
Data sources are usually more consistent in reporting when the burden of submitting the case 
report is minimized.    
 Develop record linkage capability. It is important not only to accommodate multiple case 
reporting formats, but also to use the efficiencies of technology in processing case reports from 
administrative and existing databases and linking them to case records in the program’s database.  
 Develop procedures for abstracting information from medical records. This includes using the 
NBDPN Abstractor’ Instructions (see Chapter 3 on Case Definition, Appendix 3.2), assigning 
disease codes, recording other pertinent information, and entering data into the database. Passive 
case ascertainment programs should review medical records as part of data quality evaluations. 
Additionally, medical records reviews are often conducted for other focused surveillance 
functions. For example, some programs that perform statistical monitoring regularly review 
medical records to confirm a diagnosis. Other times it is important for surveillance staff to review 
medical records to confirm a diagnosis during a community investigation or when investigating a 
suspected cluster.    
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6.6.3 Data Quality Issues in Passive Case Ascertainment 
In passive case ascertainment, reporting sources submit case reports to the surveillance system. The 
reports are accepted without prior confirmation or verification of the information. Therefore, evaluations 
for quality must be conducted, especially regarding key program outcomes such as completeness, 
accuracy, and timeliness. Evaluations are often done by reviewing medical records and comparing results 
between the review and the reported diagnosis. A result of the evaluation process should include quality 
assurance procedures to identify future problems and methods to track improvement (see also Chapter 7 
on Data Quality Management). 
 The quality of a reported diagnosis should be evaluated for accuracy and comprehensiveness. 
Errors and differences in reporting will occur, resulting in underreporting, overreporting, and 
inaccurate reporting. By “rating” the quality of a reported diagnosis, data sources can also be 
evaluated. Results can be used to adjust quality control and assurance procedures and direct 
strategic programmatic decisions.  
 The surveillance database should be evaluated for timeliness. This includes measuring how 
‘current’ the database is in relation to the program’s ability to calculate disease rates. Track 
timeliness of reporting per data source and identify reporting time lags. For example, watch 
reporting trends to identify whether some calendar months or quarters are problematic for some 
data sources. Evaluate the surveillance program’s data processing procedures for time lags.  
 The disease coding classification system should be evaluated to identify weaknesses, 
limitations, and problematic codes. This is especially important for data sources that report 
cases in ICD code format, which can happen with a data source such as an administrative or 
existing database. Additionally, although federal coding guidelines are used to direct a hospital 
or clinic medical records coder in assigning a disease code, the interpretation of medical 
documentation in the chart is often the reason for a particular code assignment. A good way for 
a surveillance program to identify potential code problems is to understand some of the 
conditions that may surface during the newborn time period. For example, a problematic code 
could be 748.0, choanal atresia or stenosis, since some newborns do experience difficulty in 
breathing in the first few hours of life. Additionally, situations that might cause a misuse of 
codes are low birth weight and prematurity (see Chapter 3 on Case Definition, Appendix 3.3). 
To gain experience in understanding these issues, medical records should be reviewed and 
results evaluated.  
 The surveillance database should be evaluated for fluctuations in counts and rates of specific 
diagnoses. It is possible that an increase in a rate may be due to a change in procedure at a data 
source. Passive case ascertainment systems must understand that procedures and processes at 
the data source affect the quality of information in the surveillance database.  
 The surveillance program should develop benchmarks for desired outcome measurements and 
develop strategies for how to improve the outcome results. For example, a critical data source 
that is consistently lagging in reporting might be the focus of a strategic plan to improve 
timeliness.  
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6.6.4  Passive Case Ascertainment Surveillance Evaluation 
Evaluation of passive case ascertainment surveillance methods should occur at two levels. Both levels 
directly impact data quality and the program’s ability to meet goals and objectives. 
 
One level targets data reporting sources, case identification, and data collection. Examples of areas that 






Programs should develop outcome measurements that will improve data quality and are important to meet 
program needs and surveillance objectives. See Chapter 7 on Data Quality Management for a more 
detailed discussion of this topic. 
 
The other level focuses on the surveillance system itself. For a comprehensive approach to evaluating 
surveillance systems refer to CDC’s Updated Guidelines for Evaluating Surveillance Systems (Centers for 
Disease Control and Prevention, 2001). 
6.6.5  Tips and Hints in Passive Case Ascertainment  
 Use record linkage to link to the vital record early in the data collection process. The vital 
records data source is excellent for establishing a unique case in the database and one that readily 
identifies the residency of the pregnancy outcome. Additionally, the birth and fetal death 
certificates fulfill many data collection variables for pregnancy outcome, maternal, and pregnancy 
information, as well as other statistical information (see Chapter 4 on Data Variables). See the 
detailed description of the vital records data source in Appendix 6.1. 
 Identify high-quality data sources that report a confirmed diagnosis. A diagnosis from a high-
quality source is an efficient way to improve the accuracy of the database. It also offsets the need 
to conduct a medical records review for quality evaluations for the specific diagnosis. 
 Ensure cooperation and compliance of data sources as critical factors in passive case 
ascertainment. Ease the burden on data sources by encouraging electronic, computerized, and 
web-based reporting formats for submitting case reports. Offer technical assistance to sites. Many 
data sources already have the information the surveillance system needs in a database. It is 
usually easier to sustain consistent, timely, and compliant reporting using a computer program to 
extract information, rather than expecting staff at the data source to complete a case report. 
 Be flexible when discussing reporting methods and reporting requirements with a data source. 
All data sources may not be able to provide all of the desired ‘minimum’ data fields easily. 
Evaluate the contribution, including efficiencies, the data source can make to the surveillance 
system and adjust reporting requirements accordingly. Identify which sources can usually be 
depended upon to report the majority of demographic information.  
 Be knowledgeable about the information flow through respective hospitals and sites. Understand 
medical records content and documentation practices, including how the ICD code classification 
is used. Passive case ascertainment systems should be proactive in understanding where to go and 
who to contact to clarify issues when problems arise.  
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 Consider conducting ‘case finding’ at a data source as an alternative to receiving the case 
report. Although ‘case finding’ is not part of the passive surveillance approach, this method 
should be considered for data sources that may not have an efficient or reliable method of 
reporting (e.g., outpatient specialty clinics), that may not be able to report in a thorough manner 
(e.g., autopsy/pathology), or that are not required to report (i.e., voluntary reporting).  
 Communicate with data sources on how birth defects data are used. Identify the users of the data 
(the customers) and some of the products produced using surveillance information. Reporting 
sources like to be recognized for the contributions they make (i.e., reporting cases) and appreciate 
knowing that the data they provide are used and serve important and valuable purposes.   
 Be active and creative in managing the quality of the database. It is possible to develop program 
strategies that not only promote the efficiencies of passive case ascertainment but also improve 
the important outcome measurements of accuracy, completeness, and timeliness.  
 Be conscious of HIPAA, especially as this relates to the privacy and security rules that covered 
entities (i.e., health care facilities) are required to follow. Be knowledgeable about the public 
health exemptions in HIPAA. Provide reassuring documentation to sites as appropriate (see 
Chapter 2 on Legislation). 
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6.7  Data and Case Identification Sources 
Information on birth defects cases can be obtained from many sources, each of which has strengths and 
limitations. Rarely is one source able to provide all of the information necessary to complete a case 
record. Some, like birth and pediatric hospitals, are ideal for identifying a large number of cases. 
However, it is important not to overlook data sources like cytogenetics laboratories and specialty 
outpatient clinics, since they may identify cases previously unknown to a birth defects program. The 
challenge for birth defects surveillance programs is to evaluate and select data sources that meet the 
objectives of the program and that can be accessed using available resources. Most data sources can be 
useful for both active and passive case identification. Differences arise between the two case 
ascertainment approaches in how the information is gathered and collected. Some data sources are more 
conducive to active case ascertainment since the only way to access the information is to physically 
gather it. Some of the major data sources – including vital records, hospital discharge data, hospital unit 
logs, and genetics clinics – are described in further detail in Appendices 6.1, 6.2, 6.3, and 6.4. 
 
Vital Records (see Appendix 6.1 for detailed description) 
 Birth certificates 
 Fetal death certificates 
 Elective termination reports  
 Death certificates 
Hospital Information (see Appendix 6.2 for detailed description) 
 Hospital discharge data set 
 Hospital disease index   
Hospital Unit Logs, including (see Appendix 6.3 for detailed description): 
 Labor and delivery 
 Surgery  
 Nursery 
 Neonatal Intensive Care Unit (NICU) 
Hospital Departments, including: 
 Pathology 
Forensic (autopsy) pathology 
Surgical pathology 
 Surgery 
Inpatient and outpatient/ambulatory 
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Prenatal and Obstetrics Centers 
 Birthing centers 
 Obstetrics services 
 Planned Parenthood, and other women’s care clinics 
 Prenatal diagnosis and high-level ultrasound referral sites 
 Prenatal genetics counseling services 
Specialty Clinics 
 Genetics (see Appendix 6.4 for detailed description) 





 Developmental and growth 
 Audiology and speech 





 Prenatal diagnosis 





Chapter 6        6-20                  Case Ascertainment Methods 
Health Care Professionals 
 Audiologists 
 Developmental therapists 
Administrative Databases 
 Statewide hospital discharge data set (see Appendix 6.2 for detailed description) 
 Medicaid data  
 HMO data sets 
Other Sources of Information 
 University-based medical clinics 
 Newborn hearing screening program 
 Newborn genetic screening program 
 Coroners and medical examiners 
 Child fatality/mortality review programs 
 Public health maternal and child health programs 
Public health clinics, including developmental clinics 
 School records 
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6.8  Sources of Information in a Data Source 
In this section we discuss the various sources of information that may be available at a given data source. 
In Section 6.8.1 we provide a general introduction to the medical record, followed by a more detailed 
discussion of the various types of documentation within a medical record in Section 6.8.2. Other sources 
of information discussed include maternal delivery medical records (Section 6.8.3); prenatal medical 
records (Section 6.8.4); cytogenetic laboratory reports (Section 6.8.5); and autopsy, pathology, and 
laboratory reports (Section 6.8.6).  
6.8.1  Medical Records 
By law, all health care facilities are required to maintain some form of medical record on every patient for 
every service encounter that occurs in the facility. A medical record provides documentation on the 
course of treatment and progress of the patient at the facility for each admission or service encounter. The 
medical record may also include information from other health care facilities that may be pertinent to the 
treatment at that facility. For additional information on the professional practices and standards for 
medical records and other issues related to health information management, please consult the American 
Health Information Management Association (http://www.ahima.org).       
 
Medical records differ according to type of health care facility. Medical records maintained by a private 
health care provider, genetic counseling facility, hospital, or cytogenetics laboratory are likely to differ in 
the documentation included in the record and how the records are organized. The medical records that 
birth defects program staff are most likely to work with are those maintained by hospitals, particularly 
birth and tertiary care pediatric hospitals, and specialty clinics.   
 
The documentation required in a hospital medical record is usually defined by state legislation. 
Additionally, accreditation organizations maintain standards regarding required documentation (e.g., the 
Joint Commission on the Accreditation of Healthcare Organizations). Therefore, although medical 
records from different hospitals in a given state may be compiled and stored differently, the required 
content is the same. This is useful to know, especially if documentation appears to be deficient.  
 
Since the early 1990s, the ‘traditional’ medical record has been undergoing change. Today, it is not 
unusual for the content of medical records to be a combination of hard copy, electronic, and computerized 
formats. Therefore, surveillance staff should be aware that the hard copy medical record that is 
traditionally stored and managed by hospital medical records departments may not appear to be 
‘complete’ with respect to documentation. Some documentation may be in computer files or on electronic 
storage files (e.g., CD-ROM, microfiche, microfilm).  
 
A hospital medical record is generated for every admission and service encounter, and each record 
follows the guidelines for standard documentation. Some exceptions to this rule may apply in certain 
pregnancy outcomes. Programs should consult with hospitals and delivery sites for their procedures for 
outcomes other than live birth. The following are offered as possible scenarios:  
 Live birth. The infant and mother will each have individual medical records.    
 Live birth with neonatal demise shortly after birth. The infant may have a newborn medical 
record. However, most useful information will be in the mother’s delivery medical record (e.g., if 
autopsy or cytogenetics laboratory work is done, the results may be placed in the mother’s chart).  
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 Fetal death. The fetus may have a medical record. However, most of the useful information will 
be in the mother’s delivery medical record (e.g, if autopsy on cytogenics laboratory work is done, 
the results may be placed in the mother’s chart).  
 Elective termination. A medical record will be created only for the mother. Sometimes the 
admission at the hospital (or other site) will be as an outpatient.  
 
There are other locations and places where births and other pregnancy outcomes can occur (e.g., in transit, 
in clinics, at home). Most, but not all, of these sites will generate a delivery medical record at least to 
fulfill federal and state requirements to complete a vital record. The depth of the information may be 
incomplete or inconclusive; therefore, additional investigative effort is usually required. 
6.8.2  Type of Documentation in the Medical Record 
Surveillance staff should be aware of the typical documents found in a medical record. This is true for 
staff conducting active case finding, as well as for staff conducting a medical records data quality audit 
for passive case ascertainment. Surveillance staff should consult with individual sites regarding records 
content requirements and how the documents are stored at the site (i.e., hard copy or computer file). The 
following are offered as examples: 
 Face sheet. Contains demographic information, facility-specific information (e.g., medical record 
number, attending physicians, primary care provider, insurance). 
 History and physical. Information is gathered and an exam is conducted at admission, at birth, 
and at various periods during the hospital stay (depending on the length of stay).  
 Discharge summary. A document that is completed by a physician after a patient leaves the 
hospital. The summary pertains to a specific hospital stay and includes: admission diagnoses; 
pertinent medical history prior to the admission and problems, progress, and treatment during the 
hospital stay; a list of discharge diagnoses; and recommendations for follow-up, such as future 
visits to specialists and medications to be taken. At some hospitals a discharge summary may not 
be required for a very brief length of stay (e.g., less than 48 hours). Sometimes discharge 
summary information is recorded in the progress notes. 
 Consultations. Specialists such as neurologists, geneticists, or cardiologists also see the patient 
and provide diagnostic clarification.  
 Progress notes. Health care providers (e.g., physicians and nurses) document treatment and plans. 
 Diagnostic reports. Any procedure, whether invasive or non-invasive, requires documentation. 
This includes: diagnostic tests, laboratory analysis, surgery, cytogenetics, pathology, and autopsy. 
Sometimes, the final report will not be in the medical record (e.g., it may be in an electronic file 
or on file in a department of the respective site). Some results will be referred to in the discharge 
summary, progress notes, or consultation, while others may not be completed for several weeks 
(e.g., autopsy cytogenetics).  
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6.8.3  Maternal Delivery Medical Record  
In addition to standard documentation required in hospital medical records, the mother’s delivery medical 
record contains unique pieces of information that are important for case ascertainment. 
 
 Labor and delivery summary. Many hospitals use a standardized form to record important aspects 
of the outcome (e.g., time, weight, pregnancy risk factors). 
 Prenatal medical records. Although the private obstetrician maintains these, some documents 
may be inserted in the mother’s delivery record (or located in other places in the mother’s 
hospital medical record). These include copies of the course of pregnancy management and 
results of prenatal diagnostic procedures, such as ultrasounds, amniocentesis, and cytogenetics 
analyses, particularly if a birth defect is detected prenatally.  
 
 Pathology and laboratory reports. Pathological analysis is important in the case of fetal demise. 
Laboratory reports are important when there are suspected infectious disease or toxicology 
concerns in the mother. For example, there may be concerns about an exposure that could be 
passed along to the infant through breast milk. 
 Autopsy. If an autopsy is performed on a fetal demise or neonatal death, the report is often 
inserted in the mother’s medical record or may need to be tracked to the appropriate department.     
6.8.4  Prenatal Medical Record   
Currently, prenatal care may result in a woman having multiple medical records generated over the course 
of the pregnancy. 
 Obstetrician’s prenatal care medical record. This record contains documentation of how the 
pregnancy is managed. The content of this medical record is very similar to a hospital-based 
medical record; thus, it is important for birth defects surveillance. Sometimes the prenatal care 
medical record is inserted into the maternal delivery medical record.  
• Prenatal care forms. These are often in a standardized format and facilitate complete 
recording of information (e.g., laboratory work, family history, risk factors, genetic screens, 
and tests). 
• Flow charts of care. Prenatal visits, care and treatment, and patient discussions are 
documented, although often written by hand. 
• Diagnostic tests. The record may contain diagnostic tests, laboratory results, genetic 
counseling reports, consultations, and referrals to diagnostic centers.  
 
Prenatal diagnosis is growing in importance for birth defects surveillance. There is a long history of 
chromosomal diagnoses that are detected prenatally through the procedures of amniocentesis and 
chorionic villus sampling. Many more diagnoses can now be detected through the use of high-level 
ultrasound. Technology and diagnostic methods will continue to advance in the area of prenatal diagnosis.  
 Referral prenatal diagnostics and diagnosticians. Referral centers specialize in high-risk 
pregnancy and have high-level diagnostic capabilities. Depending on the course of a high-risk 
pregnancy, the referral physician (diagnostician) may assume primary management of the 
pregnancy and may attend the delivery. However, usually, the referral diagnostic site and 
diagnostician do not follow the patient throughout the pregnancy. Medical records generated at 
the referral diagnostic sites may contain pertinent information from the primary obstetrician’s 
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office, including demographic information, index prenatal care history, medical history, risk 
factors, and reasons for referral. They also contain unique information for case ascertainment. 
Sometimes the referral prenatal diagnostics are inserted into the obstetrician’s prenatal care 
medical record.  
• Diagnostic and laboratory results. The medical record includes the results and discussion 
of the results.    
• Genetic counseling. Documentation in this report includes significant family history, 
discussion of prenatal diagnosis, and discussion of prognosis. 
6.8.5  Cytogenetic Laboratory Reports 
Cytogenetic analysis may be performed at the hospital (in-house) or at freestanding laboratories. 
Programs are encouraged to use cytogenetic laboratories as data sources that consistently report cases. It 
is important for birth defects program staff to have some knowledge of basic genetics and the 
chromosomal terminology they are likely to encounter in medical records. For additional information on 
cytogenetics terminology (and corresponding abbreviations and symbols) refer to the reference manual, 
International System for Human Cytogenetic Nomenclature (ISCN) (Mitelman, 1995). 
 
The report on cytogenetic findings is created by the lab that did the analysis. The report usually identifies: 
 Name of patient 
 Date of birth 
 Referring facility and/or physician 
 Reason for referral (or suspected diagnosis) 
 Result/karyotype  
 Narrative regarding the analysis  
 
Rarely does the report provide an address for the patient. This presents a challenge for a surveillance 
program that regularly receives case reports directly from the cytogenetic laboratory, since the laboratory 
may also perform analyses for patients from several states. Surveillance programs should develop quality 
control procedures that address this and other challenging issues when working with cytogenetic 
laboratories. One possible approach is to develop a list of the locations of the referring facilities and/or 
physicians. 
 
The original report of the result of a cytogenetic analysis (or other test) is the property of the laboratory 
that performed the analysis. A copy of the report may or may not be sent to the referring facility or 
physician (or included in the referring facility’s medical record). The results may be communicated orally 
or referenced in a medical record. The surveillance program should develop abstracting procedures for 
accepting a referenced cytogenetics analysis and for determining when it is necessary to locate the initial 
source of medical information.  
 
There is a growing trend for hospitals to use out-of-state laboratories. Surveillance programs should 
investigate the feasibility, including legal authority, of using and contacting out-of-state laboratories. 
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6.8.6  Autopsy, Pathology, and Laboratory Reports 
Pathology laboratories are usually associated with hospitals, while autopsies may be performed in 
selected hospitals or through coroner’s offices. Autopsy and pathology reports are usually placed in the 
patient’s medical record, but the autopsy report may be completed long after death (some states have 45- 
to 60-day time frames for completion of autopsies). Therefore, the autopsy report may not be filed with 
the admission medical record; it may be in the outpatient or ‘other’ section of the record. It is important to 
note that there are two completion status categories for autopsy findings or reports: provisional and final. 
Surveillance staff should place the highest level of diagnostic certainty on the final report.   
 
Anatomical pathology laboratories usually produce high-quality case reports due to the exacting nature of 
the procedures performed during autopsy. An important exception to this is when the specimen is 
destroyed, macerated, or otherwise compromised, as is the case with many fetal deaths. When this 
happens, the autopsy and tissue analysis may be of limited value for birth defects case identification. Still, 
the autopsy report or tissue analysis will often provide the most definitive information on structural 
defects. Additionally, the type of tissue sample can provide useful information regarding the time frame 
of the pregnancy. Therefore, it is important to track and examine these reports. 
 
Autopsy and pathology laboratories may have information management systems, manual or 
computerized, specific to the laboratory. Diagnostic information is usually accessible since these 
laboratories catalog their findings for forensic investigations, historical and legal archives, case studies, 
and medical board reviews.  
 
Surveillance programs should understand that there might be varying degrees of quality in autopsy 
reports. Much depends on the expertise of a given pathologist or coroner, the majority of whom are not 
fetal and pediatric anatomical pathologists, the experts in this area. In some states these pathologists, and 
the hospitals or sites where they work, act as referral centers for specialized autopsies. Programs should 
consult with the respective pathologists and sites to better understand referral patterns in a given state and 
to evaluate the level of expertise available in this specialized area.  
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6.9  Infant Risk Factors in Case Identification 
A condition that affects an individual’s chance of having a particular outcome is called a risk factor. 
Various maternal and pregnancy exposures and conditions have been associated with an increased risk for 
birth defects. Birth defects programs can use these risk factors to identify potential cases, either through 
including their ICD-9 codes on the discharge lists obtained from medical records departments, through 
reviewing logs for any entries citing these risk factors in addition to birth defects, or through identifying 
vital records with particular birth weights, etc. 
 
However, even though certain factors are associated with increased birth defects risk, the majority of 
infants and fetuses with these risk factors will not have a birth defect. Thus, a large number of records 
will be reviewed that do not turn out to be cases. 
 
Moreover, the list of risk factors that may be used as case-finding sources can become very large. It is 
possible that a large portion of the potential inclusion population will have at least one of the risk factors 
used as a case-finding source. Most risk factors only result in a small to moderate increase in birth defect 
risk, so the majority of records reviewed on this basis will not yield eligible cases. Such risk factor lists 
are developed from experience, logic, and research. Programs that use risk factors should evaluate the 
yield in their case identification approach and determine whether using risk factors as case-finding 
sources is useful to the program over time.  
 
In the short term, the use of risk factors as screens for identifying potential cases of birth defects may be a 
valuable effort when the program is involved in a concentrated focus on a specific outcome, exposure, 
medical condition, or cluster investigation.  
 
Surveillance staff may encounter various postnatal complications during the review of data sources and 
units. This information is most likely found in the infant’s medical record, and often in progress 
summaries. In the situation of a fetal demise or stillbirth, the information is usually found in the maternal 
delivery chart. 
 
The list below provides some examples of risk factors that may be useful as case-finding sources. 
Surveillance staff should use pediatric references to become familiar with newborn conditions and 
evaluate which conditions are appropriate to use for case finding. Passive case ascertainment programs 
should also evaluate the effectiveness of using risk factors. The majority of the items listed below are 
identified in data fields on the vital record (birth and fetal death, death certificates) and easily accessible 
to both active and passive case ascertainment surveillance systems.  
 
Examples of infant risk factors include: 
 Infants who weigh less than 2,500 grams (5 lbs, 8 oz) or are < 36 weeks gestational age 
 Fetal and neonatal deaths 
 Infants with a history of asphyxia at birth (Apgar score at 5 minutes less than 7) 
 Infants admitted to neonatal intensive care or special care nurseries 
 Multiple births 
 Infants with respiratory distress 
 Infants with heart murmurs 
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Appendix 6.1 
Data Source Described in Detail – Vital Records 
Source or Site 
 
 Birth certificates  
 Fetal death certificates 
 Elective termination reports 
 Death certificates 
 
Birth, death, and fetal death certificates provide a standardized way of reporting vital events that occur in 
a politically defined unit, a state. Vital records include facts about an individual and the specific 
circumstances regarding the reported event. Vital records are particularly important in that they fulfill two 
significant functions: they provide a mechanism for registering the occurrence of vital events, and they 
provide a mechanism for collecting demographic, social, and health information regarding the person in a 
standardized way. Integral to these functions is the fact that they are population based.  
 
Legal or Professional Mandates 
 
Federal law mandates birth and death registration. The lead federal agency is the National Center for 
Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). NCHS maintains the 
national birth and death registration system and is the recipient of vital records data from the states and 
territories. Recording births and deaths is the responsibility of the individual states and territories. The 
procedures and regulations regarding the reporting of these vital events are established by the individual 
states and territories. NCHS provides guidelines and recommendations for standardization of the 
information collected by birth and death certificates by promulgating standard certificates. Although 
federal law does not mandate the reporting of fetal deaths, there is an NCHS-recommended standard fetal 
death certificate. See http://www.cdc.gov/nchs for further information.  
 
Mission or Objective 
 
Provides a population-based statistical database of all births and deaths that occur in the United States.  
 
Scope or Breadth   
 
The birth, death, and fetal death certificates provide for registration of a defined vital event at a point in 
time. There are established criteria for what constitutes a live birth, but there is evidence to suggest that 
those criteria are not always followed. Registration of fetal deaths is usually defined on the basis of 
gestational age, with > 20 weeks as the cut-off used by most states. Some states require the reporting of 
all fetal deaths, regardless of gestational age, and there is recognized underreporting of early fetal deaths. 
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Operational Structure  
 
 Data. NCHS recommends standard data elements on birth and death (and fetal death) certificates. 
States are required to complete a minimum data set for national reporting and may add other data 
elements to their certificates. The birth certificate is usually revised and updated every decade. In 
2003, the final drafts of a new version of the certificate are being reviewed. Please refer to 
http://www.cdc.gov/nchs for further information. 
 
 Certification. State statutes, regulations, and procedures stipulate who is responsible for certifying 
a live birth, death, or fetal death. The designated person is required to certify date, time, and place 
of birth/death as well as other priority areas on the certificate. The completion of death 
certificates has additional protocols, procedures, and instructions because of the many 
circumstances that may surround a death.  
 
 Filing the certificate. State statutes, regulations, and procedures stipulate time requirements for 
filing. Although the timing varies among states, the certificate is usually filed with the state 
registrar’s office within 5 to 10 days of the event. Many states now have methods for entering and 
filing birth certificates electronically. The timing for filing a fetal death certificate depends on 
state guidelines. Although filing a death certificate is required within a specified time period, it 
may not be complete at filing, as some data elements may be missing due to autopsy, coroner 
investigation, or other legal proceeding. These data may or may not be added subsequently and 
the certificate revised. 
 
 Unique identification of an individual event. Each state has a numbering system that uniquely 
identifies the respective event.  
 
 Storing the information. Most states have a centralized database specifically designed to collect, 
amend, transmit, retrieve, sort, print, and analyze vital records information.  
 
 Reciprocity. Agreements with bordering states ensure reporting of life events occurring in 
neighboring states to the state of residence.  
 
Types of Information Collected 
 
 NCHS and other interested parties have developed a set of standardized data elements or 
minimum data variables that are required to be reported, as well as a set of recommended data 
variables and recommended standard certificates. Of importance is the unique identifying 
information per person, per event.  
 The birth certificate and fetal death certificate are each divided into two sections: legal and 
statistical. The legal section contains the unique identifying information about the person, date, 
time, place, and type of life event. It is this portion of the certificate that registers the vital event. 
The information in the legal section is certified, and this is the part of the certificate that is issued 
to individuals when proof of the life event is required. The statistical section – labeled 
“Information for medical and health purposes only” – contains demographic, prenatal care, 
pregnancy risk factors, and medical conditions of the mother and of the newborn, including 
congenital anomalies. The statistical part is not released to the public, and many states do not 
keep the statistical part attached to the legal certificate. The statistical information is usually data 
entered and maintained in a database.  
 The death certificate is a certified legal document, and it is available to authorized individuals in 
its entirety.  
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Accessibility and Retrievability 
 
States transmit vital records information to NCHS electronically. State laws and regulations stipulate how 
the information is made available for other users at the state level. Due to the confidentiality of the 
information, states protect the medical and health information on vital records from unwarranted or 
indiscriminate disclosure. Most states have legal safeguards in place to further protect the information. 
 
 The information contained in the birth, death, and fetal death master index computer file is 
usually available to authorized public health programs. Sometimes confidentiality or security 
agreements are required.  
 Many states copy the legal sections of the hard copy certificate into a permanent electronic 
storage format (e.g., microfiche, film, CD-ROM). The storage format is cataloged for easy 
information retrieval.  
 
Strengths as a Data Source 
 
 Timeliness. Electronic filing allows information to be available to users as soon as the reports are 
filed in the state database. This may be as early as 30 days after the event.  
 Population base. Provides statistical and denominator data. 
 Unique identification. States assign a unique ID to each person, per vital event. 
 Legality of case report. State laws require that some information must be certified for all births 
and deaths. Additional attention to legal procedures is required for death registration.  
 Comprehensiveness as a data source. Over 97 percent of all births occur in a hospital or birthing 
facility. Out-of-hospital births are also registered because of the necessity for a child to have a 
birth certificate. There may be some underreporting of early infant deaths, and there is marked 
underreporting of fetal deaths at early gestational ages.  
 Existing data set and one that is accessible over time. There is historical depth to vital records, 
but there have been major changes in format, content, and coding over time. 
 Record linkage. Useful in combination with other data for building the case record. The use of 
unique identifying information permits matching and linking with other data sources. Many states 
routinely link vital records to each other, for example a death certificate with the birth certificate, 
providing a linked birth-infant death file.  
 Risk factor screening tool. Some data elements can be used to identify potential birth defects 
cases. Examples include: low birth weight, prematurity, low Apgar scores, neonatal death, 
multiple births. 
 Intervention. The availability of information in a timely manner is conducive to rapid intervention 
or investigation. 
 
Weaknesses as a Data Source 
 
 Data quality. Much of the medical information on the certificate has been shown not to be 
reliable. 
 Case ascertainment. The birth certificate has been shown to underreport birth defects. As shown 
in Section 6.4, rates from this source are 1.5 percent, compared to 3 to 4 percent for hospital 
reporting and from using linked data sources.  
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Liaisons and Partnerships 
 
 Vital records/registrar’s office. These are staff that are involved in managing the activities 
involved in filing the certificate. These staff often go to hospitals to train personnel in the 
procedures and methods of filling out the certificate. Other activities include amending a 
certificate, maintaining the centralized database, and cross-referencing other vital record 
certificates.  
 Hospital. These are staff that are involved in providing information for completing the certificate. 
Includes medical records services, neonatal nursing, labor and delivery unit staff.  
 
Hints and Tips 
 
 Neonatal and infant death. A death certificate is issued upon death for any infant who was live 
born, regardless of duration of the pregnancy. These individuals will have a birth and a death 
certificate. There is no distinction in death certificates for ‘neonatal’ or ‘infant’ deaths. Many vital 
records divisions cross reference the birth and death certificate numbers to make sure that a birth 
certificate is issued if a neonatal or infant death is reported. Sometimes, the facility will overlook 
filing a birth certificate for an early neonatal death. Sometimes a fetal death certificate is filed as 
well as a birth certificate and/or a death certificate. In these situations further investigation should 
occur to determine the actual vital status at birth.  
 The timing for filing birth and death certificates is similar. However, often the birth certificate is 
processed by vital records more quickly since many hospitals use the electronic birth certificate. 
It is important for birth defects programs to be aware of these timing issues if they refer children 
to services, especially if they refer children based on low birth weight, prematurity, and other 
severe conditions. Regardless of how quickly a case report is sent to the surveillance program, it 
is a wise practice to allow a period of time to elapse before referring a child with severe 
conditions. A time period to consider before referring a child to services is 60 to 90 days past the 
date of birth.     
 
 Fetal death certificate. This certificate is usually issued for any pregnancy that results in a non-
live outcome at the end of a pregnancy that is > 20 weeks gestational age. What constitutes ‘live’ 
is subject to legal definition, and most states have clear guidelines in state statutes for what is 
considered a ‘live birth’.  Some states accept any sign of life (e.g., a pulse), regardless of the 
intent for the delivery (e.g., elective termination). Surveillance systems need to understand the 
definition of ‘live birth’ in their state. There may be instances when an Apgar score is a very low 
number (e.g., 1) at the first minute, and 0 for the fifth minute. Some states might count this as a 
live birth or a termination, depending on the age of the fetus and intent of the delivery. Some 
states have guidelines that exclude filing a fetal death certificate if the intent of the pregnancy 
delivery is for a termination, regardless of the gestational age.  
 Termination reports. Some states collect statistical information on terminations. Often there is no 
identifying information; however, a birth defect may be listed as a reason for the termination. In 
most instances these reports do not have sufficient identifying information to link to an 
individual. Additionally, although some states require the filing of these reports, compliance is 
notably poor, such that there is an underreporting of these events and conditions.  
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Appendix 6.2 
Data Source Described in Detail – Hospital Data Sets 
Source or Site 
 
 Hospital discharge data set 
 Hospital admissions reporting system 
 Hospital disease index 
 
Discharge information is collected by the data source in a standardized format on individuals admitted for 
hospital-based services. This usually includes inpatient stays and outpatient surgery but may also include 
services performed in outpatient hospital clinics and emergency rooms. 
 
Legal or Professional Mandates 
 
 Federal law. The Health Information Portability and Accountability Act of 1996 (HIPAA) 
legislation defines electronic health care transactions, health information privacy and security 
standards, electronic signature codes, transaction standards and code sets, and unique health 
identifiers.  
 
 Other professional mandates dovetail with federal requirements (e.g., Joint Commission on the 
Accreditation of Healthcare Organizations, American Hospital Association). 
 
Mission or Objectives 
 
Discharge data are collected for a wide range of possible uses. These include population-mix studies, 
market share analysis, hospital charges comparisons, length-of-stay studies, disease-specific and clinical 
information-specific case volumes, health care delivery access analysis, and crude and severity-adjusted 
death rate analysis. Discharge data are also used indirectly for financial analysis and billing. 
 
Scope or Breadth 
 
These data result from ongoing data collection and include all inpatient encounters. Some hospital data 
sets may also include outpatient encounters. The age of population served is defined by the mission of the 
site (e.g., a children’s hospital may serve patients up to age 20 years). A discharge data set may consist of 
information from one hospital or may be a large statewide discharge data set of all hospitals. A record is 
created for each defined admission for hospital service. Discharge data sets are defined by a period of 




Information for the data set is collected from many places in the hospital, incorporated into the 
individual’s medical record, and compiled in a standardized format. Health information management or 
medical records departments are responsible for processing the information that results in the data record 
for each patient encounter and in ensuring that the medical record contains the required documentation 
(content). 
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Type of Information Collected 
 
Information included in this type of data set usually does not include patient names or Social Security 
numbers. The data elements collected, however, can lead one to a specific medical record. These data sets 
usually include: hospital identifier, patient medical record number, admission and discharge dates, patient 
type, patient date of birth, patient gender, patient’s residential location (e.g., zip code, county), insurance 
source, charges, physician type, diagnosis and procedure codes in ICD format, and length of stay. Other 
information may be collected depending on the objectives of the data set.  
 
Accessibility and Retrievability 
 
Hospital discharge data sets are computerized and are used to generate routine reports and to respond to 
ad hoc queries. Some hospitals submit their discharge data to a larger organization that collects data from 
each hospital and compiles the information into a single statewide hospital discharge data set.   
 
Strengths as a Data Source/Site 
 
 Existing database. Data are easily accessible, retrievable, and available in a computerized format. 
 Specific information. Specific data fields can be identified and extracted from the data base.  
 Cross-referencing. Available data fields provide information that can be used to locate the 
medical record.  
 Disease classification system. Information on discharge diagnoses and procedures is collected in 
a coded and standardized format, currently ICD-9-CM.  
 Timeliness. Data are usually available rapidly, within 6 months of discharge. Internet technology 
has increased accessibility and improved timeliness of data from this source for some states.  
 Consistency of the data set. Data fields are filled in as required for billing and for federal 
reimbursements.  
 Follow-up. Hospitals have unique medical record numbers for patients, facilitating tracking and 
monitoring of cases. 
 Screening tool. Specific data fields, especially ICD-9-CM disease and procedure codes, can be 
selected for further investigation. 
 
Weakness as a Data Source/Site 
 
 Discharge set bias. The discharge data set is an administrative database. Information is collected 
and compiled using procedures that suit a particular health facility or meet other legal 
requirements. It is a services-, planning-, and financial-based data set.  
 Population base. The service area and patient population for most hospitals are not well defined. 
Therefore, the relationship of the hospital’s patients to a larger group of persons is difficult to 
quantify. 
 Disease classification system. Some disease categories and codes for birth defects are not specific 
and are limited in scope.  
 Accuracy and clarity of diagnosis. Federal and professional standards are used to govern 
interpreting medical record documentation, which includes identifying a diagnosis and assigning 
a representative disease code. Suspected and rule-out conditions may be coded as a final 
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diagnosis at discharge, leading to overreporting. A diagnosis may not be recorded for many 
reasons. Underreporting may occur if not all of the diagnoses documented in the patient’s medical 
record are coded. 
 Personal identifiers. Externally recognizable personal identifiers usually are not available. Data 
elements can be used to locate medical records. Some states have adopted legislation to permit 
the reporting of identifying information directly in the discharge data set for specific reportable 
conditions (e.g., Colorado adopted regulations to permit named reporting from hospital discharge 
data). 
 Maternal information. Information on the mother is not recorded on the discharge data record for 
a newborn infant or child. 
 No medical record is generated. In some circumstances a medical record is not created. For 
stillbirths and even some neonatal deaths, a medical record may not be created for the infant. 
Information pertaining to the delivery outcome, including autopsy and laboratory reports, will be 
in the mother’s delivery medical record. However, the mother’s chart cannot be coded to reflect 
an infant’s medical conditions. Therefore, in these circumstances a birth defect diagnosis will be 
missed. Surveillance staff should use other data sources, such as the vital record, to identify a 
case where a medical record might not be created. 
 
Liaisons and Partnerships 
 
 Data processing unit. Hospital staff in a data processing unit manage the computerized 
information that is collected from various departments in the hospital. These persons can assist 
surveillance staff by accessing birth defects information that is stored in computer format. 
 State hospital associations. Some state hospital associations may serve the function of producing 
the statewide hospital discharge data set. They have a vested interest in providing customer 
service to a hospital by compiling aggregate statewide hospital data. Often these associations are 
also actively involved with the major users of the discharge data set (e.g., health departments, 
epidemiology programs, health planners).    
 Health information management and medical records departments. The hospital’s medical 
records staff are responsible for managing the information contained within a medical record. In 
addition to assembling the medical record and ensuring that it contains the required 
documentation, skilled personnel – coders – assign the disease classification codes and abstract 
pertinent information for administrative purposes (e.g., billing and the discharge data set). Since 
surveillance staff often use the disease classification codes to identify cases, it is helpful to 
maintain open communication with medical records departments regarding questions about 




The hospital discharge data set is facing significant changes due to evolving federal regulations, including 
HIPAA and the conversion of the disease classification from the ICD-9-CM system to ICD-10-CM. 
HIPAA requirements address electronic transmission of data, standard data elements, and privacy and 
security issues. ICD-10 is a larger and more complex disease classification system, one that will affect the 








American Hospital Association (AHA). http://www.hospitalconnect.com/ 
 
Health Information Portability and Accountability Act of 1996. 
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Appendix 6.3 
Data Source Described in Detail – Hospital and Patient Services Logs 
Source or Site 
 
 Hospital unit logs 
 Patient services logs (in non-hospital settings) 
 
Hospital units operate within a hospital or clinic and serve specific operational functions. Traditional units 
relevant to birth defects case ascertainment include Neonatal Intensive Care, Critical Cardiac Care, Labor 
and Delivery, and the Newborn Nursery. In some hospitals, units are their own departments, like 
Pathology and Surgery. A unit log is the documentation that provides information in general terms on the 
patients who used (or were admitted to) the unit. 
 
Legal or Professional Mandates 
 
 Legal – state statute. Hospital-based unit logs are operated in accordance with hospital licensing 
and accreditation.  
 Legal – state statute. Non-hospital-based unit logs (e.g., birthing centers, prenatal diagnosis 
referral centers, genetics clinics), are usually operated in accordance with licensing guidelines. 
 
Mission or Objective 
 
Determined by site. Logs are used to record specific events or health system encounters in a particular 
hospital department or facility setting. Logs may also account for equipment use. The log represents an 
inventory of events or activities.  
 
Scope or Breadth 
 
Logs are point-in-time accounts of events. The unit log accounts for each entry or use of services into the 
specific area. Most logs identify an entrance time, and an exit time, as well as other information specific 




Determined by site. Logs are designed to be read easily and to provide sufficient information to establish 
why the patient was in the unit or department.   
 
Type of Information Collected 
 
Determined by the site. Generally, logs are used by surveillance programs as a case identification 
screening tool. Most logs provide enough cross-referencing information to support follow-through or 
tracking. This includes name, date of birth, medical record or other identification number, and current 
date and time. Additionally, information is collected specific to the purpose of the encounter. Examples 
include: 
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 Labor and delivery log. Prenatal information, maternal risk issues, prenatal diagnosis, and event 
or outcome measurements. 
 Neonatal Intensive Care Unit (NICU) log. Event/outcome measurements, perinatal medical 
issues, diagnosis, other risk factors.  
 Surgery log. Preoperative diagnosis, possible risk factors. 
 Prenatal diagnostic center log. Prenatal information, referring physician, referring diagnosis, 
procedure, medical risk factors. 
 
Accessibility and Retrievability 
 
Logs are used as management tools within individual facility units. Therefore, information is gathered for 
and used by the unit and, possibly, by the facility. While some information may be collected and entered 
into a database, most logs consist of paper copy record books or reports.  
 
Strengths as a Data Source 
 
 Timeliness. Information is recorded in real time, as events occur. Rapid identification of potential 
cases is possible.  
 Consistency in recording information. The population base is well defined for each particular unit 
since each service encounter is recorded. For example, if a surgical procedure was performed at 
the site, a surgical log will record the episode. 
 Case identification screening tool. Generally, enough information is recorded so that surveillance 
staff can identify potential cases for further investigation.  
 
Weaknesses as a Data Source 
 
 Effort to retrieve the information. Generally, logs are kept in hard copy format and are based on a 
handwritten recording of events. Review of the information can be effort intensive. 
 Accuracy and clarity of clinical information. Information recorded may be inaccurate or 
incomplete with respect to diagnoses or medical conditions. For example, a prenatal ultrasound 
log may state ‘referred for cardiac irregularity’. 
 Documentation in the log. Information recorded on a log may be of limited use for case 
identification. Sites establish criteria for log documentation to meet internal or ward management 
objectives, not for disease coding. As such, the information is most relevant for immediate patient 
management rather than as a tool in medical diagnosis and treatment.  
 Different logs within the data source may provide conflicting information on the same patient. 
Surveillance staff should develop management tools to keep track of information recorded from 
different logs.  
 
Liaisons and Partnerships 
 
 Unit staff. These persons are usually front-line staff who work in the unit and have a use for the 
information that is recorded.  
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 Office staff. These are the persons at the unit who are usually responsible for compiling statistics 
for the unit and who monitor occupancy. They may be able to assist the surveillance staff in 
identifying efficient ways to access log information. For example, they may be able to generate a 
computer listing of the log or provide a photocopy of the log sheet.  
 
Issues to Consider 
 
Surveillance program time and efficiency issues. Unit logs usually require surveillance staff to spend time 
identifying potential cases on the log and following up by reviewing medical records. Case identification 
screening criteria and the quality of information included in a log are significant factors to consider when 
evaluating the amount of time spent on finding cases using this source. Inefficiencies result when follow-
up medical records reviews result in too many non-cases. Time and effort evaluations should be 
conducted for the case identification processes involved in using unit logs. 
Unit logs serve as a management tool for individual components of a facility. Therefore, a potential birth 
defects case may show up on multiple logs. It is useful to compare the information recorded at each unit 
within the data source and to develop a surveillance management tool that tracks case-finding activity. 
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Appendix 6.4 
Data Source Described in Detail – Genetic Services 
Source or Site 
 
 Regional/state genetics networks 
 Hospital-based genetics clinics 
 University-based genetics clinics 
 Provider-based genetics clinics 
 
Geneticists and dysmorphologists are skilled at evaluating a constellation of findings, providing 
differential diagnoses, and determining the definite medical condition. They use diagnostic procedures 
such as chromosomal analysis and genetic testing, as well as drawing from their personal experiences and 
extensive literature in evaluating a patient.  
 
The information from this data source is of high quality. 
 
Legal or Professional Mandates 
 
 Legal. State statutes for hospital-based clinics. These are operated in accordance with hospital 
licensing and accreditation.  
 Legal contract. Specified in individual contracts or collaborative agreements.  
 Professional. Certification and professional credential as required. 
 
Mission or Objective 
 
Genetic diagnostic and counseling services, therapeutic management of genetic diseases. 
 
Scope or Breadth 
 
Clinics may include prenatal, pediatric, and/or general population. Some may be specialized by disease 
category (e.g., Down syndrome, cystic fibrosis). Some providers include diagnostic and research 




Genetics clinics may be set up as a referral site (i.e., to provide a diagnosis back to the referring 
physician), for services (i.e., for ongoing treatment and consultation), or for research or study (i.e., 
database).  
 
Type of Information Collected 
 
Depends on the focus of the encounter (i.e., prenatal, pediatric, and counseling). As a rule, genetics clinics 
collect a core set of information for each patient, including demographic data and family medical history. 
A detailed physical exam and diagnosis, if known, as well as a case summary, is also usually available. 
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Copies of outpatient diagnostic tests and procedures may also be found. Clinics may use multiple disease 
classification systems depending on the diagnosis (e.g., ICD-9-CM, ISCN or International System for 
Human Cytogenetic Nomenclature, [Mitelman, 1995]) and/or use proprietary coding systems (e.g., 
POSSUM, Mendelian Inheritance in Man). Clinic charts may also include letters and notes from other 
physicians, results of research studies, or diagnostic testing that borders on research.  
 
Accessibility and Retrievability 
 
Usually the medical charts for clients/patients are available at the clinic site for review and abstraction. 
Many clinics collect information in database format for insurance purposes, clinic needs, and network-
wide data collection. Due to the nature of the information gathered, the data often are retained 
permanently. However, state statutes should be consulted for statute of limitations for health information. 
 
Strengths as a Data Source 
 
 Accuracy. High quality. The status of a diagnosis is qualified (i.e., the definite, rule out, possible). 
Although some patients never get a definitive diagnosis, the differential diagnosis is usually 
provided.  
 Level of detail. High quality. Specific information on syndromes (identification and description of 
dysmorphic features) and chromosomal anomalies is often provided.  
 Case identification. Specialty clinics, like those for genetics, are important outpatient data 
sources. Previously unknown cases may be identified for the surveillance program.   
 Case identification or screening. This is a useful source for prenatal diagnosis cases. Clinics may 
provide diagnosis and/or genetic counseling services.  
 Retrievability. Most pertinent information is entered into an electronic file (i.e., a database). This 
facilitates requesting specific pieces of information that can be extracted in electronic format.  
 
Weaknesses as a Data Source 
 
 Population base. May not be well defined. 
 Incomplete information. Nature of the clinic business or the clinic encounter determines whether 
the complete diagnostic picture is available (i.e., the case may be referred for cytogenetics 
laboratory confirmation only).  
 Timeliness of diagnosis. Some diagnoses are not confirmed until multiple diagnostic procedures 
have been conducted. Some syndromes take a long time to be diagnosed definitively.  
 Follow-up. Often a case is referred for consultation and is lost to future tracking. This is 
important if the diagnosis is reported to the surveillance program as possible or rule out and is in 
the continuing or discovery phase.  
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Liaisons and Partnerships 
 
 Genetic counselors. Clinics are often staffed by genetic counselors who contribute documentation 
concerning a patient’s evaluation. They are often accessible to surveillance staff if a medical 
records review or other follow-up is needed.  
 Database managers and other office administrators at clinic sites. Clinical information is often 
abstracted from documentation in the medical record for billing, research, or other clinic use. 
These persons can assist the surveillance staff in identifying efficient reporting and case 
identification methods.  
 Network system managers. Regional genetics information may be collected and compiled in a 
database. Like hospital discharge data, regional genetics information is collected from 
participating clinics in a standardized format and compiled in a centralized format. Surveillance 
staff can utilize the efficiency of accessing a centralized database and bypass having to collect the 
case reports from individual clinics. Of importance is the fact that data from these sources are 
unlikely to include personal identifiers     
 
Issues to Consider 
 
 Scope of information collected. Genetics clinics may collect information and provide a diagnosis 
that extends beyond the types of defects included in a birth defects surveillance system. Passive 
case ascertainment systems should be precise in specifying the diagnoses that are included in the 
program’s case definition and which are reportable. Active case ascertainment programs could 
improve efficiencies by developing a more precise list of diagnoses and medical conditions that 
can be used to screen for potential birth defects cases in the database or log of the clinic.  
 Confidentiality issues. Genetics information may be protected by additional federal or state 
statutes. The surveillance system should research applicable legislation, and if necessary, 
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7.1  Introduction 
The credibility of a birth defects surveillance program is built on a foundation of high-quality data. 
Information and results that are derived from surveillance data should be accurate, complete, and timely. 
Data quality influences the results of descriptive epidemiologic studies and, therefore, their interpretation. 
Data quality also affects the extent to which information can be utilized for planning, prevention, and 
intervention.  
 
In this chapter, we will discuss some of the issues that affect the quality of data in surveillance systems 
and suggest methods for quality improvement. In Section 7.2 we present criteria designed to produce 
high-quality data. In Section 7.3 we introduce some relevant terminology. In Section 7.4 we discuss the 
relationship between data sources and quality, and in Section 7.5 we outline the distinctions between 
timeliness on the one hand versus thoroughness and completeness on the other. Sections 7.6 and 7.7 
present various aspects of quality control and quality assurance, stressing the differences between the two. 
The importance of computer technology in support of quality improvement is particularly highlighted in 
Section 7.7. Nine specific quality improvements methods are discussed in detail in Section 7.8. 
References cited in this chapter may be found in Section 7.9. 
 
This chapter contains a Data Sources Descriptive Assessment Tool that may help surveillance staff 
systematically evaluate the various data sources available to them (Appendix 7.1). 
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7.2  Criteria for High-Quality Data 
High-quality data have a positive cascading affect on a surveillance program’s outcome measurements – 
such as accuracy, completeness, and timeliness – which, in turn, can be monitored as a means to improve 
program performance. The term quality has many definitions and interpretations depending on use and 
intent. Philip Crosby, a total quality management expert, defines quality as “the conformance to agreed 
and fully understood requirements” (Dale and Bunney, 1999). In the surveillance field, this translates into 
the identification of a target, bench mark, or goal that defines the requirements against which results are 
measured. 
 
Some experts in surveillance have suggested that the most important measurement indicators (or criteria) 
related to high-quality data are described by the mnemonic TACOMA (NAACCR, 2000). Data must be 
Timely, Accurate, Complete, Oriented, Measurable, and Applicable. The relative importance of these 
factors should be weighed and balanced, individually and in total, against the program’s objectives and 
resources.  
 
In the next section we define the terms on which the TACOMA mnemonic is based – timeliness, 
accuracy, completeness, oriented, measurability, and applicability – as well as several additional terms 
important for an understanding of data quality issues. 
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7.3  Terminology 
Timeliness  The extent to which data are rapid, prompt, and responsive. For example, a birth 
defect case should be ascertained or reported to the program shortly after 
diagnosis. With rapid case identification, the program is able to provide timely 
prevention and intervention services, respond quickly to investigations, and 
monitor trends. 
Accuracy  The extent to which data are exact, correct, and valid. For example, accurate 
diagnostic data affect a program’s ability to provide reliable disease rates and to 
maintain data comparable to those from other programs. Diagnostic accuracy 
reflects the program’s standard to conform to agreed-upon case definitions and 
requirements.  
Completeness  The extent to which data are all-inclusive and comprehensive. For example, are all 
of the cases of birth defects that occur within the target population, within a 
specified time period, identified by the surveillance system?  
Oriented  The extent to which data are focused, targeted, and intended. For example, 
programs should collect only those data that are appropriate to their goals and 
objectives. Programs should determine which data variables should be collected, 
how quickly they can be collected, and the resources available to be devoted to 
their collection. Having an oriented perspective parallels the ‘minimum necessary’ 
privacy standard of the Health Insurance Portability and Accountability Act or 
HIPAA (i.e., identify and use only what is necessary). (See Chapter 2 on 
Legislation for additional information on HIPAA and Chapter 4 on Data Variables 
recommended for consideration by birth defects surveillance programs.)  
Measurability The extent to which data are quantifiable, calculable, and objective. For example, 
the conformance to agreed-upon data definitions provides the foundation for 
quantitative evaluations.  
Applicability  The extent to which information is relevant. Outcome measurements should be 
designed to promote data utilization. Information derived from the data should be 
beneficial to the target population or to public health interests. 
Comparability  The extent to which the data in one data set conform with those in other data sets. 
For example, programs that agree to adhere to standard data definitions and case 
definitions produce data that can be evaluated and weighed against one another.  
Thoroughness The extent to which data collection activities are meticulous and exhaustive in 
completing a case abstract or case record. In other words, each data field on case 
abstracts and case records should be filled in.  
Outcome 
measurements  
Strategically planned results that may be quantitative or qualitative. Criteria, such 
as those described by TACOMA, or other defined factors, are specifically selected 
(and developed) to evaluate, track, and monitor a program target, goal, or 
benchmark. Desired outcome measurements are often developed in the planning 
stages of a surveillance program, for performance evaluations, and when adding 
new projects. Staff should identify the type or category of results to be measured 
in order to evaluate progress in achieving program goals and objectives (or study 
objectives, project targets, etc.). 
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7.4  Data Sources and Quality  
Depending on the case ascertainment approach, birth defects cases are found-at or reported-from data 
sources. Therefore, the importance of the role data sources play in case ascertainment and surveillance 
should not be underestimated.  
 
Quality issues surface because of variations among data sources. Some data sources may provide 
diagnostic information, but may lack important demographic information. Some may be service-focused, 
such that a precise diagnosis may not be important. Others may provide in-depth information on a 
specialty area, but may not identify other conditions that co-occur. Still others are administrative 
databases.  
 
A single data source has the potential to affect multiple outcome measurements. For these reasons, 
programs should evaluate each data source in order to describe its basic characteristics, as well as to 
identify its potential strengths and weaknesses. A descriptive assessment tool should be designed to 
answer specific questions about each data source in relation to surveillance requirements. An example of 
such a tool is provided in Appendix 7.1 (Data Sources Descriptive Assessment Tool). 
 
Quantitative evaluations should include outcome measurements for accuracy, completeness, and 
timeliness. Often data sources are evaluated in combination with other quality assessments. For example, 
diagnostic accuracy may be evaluated by staff reviewing a medical record to confirm a diagnosis that was 
identified-at or reported-from a data source. In this example, the data source is part of the evaluation 
because it is where the diagnosis case report originates; however, other aspects of the case ascertainment 
process may be evaluated as well.  
 
Examples of quantitative evaluations are provided in Section 7.8 of this chapter on Quality Improvement 
Methods.  
 
The program should: 
 Use the data quality criteria in TACOMA as a guide when identifying outcome measurements 
and when evaluating data sources.  
 Identify other factors that are important to consider, including those that relate to staff resources, 
such as ‘location of site’ and ‘volume of case reports’ (in relation to distance traveled). 
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7.5  Timeliness Versus Thoroughness and Completeness  
Surveillance systems generally have limited resources to use in meeting program objectives. Additionally, 
staff face dilemmas in terms of prioritizing resources to achieve the outcome measurements of timeliness, 
thoroughness, and completeness. Should a program set a goal of timely data at the risk of potentially 
missing cases? Or risk losing timeliness by setting a goal of the most complete surveillance database? It is 
important for programs to achieve a balance that suits their needs, while also being responsive to external 
requirements, such as guidelines for submitting data to the National Birth Defects Prevention Network 
(NBDPN), as discussed in Chapter 10 on Data Collaboration and Dissemination. 
 
Timeliness improves a system’s ability to be responsive for investigations, up-to-date for monitoring 
trends, and current for referral to services. Thoroughness is a measure of finished versus unfinished case 
abstracts and case records. Clearly, data fields that are empty or inconclusive are not useful for most 
outcome measurements. Completeness is important because descriptive epidemiology – including the 
calculation of birth defects rates – is more comparable, accurate, and reliable when a surveillance 
program is confident that all cases have been ascertained.  
 
When prioritizing resources to balance the quality indicators of timeliness, thoroughness, and 
completeness an important outcome measurement recommended by NBDPN is that the surveillance 
database be 95% complete by two years past the date of birth or fetal demise. Some programs may have a 
longer time period for reporting birth defects and, therefore, have a longer time period for case 
ascertainment. Still, it is important that surveillance systems be sufficiently responsive so that complete 
and timely data can be turned into useful information.  
 
Programs should evaluate the factors that impact timeliness, thoroughness, and completeness. Often 
resources can be used more efficiently and effectively by streamlining or redeveloping procedures in 
individual areas, such as case finding, data collection, and data processing (see Section 7.8 on Quality 
Improvement Methods). 
 
Timeliness, thoroughness, and completeness are often intertwined and affect other quality assessments. 
For example, the quality control methods that evaluate case finding and case abstracting may include 
outcome measurements for timeliness and thoroughness. Data source evaluations include a timeliness 
measurement.  
 
The program should: 
 Develop productivity guidelines and standards.  
 Use TACOMA criteria, especially ‘oriented’ and ‘applicable’, to assess the factors that challenge 
timeliness and completeness.  
 Use computer technology to improve timeliness. For example, consider using the Internet for case 
reporting. Internet and electronic reporting also ease the burden of case reporting at data sources. 
 Monitor timeliness.
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7.6  Quality Control and Quality Assurance 
‘Quality control’ (QC) and ‘quality assurance’ (QA) can be defined as a set of methods, activities, and 
procedures designed to improve the results of specific outcomes. For birth defects surveillance programs, 
these outcomes are related directly to surveillance functions, such as case ascertainment and data 
collection. Although active and passive case ascertainment systems may use different methods and 
procedures for improving data quality, the goal is the same, namely high-quality data.  
 
Quality control is a retrospective and reactive approach to improvement that focuses on discovery and 
detection. Deficiencies and inaccuracies are found, resolved, and fixed so that final results or outcome 
measurements are accurate. As a result of QC procedures, high-quality data are created at the back end. In 
QC, the emphasis is on checking, investigating, containing, and adjusting (Dale and Bunney, 1999).  
 
QC procedures may include re-case finding, re-abstracting, validity audits, timeliness monitoring, and 
data source evaluations. QC can also be used with data linkage, especially as this involves checking 
selected data fields, including birth weight, date of birth, name, etc. The results of QC procedures are used 
to evaluate, adjust, or correct the original data that were collected or the original circumstance that 
occurred.  
 
Quality assurance is a proactive approach to improvement that focuses on prevention. Program functions 
are designed and activities are planned in advance to avoid inaccurate or deficient data. As a result of QA 
procedures, high-quality data are created at the front end or design stage. Often, the results of a QC 
method lead to QA activity. The QC method detects a deficiency, and the QA method redesigns the 
process to prevent its recurrence (Dale and Bunney, 1999).  
 
QA procedures may include documentation (e.g., case finding, abstraction, medical records review, 
disease coding, data entry), the use of selective data sources, and the development and maintenance of the 
database infrastructure. Additionally, QA procedures can be implemented when specific outcome 
measurements require consistently high-quality data. Examples include (1) using an expert clinical 
reviewer to routinely evaluate case abstracts for data accuracy and thoroughness and (2) conducting 
medical records reviews to confirm a diagnosis prior to the data being used for projects like rapid case 
ascertainment, investigative inquiries, or statistical monitoring of trends. QA is cost efficient in the long 
run. Finding and solving problems can be time consuming and resource intensive, and unless the process 
is fixed, the same problems will continue to recur.  
 
Maintaining high-quality data requires continual attention to improvement. Program performance is 
enhanced when quality improvement procedures are integrated into program operations and conducted in 
a consistent and systematic manner.  
 
Refer to Section 7.8 (Quality Improvement Methods) in this chapter for specific examples of quality 
control and quality assurance applications.  
 
The program should: 
 Maintain documentation on program procedures, especially as these affect case ascertainment 
and data collection activities. 
 Record and date decision items. 
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 Identify the sources of potential data quality issues and prioritize the impact of each on case 
ascertainment and surveillance. Some situations are provided in the ‘quality issues’ sections in 
other chapters in these guidelines.  
 Use the TACOMA quality indicators to develop outcome measurements for evaluations. Of 
particular importance are quantitative evaluations of accuracy, completeness, and timeliness. 
 Design meaningful evaluations, develop benchmarks, and track improvements. Quality 
assessments should be used to guide any decision to change or modify the program’s practices 
and procedures. 
 Use the results of quality control to design quality assurance procedures. Quality assurance is a 
self-propelling mechanism that ensures continual quality improvement.  
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7.7  Quality Control and Quality Assurance in the Surveillance Database 
Computer technology provides many opportunities to implement quality control and quality assurance 
procedures. Computerization can promote standardization, perform queries on selected criteria, monitor 
timeliness, reduce duplication, and generate reports.  
 
Quality assurance can be built into the design, development, maintenance, and expansion of the 
surveillance database. It is essential that the computer system address, at a minimum, the requirements of 
case ascertainment and data collection, data entry, information management, and statistical analysis. The 
system must also ensure security and privacy for the health information that is stored electronically (see 
Chapter 9 on Data Management and Security). 
 
A database system should be documented thoroughly, with methods in place to track changes in 
procedures and processes and to identify security safeguards.  
 
Standardization of data variables is an important quality assurance procedure. Data fields should have 
discrete definitions, and programs should standardize the information in a data field with unique codes or 
pre-formatted text. Drop-down windows can assist with this by providing choices and by placing limits 
on the options for the data field. Drop-down windows also prevent keying errors during data entry. Data 
fields can be programmed to perform logic checks for dates, time, age, gender-specific disease codes, and 
geographic information. Calculations can be programmed into data fields for measurements (such as 
weight, height, and head circumference) or can be programmed to complete a ‘missing’ measurement for 
a data field. 
 
Software technology can also provide excellent resources for quality control. Procedures can be 
developed to monitor timeliness, productivity, and progress. Transaction logs can be used to monitor key 
activities and tasks. A posting-date field can be used to track staff entries as the case ascertainment 
process proceeds. Posting fields can also be used to monitor data source reporting trends, data collection 
activities, and data processing functions.  
 
Any number of outcome measurements can be developed to track quality indicators, including measuring 
accuracy and completeness. Additionally, computer technology is uniquely suited to detect duplicate 
cases in the surveillance system. Information can be cross-linked on many different data fields, including 
name, date of birth, hospital of birth, mother’s maiden name, etc.  
 
There are almost limitless ways that computer technology can be used in quality control. The database 
integrates and supports surveillance activities. As such, the inputs and outputs of the database play a role 
in each TACOMA quality indicator. A well-designed database improves program efficiencies, outcome 
measurements, and data utilization (see Section 7.8 on Quality Improvement Methods). 
 
The program should: 
 Identify situations in case ascertainment and data collection where computer technology can be 
used to detect or prevent problems and to track measurements.  
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7.8  Quality Improvement Methods 
Methods to measure and ensure high-quality data may vary depending on the approach to case 
ascertainment.  
 
In active case ascertainment, field staff engage in the process of case identification, including gathering 
information and confirming a diagnosis for the case abstract. Quality control is directed at improving the 
way staff ascertain cases. In passive case ascertainment, the surveillance system receives case reports 
from data sources. Staff are not engaged in collecting the information on a case report. Additionally, a 
diagnosis reported on a case report is not usually confirmed prior to entry into the database. Therefore, in 
passive case ascertainment, quality control is directed at improving the results of the data collection 
process.  
 
Although the ascertainment approaches are different, quality control and quality assurance methods can 
be used to achieve comparable levels of data quality across surveillance programs regardless of the 
ascertainment approach used. 
 
While the list is not all inclusive, some of the methods used most frequently by birth defects surveillance 
programs for quality control are described below. Some are useful regardless of the case ascertainment 
approach and can be modified to suit the specific programmatic needs.  
 
On the following pages we describe the following quality improvement methods in detail: 
 Re-case finding 
 Re-abstracting 
 Validity audits and medical records reviews 
 Clinical review 
 Reliability and inter-rater agreement checks 
 Timeliness measurements 
 Data source evaluation 
 Comparison/verification between multiple data sources 
 Computer technology 
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Improving Quality through Re-Case Finding 
 
Purpose To evaluate the accuracy and comprehensiveness of the case-finding process. 
  
Background The case-finding process, used primarily in active case ascertainment, involves 
staff identifying potential birth defects cases at data sources. 
  
Method For re-case finding, perform the same steps and functions as for case finding. 
Develop procedures to evaluate results from the different pathways and steps in 
the process. Re-case finding should be conducted on a sample of information 
sources. The sample should consist of an appropriate number of entries, either 




• Evaluation of results between the original case-finding activity and the quality 
control process. This includes calculating the false positive and false negative 
rates at different steps in the case-finding process. In other words, this QC 
procedure evaluates the decision making that results in identifying a case 
versus a non-case. 
○ Compare the QC list and the original staff review list of potential cases 
found at a data source during initial case finding. This is the list that 
identifies which cases go on to a medical records review and which do not. 
○ Compare the results of re-reviewing the medical records. This involves 
QC re-reviewing medical records that were selected for review during the 
original case-finding activity and reviewing (for the first time) some 
medical records that were not on the original staff review list.   
○ Determine the timeliness of the case-finding process. 
• Evaluation of compliance with case-finding procedures, including assessing 
decision-making skills. 
  
Frequency It is important to develop a benchmark for re-case finding and to monitor outcome 
measurements periodically. The frequency with which re-case finding is conducted 




• Update case-finding procedures.  
• Streamline the process to improve timeliness. 
  
Tips The case-finding process is a critical step in case identification. Not only is it 
important to evaluate staff effectiveness in identifying cases (and not missing any), 
it is also recommended that programs evaluate program efficiencies in case 
finding. For example, programs should evaluate the types of conditions that are 
considered potential cases. An evaluation might consist of determining how many 
confirmed diagnoses resulted from using a ‘potential condition’ in the initial steps 
of case finding. Some programs include ICD codes (i.e., searching through a 
hospital’s disease index) as ‘potential conditions’. An evaluation might consist of 
evaluating the effectiveness of searching using disease codes to identify a potential 
case in relation to whether specific codes were predictive in identifying a true birth 
defects case (i.e., an abstract is created). 
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Improving Quality through Re-abstracting 
 
Purpose To evaluate the accuracy and comprehensiveness of information that is entered 
on a case abstract form (hard copy or computer screen). 
  
Background Abstracting, used in active and passive case ascertainment, is the process of 
gathering and recording specific information from logs, medical records, or other 
information sources onto standard case abstract forms or computer screens. 
  
Method For re-abstracting, gather and abstract information from the same information 
source and record the data using the same abstract format (e.g., hard copy or 
computer screen). Re-abstracting should be conducted on a sample of information 




• Comparison of the results of the quality control method to the results from 
the original case abstract and evaluation of the differences. Evaluation of the 
percentage and type of false positive cases.  
• Identification of types and categories of errors or deficiencies. This may 
include disease coding, incomplete or missing information, and data entry 
errors. Includes the types of data variables that are problematic.  
• Evaluation of compliance with abstracting procedures and guidelines. 
• Determination of the timeliness of the abstracting process. 
  
Frequency It is important to develop a benchmark for re-abstracting and to monitor outcome 
measurements periodically. The frequency with which re-abstracting is conducted 




• Update case abstracting guidelines. 
• Provide training in disease coding, as applicable. 
• Incorporate additional standardization into the data entry process. For 
example, provide drop-down windows to select and limit choices and to 
prevent key stroke errors.  
  
Tips Conduct an abstraction form review to identify differences and errors on 
completed abstraction forms. The abstraction forms should be checked for 
completeness, logic, and correct coding. Additionally, it is useful to categorize 
the types of data variables that are problematic to abstractors. For a given time 
period, QC should document, for each field staff member, the total number of 
abstraction forms reviewed and the number that have errors, such as incomplete 
or illogical data and incorrect coding.  
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Improving Quality through Validity Audits and Medical Records Reviews 
 
Purpose To evaluate the accuracy and comprehensiveness of a diagnosis that is reported 
by a data source or represented in a listing (e.g., hospital disease index) at a data 
source. 
  
Background In programs using passive case ascertainment, birth defect cases reported by data 
sources are accepted without confirmation. Active case ascertainment systems may 
use a listing of diseases provided by data sources, in disease-coded format, as part 
of case finding. 
  
Method The medical record, or other medical information report, is reviewed at the site or 
data source that reported the diagnosis or provided the diagnosis in a listing. This 




• Predictive validity. This is the degree to which an original measurement (e.g., 
reported diagnosis) successfully predicts a valid or confirmed outcome of 
interest. In other words, it represents agreement between the case report from 
the data source and the medical records review performed by surveillance 
staff.  
• Evaluation of missed diagnoses. In other words, how many more diagnoses 
were identified by the medical records review process.  
• Identification of disease-coding issues, especially as this pertains to data 
sources that report birth defects in a coded format (e.g., administrative 
databases such as the hospital discharge data set).  
• Incorporation of an evaluation of the data source with the validity audit. 
• Timeliness of the review process. 
  
Frequency Passive case ascertainment systems rarely have the resources to confirm all 
reported cases through medical records review. Therefore, the frequency of 
validity audits depends on program resources, requirements, and priorities. 
However, it is important to develop and maintain a certain level of validity audits. 





• Identify and use data sources that report a confirmed diagnosis. 
• Select diagnoses for consistent, concurrent, and timely validity audits. It is 
recommended that the diagnoses be from the set of birth defects that are 
reported to NBDPN. This QA procedure is primarily for passive case 
ascertainment systems. 
• Identify disease codes that are problematic for describing birth defects 
precisely. Prioritize which ones should have a consistent validity audit. This 
QA procedure is applicable for passive case ascertainment systems that use the 
ICD-9-CM coding system, and can be adapted to accommodate active case 
ascertainment programs that use the hospital disease index during case finding.  
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Improving Quality through Validity Audits and Medical Records Reviews 
(continued) 
  
Tips Validity checks are a quality control tool. Although used primarily by passive case 
ascertainment systems, the tool is relevant for active ascertainment programs as 
well (e.g., active ascertainment key data entry systems or on-line abstracting). 
Validity checks in birth defects surveillance provide a way of evaluating the 
accuracy of what was reported (or represented) compared with what was 
‘validated’ or confirmed after an investigation or medical records review. 
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Improving Quality through Clinical Review 
 
Purpose To review the diagnoses listed on the case abstract or in the case record for 
accuracy and plausibility. 
  
Background Information on birth defects cases is gathered and compiled by staff in active case 
ascertainment. Information is reported and collected from data sources in passive 
case ascertainment. 
  




• Evaluation of the information recorded on the case abstract. 
• Identification of abstracting or coding problems. 
• Percentage and types of agreement or disagreement with clinical review 
result. 
  
Frequency Programs should develop a benchmark for volume and types of case abstracts 
that should be reviewed and monitor the rate of agreement. In other words, the 
program should determine whether all case abstracts should be reviewed, or 




• Update and standardize abstracting and disease coding procedures.  
• Train staff in the deficiencies cited and evaluate compliance concurrently.  
• Increase the volume of clinical reviews, as required.   
  
Tips A clinical reviewer should be proficient at disease coding since the literal text of 
the diagnosis needs to be translated into the most accurate disease code.  
 
In passive case ascertainment, the medical records from all data sources that 
reported a diagnosis for a respective birth defect case should be available to the 
clinical reviewer. Document the policies and procedures for the clinical review to 
ensure standardization. Include instructions for assigning the disease code.  
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Improving Quality through Reliability and Inter-Rater Agreement Checks 
 
Purpose To evaluate rate of agreement between two or more persons for the outcomes of 
interest. 
  
Background Results of case ascertainment and data collection should be consistent, especially 
when staff are required to make abstracting decisions. 
  
Method • Dual-entry coding system (double-checking of assigned code). At least two 
coders assign codes from the same list of diagnoses.  
• Dual-entry data entry. At least two staff key information from the same case 
abstract into the surveillance database.  
• Dual clinical review. At least two clinical reviewers examine the same 
abstracts and provide results.  
• Dual medical records reviews. At least two staff review the same medical 
records and abstract information per program procedures. This may include 
evaluating disease code assignments. Some passive case ascertainment 
programs may benefit by including a clinical expert in this inter-rater 




• Rate of agreement 
• Type of deficiencies 
• Compliance with abstracting and other program procedures 
  





• Write precise procedures.  
• Develop decision-making flow charts. 
• Train staff with respect to addressing any deficiencies noted. 
• Develop standardized data definitions for each data element. When 
applicable, develop a list of acceptable responses for a data element. Use 
drop-down windows to facilitate selecting from a list. 
• Use technology to increase the accuracy of abstracting and data entry. 
  
Tips Keep a log of decision-making items and make sure it can be referred to easily. 
This is important for abstracting and coding procedures. Update procedure 
manuals, date-stamp all changes. When disease reporting rules or procedures 
change, make the changes effective as of the beginning of a calendar year. 
 
 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 06/04 
 
Chapter 7     7-16            Data Quality 
Improving Quality through Timeliness Measurements 
 
Purpose To evaluate rapidity and readiness. 
  
Background All areas of case ascertainment and data collection affect how responsive the 
program is in meeting goals and objectives with respect to timeliness. 
  
Method The time interval between two or more points of interest is measured. Often the 




Timeliness measurements can be used to evaluate and improve many areas within 
a surveillance program including productivity and program performance. 
Examples include:  
• Reporting time lags. A measurement of the time it takes for a case report to 
be received-in or identified-to the birth defects program.   
• Case-finding process. An evaluation of the time it takes to identify a case, 
review the medical record(s), abstract information, and complete the abstract.   
• Data processing time lags. A measurement of how quickly information is 
processed for use. 
  
Frequency Timeliness can be evaluated readily. Tracking measurements can be monitored 
using software technology and developing date-posting fields. Queries, internal 




• Implement changes to case ascertainment procedures or processes to improve 
timeliness. 
• Use laptops to reduce redundant steps. 
• Work with data sources to improve consistency in reporting, including using 
electronic case reporting and Internet reporting.  
• Develop computer transaction logs. 
  
Tips Evaluate the program’s desired outcome measurements in relation to how long it 
takes to achieve them. Use the criteria in TACOMA, especially as they relate to 
improving timeliness. For example, the criteria ‘oriented’ and ‘applicability’ 
focus on selecting data variables that are important to the program. Include an 
evaluation of the reasons for unfinished case abstracts or case records. Data 
variables that consume a great deal of resources to collect should be re-evaluated 
for intent and usefulness.  
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Improving Quality through Data Source Evaluation 
 
Purpose To ensure that birth defect case reporting is complete, accurate, appropriate, and 
within the guidelines for timely reporting. 
  
Background Birth defects are found-at or reported-from data sources. Data sources vary in 
purpose, organizational structure, and scope. 
  
Method The source of the diagnostic information is evaluated for accuracy, completeness, 
and timeliness. This method may combine the methodology of other procedures, 
such as validity audits and timeliness measurements, and may also include re-case 
finding. 
• Accuracy. The medical record, or other medical information report, is reviewed 
at the site or data source that reported the diagnosis or provided the diagnosis in 
a listing (see Validity Audits).  
• Accuracy. For a large data source, such as hospital discharge data (an 
administrative data base), the audit may be designed to focus on a suspected 
hospital or unusual patterns of disease-code use. 
• Timeliness. Time lags for reporting are evaluated per data source.  
• Completeness. Passive case ascertainment  utilizes the steps taken in active 
case-finding to identify all of the potential and confirmed cases of birth defects 
at the data source. This procedure is more difficult for passive case 
ascertainment to implement because of the staff resources needed to conduct 




• Completion of the descriptive assessment of the data source. 
• Refer to validity audits and timeliness audits. 
• False positive rate. What is the level of diagnostic quality from a data source? 
• Completeness rate. What is the rate of missed individuals with birth defects? 
These are individual cases that were not reported-to or identified-at the data 
source.  
• Evaluation of data collection methods. Is the format used for reporting cases 
contributing to missed case reports? 
  




• Use multiple data sources. One data source rarely provides comprehensive 
information. 
• Use data sources that report a confirmed diagnosis.  
• Involve the data source in discussions related to quality indicators. Develop 
mutually agreed-upon strategies for resolving issues.  
• Encourage data sources to report cases in an electronic format, including using 
the Internet. This may improve timeliness and completeness. Confidentiality 
and privacy can be assured via encryption and other safeguards. 
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Improving Quality through Data Source Evaluation 
(continued) 
  
Tips Staff from programs using passive case ascertainment often review medical records 
in medical records departments, and some review autopsies at pathology 
departments. However, these staff usually do not engage in case-finding (i.e., 
combing through information sources to find potential cases of birth defects). 
Passive ascertainment staff should engage the data source in discussions prior to a 
case-finding audit. It is important to involve staff at the data source in planned 
activities to answer their questions. A contact person at the data source should be 
identified to ensure minimal disruption of normal work flow once the case-finding 
process begins. 
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Improving Quality through Comparison/Verification Between Multiple Data Sources 
 
Purpose To compare diagnosis, and other information, that is reported-from or 
identified-at different data sources. 
  
Background Programs are encouraged to use multiple data sources for case ascertainment. A 
single data source is rarely able to provide comprehensive or accurate 
information. 
  
Method • Compare information that is collected from multiple data sources in order 
to determine what information is accurate and complete. Examples include: 
○ Confirm or invalidate a diagnosis based on a higher level of diagnostic 
expertise or clinical specialty. For passive case ascertainment this could 
mean that a diagnosis that is reported from a high-quality data source is 
considered to be confirmed or valid.  
○ Clarify an incomplete or imprecise diagnosis. Conduct follow-up to 
gather better information.  
○ Identify incomplete data fields on the case abstract or case record. Some 
data sources may not have complete information on a birth defect case, 
which results in an incomplete or deficient case report.  
○ Update the case abstract or case record with more timely information. 
This includes address, names, and contact information. 
• Develop procedures to identify duplicate case abstracts or case records in 
the database. Common situations that result in duplicate case abstracts or 
case records are mistakes with date of birth, use of multiple or incomplete 




• Rate the data sources. Assign ‘quality’ grades for specific criteria (e.g., 
diagnosis quality, complete address). 
• Evaluate the value-added benefit that a data source provides. For example, 
if two data sources identify the same cases but one source provides a higher 
total volume of cases, evaluate the rationale for using both data sources.  
  
Frequency The use of multiple data sources is strongly encouraged. However, a 
surveillance program needs to understand the potential differences in quality 
among data sources and adjust procedures accordingly. In active case 
ascertainment, the comparison and verification of information can be done in an 
ongoing manner. In passive case ascertainment, where each case report may not 
be read by staff upon receipt, a benchmark should be established and key 
factors evaluated. At a minimum, comparison and verification should be done 
annually; otherwise the volume of inconsistencies or differences may turn into a 
resource-intensive effort to reconcile them. Computer technology greatly 
enhances a program’s ability to systematically conduct comparison and 
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Improving Quality through Comparison/Verification Between Multiple Data Sources 
(continued) 
  
Quality Assurance • Combine or merge data that are collected or abstracted into a central case 
abstract or case record upon receipt. This minimizes the possibility of 
creating a duplicate abstract or record and reduces redundant staff work.  
• Develop data linkage procedures for the large administrative, computerized 
data sets, such as vital records, hospital discharge data, hospital disease 
index, and Medicaid. Data linkage can also be developed to accommodate 
smaller clinic-based information systems, such as cytogenetics laboratories, 
genetic services, and specialty clinics. A key factor in data linkage is using 
standardized data variables (see Chapter 4 on Data Collection Variables). 
• Develop decision-making and hierarchy models for use in comparison and 
verification of data elements. Programs should determine which data 
sources are considered a high-quality information source for specific data 
variables.  
  
Tips This QC method is enhanced by using computer technology and developing a 
systematic approach. 
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Improving Quality through Computer Technology 
Purpose To use technology in quality improvement efforts. 
Background Surveillance systems are information management systems whose operations are 
enhanced by computer technology (see Chapter 9 on Data Management and 
Security). 
Method • Quality assurance. Use software to prevent problems and enhance 
standardization.  
○ Build in range checks to prevent inaccurate abstracting and data entry. 
These checks can be created for any data variable with a defined parameter 
of acceptable or measurable values. Date range checks can be used for age, 
date of birth, date of fetal demise, date of death, LMP (date of last 
menstrual period).   These become the dates that other dates (e.g., date of 
case report) are compared to for rationale. Other types of range checks are 
Apgar scores, gestational age, and birth weight.  
○ Develop automated calculations and conversions for specific data fields. 
Examples include birth weight, time and LMP .  
○ Promote the use of coded data. Develop codes for text information. This 
method can be applied to any data variable definition that has multiple 
acceptable responses. Examples include disease, geographic, race, and 
ethnicity codes. Programs can develop code sets for data sources, specific 
sites, types of procedures, family history, physicians, etc  
○ Use drop-down windows for data fields. This approach is useful with long 
text entries and for text that has been converted to a code. 
○ Use standard data collection variables (and data definitions), to 
accommodate record linkage and electronic transfers (see Chapter 4 on Data 
Collection Variables). 
• Quality control. Develop procedures to detect, measure, and enhance 
effectiveness.  
○ Perform logic edits. Review existing program documentation and syntax to 
ensure that the computer application is performing as intended. For 
example, when computer applications are used to convert or calculate data 
field values, make sure the results using the formula(e) are accurate.  
○ Create date-posting fields to monitor timeliness. 
○ Develop transaction logs. This is a method that tracks and dates additions, 
deletions, and other changes to the database.  
○ Create queries and reports to track desired outcome measurements. 
○ Develop methods, using key data variables, to find duplicate cases in the 
database. 
○ Develop queries to identify problem situations. Examples include:  
– Some birth defects should not be counted due to prematurity or low birth 
weight. 
– Some ICD codes are problematic for birth defects.    
○ Develop information management systems to improve the efficiency of 
program operations, including case ascertainment.  
○ Develop methods to improve timeliness of case reporting. This includes 
using Internet reporting and other electronic methods, with appropriate 
security measures to protect confidentiality and privacy. 
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Track measurements from the QC and QA methods that are developed.  
Frequency Once developed, computerized quality procedures can be run on a consistent and 
systematic timeframe. Systems and software also facilitate flexibility for ad hoc 





Design, maintain, and update to:  
• Prevent problems at the source 
• Promote standardization 
• Improve program efficiencies, including timeliness 
• Facilitate data retrieval and analysis 








A dilemma that primarily affects passive case ascertainment programs is how to 
retain the integrity of the database, while also resolving data quality problems. In 
other words, how do programs identify and use accurate information, especially 
since the majority of diagnoses in the data base are accepted as reported (i.e., not 
confirmed by staff)? For example, if a diagnosis is reported from a data source and 
is determined to be inaccurate, or incomplete, it should not be counted in statistical 
analysis. However, for epidemiological and evaluation purposes, this diagnostic 
information (and the associated information that accompanies the case report) 
should not be deleted from the database. A method to resolve this issue could be to 
develop a mechanism (perhaps a data field) that identifies or flags a diagnosis that is 
not accurate (valid) or should not be counted. Programs are encourage to develop 
methods to resolve these kinds of issues in a way that best suits the program’s 
needs. 
  
Tips • Before building a computerized data collection system evaluate the current 
manual data collection instrument to determine what works and what doesn’t 
work.  
• Avoid programming an on-line data collection system based on your hard copy 
instrument. Once programming is completed, it is often difficult to undo.  
• Prior to developing and expanding the data base, evaluate the program’s needs, 
i.e., how the data will be used, how the data will be accessible, data transfer, etc. 
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Appendix 7.1 
Data Sources Descriptive Assessment Tool 
Title of Data Source: 
 
 
Evaluation Criteria Trait Explanation and Description of 
Criteria 
Specifics for This Data 
Source 
 
Source or Site 
 
 
The Source or Site is briefly defined  
 
Legal issues or professional 
requirements that govern or guide 





• Statutes or regulations  
• Accreditation agencies (e.g., 
JCAHO) 
 
• State licensing boards  
Legal or Professional Mandates 
• Federal agency requirements 




Purpose or reason that the Source or 




Mission or Objective 
• How is the information used?  
 





Scope or Breadth 
• What time span does the Source 




Flow of information is described  
 
• Where is the information 
collected? 
 
• Who collects the information?  
• When is the information 
documented? 
 




• How is the information stored?  
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Evaluation Criteria Trait Explanation and Description of 
Criteria 
Specifics for This Data 
Source 
 
Type of information collection is listed  
 
Type of Information Collected 
• Unique pieces of information that 
the Source or Site collects are 
listed 
 
Location of the information  
 
 
• Accessibility to the information  
• Retrievability of the information  
Accessibility and Retrievability 
• Data base, records merging, and 




The strengths and attributes of this 
Source/Site are described 
 
 
• Accuracy of the information  
• Completeness of the information  
• Timeliness of the information  
• Efforts and resources required 
for case finding 
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8.1  Introduction 
Statistics are useful to surveillance programs for: 
 Summarizing and comparing surveillance data 
 Assessing the potential role of chance or random variability 
 Controlling for the effects of extraneous factors 
 
The objective of this chapter is to present some common statistical concepts and tools that can be applied 
to surveillance data. For each tool, a definition is provided, along with background information, 
guidelines for use, how to calculate, and an example. This is a basic introduction only; more exhaustive 
treatment of these topics can be found in the reference literature.  
In Section 8.2 of this chapter we discuss measures of birth defect occurrence. General issues relating to 
prevalence are discussed in Section 8.3, with the distinctions between crude prevalence, specific 
prevalence, and adjusted or standardized prevalence presented in Section 8.4. Various approaches to 
presenting and displaying descriptive epidemiology are described in Section 8.5, while confidence 
intervals and their calculation are discussed in Section 8.6. Finally, in Section 8.7 we discuss means to 
rule out straightforward explanations for observed changes in the prevalence of a birth defect. References 
cited in this chapter may be found in Section 8.8. 
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8.2  Measuring Birth Defect Occurrence 
In carrying out basic epidemiologic and statistical assessment of birth defects occurrence, the analyst 
needs to decide what to count (issues of case definition are discussed in Chapter 3) and how to use those 
counts in calculations. This section presents some basic concepts, clarifies definitions with respect to 
analysis and reporting, and presents alternatives to the standard methods used to measure birth defects 
occurrence, birth prevalence. 
8.2.1  Multiple Birth Defects in the Same Child 
Analyses of birth defects surveillance data should be based on cases. An infant or fetus can have multiple 
birth defects and can be counted as a separate case for each defect. Thus, an infant/fetus with anencephaly 
and cleft lip should be counted as a case of anencephaly, and again as a case of cleft lip. When using this 
approach, it is important to recognize that the number of different cases cannot then be added to reach a 
total number of infants/fetuses.  
 
When an infant/fetus has two or more conditions coded in the same category in an analysis, count it once 
only. For example, if an infant has atrial septal defect and ventricular septal defect. Count the infant once 
in tabulations for atrial septal defect, and once in tabulations for ventricular septal defect. Additionally, 
count the infant only once in tabulations for cardiac defects. 
8.2.2  Counts, Ratios, Proportions, and Rates 
The most common measures of birth defect occurrence are counts, ratios, proportions, and rates. 
 
Counts. Counts present the simple enumeration of cases. Such information can be useful for health 
planning purposes, where it is important to measure the burden of birth defects on existing health care 
resources, to assess the need for additional resources, and for cluster investigations. However, simple 
counts of cases are not of value as a measure of disease risk, for which rates are necessary. 
 
Ratios. A ratio is composed of one number (the numerator) divided by another (the denominator). Ratios 
can be useful for comparing the number of cases in one population group with the number in another. 
Proportions and rates (discussed below), and prevalence (discussed in Section 8.3) are special types of 
ratios. 
 
FORMULA:  A / B      or      numerator / denominator. 
EXAMPLE:  The sex ratio of cleft palate cases would be represented as notated below. 
number of male cases with cleft palate  
number of female cases with cleft palate 
 
Proportions. In a proportion, the cases in the numerator must be included in the denominator. A 
percentage is a proportion multiplied by 100. Proportions are useful for describing basic characteristics of 
surveillance program data. This can help with quality control. 
FORMULA for a proportion:  A / (A+B) 
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FORMULA for a percentage:  A x 100 / (A+B) 
EXAMPLES 
The proportion of abstracted records with errors would be: 
the number of records with errors 
the total number of records 
 
The percentage of abstracted records with errors would be: 
the number of records with errors  x 
the total number of records abstracted    
100 
 
Rates. In epidemiology, rates express the frequency with which an event occurs (e.g., the number of new 
cases of disease) in a defined population in a specified period of time (Last, 1995). 
FORMULA for incidence rate: 
the number of new cases of a disease during a period of time 
population at risk 
 
As will be discussed further in Section 8.3, although some investigators and studies report ‘incidence 
rates’ when talking about birth defects occurrence, there is general consensus that the information to 
determine incidence is not available (Sever, 2004). Therefore ‘prevalence’ or ‘prevalence at birth’ is the 
more appropriate terminology. 
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8.3  Calculating Prevalence at Birth 
Prevalence expresses the number of existing cases of disease at a point in time divided by the total 
population. Prevalence is useful since it allows comparison between populations of different sizes. 
Prevalence may be measured at any time (e.g., X cases of spina bifida of any age on June 1 2003 divided 
by the entire population). However, for measuring occurrence of birth defects, it is most common to use 
prevalence at birth or birth prevalence. That is true even though many of the cases included may not have 
been live births.  
 
Ideally, incidence rates would be used instead of prevalence to measure birth defect occurrence. 
Incidence rates measure the occurrence of new events that occur in a population, so the formula for 
incidence of a birth defect would be: 
the number of new cases of birth defect A in an area and time period  x 
the number of conceptions at risk of developing defect A in  
that area and time period 
multiplier 
 
Since the number of conceptions is unknown, as is the number of cases “lost” through spontaneous 
abortions, technically speaking we cannot determine incidence. Because of this, as noted above, most 
epidemiologists working in the area of birth defects use the term ‘prevalence’ to refer to birth defect 
occurrence. For a more complete discussion of this issue see Sever (2004). 
8.3.1  Basic Calculation for Prevalence at Birth 
Surveillance programs should measure birth defect occurrence using the following formula for birth 
prevalence. Note that both the numerator (number of cases) and the denominator (number of live births) 
always come from the same area and time period, that is, the same population. Usually the denominator is 
the number of live births to residents in the same geopolitical area from which the cases came during the 
same time period. 
FORMULA for birth prevalence (expressed as cases of defect A per 10,000 live births): 
the number of cases with birth defect A in an area and time period  x 
the number of live births in that area and time period 
10,000 
 
EXAMPLE from Missouri:  
193 cases with Tetralogy of Fallot statewide delivered in 1989-1995  x 
532,592 live births 
= 3.62 cases per 10,000 live births 
10,000 
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8.3.2  Numerator and Denominator Issues 
Counting cases – the numerator. For information on how to count cases for the numerator, see Section 
8.2.1 on measuring birth defect occurrence (cases versus infants/fetuses). 
 
Pregnancy outcomes included. Most often in analyses of birth defects surveillance data, the cases in the 
numerator are derived from all pregnancy outcomes collected by the program. These may include those 
listed below (see Chapter 3 on Case Definition). 
 Live births 
 Spontaneous fetal deaths greater than or equal to 20 weeks gestational age (GA) 
 Spontaneous fetal deaths less than 20 weeks GA 
 Induced terminations greater than or equal to 20 weeks GA  
 Induced terminations less than 20 weeks GA 
 Fetal deaths, unknown if spontaneous or induced, and/or of unknown gestational age 
 
Sometimes analyses are restricted to certain pregnancy outcomes in comparing data from two surveillance 
programs that collect different pregnancy outcomes. For example, in the annual reports of EUROCAT 
(2002) and the International Clearinghouse for Birth Defects Monitoring Systems (2002) data are 
presented by live births plus stillbirths (late fetal deaths) and induced abortions (terminations of 
pregnancy), such that it is possible to make comparisons between prevalence based on comparable 
methods of case ascertainment (Sever, 2004). 
 
The reports generated by the program should document which pregnancy outcomes are included in the 
numerator. 
 
For the denominator, surveillance programs should use the total number of live births in the same area 
and time period from which the cases were ascertained. Although including induced and spontaneous 
fetal deaths would more closely approximate incidence rates calculated in other areas of epidemiology, it 
is impractical since these other pregnancy outcomes are often inaccurately counted compared to live 
births. In addition, these counts are small in comparison to the number of live births and are unlikely to 
affect prevalence to a large degree.  
 
All the cases in the numerator (e.g., spontaneous and induced fetal deaths) may not come from the 
denominator (live births). For this and other technical reasons, birth prevalence is really a ratio and not a 
rate, although it is commonly referred to as a ‘rate’. 
 
Multiplier. The multiplier 10,000 is used for convenience, so that prevalence of most defects will have at 
least one digit to the left of the decimal place. Prevalence is expressed as ‘X cases per 10,000 live births’. 
The most common multipliers for birth defects are 10,000 and 1,000. 
 
EXAMPLE. 6.3 cases per 10,000 live births is easier for the reader to understand than 0.00063 cases  
(per birth).
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8.4  General Types of Prevalence 
As with rates and other measures of morbidity and mortality, there are three general types of prevalence. 
Prevalence can be categorized based on whether it: 
 Applies to the whole population – crude prevalence 
 Applies to subgroups within the population – specific prevalence 
 Applies to the whole population, but adjusts for differing distribution of subgroups within the 
population – standardized or adjusted prevalence. 
 
Below we discuss each of these types of prevalence in turn. 
8.4.1  Crude Prevalence 
Definition Prevalence calculated for the entire population without regard to possible 
subgroups within the population. 
When to Use When a single, easily calculated number summarizing the occurrence of disease 
in a population is desired. 
How to Use  For birth defects, the basic calculation above is applied to the entire population. 
The area is usually the area covered by your birth defects surveillance program. 
The number of cases with birth defect A in an area and time period  x 




Birth Prevalence of Down Syndrome, Texas, 1996/97 Deliveries 
Cases Live Births Prevalence* 
355 300,431 11.82 
* cases per 10,000 live births Source:  Ethen and Case, 2000. 
8.4.2  Specific Prevalence 
Definition  Prevalence calculated for subgroups or strata within the population, such as age 
groups, sex groups, or racial/ethnic groups. These then would be referred to as 
age-specific prevalence, sex-specific prevalence, or race/ethnicity-specific 
prevalence. The term ‘stratified’ is also used to refer to the prevalence among 
such subgroups. 
When to Use  Specific prevalence is used in looking at disease occurrence in subgroups of a 
population. It is also used when sufficient data are available to define and 
categorize the population of interest. In using specific prevalence, it is important 
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to consider how missing values (e.g., unknown maternal ages) would affect the 
interpretation of the prevalence data presented. 
 
How to Use  For birth defects, apply the basic prevalence calculation above to each group of 
interest within the population. It is necessary to have the numerator and 
denominator from the same group of interest. The most common groups of 
interest for routine birth defects reports are based on: 
• Maternal age at delivery 
• Maternal racial/ethnic group 
• Infant sex  
However, specific prevalence can be calculated for any group for which 
numerator and denominator data are available. 
 
Each grouping of a variable of interest is also called a ‘stratum’. For example, 
common strata for maternal age at delivery are: 
• Less than 20 years old 
• 20 – 24 years old 
• 25 – 29 years old 
• 30 – 34 years old 
• Greater than or equal to 35 years old 
Calculating maternal age-specific prevalence would then yield five values.  
 
It is helpful to define the groups or strata in the same way vital statistics are 
routinely reported for the population of the area. For example, live births in 
Texas are commonly reported for four maternal racial/ethnic groups: 




Thus, those categories are used for reporting race/ethnicity-specific prevalence 
values. 
The FORMULA for calculation is: 
the number of cases with birth defect A in group X in an area and time period  x 
the number of live births in group X in that area and time period 
10,000 
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EXAMPLE  
Prevalence of Down Syndrome by Maternal Age in Years, Texas 1996/97 Deliveries 
Maternal Age 
(years) 
# Cases # Live Births Prevalence* 
< 20 39 48401 8.06 
20 – 24 53 83398 6.36 
25 – 29 45 81442 5.53 
30 – 34 84 57562 14.59 
35 + 134 29574 45.31 
* cases per 10,000 live births Source:  Ethen and Case, 2000.  
8.4.3  Adjusted or Standardized Prevalence 
Definition  Prevalence calculated for the entire population (the target population) that adjusts 
for (eliminates the influence of) possible differences in makeup between it and 
some standard or reference population. It is a summary measure that is a 
weighted average of the stratum-specific prevalence values. 
 
There are two types of adjusted or standardized prevalence: direct and indirect. 
Direct adjustment uses specific prevalence derived directly from the target 
population (hence the name) and combines them using the age distribution of the 
standard population. The prevalence is generated that the target population would 
have experienced had it had the same age structure as the standard population. 
Indirect adjustment uses age-specific prevalence figures derived from the 
standard population but applies those to the age distribution of the target 
population. This technique produces the number of cases the target population 
would have experienced had it had the same age-specific prevalence as the 
standard population. The final result is usually expressed as a ratio of the cases 
observed in the target population divided by the number of cases expected based 
on this calculation.  
 
When to Use  Adjustment is used to develop a single number summarizing the occurrence of 
birth defects within a population compared with some other population, 
removing the effect of differences between populations in the distribution of the 
factor adjusted for. An example would be to examine the occurrence of Down 
syndrome in a community near a hazardous waste site where the community has 
a larger proportion of older mothers than a comparison community or the state as 
a whole. The most common characteristics adjusted for in birth defects analyses 
are maternal age and maternal racial/ethnic group. 
 
Use direct adjustment: 
• When information is available on both the number of cases and the 
number of live births in each group/stratum/level of the factor being 
adjusted for (e.g., in each maternal age group); or 
• To compare two or more target populations with each other (e.g., 
prevalence for anencephaly in 20 counties [20 target populations], 
standardized for maternal race-ethnicity group). 
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Note that to compare two or more target populations, they must be standardized 
using the same standard population. 
Use indirect adjustment when: 
• Information is not available on the number of cases in each stratum of 
the factor being adjusted for; 
• The comparison is between a target population and a standard and not 
with another target population (e.g., is the prevalence of anencephaly 
significantly different in County X compared to the whole state?); 
• Statistical precision is very important (since stratum-specific prevalence 
used for direct standardization can sometimes vary widely if based on 
few cases); or 
• The results are to be presented as an observed-to-expected ratio 
(although a prevalence can be calculated). 
How to Use  The following instructions are based on adjusting for maternal age groups. Each 
age group is called a ‘stratum’. The same process would be used when adjusting 
for other characteristics, for example, race or ethnicity. 
Direct adjustment. For direct adjustment follow the steps below. 
1. Decide on age-group categories (strata) that can be applied to both the target 
and standard populations. 
2. Calculate age-specific prevalence for each stratum of the target population. 
Do not use the multiplier (10,000 or 1,000) for this calculation. However, the 
multiplier may be used for presenting the age-specific prevalence values.  
3. Multiply each prevalence by the number of live births in the same stratum of 
the standard population. This gives the number of cases expected in each 
stratum of the standard population, had it experienced the same age-specific 
prevalence as the target.  
4. Add up the number of expected cases across all strata.  
5. Divide the total number of expected cases by the total number of live births 
in the standard population and multiply by your multiplier (e.g., 10,000).  
This is the ‘directly standardized birth prevalence’. 
Indirect adjustment. For indirect adjustment follow the steps below. 
1. Decide on age-group categories (strata) that can be applied to both the target 
and the standard populations. 
2. Calculate age-specific prevalence for each stratum of the standard 
population. Do not use the multiplier (10,000 or 1,000) for this calculation. 
However, the multiplier may be used for presenting the age-specific 
prevalence.  
3. Multiply each prevalence by the number of live births in the same stratum of 
the target population. This gives the number of cases expected in each 
stratum of the target population, had it experienced the same age-specific 
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prevalence as the standard. 
4. Add up the number of expected cases across all strata of the target 
population. 
5. Divide the total number of observed cases in the target population by the 
calculated total number of expected cases.  
This is the ‘standardized birth prevalence ratio’, sometimes called the 
‘standardized observed-to-expected ratio’. When applied to mortality, the result 
is called the ‘standardized mortality ratio’ or SMR. 
EXAMPLES. The Texas Birth Defects Monitoring Division dealt with a cluster of 
Down syndrome in a three-county area in Texas among deliveries in 1992–1994. 
Down syndrome is influenced strongly by maternal age. Thus it was necessary to 
adjust for maternal age to see whether the excess was still apparent when 
possible differences in maternal ages between these three counties and the state 
of Texas were removed. The three counties (1992–1994 deliveries) make up the 
target population, and the entire Texas Birth Defects Registry area (1996–1997 
deliveries) the standard population. The years 1996–1997 were used because 
those were the first years with data published for most of the state.  
 
Direct adjustment. The crude Down syndrome prevalence for the three counties 
during 1992–1994 was 31.97 cases per 10,000 live births. Steps 1-4 are 
presented in the following table. 
Target Standard 




(A) (B) (A) / (B) = (C) (D) (C ) x (D) 
< 20 3 1032 0.00290698 48401 140.701 
20 – 24 3 1666 0.00180072 83398 150.176 
25 – 29 3 1498 0.00200267 81442 163.101 
30 – 34 4 1028 0.00389105 57562 223.977 
35 + 5 407 0.01228501 29574 363.317 
      
Total 18 5631 0.00319659 300377 1041.272 
* Expressed as cases per live birth. To express it the usual way, multiply by 10,000. 
 
Step 5 
total number of expected cases in standard population  x 
total number of live births in standard population 
10,000 
   = 1041.272  x 
300377 
    10,000 
                 = the standardized prevalence 
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Indirect adjustment. Steps 1-4 are presented in the following table. There are 
known to be 18 cases of Down syndrome in the target population, but the ages of 
their mothers may not be known. 
TARGET STANDARD TARGET 




(years) (E) (F) (G) (F) / (G) = (H) (E) x (H) 
      
< 20 1032 39 48401 0.00080577 0.83155307 
20 – 24 1666 53 83398 0.00063551 1.05875441 
25 – 29 1498 45 81442 0.00055254 0.82770561 
30 – 34 1028 84 57562 0.00145930 1.50015635 
35 + 407 134 29574 0.00453101 1.84411983 
      
Total 5631 355 300377 0.00118185 6.06228927 
* Expressed as cases per live birth. To express it the usual way, multiply by 10,000. 
   
Step 5 
total number of observed cases in target population  x 
total number of expected cases in target population     
 
=    18        x 
6.0623   
10,000 
     = 2.97 
     = standardized birth prevalence ratio or standardized observed-to-expected ratio 
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8.5  Descriptive Epidemiology 
Background  Surveillance data allow the description of the occurrence of birth defects in terms 
of the basic epidemiologic parameters of time, place, and person. In doing so, 
comparisons can be made among these different parameters (e.g., comparing the 
prevalence of anencephaly among different maternal ages). 
 
Note that descriptive epidemiology is really just the presentation of specific 
prevalence where the strata are time periods (e.g., year of delivery), areas (e.g., 
counties), or personal characteristics (e.g., maternal age groups or maternal 
racial/ethnic groups). See Section 8.4.2 above on calculation of specific 
prevalence.  
 
When to Use   To describe patterns of birth defect occurrence. 
 
How to Use  Choose the most appropriate measure of birth defect occurrence. This will 
usually be prevalence, but in some circumstances it may be counts. For example, 
in planning for services, the actual number of children in a population born with 
a defect, such as cleft lip, may be more important than the prevalence.   
Analyze the chosen measure according to the basic epidemiologic parameters of 
time, place, and person (Teutsch and Churchill, 2000; Seiffert, 1994). Tables, 
graphs, and maps are very useful in presenting data in an understandable form; 
suggested approaches can be found in Teutsch and Churchill (2000).  
 
Time. Surveillance programs should clearly state the relevant time period of 
study from which cases are drawn. This is usually based on ‘date of delivery’. 
Other options include ‘estimated date of conception’, ‘estimated date of 
delivery’, ‘date of diagnosis’, or ‘date of incorporation into the surveillance 
database’. Common analyses of birth defect occurrence by time include: 
• Prevalence by year: to look for long-term trends 
• Prevalence by season or month within the year: to look for seasonal 
patterns 
• Counts of cases by date of delivery or estimated date of conception: to 
look at birth defect clusters 
Place. Reports should specify the geographic area of coverage for the prevalence 
presented in the report. Common analyses of birth defect occurrence by place 
include: 
• Prevalence by state, county, or region 
• Prevalence by zip code or census tract 
• Spot maps of cases showing residence at delivery or conception 
Person. Common analyses of birth defect occurrence by person include: 
• Prevalence by maternal age (age of the mother at the time of delivery) 
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• Prevalence by maternal race/ethnicity (the most common definition is as 
stated by the mother) 
• Prevalence by infant/fetus sex. 
 
EXAMPLES 
Time trend in the prevalence of gastroschisis over several years. The numerator 
(number of cases) and denominator (number of live births) for each year is 
determined. The prevalence for each year is calculated as: 
the number of cases with gastroschisis in Metro Atlanta in year X    x 




            Source: Centers for Disease Control and Prevention, 1993, as cited in James et al., 1993. 
Occurrence of birth defects by place, specifically, county prevalence of 
gastrointestinal defects. Numerators and denominators were collected for each 
county in Florida for deliveries in 1996. The results are presented in a chloropleth 
map (a method of mapping to display quantitative information where the areas 
[e.g., counties] are colored or shaded according to the value of some variable 
[e.g., gastroschisis prevalence]). 
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Source:  Florida Department of Health, 1999. 
Occurrence of birth defects by person. Numerators and denominators were 
determined for five maternal age groups. Stratum-specific prevalence is 
calculated and presented in a table and vertical bar graph. 
 








< 20 39 48,401 8.06 
20-24 53 83,398 6.36 
25-30 45 81,442 5.53 
30-34 84 57,562 14.59 
35 + 134 29,574 45.31 
*cases per 10,000 live births 
Source:  Ethen and Case, 2000. 
Maternal age (years)








Prevalence of Down syndrome by maternal age,
Source:  Ethen and Case, 2000. 
 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                           rev. 06/04 
 
Chapter 8      8-15              Statistics 
8.6  Confidence Intervals 
In this section, we first discuss confidence intervals generally (Section 8.6.1). We then discuss the use of 
confidence intervals in comparing prevalence values (Section 8.6.2). 
8.6.1  About Confidence Intervals 
Definition An interval around a statistic that contains the true underlying value of the 
statistic a certain amount of the time. For example, a 95% confidence interval for 
the prevalence of spina bifida will contain the true underlying value of the spina 
bifida prevalence 95% of the time.  
 
The interval is bounded by an upper confidence limit and a lower confidence 
limit. 
 
Background  The birth prevalence for a particular defect is estimated by the number of cases 
with the defect of interest ascertained from the population, divided by the total 
number of live births, and multiplied by some factor such as 10,000. This number 
is the best estimate of the true birth prevalence, which can never be known with 
certainty. To provide an idea about the precision of the estimated prevalence, a 
range of values is often calculated that is highly likely to contain the true 
prevalence. This range of likely values is called a confidence interval. 
 
A confidence interval is calculated in such a way that, if the same procedure were 
to be repeated a large number of times, the proportion of intervals that contain 
the true prevalence would equal the confidence level. So, for example, if we 
choose a 95% confidence value, then 95% of all those confidence intervals will 
contain the true, but unknown, prevalence.  
 
The 95% value is the conventionally used confidence interval. However, 
sometimes people choose other values, such as 90% confidence intervals (which 
are narrower than 95% confidence intervals) and 99% confidence intervals 
(which are wider).  
 
Estimated confidence intervals for any given level (e.g., whether 90%, 95%, or 
99%) will be narrower when their prevalence values are based on more cases. 
 
Confidence intervals only measure random error, for example, when the 
occurrence of a birth defect fluctuates up and down from year to year by chance. 
They do not address systematic error or bias.  Let’s say, for example, one wanted 
to compare two surveillance programs. If program A does not ascertain cases 
from prenatal diagnosis clinics and thus consistently misses cases, while program 
B does ascertain cases from such clinics, a confidence interval around the 
prevalence of birth defects from program A should not be interpreted as 
accounting for the missing cases. The confidence interval merely addresses 
random fluctuation in the cases from program A.  
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When to Use  Confidence intervals may be calculated for any summary statistic, e.g., for 
proportions. However, we will only discuss confidence intervals for birth 
prevalence since that will be the most common statistic presented by birth defects 
surveillance programs. To learn about calculating confidence intervals for 
proportions or other types of rates, please consult one of the statistics books listed 
in the reference section (e.g., Dawson and Trapp, 2001; Fleiss et al., 2003; 
Snedecor and Cochran, 1989).  
 
Confidence intervals can be used whenever calculating birth defect prevalence, 
although their use is controversial. This issue is discussed extensively in a recent 
commentary (Costa and Kirby, 2003) and a theory and methods paper (Correa-
Villasenor et al., 2003) on the use of confidence intervals and on errors and 
undercounting in birth defects surveillance data. The interested reader is referred 
to these publications.  
 
Why to Use  From a theoretical viewpoint, prevalence (e.g., X cases per 10,000 among 
deliveries in 1999) can also be considered to be just one sample in time, and 
confidence intervals give an idea of the range of values within which the true 
value is likely to be found. From a practical viewpoint, confidence intervals are 
particularly useful when dealing with small numbers of cases or where the birth 
defect prevalence for one group will be compared with that of other groups. This 
is because confidence intervals can help minimize reader concern about 
prevalence values that appear high or different when this is most likely due to 
random fluctuation. Some states have found this to be particularly helpful, for 
example, when looking at prevalence for counties, areas smaller than counties, or 
racial/ethnic groups. While the best way to compare prevalence values between 
different areas is always to use a statistical test, it is not practical for a 
surveillance system to anticipate all the comparisons readers will want to make. 
Confidence intervals thus provide a quick way for readers to get a rough idea of 
the impact of chance on the data. 
 
Why Not to Use  Some surveillance programs ascertain all cases of birth defects, so that the 
prevalence reported is not just a sample but is considered to reflect the 
underlying true prevalence. Therefore, the use of confidence intervals is 
considered by many to be irrelevant. Calculating confidence intervals also 
increases statistical work for program staff. Finally, some data users, for example 
community groups or the media, may find confidence intervals confusing. 
 
How to Calculate  Upper and lower 95% confidence limits are shown in the table below; they are 
the end points of the corresponding confidence intervals. Note that calculation of 
confidence intervals for prevalence is merely the calculation of confidence 
intervals for the number of cases – the denominator portion of prevalence does 
not change. 
 
For a prevalence based on a small number of cases. For small numbers of cases 
(arbitrarily defined here as fewer than 30), use the Poisson distribution since birth 
defects are considered to be rare events. 
 
The easiest way to use the Poisson distribution is to refer to a table that provides 
the upper and lower 95% confidence limits for an observed number of cases 
(reproduced below for up to 29 cases). Then follow Steps 1 through 3. 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                           rev. 06/04 
 
Chapter 8      8-17              Statistics 
Table of 95% Confidence Limits for the Number of Cases, for 1-29 Cases,  
Based on the Poisson Distribution 
95% Confidence Limits Number of Cases Lower Upper 
0 0.0000 3.6889 
1 0.0253 5.5716 
2 0.2422 7.2247 
3 0.6187 8.7673 
4 1.0899 10.2416 
5 1.6235 11.6683 
6 2.2019 13.0595 
7 2.8144 14.4227 
8 3.4538 15.7632 
9 4.1154 17.0848 
10 4.7954 18.3904 
11 5.4912 19.6820 
12 6.2006 20.9616 
13 6.9220 22.2304 
14 7.6539 23.4896 
15 8.3954 24.7402 
16 9.1454 25.9830 
17 9.9031 27.2186 
18 10.6679 28.4478 
19 11.4392 29.6709 
20 12.2165 30.8884 
21 12.9993 32.1007 
22 13.7873 33.3083 
23 14.5800 34.5113 
24 15.3773 35.7101 
25 16.1787 36.9049 
26 16.9841 38.0960 
27 17.7932 39.2836 
28 18.6058 40.4678 
29 19.4218 41.6488 
Source:  Diem and Lentner, 1970. 
Step1. Calculate prevalence.  
the number of cases with birth defect A in an area and time period  x 
the number of live births in that area and time period 
10,000 
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Step 2. Look up the lower 95% confidence limit for the number of cases with 
birth defect A. Using this new number in the numerator, calculate the lower 95% 
confidence limit for prevalence:  
Lower 95% CL for prevalence = lower 95% CL for cases  x 
number of live births 
10,000 
 
Step 3. Look up the upper 95% confidence limit for the number of cases with 
birth defect A. Using this new number in the numerator calculate the upper 95% 
confidence limit for prevalence.  
Upper 95% CL for prevalence = upper 95% CL for cases  x 
number of live births 
10,000 
 
EXAMPLES using data from the California Birth Defect Monitoring Program 
1983-1986. 
Cases Prevalence6 Birth Defect 
Number1 95% CI2 
Number of 
Live Births3 Value4 95% CI5 
Anophthalmia 18 10.67 - 28.45 452,287 0.40 0.24 - 0.63 
Glaucoma 27 17.79 - 39.29 452,287 0.60 0.39 - 0.87 
Notes      Source:  Croen et al., 1990.  
(1)  Number of cases ascertained from surveillance 
(2)  95% confidence interval for that number of cases 
(3)  Number of live births derived from vital records 
(4)  Prevalence = [(1) / (3)] X 10,000 
(5)  95% confidence interval for the prevalence 
(6)  Prevalence expressed as cases per 10,000 live births 
For a prevalence based on a large number of cases. For a large number of cases  
(arbitrarily defined here as 30 cases or more), use the normal distribution. Why? 
As the number of cases grows larger, the Poisson distribution approximates (i.e., 
looks more and more like) the normal distribution. The formulae below are 
approximations for calculating confidence intervals using the normal distribution 
(Rothman and Boice, 1982, p. 29, formula 19).  
Shorthand: let c = number of cases 
     b = number of live births 
1. Calculate the lower confidence limit using the following: 
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2. Calculate the upper confidence limit using the following: 
Upper 95% CL for 



















3. To determine the 90% confidence limits, replace 1.96 with 1.645. To 
determine 99% limits, replace 1.96 with 2.575. 
4. To obtain confidence limits for the number of cases instead of the prevalence, 
apply the formulae but do not divide by births (b) or multiply by 10,000. 
EXAMPLES using data from the California Birth Defect Monitoring Program, 
1983-1986. 
Cases Prevalnce6 Birth Defect Number1 95% CI2 
Number of 
Live Births3 Value4 95% CI5 
Aortic stenosis 73 57.22 - 91.79 452,287 1.61 1.27 - 2.03 
Cleft palate 320 285.89 - 357.05 452,287 7.08 6.32 - 7.89 
Notes       Source:  Croen et al., 1990. 
(1)  Number of cases ascertained from surveillance 
(2)  95% confidence interval for that number of cases 
(3)  Number of live births derived from vital records 
(4)  Prevalence = [(1) / (3)] X 10,000 
(5)  95% confidence interval for the prevalence 
(6)  Prevalence expressed as cases per 10,000 live births 
Software support. For a few prevalence values, confidence limits (and hence the 
resulting intervals) can be calculated by hand or using statistical software such as 
PEPI. One program in PEPI (POISSON) gives the table values for any number of 
cases; for a large number of cases it gives a normal approximation. PEPI 
software and documentation are available at:  
http://sagebrushpress.com//pepibook.html  
For many prevalence values, it is useful to write programs, for example in SAS, 
to calculate the confidence limits along with the prevalence.  
8.6.2  Comparing Prevalence Values Using Confidence Intervals 
The best way to compare prevalence values (e.g., for different maternal ages) is to do a statistical test; one 
type of statistical test is described in the second section below (“When both prevalence values are based 
on 30 or more events”). However, in the first section below we present a quick method recommended by 
the National Center for Health Statistics (NCHS) that works better when one of the prevalence values is 
based on fewer than 30 cases. Note that the NCHS-recommended method is conservative (i.e., there will 
be fewer statistically significant differences than would be found by actually performing a statistical test). 
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When one of the prevalence values is based on fewer than 30 cases. First compute the 95% confidence 
intervals for both prevalence values. Check to see if those intervals overlap. If they do overlap, the 
difference is not statistically significant at the 95% level. If they do not overlap, the difference is indeed 
‘statistically significant’ or unlikely to be explained by chance alone. (Method recommended by NCHS in 
Ventura et al. [2000].) 
EXAMPLE 
The prevalence of holoprosencephaly among African-American women in Texas (2.39 cases per 10,000 
live births) is over three times higher than among White women in Texas (0.78 cases per 10,000 live 
births). Is the difference statistically significant?  First compute the 95% confidence intervals. 
Holoprosencephaly Among Two Race/Ethnic Groups in Texas, 1996/97 
Group Cases Live Births Prevalence* 95% CI for Prevalence 
African American women 7 29,254 2.39 0.96 - 4.93 
White women 8 102,193 0.78 0.34 - 1.54 
* cases per 10,000 live births     Source:  Ethen and Case, 2000. 
These two confidence intervals overlap. Thus, based on this approach, the difference between prevalence 
of holoprosencephaly in African-American women compared to White women is not statistically 
significant. 
When both prevalence values are based on 30 or more events. This approach is based on calculating 
the confidence interval for the difference between the two prevalence values. If this interval includes 0.00, 
then the difference in the values is not considered to be statistically significant. Since this approach uses 
information from both prevalence values at the same time, it is more statistically powerful than the 
NCHS-recommended method. That is, if a difference truly exists, this approach will identify that more 
often than will the NCHS-recommended method. This approach uses the standard error for the difference 
between the two prevalence values (Rothman, 1986, p. 170, formulae 11-15).  
Statistical software like the RATES2 program within the PEPI package can also be used to calculate this 
confidence interval.  
Shorthand: let RD = higher prevalence - lower prevalence 
  c1 = number of cases used to calculate the first prevalence 
  c2 = number of cases used to calculate the second prevalence 
  b1 = number of live births used to calculate the first prevalence 
  b2 = number of live births used to calculate the second prevalence 
1.  Calculate the lower confidence limit using the following: 

















cRD   
2.  Calculate the upper confidence limit using the following: 
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cRD   
3.   To obtain 90% confidence limits, replace 1.96 with 1.645.   To obtain 99% limits, replace 1.96 with 
2.575. 
4.   If the confidence interval does not include 0.00, then the difference would occur by chance less than 5 




Is there a statistically significant difference between African-American and Hispanic women in the 
prevalence of births with atrial septal defects? 
Atrial Septal Defect Among Two Race/Ethnic Groups in Texas, 1996/97 
Group Cases Live Births Prevalence * 
African-American women 133 29,254 45.46 
Hispanic women 835 160,094 52.16 
* cases per 10,000 live births     Source:  Ethen and Case, 2000. 
1. The lower 95% confidence limit for the prevalence difference = -1.80. 
2. The upper 95% confidence limit for the prevalence difference = 15.20. 
3. The 95% confidence interval for the prevalence difference thus = -1.80 to 15.20. 
4. The interval includes 0.00. Therefore, the difference between the two prevalence values is not 
statistically significant at the 95% confidence level; i.e., there is no statistically significant difference. 
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8.7  Issues to Consider If Data Reveal Unusual Patterns 
It is very important to rule out relatively straightforward explanations for a change in the birth prevalence 
of a birth defect. Among the more common reasons are:  
 Changes in medical diagnoses and technologies 
 Changes in reporting that lead to changes in case ascertainment 
 Changes in the population at risk (focus on age, period, and cohort effects) 
 Random variation 
 
Please refer to Kallen (1998, pp. 83-87) for a more extended discussion of the issues identified above. 
 
The analytical capabilities of the surveillance system should support evaluation of the likelihood of these 
factors being responsible for observed changes in prevalence. Although the remainder of this section 
addresses “changes” in birth defect prevalence over time, it can also be applied to “differences” in birth 
defect prevalence between areas.  
8.7.1  Changes in Medical Diagnoses and Technologies 
To detect changes in medical diagnoses, it is important to compare isolated and multiple birth defects 
cases. Minor changes in the way a condition is diagnosed or reported can affect the coding and 
classification of specific birth defects. For example, the prevalence of neural tube defects among live-born 
infants may have declined during the 1980s from levels reported in the 1970s, due to the development and 
widespread availability of prenatal diagnostic tests, such as maternal serum alpha-fetoprotein screening 
and ultrasonography. The severity of spina bifida cases may be less today than in the 1970s due to the 
selective therapeutic termination of the more severe cases, which are more likely to be identified 
prenatally.  
 
The birth prevalence of some disorders may increase due to new technologies. For example, fragile X 
syndrome, a chromosomal breakage disorder, is diagnosed much more often today than 10 years ago and 
was unknown 20 years ago. 
8.7.2  Changes in Reporting and Case Ascertainment 
Re-verification that the frequency is an un-duplicated count is also appropriate. Many suspected 
“clusters” reported by the media or concerned citizens involve multiple counting of the same cases. With 
a birth defects surveillance program that ascertains cases from multiple sources, it is important to ensure 
that each case is counted only once, even if reports are received from several health care providers or 
delivery settings. The same is true of changes in reporting. As hospitals shift to computerized diagnostic 
indices, reporting artifacts could decrease the numbers of cases of specific birth defects while increasing 
others. This is because a limited number of ICD-9-CM codes are retained in the index, and conditions that 
appear to be minor in the eyes of the medical records clerk may be omitted. If surveillance staff rely 
exclusively on the diagnostic indices to identify charts to abstract, some conditions may be missed. See 
also Chapter 5 on Classification and Coding and Chapter 6 on Case Ascertainment Methods. 
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8.7.3  Changes in the Population at Risk 
Population characteristics can be controlled for by using stratum-specific prevalence, age-adjustment, and 
similar methods. However, as most statistical surveillance methods are based on the frequency of events 
rather than on proportions, rates, or prevalence, separate analyses will need to be conducted to rule out 
changes in the population at risk. Analysts who routinely examine birth defects surveillance data will 
have access to detailed, current population estimates and should examine the demographic and 
reproductive health characteristics of all women giving birth to identify changes in the population at risk.  
8.7.4  Random Variation 
It is also possible, and in fact very likely, that an observed difference in the frequency of a specific birth 
defect is due to random variability. With relatively low birth prevalence, cases of a particular condition 
will be quite rare, and the coincidence of two or more cases in space and/or in time may be just that: a 
coincidence. Confidence intervals are one way to address random variation.
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9.1  Introduction 
This chapter is designed to provide basic guidance on the mechanical and administrative aspects of 
establishing and operating a birth defects surveillance program, covering a range of topics related to the 
development of an efficient, effective, and secure program. This chapter is intended to serve as a guide to 
planning the development of a new surveillance program, as well as to the review of practices and 
procedures in place within existing programs.  
 
Issues covered in this chapter include computer hardware and software, data capture procedures, 
transmission of data, data file management, personnel management, physical aspects of the surveillance 
program office and, finally, data confidentiality and security considerations. We discuss the functionality 
of a data processing system in Section 9.2, followed by more detailed discussions of hardware and 
software in Sections 9.3 and 9.4, respectively. Data management is introduced in Section 9.5 on process 
standards, while the specific topics of data entry (Section 9.6), record linkage (Section 9.7), and record 
consolidation (Section 9.8) are described in further detail in subsequent sections. The importance of 
ongoing communication with data sources to identify and correct emerging problems is discussed in 
Section 9.9, and in Section 9.10 we address physical security and confidentiality issues. 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 06/04 
  
Chapter 9     9-2            Data Management and Security 
9.2  Functional Data Processing System Features 
The functionality of the system for processing and managing surveillance data must be able to support all 
the necessary processes and activities required by a program. This chapter is intended to develop the key 
considerations and capabilities that are applicable to surveillance operations. There is a wide variation in 
case volume, approach to data collection, budgets, and goals of various birth defects surveillance 
programs. Overall mission, size, and scope will determine the best combination of procedures and 
features for a given program. 
 
The basic operations of a birth defects surveillance system can be accomplished using minimal computer 
hardware, software, and systems. The characteristics outlined below provide a broad scope of useful 
features and capabilities.  
 
Computerized data collection. As case reports on birth defects cases are received, data should be 
captured within an electronic database designed to maximize a program’s ability to manage the 
surveillance system and utilize the resulting data.  
 
A program’s capacity to receive computerized data from reporting facilities and other sources can ease 
the burden of case reporting and reduce or eliminate the need for recapturing already automated data. 
Improving the efficiency of data collection can minimize effort in the reporting facility and at the 
surveillance program, while reducing errors often due to “re-automation.” Increased efficiency can also 
improve relations with reporting facilities and support compliance with reporting requirements. Below we 
present critical considerations related to accepting and processing electronic reports from reporting 
facilities.  
 Reporting case data within electronic files, rather than paper reports, requires the exchange of 
detailed information on data submission requirements and on the characteristics of the files 
provided. Design issues, such as file formats and structures, and coding schemes must be 
understood to ensure accurate data exchange.  
 Any limitations in the reporting facility’s computer database must be identified to ensure that 
submitted data can meet programmatic needs. Any shortcomings or incompatibilities between the 
facility’s system and reporting requirements must be recognized and addressed. Examples of such 
concerns include facility data systems that are missing standard (required) data items or that code 
a given item using coding rules that are not entirely compatible with the program’s coding 
schemes. 
 As the data systems used to generate the data files are revised, any effects that such changes may 
have on the submitted data should be identified. Information of this type must be communicated 
by the reporting facility to the surveillance system. 
 Submitted data must be reviewed for quality control. This review should compare the data 
submitted with source documents or files to validate that the data are being represented faithfully 
within the surveillance database. The review should identify any data distortions caused by 
differences in processing systems, coding structures or rules, and conversion routines used to 
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Transmission of electronic data and data telecommunication. Below we present considerations related 
to transmission of electronic data. 
 
 If case reports are accepted as electronic files, a standard format, file structure, code structure and 
medium for submission, i.e., tape or disk, must be developed and documented.  
 Programs receiving passive case reports may elect to accept data in formats and code structures 
that follow the reporting facility’s database structure and rules. In this case the facility – whether 
a hospital, a diagnostic laboratory, or other facility – must be expected to refer to the standard for 
submissions and provide the data in a format and code structure that is compatible with and 
convertible into the standard format for reporting cases to the surveillance system.  
 Whether converted or nonstandard data files are supplied, each facility must identify any 
compatibility/consistency problems apparent between the source system and the standard. 
 Secure methods for delivery of forms and data files need to be recommended by the surveillance 
program and followed by each facility. 
 
Various modes for data entry. Below we present considerations related to data entry modes. 
 
 To automate the information received in the form of paper case abstracts, a data capture 
mechanism is required. Approaches to accomplish this task include: 
• Classic data entry by keying data into a fixed format file 
• Optical scanning 
• Data capture through the use of custom screens 
 Principles associated with the data entry process, which will ultimately enhance efficiency and 
data quality, include: 
• Standardizing data review, query, and preparation procedures 
• Verifying the keyed data 
• Editing at the point of entry 
• Editing of the completed input file 
 In addition to capturing case data internally, consideration should be given to developing software 
that enable facilities to report case data electronically. Providing such software to the reporting 
facilities enables them to use standard file formats and coding and editing procedures for the data 
they submit. Editing the data at the point of entry, in particular, can reduce the need for later 
follow-back. 
 
Receipt and integration of new case data while retaining data on reporting activities. Below we 
present considerations related to the integration of new case data. 
 
 To the degree practical, the program needs to be able to receive submitted data for processing in 
the form of electronic files, paper submissions, and, potentially, through web-based or other 
direct data entry across secure connections.  
 Integration of data into the system should be done such that integrity of the individual reports 
received is maintained. This allows the surveillance system to document the data source properly 
and to monitor reporting quality.  
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Ability to link surveillance data to new reports and files from other data sources. Below we present 
considerations related to linkage of surveillance data to new reports and files from other data sources. 
 
 The program must have appropriate software and system computing capacity to screen incoming 
data against existing surveillance data in order to identify accurately duplications in reporting. 
 The program must have the ability to implement a variety of strategies to link surveillance data 
with data from other sources in a manner that allows cases within other data sets to be identified 
as important. Through this means the program can augment the surveillance data base with 
information on cases identifiable through other data systems, as well as acquiring new case 
reports. This capability is essential if the surveillance program is to facilitate research studies. 
 
Ability to modify system easily and inexpensively. The system used must provide flexibility with 
respect to systems modifications, edit specifications, and other data handling processes, as well as 
permitting modifications of code structure and data set variables within the database. When possible, 
programs should avoid developing the database using software systems that require considerable time and 
expertise to modify. It is best if modifications are controlled and can be made by birth defects surveillance 
staff.  
 
Ability to handle updates. The system must provide an easy way to update registry data as new 
information on cases is received. Updates may include information on additional hospitalizations, further 
diagnostic work, or corrections to earlier reports. 
 
Editing data. The system must support data editing at various steps throughout the data collection 
process. Data editing should be carried out as data are collected, processed, and incorporated into the 
program’s database. Conducting edit checks as early as practical in the data collection process is an 
efficient way of improving data quality. Key stages for data editing include: 
 At the point of data abstraction 
 During data entry 
 As files of new report data are prepared 
 As case files are updated with new cases 
 As additional data on known cases are added 
 
Common edit procedures include field code range checks, table look-up of diagnostic and other codes, 
inter-field consistency checks, and editing across records for individual cases.  
 
Report preparation. Staff must have the computer capability and training to conduct statistical analyses; 
to interpret the resulting statistical information; and to prepare text, tables, and graphics in the form of 
reports. Examples of statistical analyses include establishing basic case counts and rates, developing 
summary data on treatment information, reviewing prevalence trends, adjusting rates, calculating variance 
components and standard errors, and developing measures of the observed and expected prevalence of 
specific conditions.  
 
On-line case queries. The database should be readily accessible to staff using different types of 
information to identify specific cases.  
 
Easy maintenance of reference tables/files. The various reference files used to process and edit 
incoming reports and to develop statistical data on those reports must be easy to maintain and update. 
Such reference files may include tables of diagnostic and procedures codes, code groupings, geographic 
code dictionaries, hospital and laboratory code dictionaries, among others. 
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Extracting files/subsets. The capacity should exist to generate readily subset files of the surveillance 
data. This capacity should allow inclusion of data on cases selected using a variety of criteria and 
inclusion of specific variables for selected cases. File subsets often are needed for statistical analyses, 
quality control work, field site visits, and other uses.  
 
Quality control information on data sources, amounts, and quality. To monitor case reporting 
timeliness and quality, the system will need to store sufficient information to support calculations of 
reporting timeliness and other data reporting quality measures. The system must allow for assessment of 
reporting quality overall and by reporting source. 
 
Systems security, administration, and backup. The system must include features to protect data and 
programs from loss due to systems failure or user error and to maintain the confidentiality of patient and 
provider data. The computer system must provide a secure environment with security features designed 
and enabled to protect data from inappropriate access. Such measures must include a system of user name 
and passwords, along with a system to control the access of users to the computer server and drive 
locations where data are stored. These must be updated promptly with staff changes. 
 
Program staff must be able to control or oversee these system administration activities. The system must 
also provide redundant back-up procedures to protect against system failure. This should include back-up 
and recovery procedures with regular and reliable copying of existing surveillance data and systems to 
tape or disk. 
 
Archiving of data and systems. The surveillance data and the systems used to develop and maintain the 
data must be archived according to a predetermined schedule to protect against catastrophic loss. 
Archiving procedures must ensure appropriate preservation of submitted case abstracts and the routines 
used to process abstracts and to analyze case information. Archiving should also encompass statistical 
analyses, special studies, and the procedures used in those studies. 
 
Cost effectiveness. The computer system and hardware used must be selected to fit both the needs and 
the budget of the surveillance program. The initial cost of the system and the cost to maintain and support 
both the operating computer system and specific programming requirements are critical considerations in 
selecting an appropriate system. 
 
Adequate performance. The system selected must be responsive and provide adequate computing speed, 
disk storage, and working memory space to address the needs of the surveillance program. 
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9.3  Hardware 
Computer hardware. Individual work stations and overall processing platforms should be selected to 
handle the work of the surveillance program and allow simultaneous on-line use of the data by multiple 
users and the various software packages used by the staff. Systems speed, number of concurrent users, 
active memory, disk capacity, robustness, and compatibility are all important considerations. 
 
Systems back-up hardware matched to size of system. Systems back-up strategies must be 
complemented by hardware of sufficient size and speed to generate systems back-up on a prescribed 
schedule without eroding systems performance. 
 
Printers, printing capacity, and quality/variety. Hardware that permits printing in the volume required 
by the program and that will produce high-quality printed tables, charts, and reports is important. Printing 
capabilities may be required for high-volume printing of envelopes or other specialized printing. If a 
surveillance program has a large-scale follow-back, the ability to print in-house materials and mailings 
that carry names and addresses significantly enhances security of the information at relatively low cost. 
 
Graphics and slide production capabilities. Hardware that can be used to develop Microsoft 
PowerPoint presentations or slides is important. Slide makers and LCD projectors should be available to 
surveillance program staff. 
 
Communications hardware and links. The staff of the birth defects surveillance program must be able 
to send and receive e-mail and to access the Internet. Data collection through hospitals and use of data by 
staff must also be supported by appropriate computer communication systems.  
 
Strategy for planned obsolescence. The hardware used by the surveillance program must be able to 
operate software and systems that are actively supported by the software or systems suppliers. Planning 
for replacement of existing hardware should be an ongoing process. This should ensure keeping pace with 
changing software and systems requirements, enabling staff to manage the surveillance database 
effectively.  
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9.4  Software 
The basic software selected to run the surveillance database must provide the features required to meet 
programmatic needs. It must have the capacity and robustness to conduct required procedures, be 
compatible with other similar data management systems, and be supportable. 
 
Data analysis software. Standard statistical software should be available to analyze surveillance data. 
Statistical packages must have a full range of capabilities for developing standard statistical tables 
(including counts and rates) and conducting more complex analyses (such as standard error calculations 
or observed-to-expected ratio estimates). In addition, the software must support the design of tables, as 
well as presentation features such as titles, footnotes, graphics and, potentially, mapping. (See also 
Chapter 8 on Statistical Methods). 
 
Record locking and file locking. The data management system must provide for data security and 
confidentiality as well. Systems should be considered with confidentiality and security features that 
enhance the proper protection of data. Depending upon the types of direct database access various system 
users are permitted, the data management software may need to control data access at the level of the file, 
the record, and the individual variables. This may require various levels of file access, which could be 
handled by using data management software with these capabilities. 
 
File security software. Software that can regulate access to file servers and to specific computer drives or 
computer files, and maintain various levels of file access rights, is essential for storage of data on a Local 
Area Network (LAN)-based or mainframe system. Staff should either manage the administrative features 
within this software, or these activities should be under their direct supervision. 
 
Multi-user capability. Software used to access and manipulate the data may need to have multi-user 
capabilities, allowing access by multiple users during most, if not all, file management routines. The need 
for this capability will depend on staff size and the scope of the surveillance program. 
 
Integrated and stand-alone utility programs. The database must be accessible to program staff. 
Software and skills needed to develop ad hoc and specialty software routines must be available, as 
necessary, to manage and maintain files or to conduct specialized analyses. Such custom routines may be 
required on an ad hoc or a routine basis. 
 
Record linkage software. Software is needed that supports data linkage. This capability is essential to 
de-duplicate new report data and to link cases to corollary files, such as birth or death files. Record 
linkage capabilities are also essential to the conduct of cohort studies that can link cases to files of study 
subjects. The ability to link data, with a high degree of accuracy, is critical to data quality, to conducting 
basic surveillance functions, and to research. Some states have developed their own custom – designed 
programs to meet record linkage requirements (e.g., Colorado). 
 
Linkage capability can take several forms, ranging from on-line case-by-case queries to electronic 
comparisons of large databases. Data can be linked electronically through either pre-programmed routines 
or ad hoc routines and can be based on deterministic or probabilistic linkage procedures. The specific 
strategy and approach used by a surveillance program will depend on its size, overall mission, and 
resources available. 
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 Deterministic record linkage procedures, which involves the literal comparison of fields or 
columns within fields for exact matches, can be developed relatively easily and can be supported 
by most database management software. If this approach is used, it is essential to audit and refine 
the procedure painstakingly to ensure a high degree of matching accuracy.  
 
 Probabilistic linkage bases record linkage decisions on determined probabilities that two records 
are likely matches. This technique generally is accepted as quite reliable when applied 
appropriately. However, it is dependent upon costly proprietary software packages that may not 
interface well with other data systems used by the surveillance program. 
 
Regardless of the approach used, the results obtained through record linkage must be reviewed 
periodically for quality. The presence of unidentified duplicates within the case data and combining report 
data for different children into a single record are two obvious hazards of improper linkage. These false 
positive and false negative rates must be minimized by reviewing linkage quality regularly. 
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9.5  Process Standards 
In this section we discuss the following aspects of process standards: inputs into the surveillance system 
(Section 9.5.1), instructions for reporting facilities on proper submission of data (9.5.2), procedures for 
initial review and query of submitted data (Section 9.5.3), procedures for receipt and logging of shipments 
(Section 9.5.4), and forms and batch control procedures (Section 9.5.5). 
9.5.1  Inputs 
Proper management of data within the surveillance program needs to begin through careful coordination 
with those providing the data and through following appropriate internal practices and procedures. These 
must be designed to promote accurate reporting and complete processing, ensuring a trackable system 
where processed data can be re-traced back through to the data originally submitted. 
 
The procedures developed need to accommodate the various forms in which data are reported and the 
sources from which the data are derived. Data coming in to a surveillance program can vary widely with 
respect to the way they are transmitted and their content. This is true across states and within a state. The 
data can be provided in the following ways: 
 Paper/electronic abstracts for reportable conditions 
 Hospital discharge data 
 Medicaid data 
 Early intervention program data 
 Data on services to children with special needs 
 Birth and death record data 
 Medical examiners reports 
9.5.2  Instructions on Proper Submission of Data 
Clear and concise instructions must be developed and distributed to all those involved in reporting cases 
to the surveillance program. Necessary components of these instructions include: 
 Precise definitions of what constitutes a reportable condition/case 
 Item-by-item explanation of information to be reported 
 Timelines for reporting 
 Acceptable reporting methods – paper, electronic, File Transfer Protocol (FTP) 
 How and where to ship reports 
 Procedures recommended to ensure secure shipment 
 Procedures for handling corrections and updates to previous reports 
 Sample of abstract 
 Detail on electronic submissions, if appropriate 
 Definition of terms, as appropriate 
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 Name of a contact person in case of questions 
 
These instructions should be readily available to those with a ‘need to know’, should be prepared to 
minimize any anticipated potential misunderstandings, and should be updated routinely. Instructions need 
to be customized and targeted to specific data sources – such as laboratories, hospitals, physicians, or 
medical examiners – to reflect differences in what is expected from each. 
 
Complete documentation of the receipt and preparation of case data from internal sources is also required. 
Examples include information from data systems for programs that provide specific information on 
children with reportable conditions. The nature of the data system and the schedule for providing or 
obtaining data, the format and technical specifications of the data all need to be documented. This is 
necessary to ensure coordination between the birth defects surveillance program and other data systems 
and/or sources. 
9.5.3  Initial Review and Query 
As reports are received, and during the intake process, it is important to establish procedures to screen 
incoming reports and data. These screens should be designed to avoid unnecessary work and to identify 
and resolve quickly any gross problems with the submission. These screening activities might result in a 
submission being returned and not processed. Other types of screening may occur at various points within 
intake processing of reports.  
 
For paper reports, potential screens could include very basic things, such as examining the mailing for 
physical damage, proper addressing or, perhaps, tampering. Paper reports could be screened, as they are 
inventoried, to be sure they are completed adequately and that the case is truly reportable. If the paper 
report is primarily a case-finding tool, it might first be screened against cases in the database to determine 
whether it is new.  
 
Pre-screening of data submissions should include checking for possible computer viruses, determining 
whether the file is readable and in an appropriate format and file structure, and establishing whether the 
count of records within the file is correct. 
9.5.4  Receipt and Logging of Shipments 
As data are received in the form of paper reports or automated files, forms- and data-control procedures 
need to be followed. Procedures should be designed to ensure that all data submissions are processed. 
They must also provide a mechanism for rechecking the status of the surveillance program database to 
validate that all information has been processed properly and appropriately. This can be accomplished by 
developing a log to record receipt and processing of reports by facility. Such a log could contain basic 
information about each submission. This might include: date received, reporting facility, number of 
reports, date span for the reports, format of the reports, date prepared, report numbers assigned to the 
batch, file or batch name assigned to the data, and the date data processing was completed. Maintenance 
of a log serves as a control point for the data. It can also be designed to permit monitoring of the reporting 
status of individual facilities.  
 
Depending upon the type of report being processed, other approaches may be appropriate to ensure 
completeness. For example, data that serve primarily for case finding may need to be screened first 
against the surveillance program’s database to determine whether the report is for a new case, thereby 
permitting previously reported cases to be quickly dropped from the case-finding data.  
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9.5.5  Forms and Batch Control Procedures 
For data control and tracking, it is important to use a systematic procedure to inventory and to identify 
unique reports. Classically this is accomplished for paper reports through use of a series of sequential 
numbers, with each form assigned a unique number. Forms are then organized sequentially into batches 
of manageable size. A similar procedure can be used for automated data submissions to assign each 
electronic record a unique identifier and to maintain a record of the file name assigned to each batch of 
reports submitted. 
 
These procedures allow staff to locate a specific report easily and provide a mechanism for data 
inventory. Missing report numbers can be listed and resolved as report file completeness is evaluated. 
Data edits for each report can reference these numbers to identify and resolve any concerns with the data 
in that report. 
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9.6  Data Entry 
The most basic aspect of developing a surveillance database is preparing an electronic file of reported 
information. While the proportion of paper case reports received varies widely across surveillance 
programs, each program must have reliable mechanisms for entering data from manual reports into an 
electronic file. In addition, many programs can provide reporting sources with software that can be used 
for submitting cases. Applying some simple concepts to the automation of information can help provide 
data files of consistent quality. 
 
Interactive edits. Developing a process for capturing data destined to reach the surveillance provides an 
opportunity to build functional editing of entries into the operating procedures. This is especially effective 
when edits are used to question incoming data at the point where the patient’s chart is available for 
review. Editing data at the point of origin is the most efficient method to ensure high quality.  
 
Interactive edits can be very simple checks, such as ensuring that only numbers are entered into a numeric 
field, ensuring a date entered is a valid date, or preventing a required field from being left blank. More 
complex edits might involve providing links to a database of valid codes for diagnoses or procedures, 
editing for consistency across fields, or screening each case to determine if the child was reported 
previously. 
 
In designing and developing interactive editing procedures, it is important that the objectives be kept in 
focus. A process is needed for producing high-quality electronic data efficiently and effectively. 
Interactive editing needs to be functional. It should be designed to screen for impossible or improbable 
entries. It must also be efficient, providing the operator with a clear explanation of the perceived problem 
and a ready mechanism for resolving the issue. 
 
Verification. Verification procedures are another tool for controlling the quality of incoming data. The 
key data processing steps of information coding and the actual process of data entry are candidates for 
verification. Verifying data is an old and time-tested method of monitoring and controlling errors 
introduced into data through data processing procedures. These practices do not improve the quality of the 
reported data, but they do minimize degradation in data quality during data processing. The purest 
example of data entry verification is blindly re-keying previously entered data using software that 
compares the newly keyed data, key stroke by key stroke, to that entered earlier. Any discrepancies are 
identified and resolved by the verifier.  
 
To verify data is to double check the data to ensure it is captured accurately. Verification procedures can 
take two basic forms, namely, independent and dependent verification. There are also two basic strategies 
relative to the scope of verification: verifying each incoming case or verifying a sample of cases. In 
independent verification, the verifier is not provided with the previous work and must essentially redo 
the work. The two versions are then compared and any discrepancies resolved. For dependent 
verification, the verifier has access to the original work and reviews the entered data, comparing it to the 
source document; in the case of data entry, essentially proof reading the work. 
 
Focusing on verification as a tool for efficiently developing data files of consistent quality, verification 
can be developed incorporating the quality and skill of the processing staff with efficient methods for 
screening and resolving processing errors. As an example, dependent verification of all the diagnostic 
coding done by new staff might be done by experienced staff and continued until a “qualified” level of 
accuracy is consistently demonstrated. Once the new staff member has qualified, only sample 
independent verification might be done. 
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Information obtained through verification can provide important insights into staff training needs. These 
results can also ensure a consistency of understanding and interpretation across staff involved in data 
preparation, highlighting any inconsistencies. 
 
Forms/record and batch controls. Since data arrive in a variety of forms and from numerous sources 
throughout the year, effective methods to inventory all incoming data are important. As a corollary to 
logging the receipt of data shipments, control of individual records is very important. 
 
As reports – both paper and electronic – are received and early on in their processing, a report number 
needs to be assigned to each report to serve as its unique identifier. This identifier provides a ready 
mechanism to inventory the incoming reports and, later, the consolidated files of processed reports. This 
report identifier also enhances coordination of the work during later stages of file editing and processing.  
 
There are a variety of schemes for assigning a report identifier. The most basic is a sequential number that 
begins with the year the report was received followed by a simple sequential number. By including record 
type/source codes within the prefix for the sequential number, the type of report or information source can 
be incorporated into this identifier. Such information is often useful in developing management 
information regarding database status. 
 
A system for numbering data entry work files needs to be developed and employed to properly control 
and inventory work batches. Each work batch needs to be assigned a unique batch identifier. A log should 
be established to record the report identifier numbers within each batch. The log should include the date 
completed, the individual completing the batch, the individual verifying the batch, and the date the batch 
was processed into the surveillance program. This information will aid in assuring all reports are 
processed and in tracking down any discrepancies. Information in the log will help assess processing 
issues, such as timeliness and staff accountability. 
 
Procedures appropriate for a variety of data inputs. It is important to map out the proper handling and 
intermeshing of data from each data source carefully to ensure data quality. As mentioned earlier, sources 
of information can vary widely, both in type and quality of data. In designing the data entry process, the 
form in which the incoming data are presented can create a need for customized procedures.  
 
Tailoring the procedures to match the data source and data format can add to efficiency and enhance final 
data quality. These adjustments might take many forms, including facilitating data entry through 
customized data entry screens for certain report types. Specialized editing to match the data source and, 
perhaps, to screen for code conversion errors may be required. Some data sources might be considered 
primarily as sources of case ascertainment. The first processing step might be screening cases against the 
program’s database to determine if the case has been reported previously.   
 
Training/certification and instruction for data preparation. Program staff members involved in data 
collection and processing must have the skills required to accomplish their work accurately. The skills 
required vary across key functional activities, namely abstracting case data, coding the information, and 
entering the data. Data management and editing routines will not correct data quality problems that occur 
if staff members are not properly trained. 
 
Surveillance programs need to have a strategy for training new staff that allows them to learn the new job; 
measures their understanding of the work; provides feedback on problems and progress; and determines, 
in some objective way, that the new staff member’s work has reached an acceptable level of quality.  
Staff skills and the rigor with which work is reviewed will vary among surveillance programs. Whether a 
surveillance program utilizes active or passive case ascertainment influences the skills needed. Hiring 
staff with training and experience in health information management may prove important. By the very 
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nature of birth defects surveillance, there will always be a need to train new staff in a number of areas that 
are unique to the program and where it is not possible to hire experienced staff. There must be a strategy 
to ensure that staff assigned to a task have the skills the task requires.  
 
As a component of continuous training, detailed manuals are needed that document procedures and serve 
as a reference source for staff. Staff should be encouraged to refer to these manuals and to identify errors, 
inconsistencies, and misinterpreted sections. Updating these guides periodically ensures that the 
manuals/instructions remain functional and current and able to serve as training guides for new staff. 
 
Future editions of The Surveillance Guidelines will address training issues for surveillance programs in 
greater depth. 
 
Input file processing functions. The management of data quality within electronic birth defects data files 
is important as well. The procedures and processes for handling the quality of processed electronic data 
are similar to those used for paper reports. The tools available to a birth defects surveillance program are 
basic data processing and management practices that are not unique to these types of data. Electronic data 
files readily lend themselves to editing and clean-up. Standard computer routines can be used to screen 
files for obvious errors or inconsistencies, to spot problems with the data efficiently, to summarize 
findings, and to organize results in ways that allow the efficient correction of any errors. 
 
Key components of input batch processing are outlined to provide an inventory of the tools available for 
functional data quality control. The combination of practices employed by a given surveillance program 
needs to match the methods and procedures used for data file development. 
 
Editing. Development of data editing procedures is a standard activity in any database development 
effort. As with interactive editing during data entry, computer routines can be developed to identify a 
variety of data problems. Standard edits often include: 
 Field range checks 
 Report number range checks to identify missing records 
 Inter-item consistency checks 
 Field validity checks  
 Code validation through table look-up, i.e., diagnostic or procedures code tables 
 Consistency across multiple reports for the same case 
 Hard versus soft edits and use of edit flags   
 
The organization of the results from edits requires the same care in design as do the edit criteria. The 
results of an edit run need to be organized to make error resolution and file correction as efficient as 
practical. 
 
Tracking information. As potential problems with data are identified, it may be necessary to ask the 
reporting source for clarification or for additional information. A basic procedure to monitor outstanding 
requests for clarification or correction should be used.  
 
Printed case abstract. In conjunction with efforts to correspond with staff at the data source about 
reports, a ready mechanism to print an abstract of a report can improve the effectiveness of 
communications and may enable correction of other errors in a report that cannot be identified by the edit 
routines. The capability to print a case summary easily can prove useful for multiple purposes. 
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Error correction. It is important to have effective and efficient procedures for error correction. Reports 
that identify edit exceptions can be linked to the edit results to pull up rapidly, or to queue, the records 
needing attention. A well-designed process can minimize the potential for introduction of errors in the 
course of record correction. 
 
Case-by-case and multi-record correction. Mechanisms to correct records one at a time are important. 
The capability to update multiple records simultaneously can also be useful. When used judiciously, 
multi-record correction can save time and reduce the potential for error. 
 
Add/delete. The capability to delete spurious or redundant records can prove to be very useful. 
 
Linkage and assignment of case identifier. As input files are processed and screened for duplication, a 
system for uniquely identifying each case is necessary. While a program may choose to number and retain 
all reports received, it is critical that a specific child’s reports all have the same case identifier. This is 
necessary for record and file linkage. In a program where data are consolidated immediately, an identifier 
for each child is still a critical component of the system. A mechanism for assigning identifiers to newly 
reported cases is necessary. In the case of electronic submissions, this process should be automated.  
 
Facility reports. Summaries of data quality relative to screening and editing of incoming reports is 
important for maintaining an accurate picture of the quality of submitted data. Summary reports that 
permit the tracking of report quality over time and across facilities can be designed. Such information is 
very useful in identifying facilities that are candidates for data quality reviews and/or in-service training. 
These reports can complement efforts to work with facility staff to correct any persistent problems. 
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9.7  Record Linkage 
The proper operation of any birth defects surveillance program depends on developing and following 
procedures for efficient and effective record linkage. These procedures should be developed carefully. 
The accuracy of the procedures used to link individual case reports needs to be measured and monitored. 
Instances of the same child being in the database as different children and different children being 
presumed to be the same child must be estimated. Developing and monitoring linkage procedures 
carefully is as crucial for programs that manually search for potential matches as it is for those that use 
electronic linkage. 
 
Not only is it important to link incoming reports accurately to the historic file to locate previously 
reported cases, but the ability to link to other databases is also essential. Procedures need to be tailored 
and evaluated specifically for each type of linkage. Goals for linkage completeness that reflect these 
expectations need to be established.  
 
Linking birth defects case data with files from other sources may be done to meet a number of objectives. 
These include: 
 Deleting duplicate data 
 Case-finding 
 Augmenting the information available for a case 
 Conducting special studies or program evaluations 
 
The level of precision and efficiency that can be expected from a matching process are functions of 
several factors. Key among these are: 
 Quality of data within the files to be linked 
 Number of fields common to both databases 
 Logic employed to compare the files 
 Time available to review and assess each link 
 
The matching strategy developed should maximize the results and minimize the resources employed to 
obtain those results. Estimating the level of precision for any linkage procedure can be used to assess the 
advisability of revision. These estimates are also important for evaluating the suitability of using the 
linked data for specific purposes. 
 
With respect to assembling the required data on each case, linkages to birth certificate files and death 
certificate files are extremely important. These sources can provide the surveillance program with 
valuable information on each case. For example, linkage to the birth certificate file has the added benefit 
of identifying reports for a single child that may not have been linked properly during the processing of 
incoming data. Linkage to birth and death records can also provide the ability to track changes to a child’s 
name over time. This can assist in collating data on a single child that might otherwise be treated as 
distinct cases. In some jurisdictions, access to this kind of information will depend on legally prescribed 
restrictions. 
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9.8  Record Consolidation 
When multiple reports are received on the same case, differences can be expected in some of the 
information across reports. By developing a summary of the information on each case, consolidating the 
information across reports into a single summary, the information about the case can be enhanced. A 
number of issues must be addressed in any information consolidation effort. The categories of 
information that could be consolidated or summarized, and the key issues relative to summarization, 
include (1) demographics and identifiers and (2) diagnostics. 
 
Demographics and identifiers. Most demographic items are constants and do not change with the age of 
the child. These include date of birth, race or ancestry, mother’s age. Updating missing data fields using 
data from subsequent reports is generally appropriate. Conflicts across reports for these fields can be 
difficult to resolve, but may be predicated on the source of the data, prioritizing data from specific files or 
facilities. Changes can be expected to occur over time in identifier fields such as name, parents’ names, 
and address. Selection of the appropriate data to be included in a summary needs to be based on the 
purpose of the summary. For example, data for referral or outreach efforts need to be current, while data 
for auditing birthing hospital records should represent information at birth. 
 
Diagnostics. As multiple reports for a child are received, collecting diagnostic information across all 
reports can result in significant redundancy. When the same diagnoses are reported repeatedly, this 
redundancy is simple to manage. As diagnostic data change across reports, there are three possible causes. 
Each of these raises specific issues relative to proper management: 
 
 New conditions being diagnosed. Newly diagnosed conditions clearly must be included in any 
summary for the child.  
 Previously diagnosed conditions reported with greater or lesser specificity. Redundancies in 
diagnostic codes caused by differences in specificity can be problematic. In the absence of 
accepted guidelines for doing so, to eliminate redundancies (increasingly specific diagnostic 
codes) using intuitive logic can be problematic. The logic must be thought through clearly, with 
the intended use of the resulting summary in mind. 
 Actual changes to a previous diagnosis. Changing a diagnosis can reflect a revision based on 
better information or an alternative diagnosis, for example, a difference of opinion. A key 
problem with such changes is the need to differentiate a changed diagnosis from a condition that 
has been newly diagnosed. Having an effective mechanism in place for facilities to report 
corrections to diagnostic information can help reduce confusion in interpreting subsequent 
reports. Making changes to diagnostic data should be done carefully and through close 
coordination with facility staff. Some programs may prefer not to change original information, 
but rather flag it as inaccurate or no longer valid. In this way, the integrity of the database remains 
intact: inaccurate information is not “counted”, data quality evaluations can be conducted, and 
new or confirmed information is accepted. This is especially useful when comparing reported 
information with the results of medical records review by surveillance staff. 
Procedures data. Redundancy can be expected in data reported for procedures, since it is not uncommon 
for a child to have some treatment or corrective procedures performed multiple times. Therefore, such 
data can be consolidated reliably only if the date each procedure was performed is reported, or available 
through medical record review, to identify specific procedures by date received. 
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9.9  Feedback to Data Sources/Abstractors 
When data problems are identified during report processing, it is important to communicate those 
problems to staff at the data source. Facilities and/or individuals providing data should be interested in 
learning of problems the surveillance system encounters with respect to the completeness and accuracy of 
their data. With passive reporting systems, communicating errors, resolving inconsistencies, and 
reviewing apparent discrepancies represent effective feedback mechanisms. An efficient mechanism is 
needed to provide feedback on problems, although the necessary corrections to the information may seem 
obvious to surveillance program staff. Staff of the reporting facility will benefit from the feedback and 
may need to correct the information within their own records. 
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9.10  Security 
Many of the data assembled by a birth defects surveillance program are extremely sensitive. For this 
reason, a program must initiate and maintain a comprehensive strategy for data security that ensures data 
are protected from improper access or inappropriate use. Developing a security plan that establishes and 
demonstrates a commitment to data protection is essential in reaching the program’s long-term goals and 
objectives.   
9.10.1  Personnel Issues 
Four aspects of security management fall under the category of personnel issues. 
 
 Hiring practices. Attention needs to be paid in selecting new staff members to screening 
candidates to ensure they can be relied upon to handle confidential data appropriately. A work 
history that includes responsibly handling confidential data is an example of desirable experience. 
It is important to request and check references for all prospective employees. If possible, security 
background checks should be conducted prior to making a hiring decision.  
 Written procedures on security and access. New employees need to be informed clearly of the 
procedures regarding appropriate access to and use of data, particularly any files that include 
personal identifiers. Written materials that describe the nature of the data and the rules and 
policies relative to data handling must be reviewed with employees. These materials must cover 
all aspects of employees’ actions for which they are accountable. These materials need to be 
discussed with each employee to ensure that the employee has every opportunity to ask questions 
so that they understand the policies explicitly. A written policy on the release of identifiable or 
potentially identifiable data must be included. It is essential that all aspects of data release be 
identified within the policy, along with who has the authority to authorize a release. Such a policy 
must include the “business activities” of returning data diskettes and corresponding on data 
editing problems with data providers, as well as release of identifiable data for research use or in 
conjunction with child-find referral activities.  
 Security and confidentiality agreement/oath. Each employee who has access to the program’s 
data must sign a confidentiality pledge. The pledge should be in the form of a comprehensive 
statement that outlines the confidentiality policy in broad terms. In addition, this document should 
include a statement that the employee understands the confidentiality policies and the potential 
consequences for violating these policies. Finally, the document must include an oath on the part 
of the employee that they will abide by these policies. As significant changes to the 
confidentiality policies are made, each employee must sign a new pledge that reflects the new 
policies. 
 Disciplinary policy. Whenever there is an allegation of mishandling confidential data or where 
unauthorized access is suspected, the incident must be investigated. Such an investigation must be 
conducted carefully and in a manner consistent with existing employment laws and personnel 
practices. Appropriate disciplinary action must be taken if it is established that an employee has 
violated the confidentiality policy. Any deliberate violation of policy that results in the 
inappropriate release of confidential data should be grounds for dismissal and for potential 
criminal action, depending upon the law governing these data.  
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9.10.2  Transportation and Information Handling 
Basic security concepts that should be considered relative to shipping and handling information are listed 
in this section. Standard office practices and procedures for handling materials that include confidential 
data need to be developed and followed. These are necessary to avoid problems due to inappropriate or 
inadvertent access to these data.  
 
The privacy regulations developed as part of the Health Insurance Portability and Accountability Act, or 
HIPAA, place significant responsibilities on hospitals, physicians, and others to properly safeguard 
confidential data on their patients. These regulations place strict procedural standards on health care 
facilities, heightening concerns about patient privacy held by health care facilities and providers. It is 
important to adopt information exchange practices with data sources that do not create a potential liability 
under the provisions of HIPAA (see Chapter 2 on Legislation). For example, common and efficient 
methods for exchanging information, such as fax or e-mail, need to be avoided or used with great 
attention to appropriate security. This is because faxed images can be intercepted and printed, can be 
inadvertently sent to the wrong fax or to a fax that is unattended or otherwise not secure. E-mail shares all 
these problems in addition to the fact that e-mailed materials will become part of the e-mail back-up 
systems and copies of sensitive materials will become interspersed with other documents that may well be 
public information. The existence of these back-up files means a loss of control over the data and access 
to the data. The problem of potentially intercepting e-mail only compounds this problem.  
 
With these thoughts in mind, key considerations relative to good data handling and transporting practices 
are provided below. 
 Instructions to data sources for addressing and shipping of incoming reports and information. 
All facilities and individuals who ship abstracts or data to the surveillance program must be 
provided with current and precise address information. Data sources should be encouraged to ship 
data in a secure manner where chain of custody signatures are required, such as certified mail or 
FedEx. If a shipment is received that was misaddressed, the data source reporting the cases 
should be contacted promptly by telephone, with a follow-up letter, and be advised of the correct 
addressing of shipments. In addition, standard practice should include prompt acknowledgement 
of shipment receipt. As staff at the data source learn to expect an acknowledgement of each data 
shipment, failure to receive an acknowledgement will alert them to the possibility that a shipment 
has been lost or delayed. 
 Use of fax or e-mail for forwarding or receiving sensitive data is not advisable. These methods of 
transmission should not be considered secure unless the sensitive information is encrypted and 
password protected. Fax machines that both send and receive such materials need to be attended 
during transmission.  
 Managing the work station. Employees need to be trained to manage their desktops. Confidential 
materials should not be on a desk if they are not being used actively and should not be left 
unattended during breaks or lunch periods. Similarly, passwords should be required for staff 
access to any personal computer that holds confidential data or that allows access to confidential 
data through a network or other computer connection. Such equipment should not be left 
unattended with connections in place that would permit unauthorized access. Care must be used 
in displaying confidential data on the computer monitor in order to ensure that persons who do 
not have authorized access cannot read them. All materials must be filed properly and locked 
when not in use. Following these common sense practices reduces the possibility of inappropriate 
access and should be applied conscientiously to the desk, the personal computer, and the files 
assigned to each staff member. 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 06/04 
  
Chapter 9     9-21            Data Management and Security 
 Physical access to abstracts, other documents. Limiting direct physical access to files and other 
materials that include confidential data is a basic step in reducing the likelihood of someone 
seeing information to which they are not privy. The design and layout of offices can be done in a 
way that enhances staff members’ ability to carry out their responsibilities without exposing 
confidential material to others. Careful planning in this regard, combined with good desktop 
management practice, will minimize inadvertent access.  
 Procedures and furnishings to lock up documents and diskettes. Employees must be provided 
with the office furnishings needed to adequately secure documents. Locking desks and locking 
file cabinets are essential, with thought given to assignment and management of keys for these 
locks and the organized storage of extra keys. 
 Procedures for shipping reports and information from the program. Program staff need to follow 
secure practices, as when they send any confidential materials to data sources. It is essential that 
such shipments are addressed properly, and the address should be confirmed if there is any doubt 
about its correctness. Materials should be shipped using a method/carrier that obtains a signature 
to verify receipt. Confidential data should not be shipped through e-mail or FTP unless the 
security of the connection is ensured or an adequate encryption technique is used to disguise the 
data. 
 Shredding and destruction. Considerable care must be taken to avoid any potential for disclosure 
of data when confidential material is discarded. Employees must be conscious of the need for care 
when discarding any program-related materials that include identifiers or that would be 
considered confidential. Computer listings, correspondence, and other materials need to be 
screened to be sure that confidential data are handled appropriately. Staff should be provided with 
access to a shredder, and paper abstracts or printouts with confidential data should be shredded 
promptly. Any large volumes of confidential materials that need to be disposed of must be 
destroyed in a secure way.  
Similar standard precautions must be established for computer storage devices. Diskettes should 
be reformatted, rather than simply deleting files. As hard drives on personal computers are 
replaced, the old drive must be reformatted or any data remnants otherwise destroyed, for 
example, by storing them between strong magnets for a period of time. 
 Transportation of data. When staff members are in the field, all confidential data must be 
carefully safeguarded. Documents should be transported in locked brief cases or otherwise 
protected. The security of portable computers must be ensured. Confidential materials must be 
kept locked in the vehicle trunk while traveling. During overnight stays these materials should be 
removed from the vehicle and placed in a hotel room rather than left in a vehicle overnight. 
9.10.3  Physical Security 
Physical features of the worksite can enhance information security significantly. There are two specific 
ways the facility housing a surveillance program can maximize security: 
 Restrict physical access to the work area. To the degree possible, access to the surveillance 
program’s work area should be controlled. Ideally, it should be isolated with a card entry access 
system. Reducing or eliminating travel into and through the work area translates directly into 
reducing or eliminating opportunity for inappropriate data access. 
 After-hours security. At a minimum, the office area must be locked securely after working hours. 
Ideally, the office area should be protected against unauthorized access through use of an alarm 
system that includes motion detectors and that is monitored centrally and continuously. If 
possible, no janitorial services should be carried on after hours.  
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Periodic maintenance work should generally not be conducted after hours unless surveillance staff are 
alerted and have an opportunity to take any and all extra precautions to ensure appropriate security of the 
data.  
9.10.4  Computer Security 
Proper data security requires a comprehensive approach to computer security. A number of key aspects to 
any plan designed to protect electronic data files are listed below. 
 User ID and password. A system for unique user IDs and passwords is a cornerstone of computer 
network security. Staff should not be allowed to share ID and password information. Departing 
employees must be deleted from the system promptly. Periodic outdating and changing of 
passwords should be standard. Employees need to understand the importance of these activities 
and know that their personal login is critical to protect. This is because activities on the system 
will be traceable to the user’s ID and password. 
 Virus scan – current. In receiving electronic data, it is essential that diskettes and other electronic 
files be scanned for viruses prior to loading onto the personal computer or the network. A 
comprehensive and continuously updated virus scanning package should be used for this purpose. 
 Control of user access to data. Careful management of user rights to the network or other 
computer system can significantly enhance data security. It is important to minimize to the extent 
possible unnecessary access to files. Steps must be taken to decrease or eliminate both potential 
misuse of data and inadvertent damage or destruction of data that are accessed inappropriately. 
Planning the architecture for data storage can complement limiting access to the various data files 
and greatly enhance security in the process. Much like user IDs and passwords, this level of 
security must be continuously maintained, with access modified as staff work assignments change 
over time. 
 Discarding of old personal computers, hard drives. There are a number of special considerations 
regarding the security of electronic files. Simply deleting a file from a hard drive or diskette does 
not actually erase the data. This problem is not always properly addressed as old computer 
equipment is swapped out or discarded. There must be procedures developed for disposal of 
computer storage devices that ensure none of the data are recoverable. 
9.10.5  Policy on Release of Data 
Written procedures must be established that describe the proper mechanisms for release of information 
from the surveillance program. Written procedures are necessary to provide surveillance staff with a clear 
understanding of proper data handling and release. The process for obtaining approval for access to the 
data, and authorization for release of the information, must be described in detail. There must be no 
confusion among the staff on this critical topic. 
 
Confidential data release procedures should include the specific practices required for proper preparation 
of tabular statistical data, as well as de-identified micro data files. These micro data files must be 
designed to guard against inadvertent disclosure of confidential data. The procedures must delineate 
clearly the approval process that governs and regulates release of identifiable or potentially identifiable 
data. Issues related to sending identifiable information to data sources and to other sources of information 
about cases of birth defects must be covered. Providing access to confidential information for research 
purposes must be discussed, describing the types of research projects that may gain access to these data 
and the system’s process for reviewing and approving such projects. Finally, the conditions under which 
the information can be used for administrative purposes must be covered. This should include using the 
data to ensure that children and families are referred appropriately for needed services, if this is part of the 
surveillance system’s objectives.  




Data Collaboration and Dissemination 
through the NBDPN 
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10.1  Data Collaboration and Dissemination through the NBDPN 
With the support and collaboration of the Centers for Disease Control and Prevention, the National Birth 
Defects Prevention Network (NBDPN) collects, analyzes, and disseminates state- and population-based 
birth defects surveillance data. In this way, the NBDPN plays an active role in turning data from 
throughout the US into useful information and encourages the use of birth defect data for decisions 
regarding health services planning, such as secondary disabilities prevention and referral to services.  
 
The NBDPN State Data Committee coordinates the procedures and processes required in this effort. One 
of this committee’s collaborative activities is the publication of an annual report of birth defects 
programs. The report includes detailed descriptions of the individual state birth defects surveillance 
programs, tables of data submitted by the participating states, and selected data analyses. The report 
includes diagnoses of interest, information regarding the format for submitting data for the annual report, 
and the criteria for the state directory that describes each birth defects surveillance program.  
 
The NBDPN State Data Committee also discusses issues related to data suppression, confidence intervals, 
statistical analysis, and presentation of data, which are often of concern to the states. Because of the 
committee members’ technical expertise in working with state data, the committee also has a role in 
evaluating the feasibility and merits of NBDPN participation in other data projects. Any use of data 
aggregated under the auspices of the NBDPN, including data projects and ad hoc studies, must be 
approved by the NBDPN Executive Committee.  
 
All decisions regarding privacy, security, and confidentiality issues related to releasing or submitting 
surveillance data from individual programs to the NBDPN are handled at the state level.  
 
Interested parties are invited to refer to the NBDPN website (at http://www.nbdpn.org) for contact 
information relating to the State Data Committee and for instructions on how to submit data to the 
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11.1  Using Data for Decision-Making 
 
This chapter focuses on the fundamentals of data presentation for a birth defects surveillance program. A 
birth defects research program will have needs that go beyond what is addressed in this chapter. Readers 
are referred to the references and technical appendices in this chapter for additional information. The 
reader may also wish to refer to Chapter 8 (Statistical Methods) of The Surveillance Guidelines for more 
in-depth treatment of some of the topics touched upon in this chapter. Finally, the Members Only section 
of the National Birth Defects Prevention Network (NBDPN) website will be posting materials on more 
advanced aspects of data presentation as they become available. 
 
Collecting data for data’s sake wastes precious resources. There is no good reason to collect data unless 
we intend to use them, generally to inform someone in a position to do something about the story our data 
tell.  
 
Surveillance data in particular are intended for use in accomplishing the purposes and objectives of the 
surveillance program. In Chapter 1 of The Surveillance Guidelines we discussed the five major purposes 
of birth defects surveillance and their related objectives, as presented below. 
 
 Epidemiologic. Epidemiologic objectives include developing timely baseline birth defects rates, 
monitoring trends and relationships to environmental factors, performing cluster investigations, 
and providing a basis for ecologic and etiologic studies 
 Planning and prevention. Planning and prevention objectives include providing data for services 
planning, providing a basis for prevention strategies, and evaluating the efficacy of preventive 
services and programs. 
 Educational and social. Educational and social objectives include informing the public about 
public health importance, informing parents about resources and care facilities, providing data for 
studies of economic impact, and providing data for follow-up studies of long-term effects. 
 Healthcare and human services. Healthcare and human services objectives include referring 
children to services and resources and evaluating services utilization. 
 Clinical. A clinical objective is providing the basis for clinical research. 
 
Of course, not all surveillance programs pursue all of these purposes and objectives, but every program 
pursues some combination of them, and all collect data as a means to achieve them.  
 
In order to fulfill the objectives of a birth defect surveillance program in all of these core areas, data must 
be collected in a complete, accurate, and timely manner. They must also be processed and interpreted in a 
way that ensures the availability of useful information to those with the responsibility to carry out specific 
activities that meet the program’s objectives. Under some circumstances, this is relatively straightforward. 
For example, if a programmatic objective is to connect babies with specific birth defects and their 
families with appropriate medical and social services, then data collected on diagnosis and parent contact 
information immediately provide the information needed to initiate an appropriate referral. Frequently, 
however, there is a need to aggregate, analyze, and interpret data and subsequently present the resulting 
information to a variety of partners capable of taking necessary action. It is this latter more complex 
process that is the focus of this chapter. 
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11.1.1  The Data-to-Action Continuum 
Yet data are, after all, only data. How is it that the data so carefully collected by surveillance program 
staff are transformed into the many different kinds of actions necessary to achieve their programmatic 
objectives?  
 
There are two points to consider in answering this question. First, surveillance staff clearly cannot 
accomplish all of these important objectives without the help of their partners. Second, the transformation 
of data into action is not a discrete one-time occurrence––such as standing up with your slide presentation 
in front of a live audience––but rather a complex process involving extended collaboration between 
surveillance staff and their partners over time. To be sure, it is through presenting data in a clear manner 
in response to expressed interests of a particular “audience” and in support of an actionable message that 
this transformation begins to occur. Yet we need to bear in mind that, while the data presentation theories 
and skills discussed in this chapter can be mobilized in aid of this transformation, they are in fact only one 
aspect of the larger collaborative process that transforms data into action.  
 
We can conceptualize this transformation as having four stages (see Figure 11.1, the Data-to-Action 
Matrix), with surveillance program staff and their partners closely involved in each one. Sources are 
abstracted to obtain data. Data are analyzed and interpreted to obtain information. Information is 
communicated to develop knowledge. And knowledge is used to inform action. Data presentation, then, is 
one of several skills that support this process, as we convey information to our program partners in order 
to generate the knowledge needed to embark on actions that meet our shared objectives.  
11.1.2  Products of the Data-to-Action Transformation 
Figure 11.1 suggests that each stage of the data-to-action transformation results in a distinct “product”: 
data (Stage 1), information (Stage 2), knowledge (Stage 3), and action (Stage 4).  
 
Let’s take a moment to clarify these terms. While this chapter is entitled “Data Presentation,” we are not 
really talking about presenting data, but rather about presenting the information generated from data in 
the expectation of building knowledge for ourselves and our partners. Although the terms ‘data’ and 
‘information’ and even ‘knowledge’ are often used somewhat interchangeably, there are important 
distinctions between them.  
 
Simply put, the purpose of data is to record “something” and the purpose of information is to build 
knowledge. Data (from the Latin meaning “something given”) consist of raw facts or unedited stimuli. 
They are based on the symbolic recording of something, such as numbers, facts, and figures. Data provide 
a foundation for and can be developed into information, but they must be combined and integrated with 
other data before they become useful.  
 
While information includes data, data do not necessarily include information. Information is data with 
semantic association and is the result of processing, manipulating, and organizing data in a way that adds 
to the knowledge of the receiver. When augmented by meaning or interpretation, data become 
information. It is the information developed from data that provides answers to our questions and those of 
our partners about birth defects, thereby increasing our knowledge.  
 
 
NBDPN Guidelines for Conducting Birth Defects Surveillance  rev. 07/08 
 
Chapter 11 11-3  Data Presentation 






From the perspective of this chapter, our goal is to obtain data from a data provider (Stage 1–Data 
Provision), analyze and interpret it so that it becomes information (Stage 2–Data to Information), and then 
present it to and discuss it with one or more potential action takers so that it becomes knowledge that can 
be used to meet programmatic objectives (Stage 3–Information to Knowledge). It is then the action 
takers’ responsibility to see that the new knowledge is used to meet the specific objectives of the program 
for which it has been collected and for which it is relevant (Stage 4–Knowledge to Action).  
 
This chapter discusses each of the stages in the model in turn. We spend less time on the first and fourth 
stages, as both are thoroughly discussed elsewhere in The Surveillance Guidelines. Stage 4 (Knowledge to 
Action) is discussed further in Section 1.4 of The Surveillance Guidelines (Uses of Surveillance-based 
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With respect to the ability of surveillance data to provide useful information, the old axiom from statistics 
“garbage in, garbage out” holds true. Before a surveillance staff member can begin to think about how to 
present data, knowing what data to present and feeling confident that the data are accurate and reliable is 
paramount. 
 
In fact, the value provided by the information developed using birth defects surveillance data depends 
heavily on the quality of those data and the completeness and accuracy with which they are collected. The 
majority of the technical content of The Surveillance Guidelines is directed toward helping to ensure 
completeness and accuracy of the data that are collected and their resulting validity.  
 
From an epidemiologic perspective, when we refer to data validity we are concerned with whether the 
data regarding cases in a study or surveillance program accurately reflect the numbers and characteristics 
of the cases that occur and that are eligible for inclusion in the data set. When we are attempting to 
determine or measure the occurrence of birth defects in a population, it is essential that we include all of 
the cases that meet the established case definition (completeness). For cross-sectional or case-control 
studies, while completeness is important, in the absence of including all cases validity is driven by 
whether the cases that are included accurately reflect all the cases that occurred in the study population 
(population at risk) with respect to epidemiologic variables related to characteristics of person, place, and 
time.  
 
In the next section we discuss some of the analytical and interpretative issues involved in turning 
surveillance data into information. 
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In The Surveillance Guidelines, we follow the Centers for Disease Control and Prevention (CDC) 
definition of surveillance as established in Chapter 1. The key themes of the CDC definition of 
surveillance are the integration of data collection, analysis, interpretation, dissemination, and application. 
It is in moving from analysis to interpretation that data are converted to information.  
 
Some aspects of birth defects lead to potential confusion or ambiguity in reporting information about 
them and their distribution. In this section we discuss a number of analytical and interpretive issues that 
should be considered when developing and presenting birth defects data. These include: 
 
 Providing contextual information (person, place, and time) 
 Missing or unknown data 
 Importance of comparison 
 Approaches to measuring occurrence (prevalence versus incidence) 
 Level of focus (which in part arises from the complex etiology and comorbid nature of many birth 
defects) 
 Risk factors and the importance of timing with respect to exposures 
 Privacy and data suppression (see also Appendix 11.1) 
 Using Geographic Information Systems (see also Appendix 11.2) 
11.3.1  Providing Contextual Information––Person, Place, and Time 
When presenting data, it is useful to consider the key epidemiologic constructs of person, place, and time. 
What population is reflected in the data? From what location were data collected? And on what time 
period are the data based? One must be able to accurately and precisely answer these questions for the 
findings to be relevant. For example, a presentation may report very interesting results based on a sample 
that was collected in a very disorganized and biased manner, making it impossible to define exactly what 
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population is reflected in the data set. Unfortunately, these results would be of limited value because it is 
impossible to define to whom the findings are relevant. 
 
Similarly, whenever variation by person, place, or time occurs, analyses should examine possible 
differences or trends. If a sample includes multiple ethnic groups, are there differences between these 
groups? Or if data were collected over a decade, were trends seen over time? A presentation should 
acknowledge that such trends were examined and differences reported if observed.  
 
In the actual presentation, it is often useful to present data grouped on the basis of person, place, and time. 
When doing so, it is important to be mindful of widely accepted groupings inside or outside your 
organization. For example, person characteristics such as age, race, and ethnicity can be grouped based on 
Office of Management and Budget classifications. Audience members will be familiar with such 
groupings and, more importantly, they will be better able to relate the findings to their own data based 
upon these common groupings than they would if the presenter organized the data in some idiosyncratic 
manner. Similarly, place can be presented in a variety of ways, including aggregating based on town, 
county, zip code, or census tract.  
 
Information collected over time can lead to more complex issues, such as the decision to report raw 
curves or a moving average. The complexity of time-varying data requires that one be clear on both the 
time period and method used in presenting such information. 
11.3.2  Missing or Unknown Data 
An aspect of data presentation often overlooked is the importance of providing information about the 
extent of missing/unknown data for study variables. Information that is missing or unknown can be just as 
important to understanding results as is the available information. This is especially true when the amount 
of missing information is more than minimal. Missing or unknown information can be reported in such 
data displays as tables, histograms, and pie charts by including a category labeled ‘unknown’ (e.g., 
maternal age < 34, maternal age 35+, and maternal age unknown). If the way the information is being 
presented does not allow for a row/column/line/bar/slice to be designated as ‘unknown’, a footnote should 
be added to the data display informing the audience about the extent of the unknown data. Maps based on 
geocoded data, for example, could add a footnote with the “percentage of data that was not geocoded” to 
the geographic resolution presented.   
11.3.3  The Importance of Comparison 
Epidemiologic data tend to be numeric and presented either as counts, ratios, proportions, or rates. In 
addition they are usually presented as information specific to the epidemiologic parameters of person, 
place, and time. Information presented in this manner provides a way of making meaningful comparisons 
between different populations and different periods of time. Note: the points made below are of particular 
importance when one will be comparing data collected at different levels (local, state, regional, national) 
or by different programs. 
 
Fundamental to epidemiology are the principles of comparisons: 
 
 Between areas/populations 
 Within an area/population over time  
 
These comparisons often involve consideration of epidemiologic variables such as sex, plurality, 
race/ethnicity, pregnancy outcome, maternal age, etc. Comparisons are also usually of some measure of 
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occurrence, in the case of birth defects prevalence of a specific malformation or groups of malformations. 
Increasingly, there is interest in making comparisons between some health status indicator at the local or 
state level and a benchmark, such as a Healthy People 2010 objective or an agency-developed objective.  
 
For comparisons to convey useful information, it is essential that like be compared with like. When 
comparative data are presented, the audience must know if this holds. In terms of birth defects data, there 
are at least four points that need to be clearly established if meaningful comparisons are to be made: 
 
 What is being counted? Are the outcomes––case definitions––comparable? (see Chapter 3) 
 How are cases ascertained? Were similar methods of case ascertainment used? (see Chapter 6) 
 Are the pregnancy outcomes from which the cases were ascertained comparable? 
 Are comparable measures used to summarize data? 
 
Each of these is worth considering with respect to the information that can be provided based on 
surveillance data. 
 
What Is Being Counted? 
 
Comparability of outcomes revolves around disease coding, classification, and the aggregation of cases. 
At the most general level, if we refer to “the occurrence of birth defects,” we need to be clear about what 
is included in that term. In the past, birth defects were usually considered to be synonymous with 
congenital malformations and referred to diagnoses with ICD-8 and ICD-9 codes 740.0 to 759.9. Some 
surveillance programs, however, may follow the much more general March of Dimes definition of birth 
defects that includes metabolic and functional abnormalities as well. When comparing data between 
programs that use different definitions of the term ‘birth defects’, there are likely to be sufficient 
differences between what programs are counting as to make comparisons difficult, if not meaningless.   
 
Even programs that use the same definition for the term ‘birth defects’ may vary in terms of what they 
include (and count) under a specific group of birth defects. One example of this relates to the reporting of 
studies of neural tube defects. In the past it was common to see reference to the occurrence of “central 
nervous system (CNS) malformations.” Anencephaly and spina bifida might make up the majority of the 
cases, but cases of hydrocephaly and microcephaly would often be included as well. Clearly, comparing 
the results of a study that reported on the occurrence of all CNS malformations with one that consisted 
only of cases of anencephaly and spina bifida would be inappropriate.  
 
Programs may also differ in the ways they define a specific birth defect. For example, most surveillance 
programs do not include preterm babies with atrial septal defects as cases. The Metropolitan Atlanta 
Congenital Defects Program (MACDP), for one, does not include infants of less than 36 weeks gestation 
at delivery among their reported cases of this defect (Correa et al., 2007). Therefore, if a program does not 
establish a gestational age criterion for atrial septal defect as part of the case definition, then comparison 
of their prevalence data with those of MACDP would be misleading. 
 
How Are Cases Ascertained? 
 
The second key aspect to data comparability relates to how the surveillance program ascertains cases. For 
example, some have expressed concern that surveillance programs relying on the reporting of cases by 
hospitals (passive case ascertainment) may identify a smaller percentage of the true cases that occur than 
will programs that send abstractors from their staff out to hospitals to actively search records for potential 
cases (active case ascertainment). Such differences may be more perceived than real, depending on the 
individual surveillance programs involved.  
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Perhaps a better example of potential differences in completeness of ascertainment based on methods of 
case identification would be an attempt to compare data from a program that identifies cases only from 
vital records (birth and fetal death certificates) with data from a program that identifies cases based on 
medical record review. Several studies have identified serious problems with under-reporting of 
malformations on vital records (Watkins et al., 1996). 
 
Are the Pregnancy Outcomes from Which Cases Were Ascertained Comparable? 
 
Another issue with respect to comparisons relates to the populations from which cases are identified. 
While some surveillance programs are able to identify prenatally diagnosed cases that result in pregnancy 
termination and include them in their numerator, many are not. This difference is particularly important 
for defects such as anencephaly and spina bifida, which are being diagnosed prenatally with increasing 
frequency. In one of the first studies conducted by the NBDPN, prevalence data over time were presented 
separately for programs that did (9 states) and did not (13 states) ascertain prenatally diagnosed and 
electively terminated pregnancies where a fetus with anencephaly or spina bifida was identified (Williams 
et al., 2002b). Figures included in this paper clearly show the potential effects of inappropriately 
comparing prevalence from programs that do and do not include cases from terminated pregnancies in 
their data. 
 
Are Comparable Measures Used to Summarize Data? 
 
Once it is decided what to count and how to collect the data on what is being counted, it is important to 
ensure that the measures used to present the resulting information are the same. If the presenter is 
calculating the measures from base data, the same measure (e.g., birth prevalence expressed as cases per 
10,000 live births) should be used for each of the different population groups, areas, or time periods. 
However, if the presenter is compiling or comparing already calculated measures, it is prudent to 
understand how these were calculated. For example, several surveillance programs within the NBDPN 
have presented birth prevalence as cases per 1,000 live births, while others have used cases per 10,000 
live births. This difference should be quite evident in most instances. Less evident is the fact that 
surveillance programs in the NBDPN tend to use only live births in the denominator (see Chapter 8 
Statistical Methods), whereas reports from other groups, such as the International Clearinghouse and 
EUROCAT, may include spontaneous fetal deaths and/or pregnancy terminations in the denominator. 
While the inclusion of these outcomes in the denominator will not have the same impact as if they are 
included in the numerator, it will result in slightly lower prevalence values (Sever, 2006).  
 
When comparing groups within a population it is also good to ensure that specific birth prevalence is 
being calculated, i.e., that both the numerator and denominator are restricted to the same population. 
Occasionally, we find prevalence figures where the denominator is based on the whole population and the 
numerator comes from a subgroup. The above issues can be checked by carefully reviewing the Methods 
section of the reports from which data are being drawn. 
11.3.4  Approaches to Measuring Occurrence––Prevalence Versus Incidence 
Birth defects arise developmentally within the first few weeks after conception. As a result, many affected 
embryos (i.e., cases) will spontaneously abort before a woman is aware she is pregnant. Consequently, in 
epidemiologic terms, it is impossible for one to reliably assess the population at risk, as the number of 
pregnancies that reach the critical gestational phase where a given birth defect can arise is unknown. In 
addition, it is unknown how many of these affected pregnancies result in spontaneous abortions. As 
discussed elsewhere, it is not possible to accurately estimate the incidence of a birth defect––the number 
of new cases of a defect occurring in a population at risk during a specific time period––because one 
NBDPN Guidelines for Conducting Birth Defects Surveillance  rev. 07/08 
 
Chapter 11 11-9  Data Presentation 
cannot establish the number of new cases of the birth defect nor the population of conceptuses that were 
viable (and thus “at risk”) at the relevant point of development (Mason et al., 2005). Most epidemiologists 
in the field suggest that data be presented and discussed in terms of prevalence, often reported as 
prevalence at birth or birth prevalence.  
 
As noted, in reporting the occurrence of birth defects, prevalence estimates are often calculated so that the 
numerator includes cases that do not appear in the denominator. For example, while the denominator 
commonly consists of the number of live births, if data are available, it is generally preferable to include 
birth defects observed among fetal deaths and induced terminations in the numerator. The resulting 
prevalence is a ratio, which generally includes a multiplier—typically 10,000––so that the reported 
prevalence of most defects will have at least one unit to the left of the decimal point. Numerically 
1.6/10,000 is the equivalent of 0.16/1,000. For further detail see Chapter 8 “Statistical Methods.”   
 
Birth prevalence provides a method of expressing the occurrence in a population in a way that supports 
comparisons. When the number of live births is used as the denominator, to be meaningful it should 
represent the same geographic and temporal “population at risk” that the birth defects cases come from. 
For example, in Missouri in 1989–1995 there were 193 cases of tetralogy of Fallot delivered statewide. 
This provides the numerator for the calculation of prevalence. The 532,592 live births delivered statewide 
in 1989–1995 are the denominator. The number of cases (193) divided by the number of live births 
(532,592) times the multiplier of 10,000 yields a prevalence of 3.62 case per 10,000 live births.  
11.3.5  Level of Focus 
Different types of birth defects can have different causes and arise through several different biologic 
pathways. Moreover, an individual child can have defects in multiple organ systems. This creates another 
fundamental issue, which can be thought of as the choice of level of focus: whether the focus is on 
individual (specific) birth defects or on individuals with birth defects. When the focus is on individual 
birth defects, the occurrence of specific birth defects is of interest. In contrast, when the focus is on 
individuals with birth defects, one is interested in the issue of how many people have birth defects.   
How one chooses between these approaches depends on the question being asked or how the data will be 
used. If one is interested in identifying possible teratological effects of environmental contaminants, for 
example, the focus may shift from a single birth defect to the occurrence of any potentially related birth 
defect. This may involve examining the potential association between various chemicals and the 
occurrence of all types of birth defects. 
Many scientists argue that analyzing all birth defects together rather than examining specific defects is of 
limited value. Importantly, how different types of defects can be aggregated in a biologically meaningful 
way is an issue of interest. Just as reports on infectious disease do not look at infectious diseases as a 
group, but present information on specific diseases (measles, shigella, AIDS, syphilis, toxoplasmosis, 
malaria, etc.), birth defects should be examined in the same way. For example, the epidemiology and 
causes of outcomes such as neural tube defects, gastroschisis, and Down syndrome are different so the 
logic of lumping them together may be questionable. Nevertheless, approaches for grouping defects in 
biologically and etiologically meaningful ways are being pursued.  
In addition, it is important to recognize that many times a child will have more than one type of birth 
defect. For example, 58% of children in the Texas registry have more than one birth defect. Therefore, 
reporting the numbers of cases of individual types of birth defects, without informing the audience of the 
extent of multiple diagnoses, may unintentionally lead to an overestimation of the number of individuals 
in the population with birth defects. Furthermore, many audiences may be specifically interested in the 
number of persons with birth defects, since this information can be relevant for advocacy and health 
planning purposes. 
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11.3.6  Risk Factors and the Importance of Timing with Respect to Exposures 
Surveillance programs often collect limited data on risk factors for birth defects, as well as on cases. 
However, there are important distinctions between those types of data routinely collected and those 
obtained as part of special studies (such as cluster investigations) or in conducting epidemiologic 
research. This discussion focuses on risk factor data that are often collected routinely and their 
presentation. 
 
Exposures known to be risk factors for birth defects are quite limited, one of the issues that makes 
additional epidemiologic studies so important. Examples include maternal metabolic imbalances (such as 
diabetes) and viral infections (such as rubella), as well as a small number of drugs and occupational/ 
environmental chemicals.  
 
Three sociodemographic variables for which data are routinely available can potentially be considered 
risk factors for some birth defects. These are maternal age (date of birth), maternal race and ethnicity, and 
maternal education. As discussed in Chapter 4 (Data Variables), the first two of these are considered as 
core variables, while the last is a recommended variable.  
 
In presenting data on these variables, maternal age is usually grouped either into quinquennia (<19, 20–
24, 25–29, 30–34 and > 35) or into two age groups (<35 and >35). The latter grouping is used as it is 
particularly relevant to Down syndrome risk and prevalence. As discussed in Chapter 4, race and 
ethnicity should be presented in categories that are comparable with the federal standards in current use. If 
data on maternal level of education are collected, then they should be presented in the same categories 
used on the birth certificate. Following these recommendations in presenting data on the above 
sociodemographic variables allows information on cases to be compared with that from the certificates of 
live births for the at-risk population. 
 
A final type of risk factor information to be considered here is maternal place of residence (address). 
This, too, is considered a core variable and is basic to the use of geographical information systems, a topic 
discussed later in this chapter. In terms of presenting data on residence, cases are usually aggregated into 
some geopolitical unit (such as counties) or into administrative units (such as health regions), for which 
information on live births is available. How these aggregated data are presented to the public or to data 
users other than surveillance program staff is considered below in the discussion of data suppression.  
 
While perhaps not pertinent to the way data are presented in a general sense, the issue of maternal 
residence as a risk factor raises an important point about presenting information in epidemiologic studies. 
Particularly with the increasing utilization of GIS, the location of the mother’s place of residence is 
sometimes used as a surrogate for exposures in studies of risk factors associated with the ambient 
environment (Sever, 1997). In considering residence as a surrogate for exposure in studying birth defect 
risk factors, it is important to know the location of the mother’s residence at the time in gestation when 
relevant developmental events are occurring. Periods of sensitivity are well known for many organs and 
structures and, for the most part, these are during the embryonic period, early in pregnancy (Mortensen et 
al., 1991). 
 
Unfortunately, most surveillance programs collect only information on the mother’s address at the time of 
delivery, when it is residence during embryogenesis that is biologically relevant. This is important in 
assessing possible risks related to the ambient environment because several studies have shown that a  
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large percentage of women move between conception and delivery (Canfield et al., 2006). Residence at 
delivery, therefore, is not only limited in its usefulness as a surrogate for exposure, but in many cases it 
does not reflect biologically relevant exposure, since it does not represent where the woman lived when 
crucial events in embryogenesis were taking place. This limitation should be noted when data on maternal 
residence are presented as part of epidemiologic studies of environmental reproductive hazards. 
11.3.7  Privacy and Data Suppression 
Specific birth defects are often rare events (sometimes extremely rare) leading to yet another set of issues 
that must be considered when presenting birth defects data. The public health professional must balance 
the potentially conflicting goals of information dissemination with protection of the privacy of persons in 
the community. When the number of cases in a diagnostic category within a group or stratum (such as 
race or sex) is small or the population from which the cases are determined is small, the risk of allowing a 
specific individual to be identified may be deemed too large to be acceptable. In such cases, steps must be 
taken to protect an individual’s privacy. In addition to protecting privacy, prevalence information is often 
suppressed when concerns exist regarding possible statistical unreliability of estimates that are based on 
small numbers. 
 
The most common method of preventing the identification of specific individuals in tabular data is 
through cell suppression. This means not providing counts in individual cells where doing so would 
potentially allow identification of a specific person. Cell suppression can also be done by combining cells 
from different small groups to create larger groupings that reduce the risk of identifying individuals. 
While there are also more sophisticated data perturbation methods that use statistical noise to mask 
sensitive information, these are generally more suitable for use with economic or financial data than with 
public health data. 
 
In general, the more restrictive a suppression rule, the less information a given table or report will 
provide. The weaker a suppression rule, the greater the potential threat of revealing confidential health 
information. It is a question of balancing the threat to individual privacy with the public health value of 
presenting the data.  
 
Overall, deciding when and how to suppress birth defects information is more a social, political, and legal 
issue than a technical one. The technical aspects are quite straightforward, but the contextual and 
procedural/policy issues are likely not to be. These all need to be considered and balanced in the local 
context before informed decisions can be made to suppress or not to suppress data in program reports or 
other documents.  
 
Surveillance program administrators and technical staff should be aware that standards used to suppress 
data may already be set in state laws or in departmental or institutional rules and regulations. It is the 
responsibility of surveillance staff and administrators to be aware of these standards and practice within 
their limits. If standards are not established, it behooves a surveillance program to establish rules that will 
be followed consistently. This is best accomplished with the assistance of an advisory committee, an 
institutional review or privacy board, or a similar body.      
 
Appendix 11.1 reviews the basic methods, issues, strengths, and vulnerabilities of cell suppression.  
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11.3.8  Geographic Information Systems (GIS) 
The application of Geographic Information Systems (GIS) methods has become an integral component of 
aggregating, analyzing, evaluating, and displaying health data. The current practical applications of GIS 
in epidemiologic studies range from descriptive statistics (i.e., plotting data on a map) to evaluation of 
spatial relations between environmental exposures and health outcomes.  
 
Several definitions exist for geographic information systems. One of the most recent, as found in Healthy 
People 2010, defines GIS as “powerful tools combining geography, data and computer mapping” (U.S. 
Department of Health and Human Services, 2000). Software packages available today, such as ArcMap 
and MapInfo, integrate many GIS functions. These include (1) database management, (2) data 
manipulation and analysis, and (3) data presentation (i.e., displaying data on a map). To be included in 
GIS, the data should have some kind of geographical or spatial component that can be translated into digit 
maps. Appendix 11.2 contains a brief introduction to GIS mapping along with a list of suggested 
references.  
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As mentioned previously, the key themes of the CDC definition of surveillance are the integration of data 
collection, analysis, interpretation, dissemination, and application. In the previous section we spoke of 
moving from analysis to interpretation, whereby data are converted to information. In this section we are 
more concerned with dissemination of information with an eye toward application, whereby information 
is converted to knowledge capable of informing action. We now turn to some of the more technical, as 
opposed to the more philosophical or theoretical aspects of data presentation. In the broadest sense, we 
are here concerned with the clarity of the information presented and a lack of ambiguity in the message to 
be communicated.  
 
We can conceive of the process of communication as having five major components––the sender 
(presenter), the medium, the message, the objective(s), and the receiver (audience). It is important in the 
development of a data presentation to keep all of these components in mind. It is also important to realize 
that communication is not simply a linear process of conveying the message from the sender to the 
receiver, but rather often involves a loop from the sender to the receiver, back to the sender, and back to 
the receiver.  
 
In general, we suggest working backward through the communication sequence when designing your 
presentation. That is, instead of beginning with yourself (the sender) and what you want to tell the 
audience, begin by thinking about the audience (the receiver) and its information needs. Beginning with 
the audience will help you determine the objectives of the presentation, formulate the message, and select 
the best medium to use in conveying that message. Below we walk you through the process of developing 
a data presentation by (a) accurately characterizing the audience and understanding its needs, (b) 
establishing the purpose or objectives for a given presentation, (c) developing the content of and ensuring 
the clarity of the message, (d) selecting the most appropriate medium for the message, and (e) being 
aware of biases you as the presenter may have. We do not mean to suggest that consideration of elements 
a-e must be undertaken sequentially. However, all need to be considered carefully in the context of the 
presentation as a whole, even if some are apparent “givens”. For example, if you are told you must 
prepare a report for the Governor on x topic, then you know the audience and the medium as well as the 
overall objective of the report, namely “to provide information on x.” Still you would do well to learn 
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more about why the Governor is interested in x, what specific information is being sought, and how the 
information will be used before developing the report.  
11.4.1  The Receiver––Understanding the Audience and Its Information Needs 
Know your audience! One of the central tenets of any presentation is identifying the audience being 
addressed and recognizing the information needs of its members. This includes taking into consideration 
the audience members’ backgrounds, interests, and bases of knowledge. For example, a presentation to 
epidemiologists may include detailed information on complex analyses, yet these should be presented 
only as a summary to an audience of policy makers. The former may expect—and insist on—a 
presentation including numerical estimates of standard errors, confidence intervals, etc., while the latter 
will respond better to straightforward graphical displays that illustrate the key points. Even in an 
apparently homogeneous audience there can be significant heterogeneity. For example, a presentation to a 
parent group may include both highly informed individuals who have extensively researched a particular 
birth defect, as well as new parents who may be wholly unfamiliar with the field.  
 
If the nature and level of expertise of your audience is not clear to you, do not hesitate to talk to someone 
in a position to know more about the audience and why the presentation has been requested or arranged. 
11.4.2  The Objective(s)––Determining the Purpose of the Presentation 
The type of information an audience is interested in and the questions posed can vary considerably, which 
in turn will influence your objectives in developing the presentation. An audience consisting of policy 
makers may be hoping to learn about population trends and attributable risk. Researchers may be 
interested in the prevalence of cases based on various demographic variables, while service providers may 
be most interested in the geographic distribution of cases and services. These differences lead to different 
types of questions that will require different analytic approaches and may lend themselves to different 
formats of data presentation. In Appendix 11.3 (the Data Users Matrix) we characterize a number of 
possible audiences for a birth defects surveillance presentation in terms of their likely information needs 
and presentation approaches that might meet those needs. 
 
In sum, one must be prepared to use different approaches to audiences that differ in current levels of 
knowledge regarding the topic, as well as in having different interests, objectives, and information needs. 
The questions of interest to a particular audience will drive both the analytic approaches and the medium 
or format selected for presentation. 
11.4.3  The Message––Developing Content and Ensuring Clarity 
Having meticulously collected, cleaned, and analyzed a surveillance program’s birth defects data, the 
proud owner of neatly tabulated findings may well wonder, why it is necessary to also express these 
findings in graph or chart form. Shouldn’t the numbers speak for themselves?  
 
The answer is yes, of course, the researcher should be able to verbally convey the most important results 
and to summarize succinctly characteristics of the data. In addition, it is certainly helpful to make 
complete tabular data available to the consumer of epidemiologic results (i.e., the audience). However, 
while individual learning styles differ, most people are primarily oriented to interpreting visual 
information as opposed to tabular data (Spence, 1990) and can more easily make judgments about that 
information based on a limited number of simple cues: smaller/larger, brighter/darker, 
increasing/diminishing. Therefore, a graphical display increases the efficiency with which your audience 
processes your information (Legge et al., 1989). Remember, too, that data presentation is aimed at 
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meeting a specific purpose; whether stated or not, you have an objective and a message to convey, and 
your audience needs to understand it.  
 
In this section we discuss graphical representations (such as graphs and charts), concluding with tips for 
you to keep in mind as you develop a data presentation. We then offer guidance on how to choose the 
appropriate format for displaying a given type of data, with further detail provided in Appendix 11.4. We 
conclude this section with a discussion of the characteristics of a clear, informative table.  
 
Graphs and Charts 
 
The discussion below will enable you to create graphical representations of your data that meet the 
following requirements:  
 Convey results accurately 
 Allow for efficient interpretation 
 Engage the interest of the audience 
 
Conveying results accurately. Essentially, all of the information conveyed through graphs and charts 
allows for comparison and answers a single question: which is larger? This is a question of 
proportionality. Therefore, it is important that visual elements reflect the same proportions as the data 
they represent. For example, Sample Figures 1A and 1B demonstrate cases per 10,000 live births for a 
specific birth defect, but the figures use a different range of values on the y-axis. This practice distorts the 
actual differences in proportion making it appear as if the rates of these two defects are quite similar, 





However, it is not always desirable to use the same scale for all charts. Sample Figure 1C demonstrates 
cases per 10,000 live births using the same scale as Sample Figure 1A, but since absence of limbs is so 
much rarer than renal agenesis, it is difficult to detect any difference among years for Limb Absence. 
Therefore, it is important to weigh the essential information you want to convey before deciding on scale 
(as well as other features); in this case, which is of primary concern: between-defect comparisons or 
illustrating a trend for one particular defect? 
 
Sample Figure 1A. Cases per 10,000 live 
births 1986–1995 
Sample Figure 1B. Cases per 10,000 live 
births 1986–1995
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Chart design characteristics that can distort proportions when changing scales across multiple graphs 
include: 
 Two different graphs examining the same outcome, but based on different time periods or 
different lengths of time.  
 A bar graph of several time-based groups, where the groups correspond to different lengths of 
time.  
 Graphs of statistical functions, such as regression lines, that extend beyond the range of values 
observed in the data. 
 Use of three-dimensional graphical elements.  
 
Allowing for efficient interpretation. To support efficient interpretation of data an important principle to 
follow is the ink-to-data ratio. Simply put, try to minimize the proportion of “ink” (or what would be ink 
on a printed page) that is employed in actually representing data. This means eliminating extraneous 
graphical elements that do not convey additional meaning, such as slide backgrounds, clip art, animations, 
and other elements of what is often referred to as “chart junk.” 
 
Chart junk can appear in two varieties. The first is extraneous material unrelated to the actual data. This 
type of junk is relatively easy to eliminate as it tends to be under the control of the person using the 
graphing software. So resist the temptation! In cases where the junk is generated by the graphing 
software, do not hesitate to edit it out wherever possible.  
 
The second form of chart junk involves certain graphic styles that require a large amount of space to 
convey a small amount of data. In this regard, the key is to focus on the data themselves, rather than the 
data “containers.” Data containers are shapes used to reflect data, such as bars and line markers, and 
minimizing their size can be particularly helpful if one is presenting a large volume of data.  
 
Sample Figure 1C. Cases per 10,000 live 
births 1986–1995 
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For example, consider which of the figures below is easier to understand, Sample Figure 2A or 2B. Hint: 






























                                                 
1 In Sample Figure 2A, the differing color backgrounds, the slide design elements, and the stylized arrow, combined 
with 3D bars, employ a great deal of “ink” to convey the same information as conveyed in Sample Figure 2B. 
 
 
Sample Figure 2A. Example of excessive “ink:data” ratio 
 



















Sample Figure 2B. All “ink” conveys essential information 
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Sample Figures 2C through 2F present further techniques to reduce the amount of “ink” in a chart or 
graph. In 2C, adding data labels to the bars allows you to eliminate additional “ink” in the form of 
gridlines, while allowing the viewer to accurately assess the value of each bar. Horizontal orientation 
allows category labels to be spelled out rather than abbreviated. Sample Figure 2D contains no legend; 
rather each data series is labeled directly, with color coding used to ensure correct pairing of label with 
series. Sample Figure 2F (versus 2E) also uses direct labeling instead of a legend, and changes X axis 




























% of mothers who moved
Controls 
Cases
Sample Figure 2C. Use of data labels to eliminate additional “ink” in the form of gridlines. 



















Sample Figure 2D. Direct labeling of data series rather than legend. Use of color coding to ensure 
correct pairing of label with series. 
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Sample Figures 2E and 2F. Note that Figure 2F uses direct labeling rather than a legend,  
and changes X-axis scaling to every other year. 
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As a general rule, an intelligent reader/observer should be able to clearly interpret a chart or graph without 
referring to supplemental text or materials. If a figure will be used in a live presentation, the information 
presented visually can be minimized to the extent that it will be supplemented orally. However, copies of 
an oral presentation or figures used in formats without benefit of augmentation by a presenter should 
contain sufficient information to stand alone yet still be understood.  
 
Engaging audience interest. While tabular data lend themselves to accurate interpretation, especially by 
those accustomed to working with numbers, they nevertheless require more time to process (Spence, 
1990), are tedious to follow in a slide presentation, and are less accessible to non-technical audiences. A 
compromise suggested by Tufte (2003) is to use handouts, including the actual data tables, in lieu of the 
standard 2x3 printed version of slides. 
 
Cautions about chart-junk notwithstanding, certain visual elements can improve audience engagement. 
For example, color can be an effective means of increasing visual interest and adding clarity to a figure 
(compare the differing impact of Sample Figures 3A and 3B). Color can also be used to portray increasing 
data density (the amount of information conveyed relative to the size of a figure) or to add an additional 
level of information to a figure. For example, the size of a dot may indicate the number of babies born at a 
hospital, while the color of the dot indicates the percentage of births who spend more than 24 hours in a 
neonatal intensive care unit. However, avoid too much color, as well as combinations of colors that may 
distract, confuse, or mislead readers. 
 
 
Sample Figure 3A. Example of a map using color 
codes 
Sample Figure 3B. Example of same map in gray 
scale 
 
Understated, subtle backgrounds, textures, and other graphical elements can be eye-catching but can also 
easily be over-used. Furthermore, no amount of visually stimulating material on a chart can take the place 
of a presenter whose tone of voice, bearing, and engagement with the audience bespeak a clear 
understanding of and excitement about the information being presented. Table 11.1 below contains some 
summary tips for graphical data presentation. 
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Table 11.1 Summary Tips for Graphical Data Presentation 
General Tips 
 Remember that the default graphing settings on your software package (e.g., 
PowerPoint) are rarely the best for creating an effective graph. If you do not have the 
time or interest to customize your own slides, consult an expert in your organization. 
 Use a clear and simple font (e.g., a sans serif font such as Arial). 
 Use footnotes to explain acronyms and methods (Muscatello et al., 2006). 
 Restrict the use of abbreviations to those that will be known to everyone in a potential 
audience or readership, or provide a list of the less well-known abbreviations used, 
keeping them few in number and usage. 
 Indicate the units that are being used (e.g., age in days, weight in grams). 
Analytical Tips 
 Emphasize differences between groups—identical patterns across groups can be stated 
and/or expressed in a bullet point and do not need to be portrayed in a figure. 
 Avoid comparisons across multiple figures. 
Visual Tips 
 Avoid the use of background pictures, or additional pictures, lines, or shapes that are 
added solely to “beautify” a figure. 
 Avoid the use of unnecessary or heavy gridlines. Use white spaces with a bar instead of 
a grid line. 
 Eliminate 3-D bar graphs, which add lines and shading while providing no additional 
information. Furthermore, two-dimensional charts are generally interpreted more quickly 
and accurately than those in 3-D (Hughes 2001).  
 Eliminate unnecessary legends. Legends—if absolutely needed—can be placed inside 
the plot area for a graph. This increases the maximum size of the graph. Rather than a 
legend, use direct labeling if possible. 
 Simplify labeling (Muscatello et al., 2006). For example, a time series on the X axis need 
not always have every year listed—it is implied that 1995 is the point between 1994 and 
1996. 
Staying on Message 
 Remember your core message and do not present irrelevant data (e.g., detailed 
methodological information if not a methodological study). 
 For certain audiences (e.g., lay persons or policy makers), consider wording the title as a 
plainly stated question that guides interpretation of the graph (Muscatello et al., 2006). 
For example, “Is gastroschisis more common among babies born to younger mothers?” 
rather than “Patterns of prevalence of gastroschisis by age of mother” 
 Show your charts and tables to someone unfamiliar with the data and ask them how they 
interpret the “bottom line” message from each. Revise to improve clarity. 
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What Type of Graph or Chart Should I Use? 
 
Appendix 11.4 contains information on some of the more common types of graphs and charts along with 
suggestions on how to choose a type appropriate to the data you are planning to display.  
 
Before making your final decision, however, you should also ask yourself two questions that relate less to 
the nature of your data and more to your own personal preferences and the needs/interests of your 
audience: 
 
 Am I comfortable explaining this graph or chart? If the answer is no, find an alternative format 
with which you are more comfortable. 
 Given my audience, should I sacrifice detail for clarity, or clarity for detail? For example, an 
audience of foster parents would probably benefit from clarity with less detail, whereas an 
audience of epidemiologists will readily comprehend your meaning and will rather be looking for 




Despite the usefulness of graphical data presentation formats such as those just described, there will be 
times when a table is still the ideal choice. Tables display data in a systematic way and help readers locate 
specific information readily. Simple tables can stand alone in a slide presentation or be used as a 
supplemental handout when presenting summary data in graphical format. 
 
Good tables have (see Sample Table 1): 
 A table number 
 A table title that clearly identifies the data displayed 
 Column and row headings  
 At least 3 horizontal lines (below the title, column headings, and data fields) 
 Decimal alignment 
 Expanded forms of abbreviations used in the tables, generally as footnotes 
 Additional explanatory footnotes as needed 
 
Sample Table 1. Counts of selected birth defects cases and  
maternal country of birth, 2004 
Maternal country of birth 
U.S.-born* Mexico/CA** Others*** Missing 
  count % count % count % count % 
Controls  539 48.4 498 44.7 68 6.2 8 0.7
Heterotaxia 63 36.6 97 56.4 11 6.4 1 0.6
Omphalocele 42 48.3 44 50.6 0 0.0 1 1.1
Gastroschisis 58 43.3 63 47.0 12 9.0 1 0.7
Oral clefts 49 52.1 38 40.5 7 7.4 0 0
CA=Central America 
*    50 U.S. States, Puerto Rico, Virgin Islands (U.S.) 
**   Mexico, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama 
*** Algeria, Argentina, Bolivia, Brazil, Others 
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11.4.4  The Medium––Ensuring Its Appropriateness 
Now that you have considered your audience and its needs, established the purpose for communicating 
your data, and developed the content and clarity of the message, it is necessary to select the most 
appropriate medium for the message so that it reaches the right people in a way that will help them to 
understand, interpret, and use the information. The selection of an appropriate medium, or communication 
channel, varies depending on the format of your message and the audience’s access to the medium.  
 
Communication channels can be active or passive. Active channels require the audience to engage with 
the information; passive channels require less interaction. Interpersonal communication, print readership, 
and Internet communication are examples of active channels, while passive channels include television 
and radio. A study comparing media type and source of information with the personal context of health-
oriented attitudes and behaviors (Dutta, 2007) has demonstrated that health-oriented individuals sought 
active channels as primary sources of information. Non health-oriented individuals were more likely to 
obtain information, such as prevention messages, through passive entertainment-education channels. 
 
Information might reach your intended audience directly, via publications, or more indirectly, such as 
through interpersonal communication by a social service professional relaying information to a family 
affected by birth defects. As you communicate information through one channel, consider how the data 
will be interpreted as they flow through other channels (Valente et al., 1996). Below we briefly discuss 
some of the more common communication channels used for the presentation of birth defects data. 
 
 Reports and publications 
 Professional presentations 
 Mass media 
 Websites 
 Community outreach 
 
Reports and Publications 
 
Birth defects data are commonly presented in reports, including internal documents, working papers, and 
scientific publications. Use guidelines from journals for content and format. The level of detail should be 
based on the audience and its needs. Follow the principle of tell ’em: “Tell ’em what you’re going to tell 
’em, tell ’em, and tell ’em what you told ’em” (Collins, 2004a). Summarize the key points of the report in 
an abstract or executive summary, highlight your message clearly, and conclude with a summary. A well-
written abstract should be able to stand alone without reference to the article or report being summarized 
and should concisely outline all relevant topics while excluding unnecessary detail, generally in 200 
words or less.  
 
Within the report, pay careful attention to describing explanatory table headings and figure legends. A 
review of graphical presentations published in Journal of American Medicine and Annals of Emergency 
Medicine (Cooper et al., 2002) identified few indicators of poor quality graphs: lack of definition of 
symbols, internal errors, contradictions with the text, numeric distortion, lack of visual clarity, 
nonstandard graphic conventions, or extraneous decoration. However, 31% of graphs were not self-
explanatory, meaning the reviewers could not unambiguously interpret the graph despite reading the study 
design and legend of the graph. Additionally, 48% of graphs did not illustrate the underlying distribution 
and 48% did not depict important covariates.  
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Professional Presentations 
 
At professional meetings, data are generally presented as poster presentations or platform presentations.  
 
Poster presentations. A poster presentation is a visual display that summarizes your research or 
programmatic project. The display is mounted on a poster board provided at the meeting. The display 
includes visual aids such as data tables, charts and photos, along with a limited amount of text presenting 
the highlights of your topic. Conference participants should be able to quickly understand the work you 
are presenting including, as appropriate, your central research question or hypothesis, your research 
approach, and your results. After reviewing your poster, many participants will ask you questions and 
share their observations. Poster presentations can be an ideal way to: 
 
 Provide a limited amount of information to a diverse audience 
 Start productive conversations with new colleagues  
 Summarize work you have recently completed 
 Obtain useful feedback in developing the study further or in developing a manuscript 
 Advertise your work to colleagues or potential employers 
 
Poster presentations provide key opportunities for scientists to network and discuss shared interests with 
colleagues.  
 
Successful posters tell an interesting story and are visually appealing, logically organized, and easy to 
read. Visually appealing posters are simple, uncluttered displays that use a variety of tools to convey 
information (e.g., data tables, figures, photographs). Color adds interest, but be conservative about the 
number of colors you use. Bright colors can be disconcerting. Judicious use of underlines, boldface type, 
and bullets can succinctly highlight important information. “White space” is critical to creating an 
uncluttered look. A poster printed on a single large (8’ x 4’ or 4’ x 4’) sheet of paper is the easiest to view 
and mount on the poster board. 
 
When constructing figures, charts, or tables, focus the viewer’s attention on the data by reducing or 
eliminating chart “junk” such as non-essential lines or redundant percent symbols (%). Limit the number 
of decimal points presented. When you can, label data directly rather than referring the reader to a legend. 
If possible, convert tabular material to figures that are easy to understand. (See Section 11.4.3 for further 
discussion of charts and graphs.) 
 
Logically organized posters start with a banner title across the top with the authors listed below, followed 
by their institutional affiliations. Poster content––text and visuals––should be organized so that they begin 
in the upper left corner of the poster and end in the bottom right corner. Readers will look at the poster 
from the top down and from left to right. The layout should follow the format of your conference abstract: 
generally covering the topics introduction or background, methods, findings, and conclusions. Many 
posters include the abstract as the initial block of text. Each section should have a brief heading, and 
sections should be separated by a little “white space.” The text should be condensed to key points and 
grouped into blocks of no more than 50–75 words. Avoid abbreviations or acronyms that may be 
unfamiliar to your viewers. 
 
Posters that are easy to read use fonts that are legible from a distance of 3–5 feet. For the poster title, use a 
very large font (84 point or larger). Author name and affiliation information can be displayed in 72 point. 
NBDPN Guidelines for Conducting Birth Defects Surveillance  rev. 07/08 
 
Chapter 11 11-25  Data Presentation 
For other elements of the poster, consider these guidelines:  
 
 Headings and subheadings – at least 32 point 
 Text, figure legends, and tables – at least 18 point  
 
Keep the font style for similar content consistent throughout. Be sure that format headings and text of the 
same level of importance use the same font size. Avoid upper-case or “ALL CAP” fonts. Dark letters on a 
light background are easiest to read. 
 
Some people may ask that you “walk” them through your poster. Avoid reading it! Instead, summarize 
the big picture of what you did and why. Use the poster’s graphics to illustrate your major findings and 
support your conclusions. Presenters often provide a condensed version of their poster for interested 
viewers (e.g., a PowerPoint handout). You might also consider handing out additional information, such 
as supplemental data tables. Always include your contact information.   
 
Platform presentations. Platform presentations are delivered through a structured talk or lecture, 
commonly using presentation visual aids, such as MS PowerPoint. Effective PowerPoint presentations 
support, rather than replace, the delivery of your presentation. Do not be tempted to read directly from 
your slides. The quality of the presentation depends on the quality of the presenter’s communication of 
the information and not entirely on the quality of the visual aids (Collins, 2004a). 
 
As with any public speaking activity, speaking softly, unclearly, or in a monotone voice; using excessive 
hand gestures; and speeding through slides without giving the audience a chance to digest the information 
will not communicate your message well. Pay attention to the pace and timing of your talk, allowing 
pauses but also following time limits. Prepare your presentation for compatibility with any computer, 
bring back-up copies of your presentation and, most importantly, rehearse. Rehearsing, especially in front 
of a representative audience, will help you become comfortable with your presentation, provide an 
opportunity to clarify any points that are potentially confusing, and enable you to assess the presentation’s 
natural and logical flow (Collins, 2004b). It will also give you another chance to proofread for potentially 
embarrassing errors. 
 
When preparing your visual aids, follow principles of clarity, readability, and simplicity. For clarity, 
design your slides with only a few key points per slide. A standard recommendation is the “rule of six”: 6 
lines per slide and 6 words per line (Collins, 2004b). Use contrasting background and text colors so your 
words are readable, but avoid hard-to-read color combinations such as red/green, brown/green, 
blue/black. Font sizes should be at least 24 pt for text and 36–40 pt for titles, but also consider the size of 
the room you are presenting in to ensure the people furthest from the screen can read the slide. Setting the 
entire text in bold can also increase readability. 
 
In terms of simplicity, emphasize the most critical point on each slide. Include pictures and graphs for 
visual interest when they are relevant, but choose them wisely to minimize distraction from the main 
point. Tables can be difficult for audiences to read and interpret; look for other ways such as graphs or 
text to communicate the same information more clearly. If you do choose to use a table, be sure to make 
use of white space so that the audience can easily see the most salient points without sifting through 
clutter (Ryder, 1995). 
 
Finally, remember that it is not the topic or data alone that creates a meaningful presentation. Strategic 
communication of understandable information is the key to successful delivery of data through the 
professional presentation medium (Thompson et al., 1987). 
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Mass Media 
 
Dissemination of birth defects data to the general public occurs through many channels: printed news 
material, television, radio, and websites are just a few examples. Since these media have a broader reach 
than presentations at professional conferences, the audiences will be more heterogeneous. It is important 
to integrate the target audience’s cultural values into the strategy when selecting the appropriate 
communication channel, but the ethical challenges of communicating information accurately through 
mass media are difficult to avoid (Guttman, 1996). A review of 10 years of health content in the media 
concludes that “popular media is not likely to facilitate understandings helpful to individuals coping with 
health challenges” (Kline, 2006). The topic of birth defects tends to be misrepresented in the media, 
generating unnecessary public anxiety (Marks, 1993). If mass media is chosen as a communication 
medium, think about how the public understands and interprets risk, so that it is not interpreted 
inaccurately (McComas, 2006). 
 
While there is no method that will match all needs for knowledge, understanding the needs of potential 
users will help determine if mass media channels are appropriate as well as the best way to tailor the 
message through the medium (Williamson, 2005). Communication strategies should consider the 
audience’s access to information channels, motivation for information, literacy and numeracy, likelihood 




Using websites to convey information about birth defects to the public is becoming increasingly common 
as health-oriented individuals actively seek knowledge, but these individuals’ trust in the information 
source is paramount. Analysis of data from the Health Information National Trends Survey (Rains, 2007) 
shows that “trust in information-oriented media, entertainment-oriented media, and one’s health care 
provider all predicted Web behavior and perceptions.” Users of the Internet as a source of information are 
most likely to be women who have high knowledge about resources, regardless of format, and are likely 
to discuss the information they find with health care providers (Warner and Procaccino, 2007). These 
women typically have a higher level of education and socioeconomic status (Pandey et al., 2003).  
 
Websites are also useful for disseminating data to research, surveillance, program, and policy users. For 
all audiences, the website should be clearly laid out, interactive, tailored to the audience, and regularly 




Another way to communicate birth defects data to the public is through community outreach. Think about 
creative ways of disseminating information in addition to more traditional routes; look beyond 
PowerPoint, posters, and reports. Your audience could be someone affected by a birth defect who may or 
may not attend conferences, read journals, or look at websites. As mentioned earlier, non-health oriented 
individuals may not actively seek information, especially if they have low literacy or numeracy skills, and 
consequently low health literacy skills. The attributes of health literacy are “reading and numeracy skills, 
comprehension, the capacity to use information in health care decision-making, and successful 
functioning as a healthcare consumer” (Speros, 2005). Over 50% of Americans have limited literacy and 
numeracy abilities according to a 1992 National Literacy Survey so health materials should be written in 
simple terms to increase understandability. The health literacy approach is not “dumbing down” data, but 
simplifying it into reader-friendly plain language so the message is communicated clearly (Stableford and 
Mettger, 2007).  
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Some examples of community outreach strategies include:  
 
 Strategically disseminating materials (brochures, posters and pamphlets) in public locations, 
 Delivering information at community events or health fairs, 
 Connecting with key community gatekeepers such as health promoters who share birth defects 
information through interpersonal communication.  
 
Understanding the local context is imperative for developing appropriate communication strategies for 
community outreach. 
 
Remember: “A word of caution that can’t be repeated often enough: The medium does NOT replace the 
message, be it Morse code or interactive video-on-demand. The principal objective remains to choose the 
right message, for the right people, at the right time and to ensure that it gets through in the most efficient 
and effective manner” (Chamberlain, 1996). 
11.4.5  The Sender––Being Aware of Biases 
 
Finally, as a presenter, one rarely faces an audience without having one’s own personal interests and 
objectives. These may range from seeking funding to promoting a particular theory or model and may or 
may not align with the objectives and interests of the audience. We should nevertheless strive to present 
information in as impartial and balanced a manner as possible. This includes not omitting or minimizing 
contrary information, or choosing or manipulating figures or statistics in order to support a given 
objective.  
11.4.6  Pulling It All Together 
 
What are the factors that drive data presentation at the stage when you are transforming information into 
knowledge? As stated previously, when planning a data presentation, it is important that you as presenter, 
and catalyst in the transformation, pay attention to all the other elements of the communication process. 
That is, that you (a) understand the audience and its needs, (b) establish the objective(s) for the 
presentation, (c) determine––based on earlier analysis and interpretation––what the message is and how 
most clearly to present it, and (d) decide upon the communication medium. That is, the elements listed 
below must all be suitably “matched” in a data presentation: 
 
 Audience and its needs 
 Objective(s) 
 Message (information being shared) 
 Communication medium 
 
The three case studies presented below demonstrate how these elements of a presentation must be 
coordinated and addressed. 
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Informing the Public about Birth Defect Prevalence 
Audience The public 
 
Objective To inform the public about the frequency of a birth defect in 
an area, e.g., a state or public health region 
 
Message The observed prevalence of birth defects during a specified 
time or trends over time 
 
Communication Medium Tables or graphs that are clearly labeled, with the terms and 
categories defined so that they are intelligible to the intended 
audience. The medium could be a published report; a press 
release, with supporting technical documentation; or a 
document on the surveillance program’s website. 
 
 
Informing Policymakers about Birth Defects Issues 
Audience Legislators or policy makers 
 
Objective To support efforts to increase health services or justify 
continuation of funding for the surveillance program itself. 
 
Message The magnitude of a problem or the resources needed to 
maintain a surveillance program. 
 




Responding to Community Members about Birth Defects Clusters 
Audience Community members 
 
Objective To respond to concerns about birth defects clusters 
 
Message Relationship (if any) between birth defects clusters and 
environmental hazards 
 
Communication Medium Established state protocols for dealing with this issue and 
including description of how information regarding the 
cluster and its investigation is communicated to concerned 
stakeholders. Important to communicate information to the 
community, both during the investigation and at its 
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11.5  Stage 4 – From Knowledge to Action 
 
 
As mentioned earlier, the key themes of the CDC definition of surveillance are the integration of data 
collection, analysis, interpretation, dissemination, and application. In the previous section we spoke of 
dissemination of information with an eye toward application, whereby knowledge capable of informing 
action is developed. In this section, we speak of application or the undertaking of action(s) in order to 
achieve programmatic objectives. To illustrate this stage, we present a vignette of a surveillance program 
as it moves through different developmental phases (nascent, developmental, mature) and how the data 
produced at each phase of a program’s development can be mobilized to inform action. 
 
The stage of development of a registry or surveillance program has important implications for data 
presentation. The following vignette describes the experiences of one program director in this regard. The 
text is in the first person to reflect the program director’s appraisal of the events surrounding the 
presentation of data to different audiences at different developmental stages of the program and with 
different types of action likely to result. 
 
In my experience, the quality of our data increased dramatically from our initial data set to the 
second and has increased incrementally thereafter. We are continuously evaluating our methods 
and data, with the goal of being more complete, more accurate and reducing bias. Nonetheless, I 
believe all of our data have had some value and were worth presenting to selected audiences.  
 
I received our first data set the day I was asked to take responsibility for the State of 
Contentment’s birth defects surveillance program. I was handed a flexible folder that in essence 
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was the registry. In it were a couple floppy disks, several sheets of paper with diagnoses listed on 
them, and a couple of envelopes containing various parts of copied discharge sheets. Not an ideal 
data set, but it was the result of a pilot project where hospitals in one region of the state reported 
their birth defects cases from one year to the department of health. The regional perinatal center 
had prepared a formatted Excel spreadsheet for the project data, but they were the only hospital 
to use it. While not standardized and not complete, these were the best data we had at the time.  
 
We compiled the data into a table based on the tables of birth defects in the NBDPN annual 
report and presented them at a meeting organized by the local chapter of the March of Dimes. 
The meeting coincided with the March of Dimes’ annual legislative lobbying day. It was a 
relatively informal meeting, and we provided handouts of the data to a mixed audience made up 
primarily of March of Dimes volunteers; a number of neonatal intensive care unit (NICU) nurses, 
geneticists, and neonatologists also attended the meeting. The March of Dimes was particularly 
interested in the data, as they had lobbied the legislature to establish a birth defects surveillance 
program, legislation which included authorization of the pilot project. The presentation was 
informal, accompanied by a warning that the data were very messy and likely to be incomplete. 
Nonetheless, the audience was enthusiastic. The volunteers asked a lot of questions, as did the 
professionals who also offered a good deal of advice. Among other things, I recall learning the 
importance of using standardized case definitions; the number of cases of patent ductus 
arteriosus was likely inflated because there was no control for low-birth-weight infants. The 
presentation was followed by a reception for the legislators whom the March of Dimes had 
lobbied earlier that day.  
 
Following the meeting, I developed a plan to use data from our Hospital Discharge Data System 
linked with the Birth Certificate Data System to identify birth defect cases. This provided a state-
wide population-based assessment. We did the extractions and linkages for a one-year birth 
cohort, the same year’s data that were used in the pilot study. At the next March of Dimes annual 
meeting we presented the overall state data, along with a comparison of the regional pilot study 
data and the linked data. Once again there was a lot of give and take, and it was readily apparent 
that the linked data were more complete and accurate. With the birth certificate linkages, we also 
had considerable data on the characteristics and conditions of the birth population, the 
denominator for the calculation of strata-specific prevalence estimates. Once again the 
presentation was followed by a reception with the legislators. A year later a number of the 
legislators who attended the reception voted to provide funding for our plan to establish a state-
wide birth defects surveillance program. The data were not perfect, but they clearly had value.  
 
In the meantime, the single-year data were also submitted for the NBDPN annual report and 
presented at the opening of a state American College of Obstetricians and Gynecologists (ACOG) 
meeting. The ACOG meeting was formal with a PowerPoint presentation and the audience, 
primarily physicians and nurses, was very interested and inquisitive. The data showed specific 
birth defects rates that appeared high relative to national rates and differences among regions of 
the state. Much of the discussion following the presentation was on the possible reasons for the 
observed differences. Some of the hypotheses involved potential artifacts in the data, whereas 
others involved regional differences in behaviors and populations. Once again the interaction 
was informative for the presenter as well as the audience.  
 
Subsequently we have given presentations at two American Public Health Association annual 
meetings; one presentation focused on a plan to evaluate the hospital discharge data, using 
active case/control reviews, and the other on risk factor analyses using the linked birth certificate 
and hospital discharge data. To date the program has compiled six years of population-based 
statewide surveillance data using the linked birth-hospital discharge data and two years of active 
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case/control reviews. A linkage of the two data sets and their evaluation should be completed 
soon and will likely provide greater depth and information than any of the previous 
presentations. The key point is that each of the above-mentioned data sets had both informative 
and intrinsic value when presented to the appropriate audience, along with clear warnings 
regarding the data’s potential limitations.  
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Appendix 11.1 Data Suppression 
 
Specific birth defects are often rare events (sometimes extremely rare) leading to a set of issues that must 
be considered when presenting birth defects data. The public health professional must balance the 
potentially conflicting goals of information dissemination with protection of the privacy of persons in the 
community. When the number of cases in a diagnostic category within a group or stratum (such as race or 
sex) is small or the population from which the cases are determined is small, the risk of allowing a 
specific individual to be identified may be deemed too large to be acceptable. In such cases, steps must be 
taken to protect an individual’s privacy.  
 
The most common method of preventing the identification of specific individuals in tabular data is 
through cell suppression. This means not providing counts in individual cells where doing so would 
potentially allow identification of a specific person. Cell suppression can also be done by combining cells 
from different small groups to create larger groupings that reduce the risk of identifying individuals. 
While there are also more sophisticated data perturbation methods that use statistical noise to mask 
sensitive information, these are generally more suitable for use with economic or financial data than with 
public health data. This appendix reviews the basic methods, issues, strengths, and vulnerabilities of cell 
suppression. In addition to protecting privacy, prevalence information is often suppressed when concerns 




The first question is whether or not to suppress. Surveillance program administrators and technical staff 
should be aware that standards used to suppress data may already be set in state laws or in departmental 
or institutional rules and regulations. It is the responsibility of surveillance staff and administrators to be 
aware of these standards and practice within their limits. If standards are not established, it behooves a 
surveillance program to establish rules that will be followed consistently. This is best accomplished with 
the assistance of an advisory committee, an institutional review or privacy board, or a similar body.   
 
Suppression rules are typically based on a predetermined criterion for the number of diagnosed cases 
and/or the number of births in the population or subpopulation from which the cases were identified. 
These numbers may also be thought of as the numerator and the denominator, respectively, of a 
prevalence estimate. Generally, suppression rules focus on the size of either the numerator or the 
denominator, the ratio of the numerator to the denominator, or the difference between the numerator and 
denominator. However the values that trigger suppression vary greatly from one institution or place to 
another, and there are no set standards. In practice, the rules used vary from relatively liberal to very 
conservative. Suppression rules for some of the population-based data systems used to assess progress 
toward the Healthy People 2010 objectives are presented in Table A11.1-1.  
Table A11.1-1 Data suppression rules for population-based data systems in the HP2010 
Data System Suppression Criteria 
HIV/AIDS Surveillance System < 4 cases 
National Notifiable Diseases  
    Surveillance System 
Race and Hispanic origin if < 4 cases 
STD Surveillance System County: < 4 cases; State: < 6 Cases;  
National: None 
Source: Klein et al., 2002 
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Each of these suppression criteria is based on simple case counts, but they vary in terms of whether the 
suppression is of the overall counts or by substrata such as race/ethnicity or geography. In contrast, some 
surveillance programs will not report data on a birth defect if the case count is less than 5, regardless of 
the population size, whereas many regularly report single cases. When evaluating the prevalence of birth 
defects or investigating potential birth defects clusters, it is often necessary to consider birth populations 
that may consist of small numbers of births. In this situation information on individual cases may be 
essential to fulfill some of the program’s public health functions but should not be included in formal 
reports. 
 
While reporting small numbers of cases may threaten privacy, the threat may be greatest when reporting 
from small populations or when the difference between the number of cases and the population count is 
small. This has led to suppression rules that assess the difference between the prevalence numerator and 
the denominator or the case count and the population size (e.g., Land, 2001). For example, given the 
suppression criteria requiring a minimum difference of 15 and a single case of anencephalus in a birth 
population of 16, the denominator minus the numerator rule would allow the data to be shown. However, 
in a birth population of 15 the same data would not be shown. Given the nature of anencephalus, an 
alternative relevant event-specific denominator may be infant deaths in the population. In that case with a 
birth population of 16, a single anencephalus case would not be shown unless all the infants had died. 
Thus, even the seemingly simple question of the relevant population to be considered may not be 
straightforward and should be considered carefully in deciding when to suppress.  
 
Extent of Suppression 
 
Having made the decision to suppress, the question becomes what and how to suppress. The solution that 
provides the greatest protection of privacy is to suppress an entire table whenever a single cell presents a 
threat, whereas the solution that provides the least protection is to suppress a single offending cell or only 
those cells deemed sensitive. Suppressing only sensitive cells is called primary suppression. However, 
when a single cell is suppressed, if column and row totals are provided, they can be used to compute the 
value of the suppressed cell. Similarly, suppressing multiple cells may allow the values of many or all of 
the suppressed cells to be revealed through a series of simple arithmetic solutions. This leads some 
agencies to practice complementary suppression, also referred to as secondary suppression, in which 
nonsensitive cells are suppressed in order to support the suppression of sensitive cells. If not properly 
done, however, the values or approximate ranges of cells in tables created with complementary 
suppression can also be obtained through the application of simultaneous equations (Geissing, 2001). 
Complex computer algorithms can be used to determine what cells must be suppressed in order to protect 
sensitive information. However, these algorithms are not always effective and become excessively 
complex in large tables (Duncan et al., 2001). One also confronts the issue of increasing data loss when 
large numbers of cells are used in complementary suppression.  
 
Threat of External Data 
 
A final issue to be considered in deciding when and how to suppress sensitive information is the potential 
availability of data in multiple tables. It is not enough to simply evaluate the present table with its 
columns and rows; one must also consider the possible availability of complementary tables. This is 
especially true in the era of web-based interactive information systems that generate tables for custom 
queries on demand. Consider a hypothetical case where, in the process of creating a table for an annual 
report, it was determined that cells showing pyloric stenosis counts for the black population were 
potentially sensitive and the decision was made to provide only the total number of cases. Subsequently it 
is determined that effectively suppressing the black population’s case counts would require 
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complementary suppression of the white population’s case counts. Given that the white population’s data 
were not sensitive, they may be subsequently published in a separate table. If so, the resulting data could 
be combined with the original table in order to reveal the black population’s data. A similar situation 
would arise if, to protect privacy and present all of the data, the population strata were collapsed and 
subsequently data for one of the strata were published.  
 
Summary on Suppression 
 
The more restrictive a suppression rule, the less information a given table or report will provide. The 
weaker a suppression rule, the greater the potential threat of revealing confidential health information. It 
is a question of balancing the threat to individual privacy with the public health value of presenting the 
data. Overall, deciding when and how to suppress birth defects information is more a social, political, and 
legal issue than a technical one. The technical aspects are quite straightforward, but the contextual and 
procedural/policy issues are likely not to be. These all need to be considered and balanced in the local 
context before informed decisions can be made to suppress or not to suppress data in program reports or 
other documents.  
 
References on Data Suppression 
 
Klein RJ, Proctor SE, Bouderault MA, Turczyn KM. Healthy People 2010 criteria for data suppression. 
In: Healthy People 2010 Statistical Notes. No. 24. Hyattsville, MD: National Center for Health Statistics; 
2002.   
 
Land G. Confidentiality data release rules. 2001. http://www.amstat.org/comm/cmtepc/images/ 
Land_confidentiality%20rules.ppt. Accessed 5/21/08.  
 
Geissing S. Non-perturbative disclosure control methods for tabular data. In: Doyle P, Lane JI, Theeuwes 
JM, Zayatz LM, eds. Confidentiality, Disclosure and Data Access: Theory and Practical Applications for 
Statistical Agencies. Amsterdam, Netherlands: Elsevier Science; 2001:185–213.  
 
Duncan GT, Feinberg SE, Rammayya K, Padman R, Roehrig SF. Disclosure limitation methods and 
information loss for tabular data. In: Doyle P, Lane JI, Theeuwes JM, Zayatz LM, eds. Confidentiality, 
Disclosure and Data Access: Theory and Practical Applications for Statistical Agencies. Amsterdam, 
Netherlands: Elsevier Science; 2001:135–166. 
 
See also American Statistical Association: http://www.amstat.org/comm/cmtepc/index.cfm?fuseaction=1. 
Accessed 5/21/08. 
 









Use of Geographic Information Systems (GIS) to 
Map Data 
NBDPN Guidelines for Conducting Birth Defects Surveillance                                                                                          rev. 07/08 
 
Appendix 11.2 A11.2-1 Data Presentation 
Appendix 11.2 Use of Geographic Information Systems (GIS) to Map Data 
 
The application of Geographic Information Systems (GIS) methods has become an integral component of 
aggregating, analyzing, and evaluating health data. The current practical applications of GIS in 
epidemiologic studies range from descriptive statistics (i.e., plotting data on a map) to evaluation of 
spatial relations between environmental exposures and health outcomes.  
 
Several definitions exist for geographic information systems. One of the most recent, as found in Healthy 
People 2010, defines GIS as “powerful tools combining geography, data and computer mapping” (U.S. 
Department of Health and Human Services, 2000). Software packages available today, such as ArcMap 
and MapInfo, integrate many GIS functions. These include (1) database management, (2) data 
manipulation and analysis, and (3) data presentation (i.e., displaying data on a map). To be included in 
GIS, the data should have some kind of geographical or spatial component that can be translated into digit 
maps.  
 
Digital Map Formats 
 
GIS applications use either a vector or a raster map format, or a combination of the two. In vector maps 
(Figure A11.2-1) geographic features are represented by points (e.g., location of infants with birth 
defects), lines (e.g., streets), and polygons (e.g., census tracts) (Rogers, 1999). These features are based 
on latitude and longitude coordinates of the different objects. The vector format is the most commonly 
used in public health. In raster maps the data are stored as digital images (e.g., orthophotos, scanned 
maps) (Vine et al., 1997). Usually a grid cell is used to represent a feature, and these cells can be 
connected. As such, smaller cells provide a more detailed resolution. Obtaining quality maps for a given 
geographical area for the time period of interest is crucial as maps are static while environments change. 
 
Bringing Health Data into GIS 
 
Ultimately, the application of GIS to birth defects data requires the transformation, as accurately as 
possible, of health records containing addresses or location information into geographic objects. This 
process is called geocoding, also known as address matching. During geocoding, latitude and longitude 
coordinates are assigned by the GIS software to each address by matching against an address-range (i.e., 
street segment) in a street reference map such as the Census Topologically Integrated Geographic 
Encoding and Referencing (TIGER) files (Croner et al., 1996). Interpolation is used to estimate the actual 
address location within the given range (Rushton, 1999). The address match rate depends on several 
factors, including the completeness of addresses in health records and the accuracy of reference maps 
(McElroy et al., 2003). In case of incorrect or missing house numbers and/or street names, coordinates are 
usually assigned to a centroid of a larger geographical entity, such as a census tract or a ZIP code. If 
available, other reference files such as tax parcel databases can also be used for geocoding purposes. 
Alternatively, in areas where latitude and longitude coordinates have not been predetermined (e.g., rural 
communities), a global positioning system (GPS) device can be used, although this may prove time and 
resource demanding. Figure A11.2-2 shows an example of how a point is placed within an address range.  
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Figure A11.2-1 An Example of GIS Data Layers 
 
 
Figure A11.2-2 A Specific Location Within an Address Range 
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Mapping Data 
 
Once health data are brought into a GIS database, users need to be aware of several important issues in 
data mapping. For example, different spatial databases must have the same scale and projection 
(McLafferty and Cromley, 1999). Otherwise data will be distorted or cannot be mapped together. Map 
scale shows the relationship between a unit of length on a map and the corresponding length on the 
ground. It is also an expression of how much the area represented has been reduced on the map. The 
smaller the scale, the larger the area displayed on a map. Map projections are attempts to 
portray/transform the surface of the three-dimensional earth or a portion of the earth on a flat map using a 
mathematical model. Some distortions of conformality, distance, direction, scale, and area always result 
from this process. Maps that focus on maintaining one feature (e.g., preserving distance) must distort 
other features (e.g., area, shape). Maps that accurately reflect area are called equal-area maps, while maps 
that correctly show the distance between points are called equidistant maps.  
 
Two types of maps frequently used in public health research are dot-density and choropleth maps 
(Rogers, 1999).  
 
Dot-density mapping. Dot-density maps are the simplest way to display events. These maps use dots or 
other symbols to represent the number of occurrences of a given data characteristic (Thrall, 1999). Each 
dot or symbol used on the map may represent a single entity (one dot = one case) or a group (one dot = 
1,000 people). Dot-density maps are useful for area comparisons. However, dot-density maps need to be 
interpreted with caution regarding the “symbol to data characteristic” ratio. It is also important to keep in 
mind that dots do not always indicate the exact location of the data. An example of a dot-density map for 
metropolitan Atlanta is presented in Figure A11.2-3 (Source: Siffel et al., 2006, Figure 1, p. 828). 
 
 
Figure A11.2-3 A Dot-Density Map of Metropolitan Atlanta 
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Choropleth mapping. Choropleth maps are area maps in which polygons (e.g., census tracts, counties) 
are shaded, colored, or patterned according to the extent to which a given attribute (such as population 
size or disease rate) is associated with each polygon. Choropleth maps are also called thematic maps or 
shaded maps. An example of a choropleth map for metropolitan Atlanta is presented in Figure A11.2-4 
(Source: Siffel et al., 2006, Figure 2, p. 828).   
 
It is important to choose the right characteristics for map presentations as the choice of color, pattern, 
size, polygon shape, and class intervals can impact how one interprets the information presented in a map. 
Single-color maps with varying color intensity (shades) are often an effective means of presenting data, 
but the use of differing patterns can help a black-and-white or grey-scale map. Similar-size polygons are 
recommended to the extent possible, as a few large polygons can dominate a map, leading to 
misinterpretation of information. Proportions or rates can be displayed by different class interval schemes, 
such as equal intervals (equal ranges of values) or quintiles (equal number of polygons falling into each 
class defined by dividing the range of values). The latter method is particularly useful for presenting 




Figure A11.2-4 Choropleth Map of Infants per Census Tract in Metropolitan Atlanta, 1990  
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Additional Technical Details 
 
Maps showing point locations or even aggregate data in a small geographic area have the potential to 
reveal the identity of individuals (Cox, 1996). Therefore, as noted elsewhere in this chapter (see Appendix 
11.1 on Data Suppression), one must generally limit the presentation of disaggregated birth defects 
information. While GIS methods and techniques exist for protecting privacy and limiting disclosure of 
information by geographically masking individual records (Armstrong et al., 1999), the use of masked 
data in small-area analysis can limit one’s ability to detect clusters of cases (Kamel Boulos et al., 2005). 
As such, careful choice of geographical units and data aggregation are vital. 
 
Below we present several practical suggestions for preparing and presenting maps above and beyond 
those already mentioned.  
 
 The use of the same scale, colors, class intervals, and legends when presenting a series of maps. 
 The inclusion of a scale bar and a “North” arrow.  
 The use of patterns when printing in black and white. Color maps produced on a black-and-white 
printer usually do not provide as good results as grey scale. 
 Avoid the use of red and green on the same map. 
 Be wary of font-related problems. If symbols, which are special GIS fonts, are used on a map, do 
not export the map as an MS Windows meta file (.wmf). This type of file requires access to the 
GIS fonts. Similarly, do not include such files in presentations being made on an unfamiliar 
computer. If the GIS fonts are not available, other fonts will be substituted for symbols in the 
image. Instead, export your maps as JPEG files.  
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Appendix 11.3 Data Users Matrix 
 
Sample Questions Asked Information Needs/Data Presentation Suggestions 
Surveillance Program Staff 
This group is likely to require process indicators useful for management. Members of this group may 
notice possible clusters. This audience also needs additional information about denominator issues and 
data quality.  
 How many abstracts were completed per 
field staff person? 
 We have noticed more cases of birth defect 
x in this hospital; is that unusual? 
 Data on labor hours and abstracting rates. 
 Data on birth prevalence, usually in comparison 
to some standard, such as the entire state. 
 Internal exhibits in terms of surveillance 
parameters: Completeness/Ascertainment, Case 
Processing Times.  
Researcher 
This audience is likely to be interested in: 
o Descriptive epidemiology (describing occurrence of birth defects by person, place, and time). 
o Analytic epidemiology (finding causes of birth defects). 
o Obtaining birth defect cases for related studies.  
o Methodological issues. 
o Availability of data on individual types of birth defects and on cases, both identified and de-
identified, for ecologic studies and etiologic research. 
 What are the patterns of birth defect 
occurrence by person, place, and time? 
 What is associated with risk of birth defect 
x? 
 How many cases of specific birth defects 
are represented in the database of the 
surveillance program? 
 How do I get access to records for persons 
included in the surveillance program for 
research studies? 
 Printed and web reports and charts with routinely 
tabulated results allow for quick response to 
many inquiries.  
 Specially tabulated results 
 Line item data with and without confidential 
information. 
 Interactive web-based tool for custom queries 
allows for easy access and reduces staff time in 
responding to simple routine and non-routine 
aggregate data requests. See, for example, 
http://soupfin.tdh.state.tx.us/bdefdoc.htm  
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Sample Questions Asked Information Needs/Data Presentation Suggestions 
Physician and Other Health Care Providers 
This audience is often interested in outcomes (pregnancy, how does the child do, survival/treatment), as 
well as birth defect prevalence. Members of this group may notice possible clusters. This audience also 
needs additional information about denominator issues and data quality. Statistical output for this 
audience may well run more detailed in terms of clinical detail. Allow for the presentation of small cases 
series. Members of this group often have the skill to interpret tabular data, but do not assume they will 
necessarily have the statistical sophistication that may be lacking in other audiences. 
 Which defects are most common? 
 What are the trends in birth defects over 
time? 
 Are there unexpectedly high rates in my 
area or facility? 
 Printed reports. 
 Web-based data. 
 
Social/Education Service Provider 
Needs from this audience are usually geographic in nature. Birth defects programs can promote use of 
data among this group by providing maps and other data that respond to these information needs. 
 Describe the population we serve in terms 
of location, income, other variables. 
 How many babies with complex congenital 
heart defects do you estimate will be born 
during the next five years in the area for 
which our children’s hospital provides 
clinical care? 
 Mapping location of clinics compared to 
appropriate birth defect cases. 
 Time series analyses with projections (e.g., how 
many children with x syndrome will be born in x 
county for the next five years in order to project 
needs for special education teachers, etc.?). 
Local Health Department 
This audience tends to be interested in epidemiological data. Members of this group may also want to 
link your data with data they have on environmental concerns (e.g., factories, toxic waste sites). There is 
a risk of misuse of data if users do not understand the unique aspects of birth defects data. 
 What are our rates?  
 How do we compare with the rest of the 
state? 
 How do we compare with the nation? 
 Are there links between birth defect 
clusters and local environmental concerns? 
 What clusters (in our area) are you dealing 
with? 
 What are the trends in birth defects over 
time? 
 Epidemiologic data provided by zip code, city, 
county, region. 
 Case characteristic summaries as tables, as well 
as rate tables and graphics, including trends. 
Consider also the presentation of rate ratios. 
 Reports of cluster investigations; maps of clusters 
investigated.  
 Have a document written in language accessible 
to the lay person explaining some of the finer 
points of interpreting birth defects data. 
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Sample Questions Asked Information Needs/Data Presentation Suggestions 
Maternal and Child Health Programs 
Members of this group might be professionals in Women Infants, and Children (WIC) or Title V 
programs. They tend to be interested in trends over time, rates, outcomes, and surveillance operations. 
 Do you have any information on folic acid 
education programs that can be targeted to 
our Hispanic clients? 
 Items here will likely address racial disparities 
and the demographics that underlie differences in 
race, including cultural health practices and SES. 
 GIS/spatial analysis may be relevant here. 
Family of Child with Birth Defect(s) 
This audience tends to like information about known causes and risk factors for particular birth defects. 
Members of this group are interested in seeing birth defects data linked with potential teratogens or 
environmental concerns and the outcomes. They may desire information on educational, social, and 
clinical services available for children with specific types of birth defects. 
 I have a child with a cleft lip. What 
information do you have on the causes of 
this condition?   
 I just had a baby with spina bifida. What 
information can you give me about this 
condition and where can I get specialized 
care for her? 
 Do you have any information on support 
groups in my community for parents of 
children with Down syndrome? 
 What caused my child’s birth defect?  
 Have there been clusters investigated in my 
area? 
 Literature summaries.   
 Maps of cluster investigations. 
 Charts comparing local/state rates to other areas. 
 Be sure to explain the difference between 
individual- and population-level information 
Students (public health, medical, nursing, allied health, or other college/university) 
Needs among this audience might include: 
o General education (e.g., lectures to a class) 
o Specific education (e.g., practicum placements) 
o Research (e.g., data and guidance on papers, theses, dissertations) 
You might present to these types of students during Grand Rounds or at local seminars or conferences. 
They may also submit specific requests as a result of papers or projects they are working on. 
 Can you provide me with information 
about changes in the occurrence of neural 
tube defects in ___ following the 
fortification of cereal grains with folic 
acid? 
 Printed reports. 
 Copies of manuscripts. 
 Interactive web-based tool for custom queries 
allows for easy access and reduces staff time in 
responding to simple routine and non-routine 
aggregate data requests. 
 Raw data. 
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Sample Questions Asked Information Needs/Data Presentation Suggestions 
News/Media Person 
Media personnel are generally interested in comparative rates region/state/nation. Also, they will likely 
need information about causes and risk factors. Their questions may or may not relate to a specific 
community concern or cluster. They tend to request large amounts of data and use very little of it.  
 What is the cause of x birth defect? 
 Are the cases of x birth defect linked with 
the toxic dump, military base, factory, 
vaccine, etc? 
 
 Printed and web reports and charts with routinely 
tabulated results allow for quick response to 
many inquiries. 
 Have a document written in language accessible 
to the lay person explaining some of the finer 
points of working with and interpreting birth 
defects data. 
Legislator/Policy Maker 
This type of information request usually comes from higher up in the agency or from advocacy groups. 
Top information needs include cost of program, cost of birth defects to the state, number of people served 
by the program, and staffing data. This audience would be interested in surveillance data connected to 
other information such as regional variation or costs. Members of this group may also request 
administrative data—improvements in program efficiency, budget information, increases in caseload 
(live births, hospitals). 
 How many staff (FTEs) does the 
surveillance program employ? 
 What is the cost of the program?   
 How many babies with birth defects are 
born each year in my legislative district? 
 What are the estimated lifetime costs of 
caring for a child with spina bifida? 
 What is the impact of this policy? (e.g., 
decrease in rates of NTDs after fortification 
of food supply with folic acid) 
 Narrative reports. 
 Graphs of birth prevalence over time (for 
before/after comparisons) or comparing 
communities with different policies. 
 Statistical exhibits intended for this audience 
should address not only descriptive aspects, but 
also the quantitative burden of disease. 
 
Advocacy Group 
The needs of this group will vary depending on what they are advocating for. This audience will need 
exhibits at two levels––exhibits for the lay public and exhibits for policy makers—and the distinction 
needs to be clear. 
 What are the rates in z location for birth 
defect x? 
 Why are you not collecting data on birth 
defect x? 
 What is the cost to y unit of government 
for treating birth defect x? 
 Cost, magnitude, impact.  
 Birth defects data linked with environmental 
data.  
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Sample Questions Asked Information Needs/Data Presentation Suggestions 
Other Community Members 
Members of this group usually contact the registry to report concern of a possible cluster. They are 
frequently interested in environmental exposures and birth defects. 
 What are the rates of birth defects in my 
community? 
 Are birth defects higher here than 
elsewhere? 
 If higher, can the excess birth defects be 
linked to environmental concerns? 
 Data on occurrence, usually in comparison to 
some standard, such as the entire state. 
 









What Type of Chart or Graph Should I Use? 
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Appendix 11.4 What Type of Chart or Graph Should I Use? 
 
Research illuminating human perceptions of graphical representations offers us clues as to how to select 
the best representation for a given type of data. Below we present examples of the most common types of 
graphs and charts, along with suggestions on when they might be used.  
 
Pie charts can be effective for communicating simple 
proportions (see Figure A11.4-1). When comparing 
several proportions, convention dictates that none of the 
radii should be at the “12 o’clock” position (Hollands, 
2003). Pie charts do not need legends, instead the series 
name and percentage should be positioned next to the 








A 100% stacked bar chart can be used to compare 
proportions between two or more data sets (see 
Figure A11.4-2). However, be careful about 
presenting too many data points as the graph may 
become too busy to convey information 
effectively. An alternative would be a series of 
several pie charts, although 100% stacked bars 



















Georgia California France Italy
B irt h D ef ect  M onit or ing  Syst em
Live Birth Elective Termination Fetal Death
Figure A11.4-2 Pregnancy Outcomes, Down Syndrome 
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Time series are nearly always demonstrated 
using a line chart, with a marker at each year. 
Figure A11.4-3 includes a regression line 
indicating that the change in rates is indeed 
statistically significant, thereby adding 












Certainly the most common need for graphical representations of birth defects data is the comparison of 
rates of cases among persons and places. Bar charts are an ideal choice for this because they give an 
impression of relative differences but, unlike line charts, do not give the impression that moving left-to-
right is a time progression (see Figure A11.4-4). (Note: This chart also demonstrates the use of white 
breaks in the bars in lieu of gridlines across the whole plot area.) 
 
 
Figure A11.4-4 Bar chart demonstrating cases per 1,000 live births 
Figure A11.4-3 Rates of Hirschsprung disease 1989–2001  
1Trend is significant; details are given in Table 3 
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Bar charts can also be used to convey information about the statistical significance of rates by using drop 
lines to represent confidence limits, as in Figure A11.4-5. Note: the best way to ensure that confidence 
limits are represented correctly is to import the results directly into your graphic software from your 
analysis software. However, it is also possible to produce the irregular confidence limits found when using 
Poisson regression in Microsoft Office products (see the document “Plotting Irregular 95% Confidence 




















Figures A11.4-6 and A11.4-7 below, respectively, present examples of maps of epidemiological data. For 















































Figure A11.4-5 Bar chart with confidence limits  
Figure A11.4-6 Spot Map Figure A11.4-7 Area Map 
Down Syndrome (Trisomy 21) 
1999−2004 
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When places are not contiguous or for some other reason would be difficult to display on a map, a bar 






















When only the general place rather than a specific site is relevant (e.g., entire state versus specific regions 































Figure A11.4-8 Displaying geographic data with a bar chart 
Figure A11.4-9 Displaying geographic data in an area map 
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In Table A11.4-1 below you will find one scheme for selecting the appropriate graphic representation 
given the type of data you will be presenting.  
 
Before making your final decision, however, you should also ask yourself two questions that relate less to 
the nature of your data and more to your own personal preferences and the needs/interests of your 
audience: 
 
 Am I comfortable explaining this graph? If the answer is no, find an alternative format with 
which you are more comfortable. 
 
 Given my audience, should I sacrifice detail for clarity, or clarity for detail? For example, an 
audience of foster parents would probably benefit from clarity, whereas an audience of 
epidemiologists will readily comprehend your meaning and will rather be looking for additional 
detail about methods or sample characteristics.  
 
 
Table A11.4-1 Selecting a method of illustrating epidemiologic data (adapted from Principles of 
Epidemiology, 3rd edition, U.S. Department of Health and Human Services). 
 
If Data Are: And These Conditions Apply: Then Choose: 
1 series Pie chart (Sample Figure 4) < 6 data points 
>1 series 100% stacked bars  
(Sample Figure 5) 
Proportions 
6+ data points 1+ series Consider combining data point 
categories or table.  
(Sample Figure 5) 
Time Series Numbers of Cases Line chart (Sample Figure 6) 
Data with  
discrete categories  
Bar chart (Sample Figures 7, 8) 
Not readily identified on map Bar chart (Sample Figure 11)  
Specific site 
important 
Spot map (Sample Figure 9) 
Number of 




Area map (Sample Figure 10) 
Place 
Rates Area map (Sample Figure 12) 
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